<graphml xmlns="http://graphml.graphdrawing.org/xmlns" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://graphml.graphdrawing.org/xmlns http://graphml.graphdrawing.org/xmlns/1.0/graphml.xsd">
  <key id="d6" for="edge" attr.name="source_id" attr.type="string" />
  <key id="d5" for="edge" attr.name="description" attr.type="string" />
  <key id="d4" for="edge" attr.name="weight" attr.type="double" />
  <key id="d3" for="node" attr.name="entity_type" attr.type="string" />
  <key id="d2" for="node" attr.name="source_id" attr.type="string" />
  <key id="d1" for="node" attr.name="description" attr.type="string" />
  <key id="d0" for="node" attr.name="type" attr.type="string" />
  <graph edgedefault="undirected">
    <node id="HIDRADENITIS SUPPURATIVA">
      <data key="d0">DISEASE</data>
      <data key="d1">Hidradenitis Suppurativa (HS) is a chronic, inflammatory, recurrent, and debilitating skin disease of the hair follicle that typically presents after puberty. It is characterized by painful, deep-seated, inflamed lesions, abscess formation, and the development of multiple draining sinus tracts. These symptoms predominantly occur in apocrine gland-bearing areas of the body, most commonly in the axillae, inguinal, anogenital regions, groin, and perineum. The condition manifests as inflamed and swollen lumps, painful nodules, and abscesses, significantly impacting the quality of life of affected individuals.</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,523bbfee1ae3b4ecabf9b11d10eea9ff,661a4cc53cee3ca36afa676952adc7fb,b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="ACNE INVERSA">
      <data key="d0">DISEASE</data>
      <data key="d1">Acne Inversa is another name for Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="ADALIMUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Adalimumab is a monoclonal antibody and a TNF-&#945; inhibitor used in the treatment of autoimmune and inflammatory diseases. It functions as a TNF antagonist, targeting and inhibiting TNF-&#945; to mitigate inflammation. Adalimumab is specifically approved for the treatment of Hidradenitis Suppurativa (HS) and is utilized in anti-TNF biologic therapy to manage various autoimmune conditions.</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,523bbfee1ae3b4ecabf9b11d10eea9ff,5ec1ebf4e260eb1f8fda8acdf06cd39e,661a4cc53cee3ca36afa676952adc7fb,c44ec79872ab10cbe7336182f183ff60,c95d22c2a90e77cd22bd0d280d55b26a,f3b0f42501dbe75c224f7af44e0885f9,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="HAIR FOLLICLE">
      <data key="d0">TISSUE</data>
      <data key="d1">Hair follicles are structures in the skin that produce hair. The hair follicle is the tissue primarily affected in Hidradenitis Suppurativa (HS).</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="KERATINOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Keratinocytes are the primary type of cell found in the epidermis, the outermost layer of the skin. They are responsible for forming a barrier against environmental damage and play a crucial role in skin barrier function. These cells are involved in epithelial differentiation and inflammation, particularly in conditions such as atopic dermatitis (AD) and hidradenitis suppurativa (HS). In the context of AD, keratinocytes express the aryl hydrocarbon receptor (AhR) and are affected by cytokines such as IL-4, IL-13, and IL-22, which lead to reduced filaggrin (FLG) expression and downregulation of FLG, respectively. Additionally, keratinocytes release cytokines in response to tissue damage in atopic dermatitis. In HS, keratinocytes produce cytokines like IL-6 and IL-1&#946;, contributing to the inflammatory response. Overall, keratinocytes are integral to maintaining skin integrity and responding to inflammatory signals in various skin conditions.</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,2e0cdefd62bed7c674d7fb93ef336c2b,3ea70e257330c812b52334ca1f90d807,41ccc4b41bd57cf2bda4dbb6c7ae4198,48288f3ec2832850282f95d4e38d10e1,4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd,523bbfee1ae3b4ecabf9b11d10eea9ff,5f37466ca41c9b8b06ed8be0303d49f2,6309eeea565f06479830cec32938abc9,661a4cc53cee3ca36afa676952adc7fb,bae090d8a29c15868ba1c4f29ae79e99,e075bccd45593ae008b2ce7f9ed8ff6c,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="OBESITY">
      <data key="d0">DISEASE</data>
      <data key="d1">Obesity is a condition characterized by excessive body fat. It is considered an important risk factor for Hidradenitis Suppurativa (HS) and is a comorbidity associated with HS. Obesity not only contributes to the development of HS but also exacerbates its severity.</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff,661a4cc53cee3ca36afa676952adc7fb,e340a83f7cba0ea5be731b1f682ea7c7,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="METABOLIC SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Metabolic Syndrome is a cluster of conditions that increase the risk of heart disease, stroke, and diabetes. It is considered an important risk factor for Hidradenitis Suppurativa (HS), a chronic skin condition. The association between Metabolic Syndrome and HS highlights the interconnected nature of metabolic and inflammatory pathways, underscoring the importance of managing metabolic health to potentially mitigate the risk and severity of HS.</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="INFLAMMATORY BOWEL DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Inflammatory Bowel Disease (IBD) is a group of chronic inflammatory conditions affecting the colon and small intestine. It is characterized by persistent inflammation of the digestive tract. Additionally, IBD is often comorbid with Hidradenitis Suppurativa (HS), indicating a potential link between these inflammatory disorders.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,4a1ab1e50481cdd86d237db424a95719,573fb6fa0673eb9462aa9862888079f3,661a4cc53cee3ca36afa676952adc7fb,7f559ad7372a4e35e90b43cc67047b0f,990bc0f89db6ad8683c7a06a3ab356d9,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="ARTHRITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Arthritis is a condition characterized by inflammation and pain in the joints. It is also recognized as a comorbid disorder associated with Hidradenitis Suppurativa (HS).</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,62b4bd8f530adae989e4349d1e58f11d,661a4cc53cee3ca36afa676952adc7fb,baf4dec7fda8d8b8571a343b034f7092,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="TYPE I DIABETES MELLITUS">
      <data key="d0">DISEASE</data>
      <data key="d1">Type I Diabetes Mellitus is a chronic autoimmune disease characterized by high blood sugar levels due to the body's inability to produce insulin. This condition arises because the pancreas produces little or no insulin. Additionally, Type I Diabetes Mellitus is a comorbid disorder associated with Hidradenitis Suppurativa (HS).</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719,661a4cc53cee3ca36afa676952adc7fb,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="ATHEROSCLEROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Atherosclerosis is a disease characterized by the buildup of fats, cholesterol, and other substances in and on the artery walls, leading to the formation of plaques inside the arteries. This condition is associated with OX40-OX40L signaling and is a type of heart fibrosis. Additionally, atherosclerosis is a comorbid disorder associated with Hidradenitis Suppurativa (HS).</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,1b656cfce91ff9ccec4223703489dab3,661a4cc53cee3ca36afa676952adc7fb,990bc0f89db6ad8683c7a06a3ab356d9,a10787d7fbb1307be263e86dc7b33a51,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="ADIPOGENESIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Adipogenesis is the process of cell differentiation by which preadipocytes become adipocytes, involved in the formation of fat cells. This pathway is dysregulated in Hidradenitis Suppurativa (HS) and is associated with the comorbid disorders linked to HS.</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719,661a4cc53cee3ca36afa676952adc7fb,f3b0f42501dbe75c224f7af44e0885f9,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="FOLLICULAR HYPERKERATOSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Follicular Hyperkeratosis is a consistent finding in Hidradenitis Suppurativa (HS), leading to follicular rupture and inflammation.</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="LYMPHOHISTIOCYTIC INFLAMMATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Lymphohistiocytic Inflammation is an initial inflammatory response in Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="GRANULOMATOUS REACTION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Granulomatous Reaction is a type of inflammation associated with Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="SINUS TRACT FORMATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Sinus Tract Formation is a symptom of Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="SCARRING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Scarring is the formation of fibrous tissue as a result of injury or disease. It is also a symptom of Hidradenitis Suppurativa (HS), a chronic skin condition characterized by inflamed and painful lumps under the skin.</data>
      <data key="d2">516e41e96d2e72d45bf1e2c69da7f18a,661a4cc53cee3ca36afa676952adc7fb</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="EPITHELIAL SKIN CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Epithelial Skin Cells are involved in the innate immunity response in Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="ADIPOSE TISSUE">
      <data key="d0">TISSUE</data>
      <data key="d1">Adipose Tissue is a type of connective tissue that stores fat. It is also involved in Hidradenitis Suppurativa (HS), as demonstrated by immune histochemical studies.</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb,b2aae16813e647959b783a39ef9a19a7,fa1f4687a5326fccd5d518845839e5f2</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="INVERSE VIRTUAL SCREENING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Inverse Virtual Screening is a technology used to identify existing compounds as potential drugs for various diseases, including Hidradenitis Suppurativa (HS).Inverse virtual screening is a technology used to identify existing compounds as potential drugs for Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="COMPUTATIONAL DRUG REPURPOSING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Computational Drug Repurposing is a technology used to identify existing compounds as potential drugs for various diseases, including Hidradenitis Suppurativa (HS).Computational drug repurposing is a technology used to identify existing compounds as potential drugs for Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="GENE EXPRESSION OMNIBUS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Gene Expression Omnibus is a database for storing gene expression data. It is also used for obtaining records related to Hidradenitis Suppurativa (HS).</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="NATIONAL INSTITUTES OF HEALTH">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">National Institutes of Health is an organization involved in the research of Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="TRANSCRIPTOME">
      <data key="d0">PATHWAY</data>
      <data key="d1">The transcriptome refers to the complete set of RNA transcripts produced by the genome under specific circumstances or in a specific cell. Transcriptome analysis involves studying the expression of genes in atopic dermatitis lesions, providing insights into the molecular mechanisms underlying this condition. Additionally, transcriptome studies are utilized to detect HS (Hidradenitis Suppurativa) signature pathways and molecular characteristics, aiding in the understanding of the disease's pathophysiology.</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb,f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PROTEOME">
      <data key="d0">PATHWAY</data>
      <data key="d1">Proteome studies are used to detect HS signature pathways and molecular characteristics.</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="HUGO GENE NOMENCLATURE COMMITTEE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The HUGO Gene Nomenclature Committee is an organization that verifies gene nomenclature in studies related to Hidradenitis Suppurativa (HS). Additionally, the HUGO Gene Nomenclature Committee is responsible for approving unique symbols and names for human loci.</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb,990bc0f89db6ad8683c7a06a3ab356d9</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="CHRONIC INFLAMMATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Chronic inflammation is a prolonged inflammatory response that can lead to tissue damage. It is also a major pathogenetic pathway of Hidradenitis Suppurativa (HS).</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1,4cf23e218b6aab3c77115173b5c7c2fd,661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="DYSREGULATED EPITHELIAL DIFFERENTIATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Dysregulated epithelial differentiation is a major pathogenetic pathway of Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="INFLAMMATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Inflammation is a biological response to harmful stimuli, such as injury or infection, characterized by redness, swelling, heat, and pain. It is a localized physical condition where part of the body becomes reddened, swollen, hot, and often painful. Inflammation is a key component in the pathogenesis of various diseases, including Hidradenitis Suppurativa (HS), Systemic Sclerosis (SSc), and Atopic Dermatitis (AD). In HS, inflammation is characterized by upregulated inflammatory responses. In AD, inflammation involves various cytokines and immune cells, with cytokines like IL-4 and IL-13 playing a significant role. Treatments for AD and other comorbidities often aim to reduce inflammation, which is a common symptom in these conditions.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,1412a7a7fef5f18cc09a030b97b18e13,143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524,27a7e95c7d3ad59a948aa46741fee456,2cec06c4d46f5ff9ee936a78d8b077cd,3ce96e927d65736b305f792977fed4b9,48de7eebab3f3b418feb35a152df38fd,6059a6e2710b7df94c6a09e5eb7b024a,661a4cc53cee3ca36afa676952adc7fb,855c455b4c9592746834ee3a4e0e6b81,8ce8c356713490cd2c680f505bcd050b,90f4809673ca34628b0e607908f0bf0b,a867a1e73cef039eb3f28e072463b838,f3b0f42501dbe75c224f7af44e0885f9,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="BACTERIAL COLONIZATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Bacterial colonization is a possible secondary effect in Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="INNATE IMMUNITY RESPONSE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Innate immunity response is induced in epithelial skin cells in Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="IMPAIRED BARRIER FUNCTION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Impaired barrier function is detected at the follicular and epidermal keratinocyte level in Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="EPIDERMAL KERATINOCYTE">
      <data key="d0">CELL</data>
      <data key="d1">Epidermal keratinocytes are involved in the inflammatory process in Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="SKIN-GLAND LEVEL">
      <data key="d0">TISSUE</data>
      <data key="d1">The skin-gland level is involved to a minor degree in Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="APOCRINE GLAND">
      <data key="d0">TISSUE</data>
      <data key="d1">Apocrine glands are sweat glands that are commonly affected by Hidradenitis Suppurativa (HS). These glands play a significant role in the pathology of HS, a chronic skin condition characterized by the formation of painful lumps under the skin, often in areas where apocrine glands are concentrated.</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="AXILLAE">
      <data key="d0">TISSUE</data>
      <data key="d1">The axillae are commonly affected areas in Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="INGUINAL REGION">
      <data key="d0">TISSUE</data>
      <data key="d1">The inguinal region is commonly affected in Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="ANOGENITAL REGION">
      <data key="d0">TISSUE</data>
      <data key="d1">The anogenital region is commonly affected in Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="FOLLICULAR RUPTURE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Follicular rupture is a consistent finding in Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="SINUS TRACT">
      <data key="d0">TISSUE</data>
      <data key="d1">A sinus tract is a channel that can form in the skin, often associated with chronic inflammation in Hidradenitis Suppurativa (HS). Sinus tracts are formed as a result of Hidradenitis Suppurativa (HS).</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606,661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="IMMUNE-RELATED DRIVERS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune-related drivers induce an innate immunity response in Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="DRUG REPURPOSING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Drug repurposing is a method used to find new treatments for Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="DRUG-GENE INTERACTION PROFILING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Drug-gene interaction profiling is used to identify potential drugs for Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="HS">
      <data key="d0">DISEASE</data>
      <data key="d1">Hidradenitis Suppurativa (HS) is a chronic, complex inflammatory skin condition distinct from psoriasis or atopic dermatitis. It is characterized by inflamed, painful, and swollen lumps under the skin, which can develop into nodules, abscesses, and scarring. As an autoimmune disease, HS involves chronic inflammation and abscess formation in the skin, leading to significant discomfort and potential complications for affected individuals.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,2e0cdefd62bed7c674d7fb93ef336c2b,411a4d246f0a9321e52971446a5a0606,4a1ab1e50481cdd86d237db424a95719,6309eeea565f06479830cec32938abc9,990bc0f89db6ad8683c7a06a3ab356d9,b28eeca0ff01a7715947d55a04978a43,b62ecc47bf54393bc78dd65986b949d6,bae090d8a29c15868ba1c4f29ae79e99,c44ec79872ab10cbe7336182f183ff60,e340a83f7cba0ea5be731b1f682ea7c7,e4d25b1cd44df240a29591bc46a875ab,f3b0f42501dbe75c224f7af44e0885f9,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="CXCL10">
      <data key="d0">GENE</data>
      <data key="d1">CXCL10 encodes C-X-C Motif Chemokine Ligand 10, a chemokine involved in immune responses and immune cell recruitment. Its expression is increased in certain conditions, such as HS (Hidradenitis Suppurativa), suggesting a role in the interferon (IFN) response.</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9,b19f42c9497f71b231222cd953036d6b,b62ecc47bf54393bc78dd65986b949d6,cdfcc39154accbac074c924676dc701e,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </node>
    <node id="IL6">
      <data key="d0">GENE</data>
      <data key="d1">IL6 encodes interleukin-6, a cytokine that plays a crucial role in the regulation of immune responses and inflammation. It is associated with the IL-1 signaling pathway and is integral to the body's defense mechanisms. Interleukin-6, produced by the IL6 gene, is pivotal in mediating inflammatory responses and modulating the immune system.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,62b4bd8f530adae989e4349d1e58f11d,990bc0f89db6ad8683c7a06a3ab356d9,c44ec79872ab10cbe7336182f183ff60,cdfcc39154accbac074c924676dc701e,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IL17A">
      <data key="d0">GENE</data>
      <data key="d1">IL17A is a gene encoding interleukin-17A (IL-17A), a pro-inflammatory cytokine produced by Th17 cells. IL-17A plays a crucial role in the immune response and is involved in inflammatory processes. Increased mRNA expression of IL17A has been observed in certain conditions, such as HS (Hidradenitis Suppurativa). This cytokine is also significantly implicated in the pathogenesis of autoimmune diseases, highlighting its importance in both normal immune function and disease states.</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,573fb6fa0673eb9462aa9862888079f3,990bc0f89db6ad8683c7a06a3ab356d9,bae090d8a29c15868ba1c4f29ae79e99,c44ec79872ab10cbe7336182f183ff60,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </node>
    <node id="IL36A">
      <data key="d0">GENE</data>
      <data key="d1">IL36A is a gene associated with the IL-1 signaling pathway and encodes for interleukin-36 alpha (IL-36A), a cytokine involved in inflammatory responses. IL-36A plays a significant role in skin inflammation and has increased mRNA expression in hidradenitis suppurativa (HS).</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,573fb6fa0673eb9462aa9862888079f3,990bc0f89db6ad8683c7a06a3ab356d9,e340a83f7cba0ea5be731b1f682ea7c7,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IL36G">
      <data key="d0">GENE</data>
      <data key="d1">IL36G is a gene encoding interleukin-36 gamma (IL-36G), a cytokine involved in inflammatory responses. It is associated with the IL-1 signaling pathway and plays a significant role in skin inflammation. Additionally, IL36G has been observed to have increased mRNA expression in conditions such as hidradenitis suppurativa (HS).</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,573fb6fa0673eb9462aa9862888079f3,990bc0f89db6ad8683c7a06a3ab356d9,bae090d8a29c15868ba1c4f29ae79e99,e340a83f7cba0ea5be731b1f682ea7c7,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="S100A8">
      <data key="d0">GENE</data>
      <data key="d1">S100A8 is a gene encoding S100 Calcium-Binding Protein A8, which is involved in the regulation of inflammatory processes and immune response. It plays a significant role in the IL-1 signaling pathway and is associated with immune response mechanisms. Additionally, S100A8 is an epidermal differentiation protein that is upregulated in atopic dermatitis lesions.</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9,baf4dec7fda8d8b8571a343b034f7092,c44ec79872ab10cbe7336182f183ff60,f66eb51473925a8084dad1745be63b78,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="S100A9">
      <data key="d0">GENE</data>
      <data key="d1">S100A9 is a gene encoding S100 Calcium-Binding Protein A9, which is involved in the regulation of inflammatory processes and immune response. It is associated with the IL-1 signaling pathway and plays a significant role in immune response. Additionally, S100A9 is an epidermal differentiation protein that is upregulated in atopic dermatitis lesions.</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9,baf4dec7fda8d8b8571a343b034f7092,c44ec79872ab10cbe7336182f183ff60,f66eb51473925a8084dad1745be63b78,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="C&#8211;C RECEPTOR INTERACTION PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">A signaling pathway involving cytokine-cytokine receptor interactions</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="JAK-STAT SIGNALING PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The JAK-STAT SIGNALING PATHWAY is a critical signaling pathway involved in the transmission of information from chemical signals outside the cell to the cell nucleus. This pathway plays a significant role in DNA transcription and subsequent changes in cellular function. Additionally, it is involved in HS (Hidradenitis Suppurativa), with genes within this pathway showing diversified regulation.</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719,990bc0f89db6ad8683c7a06a3ab356d9,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="CHEMOKINE SIGNALING PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">A signaling pathway involving chemokines, which are a type of cytokine</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="IL-17 SIGNALING PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The IL-17 SIGNALING PATHWAY is a signaling pathway involving interleukin-17, which plays a crucial role in inflammatory responses. This pathway is also involved in hidradenitis suppurativa (HS), with genes within the pathway showing diversified regulation.</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="TH17 CELL DIFFERENTIATION PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The TH17 CELL DIFFERENTIATION PATHWAY is a signaling pathway involved in the differentiation of Th17 cells, a type of T helper cell. This pathway encompasses the process by which naive T cells differentiate into Th17 cells, which play a crucial role in autoimmune and inflammatory responses.</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719,990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="TOLL-LIKE RECEPTOR PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">A signaling pathway involving Toll-like receptors, which play a key role in the innate immune system</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="INFLAMMATORY BOWEL DISEASE PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The INFLAMMATORY BOWEL DISEASE PATHWAY is a signaling pathway involved in the pathogenesis of inflammatory bowel diseases. It is associated with inflammatory bowel disease and linked to HS.</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="RHEUMATOID ARTHRITIS PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The "RHEUMATOID ARTHRITIS PATHWAY" is a signaling pathway involved in the pathogenesis of the autoimmune disease rheumatoid arthritis. This pathway is intricately linked to the development and progression of rheumatoid arthritis and is associated with HS (Hidradenitis Suppurativa). Understanding this pathway is crucial for comprehending the underlying mechanisms of rheumatoid arthritis and its association with other conditions like HS.</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9,f3b0f42501dbe75c224f7af44e0885f9,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="LIPID AND ATHEROSCLEROSIS PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The "LIPID AND ATHEROSCLEROSIS PATHWAY" is a signaling pathway involved in lipid metabolism and the development of atherosclerosis. This pathway encompasses the accumulation of lipids in the arterial walls, which subsequently leads to the formation of atherosclerotic plaques.</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719,990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="SKIN">
      <data key="d0">TISSUE</data>
      <data key="d1">The skin, the body's largest organ, serves as a protective barrier against environmental factors and is involved in various immune responses. It is the primary tissue affected by a range of dermatological conditions, including atopic dermatitis (AD), psoriasis, and hidradenitis suppurativa (HS). In atopic dermatitis, the skin is characterized by inflammation, itchiness, and eczematous lesions, often showing pathological changes such as fibrosis and epidermal barrier dysfunction. Skin biopsy specimens from AD patients are frequently analyzed to study transcriptomic and proteomic profiles, revealing the co-localization of molecules like OX40 and OX40L. 

In hidradenitis suppurativa, the skin is marked by chronic abscess formation and sinus tracts, with notable differences between lesional and non-lesional areas. Psoriasis also manifests in the skin, contributing to its role as a primary tissue affected by these conditions. Additionally, the skin is impacted by systemic diseases such as systemic sclerosis, which can lead to fibrosis and other pathological changes.

The skin's role extends beyond being a mere barrier; it is also a target for various dermatological treatments and formulations aimed at healing and reducing inflammation. As the outermost layer of the body, the skin is crucial for protection, sensation, and maintaining overall health, making it a focal point in the study and treatment of numerous diseases and conditions.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,0829313703a7d2bae5436a9ee542334d,100dd7646c10899301b3c0631183da16,104cc78517b2eca2e9cb7e00de1fe4b0,1412a7a7fef5f18cc09a030b97b18e13,143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,27a7e95c7d3ad59a948aa46741fee456,2a0384addc6e7fd709e0508b83496cd7,2cec06c4d46f5ff9ee936a78d8b077cd,2e0cdefd62bed7c674d7fb93ef336c2b,2e9a8d71f6bd251a0b13458c39e69746,3ce96e927d65736b305f792977fed4b9,3dfbb4c51838e0951f53ce951395225f,3ea70e257330c812b52334ca1f90d807,411a4d246f0a9321e52971446a5a0606,41ccc4b41bd57cf2bda4dbb6c7ae4198,442e7fad2fab75fa2449309783294d89,44f2592262cac835560b4c149fee8d2b,475995d7d211bbfde6d8ba52f324d688,48de7eebab3f3b418feb35a152df38fd,4cf23e218b6aab3c77115173b5c7c2fd,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,523bbfee1ae3b4ecabf9b11d10eea9ff,5ec1ebf4e260eb1f8fda8acdf06cd39e,6059a6e2710b7df94c6a09e5eb7b024a,68015074236b0144899baa38d01ae467,693a2aac101eaaadf92614317a1e4da8,6ada075e562abd7bd445164e9fc309b4,6aef5adb1be227170f66c76a292c25e5,6b099960b0a39866e3aa6b908f1886e4,78e26c66107dba37ac4bab65406b43a0,8246ea974dfb00cb5e3d984004e21a9e,83eb9003d42977bb83fea1d123dd5ab9,855c455b4c9592746834ee3a4e0e6b81,89dbac0da39e4de2b602052cd792b90d,90f4809673ca34628b0e607908f0bf0b,9867d43adab0ba5db44961fae4863eee,990bc0f89db6ad8683c7a06a3ab356d9,a867a1e73cef039eb3f28e072463b838,b28eeca0ff01a7715947d55a04978a43,b2aae16813e647959b783a39ef9a19a7,b62ecc47bf54393bc78dd65986b949d6,bae090d8a29c15868ba1c4f29ae79e99,bddc3b1a7f098e71f0aa64adec047124,c46e8b6ee0c29e37b7f18c42558d7a3e,cccfd5ff480e281556e2210cd0e5c4b5,d4797ed1483e5057bcd8301eaa509d5e,d8a485eb1e9435b083d5ef6a17f06ea5,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c,e340a83f7cba0ea5be731b1f682ea7c7,e4d25b1cd44df240a29591bc46a875ab,f1897c89e321a3a80924fd72a56e90df,f3b0f42501dbe75c224f7af44e0885f9,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="BLOOD">
      <data key="d0">TISSUE</data>
      <data key="d1">Blood is a bodily fluid and tissue composed of cells and plasma, which delivers necessary substances such as nutrients and oxygen to cells and transports metabolic waste products away from those same cells. It plays a crucial role in various physiological processes, including the transport of nutrients and waste. In the context of Hidradenitis Suppurativa (HS) patients, blood is used for biomarker studies, where differentially expressed genes and proteins are detected. Additionally, cell type signatures in blood are analyzed in HS patients, making it a valuable tissue for understanding and researching this condition.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,2a0384addc6e7fd709e0508b83496cd7,2e0cdefd62bed7c674d7fb93ef336c2b,990bc0f89db6ad8683c7a06a3ab356d9,c46e8b6ee0c29e37b7f18c42558d7a3e,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="FIBROSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Fibrosis is a pathological condition characterized by the excessive formation of fibrous connective tissue, leading to the thickening and scarring of connective tissue. This process, known as tissue fibrosis, is often a result of chronic inflammation and can develop from a pro-inflammatory environment. It is commonly seen in chronic inflammatory diseases, including systemic sclerosis (SSc), where it is considered a hallmark symptom. The condition is driven by various molecular pathways, including the OX40-OX40L signaling and TNFSF members, and is promoted by cytokines such as IL-13, particularly in skin remodeling. Fibrosis results from the deposition of extracellular matrix proteins and is a significant health concern, being a leading cause of death in the USA. Additionally, tissue fibrosis can be triggered by type 2 pathway activation, as observed in conditions like atopic dermatitis (AD).</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,05c97152fe02249153103be341d65b67,080b1dc5fcc0eee3645a06983a0de603,1b656cfce91ff9ccec4223703489dab3,28f548554737fcc026b968db6bbafa30,44f2592262cac835560b4c149fee8d2b,48de7eebab3f3b418feb35a152df38fd,4cf23e218b6aab3c77115173b5c7c2fd,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,516e41e96d2e72d45bf1e2c69da7f18a,5ec1ebf4e260eb1f8fda8acdf06cd39e,68015074236b0144899baa38d01ae467,7b454335c2f5651d86f712037a0dc0ff,7c13f41d7349d9d2e56c36e00c0ca2d9,855c455b4c9592746834ee3a4e0e6b81,8ce8c356713490cd2c680f505bcd050b,9867d43adab0ba5db44961fae4863eee,990bc0f89db6ad8683c7a06a3ab356d9,a10787d7fbb1307be263e86dc7b33a51,b28eeca0ff01a7715947d55a04978a43,b2aae16813e647959b783a39ef9a19a7,c525762bb827485bceeb9f09bb4bcfe0,c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e,df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="EUROPEAN BIOINFORMATICS INSTITUTE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The European Bioinformatics Institute is a center for research and services in bioinformatics</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="NATIONAL CANCER INSTITUTE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The National Cancer Institute is part of the U.S. National Institutes of Health and conducts cancer research</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="G:PROFILER">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">g:Profiler is a toolset for functional profiling of gene lists from large-scale experiments</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="KYOTO ENCYCLOPEDIA OF GENES AND GENOMES (KEGG)">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">KEGG is a database resource for understanding high-level functions and utilities of the biological system</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="REACTOME">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Reactome is a free, open-source, curated and peer-reviewed pathway database</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="WIKIPATHWAYS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">WikiPathways is a database of biological pathways maintained by and for the scientific community</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="HUMAN PHENOTYPE ONTOLOGY (HP)">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The Human Phenotype Ontology provides a standardized vocabulary of phenotypic abnormalities encountered in human disease</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="THE DRUG REPURPOSING HUB">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The Drug Repurposing Hub is a curated and annotated collection of FDA-approved drugs, clinical trial drugs, and pre-clinical tool compounds</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="GENE CARDS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Gene Cards is a database of human genes that provides concise genomic related information</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="ELI AND EDY L. BROAD INSTITUTE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The Broad Institute is a biomedical and genomic research center</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="MIT">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The Massachusetts Institute of Technology is a private research university</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="HARVARD UNIVERSITY">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Harvard University is a private Ivy League research university</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="WEIZMANN INSTITUTE OF SCIENCE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The Weizmann Institute of Science is a public research university in Rehovot, Israel</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="OREGON HEALTH AND SCIENCE UNIVERSITY">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Oregon Health and Science University is a public university in Oregon, USA</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="NEW YORK UNIVERSITY">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">New York University is a private research university in New York City</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="ONTARIO INSTITUTE FOR CANCER RESEARCH">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The Ontario Institute for Cancer Research is a collaborative research institute in Ontario, Canada</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="JACKSON LABORATORY FOR GENOMIC MEDICINE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The Jackson Laboratory for Genomic Medicine is a research institution focused on genetics and genomics</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="IL-17">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-17 (IL-17) is a family of pro-inflammatory cytokines involved in immune and inflammatory responses. This family includes members such as IL-17A and IL-17C. IL-17 is produced primarily by T cells, particularly Th17 cells, and is induced by ICOS in activated T cells. It plays a crucial role in the IL-23&#8211;IL-17 axis, which is implicated in the pathogenesis of various autoimmune and inflammatory diseases, including psoriasis and atopic dermatitis (AD). IL-17 is particularly significant in the pathophysiology of chronic lesions in AD. Due to its central role in inflammation, IL-17 is being explored in clinical studies for conditions like psoriasis and is targeted by anti-IL-17 compounds for the treatment of hidradenitis suppurativa (HS).</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,3df8535e965efb96f5094169610507ff,44f2592262cac835560b4c149fee8d2b,48288f3ec2832850282f95d4e38d10e1,4a1ab1e50481cdd86d237db424a95719,503107475d2e9dac49abd8ebcbadd9f5,6309eeea565f06479830cec32938abc9,6ada075e562abd7bd445164e9fc309b4,849e0980ffd6a7e1cf0b8d3d1fbacd98,855c455b4c9592746834ee3a4e0e6b81,8ce8c356713490cd2c680f505bcd050b,990bc0f89db6ad8683c7a06a3ab356d9,b19f42c9497f71b231222cd953036d6b,b62ecc47bf54393bc78dd65986b949d6,bae090d8a29c15868ba1c4f29ae79e99,e340a83f7cba0ea5be731b1f682ea7c7,e95d4d15e4f3110c91a3d3fcb5910d06,f3b0f42501dbe75c224f7af44e0885f9,f66eb51473925a8084dad1745be63b78,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="TH17 CELL">
      <data key="d0">CELL</data>
      <data key="d1">TH17 CELL: TH17 cells are a type of T cell involved in the immune response and inflammation. They are a subset of T helper cells that play a significant role in autoimmune diseases.</data>
      <data key="d2">849e0980ffd6a7e1cf0b8d3d1fbacd98,990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="TOLL-LIKE RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Toll-like receptors are proteins that play a key role in the innate immune system</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="CYTOKINE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Cytokines are small signaling proteins that mediate and regulate immunity, inflammation, and hematopoiesis. They play a crucial role in cell signaling, particularly in immune responses.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,1596d061dbe1a1c9e8f31a02a21e5524,44f2592262cac835560b4c149fee8d2b,7c13f41d7349d9d2e56c36e00c0ca2d9,8ce8c356713490cd2c680f505bcd050b,990bc0f89db6ad8683c7a06a3ab356d9,bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="CHEMOKINE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Chemokines are a family of small cytokines involved in the immune response and cell migration. They play a crucial role in inducing chemotaxis in nearby cells, guiding the movement of immune cells to sites of inflammation, infection, and injury.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="JAK-STAT">
      <data key="d0">PROTEIN</data>
      <data key="d1">JAK-STAT is a signaling pathway that transmits information from chemical signals outside the cell to the cell nucleus</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="C&#8211;C RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">C&#8211;C receptors are a type of cytokine receptor</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="RHEUMATOID ARTHRITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Rheumatoid Arthritis is a chronic inflammatory disorder primarily affecting the joints. It is an autoimmune disease characterized by chronic inflammation of the joints, leading to joint inflammation and damage. Rheumatoid Arthritis can also develop in children with Atopic Dermatitis. The condition is commonly treated with TNF antagonists or inhibitors to manage the inflammation and associated symptoms.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,0c7502a2bfe653785647d754ed10f4e3,423195c6b63ad0a6773374364ebf3612,4a1ab1e50481cdd86d237db424a95719,516e41e96d2e72d45bf1e2c69da7f18a,573fb6fa0673eb9462aa9862888079f3,5ec1ebf4e260eb1f8fda8acdf06cd39e,62b4bd8f530adae989e4349d1e58f11d,68015074236b0144899baa38d01ae467,6ada075e562abd7bd445164e9fc309b4,8e5a1be9981340d419f7b3ad27076009,990bc0f89db6ad8683c7a06a3ab356d9,a867a1e73cef039eb3f28e072463b838,baf4dec7fda8d8b8571a343b034f7092,c46e8b6ee0c29e37b7f18c42558d7a3e,cdfcc39154accbac074c924676dc701e,e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="TLR PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The TLR pathway involves Toll-like receptors that play a key role in the innate immune system</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="C-TYPE LEPTIN RECEPTOR SIGNALING PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The C-type leptin receptor signaling pathway is involved in regulating energy balance and body weight</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="TNF SIGNALING PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The TNF signaling pathway involves tumor necrosis factor, which is involved in systemic inflammation</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="IL-4">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-4 (IL-4) is a cytokine that plays a multifaceted role in the immune response and inflammation. It is produced by Th2 cells and mast cells and is crucial in the pathophysiology of atopic dermatitis (AD), where it contributes to tissue inflammation and epidermal barrier dysfunction. IL-4 is involved in the differentiation of naive helper T cells to Th2 cells, promoting TH2 polarization and cutaneous inflammation in AD. It signals through both type 1 and type 2 heterodimeric receptors and is a key mediator in type 2 immune responses.

IL-4 also enhances Staphylococcus aureus infections and promotes fibroblast activation and extracellular matrix synthesis, indicating its pro-fibrotic properties. It is targeted by dupilumab, a therapeutic antibody used in the treatment of atopic dermatitis, which inhibits IL-4 to reduce inflammation and improve clinical outcomes. Additionally, IL-4 levels are reduced in an AD animal model treated with CsA-loaded nanoparticles, highlighting its role in disease modulation.

Overall, IL-4 is a central cytokine in immune signaling, particularly in the context of type 2 immune responses and atopic dermatitis, making it a significant target for therapeutic interventions.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,0ba9fbea14e0c2c1d01a12ffaacfda9b,104cc78517b2eca2e9cb7e00de1fe4b0,27a7e95c7d3ad59a948aa46741fee456,286730b1c1f680ac465cc21d522fda0c,28f548554737fcc026b968db6bbafa30,2cec06c4d46f5ff9ee936a78d8b077cd,2e0cdefd62bed7c674d7fb93ef336c2b,3df8535e965efb96f5094169610507ff,3dfbb4c51838e0951f53ce951395225f,41ccc4b41bd57cf2bda4dbb6c7ae4198,44f2592262cac835560b4c149fee8d2b,4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd,4a1ab1e50481cdd86d237db424a95719,503107475d2e9dac49abd8ebcbadd9f5,6309eeea565f06479830cec32938abc9,691cb2e23ac3c6e591129d16714f8ef8,693a2aac101eaaadf92614317a1e4da8,78e26c66107dba37ac4bab65406b43a0,849e0980ffd6a7e1cf0b8d3d1fbacd98,855c455b4c9592746834ee3a4e0e6b81,96e553a44a27e728c27c4892045ec5c2,b19f42c9497f71b231222cd953036d6b,bddc3b1a7f098e71f0aa64adec047124,e075bccd45593ae008b2ce7f9ed8ff6c,e95d4d15e4f3110c91a3d3fcb5910d06,e9841b88c9fab58c5175af409653da50,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="IL-13">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-13 (IL-13) is a cytokine that plays a multifaceted role in the immune response and inflammation. It is primarily produced by Th2 cells and is a key mediator in type 2 immune responses. IL-13 is critically involved in the pathogenesis of allergic diseases, including atopic dermatitis (AD), where it contributes to tissue inflammation and epidermal barrier dysfunction. This cytokine is also implicated in the regulation of immune responses and tissue remodeling, signaling through type 2 heterodimeric receptors, and is associated with a chronic inflammatory phenotype.

IL-13 is upregulated by TL1A and serves as a major indicator of TL1A-driven inflammation. It also plays a supporting role to IL-5 in eosinophilic esophagitis (EoE) and is TRAIL dependent. In the context of AD, IL-13 impairs the skin barrier and is a key type 2 immune mediator involved in the disease's pathophysiology. 

Therapeutically, IL-13 is targeted by various monoclonal antibodies, including dupilumab and tralokinumab, which are used in the treatment of atopic dermatitis. These treatments aim to inhibit the cytokine's activity, thereby reducing inflammation and improving clinical outcomes in patients with AD and other allergic conditions.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,05c97152fe02249153103be341d65b67,0ba9fbea14e0c2c1d01a12ffaacfda9b,104cc78517b2eca2e9cb7e00de1fe4b0,1596d061dbe1a1c9e8f31a02a21e5524,286730b1c1f680ac465cc21d522fda0c,28f548554737fcc026b968db6bbafa30,2cec06c4d46f5ff9ee936a78d8b077cd,3ce96e927d65736b305f792977fed4b9,3df8535e965efb96f5094169610507ff,3dfbb4c51838e0951f53ce951395225f,3ea70e257330c812b52334ca1f90d807,41ccc4b41bd57cf2bda4dbb6c7ae4198,4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd,4a1ab1e50481cdd86d237db424a95719,5f37466ca41c9b8b06ed8be0303d49f2,6309eeea565f06479830cec32938abc9,693a2aac101eaaadf92614317a1e4da8,78e26c66107dba37ac4bab65406b43a0,8246ea974dfb00cb5e3d984004e21a9e,849e0980ffd6a7e1cf0b8d3d1fbacd98,96e553a44a27e728c27c4892045ec5c2,a867a1e73cef039eb3f28e072463b838,b19f42c9497f71b231222cd953036d6b,c525762bb827485bceeb9f09bb4bcfe0,c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e,e075bccd45593ae008b2ce7f9ed8ff6c,e95d4d15e4f3110c91a3d3fcb5910d06,e9841b88c9fab58c5175af409653da50,f2aa3fd6ae3f1853347874c50afb60ea,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="IL-10">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-10 (Interleukin-10) is a cytokine with anti-inflammatory properties involved in the immune response and inflammation. It plays a crucial role in immune regulation by modulating the activity of various immune cells. IL-10 is secreted by regulatory T cells (Treg cells) to promote the activation of M2 macrophages, which are associated with anti-inflammatory responses. Additionally, it has been observed that IL-10 production is decreased in systemic sclerosis (SSc) patient T cells after TNF-co-stimulation, indicating its potential involvement in the pathophysiology of autoimmune diseases.</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198,4a1ab1e50481cdd86d237db424a95719,503107475d2e9dac49abd8ebcbadd9f5,5ec1ebf4e260eb1f8fda8acdf06cd39e,855c455b4c9592746834ee3a4e0e6b81,a867a1e73cef039eb3f28e072463b838,b19f42c9497f71b231222cd953036d6b,b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="IL-20 FAMILY">
      <data key="d0">PROTEIN</data>
      <data key="d1">The IL-20 family consists of cytokines involved in skin inflammation and immune responses</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="IL-1 FAMILY">
      <data key="d0">PROTEIN</data>
      <data key="d1">The IL-1 family consists of cytokines involved in the regulation of immune and inflammatory responses</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="IL-18">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-18, also known as Interleukin-18, is a pro-inflammatory cytokine involved in inflammation and the immune response. It has a high receptor affinity for IL-18R&#945;, which plays a crucial role in mediating its effects. Additionally, IL-18 serves as a biomarker used to monitor the severity of autoimmune diseases, such as atopic dermatitis (AD).</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c,2cec06c4d46f5ff9ee936a78d8b077cd,4a1ab1e50481cdd86d237db424a95719,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="IL-36">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-36, also known as Interleukin-36, is a group of cytokines involved in inflammatory responses and the innate immune system. It is particularly significant in skin diseases, being upregulated in conditions such as psoriasis and atopic dermatitis (AD). Clinical studies are exploring IL-36 for its role in these conditions. Additionally, IL-36 has a notable response in the lesional skin of patients with hidradenitis suppurativa (HS), further implicating it in inflammatory skin disorders.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,2e0cdefd62bed7c674d7fb93ef336c2b,3df8535e965efb96f5094169610507ff,48288f3ec2832850282f95d4e38d10e1,4a1ab1e50481cdd86d237db424a95719,523bbfee1ae3b4ecabf9b11d10eea9ff,6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98,bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="IL-2 FAMILY">
      <data key="d0">PROTEIN</data>
      <data key="d1">The IL-2 family consists of cytokines involved in the regulation of immune responses</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="IL-21">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-21 is a cytokine involved in the regulation of immune responses</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="IL-12 FAMILY">
      <data key="d0">PROTEIN</data>
      <data key="d1">The IL-12 family consists of cytokines involved in the regulation of immune responses</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="EPIDERMAL GROWTH FACTOR RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Epidermal growth factor receptor is a cell surface receptor that binds epidermal growth factor</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="IL-1 RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-1 receptor is a receptor that binds interleukin-1</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="CORNIFIED ENVELOPE">
      <data key="d0">PATHWAY</data>
      <data key="d1">The formation of the cornified envelope is a process in the skin that provides a barrier to protect against environmental damage</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="ANTIMICROBIAL PEPTIDES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Antimicrobial peptides are part of the innate immune response and provide a first line of defense against pathogens</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="INNATE IMMUNE SYSTEM">
      <data key="d0">PATHWAY</data>
      <data key="d1">The innate immune system is the body's first line of defense against pathogens, involving non-specific immune responses. It plays a crucial role in protecting the body from infections and is also involved in conditions such as atopic dermatitis.</data>
      <data key="d2">143d2dc302af5606656797bff162e23e,3ea70e257330c812b52334ca1f90d807,4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="IFNG SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">IFNG signaling involves interferon-gamma, which is critical for innate and adaptive immunity</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="SIGNAL TRANSDUCTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Signal transduction is the process by which a chemical or physical signal is transmitted through a cell</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="NUCLEAR RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Nuclear receptors are a class of proteins involved in sensing steroid and thyroid hormones</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="GPCR">
      <data key="d0">PROTEIN</data>
      <data key="d1">G protein-coupled receptors are a large family of cell surface receptors that respond to various external signalsG protein-coupled receptors (GPCRs) are a large family of cell surface receptors that respond to various external signals</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="LEPTIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Leptin is a hormone involved in regulating energy balance and hunger.</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719,a867a1e73cef039eb3f28e072463b838</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="DEVELOPMENTAL BIOLOGY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Developmental biology is the study of the process by which organisms grow and develop</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="ABAT">
      <data key="d0">GENE</data>
      <data key="d1">ABAT is a gene encoding the enzyme 4-aminobutyrate aminotransferase</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
      <data key="d3">GENE</data>
    </node>
    <node id="ADRA1A">
      <data key="d0">GENE</data>
      <data key="d1">ADRA1A is a gene encoding the alpha-1A adrenergic receptor</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
      <data key="d3">GENE</data>
    </node>
    <node id="CYP3A4">
      <data key="d0">GENE</data>
      <data key="d1">CYP3A4 is a gene encoding an enzyme involved in drug metabolism</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
      <data key="d3">GENE</data>
    </node>
    <node id="GRM4">
      <data key="d0">GENE</data>
      <data key="d1">GRM4 is a gene encoding the metabotropic glutamate receptor 4</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
      <data key="d3">GENE</data>
    </node>
    <node id="HRH1">
      <data key="d0">GENE</data>
      <data key="d1">HRH1 is a gene encoding the histamine H1 receptor</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
      <data key="d3">GENE</data>
    </node>
    <node id="OPRD1">
      <data key="d0">GENE</data>
      <data key="d1">OPRD1 is a gene encoding the delta opioid receptor</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
      <data key="d3">GENE</data>
    </node>
    <node id="OPRM">
      <data key="d0">GENE</data>
      <data key="d1">OPRM is a gene encoding the mu opioid receptor</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
      <data key="d3">GENE</data>
    </node>
    <node id="PRKAB1">
      <data key="d0">GENE</data>
      <data key="d1">PRKAB1 is a gene encoding the protein kinase AMP-activated non-catalytic subunit beta 1, which plays a crucial role in cellular energy homeostasis. It is specifically involved in encoding the regulatory subunit of AMP-activated protein kinase (AMPK), a key enzyme in maintaining energy balance within cells.</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719,c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">GENE</data>
    </node>
    <node id="PTGS1">
      <data key="d0">GENE</data>
      <data key="d1">PTGS1 is a gene encoding the enzyme cyclooxygenase-1, also known as Prostaglandin-Endoperoxide Synthase 1.</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719,62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="PTGS2">
      <data key="d0">GENE</data>
      <data key="d1">PTGS2 is a gene encoding the enzyme cyclooxygenase-2, also known as Prostaglandin-Endoperoxide Synthase 2.</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719,62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="SLC6A4">
      <data key="d0">GENE</data>
      <data key="d1">SLC6A4 is a gene encoding the serotonin transporter</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
      <data key="d3">GENE</data>
    </node>
    <node id="CD4+ LYMPHOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">CD4+ lymphocytes are a type of white blood cell that plays a significant role in the immune system</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719,fa1f4687a5326fccd5d518845839e5f2</data>
      <data key="d3">CELL</data>
    </node>
    <node id="CD45+CD4+ T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD45+CD4+ T cells are a subset of T cells involved in immune responses. They are specifically responsible for the production of IL-17, a cytokine that plays a crucial role in inflammatory processes.</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719,fa1f4687a5326fccd5d518845839e5f2</data>
      <data key="d3">CELL</data>
    </node>
    <node id="CD11C+CD1A-CD14+ DENDRITIC CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD11c+CD1a-CD14+ dendritic cells are a type of dendritic cell involved in immune responses. They are notably the main producers of IL-1&#946; in lesional HS skin.</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719,fa1f4687a5326fccd5d518845839e5f2</data>
      <data key="d3">CELL</data>
    </node>
    <node id="IL-1&#914;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-1 beta (IL-1&#946;) is a pro-inflammatory cytokine involved in the immune response and inflammation. It is produced by various cell types, including keratinocytes, dendritic cells, and activated macrophages. IL-1&#946; plays a crucial role in the inflammatory response, particularly in conditions such as Hidradenitis Suppurativa (HS).</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,41ccc4b41bd57cf2bda4dbb6c7ae4198,4a1ab1e50481cdd86d237db424a95719,523bbfee1ae3b4ecabf9b11d10eea9ff,6aef5adb1be227170f66c76a292c25e5,b19f42c9497f71b231222cd953036d6b,b2aae16813e647959b783a39ef9a19a7,e340a83f7cba0ea5be731b1f682ea7c7,fa1f4687a5326fccd5d518845839e5f2</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="IL-17 CYTOKINE FAMILY">
      <data key="d0">PROTEIN</data>
      <data key="d1">The IL-17 cytokine family consists of cytokines involved in inflammatory responses</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="DEGS">
      <data key="d0">GENE</data>
      <data key="d1">Differentially Expressed Genes (DEGs) are genes that exhibit significant differences in expression levels between various conditions or treatments. Specifically, in the context of HS (presumably referring to a particular condition or disease state), DEGs are genes with altered expression. These genes show different levels of expression when comparing different conditions, highlighting their potential role in the underlying biological processes and responses associated with HS.</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606,4a1ab1e50481cdd86d237db424a95719,e340a83f7cba0ea5be731b1f682ea7c7,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="EGFR">
      <data key="d0">PROTEIN</data>
      <data key="d1">EGFR is a gene encoding the Epidermal Growth Factor Receptor, a cell surface receptor that binds epidermal growth factor. This receptor is critically involved in the regulation of cell growth and differentiation.</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719,62b4bd8f530adae989e4349d1e58f11d,c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="TLRS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Toll-like receptors (TLRs) are a class of proteins that play a key role in the innate immune system. They are involved in the pathophysiology of autoimmune diseases (AD), highlighting their significance in both immune response and disease mechanisms.</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c,4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="RESISTIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Resistin is a hormone secreted by adipose tissue that is involved in inflammation and insulin resistance. It is believed to link obesity to diabetes, highlighting its role in metabolic disorders.</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IFNG">
      <data key="d0">PROTEIN</data>
      <data key="d1">IFNG is a gene encoding the cytokine interferon-gamma (IFN-&#947;), which plays a crucial role in immune responses. It is involved in both innate and adaptive immunity and contributes significantly to the IFN response. IFNG is associated with the IL-1 signaling pathway and has been observed to have increased mRNA expression in certain conditions such as HS (Hidradenitis Suppurativa). Interferon-gamma, encoded by IFNG, is essential for the regulation of immune response, highlighting its importance in various immunological processes.</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,4a1ab1e50481cdd86d237db424a95719,62b4bd8f530adae989e4349d1e58f11d,b62ecc47bf54393bc78dd65986b949d6,bae090d8a29c15868ba1c4f29ae79e99,c44ec79872ab10cbe7336182f183ff60,cdfcc39154accbac074c924676dc701e,e340a83f7cba0ea5be731b1f682ea7c7,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="CD4+ T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD4+ T cells are a subset of T cells that play a key role in the immune system. These cells are a type of white blood cell that is crucial for orchestrating the body's immune response. In the context of Atopic Dermatitis (AD), CD4+ T cells express the OX40 receptor, which is involved in the disease's immune response. Additionally, na&#239;ve CD4+ T cells undergo expansion and differentiation upon T cell receptor binding, further contributing to their essential function in immune regulation.</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b,4a1ab1e50481cdd86d237db424a95719,691cb2e23ac3c6e591129d16714f8ef8,6b099960b0a39866e3aa6b908f1886e4,855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="CD11C+ DENDRITIC CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD11c+ dendritic cells are a type of dendritic cell involved in immune responses</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="EXTRANUCLEAR SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Extranuclear signaling involves signaling pathways that occur outside the cell nucleus</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="TH17">
      <data key="d0">CELL</data>
      <data key="d1">TH17 cells, also known as T helper 17 cells, are a subset of CD4+ T helper cells that play a crucial role in the immune response. They are particularly involved in autoimmune and inflammatory responses, as well as in the defense against extracellular bacteria and fungi. TH17 cells are characterized by their production of interleukin-17 (IL-17), a pro-inflammatory cytokine. These cells are implicated in various inflammatory and autoimmune conditions, including atopic dermatitis and allergic airway inflammation. Their involvement in the adaptive immune response highlights their significance in both protective immunity and pathological inflammation.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,2e0cdefd62bed7c674d7fb93ef336c2b,41ccc4b41bd57cf2bda4dbb6c7ae4198,475995d7d211bbfde6d8ba52f324d688,48288f3ec2832850282f95d4e38d10e1,5ec1ebf4e260eb1f8fda8acdf06cd39e,5f37466ca41c9b8b06ed8be0303d49f2,83eb9003d42977bb83fea1d123dd5ab9,b876251511f570468eb5b6ee6a239cc6,e075bccd45593ae008b2ce7f9ed8ff6c,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="HUMAN &#914;-DEFENSIN 2">
      <data key="d0">PROTEIN</data>
      <data key="d1">Human &#946;-defensin 2 is an antimicrobial peptide whose expression is increased by IL-17</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="PSORIASIN (S100A7)">
      <data key="d0">PROTEIN</data>
      <data key="d1">Psoriasin (S100A7) is an antimicrobial peptide whose expression is increased by IL-17</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="CALPROTECTIN (S100A8/9)">
      <data key="d0">PROTEIN</data>
      <data key="d1">Calprotectin (S100A8/9) is an antimicrobial peptide whose expression is increased by IL-17</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IL-1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-1 (IL-1) is a crucial cytokine involved in inflammatory responses and immune cell infiltration. It plays a significant role in innate immunity and inflammation, making it an essential component in the body's defense mechanisms against infections and injuries.</data>
      <data key="d2">849e0980ffd6a7e1cf0b8d3d1fbacd98,c44ec79872ab10cbe7336182f183ff60,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IL1R1">
      <data key="d0">GENE</data>
      <data key="d1">IL1R1 is a gene associated with the IL-1 signaling pathway. It encodes interleukin 1 receptor type 1, which is involved in the immune response.</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IL1RN">
      <data key="d0">GENE</data>
      <data key="d1">IL1RN is a gene associated with the IL-1 signaling pathway</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IL18">
      <data key="d0">GENE</data>
      <data key="d1">IL18, also known as Interleukin 18, is a cytokine that plays a crucial role in immune responses. It is a pro-inflammatory cytokine involved in the IL-1 signaling pathway and is known to promote the production of IFN-&#947; (Interferon-gamma). This cytokine is integral to the body's defense mechanisms, contributing to the regulation and activation of immune cells.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,bae090d8a29c15868ba1c4f29ae79e99,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IL18R1">
      <data key="d0">GENE</data>
      <data key="d1">IL18R1 is a gene associated with the IL-1 signaling pathway</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IL32">
      <data key="d0">GENE</data>
      <data key="d1">IL32 is a gene associated with the IL-1 signaling pathway. Interleukin 32, the protein product of this gene, is a cytokine involved in inflammatory responses.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IL33">
      <data key="d0">GENE</data>
      <data key="d1">IL33 is a gene associated with the IL-1 signaling pathway</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IL36B">
      <data key="d0">GENE</data>
      <data key="d1">IL36B is a gene associated with the IL-1 signaling pathway. Interleukin 36&#946;, the protein product of IL36B, is a cytokine involved in inflammatory responses.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IL36RN">
      <data key="d0">GENE</data>
      <data key="d1">IL36RN is a gene associated with the IL-1 signaling pathway. It encodes the interleukin 36 receptor antagonist, which is involved in the immune response.</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IL37">
      <data key="d0">GENE</data>
      <data key="d1">IL37, also known as Interleukin 37, is a gene associated with the IL-1 signaling pathway. This cytokine plays a crucial role in the regulation of immune responses, helping to modulate the body's defense mechanisms against various pathogens and inflammatory stimuli.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="TLR2">
      <data key="d0">GENE</data>
      <data key="d1">TLR2 is a gene associated with the IL-1 signaling pathway</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="TLR3">
      <data key="d0">GENE</data>
      <data key="d1">TLR3 is a gene associated with the IL-1 signaling pathway</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="TLR4">
      <data key="d0">GENE</data>
      <data key="d1">TLR4 is a gene associated with the IL-1 signaling pathway</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="S100A7">
      <data key="d0">GENE</data>
      <data key="d1">S100A7 is a gene encoding S100 Calcium-Binding Protein A7, which is associated with the IL-1 signaling pathway. This protein plays a significant role in skin inflammation and is involved in epidermal differentiation. Notably, S100A7 is upregulated in atopic dermatitis lesions, indicating its importance in the pathophysiology of this inflammatory skin condition.</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b,baf4dec7fda8d8b8571a343b034f7092,f66eb51473925a8084dad1745be63b78,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="S100A7A">
      <data key="d0">GENE</data>
      <data key="d1">S100A7A is a gene encoding S100 Calcium-Binding Protein A7A, which plays a crucial role in the immune response. It is associated with the IL-1 signaling pathway, highlighting its involvement in immune system regulation and inflammatory processes.</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99,baf4dec7fda8d8b8571a343b034f7092,c44ec79872ab10cbe7336182f183ff60,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="S100A12">
      <data key="d0">GENE</data>
      <data key="d1">S100A12 is a gene encoding S100 Calcium-Binding Protein A12, which is involved in the IL-1 signaling pathway. This protein plays a significant role in skin inflammation, highlighting its importance in inflammatory processes.</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b,baf4dec7fda8d8b8571a343b034f7092,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="ADIPONECTIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Adiponectin is a protein hormone involved in regulating glucose levels and fatty acid breakdown, reduced in HS patientsAdiponectin is a protein hormone involved in regulating glucose levels and fatty acid breakdown</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="ADIPOQ">
      <data key="d0">GENE</data>
      <data key="d1">ADIPOQ is a gene that encodes adiponectin, a protein that is downregulated in certain conditions such as HS (Hidradenitis Suppurativa).</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="PLIN1">
      <data key="d0">GENE</data>
      <data key="d1">PLIN1 is a gene associated with lipid metabolism and encodes the protein Perilipin 1.</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="PPAR&#915;">
      <data key="d0">PROTEIN</data>
      <data key="d1">PPAR&#947; (Peroxisome Proliferator-Activated Receptor Gamma) is a nuclear receptor that plays a crucial role in regulating the expression of genes involved in adipogenesis. It is targeted by specific ligands for the treatment of various health conditions, including those related to metabolic and autoimmune diseases.</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="THIAZOLIDINE DERIVATIVES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Thiazolidine derivatives are compounds that act as PPAR&#947; agonists</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IGF">
      <data key="d0">PROTEIN</data>
      <data key="d1">IGF is a protein involved in growth and development</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IGF-BINDING PROTEINS">
      <data key="d0">PROTEIN</data>
      <data key="d1">IGF-binding proteins regulate the availability of IGF</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="LIPID">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Lipids are a group of naturally occurring molecules that include fats, waxes, and certain vitamins</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="C-TYPE LEPTIN RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">C-type leptin receptor is involved in regulating energy balance and body weight</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="INFLAMMATORY BOWEL DISEASES">
      <data key="d0">DISEASE</data>
      <data key="d1">Inflammatory Bowel Diseases are chronic inflammatory conditions of the gastrointestinal tract.</data>
      <data key="d2">68015074236b0144899baa38d01ae467,c46e8b6ee0c29e37b7f18c42558d7a3e,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="CROHN&#8217;S DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Crohn&#8217;s disease is a chronic inflammatory bowel disease that affects the lining of the digestive tract. It is a type of gastrointestinal tract fibrosis and is classified under inflammatory bowel diseases. Crohn&#8217;s disease specifically impacts the gastrointestinal tract and is commonly treated with TNF inhibitors or TNF antagonists.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,516e41e96d2e72d45bf1e2c69da7f18a,573fb6fa0673eb9462aa9862888079f3,5ec1ebf4e260eb1f8fda8acdf06cd39e,a10787d7fbb1307be263e86dc7b33a51,baf4dec7fda8d8b8571a343b034f7092,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="AXIAL SPONDYLARTHRITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Axial spondylarthritis is a type of arthritis that affects the spine and the sacroiliac joints</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="PACHYONYCHIA CONGENITA">
      <data key="d0">DISEASE</data>
      <data key="d1">Pachyonychia congenita is a rare genetic disorder characterized by thickened nails and other skin abnormalities.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,baf4dec7fda8d8b8571a343b034f7092,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="STEATOCYSTOMA MULTIPLEX">
      <data key="d0">DISEASE</data>
      <data key="d1">Steatocystoma multiplex is a genetic disorder characterized by multiple cysts in the skin</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="DOWLING-DEGOS DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Dowling-Degos disease is a genetic disorder characterized by dark spots on the skin</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="KERATITIS&#8211;ICHTHYOSIS&#8211;DEAFNESS SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Keratitis&#8211;ichthyosis&#8211;deafness syndrome is a genetic disorder characterized by eye problems, skin abnormalities, and hearing loss</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="DOWN SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Down syndrome is a genetic disorder caused by the presence of an extra chromosome 21</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="NEUTROPHILS">
      <data key="d0">CELL</data>
      <data key="d1">Neutrophils are a type of white blood cell that play a crucial role in the body's immune response and are part of the innate immune system. They help fight infection and are involved in inflammation. Neutrophils can express TNF (Tumor Necrosis Factor) and are known to be hyperactive inflammatory cells, which can be calmed down by methotrexate. These cells are particularly prominent in the skin of patients with Hidradenitis Suppurativa (HS) and are also elevated in the skin of Atopic Dermatitis patients.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,27a7e95c7d3ad59a948aa46741fee456,286730b1c1f680ac465cc21d522fda0c,411a4d246f0a9321e52971446a5a0606,523bbfee1ae3b4ecabf9b11d10eea9ff,6ada075e562abd7bd445164e9fc309b4,7c13f41d7349d9d2e56c36e00c0ca2d9,d2c44662af9752fc9f82c86121ede7c0,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IL-1 RECEPTOR ANTAGONIST">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-1 receptor antagonist is a protein that can reverse the effects of IL-1 signaling in HS</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="EPIDERMAL CELL">
      <data key="d0">CELL</data>
      <data key="d1">Epidermal cells are the outermost cells of the skin involved in barrier function</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="FOLLICULAR KERATINOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Follicular keratinocytes are specialized cells in hair follicles involved in HS lesions</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="SKIN GLANDS">
      <data key="d0">TISSUE</data>
      <data key="d1">Skin glands, including sebaceous and apocrine glands, are involved in HS pathology</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="SERPINS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Serpins are a family of proteins involved in regulating protease activity, dysregulated in HS</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="SMALL PROLINE-RICH PROTEINS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Small proline-rich proteins are involved in skin barrier function and are dysregulated in HS</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="KERATINS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Keratins are structural proteins in the skin and hair, dysregulated in HS</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="FOLLICULAR INFUNDIBULUM">
      <data key="d0">TISSUE</data>
      <data key="d1">Follicular infundibulum is the upper part of the hair follicle involved in HS lesions</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="DUCTUS SEBOGLANDULARIS">
      <data key="d0">TISSUE</data>
      <data key="d1">Ductus seboglandularis is a duct in the skin associated with sebaceous glands, involved in HS</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="INSULIN RESISTANCE">
      <data key="d0">DISEASE</data>
      <data key="d1">Insulin resistance is a condition where cells fail to respond to the hormone insulin properly. It is also associated with HS (Hidradenitis Suppurativa).</data>
      <data key="d2">05c97152fe02249153103be341d65b67,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="EICOSANOIDS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Eicosanoids are signaling molecules involved in inflammation and immunity, function similarly to thiazolidine derivatives in HS</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="NON-STEROIDAL ANTI-INFLAMMATORY DRUGS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Non-steroidal anti-inflammatory drugs (NSAIDs) are medications that reduce inflammation and pain, function similarly to thiazolidine derivatives in HS</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IGF-BINDING PROTEINS PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">IGF-binding proteins pathway regulates the availability of IGF, dysregulated in HS</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="LIPID METABOLISM">
      <data key="d0">PATHWAY</data>
      <data key="d1">Lipid metabolism involves the synthesis and degradation of lipids, dysregulated in HS</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="C-TYPE LEPTIN RECEPTOR SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">C-type leptin receptor signaling is involved in regulating energy balance and body weight, dysregulated in HS</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="RETN SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">RETN signaling encodes resistin, a hormone linking obesity to diabetes, dysregulated in HS</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="ADIPOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Adipocytes are cells specialized in storing fat. These fat cells are involved in storing energy as fat and are affected in various conditions, including HS (Hidradenitis Suppurativa).</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="TNF-&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Tumor Necrosis Factor-alpha (TNF-&#945;) is a cytokine involved in systemic inflammation. It is a pro-inflammatory cytokine that plays a significant role in the pathophysiology of various diseases, including Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD). TNF-&#945; is inhibited by adiponectin, which modulates its inflammatory effects.</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c,3dfbb4c51838e0951f53ce951395225f,6aef5adb1be227170f66c76a292c25e5,849e0980ffd6a7e1cf0b8d3d1fbacd98,9867d43adab0ba5db44961fae4863eee,c44ec79872ab10cbe7336182f183ff60,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IL-6">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-6 (IL-6) is a pro-inflammatory cytokine involved in inflammation, immune responses, and the maturation of B cells. It is derived from keratinocytes and plays a significant role in the inflammatory response in conditions such as Hidradenitis Suppurativa (HS). IL-6's activity can be inhibited by adiponectin, and its levels are reduced by PLGA-based nanoparticles loaded with Cyclosporine A (CsA).</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,41ccc4b41bd57cf2bda4dbb6c7ae4198,503107475d2e9dac49abd8ebcbadd9f5,523bbfee1ae3b4ecabf9b11d10eea9ff,5f37466ca41c9b8b06ed8be0303d49f2,6aef5adb1be227170f66c76a292c25e5,9867d43adab0ba5db44961fae4863eee,a10787d7fbb1307be263e86dc7b33a51,b2aae16813e647959b783a39ef9a19a7,bddc3b1a7f098e71f0aa64adec047124,c44ec79872ab10cbe7336182f183ff60,e340a83f7cba0ea5be731b1f682ea7c7,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="CHEMOKINES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Chemokines are a family of small cytokines that induce chemotaxis in nearby cells. These signaling proteins play a crucial role in attracting cells to sites of infection or inflammation, thereby facilitating the immune response. Specifically, chemokines attract immune cells to the affected areas, a process that can be inhibited by adiponectin. Additionally, chemokines are involved in various conditions, including HS (Hidradenitis Suppurativa).</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198,4cf23e218b6aab3c77115173b5c7c2fd,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="TYPE I DIABETES MELLITUS SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">A signaling pathway associated with type I diabetes mellitus, linked to HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="LIPID AND ATHEROSCLEROSIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">A pathway associated with lipid metabolism and atherosclerosis, linked to HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="ADIPOGENESIS SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">A signaling pathway associated with adipogenesis, linked to HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="JAK-STAT INHIBITORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A class of drugs that inhibit the JAK-STAT signaling pathway, proposed for HS treatment</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="PI3K INHIBITORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A class of drugs that inhibit the PI3K pathway, proposed for HS treatment</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="MMP INHIBITORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A class of drugs that inhibit matrix metalloproteinases, proposed for HS treatment</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="GENTAMICIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">An antibiotic reported as a repurposing drug for HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="IBUDILAST">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A drug reported as a repurposing drug for HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="SPIRONOLACTONE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A drug reported as a repurposing drug for HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="TRASTUZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Trastuzumab is a monoclonal antibody used to treat breast cancer. Additionally, it has been reported as a repurposing drug for Hidradenitis Suppurativa (HS).</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="THALIDOMIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">THALIDOMIDE is a medication used to treat certain cancers and inflammatory conditions. Additionally, it has been reported as a repurposing drug for HS (Hidradenitis Suppurativa).</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="APREMILAST">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Apremilast is an oral PDE4 inhibitor that has been approved for the treatment of moderate to severe psoriasis. Additionally, it has been reported as a repurposing drug for Hidradenitis Suppurativa (HS).</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="GLUCOSAMINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Glucosamine is a chemical used as a dietary supplement for joint health. Additionally, it has been reported as a repurposing drug for Hidradenitis Suppurativa (HS).</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="INTERFERON-A-2B">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A drug reported as a repurposing drug for HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="BINIMETINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A drug reported as a repurposing drug for HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="MIDOSTAURIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A drug reported as a repurposing drug for HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="TYROSINE KINASE RECEPTOR INHIBITORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A class of drugs that inhibit tyrosine kinase receptors, proposed for HS treatment</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="TNF INHIBITORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">TNF INHIBITORS are a class of drugs that inhibit tumor necrosis factor (TNF), a cytokine involved in systemic inflammation. These chemical agents are used to treat various autoimmune and inflammatory diseases by suppressing the physiologic response to TNF. TNF inhibitors have been proposed for the treatment of Hidradenitis Suppurativa (HS) and are widely utilized in managing conditions such as rheumatoid arthritis, psoriasis, and Crohn's disease.</data>
      <data key="d2">516e41e96d2e72d45bf1e2c69da7f18a,df74aa1b86eeeb811ca5586767ae3a71,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="CYCLOOXYGENASE INHIBITORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A class of drugs that inhibit cyclooxygenase, proposed for HS treatment</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="EGF RECEPTOR INHIBITORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A class of drugs that inhibit epidermal growth factor receptors, proposed for HS treatment</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="PPAR&#915; LIGANDS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A class of drugs that act on peroxisome proliferator-activated receptor gamma, proposed for HS treatment</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="EPITHELIAL CELL DIFFERENTIATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">A dysregulated process in HS involving the differentiation of epithelial cells</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="OBESITY SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">A signaling pathway involving hormone regulation, linked to HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="ADAM12">
      <data key="d0">GENE</data>
      <data key="d1">ADAM Metallopeptidase Domain 12, a gene upregulated in HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
      <data key="d3">GENE</data>
    </node>
    <node id="AR">
      <data key="d0">GENE</data>
      <data key="d1">AR, or Androgen Receptor, is a gene encoding the androgen receptor, which plays a crucial role in the regulation of gene expression. This receptor is involved in various physiological processes, including the development and maintenance of male characteristics. Additionally, the Androgen Receptor gene is known to be upregulated in certain conditions, such as HS (Hidradenitis Suppurativa), indicating its potential involvement in the pathogenesis of this disease.</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,c44ec79872ab10cbe7336182f183ff60,f3b0f42501dbe75c224f7af44e0885f9</data>
      <data key="d3">GENE</data>
    </node>
    <node id="BTK">
      <data key="d0">GENE</data>
      <data key="d1">Bruton&#8217;s tyrosine kinase (BTK) is a protein that plays a crucial role in B cell receptor signaling and the regulation of B cell development. It is involved in B cell signaling and is considered a potential therapeutic target in various conditions, including hematological disorders such as HS (Hyper-IgM Syndrome). BTK's function in B cell receptor signaling makes it a significant focus for therapeutic interventions aimed at modulating immune responses.</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,411a4d246f0a9321e52971446a5a0606,b62ecc47bf54393bc78dd65986b949d6,e340a83f7cba0ea5be731b1f682ea7c7,e4d25b1cd44df240a29591bc46a875ab,f14a13d54127c3baadeb0b34d40928c9,f3b0f42501dbe75c224f7af44e0885f9</data>
      <data key="d3">GENE</data>
    </node>
    <node id="C3">
      <data key="d0">GENE</data>
      <data key="d1">Complement C3, also known as complement component 3, is a central protein in the complement system. It is a gene with mixed regulation in HS (Hemolytic Syndrome).</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab,f3b0f42501dbe75c224f7af44e0885f9</data>
      <data key="d3">GENE</data>
    </node>
    <node id="C5AR1">
      <data key="d0">GENE</data>
      <data key="d1">C5AR1 is a gene encoding complement component 5a receptor 1, which plays a crucial role in the immune response. This gene is notably upregulated in certain conditions, such as Hidradenitis Suppurativa (HS).</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60,f3b0f42501dbe75c224f7af44e0885f9</data>
      <data key="d3">GENE</data>
    </node>
    <node id="CASP1">
      <data key="d0">GENE</data>
      <data key="d1">CASP1 encodes Caspase 1, an enzyme involved in the inflammatory process. Caspase 1 is a gene that is upregulated in HS (Hidradenitis Suppurativa).</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e,f3b0f42501dbe75c224f7af44e0885f9</data>
      <data key="d3">GENE</data>
    </node>
    <node id="CCL18">
      <data key="d0">GENE</data>
      <data key="d1">CCL18, also known as C-C Motif Chemokine Ligand 18, is a gene that is upregulated in certain conditions such as HS (Hidradenitis Suppurativa). This gene encodes a chemokine involved in immune responses, particularly in the recruitment of immune cells. CCL18 plays a significant role in the immune response and inflammation, promoting the attraction of inflammatory T cells and dendritic cell (DC) subtypes. It is known to ascend in the skin during inflammatory processes, thereby contributing to the overall immune response and inflammatory environment.</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198,6059a6e2710b7df94c6a09e5eb7b024a,b19f42c9497f71b231222cd953036d6b,cdfcc39154accbac074c924676dc701e,f3b0f42501dbe75c224f7af44e0885f9</data>
      <data key="d3">GENE</data>
    </node>
    <node id="CCL26">
      <data key="d0">GENE</data>
      <data key="d1">CCL26, also known as C-C Motif Chemokine Ligand 26, is a gene that is upregulated in HS (Hidradenitis Suppurativa). It encodes a protein involved in immune responses, playing a significant role in the body's defense mechanisms.</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e,f3b0f42501dbe75c224f7af44e0885f9</data>
      <data key="d3">GENE</data>
    </node>
    <node id="CCR4">
      <data key="d0">GENE</data>
      <data key="d1">CCR4, also known as C-C Motif Chemokine Receptor 4 or CD194, is a gene that encodes a protein involved in immune responses and inflammation. This receptor is particularly significant in the context of immune cell trafficking and is found on memory TH2 cells, where it binds to chemokines. CCR4 is upregulated in conditions such as HS (Hidradenitis Suppurativa) and is implicated in the pathology of autoimmune diseases like AD (Atopic Dermatitis). The gene's expression in both skin and blood highlights its role in the immune system's response to inflammatory stimuli.</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,523bbfee1ae3b4ecabf9b11d10eea9ff,62b4bd8f530adae989e4349d1e58f11d,cdfcc39154accbac074c924676dc701e,e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9,f3b0f42501dbe75c224f7af44e0885f9</data>
      <data key="d3">GENE</data>
    </node>
    <node id="KEGG GO">
      <data key="d0">PATHWAY</data>
      <data key="d1">A database used for pathway analysis in HS studies</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="RECEPTOR INTERACTION PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">A pathway involved in HS, with genes showing diversified regulation</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="JAK INHIBITORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">JAK inhibitors are a class of small molecule drugs that inhibit Janus kinases, enzymes involved in the signal transduction pathways of multiple cytokine receptors. These compounds are used in the treatment of various autoimmune diseases, including rheumatoid arthritis and atopic dermatitis (AD). Additionally, JAK inhibitors have been proposed for the treatment of hidradenitis suppurativa (HS). By blocking the activity of Janus kinase enzymes, JAK inhibitors help to modulate the immune response, making them effective in systemic therapy for conditions like AD.</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,c46e8b6ee0c29e37b7f18c42558d7a3e,dc905ba8b6eb7d84cf2776303211010d,e30574e513dd250992d637d808759c34,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="CYTOKINE INHIBITORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A class of drugs that inhibit cytokines, proposed for HS treatment</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="TYROSINE KINASE INHIBITORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A class of drugs that inhibit tyrosine kinases, proposed for HS treatment</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="TNF">
      <data key="d0">PROTEIN</data>
      <data key="d1">Tumor Necrosis Factor (TNF), also known as TNF&#945; or TNFSF2, is a pleiotropic cytokine involved in systemic inflammation and immune system regulation. It plays a critical role in the body's immune response and is implicated in various inflammatory responses, including those seen in Hidradenitis Suppurativa (HS). TNF is an inflammatory mediator prominently colocalized with plasma cells in HS and is targeted by TNF inhibitors for HS treatment. Additionally, TNF is involved in fibrotic disease progression and resolution, and it stimulates the acute phase reaction. TNF is encoded by the TNF gene and is a key player in T helper cell responses. Despite its significant roles, TNF shows no significant response in HS lesional skin.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,1412a7a7fef5f18cc09a030b97b18e13,2a0384addc6e7fd709e0508b83496cd7,2e0cdefd62bed7c674d7fb93ef336c2b,411a4d246f0a9321e52971446a5a0606,503107475d2e9dac49abd8ebcbadd9f5,523bbfee1ae3b4ecabf9b11d10eea9ff,5ec1ebf4e260eb1f8fda8acdf06cd39e,62b4bd8f530adae989e4349d1e58f11d,7f559ad7372a4e35e90b43cc67047b0f,855c455b4c9592746834ee3a4e0e6b81,a10787d7fbb1307be263e86dc7b33a51,b62ecc47bf54393bc78dd65986b949d6,bae090d8a29c15868ba1c4f29ae79e99,c44ec79872ab10cbe7336182f183ff60,c95d22c2a90e77cd22bd0d280d55b26a,df74aa1b86eeeb811ca5586767ae3a71,e340a83f7cba0ea5be731b1f682ea7c7,e4d25b1cd44df240a29591bc46a875ab,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="CYCLOOXYGENASE">
      <data key="d0">PROTEIN</data>
      <data key="d1">An enzyme responsible for the formation of prostanoids, targeted by cyclooxygenase inhibitors for HS treatment</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="EGF RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Epidermal Growth Factor Receptor, a protein targeted by EGF receptor inhibitors for HS treatment</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="EPITHELIAL CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Epithelial cells are structural cells that line the surfaces and cavities of organs and structures throughout the body. They play crucial roles in protection, secretion, and absorption. In addition to these functions, epithelial cells are involved in the process of fibrosis and can be acted upon by LIGHT (a cytokine). Dysregulated differentiation of epithelial cells is a characteristic observed in certain conditions, such as Hidradenitis Suppurativa (HS).</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,516e41e96d2e72d45bf1e2c69da7f18a,5f37466ca41c9b8b06ed8be0303d49f2,68015074236b0144899baa38d01ae467,df74aa1b86eeeb811ca5586767ae3a71,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="HORMONES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Signaling molecules involved in obesity signaling, linked to HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="KEGG">
      <data key="d0">PATHWAY</data>
      <data key="d1">KEGG, or Kyoto Encyclopedia of Genes and Genomes, is a comprehensive collection of databases that deal with genomes, biological pathways, diseases, drugs, and chemical substances. It is widely used for pathway analysis in various studies, including those focused on human health and disease (HS studies).</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="GO">
      <data key="d0">PATHWAY</data>
      <data key="d1">Gene Ontology, a database used for pathway analysis in HS studies</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="RECEPTOR INTERACTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">A pathway involved in HS, with genes showing diversified regulation</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="IL-17 SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">A pathway involved in HS, with genes showing diversified regulation</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="JAK-STAT SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">A pathway involved in HS, with genes showing diversified regulation</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="TRANSCRIPTOMIC PROFILES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Profiles of gene expression used to study HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="PROTEIN EXPRESSION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Profiles of protein levels used to study HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="LESIONAL SKIN">
      <data key="d0">TISSUE</data>
      <data key="d1">Lesional skin refers to skin areas that are affected by lesions. In the context of certain conditions, such as Hidradenitis Suppurativa (HS), lesional skin specifically denotes the regions of the skin that are impacted by the disease's characteristic lesions.</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="NON-LESIONAL SKIN">
      <data key="d0">TISSUE</data>
      <data key="d1">Non-lesional skin refers to areas of skin that are not visibly affected by lesions or specific skin conditions such as atopic dermatitis and hidradenitis suppurativa (HS). Although these areas do not show visible signs of lesions, they can still exhibit molecular abnormalities.</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b,f3b0f42501dbe75c224f7af44e0885f9,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="HEALTHY CONTROLS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Healthy controls are individuals without atopic dermatitis or hidradenitis suppurativa (HS), used as a comparison group in studies.</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd,691cb2e23ac3c6e591129d16714f8ef8,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="BIOMARKERS">
      <data key="d0">GENE</data>
      <data key="d1">BIOMARKERS are biological markers that can help clarify autoimmune disease (AD) diagnosis and assess disease severity. They are measurable indicators of some biological state or condition, often used in clinical studies. Biomarkers can include genes or proteins that serve as indicators of various health states, such as those seen in autoimmune diseases like AD and hidradenitis suppurativa (HS).</data>
      <data key="d2">100dd7646c10899301b3c0631183da16,e95d4d15e4f3110c91a3d3fcb5910d06,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="CASPASE 1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Caspase 1 is an enzyme that plays a role in the inflammatory process</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="SCHNITZLER SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Schnitzler syndrome is a rare autoinflammatory disorder</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="FAMILIAL MEDITERRANEAN FEVER">
      <data key="d0">DISEASE</data>
      <data key="d1">Familial Mediterranean fever is an inherited inflammatory disorder</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="MINOCYCLINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Minocycline is an antibiotic used to treat bacterial infections, including various types of infections.</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="C-C MOTIF CHEMOKINE LIGAND 18">
      <data key="d0">PROTEIN</data>
      <data key="d1">C-C Motif Chemokine Ligand 18 is involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ECZEMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition characterized by itchy, inflamed, red, cracked, and rough skin. It is a group of conditions that cause the skin to become inflamed or irritated, often associated with Atopic Dermatitis (AD). This condition is caused by immune system cells in the skin and can be treated using various methods, including nanotechnology. Eczema is a symptom of Atopic Dermatitis and is considered an autoimmune skin disease.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,27a7e95c7d3ad59a948aa46741fee456,286730b1c1f680ac465cc21d522fda0c,442e7fad2fab75fa2449309783294d89,691cb2e23ac3c6e591129d16714f8ef8,6ada075e562abd7bd445164e9fc309b4,8246ea974dfb00cb5e3d984004e21a9e,89dbac0da39e4de2b602052cd792b90d,cdfcc39154accbac074c924676dc701e,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="C-C MOTIF CHEMOKINE LIGAND 26">
      <data key="d0">PROTEIN</data>
      <data key="d1">C-C Motif Chemokine Ligand 26 is involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="C-C MOTIF CHEMOKINE RECEPTOR 4">
      <data key="d0">PROTEIN</data>
      <data key="d1">C-C Motif Chemokine Receptor 4 is involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="MYCOSIS FUNGOIDES">
      <data key="d0">DISEASE</data>
      <data key="d1">Mycosis fungoides is a type of cutaneous T cell lymphoma</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CUTANEOUS T CELL LYMPHOMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Cutaneous T cell lymphoma is a type of cancer that begins in T cells</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ALLERGIC CONTACT DERMATITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Allergic contact dermatitis is a form of eczema caused by an allergic reaction. It is specifically triggered by contact with an allergen.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CD80">
      <data key="d0">GENE</data>
      <data key="d1">CD80 encodes the CD80 Molecule, also known as B7-1, which is a co-stimulatory protein involved in T cell activation. CD80 binds to CD28 and CTLA-4 to provide costimulatory signals essential for T-cell activation. It plays a crucial role in positive costimulatory pathways, facilitating the activation and proliferation of T cells.</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b,4842292208575bd45b2b5998513dd087,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81,9867d43adab0ba5db44961fae4863eee,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CD80 MOLECULE">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD80 Molecule is involved in T cell activation</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ABATACEPT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Abatacept (CTLA-4-Ig) is a recombinant fusion protein and targeted immunotherapy used to treat autoimmune diseases, including rheumatoid arthritis. It functions by blocking T-cell costimulation, thereby modulating the immune response. Clinical studies have shown that Abatacept induces clinical improvement in patients with systemic sclerosis (SSc), particularly demonstrating effectiveness in reducing inflammatory joint involvement.</data>
      <data key="d2">4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81,9867d43adab0ba5db44961fae4863eee,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="BELATACEPT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Belatacept is a medication used to prevent organ rejection</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CHI3L1">
      <data key="d0">GENE</data>
      <data key="d1">CHI3L1 encodes Chitinase 3-Like 1, involved in inflammation and tissue remodeling</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CHITINASE 3-LIKE 1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Chitinase 3-Like 1 is involved in inflammation and tissue remodeling</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ERYSIPELAS">
      <data key="d0">DISEASE</data>
      <data key="d1">Erysipelas is a bacterial infection of the skin, specifically affecting the skin's outer layers.</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CSF1">
      <data key="d0">GENE</data>
      <data key="d1">CSF1 encodes Colony-Stimulating Factor 1, involved in the production of white blood cells</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="COLONY-STIMULATING FACTOR 1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Colony-Stimulating Factor 1 is involved in the production of white blood cells</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CXCL1">
      <data key="d0">GENE</data>
      <data key="d1">CXCL1 encodes C-X-C Motif Chemokine Ligand 1, which is involved in immune responses. It is a chemokine that plays a crucial role in the recruitment of immune cells, particularly neutrophils. In the study, CXCL1 was identified as a neutrophil chemokine gene with a 2.8-fold increased expression, highlighting its significant role in immune cell recruitment and response.</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,b19f42c9497f71b231222cd953036d6b,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="C-X-C MOTIF CHEMOKINE LIGAND 1">
      <data key="d0">PROTEIN</data>
      <data key="d1">C-X-C Motif Chemokine Ligand 1 is involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="KAPOSI SARCOMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Kaposi sarcoma is a type of cancer that forms in the lining of blood and lymph vessels</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,baf4dec7fda8d8b8571a343b034f7092,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="FORMIC ACID">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Formic acid is a chemical used in various industrial processes</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CXCL8">
      <data key="d0">GENE</data>
      <data key="d1">CXCL8 encodes C-X-C Motif Chemokine Ligand 8, involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="C-X-C MOTIF CHEMOKINE LIGAND 8">
      <data key="d0">PROTEIN</data>
      <data key="d1">C-X-C Motif Chemokine Ligand 8 is involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="MELANOMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Melanoma is a type of skin cancer that develops from melanocytes. It is treated with pembrolizumab.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,855c455b4c9592746834ee3a4e0e6b81,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="SIMVASTATIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Simvastatin is a medication used to control high cholesterol</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="C-X-C MOTIF CHEMOKINE LIGAND 10">
      <data key="d0">PROTEIN</data>
      <data key="d1">C-X-C Motif Chemokine Ligand 10 is involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ELDELUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Eldelumab is a medication used to treat autoimmune diseases</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CXCL13">
      <data key="d0">GENE</data>
      <data key="d1">CXCL13 encodes C-X-C Motif Chemokine Ligand 13, which is involved in immune responses. It is a B cell chemoattractant gene that is upregulated in HS skin and has shown a 16-fold increased expression in the study.</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,523bbfee1ae3b4ecabf9b11d10eea9ff,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="C-X-C MOTIF CHEMOKINE LIGAND 13">
      <data key="d0">PROTEIN</data>
      <data key="d1">C-X-C Motif Chemokine Ligand 13 is involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="T CELL LYMPHOMA">
      <data key="d0">DISEASE</data>
      <data key="d1">T cell lymphoma is a type of cancer that begins in T cells</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CXCR5">
      <data key="d0">GENE</data>
      <data key="d1">CXCR5 encodes C-X-C Motif Chemokine Receptor 5, involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="C-X-C MOTIF CHEMOKINE RECEPTOR 5">
      <data key="d0">PROTEIN</data>
      <data key="d1">C-X-C Motif Chemokine Receptor 5 is involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="DCD">
      <data key="d0">GENE</data>
      <data key="d1">DCD encodes Dermcidin, an antimicrobial peptide</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="DERMCIDIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Dermcidin is an antimicrobial peptide involved in the immune response.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="NETHERTON SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Netherton syndrome is a genetic disorder affecting the skin, hair, and immune system</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="TINEA PEDIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Tinea pedis is a fungal infection of the foot</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="BASILIXIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Basiliximab is a medication used to prevent organ rejection</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ZINC SULFATE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Zinc sulfate is a chemical used as a dietary supplement</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="DEFB4A">
      <data key="d0">GENE</data>
      <data key="d1">DEFB4A encodes Defensin &#946; 4A, an antimicrobial peptide. This gene is known for its role in encoding a defensin, which is a type of antimicrobial peptide. DEFB4A is an antimicrobial gene that is notably upregulated in HS (Hidradenitis Suppurativa) skin, showing a 24-fold increase in expression according to the study.</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,523bbfee1ae3b4ecabf9b11d10eea9ff,bae090d8a29c15868ba1c4f29ae79e99,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="DEFENSIN &#914; 4A">
      <data key="d0">PROTEIN</data>
      <data key="d1">Defensin &#946; 4A is an antimicrobial peptide</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="TINEA CORPORIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Tinea corporis is a fungal infection of the skin</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ORAL CANDIDIASIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Oral candidiasis is a fungal infection in the mouth</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="DEFB103B">
      <data key="d0">GENE</data>
      <data key="d1">DEFB103B encodes Defensin &#946; 103B, an antimicrobial peptide</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="DEFENSIN &#914; 103B">
      <data key="d0">PROTEIN</data>
      <data key="d1">Defensin &#946; 103B is an antimicrobial peptide</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="EGF">
      <data key="d0">GENE</data>
      <data key="d1">EGF encodes Epidermal Growth Factor, involved in cell growth and differentiation</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="EPIDERMAL GROWTH FACTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Epidermal Growth Factor is involved in cell growth and differentiation</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CETUXIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cetuximab is a medication used to treat certain types of cancer</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="AG 490">
      <data key="d0">CHEMICAL</data>
      <data key="d1">AG 490 is a chemical used in research to inhibit certain signaling pathways</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CGP 52411">
      <data key="d0">CHEMICAL</data>
      <data key="d1">CGP 52411 is a chemical used in research to inhibit certain signaling pathways</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="GENISTEIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Genistein is a chemical found in soy products with various biological activities</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ZANUBRUTINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Zanubrutinib is a medication used to treat certain types of cancer. It functions as an inhibitor of JAK3, ITR, and EGFR, targeting these specific pathways to exert its therapeutic effects.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="EPGN">
      <data key="d0">GENE</data>
      <data key="d1">EPGN encodes Epithelial Mitogen, involved in cell growth and differentiation</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="EPITHELIAL MITOGEN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Epithelial Mitogen is involved in cell growth and differentiation</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="SEBORRHEIC DERMATITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Seborrheic dermatitis is a common skin condition that causes scaly patches and red skin</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ERBB4">
      <data key="d0">GENE</data>
      <data key="d1">ERBB4 encodes Erb-B2 Receptor Tyrosine Kinase 4, involved in cell signaling</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ERB-B2 RECEPTOR TYROSINE KINASE 4">
      <data key="d0">PROTEIN</data>
      <data key="d1">Erb-B2 Receptor Tyrosine Kinase 4 is involved in cell signaling</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="GEFITINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Gefitinib is a medication used to treat certain types of cancer</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="AFATINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Afatinib is a medication used to treat certain types of cancer</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="FOSTAMATINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Fostamatinib is a SYK inhibitor used as a potential therapeutic in the treatment of certain autoimmune diseases, including HS (Hidradenitis Suppurativa).</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606,b62ecc47bf54393bc78dd65986b949d6,cdfcc39154accbac074c924676dc701e,e340a83f7cba0ea5be731b1f682ea7c7,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="GAS6">
      <data key="d0">GENE</data>
      <data key="d1">GAS6 encodes Growth Arrest Specific 6, involved in cell growth and survival</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="GROWTH ARREST SPECIFIC 6">
      <data key="d0">PROTEIN</data>
      <data key="d1">Growth Arrest Specific 6 is involved in cell growth and survival</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="LUPUS ERYTHEMATOSUS">
      <data key="d0">DISEASE</data>
      <data key="d1">Lupus erythematosus is an autoimmune disease that affects various parts of the body</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="GDNF">
      <data key="d0">GENE</data>
      <data key="d1">GDNF encodes Glial Cell Derived Neurotrophic Factor, involved in the survival of neurons</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="GLIAL CELL DERIVED NEUROTROPHIC FACTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Glial Cell Derived Neurotrophic Factor is involved in the survival of neurons</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CHONDROITIN SULPHATE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Chondroitin sulphate is a chemical used as a dietary supplement for joint health</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="GJB2">
      <data key="d0">GENE</data>
      <data key="d1">GJB2 encodes Gap Junction Protein &#946;2, involved in cell communication</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="GAP JUNCTION PROTEIN &#914;2">
      <data key="d0">PROTEIN</data>
      <data key="d1">Gap Junction Protein &#946;2 is involved in cell communication</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="KERATITIS-ICHTHYOSIS-DEAFNESS SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Keratitis-Ichthyosis-Deafness Syndrome is a genetic disorder affecting the skin, eyes, and hearing</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CARBENOXOLONE DISODIUM">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Carbenoxolone disodium is a medication used to treat ulcers and inflammation</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="HBEGF">
      <data key="d0">GENE</data>
      <data key="d1">HBEGF encodes Heparin Binding EGF-Like Growth Factor, involved in cell growth and differentiation</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="HEPARIN BINDING EGF-LIKE GROWTH FACTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Heparin Binding EGF-Like Growth Factor is involved in cell growth and differentiation</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="HGF">
      <data key="d0">GENE</data>
      <data key="d1">HGF encodes Hepatocyte Growth Factor, involved in cell growth and differentiation</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="HEPATOCYTE GROWTH FACTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Hepatocyte Growth Factor is involved in cell growth and differentiation</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="DEXAMETHASONE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Dexamethasone is a corticosteroid medication used to treat inflammation and autoimmune diseases.</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="NERATINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Neratinib is a medication used to treat certain types of cancer</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ERLOTINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Erlotinib is a medication used to treat certain types of cancer</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="HRG">
      <data key="d0">GENE</data>
      <data key="d1">HRG encodes Histidine-Rich Glycoprotein, involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="HISTIDINE-RICH GLYCOPROTEIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Histidine-Rich Glycoprotein is involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IFNA1">
      <data key="d0">GENE</data>
      <data key="d1">IFNA1 encodes Interferon &#945;1, involved in antiviral responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="INTERFERON &#913;1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interferon &#945;1 is involved in antiviral responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CRYOBLOBULINEMIA">
      <data key="d0">DISEASE</data>
      <data key="d1">Cryoblobulinemia is a condition where abnormal proteins in the blood thicken in cold temperatures</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="INTERFERON &#915;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interferon &#947; is involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="OKSALAZINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Oksalazine is a medication used to treat inflammatory bowel disease</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="EMAPALUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Emapalumab is a medication used to treat certain autoimmune diseases</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IGF2">
      <data key="d0">GENE</data>
      <data key="d1">IGF2 encodes Insulin-Like Growth Factor 2, involved in growth and development</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="INSULIN-LIKE GROWTH FACTOR 2">
      <data key="d0">PROTEIN</data>
      <data key="d1">Insulin-Like Growth Factor 2 is involved in growth and development</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IGHD">
      <data key="d0">GENE</data>
      <data key="d1">IGHD encodes Immunoglobulin Heavy Constant &#948;, involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IMMUNOGLOBULIN HEAVY CONSTANT &#916;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Immunoglobulin Heavy Constant &#948; is involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IGHG3">
      <data key="d0">GENE</data>
      <data key="d1">IGHG3 encodes Immunoglobulin Heavy Constant &#947;3, involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IMMUNOGLOBULIN HEAVY CONSTANT &#915;3">
      <data key="d0">PROTEIN</data>
      <data key="d1">Immunoglobulin Heavy Constant &#947;3 is involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IGKV1D-13">
      <data key="d0">GENE</data>
      <data key="d1">IGKV1D-13 encodes Immunoglobulin &#954; Variable 1D-13, involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IMMUNOGLOBULIN &#922; VARIABLE 1D-13">
      <data key="d0">PROTEIN</data>
      <data key="d1">Immunoglobulin &#954; Variable 1D-13 is involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IGLV">
      <data key="d0">GENE</data>
      <data key="d1">IGLV encodes Immunoglobulin &#955; Variable Cluster, involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IMMUNOGLOBULIN &#923; VARIABLE CLUSTER">
      <data key="d0">PROTEIN</data>
      <data key="d1">Immunoglobulin &#955; Variable Cluster is involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IL1A">
      <data key="d0">GENE</data>
      <data key="d1">IL1A encodes Interleukin 1&#945;, involved in inflammatory responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="INTERLEUKIN 1&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 1&#945; is involved in inflammatory responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ACNE">
      <data key="d0">DISEASE</data>
      <data key="d1">Acne is a skin condition characterized by inflamed or infected sebaceous glands, red pimples often appearing on the face, and occurs when hair follicles are clogged with oil and dead skin cells.</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838,c46e8b6ee0c29e37b7f18c42558d7a3e,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IRRITANT DERMATITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Irritant dermatitis is a form of eczema caused by direct contact with an irritating substance</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ANAKINRA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Anakinra is a medication used to treat rheumatoid arthritis. It functions as an IL-1 receptor antagonist, specifically targeting IL1R1, to mitigate the inflammatory processes associated with the disease.</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="RINOLACEPT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Rinolacept is a medication used to treat certain inflammatory conditions</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="OLANZAPINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Olanzapine is a medication used to treat mental health conditions</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="PIRFENIDONE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Pirfenidone is a medication used to treat idiopathic pulmonary fibrosis</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="AMG-108">
      <data key="d0">CHEMICAL</data>
      <data key="d1">AMG-108 is a medication used in research to inhibit certain signaling pathways</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IL1B">
      <data key="d0">GENE</data>
      <data key="d1">IL1B is a gene encoding Interleukin 1 Beta (Interleukin 1&#946;), which is involved in inflammatory responses.</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,cdfcc39154accbac074c924676dc701e</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="GINGIVITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Gingivitis is a common form of gum disease</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="MUCKLE&#8211;WELLS SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Muckle&#8211;Wells syndrome is a rare autoinflammatory disorder</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="TOXIC SHOCK SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Toxic shock syndrome is a rare, life-threatening complication of certain bacterial infections</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CANAKIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Canakizumab is a medication used to treat certain inflammatory conditions</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IL2">
      <data key="d0">GENE</data>
      <data key="d1">IL2 encodes Interleukin 2, involved in the regulation of white blood cells</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="INTERLEUKIN 2">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 2 is involved in the regulation of white blood cells</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="GRAFT-VERSUS-HOST DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Graft-versus-host disease is a condition that occurs when donor bone marrow or stem cells attack the recipient</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="LEPROSY">
      <data key="d0">DISEASE</data>
      <data key="d1">Leprosy is a chronic infectious disease caused by Mycobacterium leprae</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="SUPLATAST TOSYLATE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Suplatast tosylate is a medication used to treat allergic conditions. It functions as an anti-allergic drug, providing relief from symptoms associated with allergic reactions.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="DACLIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Daclizumab is a medication used to prevent organ rejection</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="RITUXIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Rituximab is a monoclonal antibody used to treat certain autoimmune diseases and cancers. It functions by targeting CD20 on B cells, making it an effective anti-CD20 agent for conditions such as HS (Hidradenitis Suppurativa) and other immune disorders. While it is a traditional biologic, it is not recommended for treating AD (Atopic Dermatitis).</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,423195c6b63ad0a6773374364ebf3612,8246ea974dfb00cb5e3d984004e21a9e,b62ecc47bf54393bc78dd65986b949d6,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CAFAZOLIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cafazolin is an antibiotic used to treat bacterial infections</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IL2RA">
      <data key="d0">GENE</data>
      <data key="d1">IL2RA encodes Interleukin 2 Receptor Subunit &#945;, involved in the regulation of white blood cells</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="INTERLEUKIN 2 RECEPTOR SUBUNIT &#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 2 Receptor Subunit &#945; is involved in the regulation of white blood cells</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="TYPE 1 DIABETES MELLITUS">
      <data key="d0">DISEASE</data>
      <data key="d1">Type 1 diabetes mellitus is a chronic condition in which the pancreas produces little or no insulin</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="JUVENILE ARTHRITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Juvenile arthritis is a type of arthritis that occurs in children</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IL4">
      <data key="d0">GENE</data>
      <data key="d1">IL4 encodes Interleukin 4, involved in the regulation of immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="INTERLEUKIN 4">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 4 is involved in the regulation of immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ATOPY">
      <data key="d0">DISEASE</data>
      <data key="d1">Atopy is a genetic tendency to develop allergic diseases</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ALLERGIC RHINITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Allergic Rhinitis is an allergic reaction that causes sneezing, congestion, and a runny nose. It is a condition that children with Atopic Dermatitis may develop, indicating a potential association between the two conditions.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,573fb6fa0673eb9462aa9862888079f3,691cb2e23ac3c6e591129d16714f8ef8,6ada075e562abd7bd445164e9fc309b4,89dbac0da39e4de2b602052cd792b90d,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="FOOD ALLERGY">
      <data key="d0">DISEASE</data>
      <data key="d1">Food allergy is an atopic disorder that can be a comorbidity of atopic dermatitis (AD). It is characterized as an immune system reaction that occurs soon after eating a certain food.</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,1596d061dbe1a1c9e8f31a02a21e5524,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="DUPILUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Dupilumab is a fully human IgG4 monoclonal antibody that targets the interleukin-4 receptor alpha (IL-4R&#945;) subunit, which is a shared component of the IL-4 and IL-13 receptors. By antagonizing IL-4R&#945;, Dupilumab effectively blocks the signaling pathways of both IL-4 and IL-13, which are key cytokines involved in the inflammatory response associated with atopic dermatitis (AD) and other atopic conditions. This biologic drug is approved for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents and is administered via subcutaneous injection. Additionally, Dupilumab has shown efficacy in treating other inflammatory and autoimmune conditions by inhibiting the JAK/STAT pathway and regulating JAK activity. As a receptor antagonist, Dupilumab provides a targeted therapeutic approach for managing various autoimmune diseases, particularly those characterized by dysregulated IL-4 and IL-13 signaling.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,0ba9fbea14e0c2c1d01a12ffaacfda9b,104cc78517b2eca2e9cb7e00de1fe4b0,1596d061dbe1a1c9e8f31a02a21e5524,27a7e95c7d3ad59a948aa46741fee456,286730b1c1f680ac465cc21d522fda0c,28f548554737fcc026b968db6bbafa30,2cec06c4d46f5ff9ee936a78d8b077cd,3df8535e965efb96f5094169610507ff,3dfbb4c51838e0951f53ce951395225f,48de7eebab3f3b418feb35a152df38fd,573fb6fa0673eb9462aa9862888079f3,693a2aac101eaaadf92614317a1e4da8,78e26c66107dba37ac4bab65406b43a0,96e553a44a27e728c27c4892045ec5c2,a867a1e73cef039eb3f28e072463b838,cdfcc39154accbac074c924676dc701e,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c,e9841b88c9fab58c5175af409653da50,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="CALCITRIOL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Calcitriol is the active form of vitamin D, used in the treatment of various conditions. It is specifically utilized as a medication to treat calcium deficiency.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,62b4bd8f530adae989e4349d1e58f11d,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="INTERLEUKIN 6">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 6 is involved in the regulation of immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="SILTUXIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Siltuximab is a medication used to treat certain inflammatory conditions. It functions as a receptor antagonist targeting IL6, thereby modulating the inflammatory response associated with these conditions.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="TOCILIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Tocilizumab is a medication used to treat certain inflammatory conditions. It is an anti-IL-6 receptor monoclonal antibody that functions as a receptor antagonist targeting IL-6. This makes it effective in the treatment of autoimmune diseases by inhibiting the activity of the interleukin-6 (IL-6) receptor, thereby reducing inflammation and modulating the immune response.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,cdfcc39154accbac074c924676dc701e,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </node>
    <node id="SARILUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Sarilumab is a medication used to treat certain inflammatory conditions. It functions as a receptor antagonist targeting IL6, thereby helping to modulate the immune response and reduce inflammation.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="SATRALIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Satralizumab is a medication used to treat certain inflammatory conditions. It functions as a receptor antagonist targeting IL6, thereby modulating the immune response to alleviate inflammation.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="VITAMIN C">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Vitamin C is a vitamin used to prevent and treat scurvy. It is an essential nutrient involved in the repair of tissue and the enzymatic production of certain neurotransmitters.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="VITAMIN E">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Vitamin E is a fat-soluble antioxidant that protects cell membranes from oxidative damage. It is a nutrient that has the potential to increase skin hydration and is commonly used in cosmetic applications. Additionally, Vitamin E is utilized to treat and prevent vitamin E deficiency. As an antioxidant, it plays a crucial role in helping to protect cells from damage.</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456,573fb6fa0673eb9462aa9862888079f3,bddc3b1a7f098e71f0aa64adec047124,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IL10">
      <data key="d0">GENE</data>
      <data key="d1">IL10 encodes Interleukin 10, which is an anti-inflammatory cytokine involved in the regulation of immune responses.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,62b4bd8f530adae989e4349d1e58f11d,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="INTERLEUKIN 10">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 10 is involved in the regulation of immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="NICOTINAMIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Nicotinamide, also known as niacinamide, is a form of vitamin B3 that serves multiple roles in both medical and therapeutic contexts. It is commonly used as a dietary supplement and medication to treat and prevent niacin deficiency. Additionally, nicotinamide is employed in the treatment of various skin conditions and is known to improve overall skin health. Beyond its traditional uses, nicotinamide is also being explored in nanotechnology-based therapeutic approaches, highlighting its versatility and potential in advanced medical applications.</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456,573fb6fa0673eb9462aa9862888079f3,baf4dec7fda8d8b8571a343b034f7092,cccfd5ff480e281556e2210cd0e5c4b5,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="NIACIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Niacin is a form of vitamin B3 that is used to treat and prevent niacin deficiency. Additionally, it is employed in the treatment of high cholesterol and pellagra.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,baf4dec7fda8d8b8571a343b034f7092,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CYCLOSPORINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cyclosporine is an immunosuppressant drug used in the treatment of autoimmune diseases. It is commonly employed in systemic therapy for atopic dermatitis (AD) and is recognized as the only AD treatment by most countries. Additionally, Cyclosporine is used to prevent organ rejection, highlighting its broad application in managing immune responses.</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c,2cec06c4d46f5ff9ee936a78d8b077cd,cdfcc39154accbac074c924676dc701e,dc905ba8b6eb7d84cf2776303211010d,e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="INTERLEUKIN 1&#914;">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CYCLOSPORINE A">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cyclosporine A is a systemic immunosuppressant drug used to treat autoimmune diseases, including Atopic Dermatitis (AD), and to prevent organ transplant rejection. Additionally, Cyclosporine A is utilized in nanotechnology-based therapeutic approaches.</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456,48de7eebab3f3b418feb35a152df38fd,573fb6fa0673eb9462aa9862888079f3,693a2aac101eaaadf92614317a1e4da8,cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="METHOTREXATE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Methotrexate is a chemotherapy agent and immune system suppressant used to treat various conditions, including autoimmune diseases such as rheumatoid arthritis and atopic dermatitis (AD). As a systemic immunosuppressant, Methotrexate controls the skin&#8217;s immune system, modifies immunological signals, and calms down hyperactive inflammatory cells. It is particularly utilized in the systemic treatment of severe forms of AD, helping to manage and alleviate the symptoms associated with this condition.</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,1596d061dbe1a1c9e8f31a02a21e5524,27a7e95c7d3ad59a948aa46741fee456,286730b1c1f680ac465cc21d522fda0c,2cec06c4d46f5ff9ee936a78d8b077cd,48de7eebab3f3b418feb35a152df38fd,573fb6fa0673eb9462aa9862888079f3,693a2aac101eaaadf92614317a1e4da8,6aef5adb1be227170f66c76a292c25e5,dc905ba8b6eb7d84cf2776303211010d</data>
    </node>
    <node id="MYCOPHENOLATE MOFETIL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Mycophenolate Mofetil is an immunosuppressant drug used to prevent organ rejection and treat autoimmune diseases. It is a standard therapy drug used in the treatment of systemic sclerosis (SSc) and is also employed in the management of atopic dermatitis (AD), including its severe forms.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,573fb6fa0673eb9462aa9862888079f3,855c455b4c9592746834ee3a4e0e6b81,8e5a1be9981340d419f7b3ad27076009,dc905ba8b6eb7d84cf2776303211010d</data>
    </node>
    <node id="IL12A">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 12A is a subunit of the cytokine IL-12, involved in the differentiation of T cells</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="ADAMANTIADES&#8211;BEH&#199;ET&#8217;S DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Adamantiades&#8211;Beh&#231;et&#8217;s disease is a rare, chronic, inflammatory disorder</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="PRIMARY BILIARY CHOLANGIITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Primary biliary cholangiitis is a chronic disease that causes the small bile ducts in the liver to become inflamed and damaged</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="USTEKINUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Ustekinumab is a human IgG1&#954; monoclonal antibody that targets the p40 subunit of interleukins IL-12 and IL-23. It is used in the treatment of various autoimmune diseases, including moderate-to-severe atopic dermatitis. As an IL-12/23 inhibitor, Ustekinumab plays a crucial role in modulating the immune response by inhibiting these specific interleukins. Despite its efficacy in treating autoimmune conditions, it is noted that Ustekinumab is not traditionally recommended for the treatment of atopic dermatitis. Additionally, there is a mention of Ustekinumab targeting FSH, HCG, LH, and LTA4H, although this appears to be an error or misinterpretation, as its primary mechanism of action is through IL-12 and IL-23 inhibition.</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,573fb6fa0673eb9462aa9862888079f3,8246ea974dfb00cb5e3d984004e21a9e,c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="BRIAKINUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Briakinumab is a monoclonal antibody targeting IL-12/23</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="IL12B">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 12B is a subunit of the cytokine IL-12, involved in the differentiation of T cells</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="PSORIASIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Psoriasis is a chronic autoimmune skin disease characterized by red, scaly patches. It is a chronic inflammatory skin condition that causes the rapid build-up of skin cells, leading to scaling on the skin's surface. This rapid skin cell production results in the formation of abnormal skin patches. Psoriasis is also noted for having biomarkers indicative of disease progression. Additionally, advancements in treatment options, such as the use of nanotechnology, have shown promise in managing this condition.</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,1412a7a7fef5f18cc09a030b97b18e13,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,286730b1c1f680ac465cc21d522fda0c,2e0cdefd62bed7c674d7fb93ef336c2b,3ce96e927d65736b305f792977fed4b9,3df8535e965efb96f5094169610507ff,3ea70e257330c812b52334ca1f90d807,442e7fad2fab75fa2449309783294d89,48288f3ec2832850282f95d4e38d10e1,573fb6fa0673eb9462aa9862888079f3,8246ea974dfb00cb5e3d984004e21a9e,849e0980ffd6a7e1cf0b8d3d1fbacd98,b28eeca0ff01a7715947d55a04978a43,b62ecc47bf54393bc78dd65986b949d6,baf4dec7fda8d8b8571a343b034f7092,c46e8b6ee0c29e37b7f18c42558d7a3e,e95d4d15e4f3110c91a3d3fcb5910d06</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="IL13">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL13, also known as Interleukin 13, is a gene with overall decreased expression in HS (Hidradenitis Suppurativa). It encodes a cytokine that plays a crucial role in the regulation of inflammatory and immune responses.</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="PENICILLIN ALLERGY">
      <data key="d0">DISEASE</data>
      <data key="d1">Penicillin allergy is an allergic reaction to penicillin antibiotics</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="MONTELUKAST">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Montelukast is a leukotriene receptor antagonist used to manage allergies and prevent asthma attacks. This medication is specifically designed to help control and alleviate symptoms associated with allergies and asthma, making it an effective option for individuals suffering from these conditions.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,baf4dec7fda8d8b8571a343b034f7092</data>
    </node>
    <node id="OMALIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Omalizumab is a humanized IgG1&#954; monoclonal antibody that targets Immunoglobulin E (IgE). It is primarily used in the treatment of allergic asthma and severe recalcitrant atopic eczema (also known as atopic dermatitis). As a biologic drug, Omalizumab functions by inhibiting the JAK/STAT pathway, thereby regulating immune responses. Despite its applications in treating allergic conditions, it is not traditionally recommended for atopic dermatitis.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,104cc78517b2eca2e9cb7e00de1fe4b0,3df8535e965efb96f5094169610507ff,48288f3ec2832850282f95d4e38d10e1,573fb6fa0673eb9462aa9862888079f3,8246ea974dfb00cb5e3d984004e21a9e,cccfd5ff480e281556e2210cd0e5c4b5,e9841b88c9fab58c5175af409653da50,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="IL16">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 16 is a cytokine that acts as a chemoattractant for certain immune cells</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="ALLERGIC ASTHMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Allergic asthma is a type of asthma triggered by allergens. It is an atopic disorder that can be a comorbidity of atopic dermatitis (AD).</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,08e39958b85d84950ab7173daab9111b,1596d061dbe1a1c9e8f31a02a21e5524,573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="SECUKIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Secukizumab is a monoclonal antibody targeting IL-17A</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="IXEKIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Ixekizumab is a monoclonal antibody targeting IL-17A</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="BIMEKIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Bimekizumab is a monoclonal antibody that functions as an IL-17A/F inhibitor. It specifically targets the cytokines IL-17A and IL-17F, making it a valuable therapeutic agent in the treatment of autoimmune diseases.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="BRODALUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Brodalumab is a receptor antagonist targeting the IL-17 receptor. It functions as an IL-17 receptor inhibitor and targets IL17R, KRT6A, S100A7A, S100A8, and S100A9. Brodalumab is used in the treatment of psoriasis.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="VIDOFLUDIMUS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Vidofludimus is an immunomodulatory drug</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="IL17F">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL17F is a gene encoding for interleukin 17F (IL-17F), a pro-inflammatory cytokine involved in the immune response. Increased mRNA expression of IL17F has been observed in certain conditions, such as HS (Hidradenitis Suppurativa). Interleukin 17F plays a significant role in autoimmune diseases, contributing to the inflammatory processes associated with these conditions.</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,573fb6fa0673eb9462aa9862888079f3,c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CANDIDIASIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Candidiasis is a fungal infection caused by Candida species</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Acute generalized exanthematous pustulosis is a severe skin reaction characterized by pustules</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="MAIL DISEASES">
      <data key="d0">DISEASE</data>
      <data key="d1">Mail diseases refer to a group of conditions affecting the skin and mucous membranes</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="IL17R">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL17R is a gene encoding interleukin 17 receptor, which is involved in the immune response. The Interleukin 17 Receptor is a receptor for IL-17 cytokines, playing a crucial role in mediating the effects of these cytokines in the immune system.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="IAP ANTAGONIST">
      <data key="d0">CHEMICAL</data>
      <data key="d1">IAP antagonist is a class of drugs that inhibit Inhibitor of Apoptosis Proteins</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="IBOCTADEKIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Iboctadekin is a recombinant interleukin-18</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="DOXIL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Doxil is a liposomal formulation of the chemotherapy drug doxorubicin</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="IL19">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 19 is a cytokine involved in inflammatory responses</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="IL20">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 20 is a cytokine involved in inflammatory responses</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="IL21">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 21 is a cytokine involved in the regulation of immune responses</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="DACRYOADENITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Dacryoadenitis is inflammation of the lacrimal gland</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="IL22">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 22 is a cytokine involved in inflammatory responses</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="IL22RA1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 22 Receptor Subunit &#945;1 is a receptor for IL-22</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="SPONDYLOARTHROPATHY">
      <data key="d0">DISEASE</data>
      <data key="d1">Spondyloarthropathy is a group of inflammatory diseases that affect the joints and spine</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="AUTOIMMUNE UVEITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Autoimmune uveitis is inflammation of the uvea caused by an autoimmune response</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="IL23A">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 23 Subunit &#945; is a subunit of the cytokine IL-23, involved in inflammatory responses</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="AUTOIMMUNE DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">An autoimmune disease is a condition in which the immune system attacks the body's own tissues. Autoimmune diseases occur when the immune system mistakenly targets and damages the body's own cells, leading to a variety of health issues.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,573fb6fa0673eb9462aa9862888079f3,68015074236b0144899baa38d01ae467</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="GUSELKUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Guselkumab is a monoclonal antibody targeting IL-23</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="RISANKINUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Risankinumab is a monoclonal antibody targeting IL-23</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="TILDRAKIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Tildrakizumab is a monoclonal antibody targeting IL-23</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="IL24">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 24 is a cytokine involved in inflammatory responses</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CHRONIC SPONTANEOUS URTICARIA">
      <data key="d0">DISEASE</data>
      <data key="d1">Chronic spontaneous urticaria is a condition characterized by the spontaneous appearance of hives</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="SPONDYLARTHROPATHY">
      <data key="d0">DISEASE</data>
      <data key="d1">Spondylarthropathy is a group of inflammatory diseases that affect the joints and spine</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="IL26">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 26 is a cytokine involved in inflammatory responses</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CUTANEOUS DIPHTHERIA">
      <data key="d0">DISEASE</data>
      <data key="d1">Cutaneous diphtheria is a bacterial infection of the skin caused by Corynebacterium diphtheriae</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="PERIOSTITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Periostitis is inflammation of the periosteum, a layer of connective tissue that surrounds bone</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="STILL&#8217;S DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Still&#8217;s disease is a rare type of inflammatory arthritis</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="JAK3">
      <data key="d0">PROTEIN</data>
      <data key="d1">JAK3, or Janus kinase 3, is a gene encoding a protein that is a member of the JAK family of tyrosine kinases. This protein plays a crucial role in cytokine receptor signaling and is involved in the JAK/STAT signaling pathway. JAK3 is essential for the regulation of immune responses and is involved in the signaling of various cytokines.</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,3df8535e965efb96f5094169610507ff,573fb6fa0673eb9462aa9862888079f3,62b4bd8f530adae989e4349d1e58f11d,c44ec79872ab10cbe7336182f183ff60,c46e8b6ee0c29e37b7f18c42558d7a3e,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="NK CELL ENTEROPATHY">
      <data key="d0">DISEASE</data>
      <data key="d1">NK cell enteropathy is a condition characterized by the abnormal proliferation of natural killer cells in the gastrointestinal tract</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="DECERNATINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Decernatinib is a JAK3 inhibitor</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="TOFACITINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Tofacitinib is a JAK inhibitor, specifically targeting JAK1 and JAK3.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="RUXOLITINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Ruxolitinib is a small molecule drug developed by Incyte, primarily targeting JAK1 and JAK2. It functions as a dual JAK1/JAK2 inhibitor and is used in the treatment of various autoimmune conditions, including atopic dermatitis (AD), vitiligo, and cutaneous lupus. As a selective JAK inhibitor, Ruxolitinib is particularly effective in AD therapy and is available as a topical treatment. It is also the active ingredient in the medication Opzelura.</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c,3df8535e965efb96f5094169610507ff,573fb6fa0673eb9462aa9862888079f3,62b4bd8f530adae989e4349d1e58f11d,c46e8b6ee0c29e37b7f18c42558d7a3e,cccfd5ff480e281556e2210cd0e5c4b5,e075bccd45593ae008b2ce7f9ed8ff6c,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="PF-06651600">
      <data key="d0">CHEMICAL</data>
      <data key="d1">PF-06651600 is a JAK inhibitor, specifically targeting JAK3.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="AT-501">
      <data key="d0">CHEMICAL</data>
      <data key="d1">AT-501 is a JAK3 inhibitor</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="ATI-502">
      <data key="d0">CHEMICAL</data>
      <data key="d1">ATI-502 is a JAK3 inhibitor</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="CERDULATINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cerdulatinib (RVT/DMVT502) is a small molecule drug developed by Dermavant. It functions as a non-selective inhibitor targeting Janus kinases (JAK1, JAK2, JAK3) and spleen tyrosine kinase (SYK). This broad-spectrum inhibition makes Cerdulatinib effective in the treatment of autoimmune diseases such as atopic dermatitis (AD) and various haematological malignancies.</data>
      <data key="d2">3df8535e965efb96f5094169610507ff,573fb6fa0673eb9462aa9862888079f3,c46e8b6ee0c29e37b7f18c42558d7a3e,cccfd5ff480e281556e2210cd0e5c4b5,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="DELGOCITINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Delgocitinib is a small molecule drug developed by Japan Tobacco/LEO, primarily targeting the Janus kinase (JAK) family. It is a first-generation, non-selective JAK inhibitor that inhibits JAK1, JAK2, JAK3, and TYK2. Delgocitinib has been under clinical development for the treatment of Atopic Dermatitis (AD) and is also used for treating chronic hand eczema.</data>
      <data key="d2">3df8535e965efb96f5094169610507ff,573fb6fa0673eb9462aa9862888079f3,62b4bd8f530adae989e4349d1e58f11d,90f4809673ca34628b0e607908f0bf0b,c46e8b6ee0c29e37b7f18c42558d7a3e,cccfd5ff480e281556e2210cd0e5c4b5,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="PEFICITINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Peficitinib is a JAK inhibitor that specifically targets JAK1, JAK2, and JAK3.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="CERCOSPORAMIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cercosporamide is a JAK3/Mnk2 inhibitor</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="KRT6A">
      <data key="d0">GENE</data>
      <data key="d1">KRT6A is a gene encoding keratin 6A, which is involved in the structural integrity of epithelial cells. Keratin 6A is associated with several conditions, including Pachyonychia congenita, Lingua plicata, and Cheilitis.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">GENE</data>
    </node>
    <node id="LINGUA PLICATA">
      <data key="d0">DISEASE</data>
      <data key="d1">Lingua plicata is a condition characterized by grooves or fissures on the tongue</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="CHEILITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Cheilitis is inflammation of the lips</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="ZINC">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Zinc is a mineral essential for immune function and enzyme activity. It is an essential mineral involved in numerous aspects of cellular metabolism.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,baf4dec7fda8d8b8571a343b034f7092</data>
    </node>
    <node id="ZINC ACETATE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Zinc acetate is a form of zinc used as a dietary supplement and in medications. It is also employed in the treatment of various conditions.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,baf4dec7fda8d8b8571a343b034f7092</data>
    </node>
    <node id="KRT16">
      <data key="d0">GENE</data>
      <data key="d1">KRT16 is a gene encoding keratin 16, which plays a crucial role in the structural integrity of epithelial cells. Mutations or dysregulation of KRT16 are associated with several skin disorders, including Pachyonychia congenita and palmoplantar keratoderma.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,baf4dec7fda8d8b8571a343b034f7092,c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">GENE</data>
    </node>
    <node id="PALMOPLANTAR KERATODERMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Palmoplantar keratoderma is a condition characterized by thickening of the skin on the palms and soles</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="KRT77">
      <data key="d0">GENE</data>
      <data key="d1">KRT77 is a gene encoding Keratin 77. Keratin 77 is associated with Epidermolytic palmoplantar keratoderma and Buschke-Ollendorff syndrome.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="EPIDERMOLYTIC PALMOPLANTAR KERATODERMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Epidermolytic palmoplantar keratoderma is a genetic skin disorder characterized by thickened skin on the palms and soles</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="BUSCHKE-OLLENDORFF SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Buschke-Ollendorff syndrome is a rare genetic disorder characterized by skin lesions and bone abnormalities.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="LCE3D">
      <data key="d0">GENE</data>
      <data key="d1">LCE3D is a gene encoding Late Cornified Envelope 3D, which is associated with Psoriasis.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="LGR5">
      <data key="d0">GENE</data>
      <data key="d1">LGR5 is a gene encoding Leucine Rich Repeat Containing G Protein-Coupled Receptor 5. This gene is involved in stem cell regulation.</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="KERATIN 77">
      <data key="d0">PROTEIN</data>
      <data key="d1">Keratin 77 is a protein encoded by the KRT77 gene</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
    </node>
    <node id="LATE CORNIFIED ENVELOPE 3D">
      <data key="d0">PROTEIN</data>
      <data key="d1">Late Cornified Envelope 3D is a protein encoded by the LCE3D gene</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="LEUCINE RICH REPEAT CONTAINING G PROTEIN-COUPLED RECEPTOR 5">
      <data key="d0">PROTEIN</data>
      <data key="d1">Leucine Rich Repeat Containing G Protein-Coupled Receptor 5 is a protein encoded by the LGR5 gene</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="TYPE II DIABETES MELLITUS">
      <data key="d0">DISEASE</data>
      <data key="d1">Type II diabetes mellitus is a chronic condition that affects the way the body processes blood sugar (glucose)</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="LTA4H">
      <data key="d0">GENE</data>
      <data key="d1">LTA4H is a gene encoding Leukotriene A4 Hydrolase, an enzyme involved in inflammation.</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092,c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">GENE</data>
    </node>
    <node id="LEUKOTRIENE A4 HYDROLASE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Leukotriene A4 Hydrolase is an enzyme involved in the inflammatory response</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CAPTOPRIL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Captopril is a medication used to treat high blood pressure and heart failure</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="MMP1">
      <data key="d0">GENE</data>
      <data key="d1">MMP1 is a gene encoding Matrix Metallopeptidase 1, an enzyme involved in the breakdown of the extracellular matrix.</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,baf4dec7fda8d8b8571a343b034f7092,c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">GENE</data>
    </node>
    <node id="MATRIX METALLOPEPTIDASE 1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Matrix Metallopeptidase 1 is an enzyme involved in the breakdown of extracellular matrix</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="EPIDERMOLYSIS BULLOSA ATROPHICA">
      <data key="d0">DISEASE</data>
      <data key="d1">Epidermolysis bullosa atrophica is a genetic skin disorder causing fragile skin that blisters easily</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="SCLERODERMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Scleroderma is an autoimmune disease characterized by hardening and tightening of the skin and connective tissues. It is a type of skin fibrosis, where the excessive accumulation of collagen leads to the thickening and stiffening of affected areas.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="COLLAGENASE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Collagenase is an enzyme that breaks down collagen in damaged tissues</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="MMP3">
      <data key="d0">GENE</data>
      <data key="d1">MMP3 is a gene encoding Matrix Metallopeptidase 3</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="MATRIX METALLOPEPTIDASE 3">
      <data key="d0">PROTEIN</data>
      <data key="d1">Matrix Metallopeptidase 3 is an enzyme involved in the breakdown of extracellular matrix</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CORONARY HEART DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Coronary heart disease is a condition characterized by reduced blood flow to the heart muscle</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="PRAVASTATIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Pravastatin is a medication used to lower cholesterol and prevent cardiovascular disease</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="PROTHALIDONE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Prothalidone is a medication used to treat high blood pressure</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="LISINOPRIL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Lisinopril is a medication used to treat high blood pressure and heart failure</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="MMP9">
      <data key="d0">GENE</data>
      <data key="d1">MMP9 is a gene encoding Matrix Metallopeptidase 9.</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="MATRIX METALLOPEPTIDASE 9">
      <data key="d0">PROTEIN</data>
      <data key="d1">Matrix Metallopeptidase 9 is an enzyme involved in the breakdown of extracellular matrix</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="MMP12">
      <data key="d0">GENE</data>
      <data key="d1">MMP12 is a gene encoding Matrix Metallopeptidase 12, an enzyme involved in tissue remodeling.</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b,baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="MATRIX METALLOPEPTIDASE 12">
      <data key="d0">PROTEIN</data>
      <data key="d1">Matrix Metallopeptidase 12 is an enzyme involved in the breakdown of extracellular matrix</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="DERMATITIS HERPETIFORMIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Dermatitis herpetiformis is a chronic skin condition characterized by blistering, itchy skin</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="MIDDERMAL ELASTOLYSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Middermal elastolysis is a skin condition characterized by loss of elastic tissue in the mid-dermis</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="ACETOHYDROXAMIC ACID">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Acetohydroxamic acid is a medication used to treat urinary tract infections</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="BATIMASTAT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Batimastat is a medication used to inhibit matrix metalloproteinases</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="NAMPT">
      <data key="d0">GENE</data>
      <data key="d1">NAMPT is a gene encoding Nicotinamide Phosphoribosyl transferase</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Nicotinamide Phosphoribosyl transferase is an enzyme involved in NAD biosynthesis</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="SKIN AGING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Skin aging is characterized by wrinkles, loss of elasticity, and other changes in the skin</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="PELLAGRA">
      <data key="d0">DISEASE</data>
      <data key="d1">Pellagra is a disease caused by niacin deficiency, characterized by dermatitis, diarrhea, and dementia</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="DIABETES MELLITUS TYPE 2">
      <data key="d0">DISEASE</data>
      <data key="d1">Diabetes mellitus type 2 is a chronic condition that affects the way the body processes blood sugar (glucose)</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="POLYCYSTIC OVARY SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Polycystic ovary syndrome is a hormonal disorder causing enlarged ovaries with small cysts on the outer edges</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="NGF">
      <data key="d0">GENE</data>
      <data key="d1">NGF is a gene encoding Nerve Growth Factor</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="NERVE GROWTH FACTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Nerve Growth Factor (NGF) is a protein that plays a crucial role in the growth, maintenance, and survival of nerve cells. Additionally, NGF is involved in pathways related to inflammation in atopic dermatitis, highlighting its significance in both neural and inflammatory processes.</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9,baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CLENBUTEROL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Clenbuterol is a medication used to treat asthma and other respiratory conditions</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="OSM">
      <data key="d0">GENE</data>
      <data key="d1">OSM is a gene encoding Oncostatin M</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="ONCOSTATIN M">
      <data key="d0">PROTEIN</data>
      <data key="d1">Oncostatin M is a cytokine involved in inflammation and the regulation of cell growth</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="PI3">
      <data key="d0">GENE</data>
      <data key="d1">PI3 is a gene encoding Peptidase Inhibitor 3, a protein involved in skin inflammation and various cellular processes. This gene plays a crucial role in the immune response, highlighting its importance in maintaining immune system function and potentially contributing to the pathogenesis of autoimmune diseases.</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,b19f42c9497f71b231222cd953036d6b,baf4dec7fda8d8b8571a343b034f7092,c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">GENE</data>
    </node>
    <node id="PEPTIDASE INHIBITOR 3">
      <data key="d0">PROTEIN</data>
      <data key="d1">Peptidase Inhibitor 3 is a protein involved in the inhibition of serine proteases</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="PUSTULAR PSORIASIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Pustular psoriasis is a rare form of psoriasis characterized by white pustules surrounded by red skin</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="IMPETIGO HERPETIFORMIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Impetigo herpetiformis is a rare form of pustular psoriasis that occurs during pregnancy</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="PIP">
      <data key="d0">GENE</data>
      <data key="d1">PIP is a gene encoding Prolactin Induced Protein</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="PROLACTIN INDUCED PROTEIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Prolactin Induced Protein is a protein involved in the immune response and found in various bodily fluids</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="PERILIPIN 1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Perilipin 1 is a protein involved in the regulation of lipid storage in adipocytes</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="ROSIGLITAZONE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Rosiglitazone is a medication used to treat type 2 diabetes</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="S100 CALCIUM-BINDING PROTEIN A7">
      <data key="d0">PROTEIN</data>
      <data key="d1">S100 Calcium-Binding Protein A7 is a protein involved in the regulation of inflammatory processes and immune response</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="SQUAMOUS CELL CARCINOMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Squamous cell carcinoma is a type of skin cancer that begins in the squamous cells</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="ANAL FISTULA">
      <data key="d0">DISEASE</data>
      <data key="d1">Anal fistula is an abnormal connection between the epithelialized surface of the anal canal and the perianal skin</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="IBUPROFEN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Ibuprofen is a nonsteroidal anti-inflammatory drug used to reduce fever and treat pain or inflammation</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="DEXIBUPROFEN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Dexibuprofen is a nonsteroidal anti-inflammatory drug used to treat pain and inflammation</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="ZINC CHLORIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Zinc chloride is a chemical compound used in various applications, including as a dietary supplement</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="S100 CALCIUM-BINDING PROTEIN A7A">
      <data key="d0">PROTEIN</data>
      <data key="d1">S100 Calcium-Binding Protein A7A is a protein involved in the regulation of inflammatory processes and immune response</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="S100 CALCIUM-BINDING PROTEIN A8">
      <data key="d0">PROTEIN</data>
      <data key="d1">S100 Calcium-Binding Protein A8 is a protein involved in the regulation of inflammatory processes and immune response</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="COPPER">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Copper is a mineral essential for various bodily functions, including the formation of red blood cells</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="S100 CALCIUM-BINDING PROTEIN A9">
      <data key="d0">PROTEIN</data>
      <data key="d1">S100 Calcium-Binding Protein A9 is a protein involved in the regulation of inflammatory processes and immune response</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CALCIUM">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Calcium is a mineral essential for bone health and various bodily functions</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="S100 CALCIUM-BINDING PROTEIN A12">
      <data key="d0">PROTEIN</data>
      <data key="d1">S100 Calcium-Binding Protein A12 is a protein involved in the regulation of inflammatory processes and immune response</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="KAWASAKI DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Kawasaki disease is a condition that causes inflammation in the walls of some blood vessels in the body</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="PSORIATIC ARTHRITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Psoriatic arthritis is a type of inflammatory arthritis associated with psoriasis. It is a form of arthritis that affects some people who have psoriasis. This disease is treated with TNF inhibitors.</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,516e41e96d2e72d45bf1e2c69da7f18a,62b4bd8f530adae989e4349d1e58f11d,baf4dec7fda8d8b8571a343b034f7092,c46e8b6ee0c29e37b7f18c42558d7a3e</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="AMLEXANOX">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Amlexanox is a medication used to treat aphthous ulcers</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="OLOPATADINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Olopatadine is an antihistamine used to treat allergic reactions</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="SCGB1D2">
      <data key="d0">GENE</data>
      <data key="d1">SCGB1D2 is a gene encoding Secretoglobin Family 1D Member 2</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="SECRETOGLOBIN FAMILY 1D MEMBER 2">
      <data key="d0">PROTEIN</data>
      <data key="d1">Secretoglobin Family 1D Member 2 is a protein involved in the immune response</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="SCGB2A2">
      <data key="d0">GENE</data>
      <data key="d1">SCGB2A2 is a gene encoding Secretoglobin Family 2A Member 2</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="SECRETOGLOBIN FAMILY 2A MEMBER 2">
      <data key="d0">PROTEIN</data>
      <data key="d1">Secretoglobin Family 2A Member 2 is a protein involved in the immune response</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="SERPINB3">
      <data key="d0">GENE</data>
      <data key="d1">SERPINB3 is a gene encoding Serpin Family B Member 3</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="SERPIN FAMILY B MEMBER 3">
      <data key="d0">PROTEIN</data>
      <data key="d1">Serpin Family B Member 3 is a protein involved in the inhibition of serine proteases</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="PHOSPHOSERINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Phosphoserine is a phosphorylated form of the amino acid serine</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="SERPINB4">
      <data key="d0">GENE</data>
      <data key="d1">SERPINB4 is a gene encoding Serpin Family B Member 4</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="SERPIN FAMILY B MEMBER 4">
      <data key="d0">PROTEIN</data>
      <data key="d1">Serpin Family B Member 4 is a protein involved in the inhibition of serine proteases</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="SLAMF7">
      <data key="d0">GENE</data>
      <data key="d1">SLAMF7 is a gene encoding SLAM Family Member 7</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="SLAM FAMILY MEMBER 7">
      <data key="d0">PROTEIN</data>
      <data key="d1">SLAM Family Member 7 is a protein involved in the regulation of immune responses</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="IGG4-RELATED DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">IgG4-related disease is a condition characterized by inflammation and fibrosis in various organs</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="ELOTUZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Elotuzumab is a medication used to treat multiple myeloma</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="SPRR2B">
      <data key="d0">GENE</data>
      <data key="d1">SPRR2B is a gene encoding Small Proline Rich Protein 2B</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="SMALL PROLINE RICH PROTEIN 2B">
      <data key="d0">PROTEIN</data>
      <data key="d1">Small Proline Rich Protein 2B is a protein involved in the formation of the cornified cell envelope in the skin</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="PHOTOSENSITIVE TRICHOTHIODYSTROPHY 1">
      <data key="d0">DISEASE</data>
      <data key="d1">Photosensitive trichothiodystrophy 1 is a genetic disorder characterized by sensitivity to sunlight and brittle hair</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="AUTOSOMAL RECESSIVE CONGENITAL ICHTHYOSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Autosomal recessive congenital ichthyosis is a group of genetic skin disorders characterized by dry, scaly skin</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="SPRR2C (PSEUDOGENE)">
      <data key="d0">GENE</data>
      <data key="d1">SPRR2C (pseudogene) is a pseudogene related to Small Proline Rich Protein 2C</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="SMALL PROLINE RICH PROTEIN 2C (PSEUDOGENE)">
      <data key="d0">PROTEIN</data>
      <data key="d1">Small Proline Rich Protein 2C (Pseudogene) is a pseudogene related to the formation of the cornified cell envelope in the skin</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="KERATIN 16">
      <data key="d0">PROTEIN</data>
      <data key="d1">Keratin 16 is a protein encoded by the KRT16 gene</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
    </node>
    <node id="SPRR3">
      <data key="d0">GENE</data>
      <data key="d1">SPRR3 is a gene encoding Small Proline Rich Protein</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
    </node>
    <node id="LENALIDOMIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Lenalidomide is a drug used in the treatment of multiple myeloma and other conditions</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="POMALIDOMIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Pomalidomide is a drug used to treat multiple myeloma</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="BAY 11-7821">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Bay 11-7821 is an inhibitor of NF-&#954;B activation</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="(R)-DOI">
      <data key="d0">CHEMICAL</data>
      <data key="d1">(R)-DOI is a psychoactive drug and research chemical</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="CANNABIDIOL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cannabidiol is a chemical compound found in cannabis, used for various medical conditions</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="TNFRSF4">
      <data key="d0">GENE</data>
      <data key="d1">TNFRSF4 is a gene encoding the TNF Receptor Superfamily Member 4, also known as OX40. This gene plays a crucial role in immune responses and is notably upregulated in HS (Hidradenitis Suppurativa) skin and blood.</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff,62b4bd8f530adae989e4349d1e58f11d,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="DRUG REACTION WITH EOSINOPHILIA">
      <data key="d0">DISEASE</data>
      <data key="d1">Drug reaction with eosinophilia is a severe drug reaction characterized by rash, fever, and organ involvement</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="OX-40 LIGAND">
      <data key="d0">PROTEIN</data>
      <data key="d1">OX-40 ligand is a protein that binds to OX40 and is involved in T-cell activation</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="TNFSF11">
      <data key="d0">GENE</data>
      <data key="d1">TNFSF11 is a gene encoding the TNF Superfamily Member 11, also known as RANKL. This gene plays a crucial role in bone metabolism and fibrosis. TNFSF11, through its product RANKL, is integral to the regulation of bone remodeling processes, highlighting its importance in both physiological and pathological conditions related to bone health.</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,b2aae16813e647959b783a39ef9a19a7,c95d22c2a90e77cd22bd0d280d55b26a</data>
      <data key="d3">GENE</data>
    </node>
    <node id="LETROZOLE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Letrozole is a drug used to treat breast cancer</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="THIOCOLCHICOSIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Thiocolchicoside is a muscle relaxant used to treat muscle spasms</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="TNFSF13">
      <data key="d0">GENE</data>
      <data key="d1">TNFSF13 is a gene encoding the TNF Superfamily Member 13, also known as APRIL. This gene is part of the TNF superfamily, which plays a crucial role in immune system regulation and inflammation.</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,c95d22c2a90e77cd22bd0d280d55b26a</data>
      <data key="d3">GENE</data>
    </node>
    <node id="AUTOIMMUNE DISEASES">
      <data key="d0">DISEASE</data>
      <data key="d1">Autoimmune diseases are a group of conditions where the immune system mistakenly attacks the body's own tissues. These diseases occur when the immune system, which normally protects the body from infections and other foreign invaders, erroneously targets and damages the body's own cells and organs.</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b,62b4bd8f530adae989e4349d1e58f11d,7b454335c2f5651d86f712037a0dc0ff</data>
    </node>
    <node id="TACI-IG">
      <data key="d0">CHEMICAL</data>
      <data key="d1">TACI-IG is a therapeutic agent targeting BAFF and APRILTACI-IG is a therapeutic agent targeting B-cell activating factor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="TNFSF13B">
      <data key="d0">GENE</data>
      <data key="d1">TNFSF13B is a gene encoding the TNF Superfamily Member 13b, also known as BAFF. This gene is responsible for producing the protein BAFF, which is a member of the tumor necrosis factor (TNF) superfamily. The nomenclature TNFSF13B specifically refers to the gene that encodes the BAFF protein.</data>
      <data key="d2">516e41e96d2e72d45bf1e2c69da7f18a,62b4bd8f530adae989e4349d1e58f11d,c95d22c2a90e77cd22bd0d280d55b26a</data>
      <data key="d3">GENE</data>
    </node>
    <node id="SIALADENITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Sialadenitis is inflammation of the salivary glands</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="SJOGREN SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Sjogren syndrome is an autoimmune disease characterized by dry eyes and dry mouth</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="BELIMUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Belimumab is a monoclonal antibody that targets and inhibits BAFF (B-cell activating factor). It is primarily used in the treatment of autoimmune diseases, including systemic lupus erythematosus. Additionally, Belimumab has been utilized in various dosages in clinical trials for rheumatoid arthritis.</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,423195c6b63ad0a6773374364ebf3612,62b4bd8f530adae989e4349d1e58f11d,68015074236b0144899baa38d01ae467,8e5a1be9981340d419f7b3ad27076009</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="BLISIBIMOD">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Blisibimod is a therapeutic agent that inhibits B-cell activating factor (BAFF). It is used in the treatment of autoimmune diseases by targeting BAFF, which plays a crucial role in the survival and proliferation of B cells.</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,8e5a1be9981340d419f7b3ad27076009</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="LY2127399">
      <data key="d0">CHEMICAL</data>
      <data key="d1">LY2127399 (Tabalumab) is a monoclonal antibody that targets B-cell activating factor (BAFF). It is used in the treatment of autoimmune diseases. LY2127399 functions by inhibiting BAFF, which plays a crucial role in the survival and proliferation of B-cells. This drug has been utilized in clinical trials to evaluate its efficacy and safety in managing various autoimmune conditions.</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,62b4bd8f530adae989e4349d1e58f11d,8e5a1be9981340d419f7b3ad27076009</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="TNFSF14">
      <data key="d0">GENE</data>
      <data key="d1">TNFSF14 is a gene encoding the TNF Superfamily Member 14, also known as LIGHT. LIGHT is a cytokine involved in immune responses and fibrosis. The TNF superfamily nomenclature for LIGHT is TNFSF14, and this gene is responsible for encoding the protein LIGHT.</data>
      <data key="d2">516e41e96d2e72d45bf1e2c69da7f18a,62b4bd8f530adae989e4349d1e58f11d,68015074236b0144899baa38d01ae467,c95d22c2a90e77cd22bd0d280d55b26a,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">GENE</data>
    </node>
    <node id="HERPES SIMPLEX">
      <data key="d0">DISEASE</data>
      <data key="d1">Herpes Simplex is a viral infection caused by the herpes simplex virus. It primarily manifests as sores, which can appear around the mouth or genitals.</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,a867a1e73cef039eb3f28e072463b838,c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </node>
    <node id="TNIP1">
      <data key="d0">GENE</data>
      <data key="d1">TNIP1 is a gene encoding the TNFAIP3 Interacting Protein 1</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="SYSTEMIC LUPUS ERYTHEMATOSUS">
      <data key="d0">DISEASE</data>
      <data key="d1">Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by chronic inflammation that affects multiple organs.</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89,48288f3ec2832850282f95d4e38d10e1,62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="WIF1">
      <data key="d0">GENE</data>
      <data key="d1">WIF1 is a gene encoding the WNT Inhibitory Factor 1</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="3,3&#8217;-DIINDOLYLMETHANE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">3,3&#8217;-Diindolylmethane is a CHK inhibitor, cytochrome P450 activator, and indoleamine 2,3-dioxygenase inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="HIF1A">
      <data key="d0">GENE</data>
      <data key="d1">HIF1A is a gene encoding the Hypoxia-Inducible Factor 1-alpha</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="AG-490">
      <data key="d0">CHEMICAL</data>
      <data key="d1">AG-490 is an EGFR inhibitor and JAK inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="JAK2">
      <data key="d0">GENE</data>
      <data key="d1">JAK2, or Janus kinase 2, is a gene encoding a protein that is a member of the Janus kinase family of tyrosine kinases. This protein plays a crucial role in cytokine receptor signaling and is involved in the JAK/STAT signaling pathway. JAK2 is integral to the regulation of immune responses and the signaling of various cytokines. It is also a target for therapeutic agents such as baricitinib, which is used in the treatment of atopic dermatitis.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,0ba9fbea14e0c2c1d01a12ffaacfda9b,3df8535e965efb96f5094169610507ff,62b4bd8f530adae989e4349d1e58f11d,a867a1e73cef039eb3f28e072463b838,c44ec79872ab10cbe7336182f183ff60,c46e8b6ee0c29e37b7f18c42558d7a3e,e075bccd45593ae008b2ce7f9ed8ff6c,e95d4d15e4f3110c91a3d3fcb5910d06,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">GENE</data>
    </node>
    <node id="ANDROGRAPHOLIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Andrographolide is a tumor necrosis factor production inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="NFKB1">
      <data key="d0">GENE</data>
      <data key="d1">NFKB1 is a gene encoding the Nuclear Factor Kappa B Subunit 1</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="NFKB2">
      <data key="d0">GENE</data>
      <data key="d1">NFKB2 is a gene encoding the Nuclear Factor Kappa B Subunit 2</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="APRATASTAT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Apratastat is a matrix metalloprotease inhibitor and tumor necrosis factor production inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="ADAM17">
      <data key="d0">GENE</data>
      <data key="d1">ADAM17, also known as A disintegrin and metalloproteinase 17, is a gene encoding the ADAM Metallopeptidase Domain 17. It is involved in the cleavage of membrane-bound proteins.</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,a10787d7fbb1307be263e86dc7b33a51</data>
      <data key="d3">GENE</data>
    </node>
    <node id="MMP13">
      <data key="d0">GENE</data>
      <data key="d1">MMP13 is a gene encoding the Matrix Metallopeptidase 13</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="ATRACTYLENOLIDE-I">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Atractylenolide-I is a JAK inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="JAK1">
      <data key="d0">GENE</data>
      <data key="d1">JAK1, or Janus kinase 1, is a gene encoding a protein that is part of the Janus kinase family, specifically a member of the JAK family of tyrosine kinases. This protein plays a crucial role in cytokine receptor signaling and is involved in the JAK/STAT signaling pathway, which is essential for the regulation of immune responses. JAK1 is particularly important in the phosphorylation of STAT6 in IL-4 and IL-13 signaling pathways. It is targeted by therapeutic agents such as upadacitinib and abrocitinib in the treatment of atopic dermatitis and is also inhibited by cibinqo. Overall, JAK1 is integral to the signaling of various cytokines and the modulation of immune functions.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,0ba9fbea14e0c2c1d01a12ffaacfda9b,286730b1c1f680ac465cc21d522fda0c,3df8535e965efb96f5094169610507ff,48de7eebab3f3b418feb35a152df38fd,62b4bd8f530adae989e4349d1e58f11d,a867a1e73cef039eb3f28e072463b838,c44ec79872ab10cbe7336182f183ff60,c46e8b6ee0c29e37b7f18c42558d7a3e,cccfd5ff480e281556e2210cd0e5c4b5,e075bccd45593ae008b2ce7f9ed8ff6c,e95d4d15e4f3110c91a3d3fcb5910d06,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">GENE</data>
    </node>
    <node id="AZD1480">
      <data key="d0">CHEMICAL</data>
      <data key="d1">AZD1480 is a JAK inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="BALSALAZIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Balsalazide is a cyclooxygenase inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="ALOX5">
      <data key="d0">GENE</data>
      <data key="d1">ALOX5 is a gene encoding the Arachidonate 5-Lipoxygenase</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="PPARG">
      <data key="d0">GENE</data>
      <data key="d1">PPARG is a gene encoding the Peroxisome Proliferator-Activated Receptor Gamma</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="BMS-911543">
      <data key="d0">CHEMICAL</data>
      <data key="d1">BMS-911543 is a JAK inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="CIGLITAZONE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Ciglitazone is a PPAR&#947; agonist</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="GPD1">
      <data key="d0">GENE</data>
      <data key="d1">GPD1 is a gene encoding the Glycerol-3-Phosphate Dehydrogenase 1</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="TBXA2R">
      <data key="d0">GENE</data>
      <data key="d1">TBXA2R is a gene encoding the Thromboxane A2 Receptor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="CURCUMOL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Curcumol is a JAK inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="CYT387">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cyt387 is a JAK inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="FEDRATINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Fedratinib is a FLT3 inhibitor and JAK inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="BRD4">
      <data key="d0">GENE</data>
      <data key="d1">BRD4 is a gene encoding the Bromodomain Containing 4</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="TYK2">
      <data key="d0">GENE</data>
      <data key="d1">TYK2, or Tyrosine Kinase 2, is a gene encoding a protein that is a member of the JAK family of tyrosine kinases. This protein plays a crucial role in cytokine receptor signaling and is involved in the regulation of immune responses. Specifically, TYK2 is a key component of the JAK/STAT signaling pathway, which is essential for mediating the effects of various cytokines.</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,3df8535e965efb96f5094169610507ff,62b4bd8f530adae989e4349d1e58f11d,c46e8b6ee0c29e37b7f18c42558d7a3e,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">GENE</data>
    </node>
    <node id="FILGOTINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Filgotinib is a JAK inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="GANODERIC-ACID-A">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Ganoderic-acid-a is a JAK inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="JTE-607">
      <data key="d0">CHEMICAL</data>
      <data key="d1">JTE-607 is a cytokine production inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="LATAMOXEF">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Latamoxef is a cephalosporine antibiotic</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="DACB">
      <data key="d0">GENE</data>
      <data key="d1">DACB is a gene involved in antibiotic resistance</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="MRCA">
      <data key="d0">GENE</data>
      <data key="d1">MRCA is a gene involved in antibiotic resistance</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="MRCB">
      <data key="d0">GENE</data>
      <data key="d1">MRCB is a gene involved in antibiotic resistance</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="PBPC">
      <data key="d0">GENE</data>
      <data key="d1">PBPC is a gene involved in antibiotic resistance</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="LXR-623">
      <data key="d0">CHEMICAL</data>
      <data key="d1">LXR-623 is a Liver X receptor agonist</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="NR1H2">
      <data key="d0">GENE</data>
      <data key="d1">NR1H2 is a gene encoding the Nuclear Receptor Subfamily 1 Group H Member 2</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="NR1H3">
      <data key="d0">GENE</data>
      <data key="d1">NR1H3 is a gene encoding the Nuclear Receptor Subfamily 1 Group H Member 3</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="NR1I2">
      <data key="d0">GENE</data>
      <data key="d1">NR1I2 is a gene encoding the Nuclear Receptor Subfamily 1 Group I Member 2, which is involved in the regulation of drug metabolism.</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">GENE</data>
    </node>
    <node id="NR3C1">
      <data key="d0">GENE</data>
      <data key="d1">NR3C1 is a gene encoding the Nuclear Receptor Subfamily 3 Group C Member 1</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="NS-018">
      <data key="d0">CHEMICAL</data>
      <data key="d1">NS-018 is a JAK inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="PACRITINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Pacritinib is a FLT3 inhibitor and JAK inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="PARACETAMOL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Paracetamol is a cyclooxygenase inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="FAAH">
      <data key="d0">GENE</data>
      <data key="d1">FAAH is a gene encoding the Fatty Acid Amide Hydrolase</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="PLERIXAFOR">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Plerixafor is a CC chemokine receptor antagonist</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="ACKR3">
      <data key="d0">GENE</data>
      <data key="d1">ACKR3 is a gene encoding the Atypical Chemokine Receptor 3</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="CXCR4">
      <data key="d0">GENE</data>
      <data key="d1">CXCR4 is a gene encoding the C-X-C Motif Chemokine Receptor 4</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="SIROLIMUS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Sirolimus is an mTOR inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="CFD1">
      <data key="d0">GENE</data>
      <data key="d1">CFD1 is a gene involved in cellular processes</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="FKBP1A">
      <data key="d0">GENE</data>
      <data key="d1">FKBP1A is a gene encoding the FK506 Binding Protein 1A</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="MTOR">
      <data key="d0">GENE</data>
      <data key="d1">MTOR is a gene encoding the Mechanistic Target of Rapamycin</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="RPL38">
      <data key="d0">GENE</data>
      <data key="d1">RPL38 is a gene encoding the Ribosomal Protein L38</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="TROFINETIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Trofinetide is a cytokine production inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="UPADACITINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Upadacitinib is a small molecule drug developed by AbbVie, primarily targeting Janus kinase 1 (JAK1). It is an oral JAK1-selective inhibitor used in the treatment of moderate-to-severe atopic dermatitis (AD) and other autoimmune diseases. As a JAK inhibitor, Upadacitinib also has activity against JAK2 and JAK3, making it a versatile option in the management of various autoimmune conditions. This targeted therapy is specifically licensed for treating atopic dermatitis, providing a focused approach to managing this chronic inflammatory skin disease.</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,3df8535e965efb96f5094169610507ff,62b4bd8f530adae989e4349d1e58f11d,6ada075e562abd7bd445164e9fc309b4,a867a1e73cef039eb3f28e072463b838,c44ec79872ab10cbe7336182f183ff60,cccfd5ff480e281556e2210cd0e5c4b5,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c,e95d4d15e4f3110c91a3d3fcb5910d06,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="WHI-P154">
      <data key="d0">CHEMICAL</data>
      <data key="d1">WHI-P154 is a JAK inhibitor targeting EGFR, JAK1, JAK2, and JAK3, currently in preclinical development.</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="XL019">
      <data key="d0">CHEMICAL</data>
      <data key="d1">XL019 is a JAK inhibitor targeting JAK1, JAK2, and JAK3, currently in early clinical development.</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="TNFAIP3">
      <data key="d0">GENE</data>
      <data key="d1">TNFAIP3 is a gene encoding the Tumor Necrosis Factor Alpha-Induced Protein 3</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="APRIL">
      <data key="d0">PROTEIN</data>
      <data key="d1">APRIL (A Proliferation-Inducing Ligand) is a protein encoded by the TNFSF13 gene and is a member of the TNF superfamily, also known as CD256 or TALL-2. It plays a crucial role in the regulation of B cells, including their development, survival, and maturation. APRIL is also involved in broader immune regulation and responses, making it a significant target for fusion protein therapies. Additionally, APRIL has been associated with fibrosis and atopic skin diseases, highlighting its importance in both immune function and pathological conditions.</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,423195c6b63ad0a6773374364ebf3612,62b4bd8f530adae989e4349d1e58f11d,8e5a1be9981340d419f7b3ad27076009,b2aae16813e647959b783a39ef9a19a7,c525762bb827485bceeb9f09bb4bcfe0,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="BAFF">
      <data key="d0">PROTEIN</data>
      <data key="d1">BAFF (B-cell activating factor), also known as TNFSF13B, CD257, BLyS, and TALL-2, is a protein encoded by the TNFSF13B gene. It plays a crucial role in the regulation of B-cell development, survival, and maturation. BAFF acts as a ligand in the TNF superfamily and is involved in immune responses. It can influence both structural and immune cells, driving pro-fibrotic and anti-fibrotic effects, and is associated with fibrosis in various tissues. Due to its significant role in B-cell maturation and immune regulation, BAFF is a target for monoclonal antibody therapies.</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,423195c6b63ad0a6773374364ebf3612,516e41e96d2e72d45bf1e2c69da7f18a,62b4bd8f530adae989e4349d1e58f11d,8e5a1be9981340d419f7b3ad27076009,b2aae16813e647959b783a39ef9a19a7,c525762bb827485bceeb9f09bb4bcfe0,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="CHK">
      <data key="d0">PROTEIN</data>
      <data key="d1">CHK is a protein involved in cell cycle regulation</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="CYTOCHROME P450">
      <data key="d0">PROTEIN</data>
      <data key="d1">Cytochrome P450 is a family of enzymes involved in drug metabolism</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="INDOLEAMINE 2,3-DIOXYGENASE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Indoleamine 2,3-dioxygenase is an enzyme involved in tryptophan metabolism</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="TNFSF4">
      <data key="d0">GENE</data>
      <data key="d1">TNFSF4, also known as OX40L or CD252, is a gene encoding the TNF Receptor Superfamily Member 4, specifically the OX40 ligand. This gene is part of the tumour necrosis factor ligand superfamily and plays a crucial role in the immune system by encoding the T cell costimulatory molecule OX40 ligand. TNFSF4 is associated with susceptibility to several autoimmune diseases, including systemic sclerosis (SSc) and systemic lupus erythematosus (SLE). The gene's involvement in these conditions highlights its significance in the pathogenesis of autoimmune disorders.</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,1b656cfce91ff9ccec4223703489dab3,40ad2241836485e0bf264bdfb62fd789,62b4bd8f530adae989e4349d1e58f11d,7b454335c2f5651d86f712037a0dc0ff,7c13f41d7349d9d2e56c36e00c0ca2d9,8ce8c356713490cd2c680f505bcd050b,c69c7fb997f95c56cc077b3975f41923,c95d22c2a90e77cd22bd0d280d55b26a,d8a485eb1e9435b083d5ef6a17f06ea5,f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="TNFA">
      <data key="d0">GENE</data>
      <data key="d1">TNFA is a gene encoding the cytokine tumor necrosis factor-alpha, involved in systemic inflammation</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="ACITRETIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Acitretin is a retinoid receptor agonist targeting KRT16, PI3, RARA, RARB, RARG, RBP1, RXRA, RXRB, RXRG, and STAT3, used in the treatment of psoriasis</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="RARA">
      <data key="d0">GENE</data>
      <data key="d1">RARA is a gene encoding retinoic acid receptor alpha, involved in gene expression regulation</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="RARB">
      <data key="d0">GENE</data>
      <data key="d1">RARB is a gene encoding retinoic acid receptor beta, involved in gene expression regulation</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="RARG">
      <data key="d0">GENE</data>
      <data key="d1">RARG is a gene encoding retinoic acid receptor gamma, involved in gene expression regulation</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="RBP1">
      <data key="d0">GENE</data>
      <data key="d1">RBP1 is a gene encoding retinol binding protein 1, involved in vitamin A metabolism</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="RXRA">
      <data key="d0">GENE</data>
      <data key="d1">RXRA is a gene encoding retinoid X receptor alpha, involved in gene expression regulation</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="RXRB">
      <data key="d0">GENE</data>
      <data key="d1">RXRB is a gene encoding retinoid X receptor beta, involved in gene expression regulation</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="RXRG">
      <data key="d0">GENE</data>
      <data key="d1">RXRG is a gene encoding retinoid X receptor gamma, involved in gene expression regulation</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="STAT3">
      <data key="d0">GENE</data>
      <data key="d1">STAT3 is a transcription factor involved in cytokine signalingSTAT3 is a gene encoding signal transducer and activator of transcription 3, involved in cytokine signaling</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="AVACOPAN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Avacopan is a C5&#945; receptor antagonist targeting C5AR1, used in the treatment of autoimmune diseases</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="CLINDAMYCIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Clindamycin is a protein synthesis inhibitor used in the treatment of bacterial infections</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="CYPROTERONE ACETATE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cyproterone acetate is an AR antagonist targeting ADORA1 and AR, used in the treatment of androgen-dependent conditions</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="ADORA1">
      <data key="d0">GENE</data>
      <data key="d1">ADORA1 is a gene encoding adenosine A1 receptor, involved in various physiological processes</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="DOXYCYCLINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Doxycycline is a bacterial 30S ribosomal subunit inhibitor and metalloproteinase inhibitor targeting MMP1, MMP8, and PI3, used in the treatment of bacterial infections</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="MMP8">
      <data key="d0">GENE</data>
      <data key="d1">MMP8 is a gene encoding matrix metallopeptidase 8, involved in the breakdown of extracellular matrixMMP8 is an enzyme involved in the breakdown of extracellular matrix</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="ETANERCEPT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Etanercept is a biopharmaceutical that functions as a TNF antagonist, specifically targeting TNF-&#945; receptors, including TNFRSF1A. It is used in the treatment of autoimmune and inflammatory diseases by inhibiting the activity of tumor necrosis factor (TNF), thereby reducing inflammation and modulating the immune response.</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e,7f559ad7372a4e35e90b43cc67047b0f,a10787d7fbb1307be263e86dc7b33a51,c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="TNFRSF1A">
      <data key="d0">GENE</data>
      <data key="d1">TNFRSF1A is a gene encoding tumor necrosis factor receptor superfamily member 1A, which is involved in the immune response. It is also known by the TNF receptor superfamily nomenclature as TNFR1.</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60,c95d22c2a90e77cd22bd0d280d55b26a</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="GOLIMUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Golimumab is a TNF antagonist and inhibitor that targets tumor necrosis factor (TNF). It is used in the treatment of inflammatory and autoimmune diseases.</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e,c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="INCB 54707">
      <data key="d0">CHEMICAL</data>
      <data key="d1">INCB 54707 is a JAK1 inhibitor targeting JAK1, in early clinical development</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="INFLIXIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Infliximab is a TNF antagonist and inhibitor that targets both IL6 and TNF. It is used in the treatment of inflammatory and autoimmune diseases.</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e,c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="METFORMIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Metformin is an insulin sensitizer targeting ACACB and PRKAB1, used in the treatment of type 2 diabetes</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="ACACB">
      <data key="d0">GENE</data>
      <data key="d1">ACACB is a gene encoding acetyl-CoA carboxylase beta, involved in fatty acid metabolismACACB is an enzyme involved in fatty acid metabolism</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="RIFAMPICIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Rifampicin is an RNA polymerase inhibitor targeting NR1I2, SLCO1A2, SLCO1B1, and SLCO1B3, used in the treatment of bacterial infections</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="SLCO1A2">
      <data key="d0">GENE</data>
      <data key="d1">SLCO1A2 is a transporter involved in drug transportSLCO1A2 is a gene encoding solute carrier organic anion transporter family member 1A2, involved in drug transport</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="SLCO1B1">
      <data key="d0">GENE</data>
      <data key="d1">SLCO1B1 is a gene encoding solute carrier organic anion transporter family member 1B1, involved in drug transportSLCO1B1 is a transporter involved in drug transport</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="SLCO1B3">
      <data key="d0">GENE</data>
      <data key="d1">SLCO1B3 is a transporter involved in drug transportSLCO1B3 is a gene encoding solute carrier organic anion transporter family member 1B3, involved in drug transport</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="SECUKINUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Secukinumab is a human IgG1&#954;, anti&#8211;IL-17A monoclonal antibody that functions as a biologic drug targeting Interleukin-17A (IL-17A). It is administered as an injection and is primarily used in the treatment of autoimmune diseases, including moderate-to-severe atopic dermatitis (AD) and plaque psoriasis. Secukinumab has been extensively investigated for its efficacy in treating moderate to severe atopic dermatitis, making it a significant therapeutic option in the management of these conditions.</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,2cec06c4d46f5ff9ee936a78d8b077cd,48288f3ec2832850282f95d4e38d10e1,c44ec79872ab10cbe7336182f183ff60,cccfd5ff480e281556e2210cd0e5c4b5,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="SPESOLIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Spesolimab is a biologic agent that functions as an IL-36R antagonist, specifically targeting interleukin-36R (IL-36R). It is administered as an injection and is currently in early clinical development. Spesolimab has shown effectiveness in treating a rare form of pustular psoriasis and is also being explored for its potential in the treatment of atopic dermatitis.</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98,c44ec79872ab10cbe7336182f183ff60,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="FSH">
      <data key="d0">PROTEIN</data>
      <data key="d1">FSH is a protein known as follicle-stimulating hormone, involved in reproductive processesFSH is a hormone involved in reproductive processes</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="HCG">
      <data key="d0">PROTEIN</data>
      <data key="d1">HCG is a hormone involved in pregnancyHCG is a protein known as human chorionic gonadotropin, involved in pregnancy</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="LH">
      <data key="d0">PROTEIN</data>
      <data key="d1">LH is a protein known as luteinizing hormone, involved in reproductive processesLH is a hormone involved in reproductive processes</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="VILOBELIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Vilobelimab is a C5&#945; inhibitor targeting C5, in early clinical development</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="C5">
      <data key="d0">GENE</data>
      <data key="d1">C5 is a gene encoding complement component 5, involved in immune response</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="IL-17A">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-17A (Interleukin-17A) is a key Th17-related cytokine involved in the immune response and inflammation. It plays a significant role in the pathogenesis of atopic dermatitis and contributes to inflammatory responses, although its role in the inflammatory responses in Hidradenitis Suppurativa (HS) is considered to be lesser. IL-17A is also targeted by the therapeutic agent secukinumab.</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,2cec06c4d46f5ff9ee936a78d8b077cd,411a4d246f0a9321e52971446a5a0606,41ccc4b41bd57cf2bda4dbb6c7ae4198,523bbfee1ae3b4ecabf9b11d10eea9ff,c44ec79872ab10cbe7336182f183ff60,e340a83f7cba0ea5be731b1f682ea7c7,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="IL-17F">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-17F is a cytokine involved in inflammatory responses</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="IL-17R">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-17R is a receptor for IL-17 cytokines, involved in inflammatory responses</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="IL-36R">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-36R (Interleukin-36 receptor) is a protein involved in the immune response and inflammation. It serves as a receptor for IL-36 cytokines, playing a crucial role in mediating inflammatory responses.</data>
      <data key="d2">849e0980ffd6a7e1cf0b8d3d1fbacd98,c44ec79872ab10cbe7336182f183ff60,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="C5&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">C5&#945; is a component of the complement system involved in immune responses</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="JAK">
      <data key="d0">PROTEIN</data>
      <data key="d1">The JAK family of tyrosine kinases, which includes JAK1, JAK2, JAK3, and TYK2, plays a crucial role in cytokine receptor signaling. These enzymes are integral to the JAK/STAT signaling pathway, which is essential for the action of various cytokines such as IL-4, IL-13, and IL-31. JAK kinases are involved in the pathophysiology of autoimmune diseases, including atopic dermatitis (AD), by mediating immune response signaling pathways. Due to their pivotal role in cytokine signaling, JAK kinases are targeted by JAK inhibitors, which are therapeutic agents designed to modulate immune responses in various autoimmune conditions.</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c,2cec06c4d46f5ff9ee936a78d8b077cd,3df8535e965efb96f5094169610507ff,849e0980ffd6a7e1cf0b8d3d1fbacd98,c44ec79872ab10cbe7336182f183ff60,c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </node>
    <node id="IL-12">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-12 (IL-12) is a cytokine involved in immune and inflammatory responses. It plays a crucial role in driving Th1 cell differentiation and is notably upregulated in atopic dermatitis lesions.</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,c44ec79872ab10cbe7336182f183ff60,e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="IL-23">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-23 (Interleukin-23) is a cytokine involved in the immune response and inflammation. It plays a crucial role in driving Th17 cell differentiation and is upregulated in atopic dermatitis lesions. IL-23 is also a key component of the IL-23&#8211;IL-17 axis, which is implicated in psoriasis and atopic dermatitis.</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,41ccc4b41bd57cf2bda4dbb6c7ae4198,48288f3ec2832850282f95d4e38d10e1,6309eeea565f06479830cec32938abc9,c44ec79872ab10cbe7336182f183ff60,e95d4d15e4f3110c91a3d3fcb5910d06,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="OX40">
      <data key="d0">GENE</data>
      <data key="d1">OX40, also known as TNFRSF4 or CD134, is a co-stimulatory receptor and a member of the TNF receptor superfamily. It is a protein involved in the immune response, particularly in T-cell activation, survival, and functioning. OX40 is expressed predominantly on effector and regulatory T-cells, including CD4+ and CD8+ T cells, and is highly expressed by skin-homing T cells and monocytes in atopic dermatitis (AD). It plays a crucial role in the Th2 pathway and is involved in the pathogenesis of atopic dermatitis, where its expression is increased in AD lesions.

OX40 functions as a checkpoint molecule that potentiates pro-inflammatory T-cell responses and is involved in positive costimulatory pathways. It provides a potent costimulatory signal that enhances T-cell proliferation, survival, memory cell formation, and cytokine secretion. OX40 is a receptor for OX40L (also known as CD134, ACT35, TXGP1L) and is targeted by monoclonal antibodies in clinical trials, including inhibitors like rocatinlimab, for the treatment of atopic dermatitis.

In summary, OX40 is a critical protein in the immune response, particularly in T-cell subsets, and is a target for therapeutic interventions in autoimmune diseases such as atopic dermatitis.</data>
      <data key="d2">100dd7646c10899301b3c0631183da16,1412a7a7fef5f18cc09a030b97b18e13,1b656cfce91ff9ccec4223703489dab3,2cec06c4d46f5ff9ee936a78d8b077cd,2e0cdefd62bed7c674d7fb93ef336c2b,2e9a8d71f6bd251a0b13458c39e69746,3287c502f10f4651d2f56bf39ee7bb7a,3df8535e965efb96f5094169610507ff,44f2592262cac835560b4c149fee8d2b,475995d7d211bbfde6d8ba52f324d688,4842292208575bd45b2b5998513dd087,4d0e8ae9371a435885994b4161126bc3,6309eeea565f06479830cec32938abc9,68015074236b0144899baa38d01ae467,691cb2e23ac3c6e591129d16714f8ef8,6b099960b0a39866e3aa6b908f1886e4,78e26c66107dba37ac4bab65406b43a0,7c13f41d7349d9d2e56c36e00c0ca2d9,849e0980ffd6a7e1cf0b8d3d1fbacd98,855c455b4c9592746834ee3a4e0e6b81,89dbac0da39e4de2b602052cd792b90d,8ce8c356713490cd2c680f505bcd050b,b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6,c95d22c2a90e77cd22bd0d280d55b26a,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="OX40L">
      <data key="d0">GENE</data>
      <data key="d1">OX40L, also known as OX40 ligand, TNFSF4, or CD252, is a protein that plays a crucial role in the immune response and inflammation. It is a member of the TNF superfamily and is encoded by the TNFSF4 gene. OX40L is primarily expressed on activated antigen-presenting cells (APCs) such as dendritic cells (DCs) and endothelial cells, and it is highly expressed by monocytes. This protein is involved in the positive costimulatory pathways of T cells, enhancing T cell proliferation, survival, and cytokine production. 

OX40L functions as a ligand for the OX40 receptor (CD134), which is found on T cells. The interaction between OX40L and OX40 is pivotal for T-cell activation, survival, and memory cell formation. This binding potentiates pro-inflammatory T-cell responses and plays a central role in immune response modulation. OX40L is also involved in B cell proliferation and is targeted by monoclonal antibodies in clinical trials for various inflammatory and autoimmune conditions, including atopic dermatitis (AD). 

In the context of atopic dermatitis, OX40L is co-localized with OX40 in the skin of patients, indicating its significant role in the pathogenesis of this condition. It is also analyzed on the cell surface of peripheral blood mononuclear cells (PBMCs) from patients with AD and healthy controls (HC). Due to its critical role in immune responses, OX40L is a target for therapeutic interventions aimed at modulating immune activity in autoimmune diseases.</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,100dd7646c10899301b3c0631183da16,1412a7a7fef5f18cc09a030b97b18e13,1b656cfce91ff9ccec4223703489dab3,2cec06c4d46f5ff9ee936a78d8b077cd,2e9a8d71f6bd251a0b13458c39e69746,3287c502f10f4651d2f56bf39ee7bb7a,348f2797841cbef27311b03f2cd788dd,3df8535e965efb96f5094169610507ff,44f2592262cac835560b4c149fee8d2b,4842292208575bd45b2b5998513dd087,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,6309eeea565f06479830cec32938abc9,68015074236b0144899baa38d01ae467,691cb2e23ac3c6e591129d16714f8ef8,6b099960b0a39866e3aa6b908f1886e4,78e26c66107dba37ac4bab65406b43a0,7c13f41d7349d9d2e56c36e00c0ca2d9,855c455b4c9592746834ee3a4e0e6b81,89dbac0da39e4de2b602052cd792b90d,8ce8c356713490cd2c680f505bcd050b,9867d43adab0ba5db44961fae4863eee,b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6,c95d22c2a90e77cd22bd0d280d55b26a,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c,e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="ROCATINLIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Rocatinlimab, formerly known as AMG 451/KHK4083, is a fully human, non-fucosylated, immunoglobulin G1 (IgG1) anti-OX40 monoclonal antibody. It selectively depletes sOX40+ activated T-cells and is being developed primarily for the treatment of moderate-to-severe atopic dermatitis. Rocatinlimab has shown positive results in a phase-II experiment and is currently being evaluated in a phase 3 trial for its efficacy in treating head and neck disease. This biologic drug targets OX-40 and is under investigation in clinical trials for its potential benefits in treating atopic dermatitis.</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,3287c502f10f4651d2f56bf39ee7bb7a,475995d7d211bbfde6d8ba52f324d688,4842292208575bd45b2b5998513dd087,b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6,cccfd5ff480e281556e2210cd0e5c4b5,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="AMLITELIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Amlitelimab, also known as KY1005/SAR445229, is a non-depleting IgG4 human anti-OX40L monoclonal antibody that targets the OX40-OX40L pathway. It is being developed for the treatment of moderate-to-severe atopic dermatitis. Amlitelimab functions by blocking the interaction with OX40, thereby inhibiting the OX40-OX40L pathway. This mechanism of action helps reduce IL-22 serum levels, contributing to its therapeutic effects in atopic dermatitis.</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="ATOPIC DERMATITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Atopic Dermatitis (AD), also known as eczema, is a chronic, systemic, inflammatory skin disease characterized by itchy, red, swollen, and cracked skin. It frequently develops before the onset of allergic rhinitis or asthma and is associated with these conditions, dominated by Th2 cells. AD is marked by persistent itch and significant redness, and it has a complex pathophysiology with a wide spectrum of clinical phenotypes. This chronically relapsing condition has a substantial impact on the patient&#8217;s quality of life, often presenting with eczematous lesions and skin irritation.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,08e39958b85d84950ab7173daab9111b,1596d061dbe1a1c9e8f31a02a21e5524,2e0cdefd62bed7c674d7fb93ef336c2b,348f2797841cbef27311b03f2cd788dd,3dfbb4c51838e0951f53ce951395225f,48288f3ec2832850282f95d4e38d10e1,5f37466ca41c9b8b06ed8be0303d49f2,68015074236b0144899baa38d01ae467,691cb2e23ac3c6e591129d16714f8ef8,693a2aac101eaaadf92614317a1e4da8,6ada075e562abd7bd445164e9fc309b4,83eb9003d42977bb83fea1d123dd5ab9,b28eeca0ff01a7715947d55a04978a43,b2aae16813e647959b783a39ef9a19a7,cccfd5ff480e281556e2210cd0e5c4b5,df74aa1b86eeeb811ca5586767ae3a71,e075bccd45593ae008b2ce7f9ed8ff6c,e9841b88c9fab58c5175af409653da50,f1897c89e321a3a80924fd72a56e90df,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="PRURITUS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Pruritus, commonly known as itching, is a medical term for a severe itching sensation that significantly impacts the quality of life of atopic dermatitis (AD) patients. It is a symptom characterized by intense itching of the skin, often associated with inflammatory skin conditions such as atopic dermatitis. Pruritus leads to scratching and is frequently measured using the NRS score in clinical settings, particularly in patients treated with medications like rocatinlimab.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,08e39958b85d84950ab7173daab9111b,143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,28f548554737fcc026b968db6bbafa30,3287c502f10f4651d2f56bf39ee7bb7a,3ce96e927d65736b305f792977fed4b9,3df8535e965efb96f5094169610507ff,3ea70e257330c812b52334ca1f90d807,442e7fad2fab75fa2449309783294d89,475995d7d211bbfde6d8ba52f324d688,4842292208575bd45b2b5998513dd087,6309eeea565f06479830cec32938abc9,691cb2e23ac3c6e591129d16714f8ef8,90f4809673ca34628b0e607908f0bf0b,a867a1e73cef039eb3f28e072463b838,b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6,e075bccd45593ae008b2ce7f9ed8ff6c,f1897c89e321a3a80924fd72a56e90df,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="TOPICAL CORTICOSTEROIDS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Topical corticosteroids (TCSs) are a class of steroid hormones used to reduce inflammation in skin diseases. They are anti-inflammatory medications specifically utilized to treat atopic dermatitis (AD) flares. As part of the topical therapy regimen, topical corticosteroids play a crucial role in managing AD. Additionally, they are often used in combination with tralokinumab for the treatment of AD, enhancing the overall therapeutic efficacy.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,2cec06c4d46f5ff9ee936a78d8b077cd,8246ea974dfb00cb5e3d984004e21a9e,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="CALCINEURIN INHIBITORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Calcineurin Inhibitors are medications used to suppress the immune system and reduce inflammation. They are part of the topical therapy used in the treatment of atopic dermatitis. Calcineurin inhibitors, such as pimecrolimus and tacrolimus, are specifically utilized as topical treatments for atopic dermatitis.</data>
      <data key="d2">693a2aac101eaaadf92614317a1e4da8,c46e8b6ee0c29e37b7f18c42558d7a3e,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="CRISABOROLE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Crisaborole is a topical phosphodiesterase-4 (PDE4) inhibitor approved for the treatment of mild-to-moderate atopic dermatitis (AD). It is used as a topical ointment to manage the symptoms of this skin condition.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,286730b1c1f680ac465cc21d522fda0c,442e7fad2fab75fa2449309783294d89,693a2aac101eaaadf92614317a1e4da8,90f4809673ca34628b0e607908f0bf0b,e075bccd45593ae008b2ce7f9ed8ff6c,e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="PHOTOTHERAPY">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Phototherapy is a treatment approach for Atopic Dermatitis that involves the use of ultraviolet light. It is a recognized treatment option for managing the symptoms of this chronic skin condition.</data>
      <data key="d2">693a2aac101eaaadf92614317a1e4da8,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="IMMUNOSUPPRESSANTS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Immunosuppressants are systemic agents used in the treatment of atopic dermatitis. Conventional systemic immunosuppressants, while employed in managing this condition, may have limited efficacy and present long-term toxicity. Additionally, these agents often come with tolerability issues, which can complicate their use in patients.</data>
      <data key="d2">693a2aac101eaaadf92614317a1e4da8,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="TRALOKINUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Tralokinumab is a fully humanized IgG4&#955; monoclonal antibody that specifically targets interleukin-13 (IL-13). It functions as an IL-13 antagonist, preventing IL-13 from interacting with its receptors, IL-13R&#945;1 and IL-13R&#945;2. This biologic drug is used in the treatment of atopic dermatitis (AD) and has shown safety and efficacy, particularly when used in conjunction with topical corticosteroids. Tralokinumab is administered as a biologic injection and is currently approved for the treatment of AD. It is also under development and in advanced-stage clinical trials for further evaluation in atopic dermatitis treatment.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,0ba9fbea14e0c2c1d01a12ffaacfda9b,104cc78517b2eca2e9cb7e00de1fe4b0,1596d061dbe1a1c9e8f31a02a21e5524,286730b1c1f680ac465cc21d522fda0c,28f548554737fcc026b968db6bbafa30,2cec06c4d46f5ff9ee936a78d8b077cd,3df8535e965efb96f5094169610507ff,3dfbb4c51838e0951f53ce951395225f,48de7eebab3f3b418feb35a152df38fd,693a2aac101eaaadf92614317a1e4da8,78e26c66107dba37ac4bab65406b43a0,8246ea974dfb00cb5e3d984004e21a9e,96e553a44a27e728c27c4892045ec5c2,cccfd5ff480e281556e2210cd0e5c4b5,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="ABROCITINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Abrocitinib is a small molecule drug developed by Pfizer, targeting JAK1. It is a JAK1-selective inhibitor used in the treatment of autoimmune diseases, specifically atopic dermatitis (AD). Abrocitinib is licensed for treating moderate to severe atopic dermatitis and functions as a targeted therapy by inhibiting Janus kinase (JAK), thereby addressing the underlying inflammatory processes associated with the condition.</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,3df8535e965efb96f5094169610507ff,6ada075e562abd7bd445164e9fc309b4,a867a1e73cef039eb3f28e072463b838,cccfd5ff480e281556e2210cd0e5c4b5,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="BARICITINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Baricitinib is an oral small molecule drug developed by Lilly, targeting Janus kinase 1 and 2 (JAK1/JAK2). It is a JAK inhibitor licensed and approved for the treatment of moderate to severe atopic dermatitis (AD). Additionally, Baricitinib is used in the treatment of autoimmune diseases, including rheumatoid arthritis, and is being studied for its efficacy in treating atopic dermatitis.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,1596d061dbe1a1c9e8f31a02a21e5524,2cec06c4d46f5ff9ee936a78d8b077cd,3df8535e965efb96f5094169610507ff,6ada075e562abd7bd445164e9fc309b4,a867a1e73cef039eb3f28e072463b838,c46e8b6ee0c29e37b7f18c42558d7a3e,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c,e95d4d15e4f3110c91a3d3fcb5910d06,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="LEBRIKIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Lebrikizumab is a humanized IgG4&#954; monoclonal antibody that selectively binds to and inhibits interleukin-13 (IL-13) with high affinity. It is primarily used in the treatment of atopic dermatitis (AD) and is currently in advanced stages of clinical development for this condition. Additionally, Lebrikizumab has been used in the treatment of asthma and is being explored for its potential in treating other conditions associated with IL-13. As a biologic drug, it is administered via injection and functions by blocking IL-13 signaling, thereby mitigating the inflammatory processes involved in these diseases.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,0ba9fbea14e0c2c1d01a12ffaacfda9b,104cc78517b2eca2e9cb7e00de1fe4b0,28f548554737fcc026b968db6bbafa30,3df8535e965efb96f5094169610507ff,3dfbb4c51838e0951f53ce951395225f,48de7eebab3f3b418feb35a152df38fd,693a2aac101eaaadf92614317a1e4da8,96e553a44a27e728c27c4892045ec5c2,b19f42c9497f71b231222cd953036d6b,cccfd5ff480e281556e2210cd0e5c4b5,e075bccd45593ae008b2ce7f9ed8ff6c,e95d4d15e4f3110c91a3d3fcb5910d06,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="NEMOLIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Nemolizumab is a biologic drug developed by Galderma, targeting the IL-31 receptor. It is a humanized IgG2&#954;, anti-IL-31R&#945; monoclonal antibody that mitigates IL-31&#8211;dependent processes by antagonizing its cognate receptor. Nemolizumab is specifically designed to control inflammation and pruritus associated with atopic dermatitis (AD). As an IL-31 inhibitor, it is in an advanced stage of clinical development for the treatment of atopic dermatitis, aiming to reduce pruritus and improve patient outcomes.</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,3df8535e965efb96f5094169610507ff,cccfd5ff480e281556e2210cd0e5c4b5,e075bccd45593ae008b2ce7f9ed8ff6c,f14a13d54127c3baadeb0b34d40928c9,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="TH2">
      <data key="d0">CELL</data>
      <data key="d1">T helper 2 (TH2) cells are a subset of T helper cells that play a crucial role in the immune response, particularly in humoral immunity and allergic reactions. These cells are involved in the adaptive immune response, especially in conditions such as atopic dermatitis, where they lead to IgE sensitization and cutaneous inflammation. TH2 cells are known for their role in immune polarization and are central to the process of M2 macrophage polarization. They produce key cytokines, including interleukin-4 (IL-4) and interleukin-13 (IL-13), which are influential in the immune response against extracellular parasites and in allergic airway inflammation. Additionally, TH2 cells are associated with the acute phase of atopic dermatitis and are involved in cytokine production in this condition. They also contribute to central memory cell growth, further highlighting their importance in the immune system.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,05c97152fe02249153103be341d65b67,0829313703a7d2bae5436a9ee542334d,143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,2cec06c4d46f5ff9ee936a78d8b077cd,2e0cdefd62bed7c674d7fb93ef336c2b,3df8535e965efb96f5094169610507ff,3ea70e257330c812b52334ca1f90d807,41ccc4b41bd57cf2bda4dbb6c7ae4198,44f2592262cac835560b4c149fee8d2b,475995d7d211bbfde6d8ba52f324d688,48288f3ec2832850282f95d4e38d10e1,5ec1ebf4e260eb1f8fda8acdf06cd39e,5f37466ca41c9b8b06ed8be0303d49f2,6309eeea565f06479830cec32938abc9,6ada075e562abd7bd445164e9fc309b4,78e26c66107dba37ac4bab65406b43a0,83eb9003d42977bb83fea1d123dd5ab9,855c455b4c9592746834ee3a4e0e6b81,8ce8c356713490cd2c680f505bcd050b,a867a1e73cef039eb3f28e072463b838,b201c6ff3e22b2475c8c59260a0eb6a7,c46e8b6ee0c29e37b7f18c42558d7a3e,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="TH22">
      <data key="d0">CELL</data>
      <data key="d1">T helper 22 (TH22) cells are a subset of T-helper cells involved in the adaptive immune response, particularly in pro-inflammatory responses. These cells play a significant role in the immune response and are specifically implicated in skin diseases, including atopic dermatitis. TH22 cells are modulated during the acute phase of atopic dermatitis, highlighting their importance in the pathophysiology of this condition. The TH22 pathway is a crucial component of the immune system, contributing to both immune responses and inflammation.</data>
      <data key="d2">143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524,2cec06c4d46f5ff9ee936a78d8b077cd,41ccc4b41bd57cf2bda4dbb6c7ae4198,475995d7d211bbfde6d8ba52f324d688,83eb9003d42977bb83fea1d123dd5ab9,b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6,c46e8b6ee0c29e37b7f18c42558d7a3e,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="TH1">
      <data key="d0">CELL</data>
      <data key="d1">TH1 cells, also known as T helper 1 cells, are a subset of T helper cells that play a crucial role in the immune response. They are involved in cellular immune responses, particularly against intracellular pathogens. TH1 cells are part of the adaptive immune response and are known for their role in producing cytokines, especially interferon-gamma, which is pivotal in pro-inflammatory responses. These cells are also associated with inflammation and are activated in the chronic phase of atopic dermatitis. Additionally, the differentiation of TH1 cells can be inhibited by impaired TNF/TNFR2 signaling. Overall, TH1 cells are integral to the immune response and inflammation, contributing significantly to the body's defense mechanisms.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,1596d061dbe1a1c9e8f31a02a21e5524,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,41ccc4b41bd57cf2bda4dbb6c7ae4198,475995d7d211bbfde6d8ba52f324d688,48288f3ec2832850282f95d4e38d10e1,5ec1ebf4e260eb1f8fda8acdf06cd39e,5f37466ca41c9b8b06ed8be0303d49f2,83eb9003d42977bb83fea1d123dd5ab9,8ce8c356713490cd2c680f505bcd050b,b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="FILAGGRIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Filaggrin (FLG) is a protein encoded by the FLG gene, which plays a crucial role in the formation and maintenance of the skin barrier. It is involved in epidermal barrier function and binds to keratin fibers in epithelial cells. Filaggrin is essential for the structural integrity of the epidermis and is a terminal marker of epidermal differentiation. Mutations in the FLG gene are strongly associated with atopic dermatitis (AD), a condition characterized by impaired skin barrier function. In AD lesions, filaggrin levels are reduced, and its expression can be downregulated by cytokines such as IL-4 and IL-22. Additionally, the expression of filaggrin can be restored by coal tar binding to the aryl hydrocarbon receptor (AhR). Overall, filaggrin is a critical protein for skin health, and its dysfunction is a key factor in the pathogenesis of atopic dermatitis.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524,28f548554737fcc026b968db6bbafa30,3ea70e257330c812b52334ca1f90d807,48288f3ec2832850282f95d4e38d10e1,4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd,6059a6e2710b7df94c6a09e5eb7b024a,6ada075e562abd7bd445164e9fc309b4,b19f42c9497f71b231222cd953036d6b,e075bccd45593ae008b2ce7f9ed8ff6c,f2aa3fd6ae3f1853347874c50afb60ea,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="LORICRIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Loricrin is a major protein component of the cornified cell envelope in the epidermis, playing a crucial role in the formation and integrity of the skin barrier. It is involved in epidermal barrier function and serves as a terminal marker of epidermal differentiation. Loricrin is downregulated by cytokines IL-4 and IL-13, and its expression is notably reduced in conditions such as atopic dermatitis, where it is suppressed in chronic cases.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,1596d061dbe1a1c9e8f31a02a21e5524,28f548554737fcc026b968db6bbafa30,4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd,b19f42c9497f71b231222cd953036d6b,e075bccd45593ae008b2ce7f9ed8ff6c,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="TSLP">
      <data key="d0">PROTEIN</data>
      <data key="d1">Thymic stromal lymphopoietin (TSLP) is a cytokine that plays a crucial role in the immune response and inflammation. It is an epidermis-derived alarmin cytokine, particularly involved in the pathogenesis of atopic dermatitis (AD) and eosinophilic esophagitis (EoE). TSLP is highly expressed in skin epithelial cells in AD, where it contributes to generating type 2 immune responses and inducing itch. This cytokine activates antigen-presenting cells, including dendritic cells (DCs) and endothelial cells, enhancing T-cell adhesion and migration during inflammation. Additionally, TSLP's expression can be significantly reduced with the topical administration of PLG-based nanoparticles. Overall, TSLP is a key regulator of immune responses, particularly in conditions characterized by Th2 cell activation.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,27a7e95c7d3ad59a948aa46741fee456,286730b1c1f680ac465cc21d522fda0c,2cec06c4d46f5ff9ee936a78d8b077cd,3df8535e965efb96f5094169610507ff,3ea70e257330c812b52334ca1f90d807,41ccc4b41bd57cf2bda4dbb6c7ae4198,4842292208575bd45b2b5998513dd087,6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98,bddc3b1a7f098e71f0aa64adec047124,d4797ed1483e5057bcd8301eaa509d5e,e075bccd45593ae008b2ce7f9ed8ff6c,e9841b88c9fab58c5175af409653da50,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="IL-25">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-25 (IL-25) is a cytokine that plays a multifaceted role in the immune response, particularly in the activation of type 2 (Th2) immune responses. It is produced by various cell types, including mast cells and keratinocytes, and functions as an epidermis-derived alarmin. IL-25 is central to the pathogenesis of Atopic Dermatitis (AD), where it initiates and perpetuates skin-derived immune responses and inflammation. This cytokine is crucial in the immune response associated with AD, highlighting its importance in both the initiation and maintenance of inflammatory processes in the skin.</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807,41ccc4b41bd57cf2bda4dbb6c7ae4198,4842292208575bd45b2b5998513dd087,6309eeea565f06479830cec32938abc9,691cb2e23ac3c6e591129d16714f8ef8,6ada075e562abd7bd445164e9fc309b4,849e0980ffd6a7e1cf0b8d3d1fbacd98,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="IL-33">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-33 (Interleukin-33) is a cytokine involved in the immune response and inflammation. It is a member of the IL-1 family and plays a significant role in both innate and adaptive immune responses. IL-33 is produced by barrier-disrupted keratinocytes and acts as an epidermis-derived alarmin, particularly in conditions such as atopic dermatitis (AD). It stimulates type 2 immune responses by inducing the production of IL-5 and IL-13 in type 2 innate lymphoid cells (ILC2), and also enhances type 1 responses through the induction of IFN-&#947;. Additionally, IL-33 contributes to epidermal barrier dysfunction by downregulating filaggrin expression. Overall, IL-33 is a crucial mediator in the immune system, particularly in the context of skin barrier integrity and inflammatory diseases.</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807,41ccc4b41bd57cf2bda4dbb6c7ae4198,4842292208575bd45b2b5998513dd087,6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98,a10787d7fbb1307be263e86dc7b33a51,e075bccd45593ae008b2ce7f9ed8ff6c,e9841b88c9fab58c5175af409653da50,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="IGE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Immunoglobulin E (IgE) is an antibody that plays a crucial role in allergic reactions and the immune response to parasites. It is produced by plasma cells and is regulated by cytokines such as IL-4 and IL-13. IgE is a hallmark of the Th2 immune response and is commonly elevated in up to 80% of patients with atopic dermatitis (AD). It is involved in sensitization to environmental allergens and is expressed on Langerhans cells and inflammatory dendritic epidermal cells. Although IgE is frequently measured in AD patients, its exact role in the pathophysiology of the disease remains unclear.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,0829313703a7d2bae5436a9ee542334d,143d2dc302af5606656797bff162e23e,27a7e95c7d3ad59a948aa46741fee456,28f548554737fcc026b968db6bbafa30,348f2797841cbef27311b03f2cd788dd,3dfbb4c51838e0951f53ce951395225f,41ccc4b41bd57cf2bda4dbb6c7ae4198,48288f3ec2832850282f95d4e38d10e1,4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd,6309eeea565f06479830cec32938abc9,691cb2e23ac3c6e591129d16714f8ef8,6aef5adb1be227170f66c76a292c25e5,6b099960b0a39866e3aa6b908f1886e4,83eb9003d42977bb83fea1d123dd5ab9,849e0980ffd6a7e1cf0b8d3d1fbacd98,89dbac0da39e4de2b602052cd792b90d,c46e8b6ee0c29e37b7f18c42558d7a3e,d2c44662af9752fc9f82c86121ede7c0,e075bccd45593ae008b2ce7f9ed8ff6c,e9841b88c9fab58c5175af409653da50,f2aa3fd6ae3f1853347874c50afb60ea</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="PLASMA CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Plasma cells are a type of differentiated B cell that produce large volumes of antibodies, including immunoglobulin E (IgE). They are a subset of white blood cells and play a crucial role in the immune response by producing antibodies. Plasma cells are identified as a potential therapeutic target in Hidradenitis Suppurativa (HS) and are predominant in HS skin, indicating their involvement in the pathogenesis of the disease. Additionally, in conditions such as atopic dermatitis, plasma cells produce IgE in response to stimulation by interleukins IL-4 and IL-13. These immune cells are also found in the skin, further highlighting their significance in various dermatological conditions.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,2e0cdefd62bed7c674d7fb93ef336c2b,411a4d246f0a9321e52971446a5a0606,4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd,4cf23e218b6aab3c77115173b5c7c2fd,523bbfee1ae3b4ecabf9b11d10eea9ff,b62ecc47bf54393bc78dd65986b949d6,bae090d8a29c15868ba1c4f29ae79e99,e075bccd45593ae008b2ce7f9ed8ff6c</data>
      <data key="d3">CELL</data>
    </node>
    <node id="HISTAMINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Histamine is a compound involved in local immune responses and allergic reactions. It plays a significant role in pruritus, which is the sensation of itching, and this effect is amplified by IL-31 in atopic dermatitis.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,3dfbb4c51838e0951f53ce951395225f,4842292208575bd45b2b5998513dd087,e075bccd45593ae008b2ce7f9ed8ff6c</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="EASI">
      <data key="d0">SYMPTOM</data>
      <data key="d1">The Eczema Area and Severity Index (EASI) is a clinical tool and scoring system used to assess the severity and extent of atopic dermatitis (AD) and eczema. It is widely utilized in both clinical and research settings to evaluate disease severity, providing a standardized measure for the extent and severity of these skin conditions. EASI is instrumental in monitoring disease progression and treatment efficacy in patients with atopic dermatitis and eczema.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,0829313703a7d2bae5436a9ee542334d,0ba9fbea14e0c2c1d01a12ffaacfda9b,100dd7646c10899301b3c0631183da16,104cc78517b2eca2e9cb7e00de1fe4b0,143d2dc302af5606656797bff162e23e,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,28f548554737fcc026b968db6bbafa30,2cec06c4d46f5ff9ee936a78d8b077cd,3287c502f10f4651d2f56bf39ee7bb7a,3ea70e257330c812b52334ca1f90d807,442e7fad2fab75fa2449309783294d89,475995d7d211bbfde6d8ba52f324d688,48288f3ec2832850282f95d4e38d10e1,6309eeea565f06479830cec32938abc9,78e26c66107dba37ac4bab65406b43a0,8246ea974dfb00cb5e3d984004e21a9e,849e0980ffd6a7e1cf0b8d3d1fbacd98,89dbac0da39e4de2b602052cd792b90d,b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6,c46e8b6ee0c29e37b7f18c42558d7a3e,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c,f1897c89e321a3a80924fd72a56e90df,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="IL-31">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-31 (Interleukin-31) is a cytokine produced by T helper 2 (Th2) cells and mature dendritic cells. It plays a significant role in the immune response and inflammation. IL-31 is particularly involved in the pathogenesis and pathophysiology of atopic dermatitis (AD), where it is associated with pruritus (itching). Known as the "itch cytokine," IL-31 induces pruritus in AD patients and alters the expression of barrier proteins, contributing to the disease's symptoms.</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,286730b1c1f680ac465cc21d522fda0c,2cec06c4d46f5ff9ee936a78d8b077cd,3df8535e965efb96f5094169610507ff,41ccc4b41bd57cf2bda4dbb6c7ae4198,4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd,6ada075e562abd7bd445164e9fc309b4,849e0980ffd6a7e1cf0b8d3d1fbacd98,a867a1e73cef039eb3f28e072463b838,b19f42c9497f71b231222cd953036d6b,e075bccd45593ae008b2ce7f9ed8ff6c,e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9,f2aa3fd6ae3f1853347874c50afb60ea,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="IL-4R&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-4R&#945; (Interleukin-4 receptor alpha) is a protein that serves as a critical component of both type 1 and type 2 heterodimeric receptors for interleukin-4 (IL-4) and interleukin-13 (IL-13). It functions as a subunit of the interleukin-4 receptor complex and is involved in the signaling pathways of both IL-4 and IL-13, playing a significant role in the modulation and regulation of immune responses. IL-4R&#945; is a receptor chain common to type I and type II receptors for IL-4 and IL-13, mediating their effects in the immune system. Additionally, IL-4R&#945; is the receptor subunit targeted by the monoclonal antibody dupilumab, which is used in the treatment of atopic dermatitis.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,104cc78517b2eca2e9cb7e00de1fe4b0,1596d061dbe1a1c9e8f31a02a21e5524,28f548554737fcc026b968db6bbafa30,3df8535e965efb96f5094169610507ff,48de7eebab3f3b418feb35a152df38fd,693a2aac101eaaadf92614317a1e4da8,78e26c66107dba37ac4bab65406b43a0,96e553a44a27e728c27c4892045ec5c2,b19f42c9497f71b231222cd953036d6b,e075bccd45593ae008b2ce7f9ed8ff6c,e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="TH2 CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Th2 cells, or T helper 2 cells, are a subset of T-helper cells involved in the immune response. They play a significant role in allergic reactions and inflammation, particularly in conditions such as atopic dermatitis, where they are known to dominate. Th2 cells are crucial in the production of cytokines like IL-4, IL-13, and IL-31, which are essential for their development and function. Additionally, Th2 cells are influenced by OX40-OX40L signaling and are implicated in fibrosis. Their activity is stimulated by cytokines IL-4 and IL-13, further highlighting their importance in the immune response.</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,1b656cfce91ff9ccec4223703489dab3,41ccc4b41bd57cf2bda4dbb6c7ae4198,4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd,691cb2e23ac3c6e591129d16714f8ef8,7c13f41d7349d9d2e56c36e00c0ca2d9,e075bccd45593ae008b2ce7f9ed8ff6c,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="TH22 CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Th22 cells are a subtype of T helper cells involved in the immune response and inflammation. Specifically, Th22 cells play a significant role in the immune response in atopic dermatitis.</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="TH17 CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Th17 cells are a subtype of T helper cells involved in the immune response and inflammation. They play a variable role in the immune response, particularly in conditions such as atopic dermatitis.</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="TH1 CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Th1 cells are a subset of T helper cells involved in the immune response, particularly in the production of cytokines like IFN-&#947;. They play a significant role in inflammation and are notably involved in the immune response in chronic atopic dermatitis.</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198,4842292208575bd45b2b5998513dd087,7c13f41d7349d9d2e56c36e00c0ca2d9,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="INTERCELLULAR LIPIDS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Intercellular lipids are involved in skin barrier function and are disrupted in atopic dermatitis</data>
      <data key="d2">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="TIGHT JUNCTIONS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Tight junctions are involved in skin barrier function and are disrupted in atopic dermatitis</data>
      <data key="d2">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="EPIDERMIS">
      <data key="d0">TISSUE</data>
      <data key="d1">The epidermis is the outermost layer of the skin, providing a crucial barrier to infection and regulating water loss. It is involved in barrier function and is notably affected in conditions such as atopic dermatitis (AD). Higher TAC levels have been observed in the epidermis when using PLG-based nanoparticles. During sample preparation for single-cell RNA sequencing (scRNA-Seq), the epidermis is separated for analysis.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,1596d061dbe1a1c9e8f31a02a21e5524,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,27a7e95c7d3ad59a948aa46741fee456,3ce96e927d65736b305f792977fed4b9,41ccc4b41bd57cf2bda4dbb6c7ae4198,442e7fad2fab75fa2449309783294d89,48288f3ec2832850282f95d4e38d10e1,b62ecc47bf54393bc78dd65986b949d6,bddc3b1a7f098e71f0aa64adec047124,c46e8b6ee0c29e37b7f18c42558d7a3e,e075bccd45593ae008b2ce7f9ed8ff6c,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="ALARMIN CYTOKINES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Alarmin cytokines are rapidly released by keratinocytes in response to tissue damage in atopic dermatitis</data>
      <data key="d2">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="T-HELPER (TH)2 CELLS">
      <data key="d0">CELL</data>
      <data key="d1">T-helper (Th)2 cells are a subset of T-cells involved in the immune response, particularly in the production of cytokines like IL-4, IL-13, and IL-31</data>
      <data key="d2">4842292208575bd45b2b5998513dd087</data>
    </node>
    <node id="EPIDERMAL BARRIER">
      <data key="d0">TISSUE</data>
      <data key="d1">The epidermal barrier is the outermost layer of the skin that protects against environmental damage. It is a tissue structure that is crucial for maintaining skin integrity and preventing external harm. In the context of atopic dermatitis (AD), the epidermal barrier is significantly compromised, leading to its dysfunction. This disruption contributes to the pathophysiology of the disease. The dysfunction of the epidermal barrier in AD is influenced by cytokines such as IL-4 and IL-13. Consequently, restoring the epidermal barrier is a targeted approach in the treatment of atopic dermatitis.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524,3ce96e927d65736b305f792977fed4b9,4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd,6059a6e2710b7df94c6a09e5eb7b024a,693a2aac101eaaadf92614317a1e4da8,6ada075e562abd7bd445164e9fc309b4,f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="IL-22">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-22 (Interleukin-22) is a cytokine that plays a significant role in the immune response and inflammation, particularly in the skin. It contributes to epidermal hyperplasia and inhibits keratinocyte differentiation. IL-22 is involved in the pathogenesis and pathophysiology of atopic dermatitis (AD), with its serum levels correlating with disease severity, especially in chronic lesions. Additionally, IL-22 is associated with psoriasis and is being explored in clinical studies for this condition. It is also part of the transcriptomic signature in AD and is involved in the proliferation and downregulation of filaggrin (FLG) in keratinocytes.</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,286730b1c1f680ac465cc21d522fda0c,2cec06c4d46f5ff9ee936a78d8b077cd,3df8535e965efb96f5094169610507ff,41ccc4b41bd57cf2bda4dbb6c7ae4198,48288f3ec2832850282f95d4e38d10e1,4842292208575bd45b2b5998513dd087,6309eeea565f06479830cec32938abc9,6ada075e562abd7bd445164e9fc309b4,849e0980ffd6a7e1cf0b8d3d1fbacd98,a867a1e73cef039eb3f28e072463b838,b19f42c9497f71b231222cd953036d6b,b876251511f570468eb5b6ee6a239cc6,dc905ba8b6eb7d84cf2776303211010d,e9841b88c9fab58c5175af409653da50,f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="AD">
      <data key="d0">DISEASE</data>
      <data key="d1">Atopic Dermatitis (AD), also known as atopic dermatitis, is a chronic inflammatory skin disease characterized by itchy and inflamed skin. It is a complex disorder with systemic impact and comorbidities, often associated with atopic conditions. AD is marked by pruritus, epidermal barrier dysfunction, and dry, sensitive, and highly permeable skin. As an autoimmune disease, it involves chronic inflammation and dysfunction in multiple immune pathways, leading to itch-scratch cycles and chronic eczematous skin lesions. This dermatological illness significantly impacts the quality of life and can be treated with various formulations and drugs.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,0829313703a7d2bae5436a9ee542334d,0ba9fbea14e0c2c1d01a12ffaacfda9b,100dd7646c10899301b3c0631183da16,104cc78517b2eca2e9cb7e00de1fe4b0,1412a7a7fef5f18cc09a030b97b18e13,143d2dc302af5606656797bff162e23e,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,27a7e95c7d3ad59a948aa46741fee456,286730b1c1f680ac465cc21d522fda0c,28f548554737fcc026b968db6bbafa30,2cec06c4d46f5ff9ee936a78d8b077cd,2e9a8d71f6bd251a0b13458c39e69746,3287c502f10f4651d2f56bf39ee7bb7a,3ce96e927d65736b305f792977fed4b9,3df8535e965efb96f5094169610507ff,3ea70e257330c812b52334ca1f90d807,41ccc4b41bd57cf2bda4dbb6c7ae4198,442e7fad2fab75fa2449309783294d89,475995d7d211bbfde6d8ba52f324d688,4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd,6059a6e2710b7df94c6a09e5eb7b024a,6309eeea565f06479830cec32938abc9,6aef5adb1be227170f66c76a292c25e5,6b099960b0a39866e3aa6b908f1886e4,78e26c66107dba37ac4bab65406b43a0,8246ea974dfb00cb5e3d984004e21a9e,849e0980ffd6a7e1cf0b8d3d1fbacd98,89dbac0da39e4de2b602052cd792b90d,90f4809673ca34628b0e607908f0bf0b,96e553a44a27e728c27c4892045ec5c2,a867a1e73cef039eb3f28e072463b838,b19f42c9497f71b231222cd953036d6b,b201c6ff3e22b2475c8c59260a0eb6a7,b28eeca0ff01a7715947d55a04978a43,b62ecc47bf54393bc78dd65986b949d6,b876251511f570468eb5b6ee6a239cc6,bddc3b1a7f098e71f0aa64adec047124,c46e8b6ee0c29e37b7f18c42558d7a3e,dc905ba8b6eb7d84cf2776303211010d,e30574e513dd250992d637d808759c34,e95d4d15e4f3110c91a3d3fcb5910d06,f1897c89e321a3a80924fd72a56e90df,f2aa3fd6ae3f1853347874c50afb60ea,f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="MOUSE MODELS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Mouse models are used in research to study the mechanisms and treatments of diseases, including AD</data>
      <data key="d2">4842292208575bd45b2b5998513dd087</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="IMMUNE CHECKPOINT MOLECULES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Immune checkpoint molecules are proteins that regulate immune responses, including co-stimulatory and co-inhibitory signals</data>
      <data key="d2">4842292208575bd45b2b5998513dd087</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="TNFSF">
      <data key="d0">PROTEIN</data>
      <data key="d1">The tumor necrosis factor superfamily (TNFSF) refers to a group of proteins that play crucial roles in immune responses, immune regulation, inflammation, and cell death. Members of the TNFSF are involved in the regulation of immune responses and fibrosis, making them significant in the context of various diseases. Due to their involvement in these processes, TNFSF members are now considered therapeutic targets for fibrotic diseases.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,4842292208575bd45b2b5998513dd087,68015074236b0144899baa38d01ae467</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="TNFRSF">
      <data key="d0">PROTEIN</data>
      <data key="d1">The tumor necrosis factor receptor superfamily (TNFRSF) includes receptors for TNFSF proteins</data>
      <data key="d2">4842292208575bd45b2b5998513dd087</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="EFFECTOR T-CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Effector T-cells are a type of activated T-cell that actively responds to a stimulus, such as a pathogen. These cells perform crucial immune functions, including cytokine production, to combat infections and other immune challenges.</data>
      <data key="d2">3df8535e965efb96f5094169610507ff,4842292208575bd45b2b5998513dd087,b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">CELL</data>
    </node>
    <node id="REGULATORY T-CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Regulatory T-cells (Tregs) are a subset of T-cells that play a crucial role in modulating the immune response to prevent autoimmunity. As a component of the immune system, Tregs are involved in suppressing the immune responses of other cells, thereby maintaining immune homeostasis and preventing excessive or misdirected immune activity that could lead to autoimmune diseases.</data>
      <data key="d2">3df8535e965efb96f5094169610507ff,4842292208575bd45b2b5998513dd087,b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">CELL</data>
    </node>
    <node id="DENDRITIC CELLS (DCS)">
      <data key="d0">CELL</data>
      <data key="d1">Dendritic cells are antigen-presenting cells that activate T-cells</data>
      <data key="d2">4842292208575bd45b2b5998513dd087</data>
      <data key="d3">CELL</data>
    </node>
    <node id="ENDOTHELIAL CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Endothelial Cells are a type of cell that line the interior surface of blood vessels and lymphatic vessels. They play a key role in vascular biology and are involved in various functions, including inflammation and immune responses. Endothelial Cells are also antigen-presenting cells that can be activated by thymic stromal lymphopoietin (TSLP) to produce OX40L. Additionally, they are found in the skin, contributing to their diverse roles in the body's physiological processes.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,2cec06c4d46f5ff9ee936a78d8b077cd,2e0cdefd62bed7c674d7fb93ef336c2b,3df8535e965efb96f5094169610507ff,4842292208575bd45b2b5998513dd087,7c13f41d7349d9d2e56c36e00c0ca2d9,b201c6ff3e22b2475c8c59260a0eb6a7,bae090d8a29c15868ba1c4f29ae79e99,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">CELL</data>
    </node>
    <node id="MACROPHAGES">
      <data key="d0">CELL</data>
      <data key="d1">Macrophages are a type of white blood cell that play a crucial role in the immune system. They are involved in the detection, phagocytosis, and destruction of bacteria, pathogens, and other harmful organisms. These immune cells are also responsible for engulfing and digesting cellular debris and apoptotic cells. Macrophages produce tumor necrosis factor (TNF) and express various receptors, including TACI and IL-31RA, which are involved in inflammatory responses. Additionally, they can be acted upon by molecules such as LIGHT and TL1A. Through these diverse functions, macrophages are essential for maintaining immune homeostasis and responding to infections and tissue damage.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,080b1dc5fcc0eee3645a06983a0de603,3df8535e965efb96f5094169610507ff,41ccc4b41bd57cf2bda4dbb6c7ae4198,4842292208575bd45b2b5998513dd087,516e41e96d2e72d45bf1e2c69da7f18a,68015074236b0144899baa38d01ae467,7c13f41d7349d9d2e56c36e00c0ca2d9,9867d43adab0ba5db44961fae4863eee,c525762bb827485bceeb9f09bb4bcfe0,d2c44662af9752fc9f82c86121ede7c0,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">CELL</data>
    </node>
    <node id="B-CELLS">
      <data key="d0">CELL</data>
      <data key="d1">B-cells are a type of white blood cell that produces antibodies</data>
      <data key="d2">4842292208575bd45b2b5998513dd087</data>
      <data key="d3">CELL</data>
    </node>
    <node id="CD86">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD86, also known as B7-2, is a co-stimulatory molecule involved in T-cell activation. This protein plays a crucial role in the immune response by binding to CD28 and CTLA-4, providing essential costimulatory signals necessary for T-cell activation. CD86 is integral to positive costimulatory pathways, facilitating the activation and proliferation of T-cells, which are vital for an effective immune response.</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b,4842292208575bd45b2b5998513dd087,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81,9867d43adab0ba5db44961fae4863eee</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CD28">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD28 is a co-stimulatory molecule involved in T-cell activation. It is a costimulatory protein that plays a crucial role in T-cell immune responses. The CD28 gene is integral to T-cell costimulatory pathways, specifically contributing to positive costimulatory pathways.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,1b656cfce91ff9ccec4223703489dab3,2e0cdefd62bed7c674d7fb93ef336c2b,44f2592262cac835560b4c149fee8d2b,4842292208575bd45b2b5998513dd087,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81,9867d43adab0ba5db44961fae4863eee</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="MEMORY T-CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Memory T-cells are long-lived T-cells that provide a faster response upon re-exposure to an antigen</data>
      <data key="d2">4842292208575bd45b2b5998513dd087</data>
      <data key="d3">CELL</data>
    </node>
    <node id="EFFECTOR MEMORY T-CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Effector memory T-cells are a subset of memory T-cells that rapidly respond to re-exposure to an antigen</data>
      <data key="d2">4842292208575bd45b2b5998513dd087</data>
      <data key="d3">CELL</data>
    </node>
    <node id="TYPE 2 INNATE LYMPHOID CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Type 2 innate lymphoid (ILC2) cells are involved in the immune response and produce type 2 cytokines. Additionally, they play a role in the inappropriate activation observed in Atopic Dermatitis.</data>
      <data key="d2">4842292208575bd45b2b5998513dd087,693a2aac101eaaadf92614317a1e4da8</data>
      <data key="d3">CELL</data>
    </node>
    <node id="PERIPHERAL BLOOD MONONUCLEAR CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Peripheral Blood Mononuclear Cells (PBMCs) are blood cells characterized by having a single round nucleus. These cells include lymphocytes and monocytes and are commonly utilized in flow cytometry analysis.</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd,4842292208575bd45b2b5998513dd087,89dbac0da39e4de2b602052cd792b90d</data>
      <data key="d3">CELL</data>
    </node>
    <node id="GBR 830">
      <data key="d0">CHEMICAL</data>
      <data key="d1">GBR 830, also known as ISB 830, is a humanized monoclonal antibody directed against OX40. It has been investigated for the treatment of atopic dermatitis (AD) and has been used in clinical studies for this condition. Despite its mention in the context of various studies, no further studies have been developed with GBR 830.</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688,4842292208575bd45b2b5998513dd087,6309eeea565f06479830cec32938abc9,dc905ba8b6eb7d84cf2776303211010d,e9841b88c9fab58c5175af409653da50,f2aa3fd6ae3f1853347874c50afb60ea</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="ECZEMA AREA AND SEVERITY INDEX (EASI)">
      <data key="d0">SYMPTOM</data>
      <data key="d1">The Eczema Area and Severity Index (EASI) is a tool used to measure the severity of eczema</data>
      <data key="d2">4842292208575bd45b2b5998513dd087</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="MRNA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Messenger ribonucleic acid (mRNA) is a type of RNA that carries genetic information from DNA to the ribosome, where it is used for protein synthesis. It plays a crucial role in the expression of various genes, including those encoding interleukins such as IL-4 and IL-13. In the context of medical research, mRNA expression levels are often analyzed to assess the impact of treatments, such as rocatinlimab, on gene expression.</data>
      <data key="d2">28f548554737fcc026b968db6bbafa30,2a0384addc6e7fd709e0508b83496cd7,475995d7d211bbfde6d8ba52f324d688,4842292208575bd45b2b5998513dd087</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="CCL11">
      <data key="d0">PROTEIN</data>
      <data key="d1">CCL11, also known as chemokine ligand 11, is a chemokine involved in the immune response and inflammation. It plays a crucial role in the recruitment of eosinophils, which are a type of white blood cell involved in allergic reactions and asthma. During inflammatory conditions, CCL11 levels ascend in the skin, promoting the attraction of inflammatory T cells and dendritic cell (DC) subtypes. Additionally, CCL11 is a cytokine implicated in the pathogenesis of eosinophilic esophagitis (EoE), a chronic immune system disease.</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198,4842292208575bd45b2b5998513dd087,6059a6e2710b7df94c6a09e5eb7b024a,d4797ed1483e5057bcd8301eaa509d5e</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CCL17">
      <data key="d0">PROTEIN</data>
      <data key="d1">CCL17, also known as TARC (Thymus and Activation-Regulated Chemokine), is a chemokine ligand involved in the immune response and inflammation. It binds to the CCR4 receptor and plays a crucial role in the recruitment of T-cells. During inflammatory conditions, particularly in the skin, CCL17 levels ascend, promoting the attraction of inflammatory T cells and dendritic cell (DC) subtypes. It is produced in high amounts in atopic dermatitis (AD), highlighting its significant role in inflammatory skin diseases.</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,41ccc4b41bd57cf2bda4dbb6c7ae4198,4842292208575bd45b2b5998513dd087,6059a6e2710b7df94c6a09e5eb7b024a</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="S100">
      <data key="d0">PROTEIN</data>
      <data key="d1">S100 is a family of proteins involved in the regulation of a variety of cellular processes</data>
      <data key="d2">4842292208575bd45b2b5998513dd087</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="AMG 451">
      <data key="d0">CHEMICAL</data>
      <data key="d1">AMG 451, also known as Rocatinlimab, is an anti-OX40 monoclonal antibody. It is currently being used in clinical trials.</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688,4842292208575bd45b2b5998513dd087</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="KHK4083">
      <data key="d0">CHEMICAL</data>
      <data key="d1">KHK4083, also known as rocatinlimab, is a fully human, non-fucosylated IgG1, anti-OX40 monoclonal antibody. It is a biologic injection specifically targeting OX40, and it is used in the treatment of atopic dermatitis. KHK4083 has been tested in a phase Ib trial to evaluate its effects on the reduction of the Eczema Area and Severity Index (EASI) score in patients. This antibody is currently being investigated in clinical studies for its potential therapeutic benefits in managing atopic dermatitis.</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688,4842292208575bd45b2b5998513dd087,6309eeea565f06479830cec32938abc9,78e26c66107dba37ac4bab65406b43a0,e9841b88c9fab58c5175af409653da50,f2aa3fd6ae3f1853347874c50afb60ea</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="T-CELLS">
      <data key="d0">CELL</data>
      <data key="d1">T-cells are immune cells that play a crucial role in the body's immune response. They include various subtypes such as effector T-cells and regulatory T-cells (Tregs). When stimulated, these T-cells express the OX40 protein, which is involved in their activation and function. Additionally, T-cells can be selectively depleted by rocatinlimab, a therapeutic agent that targets these cells.</data>
      <data key="d2">3df8535e965efb96f5094169610507ff,475995d7d211bbfde6d8ba52f324d688</data>
    </node>
    <node id="PYREXIA">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Pyrexia is a medical term for fever. Pyrexia, or fever, is a common side effect observed after the first administration of rocatinlimab. Additionally, pyrexia, or fever, was a common infusion reaction reported in patients treated with rocatinlimab.</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688,b201c6ff3e22b2475c8c59260a0eb6a7,dc905ba8b6eb7d84cf2776303211010d</data>
    </node>
    <node id="CHILLS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Chills are sensations of coldness often accompanied by shivering. They are a common side effect observed after the first administration of rocatinlimab and were frequently reported as an infusion reaction in patients treated with this medication.</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688,b201c6ff3e22b2475c8c59260a0eb6a7,dc905ba8b6eb7d84cf2776303211010d</data>
    </node>
    <node id="APHTHOUS ULCERS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Aphthous ulcers, or canker sores, were reported in patients treated with rocatinlimab</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
    </node>
    <node id="BLOOD URIC ACID">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Blood uric acid levels increased in some patients treated with rocatinlimab</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
    </node>
    <node id="NASOPHARYNGITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Nasopharyngitis, also known as the common cold, is an inflammation of the nasal passages and pharynx, or nasopharynx. This condition has been reported in patients treated with rocatinlimab.</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688,a867a1e73cef039eb3f28e072463b838,b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </node>
    <node id="ERYTHEMA">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Erythema is a clinical sign characterized by redness of the skin, which is caused by increased blood flow to the capillaries. It is often seen in cases of atopic dermatitis (AD), including infantile atopic dermatitis. Additionally, erythema has been reported in patients treated with rocatinlimab.</data>
      <data key="d2">143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524,27a7e95c7d3ad59a948aa46741fee456,3dfbb4c51838e0951f53ce951395225f,475995d7d211bbfde6d8ba52f324d688,6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="HORDEOLUM">
      <data key="d0">DISEASE</data>
      <data key="d1">Hordeolum, or stye, was reported in patients treated with rocatinlimab</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
    </node>
    <node id="POLYMERASE CHAIN REACTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Polymerase chain reaction (PCR) is a technique used to amplify and analyze DNA and RNA sequences</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
    </node>
    <node id="SERUM">
      <data key="d0">TISSUE</data>
      <data key="d1">Serum is the liquid part of blood that remains after clotting, containing various proteins and antibodies. It is used in various diagnostic tests and biomarker analyses. Serum biomarkers are utilized to assess the severity of atopic dermatitis (AD) and are also used to measure levels of sOX40 and sOX40L. In systemic sclerosis (SSc), increased expression levels of costimulatory molecules are observed in serum. Additionally, serum samples are collected to analyze proteomic profiles in AD patients.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,104cc78517b2eca2e9cb7e00de1fe4b0,348f2797841cbef27311b03f2cd788dd,44f2592262cac835560b4c149fee8d2b,475995d7d211bbfde6d8ba52f324d688,48de7eebab3f3b418feb35a152df38fd,4cf23e218b6aab3c77115173b5c7c2fd,4d0e8ae9371a435885994b4161126bc3,855c455b4c9592746834ee3a4e0e6b81,89dbac0da39e4de2b602052cd792b90d,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="HEAD AND NECK">
      <data key="d0">TISSUE</data>
      <data key="d1">The head and neck regions were specifically evaluated for EASI score improvements in AD patients. This area of the body is a focal point in the study, highlighting its importance in assessing the effectiveness of treatments for atopic dermatitis.</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688,b876251511f570468eb5b6ee6a239cc6</data>
    </node>
    <node id="TEAE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Treatment-Emergent Adverse Events (TEAEs) are adverse events that occur during treatment. Treatment-emergent adverse events (TEAEs) were reported in patients treated with rocatinlimab.</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688,b876251511f570468eb5b6ee6a239cc6</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="NRS">
      <data key="d0">PATHWAY</data>
      <data key="d1">The Numeric Rating Scale (NRS) is a tool used to measure the intensity and severity of pruritus, particularly in patients with atopic dermatitis (AD).</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,28f548554737fcc026b968db6bbafa30,3287c502f10f4651d2f56bf39ee7bb7a,3ce96e927d65736b305f792977fed4b9,475995d7d211bbfde6d8ba52f324d688,6309eeea565f06479830cec32938abc9,b876251511f570468eb5b6ee6a239cc6</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="TH2/TH22">
      <data key="d0">CELL</data>
      <data key="d1">Th2/Th22 cells are subsets of T-helper cells involved in the immune response, particularly in atopic dermatitis</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">CELL</data>
    </node>
    <node id="PROTEOMIC ANALYSIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Proteomic analysis is the large-scale study of proteins, particularly their structures and functions. In the context of autoimmune diseases, proteomic analysis was conducted to study protein expression changes in AD (Atopic Dermatitis) patients treated with rocatinlimab. This approach allows researchers to gain insights into the molecular mechanisms underlying the disease and the effects of therapeutic interventions.</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b,475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="GENOMIC PROFILE">
      <data key="d0">PATHWAY</data>
      <data key="d1">The genomic profile analysis was conducted to study gene expression changes in AD patients treated with rocatinlimab. The genomic profile of AD can be affected by treatment, indicating that therapeutic interventions may lead to alterations in gene expression patterns.</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="TRANSCRIPTOMIC PROFILE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Transcriptomic profile analysis was conducted to study RNA expression changes in AD patients treated with rocatinlimab</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="EASI75">
      <data key="d0">PATHWAY</data>
      <data key="d1">EASI75 is a clinical endpoint indicating a 75% improvement in the Eczema Area and Severity Index (EASI) score from baseline. This measure is used to assess the severity of eczema and signifies a substantial reduction in symptoms, reflecting a 75% improvement in the condition.</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,475995d7d211bbfde6d8ba52f324d688,6309eeea565f06479830cec32938abc9,78e26c66107dba37ac4bab65406b43a0,f1897c89e321a3a80924fd72a56e90df</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PLACEBO">
      <data key="d0">CHEMICAL</data>
      <data key="d1">PLACEBO is a substance with no therapeutic effect used as a control in testing new drugs and in clinical trials. It is commonly employed to evaluate the efficacy of new treatments by providing a baseline against which the effects of the experimental drug can be compared. For instance, placebo was used as a control in clinical trials evaluating rocatinlimab.</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,423195c6b63ad0a6773374364ebf3612,475995d7d211bbfde6d8ba52f324d688,68015074236b0144899baa38d01ae467,7f559ad7372a4e35e90b43cc67047b0f,8e5a1be9981340d419f7b3ad27076009,b876251511f570468eb5b6ee6a239cc6,c95d22c2a90e77cd22bd0d280d55b26a</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="PHASE 1">
      <data key="d0">PATHWAY</data>
      <data key="d1">Phase 1 clinical trial evaluated the safety and dosage of rocatinlimab in AD patients</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PHASE 2B">
      <data key="d0">PATHWAY</data>
      <data key="d1">Phase 2b clinical trial evaluated the efficacy and safety of rocatinlimab in AD patients</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PHASE 3">
      <data key="d0">PATHWAY</data>
      <data key="d1">Phase 3 is a stage in clinical trials designed to assess the effectiveness and safety of a drug. A Phase 3 clinical trial is planned to further evaluate rocatinlimab in patients with atopic dermatitis (AD).</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IGG1">
      <data key="d0">PROTEIN</data>
      <data key="d1">IgG1 is a subclass of immunoglobulin G involved in the immune response. Immunoglobulin G1, a subclass of antibodies, is also the subclass to which rocatinlimab belongs.</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688,b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="MONOCLONAL ANTIBODY">
      <data key="d0">PROTEIN</data>
      <data key="d1">Monoclonal antibody is a type of protein that rocatinlimab is classified as</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="TH2-DRIVEN CONDITIONS">
      <data key="d0">DISEASE</data>
      <data key="d1">Th2-driven conditions are immune responses primarily mediated by Th2 cells, often associated with allergies and atopic dermatitis</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="CLONAL T-CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Clonal T-cells are a population of T-cells that expand from a single cell, targeted by rocatinlimab</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">CELL</data>
    </node>
    <node id="INFUSION REACTIONS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Infusion reactions are adverse effects that occur during or after the administration of a drug, such as rocatinlimab</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="EASI SCORE">
      <data key="d0">PATHWAY</data>
      <data key="d1">EASI score is a measure used to assess the severity of atopic dermatitis</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PRURITUS NRS SCORE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Pruritus NRS score is a measure used to assess the severity of itching in atopic dermatitis patients</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="SKIN BIOPSY">
      <data key="d0">TISSUE</data>
      <data key="d1">Skin biopsy specimens were collected to analyze the effects of rocatinlimab on gene and protein expression</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="SERUM SAMPLES">
      <data key="d0">TISSUE</data>
      <data key="d1">Serum samples were collected to analyze the effects of rocatinlimab on protein expression</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="HEAD AND NECK EASI SCORE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Head and neck EASI score is a measure used to assess the severity of atopic dermatitis in the head and neck regions</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="CATINLIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Catinlimab is a drug being evaluated for its efficacy in treating head and neck disease</data>
      <data key="d2">b876251511f570468eb5b6ee6a239cc6</data>
    </node>
    <node id="T-CELL">
      <data key="d0">CELL</data>
      <data key="d1">T-cells are a type of lymphocyte that play a central role in the body's immune response and defense mechanisms. They are crucial for cell-mediated immunity and are implicated in autoimmune diseases (AD). T-cells include various subtypes, such as effector and regulatory T-cells (Tregs), which are involved in modulating the immune response. When stimulated, T-cells express OX40, a co-stimulatory molecule important for their activation and function.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,2cec06c4d46f5ff9ee936a78d8b077cd,b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6,dc905ba8b6eb7d84cf2776303211010d</data>
      <data key="d3">CELL</data>
    </node>
    <node id="VIGA">
      <data key="d0">SYMPTOM</data>
      <data key="d1">The Validated Investigator Global Assessment (VIGA) is a tool used to measure the severity of atopic dermatitis. This scale, also referred to as the Validated Investigator's Global Assessment or Validated Investigator&#8217;s Global Assessment (vIGA), is a validated measure employed by investigators to evaluate the extent and severity of atopic dermatitis in patients.</data>
      <data key="d2">143d2dc302af5606656797bff162e23e,b876251511f570468eb5b6ee6a239cc6,dc905ba8b6eb7d84cf2776303211010d,f1897c89e321a3a80924fd72a56e90df</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="HYPERSENSITIVITY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Hypersensitivity is an exaggerated immune response to a substance</data>
      <data key="d2">b876251511f570468eb5b6ee6a239cc6</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="SCORAD">
      <data key="d0">SYMPTOM</data>
      <data key="d1">SCORing Atopic Dermatitis (SCORAD) is a clinical tool used to assess the severity and extent of atopic dermatitis. This scoring system, also referred to as the SCORAD index, is designed to evaluate the intensity of the condition, providing a comprehensive measure of the disease's impact on patients.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,0829313703a7d2bae5436a9ee542334d,0ba9fbea14e0c2c1d01a12ffaacfda9b,104cc78517b2eca2e9cb7e00de1fe4b0,143d2dc302af5606656797bff162e23e,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,28f548554737fcc026b968db6bbafa30,2cec06c4d46f5ff9ee936a78d8b077cd,348f2797841cbef27311b03f2cd788dd,442e7fad2fab75fa2449309783294d89,48288f3ec2832850282f95d4e38d10e1,691cb2e23ac3c6e591129d16714f8ef8,6b099960b0a39866e3aa6b908f1886e4,b876251511f570468eb5b6ee6a239cc6,dc905ba8b6eb7d84cf2776303211010d,f1897c89e321a3a80924fd72a56e90df</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="NCT05398445">
      <data key="d0">PATHWAY</data>
      <data key="d1">NCT05398445 is the identifier for the clinical trial ROCKET-IGNITE</data>
      <data key="d2">b876251511f570468eb5b6ee6a239cc6</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="NCT03161288">
      <data key="d0">PATHWAY</data>
      <data key="d1">NCT03161288 is a clinical trial identifier for a phase 1 study evaluating amlitelimab in healthy subjects.</data>
      <data key="d2">b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="NCT03754309">
      <data key="d0">PATHWAY</data>
      <data key="d1">NCT03754309 is a clinical trial identifier for a phase 2a study evaluating amlitelimab in patients with moderate-to-severe atopic dermatitis.</data>
      <data key="d2">b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="NCT05131477">
      <data key="d0">PATHWAY</data>
      <data key="d1">A Phase 2b study evaluating the impact of amlitelimab in patients with moderate-to-severe atopic dermatitis</data>
      <data key="d2">dc905ba8b6eb7d84cf2776303211010d</data>
    </node>
    <node id="NCT05492578">
      <data key="d0">PATHWAY</data>
      <data key="d1">A single group, phase 2, long-term extension study characterizing the safety and efficacy of amlitelimab in treated adult participants with moderate-to-severe atopic dermatitis</data>
      <data key="d2">dc905ba8b6eb7d84cf2776303211010d</data>
    </node>
    <node id="NCT05421598">
      <data key="d0">PATHWAY</data>
      <data key="d1">A study evaluating amlitelimab for the treatment of moderate-to-severe asthma</data>
      <data key="d2">dc905ba8b6eb7d84cf2776303211010d</data>
    </node>
    <node id="ASTHMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Asthma is a chronic inflammatory disease of the airways characterized by variable and recurring symptoms, airflow obstruction, and bronchospasm. It is a chronic respiratory condition marked by airway inflammation, constriction, and hyperreactivity. Asthma often presents as a comorbidity in patients with atopic diseases, including Atopic Dermatitis (AD). In individuals with asthma, the airways narrow and swell, producing extra mucus, which can lead to breathing difficulties. This condition is particularly common in children with Atopic Dermatitis, highlighting the interconnected nature of these atopic disorders.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,05c97152fe02249153103be341d65b67,0829313703a7d2bae5436a9ee542334d,348f2797841cbef27311b03f2cd788dd,3ce96e927d65736b305f792977fed4b9,3df8535e965efb96f5094169610507ff,5f37466ca41c9b8b06ed8be0303d49f2,68015074236b0144899baa38d01ae467,691cb2e23ac3c6e591129d16714f8ef8,6ada075e562abd7bd445164e9fc309b4,6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d,b19f42c9497f71b231222cd953036d6b,dc905ba8b6eb7d84cf2776303211010d,df74aa1b86eeeb811ca5586767ae3a71,e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="SYSTEMIC CORTICOSTEROIDS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Systemic corticosteroids are medications used to reduce inflammation in various conditions, including atopic dermatitis. They are particularly employed in severe cases of atopic dermatitis (AD).</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,dc905ba8b6eb7d84cf2776303211010d</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="AZATHIOPRINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Azathioprine is an immunosuppressant drug used in the systemic treatment of atopic dermatitis (AD). It is particularly employed to treat severe forms of AD, providing therapeutic benefits in managing this chronic inflammatory skin condition.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,2cec06c4d46f5ff9ee936a78d8b077cd,693a2aac101eaaadf92614317a1e4da8,dc905ba8b6eb7d84cf2776303211010d</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="ANTIGEN-PRESENTING CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Antigen-presenting Cells (APCs) are immune cells that process and present antigens to T-cells, initiating an immune response. These cells play a crucial role in the immune system by displaying antigens to T-cells, thereby triggering the body's defense mechanisms against pathogens.</data>
      <data key="d2">3df8535e965efb96f5094169610507ff,41ccc4b41bd57cf2bda4dbb6c7ae4198,b201c6ff3e22b2475c8c59260a0eb6a7,dc905ba8b6eb7d84cf2776303211010d</data>
    </node>
    <node id="FDA">
      <data key="d0">PATHWAY</data>
      <data key="d1">The Food and Drug Administration (FDA) is a federal regulatory agency responsible for protecting public health by ensuring the safety and efficacy of drugs, vaccines, and other medical products. The FDA is tasked with approving drugs and treatments for medical use, including specific approvals such as dupilumab for atopic dermatitis (AD) treatment and TNF antagonists for therapeutic use. As a key regulatory body, the FDA plays a crucial role in the clinical approval process of various medical products.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,104cc78517b2eca2e9cb7e00de1fe4b0,27a7e95c7d3ad59a948aa46741fee456,286730b1c1f680ac465cc21d522fda0c,48de7eebab3f3b418feb35a152df38fd,5ec1ebf4e260eb1f8fda8acdf06cd39e,dc905ba8b6eb7d84cf2776303211010d,e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="PHASE 3 TRIAL">
      <data key="d0">PATHWAY</data>
      <data key="d1">A clinical trial phase that evaluates the efficacy and safety of a treatment in a larger patient population</data>
      <data key="d2">dc905ba8b6eb7d84cf2776303211010d</data>
    </node>
    <node id="SKIN TRANSCRIPTOMIC ANALYSIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">A method used to study gene expression in skin tissue</data>
      <data key="d2">dc905ba8b6eb7d84cf2776303211010d</data>
    </node>
    <node id="INTERFERON-&#915;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interferon-&#947; is a cytokine critical for innate and adaptive immunity</data>
      <data key="d2">b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="VIRUS-SPECIFIC ANTIBODY">
      <data key="d0">PROTEIN</data>
      <data key="d1">Virus-specific antibodies are produced in response to viral infections</data>
      <data key="d2">b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CYTOTOXIC T-CELL">
      <data key="d0">CELL</data>
      <data key="d1">Cytotoxic T-cells are immune cells that kill cancer cells, cells that are infected (particularly with viruses), or cells that are damaged in other ways</data>
      <data key="d2">b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">CELL</data>
    </node>
    <node id="SOX40">
      <data key="d0">PROTEIN</data>
      <data key="d1">Soluble OX40 (sOX40) is a form of the OX40 protein, which is expressed on activated T-cells and plays a role in immune response modulation. sOX40 has anti-inflammatory effects when it binds to membrane-bound OX40L. It is associated with atopic comorbidities and disease activity in children with atopic dermatitis (AD). sOX40 is measured in the serum of patients with AD as well as healthy controls (HC), providing insights into its role in the disease.</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746,348f2797841cbef27311b03f2cd788dd,691cb2e23ac3c6e591129d16714f8ef8,6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d,b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="APC">
      <data key="d0">CELL</data>
      <data key="d1">Antigen-presenting cells (APCs) are cells that process and present antigens to T-cells.</data>
      <data key="d2">691cb2e23ac3c6e591129d16714f8ef8,b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">CELL</data>
    </node>
    <node id="NCT03096223">
      <data key="d0">PATHWAY</data>
      <data key="d1">NCT03096223 is a clinical trial identifier for a study on rocatinlimab in moderate-to-severe atopic dermatitis</data>
      <data key="d2">b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="NCT03703102">
      <data key="d0">PATHWAY</data>
      <data key="d1">NCT03703102 is a clinical trial identifier for a phase 2b study on rocatinlimab in moderate-to-severe atopic dermatitis</data>
      <data key="d2">b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="HEADACHE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Headache is a common symptom characterized by pain or discomfort in the head or face area.</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838,b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="VITAL SIGNS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Vital signs are clinical measurements that indicate the state of a patient's essential body functions</data>
      <data key="d2">b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="LABORATORY SAFETY DATA">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Laboratory safety data includes results from tests that monitor the safety of a treatment</data>
      <data key="d2">b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="ANTI-VIRAL ANTIBODY">
      <data key="d0">PROTEIN</data>
      <data key="d1">Anti-viral antibodies are produced by the immune system to neutralize viruses</data>
      <data key="d2">b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="VIRAL DNA">
      <data key="d0">PROTEIN</data>
      <data key="d1">Viral DNA is the genetic material of a virus</data>
      <data key="d2">b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CYTOKINES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Cytokines are small signaling proteins that play a crucial role in mediating and regulating immunity, inflammation, and hematopoiesis. They are key effectors in immune responses and are involved in various inflammatory conditions, such as atopic dermatitis and hidradenitis suppurativa (HS). Specific cytokines, including IFN-&#947;, IL-36, TNF, IL-17A, IL-13, and IL-4, are implicated in these processes. In atopic dermatitis, cytokines contribute to tissue inflammation and epidermal barrier dysfunction. Cytokines are also targeted by various biologics to modulate immune and inflammatory responses. Additionally, methotrexate, a common immunosuppressive drug, can modify cytokine activity, further highlighting their importance in therapeutic interventions for autoimmune and inflammatory diseases.</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456,286730b1c1f680ac465cc21d522fda0c,41ccc4b41bd57cf2bda4dbb6c7ae4198,523bbfee1ae3b4ecabf9b11d10eea9ff,693a2aac101eaaadf92614317a1e4da8,83eb9003d42977bb83fea1d123dd5ab9,96e553a44a27e728c27c4892045ec5c2,a867a1e73cef039eb3f28e072463b838,b201c6ff3e22b2475c8c59260a0eb6a7,e95d4d15e4f3110c91a3d3fcb5910d06</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="ELECTROCARDIOGRAMS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Electrocardiograms are tests that measure the electrical activity of the heart</data>
      <data key="d2">b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="EASI-75">
      <data key="d0">SYMPTOM</data>
      <data key="d1">EASI-75 is a measure indicating a 75% improvement in the Eczema Area and Severity Index</data>
      <data key="d2">b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="B CELLS">
      <data key="d0">CELL</data>
      <data key="d1">B cells are a type of white blood cell, specifically a lymphocyte, that play a crucial role in the adaptive immune response. They are involved in the production of antibodies, which are essential for the humoral immune response. B cells can express TNF and are professional antigen-presenting cells that express OX40L when activated. They are influenced by IL-4 signaling and can be acted upon by BAFF. B cells are significantly involved in various immune responses, including those in atopic dermatitis, where they are increased in both circulation and skin tissue. Additionally, B cells have significant signatures in HS (Hidradenitis Suppurativa) skin and are predominant in this condition. They are identified as a potential therapeutic target in HS due to their involvement in the pathogenesis of the disease.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,1b656cfce91ff9ccec4223703489dab3,2e0cdefd62bed7c674d7fb93ef336c2b,411a4d246f0a9321e52971446a5a0606,48de7eebab3f3b418feb35a152df38fd,516e41e96d2e72d45bf1e2c69da7f18a,523bbfee1ae3b4ecabf9b11d10eea9ff,693a2aac101eaaadf92614317a1e4da8,7c13f41d7349d9d2e56c36e00c0ca2d9,83eb9003d42977bb83fea1d123dd5ab9,89dbac0da39e4de2b602052cd792b90d,b62ecc47bf54393bc78dd65986b949d6,bae090d8a29c15868ba1c4f29ae79e99,f2aa3fd6ae3f1853347874c50afb60ea</data>
      <data key="d3">CELL</data>
    </node>
    <node id="IFN-&#915;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interferon-gamma (IFN-&#947;) is a type II interferon and a cytokine that plays a critical role in both innate and adaptive immunity. It is essential for the immune response against viral and intracellular bacterial infections, as well as for tumor control. IFN-&#947; is involved in type 1 immune responses and has significant roles in inflammation and immune regulation. It is a proinflammatory cytokine induced by ICOS in activated T cells and is implicated in the inflammatory responses in conditions such as chronic atopic dermatitis and hidradenitis suppurativa (HS). In HS, IFN-&#947; shows a significant response in lesional skin, highlighting its involvement in the pathophysiology of this disease. Overall, IFN-&#947; is a key player in immune responses and inflammation.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,27a7e95c7d3ad59a948aa46741fee456,2e0cdefd62bed7c674d7fb93ef336c2b,3dfbb4c51838e0951f53ce951395225f,41ccc4b41bd57cf2bda4dbb6c7ae4198,44f2592262cac835560b4c149fee8d2b,503107475d2e9dac49abd8ebcbadd9f5,523bbfee1ae3b4ecabf9b11d10eea9ff,b19f42c9497f71b231222cd953036d6b,bae090d8a29c15868ba1c4f29ae79e99,e340a83f7cba0ea5be731b1f682ea7c7,e95d4d15e4f3110c91a3d3fcb5910d06,f2aa3fd6ae3f1853347874c50afb60ea,f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="BRUTON&#8217;S TYROSINE KINASE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Bruton&#8217;s Tyrosine Kinase (BTK) is involved in B cell signaling and is a potential therapeutic target in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="SPLEEN TYROSINE KINASE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Spleen Tyrosine Kinase (SYK) is involved in B cell signaling and is a potential therapeutic target in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="ABSCESS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Abscess formation is a characteristic symptom of HS, involving localized collections of pus</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="SINUS TRACTS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Sinus tracts are abnormal channels that develop in the skin, commonly seen in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="COMPLEMENT ACTIVATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Complement activation is a biological process enriched among increased differentially expressed genes (DEGs) in hidradenitis suppurativa (HS). It is a part of the immune response implicated in the pathogenesis of HS. Complement activation enhances the ability of antibodies and phagocytic cells to clear pathogens, thereby playing a crucial role in the body's defense mechanisms.</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,523bbfee1ae3b4ecabf9b11d10eea9ff,bae090d8a29c15868ba1c4f29ae79e99,e4d25b1cd44df240a29591bc46a875ab</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="C5A">
      <data key="d0">PROTEIN</data>
      <data key="d1">C5a is a complement fragment that acts as a chemoattractant for neutrophils. It is a protein fragment released during complement activation and is elevated in HS.</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff,e340a83f7cba0ea5be731b1f682ea7c7</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="NETOSIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">NETosis is a form of cell death in which neutrophils release extracellular traps to capture pathogens. This process involves neutrophils releasing neutrophil extracellular traps (NETs), and it has been observed in various conditions, including HS (Hidradenitis Suppurativa).</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff,e340a83f7cba0ea5be731b1f682ea7c7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PLASMACYTOID DENDRITIC CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Plasmacytoid dendritic cells (pDCs) are involved in type I IFN responses and are activated in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">CELL</data>
    </node>
    <node id="CD19">
      <data key="d0">GENE</data>
      <data key="d1">CD19 is a gene associated with B cell responses and is upregulated in HS skin. In the study, CD19 exhibited a 33-fold increased expression.</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">GENE</data>
    </node>
    <node id="CD79A">
      <data key="d0">GENE</data>
      <data key="d1">CD79A is a gene associated with B cell responses and is notably upregulated in HS (Hidradenitis Suppurativa) skin. In the study, CD79A exhibited a 32-fold increase in expression, highlighting its significant role in the disease pathology.</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">GENE</data>
    </node>
    <node id="IGLV3-27">
      <data key="d0">GENE</data>
      <data key="d1">IGLV3-27 is an immunoglobulin gene that is upregulated in HS skin</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">GENE</data>
    </node>
    <node id="PBMCS">
      <data key="d0">CELL</data>
      <data key="d1">Peripheral Blood Mononuclear Cells (PBMCs) are blood cells characterized by having a round nucleus, which includes lymphocytes, monocytes, and macrophages. These cells are critical in the immune response and are commonly used in various immunological studies. In the context of autoimmune diseases, PBMCs are utilized for immunophenotyping in Alzheimer's Disease (AD) patients and are also employed in studies related to other health conditions, such as Hematopoietic Stem (HS) cell research.</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746,523bbfee1ae3b4ecabf9b11d10eea9ff,691cb2e23ac3c6e591129d16714f8ef8,6b099960b0a39866e3aa6b908f1886e4</data>
      <data key="d3">CELL</data>
    </node>
    <node id="NOTCH SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Notch signaling is a fundamental pathway involved in cell differentiation and development. It is also hypothesized to be involved in the pathogenesis of Hidradenitis Suppurativa (HS).</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff,e340a83f7cba0ea5be731b1f682ea7c7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="GAMMA-SECRETASE COMPLEX">
      <data key="d0">PROTEIN</data>
      <data key="d1">Gamma-secretase complex is involved in Notch signaling and has genetic mutations associated with HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="TYPE I IFN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Type I interferons (IFNs) are cytokines involved in antiviral responses and are increased in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="IMMUNOGLOBULINS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Immunoglobulins are antibodies produced by plasma cells and are increased in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="AFRICAN AMERICANS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">African Americans are an ethnic group with a higher incidence of HS compared to Caucasians</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="CAUCASIANS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Caucasians are an ethnic group with a lower incidence of HS compared to African Americans</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="HORMONAL COMPONENT">
      <data key="d0">PATHWAY</data>
      <data key="d1">Hormonal components are factors that influence the development and progression of HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="QUALITY OF LIFE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Quality of life refers to the general well-being of individuals and societies, encompassing both physical and mental health. It is a patient-reported outcome that is significantly affected by conditions such as atopic dermatitis (AD) and hidradenitis suppurativa (HS). Effective treatments for AD have been shown to improve quality of life, highlighting the importance of managing these conditions to enhance overall well-being.</data>
      <data key="d2">143d2dc302af5606656797bff162e23e,2cec06c4d46f5ff9ee936a78d8b077cd,48288f3ec2832850282f95d4e38d10e1,523bbfee1ae3b4ecabf9b11d10eea9ff,e30574e513dd250992d637d808759c34</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="RNA-SEQ">
      <data key="d0">PATHWAY</data>
      <data key="d1">RNA sequencing (RNA-Seq) is a powerful technique used to analyze the transcriptome, which includes the quantity and sequences of RNA in a sample. This method has been employed in various studies, including those focused on hidradenitis suppurativa (HS) and systemic sclerosis (SSc) patients. By examining the transcriptomic characteristics, RNA-Seq provides comprehensive insights into the gene expression profiles of organisms, aiding in the understanding of complex diseases and biological processes.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,2a0384addc6e7fd709e0508b83496cd7,2e0cdefd62bed7c674d7fb93ef336c2b,411a4d246f0a9321e52971446a5a0606,523bbfee1ae3b4ecabf9b11d10eea9ff,b28eeca0ff01a7715947d55a04978a43,d4797ed1483e5057bcd8301eaa509d5e</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="CYTOMETRY BY TIME OF FLIGHT">
      <data key="d0">PATHWAY</data>
      <data key="d1">Cytometry by time of flight (CyTOF) is an imaging technique used to analyze cell populations in HS studies</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE COMPLEX DEPOSITION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune complex deposition is the accumulation of immune complexes in tissues, contributing to HSImmune complex deposition is a process where immune complexes accumulate in tissues and is implicated in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNOPATHOGENESIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immunopathogenesis is the process by which an immune response contributes to the development of disease. It refers to the development of disease due to immune system dysfunction, as seen in conditions such as HS (Hidradenitis Suppurativa).</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff,7b454335c2f5651d86f712037a0dc0ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="SINGLE-CELL RNA-SEQUENCING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Single-cell RNA sequencing is a technique used to analyze the transcriptome at the single-cell level and was used in HS studies</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="BULK RNA-SEQUENCING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Bulk RNA sequencing is a technique used to analyze the transcriptome of a population of cells and was used in HS studies</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PRINCIPAL COMPONENTS ANALYSIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Principal components analysis (PCA) is a statistical technique used to reduce the dimensionality of data and was used in HS studies</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="DIFFERENTIALLY EXPRESSED GENES">
      <data key="d0">GENE</data>
      <data key="d1">Differentially expressed genes (DEGs) are genes that show significant differences in expression levels between conditions, such as HS and healthy controls</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">GENE</data>
    </node>
    <node id="FALSE DISCOVERY RATE">
      <data key="d0">PATHWAY</data>
      <data key="d1">False discovery rate (FDR) is a statistical method used to correct for multiple comparisons in gene expression studies. It represents the expected proportion of false discoveries among the rejected hypotheses. This approach helps to control the likelihood of type I errors, ensuring that the results of the study are more reliable and accurate.</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff,8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="FOLD CHANGE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Fold change is a measure of the change in expression level of a gene between conditions, such as HS and healthy controls</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="CHEMOATTRACTANT">
      <data key="d0">PATHWAY</data>
      <data key="d1">Chemoattractants are substances that attract cells, such as C5a attracting neutrophils in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="NEUTROPHIL EXTRACELLULAR TRAPS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Neutrophil extracellular traps (NETs) are networks of extracellular fibers released by neutrophils during NETosis, observed in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="AUTOSOMAL DOMINANT">
      <data key="d0">PATHWAY</data>
      <data key="d1">Autosomal dominant is a pattern of inheritance where a single copy of a mutated gene can cause a disease, such as certain forms of HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="GENETIC MUTATIONS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Genetic mutations are changes in DNA sequence that can contribute to diseases like HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="COMORBIDITIES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Comorbidities are additional diseases or conditions that occur along with a primary disease. For instance, comorbidities can include obesity when associated with Hidradenitis Suppurativa (HS) or various conditions that occur with Atopic Dermatitis.</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff,90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PROTEOMIC APPROACHES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Proteomic approaches involve the large-scale study of proteins and were used to characterize inflammatory responses in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="TRANSCRIPTOMIC APPROACHES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Transcriptomic approaches involve the study of RNA transcripts and were used to characterize inflammatory responses in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PRECLINICAL EVIDENCE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Preclinical evidence refers to data obtained from laboratory studies that support the potential effectiveness of a treatment, such as targeting BTK and SYK in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="CLINICAL TRIALS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Clinical trials are research studies conducted to evaluate the efficacy and safety of medical treatments. These studies are carried out with patients to assess the effectiveness of new treatments, including those targeting specific conditions such as Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). For instance, clinical trials may investigate the potential of new therapies targeting Bruton's tyrosine kinase (BTK) and spleen tyrosine kinase (SYK) in the treatment of HS. Overall, clinical trials play a crucial role in advancing medical knowledge and improving patient care by rigorously testing the safety and efficacy of novel therapeutic approaches.</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,48de7eebab3f3b418feb35a152df38fd,523bbfee1ae3b4ecabf9b11d10eea9ff,6ada075e562abd7bd445164e9fc309b4</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="THERAPEUTIC TARGETS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Therapeutic targets are specific molecules or pathways in the body that are identified for drug development and treatment of diseases. In the context of Atopic Dermatitis (AD), these targets are crucial for developing effective therapies. Additionally, therapeutic targets can include specific cells such as B cells and plasma cells, which are relevant in the treatment of Hidradenitis Suppurativa (HS). By focusing on these specific molecules or pathways, researchers aim to create drugs that can effectively manage and treat various autoimmune diseases.</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff,90f4809673ca34628b0e607908f0bf0b,e30574e513dd250992d637d808759c34</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="THERAPEUTIC DEVELOPMENT">
      <data key="d0">PATHWAY</data>
      <data key="d1">Therapeutic development involves the process of discovering and developing new treatments for diseases, such as HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INFLAMMATORY PATHWAYS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Inflammatory pathways are biological pathways involved in inflammation, which are dysregulated in Hidradenitis Suppurativa (HS). These pathways play a crucial role in the immune response and are also implicated in the pathogenesis of Atopic Dermatitis.</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff,90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE RESPONSES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune responses are the body's defense mechanisms against pathogens, which are dysregulated in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="ANTIBODIES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Antibodies are proteins produced by plasma cells that help neutralize pathogens and are increased in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="COMPLEMENT FRAGMENT">
      <data key="d0">PROTEIN</data>
      <data key="d1">Complement fragments are parts of the complement system involved in immune responses, such as C5a in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CHEMOATTRACTANTS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Chemoattractants are substances that attract immune cells, such as C5a attracting neutrophils in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="IMMUNE COMPLEXES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Immune complexes are formed when antibodies bind to antigens and can deposit in tissues, contributing to HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="INFLAMMATORY RESPONSES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Inflammatory responses are the body's reactions to harmful stimuli, which are dysregulated in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </node>
    <node id="V3-27">
      <data key="d0">GENE</data>
      <data key="d1">V3-27 is a gene with a 100-fold increased expression in the study</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </node>
    <node id="SPRR2F">
      <data key="d0">GENE</data>
      <data key="d1">SPRR2F is an antimicrobial gene dysregulated in lesional skin of HS, psoriasis, and atopic dermatitis</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </node>
    <node id="CD177">
      <data key="d0">GENE</data>
      <data key="d1">CD177 is an antimicrobial gene dysregulated in lesional skin of HS, psoriasis, and atopic dermatitis</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </node>
    <node id="TCN1">
      <data key="d0">GENE</data>
      <data key="d1">TCN1 is an antimicrobial gene dysregulated in lesional skin of HS, psoriasis, and atopic dermatitis</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </node>
    <node id="IL17C">
      <data key="d0">GENE</data>
      <data key="d1">IL17C is a gene with overall decreased expression in HS</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </node>
    <node id="CD4+">
      <data key="d0">CELL</data>
      <data key="d1">CD4+ cells are a type of T cell involved in the immune response</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </node>
    <node id="CD8+">
      <data key="d0">CELL</data>
      <data key="d1">CD8+ cells are a type of T cell involved in the immune response</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </node>
    <node id="MELANOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Melanocytes are a type of cell found in the skin. They are responsible for producing melanin, the pigment that gives skin its color.</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,bae090d8a29c15868ba1c4f29ae79e99</data>
      <data key="d3">CELL</data>
    </node>
    <node id="FIBROBLASTS">
      <data key="d0">CELL</data>
      <data key="d1">Fibroblasts are a type of structural cell found in the skin that play a critical role in the formation of connective tissue and fibrosis. They are primarily responsible for synthesizing the extracellular matrix and collagen, which are essential for wound healing and fibrotic processes. In addition to producing collagen and other fibers, fibroblasts express type 1 collagen after TNF-co-stimulation of SSc patient T cells and are involved in fibrotic skin remodeling in conditions such as atopic dermatitis (AD). These cells are also known to express OX40L in fibrotic tissues and can be acted upon by molecules such as LIGHT, TL1A, and BAFF. Overall, fibroblasts are crucial for collagen and extracellular matrix protein deposition in fibrosis, contributing significantly to tissue repair and pathological fibrosis.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,080b1dc5fcc0eee3645a06983a0de603,1b656cfce91ff9ccec4223703489dab3,2e0cdefd62bed7c674d7fb93ef336c2b,48de7eebab3f3b418feb35a152df38fd,4cf23e218b6aab3c77115173b5c7c2fd,516e41e96d2e72d45bf1e2c69da7f18a,5ec1ebf4e260eb1f8fda8acdf06cd39e,5f37466ca41c9b8b06ed8be0303d49f2,68015074236b0144899baa38d01ae467,a10787d7fbb1307be263e86dc7b33a51,bae090d8a29c15868ba1c4f29ae79e99,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">CELL</data>
    </node>
    <node id="SMOOTH MUSCLE CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Smooth muscle cells are a type of cell found in the walls of hollow organs such as blood vessels and the intestines. They are involved in involuntary movements and are responsible for the contractility of these hollow organs, including the gastrointestinal tract. Additionally, smooth muscle cells play a role in the process of fibrosis. They are structural cells that can be influenced by LIGHT.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,2e0cdefd62bed7c674d7fb93ef336c2b,516e41e96d2e72d45bf1e2c69da7f18a,5f37466ca41c9b8b06ed8be0303d49f2,68015074236b0144899baa38d01ae467,bae090d8a29c15868ba1c4f29ae79e99,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">CELL</data>
    </node>
    <node id="T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">T cells are a type of lymphocyte that play a central role in cell-mediated immunity and are crucial components of the body's adaptive immune response. These immune cells are involved in various immune responses, including the pathogenesis of systemic sclerosis and the inflammatory reaction in atopic dermatitis (AD). T cells can express TNF and are modulated by OX40-OX40L signaling, which promotes their survival, proliferation, and cytokine secretion. In the context of AD, T cells, particularly skin-homing memory-prone CLA+ T cells, express OX40 and are increased in both the circulation and skin tissue of patients. T cells are also haematopoietic cells affected by IL-4 signaling and can be targeted by treatments such as methotrexate. Additionally, TL1A can act upon T cells, further influencing their function. These immune cells are found in the skin and play a significant role in the immune system's response to various conditions.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,0ba9fbea14e0c2c1d01a12ffaacfda9b,1b656cfce91ff9ccec4223703489dab3,286730b1c1f680ac465cc21d522fda0c,2e0cdefd62bed7c674d7fb93ef336c2b,44f2592262cac835560b4c149fee8d2b,48de7eebab3f3b418feb35a152df38fd,516e41e96d2e72d45bf1e2c69da7f18a,5ec1ebf4e260eb1f8fda8acdf06cd39e,68015074236b0144899baa38d01ae467,693a2aac101eaaadf92614317a1e4da8,6b099960b0a39866e3aa6b908f1886e4,83eb9003d42977bb83fea1d123dd5ab9,89dbac0da39e4de2b602052cd792b90d,b19f42c9497f71b231222cd953036d6b,bae090d8a29c15868ba1c4f29ae79e99,c525762bb827485bceeb9f09bb4bcfe0,df74aa1b86eeeb811ca5586767ae3a71,f2aa3fd6ae3f1853347874c50afb60ea</data>
      <data key="d3">CELL</data>
    </node>
    <node id="MYELOID CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Myeloid cells are a group of cells derived from bone marrow progenitors, including monocytes, macrophages, and neutrophils. These cells play a crucial role in the immune system and can be found in various tissues, including the skin.</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,bae090d8a29c15868ba1c4f29ae79e99</data>
      <data key="d3">CELL</data>
    </node>
    <node id="MAST CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Mast cells are a type of immune cell that play a key role in allergic reactions and inflammation. They are found in the skin and are particularly elevated in the skin of patients with Atopic Dermatitis (AD). These cells are a type of white blood cell that express high-affinity receptors for IgE, which are crucial for their involvement in the immune response in AD. Mast cells release histamine and other substances during inflammatory and allergic reactions, contributing to immediate hypersensitivity reactions. They also express TNF and OX40L, and are involved in the production of Th2 driving cytokines in AD. Mast cells can be identified by positive tryptase staining and their expression of OX40L in AD skin.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,2e0cdefd62bed7c674d7fb93ef336c2b,41ccc4b41bd57cf2bda4dbb6c7ae4198,691cb2e23ac3c6e591129d16714f8ef8,6ada075e562abd7bd445164e9fc309b4,6b099960b0a39866e3aa6b908f1886e4,83eb9003d42977bb83fea1d123dd5ab9,89dbac0da39e4de2b602052cd792b90d,bae090d8a29c15868ba1c4f29ae79e99,f2aa3fd6ae3f1853347874c50afb60ea</data>
      <data key="d3">CELL</data>
    </node>
    <node id="PPAR SIGNALING PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">PPAR signaling pathway is a biological process enriched among decreased DEGs in HS</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="STEROID BIOSYNTHESIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Steroid biosynthesis is a biological process enriched among decreased DEGs in HS</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="CHOLESTEROL BIOSYNTHETIC PROCESS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Cholesterol biosynthetic process is a KEGG pathway among decreased DEGs in HS</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="LIPID METABOLIC PROCESS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Lipid metabolic process is a KEGG pathway among decreased DEGs in HS</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE RESPONSE">
      <data key="d0">PATHWAY</data>
      <data key="d1">The immune response is a biological process enriched among increased differentially expressed genes (DEGs) in heat shock (HS). It is the body's defense mechanism against infections, diseases, and pathogens, involving various cells and proteins. This complex process is critically implicated in the pathogenesis and treatment of atopic dermatitis (AD), where it is often dysregulated. Understanding the immune response is essential for developing effective treatments for AD and other related conditions.</data>
      <data key="d2">143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524,2cec06c4d46f5ff9ee936a78d8b077cd,2e0cdefd62bed7c674d7fb93ef336c2b,3ce96e927d65736b305f792977fed4b9,44f2592262cac835560b4c149fee8d2b,90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="REGULATION OF IMMUNE RESPONSE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Regulation of immune response is a biological process enriched among increased DEGs in HS</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="FC-GAMMA RECEPTOR SIGNALING PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Fc-gamma receptor signaling pathway is a biological process enriched among increased DEGs in HS</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INNATE IMMUNE RESPONSE">
      <data key="d0">PATHWAY</data>
      <data key="d1">The innate immune response is a biological process enriched among increased differentially expressed genes (DEGs) in heat shock (HS). It serves as the body's first line of defense against pathogens, providing an immediate, non-specific response to a wide range of infectious agents.</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,6309eeea565f06479830cec32938abc9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="B CELL RECEPTOR SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">B cell receptor signaling is a biological process enriched among increased DEGs in HS</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="NEUTROPHIL CHEMOTAXIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Neutrophil chemotaxis is a biological process that involves the movement of neutrophils towards the site of infection or inflammation. This process is notably enriched among increased differentially expressed genes (DEGs) in HS, highlighting its significance in the immune response.</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,bae090d8a29c15868ba1c4f29ae79e99</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="SCRNA-SEQ">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Single-cell RNA sequencing (scRNA-Seq) is a method used to examine the gene expression of individual cells. This technique is instrumental in outlining the cellular composition of various tissues and conditions, including hematopoietic stem cells (HS). By providing a high-resolution view of cellular heterogeneity, scRNA-Seq enables researchers to gain insights into the complex cellular landscapes and molecular mechanisms underlying various biological processes and diseases.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,2e0cdefd62bed7c674d7fb93ef336c2b</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="CTLA-4">
      <data key="d0">GENE</data>
      <data key="d1">CTLA-4, also known as cytotoxic T-lymphocyte-associated protein 4, is a protein involved in the regulation of the immune response. It functions as a T cell inhibitory molecule that binds to CD80/86, leading to a reduction in IL-2 production and T cell proliferation. CTLA-4 is a gene involved in T-cell costimulatory pathways, specifically playing a role in negative costimulatory pathways. This protein is crucial for maintaining immune homeostasis and preventing overactivation of the immune system.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,1b656cfce91ff9ccec4223703489dab3,2e0cdefd62bed7c674d7fb93ef336c2b,41ccc4b41bd57cf2bda4dbb6c7ae4198,44f2592262cac835560b4c149fee8d2b,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81,9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="ICOS">
      <data key="d0">GENE</data>
      <data key="d1">ICOS, also known as Inducible T-cell COStimulator or inducible co-stimulatory molecule, is a costimulatory protein that plays a crucial role in T-cell immune responses. It is a member of the CD28 superfamily and is highly expressed in activated T cells. The ICOS gene is involved in T-cell costimulatory pathways, contributing to T-cell activation and survival. This protein is essential for inducing proinflammatory and pro-fibrotic cytokine synthesis in activated T cells, thereby participating in positive costimulatory pathways that enhance immune responses.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,1b656cfce91ff9ccec4223703489dab3,2e0cdefd62bed7c674d7fb93ef336c2b,44f2592262cac835560b4c149fee8d2b,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="CD70">
      <data key="d0">GENE</data>
      <data key="d1">CD70 is a gene involved in T-cell costimulatory pathways and encodes a protein that is a ligand in the TNF superfamily, also known as CD27L. This protein interacts with CD27 to provide stimulatory signals crucial for the activation of T cells and B cells. CD70 plays a significant role in T and B cell signaling, particularly through the CD70-CD27 costimulatory pathway, thereby contributing to the overall activation and function of these immune cells.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,1b656cfce91ff9ccec4223703489dab3,2e0cdefd62bed7c674d7fb93ef336c2b,4cf23e218b6aab3c77115173b5c7c2fd,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="CD27">
      <data key="d0">GENE</data>
      <data key="d1">CD27 is a gene that encodes a protein found on the surface of T cells, playing a crucial role in T-cell costimulatory pathways. As a member of the TNFRSF (Tumor Necrosis Factor Receptor Superfamily), CD27 acts as a costimulatory signal essential for T cell activation and survival. It is involved in the CD70-CD27 costimulatory pathway, which is important for the activation and regulation of both T and B cells. CD27 functions as a receptor for CD70, also known as S152 or Tp55, facilitating critical signaling processes in T and B cell function.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,1b656cfce91ff9ccec4223703489dab3,2e0cdefd62bed7c674d7fb93ef336c2b,4cf23e218b6aab3c77115173b5c7c2fd,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,7c13f41d7349d9d2e56c36e00c0ca2d9,b28eeca0ff01a7715947d55a04978a43,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="CD40">
      <data key="d0">GENE</data>
      <data key="d1">CD40 is a costimulatory protein and a member of the TNF receptor superfamily that plays a crucial role in immune and inflammatory responses. It is involved in the CD40-CD154 costimulatory pathway and is essential for the activation and regulation of immune responses. CD40 functions in T-cell costimulatory pathways and is involved in positive costimulatory pathways, highlighting its importance in the modulation and activation of the immune system.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,1b656cfce91ff9ccec4223703489dab3,2e0cdefd62bed7c674d7fb93ef336c2b,44f2592262cac835560b4c149fee8d2b,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="CD154">
      <data key="d0">GENE</data>
      <data key="d1">CD154, also known as CD40 ligand (CD40L), is a gene and protein that plays a crucial role in the regulation of immune responses. It is involved in T-cell costimulatory pathways and functions as a ligand for CD40. The interaction between CD154 and CD40 is essential for the activation of antigen-presenting cells and is a key component of the CD40-CD154 costimulatory pathway. This pathway is significant in positive costimulatory signaling, which is vital for effective immune responses.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,1b656cfce91ff9ccec4223703489dab3,2e0cdefd62bed7c674d7fb93ef336c2b,44f2592262cac835560b4c149fee8d2b,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="B CELL">
      <data key="d0">CELL</data>
      <data key="d1">B cells are a type of white blood cell and lymphocyte involved in the adaptive immune response, particularly in the production of antibodies. They play a crucial role in the immune response by producing antibodies and are affected in systemic sclerosis. B cell proliferation and differentiation are enhanced by the interaction between OX40 and OX40L.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,2a0384addc6e7fd709e0508b83496cd7,2e0cdefd62bed7c674d7fb93ef336c2b,44f2592262cac835560b4c149fee8d2b,48288f3ec2832850282f95d4e38d10e1,503107475d2e9dac49abd8ebcbadd9f5,8ce8c356713490cd2c680f505bcd050b,9867d43adab0ba5db44961fae4863eee,b2aae16813e647959b783a39ef9a19a7,e340a83f7cba0ea5be731b1f682ea7c7,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="T CELL">
      <data key="d0">CELL</data>
      <data key="d1">T cells are a type of lymphocyte and white blood cell that play a central role in the body's immune response, particularly in cell-mediated immunity. They are crucial components of the adaptive immune response and are involved in various immune and inflammatory processes. T cells are notably implicated in the pathophysiology of autoimmune diseases such as atopic dermatitis (AD) and systemic sclerosis. In AD, T cells are attracted to the skin during inflammation, contributing to the disease's inflammatory response.</data>
      <data key="d2">100dd7646c10899301b3c0631183da16,1412a7a7fef5f18cc09a030b97b18e13,2a0384addc6e7fd709e0508b83496cd7,2e0cdefd62bed7c674d7fb93ef336c2b,3ce96e927d65736b305f792977fed4b9,442e7fad2fab75fa2449309783294d89,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,6059a6e2710b7df94c6a09e5eb7b024a,8ce8c356713490cd2c680f505bcd050b,9867d43adab0ba5db44961fae4863eee,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="CD4+ NAIVE CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD4+ naive cells are a type of T cell involved in the immune response</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </node>
    <node id="NOTCH SIGNALING PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The Notch signaling pathway is involved in cell differentiation, proliferation, and apoptosis</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="CCL20">
      <data key="d0">PROTEIN</data>
      <data key="d1">CCL20 is a chemokine involved in immunoregulatory and inflammatory processes</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="B CELL ACTIVATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">B cell activation is the process by which B cells respond to antigens and produce antibodies</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="ANTIBACTERIAL HUMORAL RESPONSE">
      <data key="d0">PATHWAY</data>
      <data key="d1">The antibacterial humoral response involves the production of antibodies to neutralize bacterial pathogens</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="B CELL RECEPTOR SIGNALING PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The B cell receptor signaling pathway is crucial for B cell development and activation</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="IFN-&#915; MEDIATED SIGNALING PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The IFN-&#947; mediated signaling pathway is involved in the immune response to pathogens</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="INFLAMMATORY RESPONSE">
      <data key="d0">PATHWAY</data>
      <data key="d1">The inflammatory response is the body's reaction to injury or infection, involving immune cells, blood vessels, and molecular mediators. It is a crucial part of the immune system's reaction, playing a significant role in conditions such as atopic dermatitis. This complex process mobilizes immune cells and various molecules to the site of injury or infection to initiate healing and protect against further damage.</data>
      <data key="d2">143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524,3ce96e927d65736b305f792977fed4b9,bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="T CELL RECEPTOR SIGNALING PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The T cell receptor signaling pathway is essential for T cell activation and function</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="T CELL COSTIMULATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">T cell costimulation is a secondary signal required for T cell activation and survival</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="TNF-MEDIATED SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">TNF-mediated signaling is involved in inflammation and apoptosis</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="CYTOF">
      <data key="d0">TECHNIQUE</data>
      <data key="d1">CyTOF (Cytometry by Time-Of-Flight) is a mass cytometry technique used for high-dimensional single-cell analysis. This advanced method allows for the detailed examination of cell populations by measuring various properties, including protein expression. By leveraging the principles of mass spectrometry, CyTOF provides a comprehensive and nuanced understanding of cellular characteristics, making it a valuable tool in biomedical research, particularly in the study of complex diseases such as autoimmune disorders.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,b28eeca0ff01a7715947d55a04978a43,bae090d8a29c15868ba1c4f29ae79e99</data>
      <data key="d3">TECHNIQUE</data>
    </node>
    <node id="T-SNE">
      <data key="d0">TECHNIQUE</data>
      <data key="d1">t-SNE (t-Distributed Stochastic Neighbor Embedding) is a machine learning algorithm used for dimensionality reduction, specifically designed to visualize high-dimensional data by reducing it to two or three dimensions. This technique is widely employed to make complex, high-dimensional datasets more interpretable and accessible for analysis.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,b28eeca0ff01a7715947d55a04978a43,bae090d8a29c15868ba1c4f29ae79e99</data>
      <data key="d3">TECHNIQUE</data>
    </node>
    <node id="MONOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Monocytes are a type of white blood cell that play a crucial role in immune defense and inflammation. They have the ability to differentiate into macrophages and dendritic cells, which are essential for immune responses. Monocytes produce tumor necrosis factor (TNF) and primarily express TNF-related apoptosis-inducing ligand (TRAIL). These cells are also known to express receptors for APRIL (A Proliferation-Inducing Ligand) and BAFF (B-cell Activating Factor). In both patients with autoimmune diseases (AD) and healthy controls, monocytes express high levels of OX40L, a co-stimulatory molecule. Additionally, monocytes are hyperactive inflammatory cells that can be calmed down by the administration of methotrexate, a common immunosuppressive drug.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,27a7e95c7d3ad59a948aa46741fee456,286730b1c1f680ac465cc21d522fda0c,6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d,bae090d8a29c15868ba1c4f29ae79e99,c525762bb827485bceeb9f09bb4bcfe0,d4797ed1483e5057bcd8301eaa509d5e</data>
      <data key="d3">CELL</data>
    </node>
    <node id="LEUKOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Leukocytes are white blood cells involved in protecting the body against infections</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
      <data key="d3">CELL</data>
    </node>
    <node id="STROMAL CELLS">
      <data key="d0" />
      <data key="d1">Stromal cells are connective tissue cells that support the function of the parenchymal cells.</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51,bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="GENES">
      <data key="d0">GENE</data>
      <data key="d1">Genes are units of heredity that contribute to the characteristics and functions of an organism</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="TRANSCRIPTS">
      <data key="d0">GENE</data>
      <data key="d1">Transcripts are RNA molecules transcribed from DNA, representing gene expression</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="CELLPHONEDB">
      <data key="d0">TECHNIQUE</data>
      <data key="d1">CellPhoneDB is a computational tool and database used to analyze cell-cell communication via ligand-receptor interactions. It provides a comprehensive platform for understanding the complex signaling networks between cells by cataloging and interpreting the interactions between ligands and their corresponding receptors.</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="LIGAND">
      <data key="d0">PROTEIN</data>
      <data key="d1">A ligand is a molecule that binds to a specific receptor to initiate a biological response</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">A receptor is a protein on the cell surface or within cells that binds to specific ligands to trigger a response</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="CIRCOS PLOT">
      <data key="d0">TECHNIQUE</data>
      <data key="d1">A Circos plot is a graphical representation used to visualize complex data, such as interactions between entities</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="IL-36G">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-36G is a cytokine involved in both inflammatory and immune responses.</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </node>
    <node id="UMAP">
      <data key="d0">TECHNIQUE</data>
      <data key="d1">UMAP (Uniform Manifold Approximation and Projection) is a dimensionality reduction technique used for visualizing high-dimensional data. This method is designed to simplify complex datasets by reducing their dimensions, making it easier to interpret and analyze the underlying patterns and structures.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="ANTIMICROBIAL GENES">
      <data key="d0">GENE</data>
      <data key="d1">Antimicrobial genes encode proteins that help protect against microbial infections</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="LEUKOCYTE INFILTRATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Leukocyte infiltration refers to the accumulation of white blood cells in a tissue, often indicative of inflammation or infection</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="INFLAMMATORY BURDEN">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Inflammatory burden refers to the extent of inflammation present in a tissue or organism</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="INFLAMMATORY SIGNATURE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">An inflammatory signature is a pattern of gene or protein expression indicative of inflammation</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="INFLAMMATORY STIMULI">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Inflammatory stimuli are factors that trigger an inflammatory response</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="CYTOKINE RESPONSE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Cytokine response refers to the production and action of cytokines in response to a stimulus</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="MARKER GENES">
      <data key="d0">GENE</data>
      <data key="d1">Marker genes are genes used to identify specific cell types or states</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="SUBCLUSTERS">
      <data key="d0">CELL</data>
      <data key="d1">Subclusters are smaller groups within a larger cell population, identified through clustering analysis</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="DIMENSIONAL REDUCTION">
      <data key="d0">TECHNIQUE</data>
      <data key="d1">Dimensional reduction is a process used to reduce the number of variables in a dataset while preserving important information</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="MONOCYTE/MACROPHAGES">
      <data key="d0">CELL</data>
      <data key="d1">Monocytes and macrophages are types of white blood cells involved in the immune response and are present in HS skin</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606</data>
    </node>
    <node id="CD8+ T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD8+ T cells are a subset of T cells involved in the immune response. They are a type of white blood cell that plays a crucial role in the body's defense mechanisms. CD8+ T cells are present in HS (Hidradenitis Suppurativa) skin, indicating their involvement in this condition. Additionally, in patients with AD (Atopic Dermatitis), CD8+ T cells express OX40, a marker associated with immune activation.</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606,44f2592262cac835560b4c149fee8d2b,6b099960b0a39866e3aa6b908f1886e4</data>
    </node>
    <node id="IMMUNOGLOBULIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Immunoglobulins are antibodies produced by B cells that play a crucial role in identifying and neutralizing pathogens, thereby contributing significantly to the immune response. These antibodies are also produced by plasma cells and are known to be increased in HS (Hidradenitis Suppurativa) skin.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,411a4d246f0a9321e52971446a5a0606,44f2592262cac835560b4c149fee8d2b,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="COMPLEMENT">
      <data key="d0">PROTEIN</data>
      <data key="d1">Complement is a part of the immune system that enhances the ability of antibodies and phagocytic cells to clear microbes and damaged cells. Complement proteins are also activated in HS skin, indicating their role in immune responses within this specific context.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,411a4d246f0a9321e52971446a5a0606</data>
    </node>
    <node id="BCR">
      <data key="d0">GENE</data>
      <data key="d1">The B-cell receptor (BCR) is a molecule found on the surface of B cells that is responsible for recognizing specific antigens. It plays a crucial role in the immune response by binding to these antigens. The BCR is involved in B cell activation and signaling, which are essential processes for the proper functioning of the immune system. Additionally, B cell receptor gene segments are increased in HS (Hidradenitis Suppurativa) skin, indicating a potential role in the pathology of this condition.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="TCR">
      <data key="d0">GENE</data>
      <data key="d1">The T-cell receptor (TCR) is a molecule found on the surface of T cells that is responsible for recognizing antigens. TCRs are involved in T cell activation and signaling, playing a crucial role in the immune response. They bind to major histocompatibility complex (MHC) molecules carrying peptide antigens, facilitating the recognition of foreign particles. Additionally, T cell receptor gene segments are involved in the immune response and show less pronounced shifts in hypersensitivity (HS).</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606,855c455b4c9592746834ee3a4e0e6b81,b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="C1Q">
      <data key="d0">PROTEIN</data>
      <data key="d1">C1q is a protein that plays a crucial role in the complement system, which is a part of the immune response. It is prominently expressed in HS (Hidradenitis Suppurativa) skin. As a component of the complement pathway, C1q is integral to the body's defense mechanisms, contributing to the identification and elimination of pathogens.</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="C3B">
      <data key="d0">PROTEIN</data>
      <data key="d1">C3b is a breakdown product of the complement component C3 and is prominently expressed in HS skin. It is a protein involved in the complement system and plays a crucial role in opsonization.</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="C4D">
      <data key="d0">PROTEIN</data>
      <data key="d1">C4d is a breakdown product of the complement component C4 and is prominently expressed in HS skin. It is a protein involved in the complement system and plays a significant role in the immune response.</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="CR1">
      <data key="d0">PROTEIN</data>
      <data key="d1">CR1 (CD35), also known as Complement Receptor 1, is a protein involved in the immune response. It is found on the surface of various cells and plays a crucial role in the body's defense mechanisms. Notably, the expression of Complement Receptor 1 is increased in HS (Hidradenitis Suppurativa) skin, indicating its potential involvement in the pathophysiology of this condition.</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="CR2">
      <data key="d0">PROTEIN</data>
      <data key="d1">CR2 (CD21), also known as Complement receptor 2, is a protein involved in the immune response. It is found on the surface of B cells and plays a crucial role in the immune system. Additionally, Complement receptor 2 is observed to be increased in HS (Hidradenitis Suppurativa) skin, indicating its potential involvement in the pathology of this condition.</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="IGG">
      <data key="d0">PROTEIN</data>
      <data key="d1">Immunoglobulin G (IgG) is an antibody that plays a crucial role in the immune response. It is the most common type of antibody found in blood circulation. IgG is used as a control in studies of TL1A-driven inflammation and forms immune complexes that are deposited in HS skin.</data>
      <data key="d2">104cc78517b2eca2e9cb7e00de1fe4b0,411a4d246f0a9321e52971446a5a0606,4cf23e218b6aab3c77115173b5c7c2fd,c525762bb827485bceeb9f09bb4bcfe0,e340a83f7cba0ea5be731b1f682ea7c7,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="SYK">
      <data key="d0">PROTEIN</data>
      <data key="d1">SYK, or spleen tyrosine kinase, is a protein involved in the regulation of immune responses. It plays a crucial role in signal transduction in immune cells, including B cell receptor signaling and T cell activation. SYK is also involved in signaling for IgE receptors. Given its significant role in immune cell signaling, SYK is considered a potential therapeutic target in various conditions, including HS (Hidradenitis Suppurativa).</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,411a4d246f0a9321e52971446a5a0606,b62ecc47bf54393bc78dd65986b949d6,c46e8b6ee0c29e37b7f18c42558d7a3e,e340a83f7cba0ea5be731b1f682ea7c7,e4d25b1cd44df240a29591bc46a875ab,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="GRANZYME B">
      <data key="d0">PROTEIN</data>
      <data key="d1">Granzyme B is a serine protease with enriched signals in HS</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606</data>
    </node>
    <node id="CCR5">
      <data key="d0">PROTEIN</data>
      <data key="d1">CCR5 is a chemokine receptor with enriched signals in HS</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606</data>
    </node>
    <node id="ACALABRUTINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Acalabrutinib is a BTK (Bruton's tyrosine kinase) inhibitor with multiple therapeutic applications. It has been shown to prevent plasma cell generation in HS (Hidradenitis Suppurativa) and is being explored as a potential therapeutic for this condition. Additionally, Acalabrutinib is used in the treatment of certain cancers and autoimmune diseases. It is also employed as a chemical inhibitor in B cell stimulation experiments, highlighting its versatility in both clinical and research settings.</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,411a4d246f0a9321e52971446a5a0606,b62ecc47bf54393bc78dd65986b949d6,e340a83f7cba0ea5be731b1f682ea7c7,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="IBRUTINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Ibrutinib is a BTK (Bruton's tyrosine kinase) inhibitor that has multiple applications in medical research and treatment. It is primarily known for its role in the treatment of certain cancers and autoimmune diseases. In addition to its therapeutic uses, ibrutinib has been shown to prevent plasma cell generation in Hemophagocytic Syndrome (HS) and is considered a potential therapeutic option for this condition. Furthermore, ibrutinib is utilized in B cell stimulation experiments, highlighting its importance in both clinical and experimental settings.</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,411a4d246f0a9321e52971446a5a0606,b62ecc47bf54393bc78dd65986b949d6,e340a83f7cba0ea5be731b1f682ea7c7,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="CCL4">
      <data key="d0">PROTEIN</data>
      <data key="d1">CCL4 is a chemokine involved in the recruitment of immune cells to sites of inflammation. It plays a significant role as a monocyte chemokine in the immune response in hidradenitis suppurativa (HS). Additionally, CCL4 acts as a proinflammatory mediator, and its expression is notably decreased by B cell targeting in HS. 

Carbon tetrachloride, on the other hand, is a chemical distinct from CCL4. It is commonly used to induce liver fibrosis and cirrhosis in experimental models.</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606,a10787d7fbb1307be263e86dc7b33a51,b62ecc47bf54393bc78dd65986b949d6,d4797ed1483e5057bcd8301eaa509d5e,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </node>
    <node id="CD3+ T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD3+ T cells are a type of white blood cell involved in the immune response and are present in HS skin</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606</data>
    </node>
    <node id="CD20+ B CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD20+ B cells are a type of white blood cell involved in the immune response and are present in HS skin</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606</data>
    </node>
    <node id="CD138+ PLASMA CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD138+ plasma cells are a type of white blood cell involved in the immune response and are present in HS skin</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606</data>
    </node>
    <node id="PHOSPHO-BTK">
      <data key="d0">PROTEIN</data>
      <data key="d1">Phospho-BTK is the phosphorylated form of Bruton's tyrosine kinase (BTK), an activated form of the BTK protein. It plays a crucial role in B cell receptor signaling. The levels of phosphorylated BTK are increased in certain conditions, such as HS (Hemophagocytic Syndrome).</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="PHOSPHO-SYK">
      <data key="d0">PROTEIN</data>
      <data key="d1">Phospho-SYK is the phosphorylated form of the SYK protein, which plays a crucial role in signal transduction in immune cells. This activated form of spleen tyrosine kinase is particularly involved in B cell receptor signaling and has been observed to be increased in certain conditions, such as HS.</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="LEUKOCYTE">
      <data key="d0">CELL</data>
      <data key="d1">Leukocytes, also known as white blood cells, are cells of the immune system involved in protecting the body against infections, infectious diseases, and foreign invaders. They play a crucial role in the immune response and are often clustered in HS (Hidradenitis Suppurativa) skin.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,411a4d246f0a9321e52971446a5a0606,442e7fad2fab75fa2449309783294d89,7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="CD20">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD20 is a protein expressed on the surface of B cells. It is involved in B cell activation and proliferation. CD20 serves as a marker for B cells and is targeted by the therapeutic agent rituximab.</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,b62ecc47bf54393bc78dd65986b949d6,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="CD138">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD138 is a protein marker found on the surface of plasma cells. It is involved in cell adhesion and plays a role in TNF expression in HS (Hidradenitis Suppurativa).</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,b62ecc47bf54393bc78dd65986b949d6,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="CD8">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD8 is a glycoprotein found on the surface of cytotoxic T cells, also known as CD8+ T cells. It serves as a crucial protein marker in immunology, particularly in the identification and analysis of these cells through techniques such as flow cytometry. CD8 plays a significant role in the immune response, aiding cytotoxic T cells in recognizing and eliminating infected or malignant cells.</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746,411a4d246f0a9321e52971446a5a0606,89dbac0da39e4de2b602052cd792b90d,b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="CD3">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD3 is a protein complex and T cell co-receptor found on the surface of T cells. It serves as a marker for T cells and plays a crucial role in their activation. Specifically, CD3 is involved in activating both cytotoxic T cells and T helper cells, making it essential for the immune response.</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,b62ecc47bf54393bc78dd65986b949d6,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="IGM">
      <data key="d0">PROTEIN</data>
      <data key="d1">Immunoglobulin M (IgM) is an immunoglobulin involved in the immune response. It is a basic antibody that is produced by B cells and plays a crucial role in the body's defense mechanisms. As a type of antibody, IgM is one of the first responders in the immune system, providing an initial defense against infections.</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606,e340a83f7cba0ea5be731b1f682ea7c7,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="SHANNON INDEX">
      <data key="d0">METRIC</data>
      <data key="d1">The Shannon index is a measure of diversity in a population</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606</data>
    </node>
    <node id="JACCARD DISTANCE">
      <data key="d0">METRIC</data>
      <data key="d1">The Jaccard distance is a measure of dissimilarity between sample sets</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606</data>
    </node>
    <node id="PCOA">
      <data key="d0">TECHNIQUE</data>
      <data key="d1">Principal coordinates analysis (PCoA) is a technique used to visualize similarities or dissimilarities in data. This method, also known as PCoA, is particularly useful for visualizing dissimilarities between samples, allowing researchers to better understand the relationships and variations within their data sets.</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="IHC">
      <data key="d0">TECHNIQUE</data>
      <data key="d1">Immunohistochemistry (IHC) is a technique used to visualize the presence and location of proteins in tissue sections. It is a method for detecting specific antigens in cells or tissues, allowing researchers to study the distribution and localization of these proteins within the biological samples.</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="GEPS">
      <data key="d0">TECHNIQUE</data>
      <data key="d1">GEPS, also known as the Genomatix-Pathway System, is a version of Genomatix software designed for creating and analyzing biological literature-based networks. It serves as a powerful tool for conducting literature-based network analysis, specifically focusing on signal transduction networks. By leveraging the Gene Pattern Search functionality, GEPS enables researchers to explore and interpret complex biological interactions and pathways, facilitating a deeper understanding of molecular mechanisms and their implications in various biological processes.</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="BCR SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">B cell receptor signaling is a pathway involved in B cell activation and function</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606</data>
    </node>
    <node id="SYK SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Spleen tyrosine kinase signaling is a pathway involved in immune cell activation</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606</data>
    </node>
    <node id="BTK SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Bruton&#8217;s tyrosine kinase signaling is a pathway involved in B cell activation and function</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606</data>
    </node>
    <node id="COMPLEMENT PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The COMPLEMENT PATHWAY is a part of the immune system that enhances the ability of antibodies and phagocytic cells to clear microbes and damaged cells. It plays a crucial role in augmenting the immune response to clear pathogens effectively.</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="GAMMA-SECRETASE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Gamma-secretase is an enzyme complex involved in the regulation of Notch signaling</data>
      <data key="d2">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </node>
    <node id="NCSTN">
      <data key="d0">GENE</data>
      <data key="d1">NCSTN is a gene encoding a component of the gamma-secretase complex</data>
      <data key="d2">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </node>
    <node id="PSENEN">
      <data key="d0">GENE</data>
      <data key="d1">PSENEN is a gene encoding a component of the gamma-secretase complex</data>
      <data key="d2">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </node>
    <node id="PSEN1">
      <data key="d0">GENE</data>
      <data key="d1">PSEN1 is a gene encoding a component of the gamma-secretase complex</data>
      <data key="d2">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </node>
    <node id="NEUTROPHIL">
      <data key="d0">CELL</data>
      <data key="d1">Neutrophils are a type of white blood cell involved in the innate immune response.</data>
      <data key="d2">6309eeea565f06479830cec32938abc9,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </node>
    <node id="CD4+ T CELL">
      <data key="d0">CELL</data>
      <data key="d1">CD4+ T cells are a type of T cell that play a key role in the immune system. These immune cells are crucial for orchestrating the immune response. Additionally, CD4+ T cells are involved in the production of cytokines such as IL-4 and IL-13, which are important for modulating immune functions.</data>
      <data key="d2">28f548554737fcc026b968db6bbafa30,8ce8c356713490cd2c680f505bcd050b,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </node>
    <node id="TYPE I IFNS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Type I interferons are a group of cytokines involved in the antiviral response</data>
      <data key="d2">e340a83f7cba0ea5be731b1f682ea7c7</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="MX1">
      <data key="d0">GENE</data>
      <data key="d1">MX1 is a gene encoding a protein involved in the antiviral response. The MX1 protein plays a crucial role in the body's defense mechanism against viral infections.</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b,e340a83f7cba0ea5be731b1f682ea7c7</data>
      <data key="d3">GENE</data>
    </node>
    <node id="IFI27">
      <data key="d0">GENE</data>
      <data key="d1">IFI27 is a gene encoding a protein involved in the interferon response. It is proposed to be driven by neutrophil extracellular traps (NETs) interacting with infiltrating plasmacytoid dendritic cells (pDCs) in lesional hidradenitis suppurativa (HS) skin.</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6,e340a83f7cba0ea5be731b1f682ea7c7</data>
      <data key="d3">GENE</data>
    </node>
    <node id="PDC">
      <data key="d0">CELL</data>
      <data key="d1">Plasmacytoid dendritic cells are a type of immune cell involved in the production of interferons</data>
      <data key="d2">e340a83f7cba0ea5be731b1f682ea7c7</data>
      <data key="d3">CELL</data>
    </node>
    <node id="IL-36A">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-36A is a cytokine involved in the immune response</data>
      <data key="d2">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </node>
    <node id="NETS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Neutrophil extracellular traps (NETs) are structures released by neutrophils that can interact with pDCs in lesional HS skin</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
    </node>
    <node id="PDCS">
      <data key="d0">CELL</data>
      <data key="d1">Plasmacytoid dendritic cells (pDCs) are immune cells that interact with NETs in lesional HS skin</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
    </node>
    <node id="IFN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interferons (IFNs) are a group of signaling proteins involved in the immune response. They play a crucial role in the body's defense mechanisms, with different types including type I and type II IFNs. These proteins are essential for the regulation and activation of immune cells, helping to combat infections and diseases.</data>
      <data key="d2">104cc78517b2eca2e9cb7e00de1fe4b0,b62ecc47bf54393bc78dd65986b949d6</data>
    </node>
    <node id="LCK">
      <data key="d0">PROTEIN</data>
      <data key="d1">LCK, also known as lymphocyte-specific protein tyrosine kinase, is a crucial protein involved in both B cell and T cell signaling. It functions as a protein tyrosine kinase, playing a significant role in T cell receptor signaling. Additionally, LCK has been identified as a potential therapeutic target in various conditions, including HS (Hidradenitis Suppurativa), due to its involvement in immune cell signaling pathways.</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,b62ecc47bf54393bc78dd65986b949d6,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="DERMIS">
      <data key="d0">TISSUE</data>
      <data key="d1">The dermis is the inner layer of the skin, situated beneath the epidermis. It contains connective tissue, blood vessels, and nerves. In the context of Atopic Dermatitis, the dermis is notable for the co-location of OX40+ and OX40L+ cells. Additionally, higher levels of TAC have been observed in the dermis when PLG-based nanoparticles are used. During sample preparation for single-cell RNA sequencing (scRNA-Seq), the dermis is separated for analysis.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,3ce96e927d65736b305f792977fed4b9,442e7fad2fab75fa2449309783294d89,691cb2e23ac3c6e591129d16714f8ef8,6aef5adb1be227170f66c76a292c25e5,89dbac0da39e4de2b602052cd792b90d,b62ecc47bf54393bc78dd65986b949d6,bddc3b1a7f098e71f0aa64adec047124</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="MICE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Mice are a model organism extensively used in biological experiments and biomedical research. They serve as a crucial tool in experimental studies of liver fibrosis, cardiovascular diseases, and immunogenetics. Mice are also employed in preclinical studies, although no animal models exist for HS (Hidradenitis Suppurativa). They are instrumental in studying the effects of interleukins IL-4 and IL-13 in atopic dermatitis, as well as the impact of Staphylococcus aureus on skin inflammation. Additionally, mice are used to investigate the effects of TL1A on inflammation and fibrosis, and the consequences of oxidative stress. They are valuable for examining various treatments and conditions. Notably, mice possess two TRAIL decoy receptors and a single TRAIL death receptor (mDR5), which is similar to the human DR5 receptor.</data>
      <data key="d2">28f548554737fcc026b968db6bbafa30,2a0384addc6e7fd709e0508b83496cd7,3dfbb4c51838e0951f53ce951395225f,41ccc4b41bd57cf2bda4dbb6c7ae4198,44f2592262cac835560b4c149fee8d2b,9867d43adab0ba5db44961fae4863eee,a10787d7fbb1307be263e86dc7b33a51,b28eeca0ff01a7715947d55a04978a43,b62ecc47bf54393bc78dd65986b949d6,c525762bb827485bceeb9f09bb4bcfe0,d4797ed1483e5057bcd8301eaa509d5e</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="HANK&#8217;S BALANCED SALINE SOLUTION">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hank&#8217;s Balanced Saline Solution is used in the preparation of single-cell suspensions for scRNA-Seq</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="TRYPSIN-EDTA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Trypsin-EDTA is used to digest the epidermis during sample preparation for scRNA-Seq</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="DNASE I">
      <data key="d0">CHEMICAL</data>
      <data key="d1">DNase I is used to digest DNA during sample preparation for scRNA-Seq</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="FBS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Fetal Bovine Serum (FBS) is used to quench trypsin activity during sample preparation for scRNA-Seq</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="COLLAGENASE II">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Collagenase II is used to digest the dermis during sample preparation for scRNA-Seq</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="COLLAGENASE V">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Collagenase V is used to digest the dermis during sample preparation for scRNA-Seq</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="10X GENOMICS CHROMIUM SYSTEM">
      <data key="d0">CHEMICAL</data>
      <data key="d1">The 10x Genomics Chromium system is used for constructing single-cell RNA sequencing libraries</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="ILLUMINA NOVASEQ 6000">
      <data key="d0">CHEMICAL</data>
      <data key="d1">The Illumina NovaSeq 6000 is a sequencing platform used for high-throughput sequencing. It is specifically designed to generate paired-end reads, making it highly suitable for applications such as single-cell RNA sequencing (scRNA-Seq). This advanced sequencer enables researchers to perform comprehensive and detailed genetic analyses, facilitating a wide range of genomic studies.</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,b62ecc47bf54393bc78dd65986b949d6</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="SEURAT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Seurat is a software used for normalization, data integration, and clustering analysis in scRNA-Seq</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="RNALATER">
      <data key="d0">CHEMICAL</data>
      <data key="d1">RNAlater is a solution used to preserve RNA in skin biopsy samples</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="ILLUMINA NEXTSEQ">
      <data key="d0">CHEMICAL</data>
      <data key="d1">The Illumina NextSeq is a sequencing platform used for RNA sequencing.</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43,b62ecc47bf54393bc78dd65986b949d6</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="STAR">
      <data key="d0">CHEMICAL</data>
      <data key="d1">STAR is a software used for mapping RNA-Seq reads to the human genome</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="GRCH37">
      <data key="d0">CHEMICAL</data>
      <data key="d1">GRCh37 is a human genome build used as a reference for mapping sequence reads, including RNA-Seq reads.</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43,b62ecc47bf54393bc78dd65986b949d6</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="GENCODE V24">
      <data key="d0">CHEMICAL</data>
      <data key="d1">GENCODE v24 is a gene annotation used for quantifying gene expression levels in RNA-Seq</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="CD123">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD123 is a marker for plasmacytoid dendritic cells (pDCs)</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
    </node>
    <node id="CD303">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD303 is a marker for plasmacytoid dendritic cells (pDCs)</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
    </node>
    <node id="RNA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">RNA is a molecule essential for various biological roles, including coding, decoding, regulation, and expression of genes. It is a nucleic acid involved in gene expression and regulation and plays a crucial role in the synthesis of proteins in cells.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,2a0384addc6e7fd709e0508b83496cd7,b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="HTSEQ">
      <data key="d0">CHEMICAL</data>
      <data key="d1">HTSeq is a software used for analyzing high-throughput sequencing data</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="DESEQ2">
      <data key="d0">CHEMICAL</data>
      <data key="d1">DESeq2 is a software package used for differential gene expression analysis based on RNA-Seq data</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="MIXCR">
      <data key="d0">CHEMICAL</data>
      <data key="d1">MiXCR is a software used for extracting TCR and BCR CDR3 sequences from RNA-Seq data</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="IMGT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">International ImMunoGeneTics (IMGT) is a database and nomenclature system for immunogenetics</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="CD14">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD14 is a protein expressed on the surface of macrophages and is involved in the recognition of bacterial lipopolysaccharides. Additionally, CD14 serves as a protein marker used in flow cytometry for identifying monocytes.</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746,b28eeca0ff01a7715947d55a04978a43</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CD16">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD16 is a protein found on the surface of natural killer cells and some T cells, involved in antibody-dependent cellular cytotoxicity</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CD68">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD68 is a protein highly expressed by macrophages and is used as a marker for these cells</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CD15">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD15 is a protein expressed on the surface of neutrophils and some other cells, involved in cell adhesion</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CD31">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD31 is a protein found on the surface of endothelial cells and is involved in leukocyte transmigration</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CD45">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD45 is a protein tyrosine phosphatase receptor type C found on the surface of all nucleated hematopoietic cells. It plays a crucial role in the signaling pathways of T and B cell receptors, thereby being integral to the immune response.</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="E-CADHERIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">E-Cadherin is a protein involved in cell-cell adhesion in epithelial tissues</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="COLLAGEN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Collagen is a structural protein that is a major component of connective tissues, including the skin and the extracellular matrix. It plays a crucial role in the formation and maintenance of these tissues. Collagen deposition is a key process in fibrosis, a condition characterized by excessive connective tissue formation. This protein is deposited by fibroblasts during fibrotic skin remodeling, such as in atopic dermatitis (AD). The measurement of collagen deposition is used to assess the extent of fibrosis, and its levels are known to increase in fibrotic conditions. Anti-TL1A treatment has been shown to reduce collagen deposition, highlighting its potential therapeutic role in managing fibrosis.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,1596d061dbe1a1c9e8f31a02a21e5524,48de7eebab3f3b418feb35a152df38fd,4cf23e218b6aab3c77115173b5c7c2fd,5f37466ca41c9b8b06ed8be0303d49f2,a10787d7fbb1307be263e86dc7b33a51,b28eeca0ff01a7715947d55a04978a43,b2aae16813e647959b783a39ef9a19a7,c525762bb827485bceeb9f09bb4bcfe0,d4797ed1483e5057bcd8301eaa509d5e</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CD103">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD103 is a protein found on the surface of certain T cells and is involved in cell adhesion</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="PAN-ACTIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Pan-actin is a protein involved in cell structure and motility</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="INTERCALATOR-IR">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Intercalator-Ir is a chemical used for staining cells in CyTOF imaging</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="HYPERION IMAGING SYSTEM">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hyperion Imaging System is a platform used for high-dimensional imaging of tissues</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="CELLPROFILER">
      <data key="d0">CHEMICAL</data>
      <data key="d1">CellProfiler is a software used for cell image analysis</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="PHENOGRAPH">
      <data key="d0">CHEMICAL</data>
      <data key="d1">PHENOGRAPH is a computational method and unsupervised clustering algorithm designed for identifying cell populations in high-dimensional single-cell data. It is specifically utilized in the analysis of high-dimensional single-cell data, enabling researchers to discern distinct cell populations without prior knowledge or supervision.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="HISTOCAT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">HistoCAT is a software used for high-dimensional single-cell data analysis</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="SHANNON DIVERSITY INDEX">
      <data key="d0">CHEMICAL</data>
      <data key="d1">The SHANNON DIVERSITY INDEX is a measure of diversity in a community, used here to describe BCR gene segment diversity. It incorporates both evenness and richness, providing a comprehensive assessment of the variety and distribution of elements within the community.</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="JACCARD DISTANCES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Jaccard distances are a measure of dissimilarity between sample sets</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="INTERNAL ORGANS">
      <data key="d0">TISSUE</data>
      <data key="d1">Internal organs are the organs inside the body, such as the heart, liver, and lungs. These organs are composed of tissues that can be affected by systemic diseases.</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43,c46e8b6ee0c29e37b7f18c42558d7a3e</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="CDR3">
      <data key="d0">PROTEIN</data>
      <data key="d1">CDR3, or the third complementarity-determining region, is a critical component of both T cell receptors (TCR) and B cell receptors (BCR). This region is part of the variable chains in immunoglobulins and T cell receptors, playing a crucial role in the specificity of antigen binding. The unique structure of CDR3 allows it to contribute significantly to the antigen specificity of these receptors, making it essential for the immune system's ability to recognize and respond to a diverse array of antigens.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="CD35">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD35, also known as CR1, is a protein involved in the immune response and found on the surface of various cells</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="CD21">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD21, also known as CR2, is a protein involved in the immune response and found on the surface of B cells</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="FORMALIN-FIXED, PARAFFIN-EMBEDDED TISSUE">
      <data key="d0">TISSUE</data>
      <data key="d1">Formalin-fixed, paraffin-embedded tissue is a method of preserving tissue samples for histological analysis. This technique involves fixing the tissue in formalin to preserve cellular structures and then embedding it in paraffin wax to create a stable medium for sectioning and microscopic examination.</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="HEALTHY CONTROL SKIN">
      <data key="d0">TISSUE</data>
      <data key="d1">Healthy control skin is used as a reference tissue in comparative studies</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="HIDRADENITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Hidradenitis is a chronic skin condition characterized by inflamed and swollen lumps</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="DMSO">
      <data key="d0">CHEMICAL</data>
      <data key="d1">DMSO is a solvent used in biological experiments</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
    </node>
    <node id="FOSTAMATINIB DISODIUM">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Fostamatinib disodium is a chemical inhibitor used in B cell stimulation experiments</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
    </node>
    <node id="DAPI">
      <data key="d0">CHEMICAL</data>
      <data key="d1">DAPI is a fluorescent stain that binds strongly to DNA, with a particular affinity for A-T rich regions.</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="HUMAN">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Humans are the species from which the tissue samples were obtained</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
    </node>
    <node id="GRCH38">
      <data key="d0">GENE</data>
      <data key="d1">GRCh38 is a reference genome assembly used for mapping reads in RNA-Seq experiments</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">GENE</data>
    </node>
    <node id="DESEQ">
      <data key="d0">GENE</data>
      <data key="d1">DESeq is a software tool used for differential expression analysis in RNA-Seq data</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">GENE</data>
    </node>
    <node id="SCIDAP">
      <data key="d0">PATHWAY</data>
      <data key="d1">SciDAP is a platform used for scientific data analysis, including RNA-Seq data</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="TRIM GALORE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Trim Galore is a software tool used for trimming adapters in RNA-Seq data</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
    </node>
    <node id="PCA">
      <data key="d0">PATHWAY</data>
      <data key="d1">Principal Component Analysis (PCA) is a statistical method used for principal component analysis in gene expression data. It is a statistical procedure that converts observations of possibly correlated variables into a set of values of linearly uncorrelated variables. This transformation is achieved by identifying the principal components, which are the directions in the data that maximize variance, thereby simplifying the complexity of the data while retaining its essential patterns.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="FDR">
      <data key="d0">PATHWAY</data>
      <data key="d1">False Discovery Rate (FDR) is a statistical method used to control the false discovery rate in multiple testing. It is employed in multiple hypothesis testing to correct for multiple comparisons, ensuring that the proportion of false positives among the declared significant results is minimized.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="STUDENT&#8217;S T TEST">
      <data key="d0">PATHWAY</data>
      <data key="d1">STUDENT'S T TEST is a statistical test used to compare the means of two groups.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="MANN-WHITNEY U TEST">
      <data key="d0">PATHWAY</data>
      <data key="d1">The Mann-Whitney U test is a nonparametric test used to determine whether there is a difference between two independent groups. It is specifically designed to compare differences between these groups without assuming a normal distribution of the data.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="ALEXA FLUOR 488">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Alexa Fluor 488 is a fluorescent dye used for labeling antibodies</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="ALEXA FLUOR 594">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Alexa Fluor 594 is a fluorescent dye used for labeling antibodies</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="DONKEY SERUM">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Donkey Serum is used as a blocking agent in immunofluorescence experiments. Specifically, it is employed to block slides before staining, thereby preventing non-specific binding of antibodies and ensuring more accurate and reliable results in various immunological assays.</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,2e9a8d71f6bd251a0b13458c39e69746</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="PBS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">PBS is a buffer solution used in biological experiments and research.</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3,2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="NEW ENGLAND BIOLABS">
      <data key="d0">PATHWAY</data>
      <data key="d1">New England Biolabs is a company that provides reagents for molecular biology experiments</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="QIAGEN">
      <data key="d0">PATHWAY</data>
      <data key="d1">QIAGEN is a company that provides reagents for nucleic acid isolation and purification</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="VECTASHIELD">
      <data key="d0">CHEMICAL</data>
      <data key="d1">VECTASHIELD is an antifade mounting medium used in microscopy</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="EASYSEP">
      <data key="d0">PATHWAY</data>
      <data key="d1">EasySep is a kit used for isolating specific cell types from blood</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="LYMPHOPREP">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Lymphoprep is a reagent used for isolating lymphocytes from blood</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="GOAT F(AB&#8242;)2 ANTI-HUMAN IGM">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Goat F(ab&#8242;)2 Anti-Human IgM is an antibody used for stimulating B cells</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="GOAT F(AB&#8242;)2 ANTI-HUMAN IGG">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Goat F(ab&#8242;)2 Anti-Human IgG is an antibody used for stimulating B cells</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="4&#8242;,6-DIAMIDINO-2-PHENYLINDOLE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">4&#8242;,6-diamidino-2-phenylindole (DAPI) is a fluorescent stain that binds strongly to DNA</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="ZEISS AXIOSKOP 2">
      <data key="d0">PATHWAY</data>
      <data key="d1">Zeiss Axioskop 2 is a microscope used for imaging biological samples</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">National Center for Biotechnology Information is a database for storing biological data</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="GSE154775">
      <data key="d0">PATHWAY</data>
      <data key="d1">GSE154775 is an accession number for a transcriptomic data set in the Gene Expression Omnibus database</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="GSE154773">
      <data key="d0">PATHWAY</data>
      <data key="d1">GSE154773 is an accession number for a transcriptomic data set in the Gene Expression Omnibus database</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="GENOMATIX">
      <data key="d0">PATHWAY</data>
      <data key="d1">Genomatix is a software tool used for creating biological literature-based networks</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNOFLUORESCENCE">
      <data key="d0" />
      <data key="d1">Immunofluorescence is a technique used to show the co-location of OX40+ and OX40L+ cells within the dermis in Atopic Dermatitis.</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,691cb2e23ac3c6e591129d16714f8ef8</data>
    </node>
    <node id="DONKEY ANTI-RABBIT IGG">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Donkey anti-rabbit IgG is a secondary antibody used in immunofluorescence experiments</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
    </node>
    <node id="DONKEY ANTI-MOUSE IGG">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Donkey anti-mouse IgG is a secondary antibody used in immunofluorescence experiments</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
    </node>
    <node id="BUFFY COAT">
      <data key="d0">TISSUE</data>
      <data key="d1">Buffy coat is a fraction of blood containing most of the white blood cells and platelets</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
    </node>
    <node id="POLY(A)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Poly(A) is a sequence of adenine nucleotides added to RNA molecules</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
    </node>
    <node id="STRANDED MRNA LIBRARIES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Stranded mRNA libraries are collections of mRNA sequences used for sequencing</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
    </node>
    <node id="TRIM GALORE RNA-SEQ PIPELINE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Trim Galore RNA-Seq pipeline is a software tool used for trimming adapters in RNA-Seq data</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
    </node>
    <node id="TISSUE">
      <data key="d0" />
      <data key="d1">Tissue refers to a group of cells that perform a specific function, often affected in fibrotic diseases.</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,516e41e96d2e72d45bf1e2c69da7f18a</data>
    </node>
    <node id="KERATINOCYTE">
      <data key="d0">CELL</data>
      <data key="d1">Keratinocytes are the predominant cell type in the epidermis, the outermost layer of the skin. They play a crucial role in forming a barrier against environmental damage and are integral to skin barrier function. These skin cells can be damaged by IL-4, which leads to reduced expression of essential proteins such as filaggrin, loricrin, and involucrin. This damage is particularly evident in conditions like atopic dermatitis, where keratinocyte impairment contributes to barrier dysfunction.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,28f548554737fcc026b968db6bbafa30,3ce96e927d65736b305f792977fed4b9,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="ERASMUS MC">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Erasmus University Medical Center, a medical institution involved in the study and treatment of various diseases</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13</data>
    </node>
    <node id="DECLARATION OF HELSINKI">
      <data key="d0">PATHWAY</data>
      <data key="d1">A set of ethical principles for medical research involving human subjects</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INSTITUTIONAL REVIEW BOARD">
      <data key="d0">PATHWAY</data>
      <data key="d1">A committee that reviews and approves research involving human subjects to ensure ethical standards are met</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="BIOPSY">
      <data key="d0">PATHWAY</data>
      <data key="d1">A medical test involving the extraction of sample cells or tissues for examination</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="ABDOMINOPLASTY">
      <data key="d0">PATHWAY</data>
      <data key="d1">A surgical procedure to remove excess skin and fat from the abdomen</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="SURGERY">
      <data key="d0">PATHWAY</data>
      <data key="d1">A medical procedure involving an incision with instruments to treat a condition or injury</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PROINFLAMMATORY CYTOKINE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Cytokines that promote systemic inflammation</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="DEG">
      <data key="d0">GENE</data>
      <data key="d1">Differentially Expressed Genes, genes that show statistically significant differences in expression levels between different conditions</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13</data>
      <data key="d3">GENE</data>
    </node>
    <node id="RECEPTOR-LIGAND">
      <data key="d0">PROTEIN</data>
      <data key="d1">Molecules that bind to specific receptors to initiate a cellular response</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="PLASMA CELL">
      <data key="d0">CELL</data>
      <data key="d1">PLASMA CELL: Plasma cells are a type of white blood cell that produces antibodies.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,e4d25b1cd44df240a29591bc46a875ab</data>
      <data key="d3">CELL</data>
    </node>
    <node id="B7RP1">
      <data key="d0">PROTEIN</data>
      <data key="d1">B7RP1, also known as B7-related protein 1, is a protein involved in T-cell activation and positive costimulatory pathways. It plays a crucial role in T cell costimulation, specifically through the ICOS-B7RP1 costimulatory pathway.</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="DERMATOLOGY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The branch of medicine dealing with the skin and its diseases</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INFLAMMATORY INFILTRATE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Accumulation of inflammatory cells in tissue</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="STROMAL TISSUE">
      <data key="d0">TISSUE</data>
      <data key="d1">The connective tissue cells that support the function of the parenchymal cells of an organ</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="ERASMUS UNIVERSITY MEDICAL CENTER">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Erasmus University Medical Center, a medical institution involved in the study and treatment of various diseases</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13</data>
    </node>
    <node id="JUN">
      <data key="d0">PROTEIN</data>
      <data key="d1">JUN is a protein that is part of the AP-1 transcription factor complex</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="STAT1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Signal transducer and activator of transcription 1, involved in cytokine signaling</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="BCR CDR3">
      <data key="d0">PROTEIN</data>
      <data key="d1">B cell receptor complementarity-determining region 3, a critical part of the BCR involved in antigen binding</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="BCR GENE SEGMENT">
      <data key="d0">GENE</data>
      <data key="d1">Segments of the B cell receptor gene involved in the diversity of the immune response</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="TCR V/J GENE SEGMENT">
      <data key="d0">GENE</data>
      <data key="d1">Segments of the T cell receptor gene involved in the diversity of the immune response</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="B CELL SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">A signaling pathway involved in the activation and function of B cells</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INFLAMMATORY NODES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Critical points in signaling pathways that regulate inflammation</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="SIGNAL TRANSDUCTION NETWORKS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Networks of molecular signals that control cellular responses</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="JACCARD DISSIMILARITIES">
      <data key="d0">PATHWAY</data>
      <data key="d1">A measure of how dissimilar two sets are, used in PCoA</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="CLONAL ABUNDANCE">
      <data key="d0">PATHWAY</data>
      <data key="d1">The frequency of specific clones of cells, used here to describe BCR and TCR repertoires</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IG HEAVY CHAIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">The heavy chain of an immunoglobulin molecule, part of the antibody structure</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="&#922; LIGHT CHAIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Kappa light chain, one of the two types of light chains in antibodies</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="&#923; LIGHT CHAIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Lambda light chain, one of the two types of light chains in antibodies</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="BCR CDR3 EXPRESSION">
      <data key="d0">PROTEIN</data>
      <data key="d1">B cell receptor complementarity-determining region 3 expression, involved in antigen binding and immune response</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="BCR GENE SEGMENT EXPRESSION">
      <data key="d0">GENE</data>
      <data key="d1">Expression of gene segments of the B cell receptor, contributing to immune diversity</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="TCR V/J GENE SEGMENT EXPRESSION">
      <data key="d0">GENE</data>
      <data key="d1">Expression of gene segments of the T cell receptor, contributing to immune diversity</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="C4">
      <data key="d0">PROTEIN</data>
      <data key="d1">Complement component 4, a protein involved in the complement system</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="TYPE 2 T HELPER CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Type 2 T helper (Th2) cells are involved in the inappropriate activation in Atopic Dermatitis</data>
      <data key="d2">693a2aac101eaaadf92614317a1e4da8</data>
    </node>
    <node id="CORTICOSTEROIDS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Corticosteroids are systemic immunosuppressants and anti-inflammatory drugs used in the treatment of Atopic Dermatitis (AD). While they are effective in managing the symptoms of AD, they present tolerability issues that need to be considered in their use.</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,48de7eebab3f3b418feb35a152df38fd,693a2aac101eaaadf92614317a1e4da8</data>
    </node>
    <node id="PIMECROLIMUS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Pimecrolimus is a topical calcineurin inhibitor approved for the treatment of Atopic Dermatitis (AD). It is an immunosuppressive drug used to treat eczema and other inflammatory skin conditions.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,27a7e95c7d3ad59a948aa46741fee456,442e7fad2fab75fa2449309783294d89,693a2aac101eaaadf92614317a1e4da8</data>
    </node>
    <node id="TACROLIMUS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Tacrolimus is a topical calcineurin inhibitor approved for the treatment of Atopic Dermatitis (AD). It is an immunosuppressive drug used to treat eczema and other inflammatory skin conditions. Additionally, Tacrolimus is utilized in nanotechnology-based therapeutic approaches, highlighting its versatility in medical applications.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,27a7e95c7d3ad59a948aa46741fee456,693a2aac101eaaadf92614317a1e4da8,cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="STAPHYLOCOCCUS AUREUS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Staphylococcus aureus (S.a.) is a bacterium known for its ability to produce toxins. It is particularly significant in the context of atopic dermatitis, a chronic skin condition. Patients with atopic dermatitis are at an increased risk of infection from Staphylococcus aureus, as this bacterium tends to overgrow on their skin. The presence of Staphylococcus aureus can exacerbate the symptoms of atopic dermatitis, potentially triggering flare-ups. Additionally, Staphylococcus hominis A9 has been identified as a target for combating Staphylococcus aureus, highlighting the ongoing research efforts to manage and mitigate its impact on atopic dermatitis patients.</data>
      <data key="d2">143d2dc302af5606656797bff162e23e,693a2aac101eaaadf92614317a1e4da8,83eb9003d42977bb83fea1d123dd5ab9,f1897c89e321a3a80924fd72a56e90df</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="HERPES SIMPLEX TYPE 1 VIRUS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Herpes simplex type 1 virus is a virus that patients with Atopic Dermatitis are at increased risk of infection from</data>
      <data key="d2">693a2aac101eaaadf92614317a1e4da8</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="CARDIOVASCULAR DISEASES">
      <data key="d0">DISEASE</data>
      <data key="d1">Cardiovascular diseases are comorbidities associated with Atopic Dermatitis</data>
      <data key="d2">693a2aac101eaaadf92614317a1e4da8</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="NEUROPSYCHIATRIC DISEASES">
      <data key="d0">DISEASE</data>
      <data key="d1">Neuropsychiatric diseases are comorbidities associated with Atopic Dermatitis</data>
      <data key="d2">693a2aac101eaaadf92614317a1e4da8</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="MALIGNANT DISEASES">
      <data key="d0">DISEASE</data>
      <data key="d1">Malignant diseases are comorbidities associated with Atopic Dermatitis</data>
      <data key="d2">693a2aac101eaaadf92614317a1e4da8</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="ANXIETY">
      <data key="d0">DISEASE</data>
      <data key="d1">Anxiety is a mental health disorder characterized by feelings of worry, anxiety, or fear. It is more common in patients with Atopic Dermatitis.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,693a2aac101eaaadf92614317a1e4da8</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="DEPRESSION">
      <data key="d0">DISEASE</data>
      <data key="d1">Depression is a mental health disorder characterized by a persistently depressed mood or loss of interest in activities. It is more common in patients with Atopic Dermatitis and can also occur as a side effect of corticosteroids.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,48de7eebab3f3b418feb35a152df38fd,693a2aac101eaaadf92614317a1e4da8</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="ATTENTION-DEFICIT/HYPERACTIVITY DISORDER">
      <data key="d0">DISEASE</data>
      <data key="d1">Attention-deficit/hyperactivity disorder (ADHD) is a mental health disorder more common in patients with Atopic Dermatitis</data>
      <data key="d2">693a2aac101eaaadf92614317a1e4da8</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="ITCH">
      <data key="d0">SYMPTOM</data>
      <data key="d1">ITCH is a common and persistent symptom associated with atopic dermatitis (AD). It is an uncomfortable sensation on the skin that provokes the urge to scratch, often leading to further skin damage and contributing to the itch-scratch cycle. Itch is frequently associated with cytokines like IL-31 and is a key symptom considered in the SCORAD assessment for AD.</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,143d2dc302af5606656797bff162e23e,3ce96e927d65736b305f792977fed4b9,6059a6e2710b7df94c6a09e5eb7b024a,693a2aac101eaaadf92614317a1e4da8,83eb9003d42977bb83fea1d123dd5ab9,f1897c89e321a3a80924fd72a56e90df,f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="REDNESS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Marked redness is a primary symptom of Atopic Dermatitis</data>
      <data key="d2">693a2aac101eaaadf92614317a1e4da8</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="CRACKING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Cracking is one of the symptoms assessed in the POEM tool. Cracking of the skin is a symptom of Atopic Dermatitis.</data>
      <data key="d2">693a2aac101eaaadf92614317a1e4da8,f1897c89e321a3a80924fd72a56e90df</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="DRYNESS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Dryness is a clinical sign of atopic dermatitis characterized by a lack of moisture in the skin. It is a common symptom of atopic dermatitis, indicating the skin's inability to retain adequate hydration.</data>
      <data key="d2">143d2dc302af5606656797bff162e23e,693a2aac101eaaadf92614317a1e4da8</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="EMOLLIENTS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Emollients are topical therapies used in the treatment of Atopic Dermatitis to moisturize and soothe the skin. These substances are specifically designed to soften and moisturize the skin, providing relief from dryness and irritation associated with various dermatological conditions.</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807,693a2aac101eaaadf92614317a1e4da8</data>
    </node>
    <node id="PHOSPHODIESTERASE-4">
      <data key="d0">PROTEIN</data>
      <data key="d1">Phosphodiesterase-4 is an enzyme targeted by crisaborole in the treatment of Atopic Dermatitis</data>
      <data key="d2">693a2aac101eaaadf92614317a1e4da8</data>
    </node>
    <node id="T HELPER CELLS">
      <data key="d0">CELL</data>
      <data key="d1">T helper cells, including Th2 cells, are involved in the immune response in Atopic Dermatitis</data>
      <data key="d2">693a2aac101eaaadf92614317a1e4da8</data>
    </node>
    <node id="INNATE LYMPHOID CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Innate lymphoid cells, including ILC2 cells, are involved in the immune response in Atopic Dermatitis</data>
      <data key="d2">693a2aac101eaaadf92614317a1e4da8</data>
    </node>
    <node id="TH2 CELL">
      <data key="d0">CELL</data>
      <data key="d1">TH2 CELL, also known as T helper cell type 2, is a type of T cell involved in the immune response. These cells play a crucial role in the differentiation and development of immune responses. TH2 cells are particularly significant in the pathogenesis and inflammation of atopic dermatitis (AD), highlighting their importance in this specific immune-mediated condition.</data>
      <data key="d2">28f548554737fcc026b968db6bbafa30,3ce96e927d65736b305f792977fed4b9,442e7fad2fab75fa2449309783294d89,849e0980ffd6a7e1cf0b8d3d1fbacd98,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="ILC2">
      <data key="d0">CELL</data>
      <data key="d1">ILC2, or innate lymphoid cells type 2, are a subset of innate lymphoid cells that play a crucial role in the immune system. They are activated by TL1A and are significantly involved in the regulation of inflammation. ILC2 cells contribute to the immune response in various conditions, including atopic dermatitis, by producing cytokines that modulate inflammatory processes.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,c525762bb827485bceeb9f09bb4bcfe0,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="IL-5">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-5 (IL-5) is a cytokine that plays a multifaceted role in the immune system. It is primarily involved in the TH2 immune response and is crucial for the growth, differentiation, and activation of eosinophils. IL-5 is a key player in type 2 immune responses and is significant in the inflammatory response. It is also implicated in the pathogenesis of atopic diseases, including atopic dermatitis (AD) and eosinophilic esophagitis (EoE). IL-5 facilitates the migration of eosinophils, contributing to their accumulation at sites of inflammation. In animal models of AD, levels of IL-5 are reduced when treated with CsA-loaded nanoparticles, indicating its potential as a therapeutic target. Overall, IL-5 is a central cytokine in the immune response, particularly in conditions characterized by eosinophilic inflammation and TH2 polarization.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,286730b1c1f680ac465cc21d522fda0c,3df8535e965efb96f5094169610507ff,3dfbb4c51838e0951f53ce951395225f,41ccc4b41bd57cf2bda4dbb6c7ae4198,6309eeea565f06479830cec32938abc9,78e26c66107dba37ac4bab65406b43a0,849e0980ffd6a7e1cf0b8d3d1fbacd98,a867a1e73cef039eb3f28e072463b838,b19f42c9497f71b231222cd953036d6b,bddc3b1a7f098e71f0aa64adec047124,c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e,f2aa3fd6ae3f1853347874c50afb60ea,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="K16">
      <data key="d0">PROTEIN</data>
      <data key="d1">K16, also known as Keratin 16, is a type of keratin involved in skin structure. It serves as a marker of epidermal proliferation and is notably increased in atopic dermatitis lesions.</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="KI67">
      <data key="d0">PROTEIN</data>
      <data key="d1">Ki67 is a protein associated with cell proliferation. It serves as a marker of cell proliferation and is notably increased in atopic dermatitis lesions.</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="PERIPLAKIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Periplakin is a terminal marker of epidermal differentiation suppressed in chronic atopic dermatitis</data>
      <data key="d2">f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="DC">
      <data key="d0">CELL</data>
      <data key="d1">Dendritic cells (DCs) are antigen-presenting immune cells that play a crucial role in the immune response. They are involved in antigen presentation and are essential for inducing an adaptive immune response, particularly after the inactivation of regulatory T cells (T-reg cells). DCs are attracted to the skin during inflammation, which is notably observed in patients with atopic dermatitis (AD). In the context of AD, both mature dendritic cells and inflammatory dendritic epidermal cells contribute to the disease's pathophysiology. These cells reside in the epidermis and are integral to the body's defense mechanisms against pathogens.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,44f2592262cac835560b4c149fee8d2b,6059a6e2710b7df94c6a09e5eb7b024a,6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="MYELOID CELL">
      <data key="d0">CELL</data>
      <data key="d1">Myeloid cells are immune cells involved in the pathophysiology of atopic dermatitis</data>
      <data key="d2">f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="SPONGIOSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Spongiosis is the presence of intercellular edema in the epidermis, seen in atopic dermatitis</data>
      <data key="d2">f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="EPIDERMAL THICKNESS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Epidermal thickness is increased in atopic dermatitis (AD) lesions. Increased epidermal thickness is a characteristic of AD.</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd,f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="EPIDERMAL HYPERPLASIA">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Epidermal hyperplasia is characterized by increased cell proliferation in the epidermis, leading to the thickening of the epidermis. This condition is often observed in inflammatory skin conditions, such as atopic dermatitis.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="LESION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Lesions are areas of damaged skin seen in atopic dermatitis</data>
      <data key="d2">f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="CHRONIC LESION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Chronic lesions are long-lasting areas of skin damage in atopic dermatitis, characterized by increased inflammation and cytokine expression</data>
      <data key="d2">f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="ACUTE LESION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Acute lesions are short-term areas of skin damage in atopic dermatitis, characterized by significant increases in type 2 and type 22 cytokines</data>
      <data key="d2">f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="BIOMARKER">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Biomarkers are measurable indicators of the severity or presence of atopic dermatitis</data>
      <data key="d2">f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="HISTOLOGIC PROFILING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Histologic profiling involves studying the tissue structure and cellular composition in atopic dermatitis lesions</data>
      <data key="d2">f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="TYPE 2 PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The Type 2 pathway involves cytokines such as IL-4, IL-5, IL-13, and IL-31, playing a key role in the pathophysiology of atopic dermatitis (AD). Specifically, IL-4 and IL-13 signaling are significant contributors to the disease process. This pathway's involvement in AD highlights the importance of these cytokines in the development and progression of the condition.</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd,b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="TYPE 22 PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The TYPE 22 PATHWAY involves cytokines such as IL-22 and IL-32, playing a significant role in chronic atopic dermatitis.</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="TYPE 1 PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The type 1 pathway involves cytokines such as IFN-&#947; and IL-1&#946;. This pathway plays a significant role in chronic atopic dermatitis, highlighting its importance in the immune response associated with this condition.</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="TYPE 17 PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The type 17 pathway involves cytokines such as IL-17 and IL-23, playing a significant role in atopic dermatitis.</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="TYPE 9 PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The type 9 pathway involves cytokines like IL-9, playing a role in atopic dermatitis</data>
      <data key="d2">f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IL-9">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-9 is a cytokine involved in the pathophysiology of atopic dermatitis, particularly in pediatric cases</data>
      <data key="d2">f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="IL-13R&#913;1">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-13R&#945;1 (Interleukin-13 receptor alpha 1) is a protein that serves as a subunit of the interleukin-13 receptor complex. It is a crucial component of the type 2 heterodimeric receptor for IL-13 and also forms part of the type II receptor for IL-4 and IL-13. IL-13R&#945;1 binds interleukin-13 and is involved in the regulation of immune responses. This receptor subunit forms a heterodimer with IL-4R&#945;, facilitating type 2 receptor signaling. Through its involvement in IL-13 and IL-4 signaling pathways, IL-13R&#945;1 plays a significant role in mediating immune responses.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,104cc78517b2eca2e9cb7e00de1fe4b0,28f548554737fcc026b968db6bbafa30,3df8535e965efb96f5094169610507ff,48de7eebab3f3b418feb35a152df38fd,78e26c66107dba37ac4bab65406b43a0,96e553a44a27e728c27c4892045ec5c2,b19f42c9497f71b231222cd953036d6b,e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="STAT6">
      <data key="d0">PROTEIN</data>
      <data key="d1">STAT6, or Signal Transducer and Activator of Transcription 6, is a gene that encodes a protein involved in the immune response. This transcription factor is activated by IL-4 and IL-13 signaling pathways. STAT6 plays a crucial role in the development of atopic dermatitis (AD) by acting as an activator of transcription, thereby influencing the expression of genes involved in this condition.</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198,48de7eebab3f3b418feb35a152df38fd,6059a6e2710b7df94c6a09e5eb7b024a</data>
    </node>
    <node id="TYPE 1 IL-4 RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Type 1 IL-4 receptor is composed of IL-4R&#945; and the common gamma chain, expressed on haematopoietic cells</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd</data>
    </node>
    <node id="INVOLUCRIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Involucrin is a protein crucial for the formation and function of the epidermal barrier, playing a significant role in maintaining skin barrier integrity. It is involved in the overall epidermal barrier function and is known to be downregulated by cytokines IL-4 and IL-13.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,28f548554737fcc026b968db6bbafa30,48de7eebab3f3b418feb35a152df38fd,b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="FIBROCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Fibrocytes are recruited to inflamed skin lesions in AD, contributing to fibrosis</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd</data>
    </node>
    <node id="SENSORY NEURONS">
      <data key="d0">CELL</data>
      <data key="d1">Sensory neurons are activated by type 2 cytokines, causing chronic itch in AD</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd</data>
    </node>
    <node id="MURINE MODELS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Mouse models are used to study AD and the effects of IL-4 and IL-13</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd</data>
    </node>
    <node id="DORSAL ROOT GANGLIA">
      <data key="d0">TISSUE</data>
      <data key="d1">Dorsal root ganglia are involved in sensory neuron activation and chronic itch in AD</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd</data>
    </node>
    <node id="GLUCOSE INTOLERANCE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Glucose intolerance is a side effect of corticosteroids</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="HEADACHES">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Headaches are a side effect of corticosteroids and cyclosporine A</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="NEPHROTOXICITY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Nephrotoxicity is a side effect of cyclosporine A</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="HYPERTENSION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Hypertension, also known as high blood pressure, is a condition characterized by consistently high blood pressure. It is also noted as a side effect of cyclosporine A.</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd,d2c44662af9752fc9f82c86121ede7c0,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="ANAEMIA">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Anaemia is a side effect of methotrexate</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="LEUKOPENIA">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Leukopenia is a side effect of methotrexate</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="HEPATOTOXICITY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Hepatotoxicity is a side effect of methotrexate</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="HAEMATOPOIETIC CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Haematopoietic cells, including T cells and B cells, are involved in immune responses and affected by IL-4 signaling</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd</data>
    </node>
    <node id="TYPE 2 IL-4 RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Type 2 IL-4 receptor is a heterodimeric receptor composed of IL-13R&#945;1 and IL-4R&#945;, involved in IL-4 and IL-13 signaling</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd</data>
    </node>
    <node id="CHRONIC ITCH">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Chronic itch is a symptom of AD, caused by activation of sensory neurons by type 2 cytokines</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd</data>
    </node>
    <node id="BIOLOGICS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Biologics are a category of drugs derived from living organisms, designed to target specific mechanistic pathways in diseases such as Atopic Dermatitis (AD). These therapeutic agents specifically target components of the immune system, providing a pathway-specific mode of action. Although biologics typically exhibit a slow onset of action, they are used for long-term control and disease modification in AD, making them a crucial component in the treatment of this condition.</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd,90f4809673ca34628b0e607908f0bf0b,e30574e513dd250992d637d808759c34,e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="EUROPE">
      <data key="d0">GEOGRAPHIC_LOCATION</data>
      <data key="d1">Europe is a region where cost-effectiveness considerations impact drug development for Atopic Dermatitis. Additionally, Europe is a region where cyclosporine A is approved for the treatment of Atopic Dermatitis.</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd,90f4809673ca34628b0e607908f0bf0b</data>
    </node>
    <node id="IL-13R&#913;2">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-13R&#945;2, also known as Interleukin-13 receptor alpha 2, is a receptor subunit involved in the binding and signaling of IL-13. It forms part of the IL-13 receptor complex and is characterized by a short cytoplasmic tail. This structural feature is thought to confer an anti-inflammatory, decoy function to IL-13R&#945;2, modulating the activity of IL-13 in immune responses.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,3df8535e965efb96f5094169610507ff,78e26c66107dba37ac4bab65406b43a0,96e553a44a27e728c27c4892045ec5c2,b19f42c9497f71b231222cd953036d6b</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="IMA-638">
      <data key="d0">CHEMICAL</data>
      <data key="d1">IMA-638 is an anti-human IL-13 monoclonal antibody that prevents the IL-13/IL-13R&#945;1 complex from accessing IL-4R&#945;</data>
      <data key="d2">96e553a44a27e728c27c4892045ec5c2</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="IMA-026">
      <data key="d0">CHEMICAL</data>
      <data key="d1">IMA-026 is an anti-human IL-13 monoclonal antibody that interferes with IL-13 binding to IL-13R&#945;1 and IL-13R&#945;2</data>
      <data key="d2">96e553a44a27e728c27c4892045ec5c2</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="MOUSE MODEL">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The mouse model is utilized to investigate the effects of colonization with Staphylococcus aureus on IL-36R- and IL-1R-dependent inflammation. Additionally, this model is employed to study cutaneous inflammation and the consequences of IL-13 decoy receptor loss.</data>
      <data key="d2">6309eeea565f06479830cec32938abc9,96e553a44a27e728c27c4892045ec5c2</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="TCS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Topical Corticosteroids (TCS) are a class of steroid medications applied to the skin to reduce inflammation. They are commonly used in the treatment of inflammatory skin conditions, including atopic dermatitis (AD). TCS are frequently utilized in combination therapy studies for atopic dermatitis to enhance treatment efficacy.</data>
      <data key="d2">104cc78517b2eca2e9cb7e00de1fe4b0,28f548554737fcc026b968db6bbafa30,48288f3ec2832850282f95d4e38d10e1,6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98,96e553a44a27e728c27c4892045ec5c2,c46e8b6ee0c29e37b7f18c42558d7a3e</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="CYTOKINE RECEPTORS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Cytokine receptors are proteins that bind cytokines and mediate their effects. These receptors are targeted by various biologics, which are therapeutic agents designed to modulate the immune response by interacting with these receptors.</data>
      <data key="d2">96e553a44a27e728c27c4892045ec5c2,e95d4d15e4f3110c91a3d3fcb5910d06</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="PF-04965842">
      <data key="d0">CHEMICAL</data>
      <data key="d1">An oral JAK1 inhibitor under investigation for the treatment of moderate-to-severe AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="PDE-4">
      <data key="d0">PROTEIN</data>
      <data key="d1">Phosphodiesterase-4, an enzyme involved in chronic inflammatory pathways</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="CAMP">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cyclic adenosine monophosphate (cAMP) is a molecule that mediates downstream events in inflammatory pathways. In the context of atopic dermatitis, cAMP levels are increased by PDE4 inhibitors, which subsequently generate anti-inflammatory cytokines.</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9,e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="PERIOSTIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">PERIOSTIN is a protein induced by type 2 cytokines IL-4 and IL-13. It is involved in tissue repair and remodeling and is often associated with type II inflammatory responses. Additionally, periostin is used as a biomarker in asthma, highlighting its significance in the context of type 2 cytokine activity and inflammatory diseases.</data>
      <data key="d2">5f37466ca41c9b8b06ed8be0303d49f2,b19f42c9497f71b231222cd953036d6b,e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="FEV1">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Forced expiratory volume in one second, a measure of lung function</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b,e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="TYPE 1 IMMUNE PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">An immune response pathway involving type 1 cytokines</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="TYPE 2 IMMUNE PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">An immune response pathway involving type 2 cytokines</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="TYPE 17 IMMUNE PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">An immune response pathway involving type 17 cytokines</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="TYPE 22 IMMUNE PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">An immune response pathway involving type 22 cytokines</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="INTRINSIC AD">
      <data key="d0">DISEASE</data>
      <data key="d1">Intrinsic Atopic Dermatitis (INTRINSIC AD) is a subtype of atopic dermatitis characterized by the absence of detectable allergen-specific IgE. Unlike other forms of atopic dermatitis, INTRINSIC AD does not involve typical allergic responses. Research suggests that this subtype may involve the IL-23&#8211;IL-17 axis, indicating a potential immunological pathway distinct from the classic IgE-mediated mechanisms.</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1,e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="EXTRINSIC AD">
      <data key="d0">DISEASE</data>
      <data key="d1">A subtype of atopic dermatitis with detectable allergen-specific IgE</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="ADULT AD">
      <data key="d0">DISEASE</data>
      <data key="d1">Atopic dermatitis occurring in adults</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="PAEDIATRIC AD">
      <data key="d0">DISEASE</data>
      <data key="d1">Atopic dermatitis occurring in children</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="ETHNIC ORIGIN AD">
      <data key="d0">DISEASE</data>
      <data key="d1">Atopic dermatitis with variations in prevalence and clinical features based on ethnic origin</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="ENDOTYPES">
      <data key="d0">DISEASE</data>
      <data key="d1">Subsets of patients with common underlying mechanisms of disease</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="NCT02925117">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 2b, 88-week, randomized controlled trial for upadacitinib in AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="NCT03569293">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 3, randomized controlled trial for upadacitinib monotherapy in AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="NCT03607422">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 3, randomized controlled trial for upadacitinib monotherapy in AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="NCT03568318">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 3, randomized controlled trial for upadacitinib with topical corticosteroids in AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="NCT02576938">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 2 trial for baricitinib in AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="BREEZE-AD1">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 3, 16-week randomized controlled trial for baricitinib in AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="BREEZE-AD2">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 3, 16-week randomized controlled trial for baricitinib in AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="BREEZE-AD3">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 3, 52-week long-term safety and efficacy study for baricitinib in AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="BREEZE-AD5">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 3, 16-week randomized controlled trial for baricitinib in AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="BREEZE-AD6">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 3, 116-week open-label extension study for baricitinib in AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="BREEZE-AD4">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 3, randomized controlled trial for baricitinib in AD patients with inadequate response to cyclosporine</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="NCT03428100">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 3, randomized controlled trial for baricitinib in AD patients with inadequate response to cyclosporine</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="NCT02780167">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 2 study for PF-04965842 in AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="JADE MONO-1">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 3, 12-week randomized controlled trial for PF-04965842 in AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="JADE MONO-2">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 3, 12-week randomized controlled trial for PF-04965842 in AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="JADE EXTEND">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 3, 96-week long-term extension study for PF-04965842 in AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="CCL5">
      <data key="d0">PROTEIN</data>
      <data key="d1">CCL5, also known as chemokine ligand 5, is a chemokine involved in the immune response and inflammation. It plays a crucial role in immune cell recruitment, particularly during inflammatory processes. CCL5 ascends in the skin during inflammation and promotes the attraction of inflammatory T cells and dendritic cell (DC) subtypes, thereby contributing to the body's defense mechanisms.</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198,6059a6e2710b7df94c6a09e5eb7b024a,b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="CCL13">
      <data key="d0">PROTEIN</data>
      <data key="d1">CCL13 is a chemokine involved in immune cell recruitment</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="IL-32">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-32 is a cytokine involved in immune response and inflammation</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="CXCL9">
      <data key="d0">PROTEIN</data>
      <data key="d1">CXCL9 is a chemokine involved in immune cell recruitment</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="IL-23P19">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-23p19 is a subunit of the cytokine IL-23</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="IL-23P40">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-23p40 is a subunit of the cytokine IL-23</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="ILC2S">
      <data key="d0">CELL</data>
      <data key="d1">ILC2s, or type 2 innate lymphoid cells, are a type of innate lymphoid cell involved in the immune response and inflammation. These immune cells play a crucial role in the body's defense mechanisms and can be acted upon by TL1A, a cytokine involved in immune regulation.</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198,516e41e96d2e72d45bf1e2c69da7f18a,b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="DCS">
      <data key="d0">CELL</data>
      <data key="d1">Dendritic cells (DCs) are antigen-presenting cells that play a crucial role in initiating and regulating immune responses. They are activated by thymic stromal lymphopoietin (TSLP) and express interleukin-31 receptor A (IL-31RA). Additionally, DCs are resident in the epidermis and express the aryl hydrocarbon receptor (AhR), which is involved in atopic dermatitis (AD).</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,2cec06c4d46f5ff9ee936a78d8b077cd,3df8535e965efb96f5094169610507ff,3ea70e257330c812b52334ca1f90d807,7c13f41d7349d9d2e56c36e00c0ca2d9,b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="IDECS">
      <data key="d0">CELL</data>
      <data key="d1">Inflammatory dendritic epidermal cells are a type of dendritic cell involved in skin inflammation</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="PPL">
      <data key="d0">PROTEIN</data>
      <data key="d1">Periplakin is a protein involved in skin barrier function</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="IVL">
      <data key="d0">PROTEIN</data>
      <data key="d1">Involucrin is a protein involved in skin barrier function</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="ELAFIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Elafin is a protein involved in skin inflammation</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="&#915;C">
      <data key="d0">PROTEIN</data>
      <data key="d1">&#947;c is a common gamma chain receptor subunit involved in cytokine signaling</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="IL-13R&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-13R&#945; is a receptor subunit involved in IL-13 signaling</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="IL-4R&#913; AND &#915;C">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-4R&#945; and &#947;c form a heterodimeric receptor for IL-4 signaling</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="IL-4R&#913; AND IL-13R&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-4R&#945; and IL-13R&#945; form a heterodimeric receptor for IL-4 and IL-13 signaling</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="TYPE 1 RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Type 1 receptor is a heterodimeric receptor involving IL-4R&#945; and &#947;c</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="TYPE 2 RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Type 2 receptor is a heterodimeric receptor involving IL-4R&#945; and IL-13R&#945;</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="IL-13R&#913;1 AND IL-13R&#913;2">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-13R&#945;1 and IL-13R&#945;2 form a heterodimeric receptor for IL-13 signalingIL-13R&#945;1 and IL-13R&#945;2 are receptor subunits involved in IL-13 signaling</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="IL-13R&#913;1 AND IL-4R&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-13R&#945;1 and IL-4R&#945; form a heterodimeric receptor for IL-13 signaling</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="IL-13R&#913;2 AND IL-4R&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-13R&#945;2 and IL-4R&#945; form a heterodimeric receptor for IL-13 signaling</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="CD8+ T CELL">
      <data key="d0">CELL</data>
      <data key="d1">CD8+ T cells are a type of T cell that are involved in the direct killing of infected cells. Additionally, CD8+ T cells are a type of immune cell that produce cytokines such as IL-4 and IL-13.</data>
      <data key="d2">28f548554737fcc026b968db6bbafa30,8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">CELL</data>
    </node>
    <node id="MAST CELL">
      <data key="d0">CELL</data>
      <data key="d1">Mast cells are a type of immune cell involved in allergic reactions and inflammation. They play a crucial role in the inflammation of the esophagus in eosinophilic esophagitis (EoE) and are known to produce cytokines such as IL-4 and IL-13. During allergic reactions, mast cells release histamine and other mediators, contributing to the symptoms experienced. Additionally, research has shown that mast cell infiltration is decreased in DNCB-induced atopic dermatitis (AD) skin lesions treated with NIC-CS-NPs, indicating their involvement in various inflammatory skin conditions.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,28f548554737fcc026b968db6bbafa30,6aef5adb1be227170f66c76a292c25e5,8246ea974dfb00cb5e3d984004e21a9e,849e0980ffd6a7e1cf0b8d3d1fbacd98,d4797ed1483e5057bcd8301eaa509d5e</data>
      <data key="d3">CELL</data>
    </node>
    <node id="BASOPHIL">
      <data key="d0">CELL</data>
      <data key="d1">Basophils are immune cells that produce IL-4 and IL-13</data>
      <data key="d2">28f548554737fcc026b968db6bbafa30</data>
      <data key="d3">CELL</data>
    </node>
    <node id="EOSINOPHIL">
      <data key="d0">CELL</data>
      <data key="d1">Eosinophils are a type of white blood cell involved in allergic reactions and inflammation. These immune cells play a crucial role in the body's immune response by producing cytokines such as IL-4 and IL-13, which are important for modulating immune functions and contributing to the inflammatory process.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,28f548554737fcc026b968db6bbafa30</data>
      <data key="d3">CELL</data>
    </node>
    <node id="ILC">
      <data key="d0">CELL</data>
      <data key="d1">Innate lymphoid cells (ILCs) are a type of immune cell involved in the body's defense mechanisms. These cells play a crucial role in the immune response by producing various cytokines, including IL-13, which is important for their function in immune regulation and defense.</data>
      <data key="d2">104cc78517b2eca2e9cb7e00de1fe4b0,28f548554737fcc026b968db6bbafa30</data>
      <data key="d3">CELL</data>
    </node>
    <node id="INKT">
      <data key="d0">CELL</data>
      <data key="d1">Invariant natural killer T cells, a type of immune cell that produce IL-13</data>
      <data key="d2">28f548554737fcc026b968db6bbafa30</data>
      <data key="d3">CELL</data>
    </node>
    <node id="SOLO 1">
      <data key="d0">TRIAL</data>
      <data key="d1">SOLO 1 is a phase 3 clinical trial of Dupilumab monotherapy in adult patients with moderate to severe atopic dermatitis</data>
      <data key="d2">28f548554737fcc026b968db6bbafa30</data>
      <data key="d3">TRIAL</data>
    </node>
    <node id="SOLO 2">
      <data key="d0">TRIAL</data>
      <data key="d1">SOLO 2 is a phase 3 clinical trial of Dupilumab monotherapy in adult patients with moderate to severe atopic dermatitis</data>
      <data key="d2">28f548554737fcc026b968db6bbafa30</data>
      <data key="d3">TRIAL</data>
    </node>
    <node id="ARBAN">
      <data key="d0">TRIAL</data>
      <data key="d1">ARBAN is a phase 2 open-label, monotherapy study of Lebrikizumab in adult patients with moderate to severe atopic dermatitis</data>
      <data key="d2">28f548554737fcc026b968db6bbafa30</data>
      <data key="d3">TRIAL</data>
    </node>
    <node id="CHRONOS">
      <data key="d0">TRIAL</data>
      <data key="d1">CHRONOS is a phase 3 randomized, double-blind study of Dupilumab plus TCS versus placebo plus TCS in adult patients with moderate to severe atopic dermatitis</data>
      <data key="d2">28f548554737fcc026b968db6bbafa30</data>
      <data key="d3">TRIAL</data>
    </node>
    <node id="TREBLE">
      <data key="d0">TRIAL</data>
      <data key="d1">TREBLE is a phase 2 randomized, double-blind study of Lebrikizumab plus TCS in adult patients with moderate to severe atopic dermatitis</data>
      <data key="d2">28f548554737fcc026b968db6bbafa30</data>
      <data key="d3">TRIAL</data>
    </node>
    <node id="TCI">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Topical calcineurin inhibitors, used as rescue therapy in combination therapy studies for atopic dermatitis</data>
      <data key="d2">28f548554737fcc026b968db6bbafa30</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="IGA">
      <data key="d0">SCORE</data>
      <data key="d1">Immunoglobulin A (IGA) is an antibody that plays a critical role in mucosal immunity, specifically in the immune function of mucous membranes. It is essential for protecting mucosal surfaces from pathogens.

The Investigator's Global Assessment (IGA) is a scale used to assess the severity of diseases, particularly skin conditions such as atopic dermatitis. This tool measures the overall severity of atopic dermatitis, providing a standardized method for evaluating disease progression and treatment efficacy.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,0ba9fbea14e0c2c1d01a12ffaacfda9b,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,28f548554737fcc026b968db6bbafa30,78e26c66107dba37ac4bab65406b43a0,849e0980ffd6a7e1cf0b8d3d1fbacd98,a867a1e73cef039eb3f28e072463b838,c46e8b6ee0c29e37b7f18c42558d7a3e,f1897c89e321a3a80924fd72a56e90df</data>
      <data key="d3">SCORE</data>
    </node>
    <node id="VAS">
      <data key="d0">SCORE</data>
      <data key="d1">The Visual Analog Scale (VAS) is a tool used to measure the intensity of pain or other symptoms. It is commonly employed to assess pruritus severity in conditions such as atopic dermatitis. The VAS provides a quantitative measure of symptom intensity, allowing for a standardized assessment of pruritus and other subjective experiences.</data>
      <data key="d2">104cc78517b2eca2e9cb7e00de1fe4b0,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,28f548554737fcc026b968db6bbafa30</data>
      <data key="d3">SCORE</data>
    </node>
    <node id="BSA">
      <data key="d0">SCORE</data>
      <data key="d1">Body Surface Area (BSA) is a measure used to assess the extent of skin involvement in dermatological conditions. It is particularly utilized to measure the extent of atopic dermatitis, providing a quantifiable metric for the body surface area affected by this condition.</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,28f548554737fcc026b968db6bbafa30</data>
      <data key="d3">SCORE</data>
    </node>
    <node id="IL-17C">
      <data key="d0">PROTEIN</data>
      <data key="d1">A member of the IL-17 family of cytokines involved in the pathogenesis of atopic dermatitis</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </node>
    <node id="MOR106">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A human IgG1, anti-IL-17C monoclonal antibody used in the treatment of moderate-to-severe atopic dermatitis</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </node>
    <node id="FEZAKINUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Fezakinumab is an intravenous, human IgG1&#955;, anti-IL-22 monoclonal antibody used in the treatment of moderate-to-severe atopic dermatitis. As a biologic injection, Fezakinumab specifically targets IL-22, playing a crucial role in the downregulation of this cytokine. It has been investigated and utilized for its efficacy in managing autoimmune diseases, particularly atopic dermatitis.</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,2cec06c4d46f5ff9ee936a78d8b077cd,48288f3ec2832850282f95d4e38d10e1,e9841b88c9fab58c5175af409653da50,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="DENDRITIC CELL">
      <data key="d0">CELL</data>
      <data key="d1">Dendritic cells are immune cells that play a crucial role in the immune response. They are specialized antigen-presenting cells that process antigen material and present it to T cells. This function is essential for initiating and regulating the adaptive immune response, making dendritic cells a key component in the body's defense against pathogens.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,8ce8c356713490cd2c680f505bcd050b</data>
    </node>
    <node id="ANKYLOSING SPONDYLITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Ankylosing spondylitis is a type of arthritis that affects the spine and large joints. This disease is commonly treated with TNF inhibitors.</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,516e41e96d2e72d45bf1e2c69da7f18a</data>
    </node>
    <node id="TOPICAL CALCINEURIN INHIBITOR">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A class of drugs used to treat inflammatory skin diseases by inhibiting calcineurin</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </node>
    <node id="TREATMENT-EMERGENT ADVERSE EVENT">
      <data key="d0">SYMPTOM</data>
      <data key="d1">An adverse event that emerges during treatment with a drug</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </node>
    <node id="INTERLEUKIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">A group of cytokines that play important roles in the immune system</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </node>
    <node id="IGG1&#922;">
      <data key="d0">PROTEIN</data>
      <data key="d1">A subtype of immunoglobulin G used in monoclonal antibodies for therapeutic purposes</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </node>
    <node id="IGG1&#923;">
      <data key="d0">PROTEIN</data>
      <data key="d1">A subtype of immunoglobulin G used in monoclonal antibodies for therapeutic purposes</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </node>
    <node id="IMMUNE SYSTEM">
      <data key="d0" />
      <data key="d1">The immune system is a complex network of cells, tissues, and organs that work together to defend the body against harmful invaders. It serves as the body's defense system against infections and diseases. Additionally, the immune system plays a significant role in the pathogenesis of Atopic Dermatitis, involving dysregulation that contributes to the disease.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,442e7fad2fab75fa2449309783294d89,6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="MONOCLONAL ANTIBODIES">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </node>
    <node id="DENDRITIC CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Dendritic cells (DCs) are professional antigen-presenting cells that play a crucial role in the initiation and regulation of the immune response. As key regulators of the immune system, they activate the adaptive immune response by presenting antigens to T cells. Dendritic cells express high-affinity receptors for IgE and are involved in the immune response in conditions such as atopic dermatitis. Additionally, they express OX40L, which further underscores their importance in modulating immune functions.</data>
      <data key="d2">143d2dc302af5606656797bff162e23e,1b656cfce91ff9ccec4223703489dab3,41ccc4b41bd57cf2bda4dbb6c7ae4198,83eb9003d42977bb83fea1d123dd5ab9,df74aa1b86eeeb811ca5586767ae3a71,e9841b88c9fab58c5175af409653da50,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="ANB020">
      <data key="d0">CHEMICAL</data>
      <data key="d1">ANB020 is a humanized IgG1, anti&#8211;IL-33 monoclonal antibody</data>
      <data key="d2">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="PF-06817024">
      <data key="d0">CHEMICAL</data>
      <data key="d1">PF-06817024 is an anti&#8211;IL-33 monoclonal antibody</data>
      <data key="d2">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="TSLPR">
      <data key="d0">PROTEIN</data>
      <data key="d1">TSLPR is the cognate receptor for TSLP, expressed on multiple immune cells including T cells, B cells, dendritic cells, mast cells, basophils, and eosinophils</data>
      <data key="d2">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="TEZEPELUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Tezepelumab, also known as AMG 157, is a human IgG2&#955; monoclonal antibody that targets thymic stromal lymphopoietin (TSLP). It is used as a biologic agent in the treatment of severe and uncontrolled allergic asthma, as well as atopic dermatitis. By inhibiting TSLP, Tezepelumab helps manage symptoms associated with these allergic conditions.</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,3ea70e257330c812b52334ca1f90d807,6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98,e9841b88c9fab58c5175af409653da50,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="BASOPHILS">
      <data key="d0">CELL</data>
      <data key="d1">Basophils are a type of white blood cell involved in immune responses, particularly in allergic reactions and inflammation. These immune cells express IL-31RA and play a crucial role in mediating allergic reactions.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,3df8535e965efb96f5094169610507ff,41ccc4b41bd57cf2bda4dbb6c7ae4198,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="EOSINOPHILS">
      <data key="d0">CELL</data>
      <data key="d1">Eosinophils are a type of white blood cell involved in the immune response, particularly in combating multicellular parasites and certain infections. They play a significant role in allergic reactions and atopic diseases, including asthma and atopic dermatitis. Eosinophils are also elevated in the skin of patients with atopic dermatitis and are involved in the inflammatory response to allergens.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,3df8535e965efb96f5094169610507ff,41ccc4b41bd57cf2bda4dbb6c7ae4198,4cf23e218b6aab3c77115173b5c7c2fd,6ada075e562abd7bd445164e9fc309b4,df74aa1b86eeeb811ca5586767ae3a71,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="IL">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin, a group of cytokines that play important roles in the immune system</data>
      <data key="d2">104cc78517b2eca2e9cb7e00de1fe4b0</data>
    </node>
    <node id="TH">
      <data key="d0">CELL</data>
      <data key="d1">T helper cell, a type of T cell that plays an important role in the immune system</data>
      <data key="d2">104cc78517b2eca2e9cb7e00de1fe4b0</data>
    </node>
    <node id="JAK/STAT PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">A signaling pathway involved in the transmission of information from chemical signals outside the cell to the cell nucleus</data>
      <data key="d2">104cc78517b2eca2e9cb7e00de1fe4b0</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="NCT02300701">
      <data key="d0">DISEASE</data>
      <data key="d1">A phase 4 study ongoing in children with severe recalcitrant atopic eczema</data>
      <data key="d2">104cc78517b2eca2e9cb7e00de1fe4b0</data>
    </node>
    <node id="IL-4RA">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-4RA, also known as the interleukin-4 receptor alpha, is a biologic target and inhibitor involved in the production of interleukins IL-4 and IL-13. This receptor plays a crucial role in modulating the immune response, making it a significant focus in the study and treatment of autoimmune diseases.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,286730b1c1f680ac465cc21d522fda0c</data>
    </node>
    <node id="JAK1/2">
      <data key="d0">PROTEIN</data>
      <data key="d1">JAK1/2 are Janus kinases involved in signal transduction pathways linked to cytokine receptors</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="ECZEMATOUS LESIONS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Eczematous lesions are inflamed, itchy, and scaly patches of skin commonly seen in AD</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="ITCHING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Itching is a common symptom of Atopic Dermatitis (AD) that treatments aim to eliminate. It often leads to scratching and subsequent skin damage. This severe sensation frequently accompanies eczematous lesions in AD, exacerbating the condition and contributing to the overall discomfort experienced by patients.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,2cec06c4d46f5ff9ee936a78d8b077cd,6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="IMMUNOGLOBULIN E">
      <data key="d0">PROTEIN</data>
      <data key="d1">Immunoglobulin E (IgE) is an antibody involved in allergic reactions. It is notably elevated in individuals with atopic diseases, including Atopic Dermatitis.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,6ada075e562abd7bd445164e9fc309b4,cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="CICLOSPORIN A">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Ciclosporin A is an immunosuppressant used to treat severe forms of AD</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="SKIN MICROBIOME">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The skin microbiome is the collection of microorganisms living on the skin. This community of microorganisms can influence atopic dermatitis (AD).</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,1596d061dbe1a1c9e8f31a02a21e5524,83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="ITCH-SCRATCH CYCLE">
      <data key="d0">PATHWAY</data>
      <data key="d1">The itch-scratch cycle is a feedback loop where itching leads to scratching, worsening AD symptoms</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="ALLERGIC RHINO-CONJUNCTIVITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Allergic rhino-conjunctivitis is an allergic reaction affecting the eyes and nose. It is an atopic disorder that can be a comorbidity of atopic dermatitis (AD).</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="CARDIOVASCULAR DISORDERS">
      <data key="d0">DISEASE</data>
      <data key="d1">Cardiovascular disorders are diseases that involve the heart or blood vessels. They are significant comorbidities associated with Atopic Dermatitis (AD) and are potential comorbidities of AD.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,1596d061dbe1a1c9e8f31a02a21e5524,6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="NEUROPSYCHIATRIC DISORDERS">
      <data key="d0">DISEASE</data>
      <data key="d1">Neuropsychiatric disorders are significant comorbidities associated with Atopic Dermatitis (AD). These disorders are potential comorbidities of AD, indicating a notable link between neuropsychiatric conditions and the presence of Atopic Dermatitis.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="JANUS KINASE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Janus Kinase (JAK) is a family of enzymes involved in cytokine receptor signaling. These enzymes play a crucial role in the immune response and are significant targets in the treatment of autoimmune diseases. Inhibitors such as Baricitinib, Upadacitinib, and Abrocitinib have been developed to target JAK enzymes specifically for the treatment of Atopic Dermatitis, highlighting their therapeutic potential in managing inflammatory conditions.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="PHOSPHODIESTERASE 4">
      <data key="d0">PROTEIN</data>
      <data key="d1">Phosphodiesterase 4 (PDE4) is an enzyme involved in the breakdown of cyclic AMP (cAMP). It plays a crucial role in regulating cellular levels of cAMP, which is important for various cellular functions. By breaking down cAMP, PDE4 can influence the generation of anti-inflammatory cytokines. PDE4 is targeted by inhibitors, such as crisaborole, to increase cellular levels of cAMP and reduce inflammation, particularly in conditions like atopic dermatitis.</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,1596d061dbe1a1c9e8f31a02a21e5524,83eb9003d42977bb83fea1d123dd5ab9,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="CALCINEURIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Calcineurin is a protein phosphatase involved in T-cell activation, targeted by tacrolimus and pimecrolimus</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="B-CELL">
      <data key="d0">CELL</data>
      <data key="d1">B-cells are a type of lymphocyte involved in the immune response, implicated in AD</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="FIBROBLAST">
      <data key="d0">CELL</data>
      <data key="d1">Fibroblasts are cells that synthesize the extracellular matrix and collagen, playing a crucial role in fibrosis and skin repair. They are activated by M2 macrophages, which leads to excessive extracellular matrix production. These cells are essential for producing collagen and other fibers, contributing significantly to the structural integrity and repair of tissues.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,3dfbb4c51838e0951f53ce951395225f,44f2592262cac835560b4c149fee8d2b,503107475d2e9dac49abd8ebcbadd9f5,5ec1ebf4e260eb1f8fda8acdf06cd39e,855c455b4c9592746834ee3a4e0e6b81,b2aae16813e647959b783a39ef9a19a7,df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="MACROPHAGE">
      <data key="d0">CELL</data>
      <data key="d1">Macrophages are immune cells involved in the detection, phagocytosis, and destruction of bacteria and other harmful organisms. They play a crucial role in engulfing and digesting cellular debris and pathogens, thereby contributing to the body's defense mechanisms against infections and maintaining tissue homeostasis.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,8ce8c356713490cd2c680f505bcd050b</data>
    </node>
    <node id="INTERLEUKIN-4">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-4 (IL-4) is a cytokine involved in the differentiation of Th2 cells</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="INTERLEUKIN-13">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-13 (IL-13) is a cytokine involved in the immune response and inflammation.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="INTERLEUKIN-31">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-31 (IL-31) is a cytokine involved in the immune response and is associated with itching.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="INTERLEUKIN-22">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-22 (IL-22) is a cytokine involved in the immune response and skin barrier function. It plays a crucial role in modulating the immune system and maintaining the integrity of the skin barrier, thereby contributing to the body's defense mechanisms.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="INTERLEUKIN-17">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-17 (IL-17) is a cytokine involved in the immune response and inflammation</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="INTERLEUKIN-1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-1 (IL-1) is a cytokine involved in the immune response and inflammation</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="INTERLEUKIN-6">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-6 (IL-6) is a cytokine involved in the immune response and inflammation</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="INTERLEUKIN-10">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-10 (IL-10) is a cytokine involved in the immune response and inflammation</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="INTERLEUKIN-12">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-12 (IL-12) is a cytokine involved in the immune response and inflammation</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="INTERLEUKIN-23">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-23 (IL-23) is a cytokine involved in the immune response and inflammation.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="INTERLEUKIN-33">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-33 (IL-33) is a cytokine involved in the immune response and inflammation</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="TUMOR NECROSIS FACTOR-ALPHA">
      <data key="d0">PROTEIN</data>
      <data key="d1">Tumor Necrosis Factor-alpha (TNF-&#945;) is a cytokine involved in systemic inflammation</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="INTERFERON-GAMMA">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interferon-gamma (IFN-&#947;) is a cytokine involved in the immune response and inflammation</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="TRANSFORMING GROWTH FACTOR-BETA">
      <data key="d0">PROTEIN</data>
      <data key="d1">Transforming Growth Factor-beta (TGF-&#946;) is a cytokine involved in cell growth and differentiation</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="PROSTAGLANDIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Prostaglandins are lipid compounds involved in inflammation and immune responses</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="LEUKOTRIENE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Leukotrienes are lipid compounds involved in inflammation and allergic reactions</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="CORTICOSTEROID">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Corticosteroids are a class of steroid hormones used to reduce inflammation</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="CALCINEURIN INHIBITOR">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Calcineurin inhibitors are drugs that suppress the immune system by inhibiting the activity of calcineurin.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,442e7fad2fab75fa2449309783294d89</data>
    </node>
    <node id="PHOSPHODIESTERASE INHIBITOR">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Phosphodiesterase inhibitors are drugs that block the degradation of cyclic AMP</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="JANUS KINASE INHIBITOR">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Janus kinase inhibitors are drugs that block the activity of Janus kinases</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="BIOLOGIC THERAPY">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Biologic therapies are treatments derived from living organisms used to target specific components of the immune system</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="SMALL MOLECULE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Small molecules are low molecular weight compounds used in drug development</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="PRECISION MEDICINE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Precision medicine is an approach to patient care that allows for more personalized treatment based on individual variability and tailored treatments based on individual characteristics. This method leverages the unique genetic, environmental, and lifestyle factors of each patient to develop more effective and targeted therapeutic strategies.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="IMMUNE PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune pathways are the series of interactions between immune cells and molecules that lead to an immune response</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="SIGNAL TRANSDUCTION PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Signal transduction pathways are the processes by which a cell converts a signal from outside the cell into a functional response</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="EPIDERMAL BARRIER DYSFUNCTION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Epidermal Barrier Dysfunction is a condition where the skin barrier is compromised, leading to increased permeability and susceptibility to irritants. It is a symptom of Atopic Dermatitis, causing dry skin and inflammation.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,691cb2e23ac3c6e591129d16714f8ef8</data>
    </node>
    <node id="CHRONIC INFLAMMATORY REACTION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Chronic inflammatory reaction is a prolonged inflammatory response that can lead to tissue damage</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="DRY SKIN">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Dry skin is a condition where the skin lacks moisture, often seen in Atopic Dermatitis (AD). It is a symptom of Atopic Dermatitis caused by skin inflammation and epidermal barrier dysfunction.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,691cb2e23ac3c6e591129d16714f8ef8</data>
    </node>
    <node id="SENSITIVE SKIN">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Sensitive skin is a condition where the skin reacts easily to irritants, often seen in atopic dermatitis (AD). It is prone to irritation and adverse reactions to environmental factors and products.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="SEVERE ITCHING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Severe itching is an intense itching sensation often seen in AD</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="LOCALIZED LESIONS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Localized lesions are specific areas of inflamed skin seen in AD</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="DISSEMINATED LESIONS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Disseminated lesions are widespread areas of inflamed skin seen in AD</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="EDEMA">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Edema is swelling caused by excess fluid trapped in the body's tissues. It is often observed in various conditions, including Atopic Dermatitis (AD) and infantile Atopic Dermatitis. This swelling can manifest in different parts of the body, including the skin.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,6ada075e562abd7bd445164e9fc309b4,6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="LICHENIFICATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Lichenification is a clinical sign of atopic dermatitis characterized by the thickening of the skin with exaggerated skin markings. This condition often results from chronic scratching and is frequently observed in childhood atopic dermatitis.</data>
      <data key="d2">143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524,6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="EXCORIATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Excoriation is a clinical sign of atopic dermatitis (AD) characterized by the act of scratching or scraping the skin. This behavior, often seen in individuals with AD, involves skin picking or scratching, which can exacerbate the condition and lead to further skin damage.</data>
      <data key="d2">143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="HYPERPIGMENTATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Hyperpigmentation is darkening of the skin, often seen in AD</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="HYPOPIGMENTATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Hypopigmentation is lightening of the skin, often seen in AD</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="XEROSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Xerosis is the medical term for dry skin, characterized by increased dryness of the skin. It is often seen as a symptom in Atopic Dermatitis (AD), including childhood Atopic Dermatitis.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,3df8535e965efb96f5094169610507ff,6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="SUBCUTANEOUS TISSUE">
      <data key="d0">TISSUE</data>
      <data key="d1">Subcutaneous tissue is the layer of tissue beneath the dermis, containing fat and connective tissue</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="LYMPH NODE">
      <data key="d0">TISSUE</data>
      <data key="d1">Lymph nodes are small, bean-shaped structures that filter lymph and store white blood cells</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="BLOOD VESSEL">
      <data key="d0">TISSUE</data>
      <data key="d1">Blood vessels are tubular structures that carry blood throughout the body</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="NERVE">
      <data key="d0">TISSUE</data>
      <data key="d1">Nerves are bundles of fibers that transmit electrical signals between the brain and the rest of the body</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="SWEAT GLAND">
      <data key="d0">TISSUE</data>
      <data key="d1">Sweat glands are structures in the skin that produce sweat</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="SEBACEOUS GLAND">
      <data key="d0">TISSUE</data>
      <data key="d1">Sebaceous glands are structures in the skin that produce sebum, an oily substance</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="STRATUM CORNEUM">
      <data key="d0">TISSUE</data>
      <data key="d1">The Stratum Corneum (SC) is the outermost layer of the skin, specifically the epidermis, and plays a crucial role in the skin's barrier function. It is essential for maintaining the integrity of the skin barrier and is involved in keratin buildup.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="STRATUM GRANULOSUM">
      <data key="d0">TISSUE</data>
      <data key="d1">The stratum granulosum is a layer of the epidermis involved in the formation of the skin barrier</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="STRATUM SPINOSUM">
      <data key="d0">TISSUE</data>
      <data key="d1">The stratum spinosum is a layer of the epidermis involved in the strength and flexibility of the skin</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="STRATUM BASALE">
      <data key="d0">TISSUE</data>
      <data key="d1">The stratum basale is the deepest layer of the epidermis, involved in the production of new skin cells</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="BASEMENT MEMBRANE">
      <data key="d0">TISSUE</data>
      <data key="d1">The basement membrane is a thin layer of extracellular matrix that separates the epidermis from the dermis</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="ELASTIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Elastin is a protein in connective tissue that allows tissues to resume their shape after stretching or contracting.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="FIBRONECTIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Fibronectin is a high-molecular-weight glycoprotein involved in cell adhesion and wound healing.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,1596d061dbe1a1c9e8f31a02a21e5524,4cf23e218b6aab3c77115173b5c7c2fd,a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="LAMININ">
      <data key="d0">PROTEIN</data>
      <data key="d1">Laminin is a protein in the basement membrane involved in cell adhesion</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="INTEGRIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Integrins are proteins that mediate the attachment between a cell and its surroundings</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="CADHERIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Cadherins are proteins involved in cell-cell adhesion</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="CLAUDIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Claudins are proteins involved in the formation of tight junctions between cells</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="OCCLUDIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Occludin is a protein involved in the formation of tight junctions between cells</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="DESMOGLEIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Desmogleins are proteins involved in cell-cell adhesion in the epidermis</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="DESMOCOLLIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Desmocollins are proteins involved in cell-cell adhesion in the epidermis</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="KERATIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Keratin is a structural protein found in the skin, hair, and nails. Its buildup is crucial for the formation of the stratum corneum, the outermost layer of the skin, which is affected in Atopic Dermatitis.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="S100 PROTEIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">S100 proteins are a family of proteins involved in the regulation of a variety of cellular processes</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="DEFENSIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Defensins are antimicrobial peptides involved in the immune response</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="CATHELICIDIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Cathelicidins are antimicrobial peptides involved in the immune response</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="PSORIASIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Psoriasin is an antimicrobial peptide involved in the immune response</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="HISTONE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Histones are proteins involved in the packaging of DNA in the cell nucleus</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="DNA">
      <data key="d0">PROTEIN</data>
      <data key="d1">DNA is the molecule that carries genetic information in cells</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="MICRORNA">
      <data key="d0">PROTEIN</data>
      <data key="d1">MicroRNAs are small non-coding RNAs involved in the regulation of gene expression</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="LONG NON-CODING RNA">
      <data key="d0">PROTEIN</data>
      <data key="d1">Long non-coding RNAs are RNA molecules involved in the regulation of gene expression</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="EPIGENETIC">
      <data key="d0">PATHWAY</data>
      <data key="d1">Epigenetic mechanisms refer to changes in gene expression that do not involve alterations to the DNA sequence. These changes can potentially be involved in various conditions, including atopic dermatitis. Epigenetics, as a field of study, focuses on understanding these changes in gene expression that occur without modifications to the underlying DNA sequence.</data>
      <data key="d2">143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524,4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="GENETIC">
      <data key="d0">PATHWAY</data>
      <data key="d1">Genetics is the study of genes and heredity</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="EXPOSOME">
      <data key="d0">PATHWAY</data>
      <data key="d1">The exposome is the measure of all the exposures of an individual in a lifetime and how those exposures relate to health</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="MICROBIOME">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The microbiome consists of the community of microorganisms that live in a particular environment, including the body. This collection of microorganisms can be found in various environments such as the skin and the gut. The skin microbiome, in particular, can be modulated to treat atopic dermatitis. Both the skin and gut microbiomes play a significant role in the pathogenesis and treatment of atopic dermatitis.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,1596d061dbe1a1c9e8f31a02a21e5524,90f4809673ca34628b0e607908f0bf0b,f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="ALLERGIC REACTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">An allergic reaction is an immune response to a substance that is not harmful to most people</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="CHRONIC DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">A chronic disease is a long-lasting condition that can be controlled but not cured</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="INFLAMMATORY DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">An inflammatory disease is a condition characterized by inflammation</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="SKIN DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">A skin disease is a condition that affects the skin</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="ALLERGIC DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Allergic diseases are conditions caused by an overreaction of the immune system to allergens. An allergic disease is a condition caused by an allergic reaction.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="COMORBIDITY">
      <data key="d0">DISEASE</data>
      <data key="d1">A comorbidity is the presence of one or more additional conditions co-occurring with a primary condition</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="PATHOPHYSIOLOGY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Pathophysiology is the study of the functional changes that occur in the body as a result of a disease. It refers to the functional changes associated with or resulting from disease or injury, particularly in autoimmune diseases (AD).</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="PHARMACOLOGICAL INTERVENTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Pharmacological intervention involves the use of drugs to treat or prevent diseases or conditions, including Atopic Dermatitis and its comorbidities.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,90f4809673ca34628b0e607908f0bf0b</data>
    </node>
    <node id="THERAPEUTIC TARGET">
      <data key="d0">PATHWAY</data>
      <data key="d1">A therapeutic target is a molecule or pathway that can be modulated by treatment to achieve a therapeutic effect.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="SCRATCH">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Scratching is a response to itch, exacerbating the condition in atopic dermatitis</data>
      <data key="d2">143d2dc302af5606656797bff162e23e</data>
    </node>
    <node id="LANGERHANS CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Langerhans Cells are a type of dendritic cell found in the epidermis of the skin. These cells play a crucial role in immune responses by educating the adaptive immune system. They are particularly significant in the context of atopic dermatitis, where they are known to be defective.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,143d2dc302af5606656797bff162e23e,c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </node>
    <node id="OEDEMA">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Oedema is a clinical sign of atopic dermatitis characterized by swelling</data>
      <data key="d2">143d2dc302af5606656797bff162e23e</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="INDURATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Induration is a clinical sign of atopic dermatitis characterized by hardening of the skin</data>
      <data key="d2">143d2dc302af5606656797bff162e23e</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="PAPULATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Papulation is a clinical sign of atopic dermatitis characterized by raised bumps on the skin</data>
      <data key="d2">143d2dc302af5606656797bff162e23e</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="OOZING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Oozing is a clinical sign of atopic dermatitis characterized by fluid discharge from the skin</data>
      <data key="d2">143d2dc302af5606656797bff162e23e</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="SLEEPLESSNESS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Sleeplessness is a subjective symptom considered in the SCORAD (Scoring Atopic Dermatitis) assessment. It is a symptom of atopic dermatitis, often caused by pruritus (itching).</data>
      <data key="d2">143d2dc302af5606656797bff162e23e,f1897c89e321a3a80924fd72a56e90df</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="DISEASE CONTROL">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Disease control is a patient-reported outcome in the management of atopic dermatitis</data>
      <data key="d2">143d2dc302af5606656797bff162e23e</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="ADAPTIVE IMMUNE SYSTEM">
      <data key="d0">PATHWAY</data>
      <data key="d1">The adaptive immune system is responsible for long-term immunity and is involved in atopic dermatitis</data>
      <data key="d2">143d2dc302af5606656797bff162e23e</data>
    </node>
    <node id="TH2 RESPONSE">
      <data key="d0">PATHWAY</data>
      <data key="d1">TH2 response is an immune pathway involving T helper 2 cells, playing a key role in atopic dermatitis</data>
      <data key="d2">143d2dc302af5606656797bff162e23e</data>
    </node>
    <node id="TH17 RESPONSE">
      <data key="d0">PATHWAY</data>
      <data key="d1">TH17 response is an immune pathway involving T helper 17 cells, implicated in atopic dermatitis</data>
      <data key="d2">143d2dc302af5606656797bff162e23e</data>
    </node>
    <node id="TH22 RESPONSE">
      <data key="d0">PATHWAY</data>
      <data key="d1">TH22 response is an immune pathway involving T helper 22 cells, implicated in atopic dermatitis</data>
      <data key="d2">143d2dc302af5606656797bff162e23e</data>
    </node>
    <node id="NEURO-IMMUNOLOGICAL">
      <data key="d0">PATHWAY</data>
      <data key="d1">Neuro-immunological mechanisms involve interactions between the nervous and immune systems, relevant in atopic dermatitis</data>
      <data key="d2">143d2dc302af5606656797bff162e23e</data>
    </node>
    <node id="KERATINOCYTE DAMAGE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Keratinocyte damage refers to injury to skin cells, contributing to barrier dysfunction in atopic dermatitis</data>
      <data key="d2">143d2dc302af5606656797bff162e23e</data>
    </node>
    <node id="DENDRITIC CELL ACTIVATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Dendritic cell activation refers to the stimulation of dendritic cells, which play a role in the immune response in atopic dermatitis</data>
      <data key="d2">143d2dc302af5606656797bff162e23e</data>
    </node>
    <node id="EASI90">
      <data key="d0">SYMPTOM</data>
      <data key="d1">90% improvement in Eczema Area and Severity Index from baseline</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="OSCORAD">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Objective Scoring of Atopic Dermatitis, a version of SCORAD excluding subjective symptoms</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="SCORAD75">
      <data key="d0">SYMPTOM</data>
      <data key="d1">75% improvement in Scoring of Atopic Dermatitis from baseline</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="PP-NRS-11">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Peak Pruritus Numerical Rating Scale, a tool used to measure peak itch sensation</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="DLQI">
      <data key="d0">SYMPTOM</data>
      <data key="d1">The Dermatology Life Quality Index (DLQI) is a measure used to evaluate the impact of skin diseases on quality of life. It is a questionnaire specifically designed to assess how skin conditions affect various aspects of a patient's daily life and overall well-being.</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e,f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="POEM">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Patient-Oriented Eczema Measure, a tool used for self-assessment of eczema symptoms</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="RECAP">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Recap of Atopic Eczema, a tool used to measure disease control in atopic dermatitis</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="ADCT">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Atopic Dermatitis Control Tool, a tool used to measure disease control in atopic dermatitis</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="ROSEOMONAS MUCOSA">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">A Gram-negative bacterium found in healthy skin microbiome</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="FB-401">
      <data key="d0">CHEMICAL</data>
      <data key="d1">FB-401 is a therapeutic agent developed for the treatment of atopic dermatitis in both children and adults. It combines three strains of Roseomonas mucosa and functions as a bacterial replacement therapy. FB-401 exhibits anti-inflammatory effects primarily through the activation of TLR5 and TNFR. Additionally, it has therapeutic capabilities that include promoting tissue healing and inhibiting TLR5 signaling. Currently, FB-401 is undergoing clinical trials to evaluate its efficacy and safety in managing atopic dermatitis.</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,6059a6e2710b7df94c6a09e5eb7b024a,83eb9003d42977bb83fea1d123dd5ab9,e9841b88c9fab58c5175af409653da50,f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="TLR5">
      <data key="d0">PROTEIN</data>
      <data key="d1">Toll-like receptor 5 (TLR5) is a protein that plays a crucial role in the immune response to bacterial flagellin. It is involved in immune response signaling, contributing to the body's defense mechanisms against bacterial infections. Additionally, TLR5 is implicated in tissue repair and exhibits anti-inflammatory activity, highlighting its multifaceted role in maintaining immune homeostasis and promoting recovery from tissue damage.</data>
      <data key="d2">6059a6e2710b7df94c6a09e5eb7b024a,e9841b88c9fab58c5175af409653da50,f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="TNFR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Tumor necrosis factor receptor (TNFR) is a protein involved in the immune response and inflammation. It plays a crucial role in immune response signaling and is also involved in tissue repair and anti-inflammatory activity.</data>
      <data key="d2">6059a6e2710b7df94c6a09e5eb7b024a,e9841b88c9fab58c5175af409653da50,f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="STAPHYLOCOCCUS HOMINIS A9">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Staphylococcus hominis A9 (ShA9) is a strain of bacteria known for its dual activity of killing Staphylococcus aureus and inhibiting its toxin production. This bacterium is utilized in a bacteriotherapeutic approach specifically designed to target and neutralize S. aureus, thereby preventing the harmful effects of its toxins.</data>
      <data key="d2">6059a6e2710b7df94c6a09e5eb7b024a,f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="SHA9">
      <data key="d0">CHEMICAL</data>
      <data key="d1">SHA9, also referred to as ShA9, is a lyophilized strain of Staphylococcus hominis A9 specifically selected for its role in microbiome recovery and transplant in the treatment of atopic dermatitis. This targeted microbiome transplant aims to restore the natural microbial balance on the skin, thereby alleviating symptoms associated with atopic dermatitis.</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50,f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="NITRIC OXIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">An important mediator with beneficial metabolic and potential anti-inflammatory properties</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="NITROSOMONAS EUTROPHA">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Nitrosomonas eutropha is an ammonia-oxidizing bacterium capable of producing nitric oxide. Specifically, Nitrosomonas eutropha (B244) generates nitric oxide through the oxidation of ammonia. This bacterium has applications in the treatment of autoimmune diseases (AD), leveraging its unique biochemical properties for therapeutic purposes.</data>
      <data key="d2">6059a6e2710b7df94c6a09e5eb7b024a,f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="B244">
      <data key="d0">CHEMICAL</data>
      <data key="d1">B244 is a product containing the ammonia-oxidizing bacterium Nitrosomonas eutropha, which is currently in clinical development for the treatment of atopic dermatitis (AD). This bacterial strain is utilized for microbiome modulation and functions as a nitric oxide donor, contributing to its therapeutic effects in managing AD.</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,3ea70e257330c812b52334ca1f90d807,e9841b88c9fab58c5175af409653da50,f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="CLINICAL SIGNS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Clinical signs are used to stratify patients according to severity in atopic dermatitis</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="BLEEDING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Bleeding can occur in Atopic Dermatitis patients due to intense scratching. It is also one of the symptoms assessed in the POEM (Patient-Oriented Eczema Measure) tool.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4,f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="WEEPING/OOZING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Weeping/oozing is one of the symptoms assessed in the POEM tool</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="FLAKING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Flaking is one of the symptoms assessed in the POEM tool</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="DRYNESS OF THE SKIN">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Dryness of the skin is one of the symptoms assessed in the POEM tool</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="SKIN LESIONS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Skin lesions are measured by EASI and SCORAD in atopic dermatitis</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="INFLAMMATORY REACTION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Inflammatory reaction is a response measured in clinical trials for atopic dermatitis</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="MSB-01">
      <data key="d0">CHEMICAL</data>
      <data key="d1">MSB-01 is a topical product currently in clinical development, designed to modulate the skin microbiome. It is being investigated in clinical trials for its potential in microbiome transplantation and bacterial modulation, specifically targeting conditions such as atopic dermatitis (AD).</data>
      <data key="d2">6059a6e2710b7df94c6a09e5eb7b024a,f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="DB-001">
      <data key="d0">CHEMICAL</data>
      <data key="d1">DB-001 is a topical product currently in clinical development, designed to modulate the skin microbiome. It is being investigated in clinical trials for its potential to facilitate microbiome transplantation and bacterial modulation, specifically in the context of atopic dermatitis (AD).</data>
      <data key="d2">6059a6e2710b7df94c6a09e5eb7b024a,f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="AOBIOME">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">AOBiome is a company involved in the development of B244 for atopic dermatitis. Additionally, AOBiome is conducting clinical trials for pruritus associated with atopic dermatitis.</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b,f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="S. AUREUS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Staphylococcus aureus (S. aureus) is a bacterium that can colonize the skin and is often found on the skin of atopic dermatitis (AD) patients. It is known to cause skin infections and can exacerbate AD by inducing IL-36R- and IL-1R-dependent inflammation. The infections caused by S. aureus are further enhanced by the cytokines IL-4 and IL-13 in AD. Additionally, the toxins produced by S. aureus are inhibited by ShA9.</data>
      <data key="d2">3df8535e965efb96f5094169610507ff,3ea70e257330c812b52334ca1f90d807,41ccc4b41bd57cf2bda4dbb6c7ae4198,6059a6e2710b7df94c6a09e5eb7b024a,6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="NICLOSAMIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Niclosamide, also known as ATx201, is a small molecule that has demonstrated efficacy in inhibiting bacterial growth. It is particularly utilized for the decolonization of Staphylococcus aureus (S. aureus). Additionally, Niclosamide is employed in the treatment of atopic dermatitis, showcasing its versatility in addressing both bacterial infections and inflammatory skin conditions.</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="OMIGANAN PENTACHLORIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">CLS-001, a synthetic antimicrobial cationic peptide in clinical development for controlling dysbiosis in AD</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="EDP1815">
      <data key="d0">CHEMICAL</data>
      <data key="d1">EDP1815 is a microbiome modulator and bacterial strain designed for oral application, currently in phase I clinical trials. It is specifically used for the regulation of systemic inflammation and is being investigated for the treatment of autoimmune diseases, including atopic dermatitis (AD).</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,3ea70e257330c812b52334ca1f90d807,6059a6e2710b7df94c6a09e5eb7b024a,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="STMC-103H">
      <data key="d0">CHEMICAL</data>
      <data key="d1">STMC-103H is a bacterial strain designed for oral use that modulates the immune system through microbiome manipulation. It is currently in phase I clinical trials for the treatment of atopic dermatitis (AD). As a microbiome modulator, STMC-103H aims to alter the composition and function of the gut microbiota to achieve therapeutic effects in managing AD.</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,3ea70e257330c812b52334ca1f90d807,6059a6e2710b7df94c6a09e5eb7b024a,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="KBL697">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A microbiome modulator in phase I clinical trials for oral application</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="PETROLATUM">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A simple product used to modulate antimicrobial and epidermal barrier function in AD</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="AHR">
      <data key="d0">PROTEIN</data>
      <data key="d1">AHR (Aryl hydrocarbon receptor) is a protein involved in the regulation of biological responses to planar aromatic (aryl) hydrocarbons and environmental toxins. It is a ligand-activated transcriptional factor that plays a crucial role in the development of skin inflammation, including atopic dermatitis (AD). Additionally, AHR is involved in keratinocyte expression and the residence of epidermal dendritic cells (DCs), contributing to its significance in the pathophysiology of AD.</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807,6059a6e2710b7df94c6a09e5eb7b024a,849e0980ffd6a7e1cf0b8d3d1fbacd98,e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="COAL TAR">
      <data key="d0">CHEMICAL</data>
      <data key="d1">COAL TAR is a substance that binds to the aryl hydrocarbon receptor (AhR) and restores the expression of filaggrin (FLG).</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="TAPINAROF">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Tapinarof, also known as benvitimod, is a natural agonist of the aryl hydrocarbon receptor (AhR). It is a small molecule biologic agent that decreases inflammatory reactions when topically administered. Tapinarof is used in the treatment of atopic dermatitis (AD) and psoriasis, where it effectively reduces inflammatory responses.</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,3ea70e257330c812b52334ca1f90d807,6059a6e2710b7df94c6a09e5eb7b024a,849e0980ffd6a7e1cf0b8d3d1fbacd98,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="SPINK5">
      <data key="d0">GENE</data>
      <data key="d1">SPINK5 is a gene prevalent in keratinocytes and associated with skin differentiation. Mutations or variants in SPINK5 are known to favor allergen-independent inflammation in atopic dermatitis (AD).</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="EASI50">
      <data key="d0">SYMPTOM</data>
      <data key="d1">EASI50 is a clinical endpoint indicating a 50% improvement in the Eczema Area and Severity Index. It is used as a measure in studies related to atopic dermatitis (AD) to assess the efficacy of treatments by quantifying the reduction in the severity and extent of eczema.</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807,6309eeea565f06479830cec32938abc9</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="RCT">
      <data key="d0">PATHWAY</data>
      <data key="d1">Randomized Controlled Trial, a type of scientific experiment used in clinical trials</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="PHASE IIA">
      <data key="d0">PATHWAY</data>
      <data key="d1">A phase in clinical trials where the efficacy and side effects of a drug are studied</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="PHASE IB">
      <data key="d0">PATHWAY</data>
      <data key="d1">A phase in clinical trials focusing on the safety and dosage of a drug in a small group of patients</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="PHASE IIB">
      <data key="d0">PATHWAY</data>
      <data key="d1">A phase in clinical trials focusing on the efficacy and side effects of a drug in a larger group of patients</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="HISTOLOGICAL MODIFICATIONS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Changes in tissue structure observed under a microscope</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="TRANSCRIPTIONAL MODIFICATIONS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Changes in gene expression levels</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="BARRIER FUNCTION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">The ability of the skin to act as a barrier to protect against environmental factors</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="DYSBIOSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">An imbalance in the microbial communities, often associated with disease</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="EPIDERMAL BARRIER FUNCTION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">The protective function of the outermost layer of the skin</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="MOISTURIZERS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Products used to hydrate and protect the skin</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="ADAPTIVE IMMUNE RESPONSE">
      <data key="d0">PATHWAY</data>
      <data key="d1">The adaptive immune response is the body's targeted defense mechanism against specific pathogens. This sophisticated immune response involves T and B cells, which play crucial roles in identifying and neutralizing foreign invaders. A key feature of the adaptive immune response is the involvement of memory cells, which enable the body to recognize and respond more efficiently to pathogens that it has encountered previously.</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807,48288f3ec2832850282f95d4e38d10e1,6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="INVESTIGATOR GLOBAL ASSESSMENT (IGA)">
      <data key="d0">SYMPTOM</data>
      <data key="d1">A clinical endpoint used to assess the overall severity of a disease</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="ALARMINS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Alarmins are proinflammatory cytokines and danger signals produced during the innate immune response. These proteins signal tissue damage and initiate immune responses, making them critical in the body's defense mechanisms. Alarmins are also targeted for intervention in the early stages of atopic dermatitis, highlighting their role in inflammatory skin conditions.</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,3ea70e257330c812b52334ca1f90d807,83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="SEVERE AND UNCONTROLLED ALLERGIC ASTHMA">
      <data key="d0">DISEASE</data>
      <data key="d1">A chronic inflammatory disease of the airways characterized by severe and uncontrolled symptoms</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="ETOKIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Etokimab, also known as ANB020, is a humanized anti-IL-33 monoclonal antibody. It is a biologic agent specifically designed to target interleukin-33 (IL-33) and has been investigated in clinical studies for the treatment of atopic dermatitis. Despite its potential, Etokimab failed to meet the primary endpoint in a phase 2b clinical trial for atopic dermatitis.</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98,90f4809673ca34628b0e607908f0bf0b,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="CXCR1">
      <data key="d0">PROTEIN</data>
      <data key="d1">CXCR1 is a receptor involved in neutrophil migration</data>
      <data key="d2">6309eeea565f06479830cec32938abc9</data>
    </node>
    <node id="ASTEGOLIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Astegolimab (MSTT1041A/AMG282) is an anti-IL-33 antibody currently in clinical development. It is a biologic agent specifically targeting interleukin-33 (IL-33) and is used in the treatment of atopic dermatitis. Astegolimab is administered as a biologic injection, aiming to modulate the immune response associated with this condition.</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,6309eeea565f06479830cec32938abc9,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="MEDI3506">
      <data key="d0">CHEMICAL</data>
      <data key="d1">MEDI3506 is a biologic agent in clinical development that targets interleukin-33 (IL-33). It is designed as an anti-IL-33 antibody and is administered via injection. MEDI3506 is being investigated for its potential use in the treatment of atopic dermatitis.</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,6309eeea565f06479830cec32938abc9,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="REGN3500">
      <data key="d0">CHEMICAL</data>
      <data key="d1">REGN3500 is a biologic agent in clinical development that targets interleukin-33 (IL-33). It is designed as an anti-IL-33 antibody and is administered via injection. REGN3500 is being investigated for its potential use in the treatment of atopic dermatitis.</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,6309eeea565f06479830cec32938abc9,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="IL-1&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-1&#945; (Interleukin-1 alpha) is a cytokine involved in the immune response and inflammation. It is a proinflammatory cytokine released by keratinocytes after injury and by skin dysbiosis.</data>
      <data key="d2">6309eeea565f06479830cec32938abc9,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="BERMEKIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Bermekimab (MABp1) is an anti-IL-1&#945; monoclonal antibody initially developed for oncological indications. It is now being used in the treatment of various inflammatory conditions, including hidradenitis suppurativa and atopic dermatitis. As a biologic agent, Bermekimab targets interleukin-1&#945; (IL-1&#945;) and is administered via injection to manage these inflammatory diseases effectively.</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="IGA 0/1">
      <data key="d0">SYMPTOM</data>
      <data key="d1">IGA 0/1 is a clinical endpoint indicating clear or almost clear skin</data>
      <data key="d2">6309eeea565f06479830cec32938abc9</data>
    </node>
    <node id="KY1005">
      <data key="d0">CHEMICAL</data>
      <data key="d1">KY1005 is a non-depleting anti-OX40L biologic antibody that has been used in clinical trials for immune system diseases, specifically targeting OX40L. It functions by inhibiting effector T cell response while maintaining regulatory T cell activity. KY1005 has shown positive results in phase 2a clinical trials for the treatment of moderate to severe atopic dermatitis. This biologic injection is being studied for its potential to treat atopic dermatitis, with promising outcomes observed in the completed phase 2a trials.</data>
      <data key="d2">6309eeea565f06479830cec32938abc9,68015074236b0144899baa38d01ae467,78e26c66107dba37ac4bab65406b43a0,83eb9003d42977bb83fea1d123dd5ab9,90f4809673ca34628b0e607908f0bf0b,e9841b88c9fab58c5175af409653da50</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="PHASE IIA STUDY">
      <data key="d0">PATHWAY</data>
      <data key="d1">A Phase IIa study is an early phase of clinical trials designed to assess the efficacy and safety of a treatment. This phase specifically focuses on evaluating the efficacy and side effects of a drug, providing crucial data on its therapeutic potential and safety profile.</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,48288f3ec2832850282f95d4e38d10e1,6309eeea565f06479830cec32938abc9,78e26c66107dba37ac4bab65406b43a0</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PHASE IIB TRIAL">
      <data key="d0">PATHWAY</data>
      <data key="d1">A Phase IIb trial is a clinical study phase designed to test the efficacy and optimal dosing of a drug. It also aims to assess the efficacy and side effects in a larger group of participants. This phase is crucial for determining the therapeutic potential and safety profile of the drug before proceeding to more extensive Phase III trials.</data>
      <data key="d2">6309eeea565f06479830cec32938abc9,78e26c66107dba37ac4bab65406b43a0</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="ANTIGEN PRESENTATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Antigen presentation is a crucial process in the adaptive immune response leading to inflammation</data>
      <data key="d2">6309eeea565f06479830cec32938abc9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="SEVERE ALLERGIC ASTHMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Severe allergic asthma is a chronic inflammatory disease of the airways</data>
      <data key="d2">6309eeea565f06479830cec32938abc9</data>
    </node>
    <node id="TEFF CELL">
      <data key="d0">CELL</data>
      <data key="d1">Effector T cells (Teff cells) are a type of T cell involved in the immune response</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
    </node>
    <node id="TREG CELL">
      <data key="d0">CELL</data>
      <data key="d1">Regulatory T cells (Treg cells) are a type of T cell that modulates the immune system. They are a component of the immune system that suppresses immune responses of other cells. Treg cells help regulate the immune system and maintain tolerance to self-antigens, thereby playing a crucial role in maintaining immune tolerance.</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89,48288f3ec2832850282f95d4e38d10e1,78e26c66107dba37ac4bab65406b43a0,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="IL-2R&#915;">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-2R&#947; is a receptor chain involved in the type I receptor for IL-4</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
    </node>
    <node id="CBP-201">
      <data key="d0">CHEMICAL</data>
      <data key="d1">CBP-201 is a biologic agent targeting interleukin-4 receptor alpha (IL-4R&#945;) used in the treatment of atopic dermatitis. It is administered as a biologic injection and functions as an IL-4R&#945; antagonist. Notably, CBP-201 has a faster onset of action compared to dupilumab, another treatment option for atopic dermatitis.</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,78e26c66107dba37ac4bab65406b43a0,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="AK120">
      <data key="d0">CHEMICAL</data>
      <data key="d1">AK120 is a biologic injection targeting IL-4R&#945;, used in the treatment of atopic dermatitis. It is an antibody directed against IL-4R&#945; and is currently undergoing phase Ib studies.</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="ASLAN004">
      <data key="d0">CHEMICAL</data>
      <data key="d1">ASLAN004 is a fully humanized monoclonal antibody used in the treatment of atopic dermatitis. It targets interleukin-4 receptor alpha (IL-4Ra) and interleukin-13 receptor alpha 1 (IL-13R&#945;1). ASLAN004 is currently undergoing multiple ascending dose studies to evaluate its efficacy and safety in treating atopic dermatitis.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,3dfbb4c51838e0951f53ce951395225f,78e26c66107dba37ac4bab65406b43a0,83eb9003d42977bb83fea1d123dd5ab9,cccfd5ff480e281556e2210cd0e5c4b5,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="EMA">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The European Medicines Agency (EMA) is a regulatory body that provides opinions on drug approvals. The EMA is responsible for the approval of drugs, including crisaborole, in Europe.</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0,90f4809673ca34628b0e607908f0bf0b</data>
    </node>
    <node id="ECZTRA1">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">ECZTRA1 is a phase III pivotal monotherapy study evaluating the efficacy of tralokinumab in patients.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,78e26c66107dba37ac4bab65406b43a0</data>
    </node>
    <node id="ECZTRA2">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">ECZTRA2 is a phase III pivotal monotherapy study evaluating the efficacy of tralokinumab in patients.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,78e26c66107dba37ac4bab65406b43a0</data>
    </node>
    <node id="CONJUNCTIVITIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Conjunctivitis is an inflammation or infection of the outer membrane of the eyeball and the inner eyelid, also known as the conjunctiva. This eye disorder can develop as a side effect of dupilumab.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,3df8535e965efb96f5094169610507ff,78e26c66107dba37ac4bab65406b43a0</data>
    </node>
    <node id="PHASE IB TRIAL">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Phase Ib trial is a clinical study phase to test the safety and efficacy of a drug</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
    </node>
    <node id="PHASE III PROGRAMME">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Phase III programme is a clinical study phase to confirm the efficacy and monitor side effects of a drug</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
    </node>
    <node id="TYPE I RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Type I receptor is a receptor complex involving IL-4R&#945; and IL-2R&#947;</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
    </node>
    <node id="TYPE II RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Type II receptor is a receptor complex involving IL-4R&#945; and IL-13R&#945;1</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
    </node>
    <node id="EYE DISORDERS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Eye disorders encompass a range of adverse events, including conjunctivitis, keratoconjunctivitis, and keratitis. These conditions can manifest as side effects of certain treatments, highlighting the importance of monitoring and managing ocular health in patients undergoing various medical therapies.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,78e26c66107dba37ac4bab65406b43a0</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="CHILDREN">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Children are a population group often included in clinical studies for pediatric indications</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="ADULTS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Adults are a population group often included in clinical studies for adult indications</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="PATIENTS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Patients are individuals receiving medical treatment or participating in clinical studies</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="PLACEBO GROUP">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The placebo group is a control group in clinical studies receiving a placebo treatment. This group refers to the patients who are administered a placebo, which is an inactive substance, during a clinical trial. The purpose of the placebo group is to serve as a benchmark to compare the effects of the actual treatment being tested, thereby helping to determine the treatment's efficacy and safety.</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1,78e26c66107dba37ac4bab65406b43a0</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="MODERATE-TO-SEVERE AD">
      <data key="d0">DISEASE</data>
      <data key="d1">Moderate-to-severe atopic dermatitis is a more severe form of atopic dermatitis requiring intensive treatment</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="HEALTHY SUBJECTS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Healthy subjects are individuals without the disease being studied, often included in clinical trials for comparison</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="EMA/CHMP/202204/2021">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">EMA/CHMP/202204/2021 is a document reference for the European Medicines Agency's positive opinion on tralokinumab</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="KYMAB">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Kymab is a biopharmaceutical company involved in the development of biologic therapies. Notably, Kymab has developed KY1005, a promising therapeutic agent. The company has demonstrated positive phase 2a results for KY1005 in the treatment of atopic dermatitis, highlighting its potential efficacy in managing this autoimmune condition.</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,78e26c66107dba37ac4bab65406b43a0,83eb9003d42977bb83fea1d123dd5ab9</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="ASLAN">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">ASLAN is a biopharmaceutical company involved in the development of ASLAN004</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="USA">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">USA is a country where clinical studies for dupilumab are being conducted</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="EU">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">EU is a region where clinical studies for dupilumab are being conducted</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="KERATOCONJUNCTIVITIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Inflammation of the cornea and conjunctiva of the eye</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41</data>
    </node>
    <node id="KERATITIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Inflammation of the cornea of the eye</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41</data>
    </node>
    <node id="EOSINOPHIL-DERIVED NEUROTOXIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">A protein released by eosinophils that is involved in the immune response</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="EOSINOPHIL CATIONIC PROTEIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">A protein released by eosinophils that is involved in the immune response</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="MEPOLIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Mepolizumab is a monoclonal antibody that targets Interleukin-5 (IL-5). It is classified as an IgG1k IL-5 inhibitor and is primarily used in the treatment of severe eosinophilic asthma. By inhibiting IL-5, Mepolizumab effectively reduces peripheral blood eosinophils, which are a key component in the pathophysiology of eosinophilic asthma. Additionally, Mepolizumab is reserved for treating cases of atopic dermatitis (AD) that are unresponsive to standard therapies.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,0829313703a7d2bae5436a9ee542334d,3df8535e965efb96f5094169610507ff,8246ea974dfb00cb5e3d984004e21a9e,cccfd5ff480e281556e2210cd0e5c4b5</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="TARC">
      <data key="d0">PROTEIN</data>
      <data key="d1">Thymus and activation-regulated chemokine, a biomarker for atopic dermatitis severity</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="BENRALIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Benralizumab is a monoclonal antibody that targets the Interleukin-5 receptor alpha (IL-5R&#945;). It is used primarily in the treatment of eosinophilic asthma. As a biologic drug, Benralizumab functions by inhibiting IL-5 through its action on IL-5R&#945;. Additionally, it is also utilized as a biologic injection for the treatment of atopic dermatitis.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,3df8535e965efb96f5094169610507ff,cccfd5ff480e281556e2210cd0e5c4b5,e9841b88c9fab58c5175af409653da50</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="IL-5R&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-5R&#945; (Interleukin-5 receptor alpha) is a protein that binds interleukin-5 and is involved in the growth and differentiation of eosinophils. It is also known as the &#945;-chain of the IL-5 receptor and plays a crucial role in the regulation of immune responses. As a component of the IL-5 receptor, IL-5R&#945; is integral to the receptor's function in mediating the effects of interleukin-5 on target cells.</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="ADAPT">
      <data key="d0">STUDY</data>
      <data key="d1">Atopic Dermatitis Anti-IgE study, designed to verify the role of IgE in the paediatric population with atopic dermatitis</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41</data>
      <data key="d3">STUDY</data>
    </node>
    <node id="NASAL POLYPOSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">A condition characterized by the growth of polyps in the nasal cavity</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="MIGE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Membrane-bound IgE (mIgE) is a form of Immunoglobulin E (IgE) expressed on B cells. This protein plays a crucial role in the immune response and inflammation.</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="ANTI-C&#917;MX (FB825)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Anti-C&#949;mX (FB825) is an antibody directed against mIgE to deplete IgE-committed B cells</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="IL-22R">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-22R is the receptor for IL-22, involved in mediating its biological activities</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="IL-22R1">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-22R1 (Interleukin-22 receptor 1) is a protein that binds interleukin-22 and is involved in the immune response. It is a subunit of the IL-22 receptor complex and forms a complex with IL-10R2. IL-22R1 plays a crucial role in the regulation of immune responses.</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1,e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="IL-10R2">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-10R2 is a subunit of the IL-22 receptor complex that heterodimerizes with IL-22R1</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="IL-20">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-20 is a cytokine that binds to IL-22R1 and IL-20R2 receptor complexes</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="IL-24">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-24 is a cytokine that binds to IL-22R1 and IL-20R2 receptor complexes</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="LEO 138559">
      <data key="d0">CHEMICAL</data>
      <data key="d1">LEO 138559 is a biologic injection targeting IL-22R1, used in the treatment of atopic dermatitis. It is an antibody directed against IL-22R1 and is currently in phase I studies.</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="RISANKIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Risankizumab is a biologic drug that functions as an anti-IL-23 antibody. It specifically targets Interleukin-23 (IL-23) and is administered via injection. Risankizumab has been investigated and is used in the treatment of atopic dermatitis (AD).</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1,cccfd5ff480e281556e2210cd0e5c4b5,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="IL-2">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-2 (IL-2) is a cytokine that plays a central role in the activation and proliferation of T cells. IL-2 production is upregulated by the interaction between OX40 and OX40L. Additionally, the expression of IL-2 can be reduced by TAC-loaded PLG-based nanoparticles.</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456,442e7fad2fab75fa2449309783294d89,44f2592262cac835560b4c149fee8d2b,48288f3ec2832850282f95d4e38d10e1,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="LY3471851">
      <data key="d0">CHEMICAL</data>
      <data key="d1">LY3471851 is a pegylated recombinant human IL-2 biologic injection designed to target the IL-2 receptor complex on T cells, specifically aiming to direct rhIL-2 to Treg cells. It is used in the treatment of atopic dermatitis.</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="ULCERATIVE COLITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Ulcerative Colitis is a chronic inflammatory bowel disease that causes long-lasting inflammation and ulcers in the digestive tract, specifically in the colon. It is a type of gastrointestinal tract fibrosis. Treatment options for Ulcerative Colitis include anti-TL1A antibody to reduce fibrosis and TNF antagonists to manage inflammation.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,423195c6b63ad0a6773374364ebf3612,442e7fad2fab75fa2449309783294d89,48288f3ec2832850282f95d4e38d10e1,516e41e96d2e72d45bf1e2c69da7f18a,5ec1ebf4e260eb1f8fda8acdf06cd39e,68015074236b0144899baa38d01ae467,7f559ad7372a4e35e90b43cc67047b0f,c525762bb827485bceeb9f09bb4bcfe0,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="ANTI-IGE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Anti-IgE refers to biologics that target IgE to treat allergic conditions</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="IMMUNOADSORPTION">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Immunoadsorption is a process used to remove specific antibodies from the blood</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="IL-20R2">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-20R2 is a receptor subunit that forms complexes with IL-22R1 and IL-20R1</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="IL-20R1">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-20R1 is a receptor subunit that forms complexes with IL-20R2</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="ASIAN PATIENTS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Asian patients are a demographic group studied in the context of AD and the IL-23&#8211;IL-17 axis</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="LYMPHOBLASTS">
      <data key="d0">CELL</data>
      <data key="d1">Lymphoblasts are immature lymphocytes involved in the immune response</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="STAPHYLOCOCCAL EXOTOXINS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Staphylococcal exotoxins are toxins produced by Staphylococcus bacteria that induce cytokine production</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="RECEPTOR COMPLEX">
      <data key="d0">PROTEIN</data>
      <data key="d1">Receptor complex refers to the combination of receptor subunits that mediate cytokine signaling</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="TRANSCRIPTOMIC SIGNATURE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Transcriptomic signature refers to the pattern of gene expression associated with a specific condition, such as AD</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="IMMUNE POLARIZATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune polarization refers to the skewing of the immune response towards a specific type, such as TH2 in allergies</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="ALLERGIC REACTIONS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Allergic reactions are immune responses to allergens, often involving IgE</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="POLYSENSITIZATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Polysensitization refers to being allergic to multiple allergens</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="OLIGOSENSITIZATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Oligosensitization refers to being allergic to a few specific allergens</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="ENVIRONMENTAL ALLERGENS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Environmental allergens are substances in the environment that can cause allergic reactions</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="AUTOIMMUNE DISORDERS">
      <data key="d0">DISEASE</data>
      <data key="d1">Autoimmune disorders are conditions where the immune system attacks the body's own tissues</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="ALLERGIC DISEASES">
      <data key="d0">DISEASE</data>
      <data key="d1">Allergic diseases are conditions caused by hypersensitivity of the immune system to allergens</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="RECOMBINANT HUMAN IL-2">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Recombinant human IL-2 is a lab-produced, synthetic form of interleukin-2 used in immunotherapy. It is designed to mimic the natural IL-2 protein, which plays a crucial role in the immune system. This recombinant form is utilized in various therapeutic applications to enhance the body's immune response, particularly in the treatment of certain autoimmune diseases and cancers.</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="PEGYLATED">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Pegylated refers to the modification of a molecule with polyethylene glycol to improve its properties</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="PHASE I STUDIES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Phase I studies are initial clinical trials to assess the safety of a treatment</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="PROOF-OF-CONCEPT STUDY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Proof-of-concept study is a preliminary study to evaluate the feasibility of a treatment</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="CLINICAL IMPROVEMENT">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Clinical improvement refers to the positive changes in a patient's condition as a result of treatment.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,44f2592262cac835560b4c149fee8d2b,48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="RHIL-2">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Recombinant human IL-2 (rhIL-2; LY3471851) is a pegylated form designed to target the IL-2 receptor complex on T cells. This cytokine is used to stimulate the growth of immune cells and is involved in the regulation of immune responses.</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89,e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="PDE4">
      <data key="d0">PROTEIN</data>
      <data key="d1">Phosphodiesterase 4 (PDE4) is an enzyme involved in the breakdown of cyclic AMP. It plays a crucial role in cellular signaling pathways by regulating the levels of cyclic AMP, a key secondary messenger. PDE4 is a significant target for anti-inflammatory drugs due to its role in modulating immune responses. By influencing the release of various cytokines from immune cells, PDE4 inhibitors can help manage inflammatory conditions, making it a valuable focus in the treatment of autoimmune diseases.</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c,442e7fad2fab75fa2449309783294d89,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="LOTAMILAST">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Lotamilast (RVT-501/E6005) is a small molecule drug developed by Dermavant. It functions as a PDE4 inhibitor and is currently in development for the treatment of atopic dermatitis.</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="DIFAMILAST">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Difamilast (OPA-15406/MM36) is a novel, selective phosphodiesterase 4 (PDE4) inhibitor developed by Otsuka. It is a small molecule drug candidate specifically targeting the PDE4 enzyme and is currently undergoing phase 3 clinical trials in Japan for the treatment of atopic dermatitis.</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,442e7fad2fab75fa2449309783294d89,83eb9003d42977bb83fea1d123dd5ab9,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="ROFLUMILAST">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Roflumilast (AQR-151) is a small molecule drug developed by AstraZeneca, targeting the PDE4 enzyme. It functions as a PDE4 inhibitor and has been tested for the treatment of atopic dermatitis.</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="LEO 29102">
      <data key="d0">CHEMICAL</data>
      <data key="d1">LEO 29102 is a small molecule drug developed by LEO Pharma, targeting the PDE4 enzyme. It is a PDE inhibitor with selectivity for the PDE4D isoform.</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="HISTAMINE H4 RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Histamine H4 receptor (H4R) is a G protein-coupled receptor involved in immunoregulatory activities on leukocytes</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89</data>
    </node>
    <node id="JNJ-7777120">
      <data key="d0">CHEMICAL</data>
      <data key="d1">JNJ-7777120 is a reference compound for selective H4R antagonists</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89</data>
    </node>
    <node id="ADRIFORANT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Adriforant (formerly ZPL-389) is a small molecule drug developed by Novartis, targeting the H4R receptor. It functions as an H4R antagonist and has been tested for its efficacy in treating inflammatory skin disorders, including atopic dermatitis.</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89,e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="LEO 152020">
      <data key="d0">CHEMICAL</data>
      <data key="d1">LEO 152020, also known as JW1601, is an oral H4R antagonist currently in phase I clinical trials. This small molecule targets the H4 receptor (H4R) and is being investigated for its potential use in the treatment of atopic dermatitis.</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="PATIENT-ORIENTED ECZEMA MEASURE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Patient-Oriented Eczema Measure (POEM) is a tool used to assess the severity of eczema from the patient's perspective</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89</data>
    </node>
    <node id="VISUAL ANALOGUE SCALE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Visual analogue scale (VAS) is a tool used to measure the intensity of pruritus</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89</data>
    </node>
    <node id="IL-2 RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-2 receptor is a protein complex on T cells that binds IL-2, leading to T cell activation and proliferation</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89</data>
    </node>
    <node id="PDE4 INHIBITOR">
      <data key="d0">CHEMICAL</data>
      <data key="d1">PDE4 inhibitors are compounds that inhibit the activity of phosphodiesterase 4, reducing inflammation</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89</data>
    </node>
    <node id="H1R">
      <data key="d0">PROTEIN</data>
      <data key="d1">Histamine H1 receptor (H1R) is a G protein-coupled receptor involved in allergic responses and pruritus</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89</data>
    </node>
    <node id="H2R">
      <data key="d0">PROTEIN</data>
      <data key="d1">Histamine H2 receptor (H2R) is a G protein-coupled receptor involved in regulating smooth muscle relaxation in the gastrointestinal tract</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89</data>
    </node>
    <node id="H3R">
      <data key="d0">PROTEIN</data>
      <data key="d1">Histamine H3 receptor (H3R) is a G protein-coupled receptor involved in the central nervous system, regulating histamine synthesis</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89</data>
    </node>
    <node id="ANTIGEN">
      <data key="d0">PROTEIN</data>
      <data key="d1">An antigen is a substance that induces an immune response, particularly in the adaptive immune system. Antigens are molecules capable of triggering this immune response, which is a critical function in the body's defense mechanism against pathogens.</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,442e7fad2fab75fa2449309783294d89,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="CHEMOTACTIC MEDIATOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Chemotactic mediators are substances that attract cells to the site of inflammation or infection</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89</data>
    </node>
    <node id="GASTROINTESTINAL TRACT">
      <data key="d0">TISSUE</data>
      <data key="d1">The gastrointestinal tract is a series of hollow organs that form a system responsible for digestion and the absorption of nutrients. This organ system can be affected by fibrotic diseases, including those driven by TL1A. Fibrosis in the gastrointestinal tract can significantly impact its function, leading to various digestive issues.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,442e7fad2fab75fa2449309783294d89,68015074236b0144899baa38d01ae467,c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="CENTRAL NERVOUS SYSTEM">
      <data key="d0">TISSUE</data>
      <data key="d1">The central nervous system consists of the brain and spinal cord, responsible for processing and transmitting information</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89</data>
    </node>
    <node id="H4R">
      <data key="d0" />
      <data key="d1">H4R, or type 4 histamine receptor, is a protein involved in immune response modulation and inflammation. This histamine receptor plays a crucial role in the body's immune response, highlighting its significance in the regulation of inflammatory processes.</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,442e7fad2fab75fa2449309783294d89,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="152020">
      <data key="d0">CHEMICAL</data>
      <data key="d1">152020 is an oral H4R antagonist currently in phase I clinical trials</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="PROSTAGLANDIN D2">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Prostaglandin D2 is a mediator involved in the generation of inflammation</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="CRTH2">
      <data key="d0">PROTEIN</data>
      <data key="d1">CRTH2 is a receptor for Prostaglandin D2, involved in TH2-mediated inflammation in AD</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="FEVIPIPRANT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Fevipiprant (QAW039) is a CRTH2 antagonist that failed to significantly improve AD in phase II studies</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="TEMAPIPRANT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Temapiprant (OC000459) is a CRTH2 antagonist that failed to significantly improve AD in phase II studies</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="RANTES">
      <data key="d0">PROTEIN</data>
      <data key="d1">RANTES is a chemokine that binds to CCR4 and is produced in high amounts in AD</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="MCP1">
      <data key="d0">PROTEIN</data>
      <data key="d1">MCP1 is a chemokine that binds to CCR4 and is produced in high amounts in AD</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="CCL22">
      <data key="d0">PROTEIN</data>
      <data key="d1">CCL22 (MDC) is a chemokine involved in the immune response and inflammation. It binds to the CCR4 receptor and is produced in high amounts in atopic dermatitis (AD). During inflammation, CCL22 ascends in the skin and promotes the attraction of inflammatory T cells and dendritic cell (DC) subtypes.</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,41ccc4b41bd57cf2bda4dbb6c7ae4198,6059a6e2710b7df94c6a09e5eb7b024a</data>
    </node>
    <node id="RPT193">
      <data key="d0">CHEMICAL</data>
      <data key="d1">RPT193 is a small molecule drug developed by RAPT Therapeutics, targeting the CCR4 receptor. It is currently being tested in a phase 1b trial for the treatment of atopic dermatitis. As a CCR4 antagonist, RPT193 blocks the recruitment of TH2 cells, which play a crucial role in allergic diseases, thereby offering a potential therapeutic approach for conditions such as atopic dermatitis.</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,83eb9003d42977bb83fea1d123dd5ab9,e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="S1P">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Sphingosine 1-phosphate (S1P) is an active terminal derivative of sphingosine metabolism involved in immune cell migration. As a signaling lipid, S1P plays a crucial role in regulating immune cell trafficking and vascular development.</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="S1PR1">
      <data key="d0">PROTEIN</data>
      <data key="d1">S1PR1 (Sphingosine-1-phosphate receptor 1) is a protein involved in the immune response and inflammation. It functions as a receptor for sphingosine-1-phosphate (S1P) and is expressed on T cells and dendritic cells (DCs). S1PR1 plays a crucial role in immune cell migration, facilitating the movement of these cells to sites where they are needed for immune surveillance and response.</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="S1PR3">
      <data key="d0">PROTEIN</data>
      <data key="d1">S1PR3 is a receptor for S1P, expressed on DCs, involved in immune cell migration</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="S1PR4">
      <data key="d0">PROTEIN</data>
      <data key="d1">S1PR4, or sphingosine 1-phosphate receptor 4, is a receptor for S1P that is expressed on T cells and dendritic cells (DCs). It plays a crucial role in immune cell migration.</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="S1PR5">
      <data key="d0">PROTEIN</data>
      <data key="d1">S1PR5, or sphingosine 1-phosphate receptor 5, is a receptor for S1P (sphingosine 1-phosphate) and plays a crucial role in immune cell migration. This protein is integral to the movement and positioning of immune cells within the body, highlighting its importance in the immune response.</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="FINGOLIMOD">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Fingolimod is an S1PR1,3&#8211;5 agonist approved for the therapy of multiple sclerosis</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="SIPONIMOD">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Siponimod is an S1PR1,5 agonist approved for the therapy of multiple sclerosis</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="ETRASIMOD">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Etrasimod (APD334) is a next-generation small molecule drug developed by Arena Pharma. It functions as an S1PR agonist, specifically targeting the S1PR1, S1PR4, and S1PR5 receptors. Etrasimod induces sustained internalization of the S1PR1 receptor and is currently advancing into phase 3 clinical trials for the treatment of atopic dermatitis.</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,83eb9003d42977bb83fea1d123dd5ab9,90f4809673ca34628b0e607908f0bf0b,e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="SCD-044">
      <data key="d0">CHEMICAL</data>
      <data key="d1">SCD-044 is a small molecule drug developed by Sun Pharma, targeting the S1PR1 receptor. It functions as a selective S1PR1 agonist and is currently in development for the treatment of autoimmune diseases such as atopic dermatitis (AD) and psoriasis.</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="LC51-0255">
      <data key="d0">CHEMICAL</data>
      <data key="d1">LC51-0255 is a small molecule drug developed by LG Chem, targeting the S1PR1 receptor. It functions as a selective S1PR1 agonist and is currently in development for the treatment of autoimmune diseases such as atopic dermatitis (AD) and psoriasis.</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="BMS-986166">
      <data key="d0">CHEMICAL</data>
      <data key="d1">BMS-986166 is a small molecule drug developed by Bristol Myers Squibb, targeting the S1PR1 receptor. It is a selective S1PR1 agonist currently in development for the treatment of autoimmune diseases such as atopic dermatitis (AD) and psoriasis.</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="KT-474">
      <data key="d0">CHEMICAL</data>
      <data key="d1">KT-474 is a small molecule drug developed by Kymera that functions as a selective S1PR1 agonist. It is currently in development for the treatment of autoimmune diseases such as atopic dermatitis (AD) and psoriasis.</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="AKP-11">
      <data key="d0">CHEMICAL</data>
      <data key="d1">AKP-11 is a highly selective S1PR1 agonist in clinical development for psoriasis and AD</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="CHEMOTACTIC MEDIATORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Chemotactic mediators are substances that attract cells to sites of inflammation</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="MEMORY TH2 CELL">
      <data key="d0">CELL</data>
      <data key="d1">Memory TH2 cells are a subset of T cells that remember past infections and are involved in allergic responses</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="LYMPHATIC TISSUE">
      <data key="d0">TISSUE</data>
      <data key="d1">Lymphatic tissue is part of the immune system and includes lymph nodes and other structures</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="LYMPHOCYTE">
      <data key="d0">CELL</data>
      <data key="d1">Lymphocytes are a type of white blood cell involved in the immune response</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="PERIPHERAL LYMPHOCYTE">
      <data key="d0">CELL</data>
      <data key="d1">Peripheral lymphocytes are white blood cells found in the bloodstream and tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL">
      <data key="d0">CELL</data>
      <data key="d1">Immune cells are cells involved in the body's defense against infections and diseases</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="CARDIOVASCULAR TOXICITY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Cardiovascular toxicity refers to harmful effects on the heart and blood vessels</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="SPHINGOSINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Sphingosine is a type of lipid involved in cell signaling and metabolism</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="SPHINGOSINE METABOLISM">
      <data key="d0">PATHWAY</data>
      <data key="d1">Sphingosine metabolism is the process by which sphingosine is broken down and converted into other molecules</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="MULTIPLE SCLEROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Multiple sclerosis is a chronic autoimmune disease affecting the central nervous system. In this condition, the immune system erroneously attacks and eats away at the protective covering of nerves, known as myelin. This damage disrupts communication between the brain and the rest of the body, leading to a wide range of neurological symptoms.</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,423195c6b63ad0a6773374364ebf3612,8ce8c356713490cd2c680f505bcd050b</data>
    </node>
    <node id="NEURODEGENERATION">
      <data key="d0">DISEASE</data>
      <data key="d1">Neurodegeneration refers to the progressive loss of structure or function of neurons</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="PNEUMONIA">
      <data key="d0">DISEASE</data>
      <data key="d1">Pneumonia is an infection that inflames the air sacs in one or both lungs</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="ALLERGIC INFLAMMATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Allergic inflammation is an immune response to allergens, characterized by symptoms such as swelling, redness, and itching. This response occurs when the immune system reacts to substances that are typically harmless to most people, leading to the hallmark signs of allergic inflammation, which include redness, swelling, and itching.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE MODULATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune modulation refers to the alteration of the immune response to achieve a desired therapeutic effect</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL MIGRATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell migration is the movement of immune cells to sites of infection or inflammationImmune cell migration is the movement of immune cells to sites of infection or injury</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="LYMPHOCYTE TRAFFICKING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Lymphocyte trafficking is the movement of lymphocytes within the body to perform immune functions</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL RECRUITMENT">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell recruitment is the process by which immune cells are attracted to sites of infection or injuryImmune cell recruitment is the process of attracting immune cells to sites of infection or inflammation</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL ACTIVATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell activation is the process by which immune cells are stimulated to respond to infections or diseases</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL EMIGRATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell emigration is the movement of immune cells from lymphatic sites to other parts of the body</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL INFILTRATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell infiltration is the movement of immune cells into tissues, often associated with inflammationImmune cell infiltration is the process by which immune cells enter tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL SEGREGATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell segregation is the separation of immune cells into different compartments or tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL PROLIFERATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell proliferation is the rapid increase in the number of immune cells in response to infection or disease</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL DIFFERENTIATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell differentiation is the process by which immune cells develop into specialized types</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL FUNCTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell function refers to the various activities performed by immune cells to protect the body</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell signaling is the communication between immune cells through chemical signals</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL INTERACTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell interaction refers to the interactions between different types of immune cells</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL REGULATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell regulation is the control of immune cell activities to maintain immune homeostasis</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL SUPPRESSION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell suppression is the inhibition of immune cell activities to prevent excessive immune responses</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL DEACTIVATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell deactivation is the process by which immune cells are turned off or suppressed</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL APOPTOSIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell apoptosis is the programmed cell death of immune cells</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL SURVIVAL">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell survival refers to the ability of immune cells to remain alive and functional</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL HOMEOSTASIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell homeostasis is the maintenance of a stable number and function of immune cells</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL METABOLISM">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell metabolism refers to the biochemical processes that occur within immune cells</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL ENERGY PRODUCTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell energy production is the generation of energy within immune cells to support their functions</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL NUTRIENT UPTAKE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell nutrient uptake is the absorption of nutrients by immune cells to support their functions</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL WASTE REMOVAL">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell waste removal is the elimination of waste products by immune cells</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL DETOXIFICATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell detoxification is the process by which immune cells neutralize and eliminate toxins</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL REPAIR">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell repair is the process by which immune cells fix damage to their structures or functions</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL REGENERATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell regeneration is the process by which immune cells are renewed or replaced</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL ADAPTATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell adaptation is the ability of immune cells to adjust to changes in their environment</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL PLASTICITY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell plasticity is the ability of immune cells to change their function or phenotype</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL MEMORY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell memory is the ability of immune cells to remember past infections and respond more effectively</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL TOLERANCE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell tolerance is the ability of immune cells to avoid attacking the body's own tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL EXHAUSTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell exhaustion is the state of reduced function and responsiveness in immune cells</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL SENESCENCE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell senescence is the process by which immune cells age and lose their function</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL REJUVENATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell rejuvenation is the process by which aged immune cells regain their function</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL REPROGRAMMING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell reprogramming is the process by which immune cells are genetically or epigenetically modified</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL ENGINEERING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell engineering is the process of designing and creating immune cells with specific functions</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL THERAPY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell therapy is the use of immune cells to treat diseases</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL TRANSPLANTATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell transplantation is the transfer of immune cells from one individual to another</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL INFUSION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell infusion is the administration of immune cells into the bloodstream</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL INJECTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell injection is the administration of immune cells into tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL DELIVERY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell delivery is the process of transporting immune cells to specific sites in the body</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL TARGETING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell targeting is the process of directing immune cells to specific cells or tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL HOMING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell homing is the process by which immune cells migrate to specific tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL LOCALIZATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell localization is the process by which immune cells are positioned within tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL RETENTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell retention is the process by which immune cells remain in specific tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL RELEASE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell release is the process by which immune cells are released from tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL MOBILIZATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell mobilization is the process by which immune cells are activated and moved to sites of infection or injury</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL ADHESION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell adhesion is the process by which immune cells stick to other cells or tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL DETACHMENT">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell detachment is the process by which immune cells separate from other cells or tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL INVASION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell invasion is the process by which immune cells penetrate tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL EXTRAVASATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell extravasation is the process by which immune cells move out of blood vessels into tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL ACCUMULATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell accumulation is the buildup of immune cells in tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL CLEARANCE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell clearance is the removal of immune cells from tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL TURNOVER">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell turnover is the replacement of old immune cells with new ones</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL LIFESPAN">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell lifespan is the duration of time that immune cells remain functional</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL DEATH">
      <data key="d0">PATHWAY</data>
      <data key="d1">ImmuneImmune cell death is the process by which immune cells die</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL NECROSIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell necrosis is the death of immune cells due to injury or disease</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL AUTOPHAGY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell autophagy is the process by which immune cells degrade and recycle their own components</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL PHAGOCYTOSIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell phagocytosis is the process by which immune cells engulf and digest pathogens or debris</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL ENDOCYTOSIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell endocytosis is the process by which immune cells take in substances from their environment</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL EXOCYTOSIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell exocytosis is the process by which immune cells release substances into their environment</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL SECRETION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell secretion is the process by which immune cells produce and release substances</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL EXCRETION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell excretion is the process by which immune cells eliminate waste products</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL ABSORPTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell absorption is the process by which immune cells take in nutrients or other substances</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL TRANSPORT">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell transport is the movement of immune cells within the body</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL TRAFFICKING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell trafficking is the movement of immune cells to different parts of the body</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL CIRCULATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell circulation is the movement of immune cells through the bloodstream</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="EPIDERMAL KERATINOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Epidermal keratinocytes are the primary type of cell found in the epidermis, the outermost layer of the skin. These skin cells express IL-31RA and are involved in inflammation, playing a crucial role in the body's immune response and skin health.</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,3df8535e965efb96f5094169610507ff</data>
      <data key="d3">CELL</data>
    </node>
    <node id="PERIPHERAL SENSORY NEURONS">
      <data key="d0">CELL</data>
      <data key="d1">Peripheral sensory neurons are nerve cells responsible for transmitting sensory information from the periphery to the central nervous system</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
      <data key="d3">CELL</data>
    </node>
    <node id="IL-31R&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-31 receptor alpha, a receptor that mediates the effects of IL-31</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="OSMR&#914;">
      <data key="d0">PROTEIN</data>
      <data key="d1">OSMR&#946;, or oncostatin M receptor-&#946;, is a protein involved in the regulation of inflammation and immune responses. It functions as a receptor subunit that pairs with IL-31R&#945; to mediate IL-31 signaling.</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="TCSS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Topical corticosteroids, a class of steroid medications applied to the skin to reduce inflammation</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="PP-NRS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">The Peak Pruritus Numerical Rating Scale (PP-NRS) is a tool used to measure the intensity of itch. It is also referred to as the Pruritus Patient-Reported Outcome Numeric Rating Scale, which serves as a measure of itch severity. This scale is utilized to quantify the subjective experience of pruritus, providing a standardized method for patients to report the severity of their itch.</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,a867a1e73cef039eb3f28e072463b838,c46e8b6ee0c29e37b7f18c42558d7a3e</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="PRURIGO NODULARIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Prurigo Nodularis is a chronic skin disease characterized by itchy nodules.</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,c46e8b6ee0c29e37b7f18c42558d7a3e</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="VIXARELIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Vixarelimab is a biologic drug developed by Kiniksa Pharma. It is a fully human antibody that targets the OSMR&#946; receptor. Vixarelimab is used to reduce pruritus in atopic dermatitis, providing relief for patients suffering from this condition.</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="SUBSTANCE P">
      <data key="d0">PROTEIN</data>
      <data key="d1">Substance P is a neuropeptide involved in the transmission of pain and itch signals</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="NK1R">
      <data key="d0">PROTEIN</data>
      <data key="d1">NK1R (Neurokinin 1 receptor) is a protein that plays a multifaceted role in the body's physiological processes. It is involved in the immune response and inflammation, as well as in the regulation of pain and itch signals. NK1R is a receptor for substance P, a neuropeptide that is crucial for the transmission of pain and itch signals. This receptor's involvement in both immune response and sensory signal transmission underscores its significance in various pathological and physiological conditions.</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="MRGPRS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Mas-related G protein-coupled receptors, involved in the transmission of itch signals</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="SERLOPITANT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Serlopitant is a small molecule drug developed by Menlo that functions as an NK1R antagonist. It is used to reduce pruritus in prurigo nodularis by targeting the NK1R receptor.</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="TRADIPITANT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Tradipitant is a small molecule drug developed by Vanda, targeting the NK1R receptor. It is used to reduce pruritus in atopic dermatitis by acting as an NK1R antagonist.</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="P2XR3">
      <data key="d0">PROTEIN</data>
      <data key="d1">P2X purinoreceptor 3, a cation channel involved in sensory neuron activation and associated with itch</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="BLU-5937">
      <data key="d0">CHEMICAL</data>
      <data key="d1">BLU-5937 is a small molecule drug developed by Bellus that acts as a selective P2X3 antagonist. It is currently in development for the treatment of chronic cough and pruritus.</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="JAK FAMILY">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </node>
    <node id="NEURONS">
      <data key="d0">CELL</data>
      <data key="d1">Neurons are nerve cells that transmit information through electrical and chemical signals</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </node>
    <node id="NERVE ENDINGS">
      <data key="d0">CELL</data>
      <data key="d1">Nerve endings are the terminal parts of neurons where signals are transmitted to other cells</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </node>
    <node id="PHASE I TRIAL">
      <data key="d0">PATHWAY</data>
      <data key="d1">Phase I trial is the first stage of clinical testing of a new drug in humans</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </node>
    <node id="PHASE III STUDY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Phase III study is a late-stage clinical trial to confirm the effectiveness and monitor adverse reactions of a drug</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </node>
    <node id="PHASE IB STUDY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Phase Ib study is a clinical trial phase to evaluate the safety and biological activity of a drug</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </node>
    <node id="ATOMIK STUDY">
      <data key="d0">PATHWAY</data>
      <data key="d1">ATOMIK study is a clinical trial to evaluate the efficacy of a drug in patients with atopic dermatitis</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </node>
    <node id="EPIONE STUDY">
      <data key="d0">PATHWAY</data>
      <data key="d1">EPIONE study is a clinical trial to evaluate the efficacy of a drug in reducing pruritus</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </node>
    <node id="BLUEPRINT TRIAL">
      <data key="d0">PATHWAY</data>
      <data key="d1">BLUEPRINT trial is a clinical trial to explore the effect of a drug on pruritus in patients with atopic dermatitis</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </node>
    <node id="SARS-COV-2">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">SARS-CoV-2 is the virus responsible for the COVID-19 pandemic</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="INFLAMMATORY DENDRITIC EPIDERMAL CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Inflammatory Dendritic Epidermal Cells are involved in immune responses in the skin</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
      <data key="d3">CELL</data>
    </node>
    <node id="VITILIGO">
      <data key="d0">DISEASE</data>
      <data key="d1">Vitiligo is a condition characterized by loss of skin pigmentation</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="CUTANEOUS LUPUS">
      <data key="d0">DISEASE</data>
      <data key="d1">Cutaneous Lupus is a form of lupus affecting the skin</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="BREPOCITINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Brepocitinib is a small molecule drug developed by Pfizer, targeting JAK1 and TYK2. It is a selective JAK inhibitor currently in clinical development for treating atopic dermatitis (AD).</data>
      <data key="d2">3df8535e965efb96f5094169610507ff,c46e8b6ee0c29e37b7f18c42558d7a3e,cccfd5ff480e281556e2210cd0e5c4b5,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="JAKTINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Jaktinib is a small molecule drug developed by Suzhou Zeigen Biopharma. It functions as a pan-JAK inhibitor and is currently in clinical development for the treatment of autoimmune diseases, specifically atopic dermatitis (AD).</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="ATI-1777">
      <data key="d0">CHEMICAL</data>
      <data key="d1">ATI-1777 is a small molecule drug developed by Aclaris, targeting JAK1/JAK3. It is currently in clinical development for treating atopic dermatitis (AD).</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="CEE321">
      <data key="d0">CHEMICAL</data>
      <data key="d1">CEE321 is a small molecule drug developed by Novartis, targeting Pan-JAK. It is currently in clinical development for treating autoimmune diseases, specifically atopic dermatitis (AD). As a pan-JAK inhibitor, CEE321 works by inhibiting the activity of Janus kinases, which are enzymes involved in the signaling pathways that contribute to the inflammatory processes underlying autoimmune conditions.</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="SHR0302">
      <data key="d0">CHEMICAL</data>
      <data key="d1">SHR0302 is a small molecule drug developed by Reistone Biopharma, targeting JAK1. It is a JAK1-selective inhibitor currently in clinical development for the treatment of atopic dermatitis (AD).</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838,c46e8b6ee0c29e37b7f18c42558d7a3e,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="ECZEMA HERPETICUM">
      <data key="d0">DISEASE</data>
      <data key="d1">Eczema Herpeticum is a severe skin infection caused by the herpes simplex virus.</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838,c46e8b6ee0c29e37b7f18c42558d7a3e</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="HAEMATOPOIESIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Haematopoiesis is the process of forming blood cellular components</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="CHRONIC HAND ECZEMA">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </node>
    <node id="ALOPECIA AREATA">
      <data key="d0">DISEASE</data>
      <data key="d1">Alopecia Areata is an autoimmune disorder that causes hair loss. This autoimmune disease leads to hair loss by attacking the hair follicles, resulting in patchy baldness on the scalp and other areas of the body.</data>
      <data key="d2">849e0980ffd6a7e1cf0b8d3d1fbacd98,c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </node>
    <node id="CYTOKINE STORM">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Cytokine Storm is a severe immune reaction in which the body releases too many cytokines into the blood too quickly</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </node>
    <node id="COLONY-STIMULATING FACTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Colony-Stimulating Factors are proteins that stimulate the production of blood cells</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </node>
    <node id="HORMONE RECEPTORS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Hormone Receptors are proteins that bind to specific hormones and mediate their effects</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </node>
    <node id="INTERFERON">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interferons are proteins released by host cells in response to the presence of pathogens</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </node>
    <node id="TYPE I CYTOKINE RECEPTORS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Type I Cytokine Receptors are receptors involved in the immune response</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </node>
    <node id="TYPE II CYTOKINE RECEPTORS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Type II Cytokine Receptors are receptors involved in the immune response</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </node>
    <node id="HAND">
      <data key="d0">TISSUE</data>
      <data key="d1">The hand is the terminal part of the human arm used for grasping and holding</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </node>
    <node id="VENOUS THROMBOSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Venous thrombosis is the formation of blood clots within a vein</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="GM-CSF">
      <data key="d0">PROTEIN</data>
      <data key="d1">GM-CSF (Granulocyte-macrophage colony-stimulating factor) is a protein involved in haematopoiesis</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="G-CSF">
      <data key="d0">PROTEIN</data>
      <data key="d1">G-CSF (Granulocyte colony-stimulating factor) is a protein that stimulates the bone marrow to produce granulocytes and stem cells</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="EPO">
      <data key="d0">PROTEIN</data>
      <data key="d1">EPO (Erythropoietin) is a hormone that regulates red blood cell production</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="PROS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Patient-related outcomes are measures of a patient's health status</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="UPPER RESPIRATORY TRACT INFECTIONS">
      <data key="d0">DISEASE</data>
      <data key="d1">Upper Respiratory Tract Infections are infections that affect the nose, throat, and airways, specifically targeting the upper part of the respiratory system.</data>
      <data key="d2">3df8535e965efb96f5094169610507ff,a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="TRKS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Tropomyosin receptor kinases are proteins that bind neurotrophins and are involved in skin inflammation</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="BEN2293">
      <data key="d0">CHEMICAL</data>
      <data key="d1">BEN2293 is a small molecule drug developed by BenevolentiAI, targeting the TRK receptor. It is currently in a phase I/II proof-of-concept study for mild to moderate forms of atopic dermatitis. BEN2293 is being developed specifically for the treatment of atopic dermatitis, leveraging its TRK inhibitory properties.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,a867a1e73cef039eb3f28e072463b838,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="TAUREOXYCHOLIC ACID">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Taureoxycholic acid (HY209) is an agonist of G protein-coupled receptor 19</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="G PROTEIN-COUPLED RECEPTOR 19">
      <data key="d0">PROTEIN</data>
      <data key="d1">G protein-coupled receptor 19 is a receptor involved in various cellular responses. Additionally, it is a receptor that HY209 acts upon.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="NF-&#922;B">
      <data key="d0">PROTEIN</data>
      <data key="d1">NF-&#954;B (Nuclear factor kappa-light-chain-enhancer of activated B cells) is a protein complex involved in cellular responses to stimuli. It plays a crucial role in controlling the transcription of DNA, cytokine production, and cell survival. Additionally, NF-&#954;B is implicated in the pathophysiology of autoimmune diseases (AD).</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,286730b1c1f680ac465cc21d522fda0c,5ec1ebf4e260eb1f8fda8acdf06cd39e,a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="P38 KINASE">
      <data key="d0">PROTEIN</data>
      <data key="d1">P38 kinase is a type of mitogen-activated protein kinase involved in cellular responses to stress and inflammation. This protein plays a crucial role in mediating the cellular mechanisms that respond to various stress signals and inflammatory stimuli.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="ANIMAL MODEL">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Animal models are non-human species used in research to understand biological processes</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="TH2 INFLAMMATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">TH2 inflammation is a type of immune response associated with allergic reactions and asthma</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="JAKI">
      <data key="d0">CHEMICAL</data>
      <data key="d1">JAK inhibitors (JAKI) are a class of medication that inhibit the activity of one or more enzymes in the Janus kinase family. These small molecules are used in the treatment of autoimmune diseases and provide rapid relief from pruritus and inflammation in conditions such as Atopic Dermatitis.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,90f4809673ca34628b0e607908f0bf0b,a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="JOINTS">
      <data key="d0">TISSUE</data>
      <data key="d1">Joints are the connections between bones that allow for movement and flexibility</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="ANTI-INFLAMMATORY COMPOUNDS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Anti-inflammatory compounds are substances that reduce inflammation</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="ANTITUMOUR DEFENCE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Antitumour defence mechanisms are biological processes that protect the body from cancer</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="DRUG&#8211;DRUG INTERACTIONS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Drug&#8211;drug interactions occur when one drug affects the activity of another drug, potentially causing adverse effects. These interactions happen when the effects of one drug are altered by the presence of another drug.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="POST-AUTHORIZATION SAFETY STUDIES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Post-authorization safety studies are conducted to monitor the safety of a drug after it has been approved for use</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="REAL-WORLD REGISTRIES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Real-world registries collect data on the use and outcomes of drugs in routine clinical practice</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="NEUROTROPHINS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Neurotrophins are a family of proteins that promote the survival, development, and function of neurons</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="TRK">
      <data key="d0">PROTEIN</data>
      <data key="d1">TRK, or tropomyosin receptor kinase, is a family of tyrosine kinase receptors involved in the development and function of the nervous system. These receptors play a crucial role in neurotrophin signaling, which is essential for the growth, survival, and differentiation of neurons.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="HY209">
      <data key="d0">CHEMICAL</data>
      <data key="d1">HY209 is a small molecule drug developed by Shaperon, targeting the GPCR19 receptor. HY209 is an agonist of G protein-coupled receptor 19, also known as Taureoxycholic acid.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="CCL17/TARC">
      <data key="d0">PROTEIN</data>
      <data key="d1">CCL17, also known as TARC (thymus and activation-regulated chemokine), is a chemokine involved in the pathogenesis of atopic dermatitis</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="LXR&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Liver X receptor alpha is a nuclear receptor involved in the regulation of lipid metabolism and inflammation</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="LXR&#914;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Liver X receptor beta is a nuclear receptor involved in the regulation of lipid metabolism and inflammation</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="VTP-38543">
      <data key="d0">CHEMICAL</data>
      <data key="d1">VTP-38543 is a small molecule drug developed by Vitae Pharma, targeting the Liver X receptor-&#946; (LXR&#946;). It functions as an LXR&#946; agonist and has been utilized in a phase I/II study for the treatment of atopic dermatitis.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="ALX 101">
      <data key="d0">CHEMICAL</data>
      <data key="d1">ALX 101 is a small molecule drug developed by Ralexar, targeting the Liver X receptor. Specifically, ALX 101 is an LXR&#946; agonist and is currently being tested in a phase IIb study for the treatment of atopic dermatitis.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="BREAST CANCER">
      <data key="d0">DISEASE</data>
      <data key="d1">Breast cancer is a type of cancer that forms in the cells of the breasts</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="TAPE-STRIP">
      <data key="d0">TISSUE</data>
      <data key="d1">Tape-strip specimens are non-invasive samples collected from the skin surface</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="TRANSCUTOLP">
      <data key="d0">CHEMICAL</data>
      <data key="d1">TranscutolP is a penetration enhancer used in topical formulations</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="PHASE I/II STUDY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Phase I/II study is a clinical trial phase that assesses the safety, efficacy, and optimal dosing of a drug</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="PHASE II TRIAL">
      <data key="d0">PATHWAY</data>
      <data key="d1">Phase II trial is a clinical trial phase that focuses on the efficacy of a drug and further evaluates its safety</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="PHASE IIB STUDY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Phase IIb study is a clinical trial phase that focuses on the efficacy and optimal dosing of a drug</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="PHASE III TRIALS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Phase III trials are clinical trial phases that confirm the efficacy of a drug, monitor side effects, and compare it to commonly used treatments</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="ATOPIC MARCH">
      <data key="d0">DISEASE</data>
      <data key="d1">Atopic march refers to the progression of allergic diseases such as atopic dermatitis, allergic rhinitis, and asthma. This progression can be impacted by early intervention in atopic dermatitis, highlighting the importance of timely and effective management of initial allergic conditions to potentially alter the course of subsequent allergic diseases.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,90f4809673ca34628b0e607908f0bf0b</data>
    </node>
    <node id="NEUROPSYCHIATRIC COMORBIDITIES">
      <data key="d0">DISEASE</data>
      <data key="d1">Neuropsychiatric comorbidities include mental health disorders such as anxiety and depression</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="NON-ATOPIC COMORBIDITIES">
      <data key="d0">DISEASE</data>
      <data key="d1">Non-atopic comorbidities are additional conditions that are not related to allergies but occur alongside atopic dermatitisNon-atopic comorbidities include conditions such as cardiovascular disorders that are not related to allergies</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="GENOTYPE">
      <data key="d0">GENE</data>
      <data key="d1">Genotype refers to the genetic constitution of an individual organism</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="FLUID BLOOD SAMPLES">
      <data key="d0">TISSUE</data>
      <data key="d1">Fluid blood samples are collected for analysis of various biomarkers and cells. Additionally, fluid blood samples are collected for research in Atopic Dermatitis.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="SKIN BIOPSY SAMPLES">
      <data key="d0">TISSUE</data>
      <data key="d1">Skin biopsy samples are collected for histological and molecular analysis</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="CELLULAR SAMPLES">
      <data key="d0">TISSUE</data>
      <data key="d1">Cellular samples are collected for analysis of cell types and functions. Additionally, these samples are collected for research in Atopic Dermatitis.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="BIOREPOSITORIES">
      <data key="d0">TISSUE</data>
      <data key="d1">Biorepositories are facilities that collect, store, and manage biological samples for research. They collect samples such as microbiome, cellular, and fluid blood samples specifically for research in Atopic Dermatitis. These biorepositories play a crucial role in advancing the understanding and treatment of Atopic Dermatitis by providing well-preserved and systematically organized biological samples for scientific studies.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,90f4809673ca34628b0e607908f0bf0b</data>
    </node>
    <node id="MICROBIOME SAMPLES">
      <data key="d0">TISSUE</data>
      <data key="d1">Microbiome samples are collected to study the microorganisms present in a particular environment</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="TAPE-STRIP SPECIMENS">
      <data key="d0">TISSUE</data>
      <data key="d1">Tape-strip specimens are non-invasive samples collected from the skin surface for research and analysis in Atopic Dermatitis.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="REGULATORY GRADE PATIENT REGISTRIES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Regulatory grade patient registries are high-quality databases that collect detailed patient information for research and regulatory purposes</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="HIGH-QUALITY BIOREPOSITORIES">
      <data key="d0">PATHWAY</data>
      <data key="d1">High-quality biorepositories are facilities that collect, store, and manage biological samples for research</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="LONGITUDINAL PATIENT REGISTRIES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Longitudinal patient registries collect patient data over an extended period to study disease progression and treatment outcomes</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="MULTIDIMENSIONAL MODEL">
      <data key="d0">PATHWAY</data>
      <data key="d1">Multidimensional model refers to a comprehensive framework that integrates various data types to understand complex diseases</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="NEW DRUG TARGETS">
      <data key="d0">PATHWAY</data>
      <data key="d1">New drug targets are specific molecules or pathways identified for the development of new therapies</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="THERAPEUTIC RESPONSE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Therapeutic response refers to the reaction of a patient to a particular treatmentTherapeutic response refers to</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="ADVERSE EVENTS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Adverse events are unwanted side effects or reactions to a treatment</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="BODY SURFACE AREA">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Body surface area is a measurement used to assess the extent of skin involvement in diseases like atopic dermatitis</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="TREATMENT-RELATED ADVERSE EVENTS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Treatment-related adverse events are side effects or reactions directly linked to a treatment</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="ENVIRONMENTAL INFLUENCES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Environmental influences are external factors that can affect the development, progression, onset, and severity of diseases, including Atopic Dermatitis.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,6ada075e562abd7bd445164e9fc309b4</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="DYNAMIC IMMUNE RESPONSE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Dynamic immune response refers to the changing activity of the immune system in response to various stimuli</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="DISEASE-MODIFYING PREVENTION STRATEGY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Disease-modifying prevention strategy aims to alter the course of a disease to prevent its onset or progression</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="RISK MITIGATION STRATEGIES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Risk mitigation strategies are approaches to reduce the likelihood or impact of adverse events</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="AGE OF DISEASE ONSET">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Age of disease onset refers to the age at which a patient first develops symptoms of a disease</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="CLINICAL PHENOTYPE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Clinical phenotype refers to the observable characteristics or traits of a disease in a patient</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="ETHNIC BACKGROUNDS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Ethnic backgrounds refer to the diverse genetic and cultural heritage of patient populations</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="GENETICALLY DRIVEN EPIDERMAL BARRIER DYSFUNCTION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Genetically driven epidermal barrier dysfunction refers to skin barrier issues caused by genetic factors</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="SENSITIVE AND PERMEABLE SKIN">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Sensitive and permeable skin is a characteristic of atopic dermatitis, making it more prone to irritation and infection</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="INFANCY">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Infancy is the early stage of human development, often considered from birth to one year of age</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="PAEDIATRIC PATIENTS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Paediatric patients are children and adolescents receiving medical care</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="ELDERLY">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Elderly refers to older adults, typically aged 65 and above</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="COMPLEX GENOTYPE">
      <data key="d0">GENE</data>
      <data key="d1">Complex genotype refers to the intricate genetic makeup that contributes to the development of diseases</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="MICROBIOME-DERIVED SIGNALS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Microbiome-derived signals are biochemical messages from the microbiome that influence host physiology and disease</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="COMPLEX PHENOTYPES">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Complex phenotypes are the diverse and multifaceted characteristics of a disease</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="ENDOTYPE-BASED STRATIFICATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Endotype-based stratification is the classification of patients based on specific biological markers to tailor treatments</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="OPTIMAL RISK&#8211;BENEFIT RATIO">
      <data key="d0">PATHWAY</data>
      <data key="d1">Optimal risk&#8211;benefit ratio refers to the balance between the positive effects of a treatment and its potential risks</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="SKIN CARE PRODUCTS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Skin care products are formulations designed to improve and protect the skin</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="PERMEABLE SKIN">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Permeable skin has a compromised barrier function, allowing easier penetration of substances</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="EARLY IDENTIFICATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Early identification refers to the timely detection of disease risk factors or early symptoms</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="DISEASE-MODIFYING PREVENTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Disease-modifying prevention aims to alter the course of a disease to prevent its onset or progression</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="RISK FACTORS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Risk factors are characteristics or conditions that increase the likelihood of developing a disease</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="ATOPIC COMORBIDITIES">
      <data key="d0">DISEASE</data>
      <data key="d1">Atopic comorbidities are additional allergic conditions that occur alongside atopic dermatitis</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="PREVENTION STRATEGIES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Prevention strategies are approaches to reduce the risk of developing a disease</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="RISK MITIGATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Risk mitigation refers to strategies to reduce the likelihood or impact of adverse events</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="LONGITUDINAL ANALYSIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Longitudinal analysis involves studying data collected over an extended period to observe changes and trends</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="REGULATORY GRADE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Regulatory grade refers to the high-quality standards required for data and samples used in regulatory submissions</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PATIENT REGISTRIES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Patient registries are databases that collect detailed information about patients for research and clinical purposes. Specifically, patient registries collect data on patients for research and drug development in Atopic Dermatitis.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="SKIN TISSUE">
      <data key="d0">TISSUE</data>
      <data key="d1">Skin tissue is collected for histological and molecular analysis, as well as for research in Atopic Dermatitis.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="INTEGRATED TECHNOLOGICAL PLATFORMS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Integrated technological platforms combine various technologies to facilitate research and discovery</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="GUT MICROBIOME">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The gut microbiome is involved in the pathogenesis and treatment of Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="EPITHELIAL EVENTS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Epithelial events are dynamic processes involved in the immune response in Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="ARENA PHARMACEUTICALS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Arena Pharmaceuticals is a company advancing etrasimod into phase 3 clinical trials for atopic dermatitis.</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9,90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="JAPAN">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Japan is a country where delgocitinib was approved for Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="HEALTH TECHNOLOGY ASSESSMENT AGENCIES">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Health technology assessment agencies influence drug development and market access in dermatology</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="THIRD-PARTY PAYERS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Third-party payers are entities that impact drug development and patient access in dermatology</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="PHARMACOVIGILANCE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Pharmacovigilance is the process of monitoring the benefit-risk ratio of drugs like JAK inhibitors in Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PREDICTIVE BIOMARKERS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Predictive biomarkers are used for innovative molecular taxonomy and companion diagnostics in Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PROGNOSTIC BIOMARKERS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Prognostic biomarkers are used for predicting disease outcomes and guiding treatment in Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="DRUG TARGETS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Drug targets are specific molecules or pathways identified for therapeutic intervention in Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="THERAPEUTICS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Therapeutics are drugs or treatments developed for managing Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="TRANSLATIONAL EFFORTS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Translational efforts convert scientific knowledge into drug discovery and development for Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PRECLINICAL DEVELOPMENT">
      <data key="d0">PATHWAY</data>
      <data key="d1">Preclinical development involves testing new drugs in the lab before clinical trials in Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="CLINICAL DEVELOPMENT">
      <data key="d0">PATHWAY</data>
      <data key="d1">Clinical development involves testing new drugs in human trials for Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="COMPANION DIAGNOSTICS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Companion diagnostics are tests used alongside therapeutics to guide treatment decisions in Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="MARKET ACCESS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Market access involves the process of making new drugs available to patients, influenced by cost-effectiveness considerations</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="COST-EFFECTIVENESS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Cost-effectiveness is a consideration for third-party payers when evaluating new drugs for Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="REAL-WORLD DATA">
      <data key="d0">PATHWAY</data>
      <data key="d1">Real-world data provides evidence from actual patient experiences to support drug development in Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PATIENT ADVOCACY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Patient advocacy involves efforts by patients to influence drug development and access in Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="SYSTEMIC THERAPY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Systemic therapy involves using drugs that affect the entire body to treat Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="TOPICAL THERAPY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Topical therapy involves applying drugs directly to the skin to treat Atopic Dermatitis (AD). This method is specifically used to manage and alleviate the symptoms associated with AD.</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="SEVERITY SCALES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Severity scales are used to define the severity of Atopic Dermatitis and guide treatment decisions</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="DISEASE MODIFICATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Disease modification involves altering the course of Atopic Dermatitis to prevent progression and comorbidities</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PHARMACEUTICAL COMPANIES">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Pharmaceutical companies develop and market new drugs for Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="DRUG DISCOVERY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Drug discovery involves identifying new compounds for treating Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="DRUG DEVELOPMENT">
      <data key="d0">PATHWAY</data>
      <data key="d1">Drug development involves the process of bringing new drugs to market for Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="EPITHELIAL PATHWAYS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Epithelial pathways are involved in the immune response and pathogenesis of Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNOLOGICAL PATHWAYS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immunological pathways are involved in the immune response and pathogenesis of Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="MOLECULAR TAXONOMY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Molecular taxonomy involves classifying diseases based on molecular characteristics for targeted treatment in Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="TAILORED THERAPEUTICS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Tailored therapeutics are drugs specifically designed for individual patients based on molecular characteristics in Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="STAPHYLOCOCCUS HOMINIS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Staphylococcus hominis (S.h.) is a commensal bacterium that can help in the recovery of skin microbiome in atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="STAPHYLOCOCCUS EPIDERMIDIS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Staphylococcus epidermidis (S.e.) is a commensal bacterium that can help in the recovery of skin microbiome in atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="ARYL-HYDROCARBON RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Aryl-hydrocarbon receptor (AhR) is a ligand-activated transcriptional factor involved in the development of skin inflammation, including atopic dermatitis (AD). AhR is a protein targeted for intervention in the early stages of atopic dermatitis, highlighting its significance in the pathogenesis and potential treatment of this condition.</data>
      <data key="d2">6059a6e2710b7df94c6a09e5eb7b024a,83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="SPHINGOSINE 1-PHOSPHATE RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Sphingosine 1-phosphate receptor (S1PR) is involved in the migratory activity of T cells in atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="C-C CHEMOKINE RECEPTOR 4">
      <data key="d0">PROTEIN</data>
      <data key="d1">C-C chemokine receptor 4 (CCR4) is involved in the migration of T cells into the skin in atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="JANUS KINASES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Janus kinases (JAKs) are involved in the signal transduction of cytokine receptors and are targeted by JAK inhibitors in atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="TROPOMYOSIN RECEPTOR KINASE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Tropomyosin receptor kinase (TRK) is a receptor involved in neurotrophic signaling and plays a crucial role in pathways related to nerve growth factor, particularly in the context of atopic dermatitis.</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="BRUTON TYROSINE KINASE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Bruton tyrosine kinase (BTK) is involved in the signal transduction of the B cell receptor in atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="HISTAMINE RECEPTOR 4">
      <data key="d0">PROTEIN</data>
      <data key="d1">Histamine receptor 4 (H4R) is involved in immunomodulatory mechanisms and is widely expressed. It plays a significant role in the immunomodulatory mechanisms specifically in atopic dermatitis.</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="SENSING NEURONS">
      <data key="d0">CELL</data>
      <data key="d1">Sensing neurons in the skin can be activated by multiple mediators generated during the inflammatory reaction in atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
      <data key="d3">CELL</data>
    </node>
    <node id="ASAN PHARMACEUTICALS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Asan Pharmaceuticals is a company conducting studies on ASLAN004 for atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="FORTE BIOSCIENCES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Forte Biosciences is a company conducting clinical trials of FB-401 for atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="OTSUKA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Otsuka is a company conducting phase 3 studies on difamilast for atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="RAPT THERAPEUTICS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">RAPT Therapeutics is a company conducting a phase 1b trial of RPT193 for atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="INNATE IMMUNITY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Innate immunity is the body's first line of defense against pathogens, involving non-specific immune responses. It is the immune response that includes non-specific defense mechanisms and is also the first line of defense activated in atopic dermatitis.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,83eb9003d42977bb83fea1d123dd5ab9,c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="ADAPTIVE IMMUNITY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Adaptive immunity is the body's specific immune response to pathogens, involving the activation of lymphocytes. It is activated following innate immunity in atopic dermatitis, involving TH2, TH1, TH17, and TH22 responses. This immune response is characterized by its specificity and memory, allowing the body to effectively target and remember specific pathogens.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,83eb9003d42977bb83fea1d123dd5ab9,c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="IMMUNOLOGICAL MARCH">
      <data key="d0">PATHWAY</data>
      <data key="d1">The immunological march is the sequence of events leading to different types of immune responses. It is a model describing the progression of immune responses in atopic dermatitis.</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="SPHINGOSINE 1-PHOSPHATE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Sphingosine 1-phosphate is a signaling molecule involved in the migration of T cells in atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="C-C CHEMOKINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">C-C chemokine is involved in the migration of T cells into the skin in atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="JANUS KINASE INHIBITORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Janus kinase inhibitors (JAKi) are used to target JAKs involved in cytokine receptor signal transduction in atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="B CELL RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">B cell receptor is involved in the immune response in atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="HIGH-AFFINITY IGE RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">High-affinity IgE receptor is expressed in mast cells and dendritic cells in atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="ANTI-INFLAMMATORY CYTOKINES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Anti-inflammatory cytokines are generated by increasing cAMP levels through PDE4 inhibitors in atopic dermatitis. These cytokines, such as IL-37, play a crucial role in reducing inflammation in atopic dermatitis (AD).</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="IL-31 RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-31 receptor (IL-31R) is involved in the generation of itching during inflammatory reactions</data>
      <data key="d2">e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="NEUROKININ 1 RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Neurokinin 1 receptor (NK1R) is a protein involved in various physiological processes. It plays a significant role in the generation of itching during inflammatory reactions.</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="PURINORECEPTOR 3">
      <data key="d0">PROTEIN</data>
      <data key="d1">Purinoreceptor 3 (P2X3) is a receptor involved in the response to extracellular ATP. It plays a significant role in the generation of itching during inflammatory reactions.</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="LIVER X RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Liver X receptor (LXR) is involved in cholesterol metabolism and inflammation.</data>
      <data key="d2">e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="MEMBRANE FORM OF IGE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Membrane form of IgE (mIgE) is involved in allergic reactions</data>
      <data key="d2">e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="OX40 LIGAND">
      <data key="d0">PROTEIN</data>
      <data key="d1">OX40 ligand (OX40L) is a costimulatory molecule involved in T cell activation.</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="T HELPER CELL">
      <data key="d0">CELL</data>
      <data key="d1">T helper cell (TH cell) is a type of T cell that plays a crucial role in the immune response</data>
      <data key="d2">e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="THYMIC STROMAL LYMPHOPOIETIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Thymic stromal lymphopoietin (TSLP) is a cytokine involved in the regulation of immune responses and inflammation. It plays a crucial role in the initiation and development of allergic inflammation.</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,5f37466ca41c9b8b06ed8be0303d49f2,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="CLS-001">
      <data key="d0">CHEMICAL</data>
      <data key="d1">CLS-001, also known as omiganan, is a small molecule with cell membrane enhancing activity used in the treatment of atopic dermatitis.</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="ATX201">
      <data key="d0">CHEMICAL</data>
      <data key="d1">ATX201, also known as niclosamide, is a small molecule with protonophore activity. It is utilized in the treatment of atopic dermatitis.</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="FB825">
      <data key="d0">CHEMICAL</data>
      <data key="d1">FB825, also known as anti-C&#949;mX, is a biologic injection targeting mIgE used in the treatment of atopic dermatitis</data>
      <data key="d2">e9841b88c9fab58c5175af409653da50</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="TREG CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Treg cells (Regulatory T cells) are a type of T cell involved in maintaining immune tolerance and preventing autoimmune disease</data>
      <data key="d2">e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="P2X3">
      <data key="d0">PROTEIN</data>
      <data key="d1">P2X3 (Purinoreceptor 3) is a protein that plays a crucial role in the immune response and inflammation. Additionally, P2X3 is involved in the regulation of pain, highlighting its significance in both inflammatory processes and pain management.</data>
      <data key="d2">e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="LXR">
      <data key="d0">PROTEIN</data>
      <data key="d1">LXR (Liver X receptor) is a protein involved in the regulation of cholesterol, fatty acid, and glucose homeostasis</data>
      <data key="d2">e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="TH CELL">
      <data key="d0">CELL</data>
      <data key="d1">TH cell (T helper cell) is a type of T cell involved in the immune response and inflammation</data>
      <data key="d2">e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="LEO 152020/JW1601">
      <data key="d0">CHEMICAL</data>
      <data key="d1">LEO 152020/JW1601 is a small molecule drug developed by LEO Pharma, targeting the H4R receptor</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="AKP-19">
      <data key="d0">CHEMICAL</data>
      <data key="d1">AKP-19 is a small molecule drug developed by Akaal Pharma, targeting the S1PR1 receptor</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="DRM02">
      <data key="d0">CHEMICAL</data>
      <data key="d1">DRM02 is a small molecule drug developed by Dermira, targeting the PDE4 enzyme</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="HEMAY-808">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hemay-808 is a small molecule drug developed by Tianjin Hemay Pharmaceutical, targeting the PDE4 enzyme</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="PF-07038124">
      <data key="d0">CHEMICAL</data>
      <data key="d1">PF-07038124 is a small molecule drug developed by Pfizer, targeting the PDE4 enzyme</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="GPCR19">
      <data key="d0">PROTEIN</data>
      <data key="d1">GPCR19, or G protein-coupled receptor 19, is a protein involved in various cellular signaling pathways</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="LIVER X RECEPTOR-&#914;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Liver X receptor-&#946; is a nuclear receptor involved in the regulation of cholesterol, fatty acid, and glucose homeostasis</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="PAN-JAK">
      <data key="d0">PROTEIN</data>
      <data key="d1">Pan-JAK refers to the family of Janus kinases involved in the regulation of immune responses</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04081350">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Treg cells</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03517566">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Adriforant</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04203836">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving LEO 152020/JW1601</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04271514">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving RPT193</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04162769">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Etrasimod</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04684485">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving SCD-044</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03038711">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving BMS-986166</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04772885">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving KT-474</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03394677">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Lotamilast</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT02950922">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Lotamilast</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT02945657">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Difamilast</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT01993420">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving DRM02</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT01037881">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving LEO 29102</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04156191">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Roflumilast</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04352595">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Hemay-808</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04664153">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving PF-07038124</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04737304">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving BEN2293</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04530643">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving HY209</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT02655679">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving VTP-38543</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03859986">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving ALX 101</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03989349">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Nemolizumab</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03985943">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Nemolizumab</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03816891">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Vixarelimab</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT02975206">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Serlopitant</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03568331">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Tradipitant</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04693195">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving BLU-5937</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03725722">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Delgocitinib</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03745638">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Ruxolitinib</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03745651">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Ruxolitinib</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03903822">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Brepocitinib</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04598269">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving ATI-1777</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04612062">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving CEE321</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04539639">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Jaktinib</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04717310">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving SHR0302</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03952559">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Baricitinib</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03646604">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Upadacitinib</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03627767">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Abrocitinib</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04162899">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving SHR0302</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="ONCOSTATIN M RECEPTOR-&#914;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Oncostatin M receptor-&#946; is a protein involved in the signaling of oncostatin M</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="SPHINGOSINE 1-PHOSPHATE RECEPTOR 1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Sphingosine 1-phosphate receptor 1 is a receptor involved in immune cell trafficking</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="REGULATORY T CELL">
      <data key="d0">CELL</data>
      <data key="d1">Regulatory T cell is a type of T cell involved in maintaining immune tolerance</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
      <data key="d3">CELL</data>
    </node>
    <node id="BIOLOGIC THERAPIES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Biologic therapies are treatments using antibodies or other biological products to target specific pathways</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="EXPOSOMAL FACTORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Exposomal factors are exogenous and environmental factors that influence the human body and immune system</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="BACTERIOTHERAPY">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Bacteriotherapy is the use of living bacteria to influence the microbiome composition</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="CATIONIC HOST DEFENCE PEPTIDES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Cationic host defence peptides are short peptides with antibacterial, antifungal, and antiviral properties</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="EOSINOPHILIC ASTHMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Eosinophilic asthma is a subtype of asthma characterized by eosinophilic infiltration of the lungs</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="AEROALLERGENS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Aeroallergens are airborne particles that can cause allergic reactions</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="EXOTOXINS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Exotoxins are toxins released by bacteria that can affect other bacteria or the host</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="CHEMOTACTIC FACTORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Chemotactic factors are mediators that lead to the migration and attraction of cellsChemotactic factors are mediators that lead to the migration and attraction of cells)&lt;|COMPLETE|&gt;</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="ABBVIE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">AbbVie is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="ALLMIRAL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Allmiral is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="ANAPTYSBIO">
      <data key="d0">CHEMICAL</data>
      <data key="d1">AnaptysBio is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="ARENA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Arena is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="ASANA BIOSCIENCES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Asana Biosciences is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="BAYER HEALTH">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Bayer Health is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="BIOVERSYS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">BioVerSys is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="B&#214;HRINGER-INGELHEIM">
      <data key="d0">CHEMICAL</data>
      <data key="d1">B&#246;hringer-Ingelheim is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="BRISTOL MYERS SQUIBB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Bristol Myers Squibb is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="DOMAIN THERAPEUTICS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Domain Therapeutics is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="GALAPAGOS/MORPHOSYS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Galapagos/MorphoSys is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="GALDERMA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Galderma is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="GLENMARK">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Glenmark is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="GSK">
      <data key="d0">CHEMICAL</data>
      <data key="d1">GSK is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="INCYTE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Incyte is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="IQVIA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">IQVIA is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="JANSSEN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Janssen is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="KIRIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Kirin is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="LEO PHARMA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">LEO Pharma is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="LG CHEM">
      <data key="d0">CHEMICAL</data>
      <data key="d1">LG Chem is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="LILLY">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Lilly is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="L&#8217;OR&#201;AL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">L&#8217;Or&#233;al is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="MENLOTX">
      <data key="d0">CHEMICAL</data>
      <data key="d1">MenloTx is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="NOVARTIS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Novartis is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="VIFOR PHARMA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Vifor Pharma is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="PFIZER">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Pfizer is a pharmaceutical company involved in the development and testing of new drugs, as well as the development of biologic therapies.</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="PIERRE FABRE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Pierre Fabre is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="SANOFI/REGENERON">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Sanofi/Regeneron is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="UCB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">UCB is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="DAVOS BIOSCIENCES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Davos Biosciences is a non-profit biotech company within the International K&#252;hne Foundation</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="LYMPHOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Lymphocytes are a type of white blood cell involved in the immune response. They play a crucial role in the adaptive immune response, which is the body's targeted defense against specific pathogens. In the context of Atopic Dermatitis, lymphocytes infiltrate the skin, contributing to the inflammatory process observed in patients. Additionally, lymphocytes primarily express TRAIL (TNF-related apoptosis-inducing ligand), which is involved in the regulation of immune responses and apoptosis.</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e,6ada075e562abd7bd445164e9fc309b4,c525762bb827485bceeb9f09bb4bcfe0,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="RASH">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Rash is a common symptom of Atopic Dermatitis, characterized by red, inflamed skin.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="EROSIONS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Erosions are areas of skin damage that can occur in Atopic Dermatitis patients due to scratching.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="PLAQUES">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Plaques are thickened areas of skin that are common in Atopic Dermatitis patients.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="ELBOWS">
      <data key="d0">TISSUE</data>
      <data key="d1">The elbows are one of the common sites affected by Atopic Dermatitis plaques.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="KNEES">
      <data key="d0">TISSUE</data>
      <data key="d1">The knees are one of the common sites affected by Atopic Dermatitis plaques.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="FACE">
      <data key="d0">TISSUE</data>
      <data key="d1">The face is one of the common sites affected by Atopic Dermatitis plaques.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="NECK">
      <data key="d0">TISSUE</data>
      <data key="d1">The neck is one of the common sites affected by Atopic Dermatitis plaques.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="WRISTS">
      <data key="d0">TISSUE</data>
      <data key="d1">The wrists are one of the common sites affected by Atopic Dermatitis plaques.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="FOOD ALLERGIES">
      <data key="d0">DISEASE</data>
      <data key="d1">Food Allergies are conditions that children with Atopic Dermatitis may develop.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="COMMON COLD">
      <data key="d0">DISEASE</data>
      <data key="d1">The common cold is a condition that children with Atopic Dermatitis have a 75% risk of developing.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="VESICLES">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Vesicles are small blisters seen in infantile Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="EXCORIATIONS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Excoriations are scratch marks seen in infantile Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="SEROUS EXUDATE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Serous Exudate is a clear fluid discharge seen in infantile Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="CHEEKS">
      <data key="d0">TISSUE</data>
      <data key="d1">The cheeks are one of the common sites affected by infantile Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="SCALP">
      <data key="d0">TISSUE</data>
      <data key="d1">The scalp is one of the common sites affected by infantile Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="HANDS">
      <data key="d0">TISSUE</data>
      <data key="d1">The hands are commonly affected by chronic hand eczema in adult Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="HEAD&#8211;NECK DERMATITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Head&#8211;Neck Dermatitis is a form of Atopic Dermatitis affecting the upper trunk, shoulders, and scalp in adults.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="PRO-FLG">
      <data key="d0">PROTEIN</data>
      <data key="d1">Pro-FLG is a polymer that is dephosphorylated and proteolytically cleaved to form FLG monomers.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="INFANTILE ATOPIC DERMATITIS">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="CHILDHOOD ATOPIC DERMATITIS">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="ADULT ATOPIC DERMATITIS">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="GENETICS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Genetics refers to the study of genes and their roles in inheritance, which is a factor in the onset and severity of Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="SKIN BARRIER">
      <data key="d0">PATHWAY</data>
      <data key="d1">The skin barrier is a critical component in the pathophysiology of Atopic Dermatitis, involving abnormalities that contribute to the disease.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="INTERLEUKINS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukins are a group of cytokines that play a crucial role in the immune response and are involved in the pathophysiology of Atopic Dermatitis. These cytokines are regulated by cibinqo, a medication used to manage certain immune-related conditions.</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c,6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="BIOLOGIC MEDICATIONS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Biologic medications are a class of drugs derived from living organisms, used in various stages of approval or development for treating Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="SMALL MOLECULES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Small molecules are a type of non-biologic targeted therapy that have emerged as treatment options for Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="PERSONALIZED MEDICINE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Personalized medicine involves tailoring medical treatment to the individual characteristics of each patient, which is a potential approach for Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="PSYCHOLOGICAL FACTORS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Psychological factors are elements that can influence the onset and severity of Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="DRUGS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Drugs refer to substances used to treat or manage Atopic Dermatitis, including both biologic and non-biologic therapies.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="DNA METHYLATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">DNA methylation is an epigenetic mechanism that can influence gene expression, including the FLG gene associated with Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="FLG GENE">
      <data key="d0">GENE</data>
      <data key="d1">The FLG gene encodes the protein filaggrin, which is crucial for skin barrier function and is associated with Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="FLG NULL MUTATIONS">
      <data key="d0">GENE</data>
      <data key="d1">FLG null mutations are genetic alterations that result in a lack of functional filaggrin protein, increasing the risk of Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="FLG COPY NUMBER VARIATIONS">
      <data key="d0">GENE</data>
      <data key="d1">FLG copy number variations are changes in the number of copies of the FLG gene, which can affect filaggrin levels and Atopic Dermatitis risk.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="SKIN MICROORGANISMS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Skin microorganisms are part of the skin's microbiome and can influence the development and severity of Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="TOPICAL TREATMENTS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Topical treatments are medications applied directly to the skin to manage Atopic Dermatitis symptoms.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="SYSTEMIC TREATMENTS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Systemic treatments are medications that affect the entire body and are used to manage Atopic Dermatitis (AD) symptoms. These treatments are an integral part of the overall treatment strategy for AD.</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="STRATUM CORNEUM FORMATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Stratum corneum formation is the process of creating the outermost layer of the skin, which is crucial for barrier function and is affected in Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="EPIDERMAL COMPLEX">
      <data key="d0">TISSUE</data>
      <data key="d1">The epidermal complex includes various components of the skin's outer layer, which are crucial for barrier function and are affected in Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="FLG">
      <data key="d0">PROTEIN</data>
      <data key="d1">FLG, or filaggrin, is a protein crucial for the development and maintenance of the skin barrier. The filaggrin (FLG) gene plays a significant role in skin barrier function. Its expression can be restored by coal tar binding to the aryl hydrocarbon receptor (AhR). However, the protein is downregulated by the cytokine IL-22 in keratinocytes.</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,41ccc4b41bd57cf2bda4dbb6c7ae4198,6059a6e2710b7df94c6a09e5eb7b024a,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="SPINK">
      <data key="d0">PROTEIN</data>
      <data key="d1">SPINK, or serine protease inhibitor Kazal-type, is a protein involved in skin barrier function</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </node>
    <node id="CLAUDINS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Claudins are proteins that play a role in the formation of tight junctions in the skin barrier</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </node>
    <node id="&#916;-TOXIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">&#948;-toxin is a toxin produced by Staphylococcus aureus that can trigger mast cells</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </node>
    <node id="&#913;-TOXIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">&#945;-toxin is a toxin produced by Staphylococcus aureus that can damage host cells</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </node>
    <node id="IL-8">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-8 (IL-8) is a chemokine and cytokine involved in the immune response and inflammation. It plays a crucial role in the recruitment of neutrophils to sites of inflammation. As a pro-inflammatory cytokine, IL-8's levels can be modulated by therapeutic interventions, such as PLGA-based nanoparticles loaded with CsA, which have been shown to reduce IL-8 levels.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,41ccc4b41bd57cf2bda4dbb6c7ae4198,bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="MIP-1&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Macrophage inflammatory protein-1&#945; (MIP-1&#945;) is a chemokine involved in the immune response and inflammation</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </node>
    <node id="MIP-1&#914;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Macrophage inflammatory protein-1&#946; (MIP-1&#946;) is a chemokine involved in the immune response and inflammation</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </node>
    <node id="MCP-1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Monocyte chemoattractant protein-1 (MCP-1) is a chemokine involved in the immune response and inflammation. MCP-1 plays a crucial role in the recruitment of monocytes to sites of injury and inflammation, thereby contributing to the body's defense mechanisms and the inflammatory process.</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198,a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="KLK7">
      <data key="d0">PROTEIN</data>
      <data key="d1">Kallikrein 7 (KLK7) is a serine protease involved in skin barrier function</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </node>
    <node id="STAT 6">
      <data key="d0">PROTEIN</data>
      <data key="d1">Signal transducer and activator of transcription 6 (STAT 6) is a protein involved in the immune response</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </node>
    <node id="CTLA4">
      <data key="d0">PROTEIN</data>
      <data key="d1">CTLA4 is a gene that encodes the cytotoxic T-lymphocyte-associated protein 4, which plays a crucial role in the immune response. This protein is involved in the development of atopic dermatitis (AD), highlighting its significance in autoimmune diseases.</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198,6059a6e2710b7df94c6a09e5eb7b024a</data>
    </node>
    <node id="POLLUTION">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Pollution refers to harmful substances in the environment that can affect health</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </node>
    <node id="SOAP">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Soap is a chemical substance used for cleaning that can affect the skin barrier</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </node>
    <node id="PERIPHERAL BLOOD LYMPHOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Peripheral blood lymphocytes are immune cells found in the bloodstream</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </node>
    <node id="NA&#207;VE T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Na&#239;ve T cells are T lymphocytes that have not yet encountered their specific antigen. These immature T cells are primed by CD27:CD70 signaling, which prepares them for future encounters with antigens.</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3,41ccc4b41bd57cf2bda4dbb6c7ae4198,4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="SERINE PROTEASE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Serine protease is an enzyme that cleaves peptide bonds in proteins</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </node>
    <node id="KALLIKREIN 7">
      <data key="d0">PROTEIN</data>
      <data key="d1">Kallikrein 7 (KLK7) is a serine protease involved in skin barrier function</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </node>
    <node id="ROSEMONAS MUCOSA">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Rosemonas mucosa is a Gram-negative bacterium found in the skin microbiome of AD patients</data>
      <data key="d2">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </node>
    <node id="OMEGANAN PENTACHLORIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Omeganan pentachloride (CLS-001) is a synthetic antimicrobial cationic peptide undergoing clinical testing as a topical treatment for managing dysbiosis in AD</data>
      <data key="d2">6059a6e2710b7df94c6a09e5eb7b024a</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="KBL69">
      <data key="d0">CHEMICAL</data>
      <data key="d1">KBL69 is a microbiome modifier designed for oral use currently in phase I trials for AD treatment</data>
      <data key="d2">6059a6e2710b7df94c6a09e5eb7b024a</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="IMMUNE CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Various types of immune cells work together in specific locations and at specific times in the inflamed skin of AD patients</data>
      <data key="d2">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </node>
    <node id="NATURAL KILLER CELL">
      <data key="d0">CELL</data>
      <data key="d1">A type of immune cell involved in the body's defense against tumors and virally infected cells</data>
      <data key="d2">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="IL-1R">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-1 receptor, involved in inflammation and immune response</data>
      <data key="d2">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="ITCHINESS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">A common symptom in inflammatory skin conditions</data>
      <data key="d2">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="ITEPEKIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">An IL-33 inhibitor</data>
      <data key="d2">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="IL-37">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-37, also known as Interleukin-37, is an anti-inflammatory cytokine within the IL-1 family. It plays a significant role in modulating inflammation and the immune response. Notably, lower levels of IL-37 have been observed in children with atopic dermatitis (AD), suggesting its potential involvement in the pathophysiology of this condition.</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="IL-4R">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-4R, or Interleukin-4 receptor, is a receptor involved in the pathophysiology of atopic dermatitis (AD). It plays a crucial role in the signaling pathways of both IL-4 and IL-13, acting as a common receptor chain for these interleukins. This receptor's involvement in these signaling processes underscores its significance in immune response modulation and its potential as a therapeutic target in autoimmune diseases.</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c,2cec06c4d46f5ff9ee936a78d8b077cd,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="FOLLICULITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Inflammation of hair follicles, often resulting in red, bumpy skin</data>
      <data key="d2">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="UPPER-RESPIRATORY-TRACT INFECTIONS">
      <data key="d0">DISEASE</data>
      <data key="d1">Infections affecting the upper respiratory tract, including the nose, throat, and sinuses</data>
      <data key="d2">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="TH1 CELL">
      <data key="d0">CELL</data>
      <data key="d1">A type of T cell involved in the immune response, particularly in the formation of Th17 and Th2 cells</data>
      <data key="d2">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="PAIN">
      <data key="d0">SYMPTOM</data>
      <data key="d1">A common symptom in inflammatory skin conditions</data>
      <data key="d2">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="IL-13R1">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-13R1 is a receptor for IL-13 involved in the signaling pathway</data>
      <data key="d2">3df8535e965efb96f5094169610507ff</data>
    </node>
    <node id="IL-13R2">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-13R2 is a receptor for IL-13 involved in the signaling pathway</data>
      <data key="d2">3df8535e965efb96f5094169610507ff</data>
    </node>
    <node id="EOSINOPHILIC ESOPHAGITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Eosinophilic Esophagitis (EoE) is a chronic immune system disease characterized by the accumulation of eosinophils in the esophagus. This atopic condition leads to inflammation and difficulty swallowing. Additionally, EoE is associated with gastrointestinal tract fibrosis, further complicating the disease's impact on the esophagus.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,3df8535e965efb96f5094169610507ff,5f37466ca41c9b8b06ed8be0303d49f2,df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="IL5R">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL5R is a receptor for IL-5 involved in the signaling pathway</data>
      <data key="d2">3df8535e965efb96f5094169610507ff</data>
    </node>
    <node id="CUTANEOUS PERIPHERAL NERVES">
      <data key="d0">TISSUE</data>
      <data key="d1">Cutaneous Peripheral Nerves are nerves in the skin that express IL-31RA and are involved in pruritus</data>
      <data key="d2">3df8535e965efb96f5094169610507ff</data>
    </node>
    <node id="IL-31RA">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-31RA is a receptor for IL-31 involved in the signaling pathway</data>
      <data key="d2">3df8535e965efb96f5094169610507ff</data>
    </node>
    <node id="JAK/STAT">
      <data key="d0">PATHWAY</data>
      <data key="d1">JAK/STAT is a signaling pathway involved in immune function and homeostasis</data>
      <data key="d2">3df8535e965efb96f5094169610507ff</data>
    </node>
    <node id="ECZEMATOUS PLAQUES">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Eczematous Plaques are areas of inflamed, itchy, and red skin, often seen in eczema and AD</data>
      <data key="d2">3df8535e965efb96f5094169610507ff</data>
    </node>
    <node id="TREGS">
      <data key="d0">CELL</data>
      <data key="d1">Regulatory T cells (Tregs) are a subset of T cells that play a crucial role in the immune system. They are primarily involved in maintaining immune tolerance and preventing autoimmune diseases by suppressing the immune responses of other cells. This function is essential for preventing the immune system from attacking the body's own tissues, thereby maintaining overall immune homeostasis.</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,7c13f41d7349d9d2e56c36e00c0ca2d9,d2c44662af9752fc9f82c86121ede7c0</data>
      <data key="d3">CELL</data>
    </node>
    <node id="GBR830">
      <data key="d0">CHEMICAL</data>
      <data key="d1">GBR830 is an anti-OX40 monoclonal IgG1 antibody that has passed phase IIa testing</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="IL-18R&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-18R&#945; is a receptor with high affinity for IL-18</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="TOPICAL CALCINEURIN INHIBITORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Topical calcineurin inhibitors (TCIs) are used for anti-inflammatory therapy in AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="PLAQUE PSORIASIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Plaque psoriasis is a chronic autoimmune condition that causes raised, red, scaly patches on the skin. It is a chronic autoimmune skin disease that can be treated with TNF inhibitors and secukinumab.</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,516e41e96d2e72d45bf1e2c69da7f18a</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="NANOPARTICLE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Nanoparticles are used in novel drug delivery systems for AD treatment</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="LIPOSOME">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Liposomes are used in novel drug delivery systems for AD treatment</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="PATCH">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Patches are used in novel drug delivery systems for AD treatment</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="NANOTECHNOLOGY">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Nanotechnology is a cutting-edge field that is utilized to develop novel drug delivery systems for the treatment of atopic dermatitis (AD). Additionally, nanotechnology offers promising methods for treating various skin conditions, including AD, psoriasis, eczema, and cancer. This innovative approach leverages the unique properties of nanoscale materials to enhance the efficacy and precision of therapeutic interventions, thereby improving patient outcomes across a range of dermatological diseases.</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="BIOLOGICAL AGENTS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Biological agents are used in systemic therapy for AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="SYNTHETIC ANTI-INFLAMMATORY CYTOKINES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Synthetic anti-inflammatory cytokines are potential future treatments for AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="IMMUNE PATHWAYS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune pathways are involved in the development and treatment of AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="INFLAMMATORY PROCESSES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Inflammatory processes are targeted in the treatment of AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="SKIN INFECTIONS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Skin infections are a complication of AD that require treatment</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="PREVENTIVE MEASURES">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Preventive measures are part of the treatment strategy for AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="SKINCARE ROUTINES">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Skincare routines are part of the treatment strategy for AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="TOPICAL SOLUTIONS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Topical solutions are part of the treatment strategy for AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="COMBINED THERAPY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Combined therapy is used to improve treatment efficacy and safety in ADCombined therapy is used to improve AD treatment</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="FORMULATION EFFICACY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Formulation efficacy is an important consideration in AD treatmentFormulation efficacy is a focus in developing AD treatments</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="ADVERSE EFFECTS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Adverse effects are minimized in developing AD treatmentsAdverse effects are minimized in AD treatment</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="TREATMENT SAFETY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Treatment safety is a focus in developing AD treatmentsTreatment safety is an important consideration in AD management</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="MULTI-TARGETED STRATEGY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">A multi-targeted strategy is used in the management and therapy of ADA multi-targeted strategy is used in AD management</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="CARETAKER AWARENESS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Caretaker awareness is important in AD managementCaretaker awareness is important in the management of AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="PATIENT AWARENESS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Patient awareness is important in the management of ADPatient awareness is important in AD management</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="ECONOMIC IMPACT">
      <data key="d0">SYMPTOM</data>
      <data key="d1">The economic impact of AD treatments is a significant considerationThe economic impact of AD treatments is an important consideration</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="AFFORDABILITY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Affordability of AD treatments is a significant considerationAffordability of AD treatments is an important consideration</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="CHRONIC NATURE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">The chronic nature of AD affects treatment strategies and considerationsThe chronic nature of AD affects treatment strategies</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="LONG-TERM SAFETY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Long-term safety data are needed for AD treatments</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="RAPID ITCH RELIEF">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Rapid itch relief is a benefit of JAK inhibitors in AD treatment</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="CLINICAL IMPROVEMENTS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Clinical improvements are measured in AD treatment studies</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="PHASE-3 TRIALS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Phase-3 trials are conducted to test the efficacy and safety of AD treatments</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="PHASE-II EXPERIMENT">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Phase-II experiments are conducted to test the efficacy and safety of AD treatments</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="PHASE IIA TESTING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Phase IIa testing is conducted to test the efficacy and safety of AD treatments</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="FDA AUTHORIZATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">FDA authorization is required for the use of new AD treatments</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="MANUFACTURING AND MARKETING APPROVAL">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Manufacturing and marketing approval is required for new AD treatments</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="BASELINE SERUM LEVELS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Baseline serum levels are measured in AD treatment studies</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="RESPONDER">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Responders are patients who show improvement with AD treatment</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="NONRESPONDER">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Nonresponders are patients who do not show improvement with AD treatment</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="THERAPEUTIC APPROACH">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Therapeutic approaches are strategies used to treat AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="TREATMENT STRATEGIES">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Treatment strategies are plans for managing and treating AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="NOVEL DRUG DELIVERY SYSTEM">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Novel drug delivery systems are used to improve AD treatment</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="SPECIFIC DELIVERY SYSTEMS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Specific delivery systems are used to improve AD treatment</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="CONVENTIONAL SYSTEMIC THERAPIES">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Conventional systemic therapies are used to treat AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="NOVEL SYSTEMIC MEDICATIONS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Novel systemic medications are used to treat AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="BIOLOGICAL DRUGS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Biological drugs are used to treat AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="MODERATE TO SEVERE AD">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Moderate to severe AD requires more intensive treatment</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="SAFETY PROFILE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">The safety profile of AD treatments is an important consideration</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="EFFICACY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">The efficacy of AD treatments is an important consideration</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="COST">
      <data key="d0">SYMPTOM</data>
      <data key="d1">The cost of AD treatments is an important consideration</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="ACCESS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Access to AD treatments is an important consideration</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="TREATMENT PLANS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Treatment plans are strategies for managing and treating AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="TREATMENT EFFICACY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Treatment efficacy is an important consideration in AD management</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="PRURITUS/ITCH NUMERIC RATING SCALE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">A scale used to evaluate the severity of itching in skin conditions</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="CANCER">
      <data key="d0">DISEASE</data>
      <data key="d1">Cancer is a condition that can be treated using nanotechnology</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="CERAMIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Ceramide levels drop in AD, leading to increased trans-epidermal water loss and compromised skin barrier</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="LIPOSOMES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Liposomes are nanosized systems developed to improve the deep absorption of drugs into the skin</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="SOLID LIPID NANOPARTICLES (SLNS)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">SLNs are lipid nanoparticles that showed potential for cutaneous application</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="NANOSTRUCTURED LIPID CARRIERS (NLCS)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">NLCs are lipid nanoparticles that showed potential for cutaneous application</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="CHITOSAN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Chitosan is a biopolymer and polysaccharide extensively utilized in various biomedical applications. It is prominently used in drug delivery systems, including nanoparticle formulations, to enhance the targeted delivery of medications. In addition to its role in drug delivery, chitosan is employed in tissue engineering, where it aids in the development of scaffolds and other structures for tissue regeneration. Furthermore, chitosan is incorporated into gel formulations to improve drug accumulation at the target site while minimizing systemic toxicity, thereby enhancing the overall efficacy and safety of therapeutic interventions.</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,6aef5adb1be227170f66c76a292c25e5,8246ea974dfb00cb5e3d984004e21a9e,bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="TACROLIMUS (FK506)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Tacrolimus is a drug used in chitosan-based nanoparticles for treating AD</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="NICOTINAMIDE (NIC)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Nicotinamide is used as a hydrotropic agent in chitosan-based nanoparticles for treating AD</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="SPRAGUE DAWLEY RATS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Sprague Dawley rats are used in in vivo studies for sustained skin permeation</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="BABL/C MICE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">BABL/c mice are used in studies for DNCB-induced AD-like skin lesions</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="DNCB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">DNCB is used to induce AD-like skin lesions in mice</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="SPLEEN">
      <data key="d0">TISSUE</data>
      <data key="d1">The spleen is an organ where weight and index are measured in AD studies</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="PROTOPIC">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Protopic is a treatment compared to NIC-CS-NPs loaded with FK506 in AD studies</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="HYALURONIC ACID (HA)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hyaluronic Acid is used to decorate TAC-loaded nanoparticles for treating AD</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="NIOSOMES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Niosomes are nonionic, drug-containing vesicular systems used for drug delivery</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="BETAMETHASONE VALERATE (BMV)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Betamethasone Valerate is loaded into chitosan nanoparticles for treating AD</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="CARBOPOL&#174;980">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Carbopol&#174;980 is a gel utilized in various formulations for drug delivery, including its application in nanocarriers for enhanced drug delivery systems.</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5,8246ea974dfb00cb5e3d984004e21a9e</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="PHYTOCERAMIDES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Phytoceramides are plant-derived ceramides that are primarily used in skincare products for their moisturizing properties. These ceramides are produced from oats and are often included in nanocarriers to enhance their absorption into the skin.</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5,8246ea974dfb00cb5e3d984004e21a9e</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="STARCH">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Starch is a carbohydrate and polysaccharide that is extensively utilized in drug delivery systems. It serves as a drug delivery agent and is employed in the formulation of nanocarriers for the efficient delivery of therapeutic agents.</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,6aef5adb1be227170f66c76a292c25e5,8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="LECITHIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Lecithin is a fatty substance that plays a crucial role in drug delivery systems. It is commonly utilized in nanocarriers for the efficient delivery of drugs, enhancing the bioavailability and targeted delivery of therapeutic agents.</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5,8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="MICROEMULSIONS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Microemulsions are colloidal dispersions utilized to enhance drug delivery. They are employed in nanocarriers for drug delivery, leveraging their unique properties to improve the efficacy and bioavailability of therapeutic agents.</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5,8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="NIC-CS-NPS">
      <data key="d0" />
      <data key="d1">NIC-CS-NPs are chitosan-based nanoparticles containing tacrolimus and nicotinamide for treating AD</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="TAC-LOADED NANOPARTICLES">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="NANOPARTICLES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Nanoparticles are used in drug delivery systems to enhance drug delivery to the skin</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="POLYMERIC PARTICULATES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Polymeric particulates are used as carriers in drug delivery systems for skin conditions</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="DENDRIMERS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Dendrimers are used as carriers in drug delivery systems for skin conditions</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="DENDRITIC-CORE MULTI-SHELL NANO TRANSPORTERS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Dendritic-core multi-shell nano transporters are used as carriers in drug delivery systems for skin conditions</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="LIPID NANOPARTICLES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Lipid nanoparticles serve as carriers in drug delivery systems for skin conditions</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="CHITOSAN-BASED NANOPARTICLES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Chitosan-based nanoparticles are used for drug delivery in treating AD</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="EAR SKIN">
      <data key="d0">TISSUE</data>
      <data key="d1">Ear skin thickness is measured in AD studies</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="SPLEEN INDEX">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Spleen index is measured to assess immune activation in AD studies</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="HISTOPATHOLOGY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Histopathology is the microscopic examination of tissue to study the manifestations of disease. It is used to examine DNCB-induced atopic dermatitis (AD) skin lesions.</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5,8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="HYALURONIC ACID (HA)-DECORATED TAC-LOADED NPS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hyaluronic Acid (HA)-decorated TAC-loaded NPs are nanoparticles used for treating AD</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="POLYMERIC NANOPARTICLES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Polymeric nanoparticles are used for the topical administration of medicinal compounds</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="BETAMETHASONE VALERATE (BMV)-LOADED CHITOSAN NPS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Betamethasone Valerate (BMV)-loaded chitosan NPs are nanoparticles used for treating AD</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="STARCH-BASED MICROEMULSIONS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Starch-based microemulsions are used in nanocarriers for drug delivery</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="LECITHIN-BASED MICROEMULSIONS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Lecithin-based microemulsions are used in nanocarriers for drug delivery</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="OATS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Oats are a species of cereal grain used in various formulations for their beneficial properties</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="NPS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Nanoparticles (NPs) are tiny particles utilized in drug delivery systems. They are employed in various formulations to enhance the delivery and efficacy of therapeutic agents.</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="SC">
      <data key="d0">TISSUE</data>
      <data key="d1">The Stratum Corneum (SC) is the outermost layer of the skin. It is noteworthy that higher Total Antioxidant Capacity (TAC) levels were observed in the Stratum Corneum when PLG-based nanoparticles were utilized.</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5,bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="PIOGLITAZONE (PGZ)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Pioglitazone (PGZ) is a drug recognized for its anti-diabetic properties and potential in modulating inflammatory responses</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="CLOBETASOL PROPIONATE (CP)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Clobetasol Propionate (CP) is a corticosteroid used to treat skin diseases</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="BMV">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Betamethasone Valerate (BMV) is a corticosteroid used to treat inflammatory skin conditions. Additionally, Betamethasone Valerate (BMV) can be encapsulated in PLGA or lecithin/chitosan-based nanoparticles, which may enhance its delivery and efficacy in therapeutic applications.</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5,bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="DIFLUCORTOLONE VALERATE (DFV)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Diflucortolone Valerate (DFV) is a corticosteroid used to treat skin conditions</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="ALBINO WISTAR RATS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Albino Wistar Rats are a common model organism used in biomedical research</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="TEWL">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Transepidermal Water Loss (TEWL) is a measure of the water loss through the skin, specifically through the epidermis, and serves as an indicator of the skin's barrier function. In an atopic dermatitis (AD) animal model, TEWL is reduced when treated with CsA-loaded nanoparticles, suggesting an improvement in the skin barrier function.</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456,3dfbb4c51838e0951f53ce951395225f,6aef5adb1be227170f66c76a292c25e5,bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="NICOTINAMIDE (VITAMIN B3)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Nicotinamide (Vitamin B3) is a form of vitamin B3 used in skincare for its anti-inflammatory properties</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="GLYCYRRHIZIC ACID (GA)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Glycyrrhizic Acid (GA) is a compound derived from licorice root with anti-inflammatory properties</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="BALB/C MICE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">BALB/c mice are a common inbred strain of laboratory mice extensively used in research. They serve as a genetic background model to study the effects of OX40L signaling and are also utilized in in vivo skin irritation tests.</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3,6aef5adb1be227170f66c76a292c25e5,bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="CYCLOSPORINE A (CSA)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cyclosporine A (CsA) is an immunosuppressive medication used in the treatment of autoimmune diseases</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="HUMAN EPIDERMIS">
      <data key="d0">TISSUE</data>
      <data key="d1">The human epidermis is the outermost layer of the skin</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="TAC">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Tacrolimus (TAC) is an immunosuppressive drug used in the treatment of skin conditions, including eczema and other inflammatory skin conditions. It is also utilized in dermatological treatments to improve skin penetration. Additionally, Transverse aortic constriction (TAC) is a surgical model used to study cardiac hypertrophy and heart failure.</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456,6aef5adb1be227170f66c76a292c25e5,bddc3b1a7f098e71f0aa64adec047124,d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="RABBITS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Rabbits are used as model organisms in biomedical research</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="BETAMETHASONE DIPROPIONATE (BMD)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Betamethasone Dipropionate (BMD) is a corticosteroid used to treat inflammatory skin conditions</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="VITAMIN E (VE)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Vitamin E (VE) is a fat-soluble antioxidant used in skincare for its moisturizing properties</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="TESSEMA">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Tessema is a researcher involved in the study of phytoceramides in nanocarriers</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="ESPINOZA">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Espinoza is a researcher who developed a nanoemulsion of pioglitazone for topical application</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="INFLAMMATORY CYTOKINES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Inflammatory cytokines are signaling molecules involved in the inflammatory response</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="ALAM">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Alam is a researcher who designed a nanoemulsion for topical application using clobetasol propionate</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="EROGLU">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Eroglu is a researcher who studied the effects of liposomes encapsulating BMV and DFV in chitosan gel</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="EL-MENSHAWE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">El-Menshawe is a researcher who designed thermally sensitive ethosomal gels for topical nicotinamide delivery</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="CHAUHAN">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Chauhan is a researcher who developed a transfersome loaded with glycyrrhizic acid for the treatment of AD</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="CARRERAS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Carreras is a researcher who developed ultra-flexible lipid vesicles for the topical administration of cyclosporine A</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="KANG">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Kang is a researcher who investigated the use of thermosensitive solid lipid nanoparticles for TAC delivery</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="NAGAICH">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Nagaich is a researcher who developed nanostructured lipid carriers for delivering betamethasone dipropionate</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="EIRAS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Eiras is a researcher who developed nanostructured lipid carriers incorporating vitamin E into hydrogel</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="FERREIRA">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Ferreira is a researcher who developed methotrexate formulations</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="NLCS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Nanostructured lipid carriers (NLCs) are advanced drug delivery systems that enhance drug permeation and provide controlled release. These carriers are particularly effective in improving skin moisture, making them highly recommended for cosmetic and dermatological applications. NLCs are well-known for their ability to improve the efficacy of topical treatments, thereby offering significant benefits in both medical and cosmetic fields.</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456,bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="HG-NLCVE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">HG-NLCVE is a formulation that could be utilized in cosmetic applications or treating dermatological illnesses</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="METHOTREXATE (MTX)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Methotrexate (MTX) is a drug used to enhance bioavailability and dermal penetration in treatments</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="BECLOMETHASONE DIPROPIONATE (BDP)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Beclomethasone dipropionate (BDP) is a topical medication used as an anti-inflammatory agent for treating AD</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="MOUSE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Mouse is a model organism used in scientific research, including skin penetration studies.</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124,d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="HA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hyaluronic acid (HA) is used in polymeric nanoparticles to improve skin penetration</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="CHOLESTEROL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cholesterol is used in polymeric nanoparticles to improve skin penetration</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="NIC">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Nicotinamide (NIC) is used to improve solubility and skin penetration in nanoparticle formulations</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="HACAT CELLS">
      <data key="d0">CELL</data>
      <data key="d1">HaCaT cells are a type of human keratinocyte cell line used in cell uptake experiments</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="C6">
      <data key="d0">CHEMICAL</data>
      <data key="d1">C6 is a fluorescent marker used in confocal laser scanning microscopy</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="PLA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Polylactic acid (PLA) is used in nanoparticle formulations for anti-inflammatory purposes</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="PLG">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Polylactide-co-glycerol (PLG) is used in nanoparticles for topical delivery of TAC</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="PLGA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Poly(lactic-co-glycolic acid) (PLGA) is used in nanoparticles for topical drug delivery</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="CSA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cyclosporine A (CsA) is a drug used in PLGA-based nanoparticles for anti-inflammatory effects</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="INF-&#915;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interferon-gamma (INF-&#947;) is a cytokine whose levels are reduced in an AD animal model treated with CsA-loaded nanoparticles</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="OVA-IGE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Ovalbumin-specific IgE (OVA-IgE) is a serum level reduced in an AD animal model treated with CsA-loaded nanoparticles</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="HYDROCORTISONE (HC)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hydrocortisone (HC) is a corticosteroid used in chitosan-based nanoparticles for topical administration</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="HYDROXYTYROSOL (HT)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hydroxytyrosol (HT) is used in chitosan-based nanoparticles for topical administration</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="HYDROCORTISONE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hydrocortisone (HC) is a corticosteroid used to reduce inflammation and treat various skin conditions.</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456,3dfbb4c51838e0951f53ce951395225f</data>
    </node>
    <node id="HYDROXYTYROSOL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hydroxytyrosol (HT) is a phenolic compound with antioxidant properties.</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456,3dfbb4c51838e0951f53ce951395225f</data>
    </node>
    <node id="DERMATITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Dermatitis is a general term for inflammation of the skin. It is an inflammatory condition of the skin.</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456,3dfbb4c51838e0951f53ce951395225f</data>
    </node>
    <node id="IL-12P70">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-12p70 (IL-12p70) is a cytokine involved in the immune response</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f</data>
    </node>
    <node id="PROSTAGLANDIN-E2">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Prostaglandin-E2 (PGE2) is a lipid compound involved in inflammation</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f</data>
    </node>
    <node id="VEGF-&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Vascular endothelial growth factor-alpha (VEGF-&#945;) is a protein involved in angiogenesis</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="ELASTIC FIBER">
      <data key="d0">CELL</data>
      <data key="d1">Elastic fibers are components of the extracellular matrix that provide elasticity to tissues</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f</data>
      <data key="d3">CELL</data>
    </node>
    <node id="FUCOIDAN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Fucoidan is a sulfated polysaccharide found in brown seaweed</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="MTX">
      <data key="d0">CHEMICAL</data>
      <data key="d1">MTX (Methotrexate) is a medication used to treat autoimmune diseases, inflammatory diseases, and certain types of cancer.</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,423195c6b63ad0a6773374364ebf3612,8e5a1be9981340d419f7b3ad27076009</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="HNE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Human neutrophil elastase (HNE) is an enzyme involved in the breakdown of elastin</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="ER143">
      <data key="d0">CHEMICAL</data>
      <data key="d1">ER143 is a synthetic inhibitor of human neutrophil elastase (HNE) used to reduce inflammation. This human neutrophil elastase inhibitor plays a crucial role in mitigating inflammatory responses, making it a valuable therapeutic agent in conditions where excessive inflammation is a concern.</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456,3dfbb4c51838e0951f53ce951395225f</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="DESONIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Desonide (DES) is a corticosteroid used to treat inflammation and itching caused by skin conditions.</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456,3dfbb4c51838e0951f53ce951395225f</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="ACAI OIL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Acai oil (AO) is an oil extracted from the acai berry, used in formulations for its antioxidant properties</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="MEDIUM-CHAIN TRIGLYCERIDES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Medium-chain triglycerides (MCT) are fats used in drug formulations</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="BDP">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Beclomethasone dipropionate (BDP) is a corticosteroid used to treat inflammation</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="HPMC">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hydroxypropyl methylcellulose (HPMC) is a polymer used in drug formulations</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="CD-1 MOUSE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">CD-1 mouse is a strain of laboratory mouse used in research</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="OMIGANAN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Omiganan is a small molecule used in atopic dermatitis treatment</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="EUDRAGIT&#174; RL100">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">3dfbb4c51838e0951f53ce951395225f</data>
    </node>
    <node id="INTERLEUKIN-4RA">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-4 receptor alpha, involved in immune response modulation</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="INTERLEUKIN-13RA1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-13 receptor alpha 1, involved in immune response modulation</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="INTERLEUKIN-5RA">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-5 receptor alpha, involved in immune response modulation</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="FB825/ANTI-C&#917;MX">
      <data key="d0">CHEMICAL</data>
      <data key="d1">FB825/anti-C&#949;mX is a biologic drug targeting Immunoglobulin E</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="FEZAKIMUAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Fezakimuab is a biologic drug targeting Interleukin-22</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="INTERLEUKIN-17A">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-17a, a cytokine involved in immune response</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="INTERLEUKIN-5">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-5, a cytokine involved in immune response</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="AMDITELIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Amditelimab is a biologic drug targeting OX-40</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="OX-40">
      <data key="d0">PROTEIN</data>
      <data key="d1">OX-40, a protein involved in T-cell costimulation</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="BACRICITINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Bacricitinib is a small molecule drug targeting JAK1</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="HYALURONIC ACID">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hyaluronic acid is a substance used in nanotechnology-based therapeutic approaches</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="BETAMETHASONE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Betamethasone is a corticosteroid used in nanotechnology-based therapeutic approaches</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="OAT-CERAMIDES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Oat-ceramides are used in nanotechnology-based therapeutic approaches</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="PIOGLITAZONE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Pioglitazone is a drug used in nanotechnology-based therapeutic approaches</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="CLOBETASOL PROPIONATE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Clobetasol propionate is a corticosteroid used in nanotechnology-based therapeutic approaches</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="DIFLUCORTOLONE VALERATE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Diflucortolone valerate is a corticosteroid used in nanotechnology-based therapeutic approaches</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="GLYCYRRHIZIC ACID">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Glycyrrhizic acid is a compound used in nanotechnology-based therapeutic approaches</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="VITAMIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Vitamin is used in nanotechnology-based therapeutic approaches</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="BETAMETHASONE VALERATE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Betamethasone valerate is a corticosteroid used to reduce inflammation and treat various skin conditions</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
    </node>
    <node id="BETAMETHASONE DIPROPIONATE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Betamethasone dipropionate is a corticosteroid used to treat inflammation and skin conditions</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
    </node>
    <node id="AURAPTENE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Auraptene is a natural compound with anti-inflammatory properties</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
    </node>
    <node id="MIZOLASTINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Mizolastine is an antihistamine used to treat allergic conditions</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
    </node>
    <node id="LEVOCETIRIZINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Levocetirizine is an antihistamine used to treat allergy symptoms</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
    </node>
    <node id="LYMPHOMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Lymphoma is a type of cancer that affects the lymphatic system. It is treated with pembrolizumab.</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456,855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="SKIN CANCER">
      <data key="d0">DISEASE</data>
      <data key="d1">Skin cancer is a type of cancer that develops in the skin cells</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
    </node>
    <node id="CELL PROLIFERATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Cell proliferation is the process by which cells divide and multiply</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="SKIN THICKENING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Skin thickening is an increase in the thickness of the skin, often due to chronic inflammation or other conditions</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="SWELLING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Swelling is an abnormal enlargement of a body part, often due to inflammation or fluid accumulation</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="BLANCHING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Blanching is the whitening of the skin due to reduced blood flow</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="SKIN RETENTION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Skin retention refers to the ability of the skin to retain substances, such as drugs, within its layers</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="PERMEATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Permeation is the process by which a substance passes through a barrier, such as the skin</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="FLUX">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Flux refers to the rate of flow of a substance through a barrier, such as the skin</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="NON-FICKIAN DIFFUSION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Non-Fickian diffusion is a type of diffusion where the rate of drug release is not solely dependent on concentration gradients</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="CONTROLLED RELEASE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Controlled release is a drug delivery method that allows for the gradual release of a drug over time</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="SUSTAINED RELEASE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Sustained release is a drug delivery method that maintains a consistent drug concentration over an extended period</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="BIOCOMPATIBILITY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Biocompatibility refers to the ability of a material to be compatible with living tissue without causing an immune response</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="NON-TOXICITY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Non-toxicity refers to the property of a substance being non-toxic or not harmful to living organisms</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="ANTI-INFLAMMATORY ACTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Anti-inflammatory action refers to the ability of a substance to reduce inflammation</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INHIBITION OF CELL PROLIFERATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Inhibition of cell proliferation refers to the process of preventing or slowing down the multiplication of cells</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INHIBITION OF IL-2 SECRETION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Inhibition of IL-2 secretion refers to the process of preventing or reducing the release of interleukin-2</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INHIBITION OF TSLP">
      <data key="d0">PATHWAY</data>
      <data key="d1">Inhibition of TSLP refers to the process of preventing or reducing the release of thymic stromal lymphopoietin</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PREVENTION OF SKIN THICKENING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Prevention of skin thickening refers to the process of stopping or reducing the increase in skin thickness</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PRESERVATION OF SKIN INTEGRITY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Preservation of skin integrity refers to maintaining the skin's structure and function</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="REDUCTION OF SWELLING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Reduction of swelling refers to the process of decreasing abnormal enlargement of a body part</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="REDUCTION OF ERYTHEMA">
      <data key="d0">PATHWAY</data>
      <data key="d1">Reduction of erythema refers to the process of decreasing redness of the skin</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="REDUCTION OF TEWL">
      <data key="d0">PATHWAY</data>
      <data key="d1">Reduction of transepidermal water loss refers to the process of decreasing water loss through the epidermis</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="REDUCTION OF DERMATITIS INDEX">
      <data key="d0">PATHWAY</data>
      <data key="d1">Reduction of dermatitis index refers to the process of decreasing the severity of dermatitis</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="REDUCTION OF EAR THICKNESS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Reduction of ear thickness refers to the process of decreasing the thickness of the ear, often used as a measure in inflammation studies</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="SUPPRESSION OF CELL INFILTRATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Suppression of cell infiltration refers to the process of preventing or reducing the movement of cells into a tissue, often related to inflammation</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="SUPPRESSION OF IMMUNOGLOBULIN E">
      <data key="d0">PATHWAY</data>
      <data key="d1">Suppression of immunoglobulin E refers to the process of preventing or reducing the production of IgE, an antibody associated with allergic reactions</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INCREASE IN DRUG ACCUMULATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Increase in drug accumulation refers to the process of enhancing the concentration of a drug within a specific area, such as the skin</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INCREASE IN SKIN RETENTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Increase in skin retention refers to the process of enhancing the ability of the skin to retain substances, such as drugs, within its layers</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INCREASE IN SKIN PERMEATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Increase in skin permeation refers to the process of enhancing the passage of substances through the skin</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INCREASE IN ANTI-INFLAMMATORY PROPERTIES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Increase in anti-inflammatory properties refers to the process of enhancing the ability of a substance to reduce inflammation</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INCREASE IN ERYTHEMA INHIBITION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Increase in erythema inhibition refers to the process of enhancing the ability to reduce skin redness</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INCREASE IN INHIBITION OF CELL PROLIFERATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Increase in inhibition of cell proliferation refers to the process of enhancing the ability to prevent or slow down the multiplication of cells</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INCREASE IN INHIBITION OF IL-2 SECRETION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Increase in inhibition of IL-2 secretion refers to the process of enhancing the ability to prevent or reduce the release of interleukin-2</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INCREASE IN INHIBITION OF TSLP">
      <data key="d0">PATHWAY</data>
      <data key="d1">IncreaseIncrease in inhibition of TSLP refers to the process of enhancing the ability to prevent or reduce the release of thymic stromal lymphopoietin</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INCREASE IN SKIN LAYER PENETRATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Increase in skin layer penetration refers to the process of enhancing the ability of a substance to penetrate deeper layers of the skin</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INCREASE IN PERMEATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Increase in permeation refers to the process of enhancing the passage of substances through a barrier, such as the skin</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="CIBINQO">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cibinqo, also known as abrocitinib, is a JAK1 inhibitor approved for AD treatment</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c</data>
    </node>
    <node id="JADE TEEN">
      <data key="d0">STUDY</data>
      <data key="d1">JADE TEEN is a Phase III clinical trial supporting cibinqo label expansion</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c</data>
    </node>
    <node id="SANOFI">
      <data key="d0">ORGANIZATION</data>
      <data key="d1">Sanofi is a company that produces dupilumab</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c</data>
    </node>
    <node id="REGENERON">
      <data key="d0">ORGANIZATION</data>
      <data key="d1">Regeneron is a company that produces dupilumab</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c</data>
    </node>
    <node id="ADBRY">
      <data key="d0">CHEMICAL</data>
      <data key="d1">ADBRY is a medication approved for AD treatment</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c</data>
    </node>
    <node id="OPZELURA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Opzelura is a cream approved as the first topical JAK inhibitor for AD treatment</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c</data>
    </node>
    <node id="IL-13R">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-13R is a receptor involved in the pathophysiology of AD</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="NOS2">
      <data key="d0">PROTEIN</data>
      <data key="d1">NOS2 is a biomarker used to monitor the severity of AD</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="INOS">
      <data key="d0">PROTEIN</data>
      <data key="d1">iNOS is a biomarker used to monitor the severity of AD</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="BIOLOGICAL THERAPIES">
      <data key="d0">TREATMENT</data>
      <data key="d1">Biological therapies are advanced treatments for dermatological conditions like AD</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c</data>
      <data key="d3">TREATMENT</data>
    </node>
    <node id="NANOCARRIERS">
      <data key="d0">TREATMENT</data>
      <data key="d1">Nanocarriers are nanoscale vehicles designed for targeted drug delivery. These innovative therapeutic delivery systems are particularly utilized for the treatment of autoimmune diseases (AD). By leveraging their small size and ability to deliver drugs directly to specific sites within the body, nanocarriers enhance the efficacy and reduce the side effects of treatments for autoimmune conditions.</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c,e30574e513dd250992d637d808759c34</data>
      <data key="d3">TREATMENT</data>
    </node>
    <node id="BIOLOGICAL PHARMACEUTICALS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Biological pharmaceuticals are drugs derived from living organisms used in the treatment of various diseases, including AD</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="NANOPARTICLE SYSTEMS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Nanoparticle systems are engineered particles at the nanoscale used for drug delivery and therapeutic purposes</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="NANOMEDICINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Nanomedicine involves the application of nanotechnology for medical purposes, including drug delivery and therapy</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="MYELOFIBROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Myelofibrosis is a rare bone marrow cancer that disrupts the body's normal production of blood cells</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="BIOTHERAPEUTICS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Biotherapeutics are therapeutic materials produced using biological processes, often involving recombinant DNA technology</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="PATHWAYS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Pathways refer to the series of actions among molecules in a cell that leads to a certain product or change in the cell, often implicated in disease mechanisms</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="THERAPEUTIC STRATEGIES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Therapeutic strategies refer to the methods and plans designed to treat diseases, including AD</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="DRUG DELIVERY MECHANISMS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Drug delivery mechanisms are methods or processes of administering a pharmaceutical compound to achieve a therapeutic effect</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="PRECLINICAL RESEARCH">
      <data key="d0">PATHWAY</data>
      <data key="d1">Preclinical research involves studies that test a drug, procedure, or other medical treatment in animals before it is tested in humans</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="CLINICAL RESEARCH">
      <data key="d0">PATHWAY</data>
      <data key="d1">Clinical research involves studies or trials that test the safety and effectiveness of drugs, procedures, or other medical treatments in humans</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="MULTIDISCIPLINARY APPROACH">
      <data key="d0">PATHWAY</data>
      <data key="d1">A multidisciplinary approach involves integrating multiple fields of study to address complex issues, such as the management of AD</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="THERAPY COMPLIANCE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Therapy compliance refers to the degree to which a patient correctly follows medical advice and treatment plans</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="SEVERE AD">
      <data key="d0">DISEASE</data>
      <data key="d1">Severe AD refers to a more intense and debilitating form of atopic dermatitis</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="TRADITIONAL TREATMENTS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Traditional treatments refer to conventional methods of treating diseases, which may include medications, therapies, and procedures</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="NANOTECHNOLOGY-BASED DRUG DELIVERY SYSTEMS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Nanotechnology-based drug delivery systems use nanoscale materials to deliver drugs more effectively to specific sites in the body</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="MEMORY T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Memory T cells are a type of T cell involved in the long-term immune response, and their function is influenced by CD27:CD70 signaling. These cells are believed to be central to the chronicity of Atopic Dermatitis, highlighting their significant role in the persistence of this condition.</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3,691cb2e23ac3c6e591129d16714f8ef8</data>
    </node>
    <node id="ANTIGEN-PRESENTING CELLS (APC)">
      <data key="d0">CELL</data>
      <data key="d1">APCs express OX40L and are involved in the immune response in Atopic Dermatitis</data>
      <data key="d2">691cb2e23ac3c6e591129d16714f8ef8</data>
    </node>
    <node id="PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS)">
      <data key="d0">CELL</data>
      <data key="d1">PBMCs are blood cells that are critical in the immune response and are isolated for research in Atopic Dermatitis</data>
      <data key="d2">691cb2e23ac3c6e591129d16714f8ef8</data>
    </node>
    <node id="PLASMA">
      <data key="d0">TISSUE</data>
      <data key="d1">Plasma is the liquid component of blood, collected for research in Atopic Dermatitis. Plasma, the liquid component of blood, is collected from patients with Atopic Dermatitis (AD) and healthy controls (HC).</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746,691cb2e23ac3c6e591129d16714f8ef8</data>
    </node>
    <node id="HEALTHY CONTROLS (HC)">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Healthy Controls (HC) are individuals without Atopic Dermatitis or other systemic inflammatory diseases, used as a comparison group in research</data>
      <data key="d2">691cb2e23ac3c6e591129d16714f8ef8</data>
    </node>
    <node id="ENZYME-LINKED IMMUNOASSAY (ELISA)">
      <data key="d0">PATHWAY</data>
      <data key="d1">ELISA is a laboratory technique used to measure the concentration of soluble OX40 in blood samples from patients with Atopic Dermatitis</data>
      <data key="d2">691cb2e23ac3c6e591129d16714f8ef8</data>
    </node>
    <node id="FLOW CYTOMETRY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Flow Cytometry is a technique used to analyze the physical and chemical characteristics of cells. It is also employed to analyze the expression of OX40 by activated skin-homing CD4+ T cells in Atopic Dermatitis.</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd,691cb2e23ac3c6e591129d16714f8ef8</data>
    </node>
    <node id="ANTIGEN-ACTIVATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Antigen-Activation is the process that triggers T-cell expression of OX40 and APC expression of OX40L in Atopic Dermatitis</data>
      <data key="d2">691cb2e23ac3c6e591129d16714f8ef8</data>
    </node>
    <node id="MAST CELL DEGRANULATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Mast Cell Degranulation is inhibited by soluble OX40, reducing the inflammatory response in Atopic Dermatitis</data>
      <data key="d2">691cb2e23ac3c6e591129d16714f8ef8</data>
    </node>
    <node id="HANIFIN &amp; RAJKA CRITERIA">
      <data key="d0">PATHWAY</data>
      <data key="d1">Hanifin &amp; Rajka Criteria are used to diagnose patients with Atopic Dermatitis</data>
      <data key="d2">691cb2e23ac3c6e591129d16714f8ef8</data>
    </node>
    <node id="FICOLL-PAQUE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Ficoll-Paque is a chemical used for density gradient centrifugation to isolate peripheral blood mononuclear cells (PBMCs). It is commonly utilized in research on various conditions, including Atopic Dermatitis.</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746,691cb2e23ac3c6e591129d16714f8ef8</data>
    </node>
    <node id="HC">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Healthy Controls (HC) are individuals without the disease, used as a comparison group in studies. These individuals do not have atopic diseases or systemic inflammatory diseases, making them an ideal baseline for comparison in medical research.</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746,6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d</data>
    </node>
    <node id="SOX40L">
      <data key="d0">PROTEIN</data>
      <data key="d1">SOX40L, also referred to as soluble OX40L (sOX40L), is a protein that can be measured in the serum of patients with atopic dermatitis (AD) as well as healthy controls (HC). This soluble form of the OX40L protein plays a role in the modulation of immune responses. Despite its involvement in immune response modulation, studies have shown that there are no significant differences in the levels of soluble OX40L between patients with atopic dermatitis and healthy controls.</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746,348f2797841cbef27311b03f2cd788dd,6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d</data>
    </node>
    <node id="CD4">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD4 is a glycoprotein found on the surface of immune cells such as T helper cells. It serves as a protein marker on T cells and is involved in the immune response, particularly influenced by OX40-OX40L signaling. CD4 is also commonly used in flow cytometry for identifying and studying T cells.</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3,2e9a8d71f6bd251a0b13458c39e69746,89dbac0da39e4de2b602052cd792b90d</data>
    </node>
    <node id="CD45RO">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD45RO is an isoform of the CD45 protein, expressed on memory T cells. It serves as a protein marker used in flow cytometry for identifying memory T cells.</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746,89dbac0da39e4de2b602052cd792b90d</data>
    </node>
    <node id="CD56">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD56, a protein marker used in flow cytometry for natural killer cells</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746</data>
    </node>
    <node id="CLA">
      <data key="d0">PROTEIN</data>
      <data key="d1">Cutaneous Lymphocyte Antigen (CLA) is a protein marker used in flow cytometry. It is expressed on T cells and plays a crucial role in skin homing, guiding these immune cells to the skin.</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746,89dbac0da39e4de2b602052cd792b90d</data>
    </node>
    <node id="FORMALDEHYDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Formaldehyde, a chemical used for fixing cells and tissuesFormaldehyde, used to fix cells in flow cytometry</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="TRYPTASE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Tryptase is a protease enzyme found in mast cells and is commonly used as a marker for mast cell activation. It is a protein targeted by monoclonal rabbit antibodies for analytical purposes. Tryptase serves as a marker to confirm the presence of mast cells expressing OX40L in atopic dermatitis (AD) skin. Additionally, it is a protein frequently analyzed in skin biopsies to study various dermatological conditions.</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746,348f2797841cbef27311b03f2cd788dd,6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d</data>
    </node>
    <node id="MOUSE IGG">
      <data key="d0">PROTEIN</data>
      <data key="d1">Mouse IgG, used to block unspecific binding in flow cytometry</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746</data>
    </node>
    <node id="BOVINE SERUM ALBUMIN (BSA)">
      <data key="d0">PROTEIN</data>
      <data key="d1">Bovine Serum Albumin, used in wash buffer for flow cytometry</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746</data>
    </node>
    <node id="SODIUM AZIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Sodium Azide, used in wash buffer for flow cytometry</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746</data>
    </node>
    <node id="PARAFFIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Paraffin, used to embed skin biopsies</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746</data>
    </node>
    <node id="CITRATE-PHOSPHATE BUFFER">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Citrate-Phosphate Buffer, used for heat-induced antigen retrieval</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746</data>
    </node>
    <node id="ALEXA 488">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Alexa 488, a fluorescent dye used for staining in confocal microscopy</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746</data>
    </node>
    <node id="RHINITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Rhinitis is a common comorbidity in patients with atopic dermatitis</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="MONOCLONAL RABBIT ANTI-TRYPTASE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Monoclonal rabbit anti-tryptase is an antibody used for targeting tryptase in immunohistochemistry</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="MONOCLONAL MOUSE ANTI-OX40L">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Monoclonal mouse anti-OX40L is an antibody used for targeting OX40L in immunohistochemistry</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="DONKEY ANTI-MOUSE ALEXA 488">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Donkey anti-mouse Alexa 488 is a secondary antibody used for fluorescence detection</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="DONKEY ANTI-RABBIT ALEXA 647">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Donkey anti-rabbit Alexa 647 is a secondary antibody used for fluorescence detection</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="MOUSE IGG1 ISOTYPE CONTROL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Mouse IgG1 isotype control is used as a negative control for unspecific binding in immunohistochemistry</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="MOUNTING MEDIUM">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Mounting Medium is used to fix tissue sections for microscopy analysis</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="PRISM 6">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Prism 6 is a software used for statistical analysis and graphing</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="MANN-WHITNEY RANK SUM TEST">
      <data key="d0">PATHWAY</data>
      <data key="d1">Mann-Whitney rank sum test is a non-parametric test used for comparing unpaired data</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="WILCOXON SIGNED-RANK TEST">
      <data key="d0">PATHWAY</data>
      <data key="d1">Wilcoxon signed-rank test is a non-parametric test used for comparing paired data</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="SPEARMAN&#8217;S RHO">
      <data key="d0">PATHWAY</data>
      <data key="d1">Spearman&#8217;s rho is a statistical measure used to test correlations</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="ENZYME-LINKED IMMUNOASSAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Enzyme-linked immunoassay (ELISA) is a technique used to measure levels of sOX40 and sOX40L in serum</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="CHILDREN WITH AD">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Children with atopic dermatitis are a group studied for serum levels of sOX40 and sOX40L</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="ADULTS WITH AD">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Adults with atopic dermatitis are a group studied for serum levels of sOX40 and sOX40L</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="TISSUE SECTIONS">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="STATISTICAL ANALYSIS">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="UNPAIRED DATA">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="PAIRED DATA">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="CORRELATION">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="CLA+ T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CLA+ T cells are skin-homing memory-prone T cells expressing OX40 in AD patients</data>
      <data key="d2">6b099960b0a39866e3aa6b908f1886e4</data>
    </node>
    <node id="CLA- T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CLA- T cells are a subset of T cells expressing OX40 in AD patients</data>
      <data key="d2">6b099960b0a39866e3aa6b908f1886e4</data>
    </node>
    <node id="CD4+CD45RO+CLA+ T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD4+CD45RO+CLA+ T CELLS are a subset of T cells expressing CD4, CD45RO, and cutaneous lymphocyte-associated antigen (CLA). These cells are involved in immune responses in atopic dermatitis (AD). Additionally, CD4+CD45RO+CLA+ T cells express the highest amount of OX40 in AD patients, indicating their significant role in the pathophysiology of this condition.</data>
      <data key="d2">6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d</data>
    </node>
    <node id="CD4+CD45RO+CLA- T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD4+CD45RO+CLA- T cells are a subset of T cells expressing OX40 in AD patients</data>
      <data key="d2">6b099960b0a39866e3aa6b908f1886e4</data>
    </node>
    <node id="CD8+CD45RO+CLA+ T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD8+CD45RO+CLA+ T cells are a subset of T cells expressing OX40 in AD patients</data>
      <data key="d2">6b099960b0a39866e3aa6b908f1886e4</data>
    </node>
    <node id="CD8+CD45RO+CLA- T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD8+CD45RO+CLA- T cells are a subset of T cells expressing OX40 in AD patients</data>
      <data key="d2">6b099960b0a39866e3aa6b908f1886e4</data>
    </node>
    <node id="MURINE ASTHMA MODELS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Murine asthma models are mouse models used to study asthma and allergic reactions</data>
      <data key="d2">89dbac0da39e4de2b602052cd792b90d</data>
    </node>
    <node id="LUNG">
      <data key="d0">TISSUE</data>
      <data key="d1">The lung is a vital respiratory organ involved in gas exchange, playing a crucial role in respiration. It is affected by various conditions, including interstitial lung disease in systemic sclerosis (SSc) and asthma. Additionally, the lung is a tissue where TL1A-driven inflammation and fibrosis have been observed. Pulmonary fibrosis is another condition that impacts the lung, and it is also notably affected by systemic sclerosis, particularly in the context of fibrosis.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,44f2592262cac835560b4c149fee8d2b,7c13f41d7349d9d2e56c36e00c0ca2d9,855c455b4c9592746834ee3a4e0e6b81,89dbac0da39e4de2b602052cd792b90d,b2aae16813e647959b783a39ef9a19a7,c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="ATOPIC DISEASES">
      <data key="d0">DISEASE</data>
      <data key="d1">Atopic diseases are a group of diseases characterized by a tendency to develop allergic reactions</data>
      <data key="d2">100dd7646c10899301b3c0631183da16</data>
    </node>
    <node id="SKIN THICKNESS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Skin thickness is a measure often used to assess the severity of skin conditions like atopic dermatitis</data>
      <data key="d2">100dd7646c10899301b3c0631183da16</data>
    </node>
    <node id="SYSTEMIC SCLEROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Systemic sclerosis (SSc) is an idiopathic autoimmune disease characterized by pathological fibrosis of the skin and internal organs. This condition primarily affects the skin but also extends to visceral organs, including the lungs and heart. As an autoimmune T-cell disease, systemic sclerosis involves complex immune system dysfunction leading to the excessive deposition of connective tissue, resulting in the thickening and hardening of affected areas.</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612,503107475d2e9dac49abd8ebcbadd9f5,5ec1ebf4e260eb1f8fda8acdf06cd39e,5f37466ca41c9b8b06ed8be0303d49f2,8e5a1be9981340d419f7b3ad27076009,d8a485eb1e9435b083d5ef6a17f06ea5</data>
    </node>
    <node id="SSC">
      <data key="d0">DISEASE</data>
      <data key="d1">Systemic sclerosis (SSc), also known as scleroderma, is a very severe and chronic multisystem autoimmune disease characterized by progressive fibrosis of the skin and internal organs. This clinically heterogeneous disease is associated with OX40-OX40L signaling, with significantly increased OX40 levels found in patients. Additionally, systemic sclerosis is linked to the TNFSF4 gene and various single nucleotide polymorphisms (SNPs), including rs2205960 and rs855648.</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,05c97152fe02249153103be341d65b67,1b656cfce91ff9ccec4223703489dab3,40ad2241836485e0bf264bdfb62fd789,44f2592262cac835560b4c149fee8d2b,4cf23e218b6aab3c77115173b5c7c2fd,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,5ec1ebf4e260eb1f8fda8acdf06cd39e,7b454335c2f5651d86f712037a0dc0ff,855c455b4c9592746834ee3a4e0e6b81,8ce8c356713490cd2c680f505bcd050b,9867d43adab0ba5db44961fae4863eee,b2aae16813e647959b783a39ef9a19a7,c69c7fb997f95c56cc077b3975f41923,d4797ed1483e5057bcd8301eaa509d5e,d8a485eb1e9435b083d5ef6a17f06ea5,df74aa1b86eeeb811ca5586767ae3a71,f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="RA">
      <data key="d0">DISEASE</data>
      <data key="d1">Rheumatoid arthritis (RA) is an autoimmune disease primarily affecting the joints. It causes inflammation of the joints, leading to pain, swelling, and potential loss of function. As a rheumatic disease, RA has been extensively studied, and treatments such as abatacept have a well-documented safety profile.</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81,8ce8c356713490cd2c680f505bcd050b</data>
    </node>
    <node id="SLE">
      <data key="d0">DISEASE</data>
      <data key="d1">Systemic lupus erythematosus (SLE) is an autoimmune disease associated with OX40-OX40L signaling. In SLE, OX40 levels are compared to those in systemic sclerosis (SSc) patients.</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,1b656cfce91ff9ccec4223703489dab3,44f2592262cac835560b4c149fee8d2b,503107475d2e9dac49abd8ebcbadd9f5,8ce8c356713490cd2c680f505bcd050b,f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="SJ&#214;GREN'S SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Sj&#246;gren's syndrome is an autoimmune disease affecting moisture-producing glands</data>
      <data key="d2">503107475d2e9dac49abd8ebcbadd9f5</data>
    </node>
    <node id="POLYMYOSITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Polymyositis is an autoimmune disease causing muscle inflammation</data>
      <data key="d2">503107475d2e9dac49abd8ebcbadd9f5</data>
    </node>
    <node id="DCSSC">
      <data key="d0">DISEASE</data>
      <data key="d1">Diffuse cutaneous systemic sclerosis (DCSSC) is a severe form of systemic sclerosis characterized by widespread skin involvement. It is a subtype of systemic sclerosis that involves rapid skin thickening and can also affect internal organs. Early diffuse cutaneous systemic sclerosis is particularly noted for its rapid progression and extensive impact on both the skin and internal organs.</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81,9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="ASSET TRIAL">
      <data key="d0">PATHWAY</data>
      <data key="d1">The ASSET trial (NCT02161406) is a phase II clinical trial assessing the efficacy of abatacept in treating diffuse cutaneous systemic sclerosis (SSc). This study, formally known as the Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis, is a randomized, placebo-controlled, double-blind trial designed to evaluate the therapeutic potential of abatacept in patients with this condition.</data>
      <data key="d2">503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="CTLA4-B7">
      <data key="d0">PATHWAY</data>
      <data key="d1">CTLA4-B7 is a negative costimulatory pathway that restrains adaptive immune response</data>
      <data key="d2">503107475d2e9dac49abd8ebcbadd9f5</data>
    </node>
    <node id="PD1-PDL1/2">
      <data key="d0">PATHWAY</data>
      <data key="d1">PD1-PDL1/2 is a negative costimulatory pathway that restrains adaptive immune response</data>
      <data key="d2">503107475d2e9dac49abd8ebcbadd9f5</data>
    </node>
    <node id="IL-2 SECRETION">
      <data key="d0">PATHWAY</data>
      <data key="d1">IL-2 secretion is induced by CD28 binding to CD80 and CD86, promoting T-cell proliferation</data>
      <data key="d2">503107475d2e9dac49abd8ebcbadd9f5</data>
    </node>
    <node id="INFLAMMATION-DRIVEN DERMAL FIBROSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Inflammation-driven dermal fibrosis is a symptom of systemic sclerosis</data>
      <data key="d2">503107475d2e9dac49abd8ebcbadd9f5</data>
    </node>
    <node id="DIGESTIVE INVOLVEMENT">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Digestive involvement is a symptom of systemic sclerosis</data>
      <data key="d2">503107475d2e9dac49abd8ebcbadd9f5</data>
    </node>
    <node id="LUNG FIBROSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Lung fibrosis is a type of fibrosis affecting the lungs, characterized by the thickening and scarring of lung tissue. It is a symptom commonly observed in systemic sclerosis, a chronic connective tissue disease. Additionally, lung fibrosis is associated with OX40-OX40L signaling, a pathway that plays a role in the immune response and inflammation.</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3,503107475d2e9dac49abd8ebcbadd9f5</data>
    </node>
    <node id="PULMONARY HYPERTENSION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Pulmonary hypertension is a condition characterized by high blood pressure in the lungs. It is a clinical manifestation observed in systemic sclerosis (SSc) and is considered a symptom of this autoimmune disease.</data>
      <data key="d2">503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81,9867d43adab0ba5db44961fae4863eee,c69c7fb997f95c56cc077b3975f41923</data>
    </node>
    <node id="INFLAMMATORY JOINT INVOLVEMENT">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Inflammatory joint involvement is a symptom of systemic sclerosis</data>
      <data key="d2">503107475d2e9dac49abd8ebcbadd9f5</data>
    </node>
    <node id="PLACEBO-CONTROLLED RANDOMIZED TRIAL">
      <data key="d0">PATHWAY</data>
      <data key="d1">A placebo-controlled randomized trial is a type of clinical trial used to assess the efficacy of treatments</data>
      <data key="d2">503107475d2e9dac49abd8ebcbadd9f5</data>
    </node>
    <node id="NCT02161406">
      <data key="d0">PATHWAY</data>
      <data key="d1">NCT02161406 is the clinical trial identifier for the ASSET trial assessing abatacept in SSc</data>
      <data key="d2">503107475d2e9dac49abd8ebcbadd9f5</data>
    </node>
    <node id="T CELL RECEPTOR (TCR)">
      <data key="d0">PROTEIN</data>
      <data key="d1">T cell receptor (TCR) is involved in the recognition of antigens by T cells</data>
      <data key="d2">503107475d2e9dac49abd8ebcbadd9f5</data>
    </node>
    <node id="NAIVE T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Naive T cells require costimulatory signals for activation and proliferation</data>
      <data key="d2">503107475d2e9dac49abd8ebcbadd9f5</data>
    </node>
    <node id="EXTRACELLULAR MATRIX">
      <data key="d0">TISSUE</data>
      <data key="d1">The extracellular matrix (ECM) is a network of non-cellular components present within tissues and organs. It is composed of proteins and other molecules outside cells that provide structural and biochemical support to surrounding cells. The ECM is produced by fibroblasts and plays a crucial role in maintaining tissue structure and integrity. Additionally, it is involved in processes such as fibrosis, where excessive ECM production can lead to tissue scarring. Overall, the extracellular matrix is essential for providing both structural and biochemical support to cells within various tissues and organs.</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,44f2592262cac835560b4c149fee8d2b,4cf23e218b6aab3c77115173b5c7c2fd,503107475d2e9dac49abd8ebcbadd9f5,b2aae16813e647959b783a39ef9a19a7,df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="PD1">
      <data key="d0" />
      <data key="d1">PD1, also known as programmed death 1, is a protein involved in the regulation of immune responses. It plays a crucial role in negative costimulatory pathways, which are essential for maintaining immune homeostasis and preventing autoimmunity.</data>
      <data key="d2">4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="T-REG CELL">
      <data key="d0">CELL</data>
      <data key="d1">T-reg cell function is inactivated by OX40, unleashing nearby DCs</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="DERMAL FIBROBLASTS">
      <data key="d0">CELL</data>
      <data key="d1">Dermal fibroblasts are fibroblasts located in the skin that produce extracellular matrix and collagen. They play a critical role in wound healing and fibrosis.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,44f2592262cac835560b4c149fee8d2b,5f37466ca41c9b8b06ed8be0303d49f2</data>
    </node>
    <node id="MMP">
      <data key="d0">PROTEIN</data>
      <data key="d1">Matrix metalloproteinases (MMP) are a family of enzymes involved in the proteolytic cleavage of CD27 from cells. These enzymes play a crucial role in breaking down proteins in the extracellular matrix, which is essential for various physiological processes, including tissue remodeling, wound healing, and the regulation of immune responses.</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3,44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="MMP-2">
      <data key="d0">PROTEIN</data>
      <data key="d1">Matrix metalloproteinase-2 (MMP-2) is a specific type of enzyme involved in the breakdown of extracellular matrix proteins.</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b,d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="PAH">
      <data key="d0">DISEASE</data>
      <data key="d1">Pulmonary arterial hypertension (PAH) is a disease characterized by severe pulmonary hypertension and fibrosis. It is also recognized as a vascular complication associated with systemic sclerosis.</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3,44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="DIGITAL ULCERS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Digital ulcers are sores that occur on the fingers or toes, often associated with systemic sclerosis (SSc). They are a clinical manifestation observed in SSc, highlighting their relevance in the context of this autoimmune disease.</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b,855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="PERIPHERAL MICROANGIOPATHY">
      <data key="d0">DISEASE</data>
      <data key="d1">Peripheral microangiopathy is a condition involving small blood vessel damage, often assessed by nailfold videocapillaroscopy</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="IMATINIB MESYLATE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Imatinib Mesylate is a drug used in the treatment of certain cancers and has shown clinical improvement in systemic sclerosis</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="DNAM-1">
      <data key="d0">PROTEIN</data>
      <data key="d1">DNAM-1, also known as CD226 or DNAX accessory molecule 1, is a gene that encodes a protein involved in immune cell signaling. This protein plays a crucial role in the modulation of immune responses. Specifically, DNAM-1 acts as a regulator of adhesion and costimulation of T cells, thereby influencing the overall immune response.</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b,4d0e8ae9371a435885994b4161126bc3,9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="CD226">
      <data key="d0">GENE</data>
      <data key="d1">CD226 encodes DNAM-1 and is associated with genetic susceptibility to systemic sclerosis</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="PD-1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Programmed cell death protein 1 (PD-1) is an inhibitory molecule that plays a crucial role in regulating T cell tolerance and overall immune responses. As an immune checkpoint protein, PD-1 is essential in maintaining immune homeostasis and preventing autoimmunity. It is also a significant target for immunotherapeutic agents, such as pembrolizumab, which are designed to modulate immune responses in various diseases, including cancer.</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b,855c455b4c9592746834ee3a4e0e6b81,9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="PD-L1">
      <data key="d0">PROTEIN</data>
      <data key="d1">PD-L1, also known as Programmed cell death ligand 1, is a protein that binds to PD-1 and plays a crucial role in immune regulation. It functions as a ligand of PD-1, antagonizing T cell responses. This interaction is significant in the context of immune system modulation, particularly in the regulation of immune responses.</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b,9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="SCTLA-4">
      <data key="d0">PROTEIN</data>
      <data key="d1">Soluble CTLA-4 (sCTLA-4) is a form of CTLA-4 found in the serum, which is associated with disease severity in systemic sclerosis. sCTLA-4 may inhibit early T-cell activation by blocking the interaction between CD80/CD86 and CD28. This inhibition can play a significant role in the modulation of immune responses, potentially impacting the progression and severity of autoimmune diseases such as systemic sclerosis.</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b,9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="CD40L">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="CD80/86">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD80 and CD86 are proteins that bind to CTLA-4 and CD28, involved in T cell activation</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="NAILFOLD VIDEOCAPILLAROSCOPY">
      <data key="d0">TISSUE</data>
      <data key="d1">Nailfold videocapillaroscopy is a technique used to assess peripheral microangiopathy</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="MEMORY B CELL">
      <data key="d0">CELL</data>
      <data key="d1">Memory B cells are a type of B cell that retains information about pathogens for faster response upon re-exposure</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="GERMINAL CENTER">
      <data key="d0">TISSUE</data>
      <data key="d1">Germinal centers are sites within lymph nodes where mature B cells proliferate, differentiate, and mutate their antibody genes</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="EPIGENETIC MODIFICATIONS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Epigenetic modifications are changes in gene expression without altering the DNA sequence, such as demethylation of regulatory elements</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="SOLUBLE CD40L">
      <data key="d0">PROTEIN</data>
      <data key="d1">Soluble CD40L is a form of CD40L found in the serum, associated with vascular complications in systemic sclerosis</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="MULTIANALYTE SIGNATURE">
      <data key="d0">PATHWAY</data>
      <data key="d1">A multianalyte signature is a combination of multiple biomarkers used to predict clinical outcomes</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="IMMUNE CHECKPOINT INHIBITORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Immune checkpoint inhibitors are drugs that block proteins like PD-1 and CTLA-4 to boost the immune response against cancer</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="IMMUNE-RELATED ADVERSE EVENTS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Immune-related adverse events are side effects that occur when immune checkpoint inhibitors cause the immune system to attack normal tissues</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="NEOPLASTIC CONDITIONS">
      <data key="d0">DISEASE</data>
      <data key="d1">Neoplastic conditions are diseases that involve the growth of abnormal tissue, such as cancer</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="IMMUNE CHECKPOINT">
      <data key="d0">PROTEIN</data>
      <data key="d1">Immune checkpoints are proteins that regulate the immune response to maintain self-tolerance and prevent autoimmunity</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="ADHESION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Adhesion is the process by which cells interact and attach to neighboring cells through specialized molecules on their surface</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="COSTIMULATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Costimulation is a secondary signal that immune cells require to fully activate and respond to pathogens</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="T CELL PROLIFERATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">T cell proliferation is the process of T cells rapidly dividing and increasing in number in response to an antigen</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="T CELL ACTIVATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">T cell activation is the process by which T cells are primed to respond to pathogens</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="DISEASE SEVERITY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Disease severity refers to the extent and seriousness of a disease's impact on the body</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="DISEASE ACTIVITY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Disease activity refers to the current level of disease manifestation and progression</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="GENETIC SUSCEPTIBILITY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Genetic susceptibility refers to the increased likelihood of developing a disease due to genetic factors</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="IMMUNOLOGIC HOMEOSTASIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immunologic homeostasis is the balance of immune responses to maintain health and prevent autoimmunity</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="IMMUNE CHECKPOINT BLOCKADE THERAPY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune checkpoint blockade therapy is a treatment that inhibits immune checkpoints to enhance the immune response against cancer</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="T CELL INHIBITORY MOLECULE">
      <data key="d0">PROTEIN</data>
      <data key="d1">T cell inhibitory molecules are proteins that downregulate T cell activity to prevent overactivation</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="SERUM SOLUBLE CTLA-4">
      <data key="d0">PROTEIN</data>
      <data key="d1">Serum soluble CTLA-4 is a form of CTLA-4 found in the serum, associated with disease severity in systemic sclerosis</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="META-ANALYSIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Meta-analysis is a statistical analysis that combines the results of multiple scientific studies</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="PUBLISHED DATA">
      <data key="d0">PATHWAY</data>
      <data key="d1">Published data refers to information that has been made publicly available through scientific publications</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="M2 MACROPHAGES">
      <data key="d0">CELL</data>
      <data key="d1">M2 macrophages are a profibrotic phenotype of macrophages that may perpetuate systemic sclerosis. These profibrotic type 2 macrophages are induced by T helper cell cytokines.</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81,9867d43adab0ba5db44961fae4863eee</data>
      <data key="d3">CELL</data>
    </node>
    <node id="PD-L2">
      <data key="d0">PROTEIN</data>
      <data key="d1">PD-L2 is a ligand of PD-1 that antagonizes T cell responses</data>
      <data key="d2">9867d43adab0ba5db44961fae4863eee</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="BLEOMYCIN MOUSE MODEL">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The Bleomycin mouse model is used to study dermal fibrosis and the effects of OX40L signaling. This model is instrumental in understanding the mechanisms underlying dermal fibrosis, providing insights into potential therapeutic targets and interventions.</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3,9867d43adab0ba5db44961fae4863eee</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="INTERSTITIAL LUNG DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Interstitial Lung Disease is a group of lung disorders that primarily affect the interstitium, the tissue and space around the air sacs of the lungs. These disorders are characterized by progressive scarring, or fibrosis, of lung tissue, which can lead to significant respiratory issues and impaired lung function.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,7f559ad7372a4e35e90b43cc67047b0f,9867d43adab0ba5db44961fae4863eee</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="FRA-2 TRANSGENIC MOUSE MODEL">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The Fra-2 transgenic mouse model is used to study inflammatory infiltrates and vasculopathy</data>
      <data key="d2">9867d43adab0ba5db44961fae4863eee</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="CGVHD">
      <data key="d0">DISEASE</data>
      <data key="d1">Chronic graft-vs.-host disease is a condition that occurs after a stem cell or bone marrow transplant</data>
      <data key="d2">9867d43adab0ba5db44961fae4863eee</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="LIVER">
      <data key="d0">TISSUE</data>
      <data key="d1">The liver is an organ involved in metabolism, detoxification, and protein synthesis. It plays a crucial role in various metabolic processes and is essential for detoxifying harmful substances. Additionally, the liver is a tissue where TL1A has been implicated in fibrosis and is one of the organs affected by fibrotic diseases, including liver cirrhosis.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,080b1dc5fcc0eee3645a06983a0de603,68015074236b0144899baa38d01ae467,7c13f41d7349d9d2e56c36e00c0ca2d9,9867d43adab0ba5db44961fae4863eee,a10787d7fbb1307be263e86dc7b33a51,b2aae16813e647959b783a39ef9a19a7,c525762bb827485bceeb9f09bb4bcfe0</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="COLON">
      <data key="d0">TISSUE</data>
      <data key="d1">The colon is part of the large intestine involved in water absorption and feces formation</data>
      <data key="d2">9867d43adab0ba5db44961fae4863eee</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="RODNAN SKIN SCORE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">The Rodnan skin score is a measure of skin thickness used in systemic sclerosis</data>
      <data key="d2">9867d43adab0ba5db44961fae4863eee</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="EUSTAR">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">EUSTAR, or the European League Against Rheumatism Scleroderma Trials and Research group, is a cohort specifically utilized for studying systemic sclerosis (SSc). This group is instrumental in advancing research and understanding of SSc, providing valuable data and insights into the disease.</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81,9867d43adab0ba5db44961fae4863eee</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="MONOCYTE">
      <data key="d0">CELL</data>
      <data key="d1">Monocytes are a type of white blood cell that can differentiate into macrophages and dendritic cells</data>
      <data key="d2">9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="PROINFLAMMATORY CYTOKINES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Proinflammatory cytokines are signaling molecules that promote inflammation</data>
      <data key="d2">05c97152fe02249153103be341d65b67,9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="PROFIBROTIC CYTOKINES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Profibrotic cytokines are signaling molecules that promote fibrosis</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e,9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="TIGHT SKIN-1 MOUSE MODEL">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The Tight skin-1 mouse model is used to study non-inflammatory dermal fibrosis</data>
      <data key="d2">9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="GASTROINTESTINAL INVOLVEMENT">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Gastrointestinal involvement refers to the impact of a disease on the digestive system</data>
      <data key="d2">9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="CARDIAC HEMODYNAMIC IMPAIRMENT">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Cardiac hemodynamic impairment refers to the dysfunction of blood flow dynamics in the heart</data>
      <data key="d2">9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="FIBROGENIC MARKERS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Fibrogenic markers are indicators of fibrosis in tissues</data>
      <data key="d2">9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="T-CELL PROLIFERATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">T-cell proliferation refers to the rapid increase in the number of T cells</data>
      <data key="d2">9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="M1 MACROPHAGES">
      <data key="d0">CELL</data>
      <data key="d1">M1 macrophages are a proinflammatory phenotype of macrophages</data>
      <data key="d2">9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="MRSS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">The Modified Rodnan Skin Score (MRSS) is a measure used to assess skin fibrosis in patients with systemic sclerosis (SSc). It evaluates skin thickness, providing a quantifiable method to monitor the extent and progression of skin involvement in SSc patients.</data>
      <data key="d2">4d0e8ae9371a435885994b4161126bc3,855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="PEMBROLIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Pembrolizumab is a PD-1 inhibitor approved for the treatment of advanced melanoma, selected lymphomas, and advanced non-small cell lung cancer</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="NON-SMALL CELL LUNG CANCER">
      <data key="d0">DISEASE</data>
      <data key="d1">A type of lung cancer treated with pembrolizumab</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="CYCLOPHOSPHAMIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cyclophosphamide is a standard therapy drug used in the treatment of SSc</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="MHC">
      <data key="d0">PROTEIN</data>
      <data key="d1">Major histocompatibility complex, involved in presenting peptide antigens to T cells</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="DNAM">
      <data key="d0">PROTEIN</data>
      <data key="d1">DNAX accessory molecule, involved in positive costimulatory pathways</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="CD112">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD112, also known as Nectin-2, is a protein involved in immune response modulation. It plays a crucial role in positive costimulatory pathways, contributing to the regulation and enhancement of immune responses.</data>
      <data key="d2">4d0e8ae9371a435885994b4161126bc3,855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="CD115">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD115 is involved in positive costimulatory pathways</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="PDL1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Programmed death-ligand 1, involved in negative costimulatory pathways</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="PDL2">
      <data key="d0">PROTEIN</data>
      <data key="d1">Programmed death-ligand 2, involved in negative costimulatory pathways</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="IFN&#915;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interferon gamma, a cytokine involved in T helper cell responses</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="TREG">
      <data key="d0">CELL</data>
      <data key="d1">Regulatory T cells, promoting M2 macrophage polarization and activation</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81</data>
      <data key="d3">CELL</data>
    </node>
    <node id="TGF&#914;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Transforming growth factor-beta (TGF&#946;) is a cytokine that plays a crucial role in cell growth, proliferation, differentiation, and fibrosis. It is a central fibrogenic cytokine involved in the pathogenesis of fibrosis and is also implicated in the pathogenesis of eosinophilic esophagitis (EoE). TGF&#946; is secreted by regulatory T cells (Treg cells) to promote M2 macrophage activation. Additionally, the mRNA expression of TGF&#946; is reduced by TAPI-1 treatment.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,080b1dc5fcc0eee3645a06983a0de603,5ec1ebf4e260eb1f8fda8acdf06cd39e,5f37466ca41c9b8b06ed8be0303d49f2,855c455b4c9592746834ee3a4e0e6b81,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="MMPS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Metalloproteinases, stimulating antigen-presenting cells to upregulate positive costimulatory molecules</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="APCS">
      <data key="d0">CELL</data>
      <data key="d1">Antigen-presenting cells, upregulated by MMPs to express positive costimulatory molecules</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81</data>
      <data key="d3">CELL</data>
    </node>
    <node id="JOINT">
      <data key="d0">TISSUE</data>
      <data key="d1">Joints are affected by inflammatory involvement in SSc</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="NVC PATTERN">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Nailfold videocapillaroscopy pattern, used to assess microvascular changes in SSc</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="ILD">
      <data key="d0">DISEASE</data>
      <data key="d1">Interstitial lung disease (ILD) is a group of lung disorders affecting the interstitium, the tissue and space around the air sacs of the lungs. ILD is characterized by causing scarring of lung tissue, which can lead to significant respiratory issues. This condition is also associated with systemic sclerosis (SSc), highlighting its relevance in autoimmune disease research.</data>
      <data key="d2">4d0e8ae9371a435885994b4161126bc3,855c455b4c9592746834ee3a4e0e6b81,b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="CD155">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD155 is a protein involved in immune response modulation, also known as PVR</data>
      <data key="d2">4d0e8ae9371a435885994b4161126bc3</data>
    </node>
    <node id="DERMAL FIBROSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Dermal fibrosis is a type of fibrosis affecting the skin, characterized by excessive scarring. It is associated with OX40-OX40L signaling, which plays a significant role in its pathogenesis.</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3,4d0e8ae9371a435885994b4161126bc3</data>
    </node>
    <node id="PD1-L">
      <data key="d0">PROTEIN</data>
      <data key="d1">PD1-L is a ligand for PD1, involved in immune response regulation</data>
      <data key="d2">4d0e8ae9371a435885994b4161126bc3</data>
    </node>
    <node id="PH">
      <data key="d0">DISEASE</data>
      <data key="d1">Pulmonary hypertension is a condition characterized by high blood pressure in the lungs</data>
      <data key="d2">4d0e8ae9371a435885994b4161126bc3</data>
    </node>
    <node id="NVC">
      <data key="d0">PATHWAY</data>
      <data key="d1">Nailfold vascular capillaroscopy is a diagnostic technique used to examine capillaries</data>
      <data key="d2">4d0e8ae9371a435885994b4161126bc3</data>
    </node>
    <node id="AUTOIMMUNITY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Autoimmunity is a condition in which the immune system attacks the body's own tissues.</data>
      <data key="d2">4d0e8ae9371a435885994b4161126bc3,8ce8c356713490cd2c680f505bcd050b</data>
    </node>
    <node id="ANIMAL MODELS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Animal models are used in research to study disease mechanisms and test treatments</data>
      <data key="d2">4d0e8ae9371a435885994b4161126bc3</data>
    </node>
    <node id="RS1234314">
      <data key="d0">SNP</data>
      <data key="d1">Single nucleotide polymorphism rs1234314 in the TNFSF4 gene region is associated with systemic sclerosis susceptibility. This polymorphism, located within the TNFSF4 gene, has been consistently linked to an increased risk of developing systemic sclerosis.</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,40ad2241836485e0bf264bdfb62fd789,c69c7fb997f95c56cc077b3975f41923,d8a485eb1e9435b083d5ef6a17f06ea5,f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">SNP</data>
    </node>
    <node id="RS2205960">
      <data key="d0">SNP</data>
      <data key="d1">RS2205960 is a single nucleotide polymorphism (SNP) located in the TNFSF4 gene region. This SNP, rs2205960, is associated with systemic sclerosis susceptibility, indicating a potential genetic link to the disease. Research has consistently shown that rs2205960 in the TNFSF4 gene is linked to systemic sclerosis, highlighting its significance in the context of this autoimmune condition.</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,40ad2241836485e0bf264bdfb62fd789,8ce8c356713490cd2c680f505bcd050b,c69c7fb997f95c56cc077b3975f41923,d8a485eb1e9435b083d5ef6a17f06ea5,f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">SNP</data>
    </node>
    <node id="RS844648">
      <data key="d0">SNP</data>
      <data key="d1">RS844648 is a single nucleotide polymorphism (SNP) located in the TNFSF4 gene region. This SNP, rs844648, has been associated with susceptibility to systemic sclerosis, a chronic autoimmune disease characterized by fibrosis of the skin and internal organs.</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,40ad2241836485e0bf264bdfb62fd789,c69c7fb997f95c56cc077b3975f41923,d8a485eb1e9435b083d5ef6a17f06ea5,f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">SNP</data>
    </node>
    <node id="RS844644">
      <data key="d0">SNP</data>
      <data key="d1">RS844644 is a single nucleotide polymorphism (SNP) located in the TNFSF4 gene region. This SNP has been studied in the context of systemic sclerosis, a chronic autoimmune disease. Research indicates that rs844644 is associated with systemic sclerosis, and it has been identified as having a protective effect against the disease.</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,40ad2241836485e0bf264bdfb62fd789,c69c7fb997f95c56cc077b3975f41923,d8a485eb1e9435b083d5ef6a17f06ea5,f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">SNP</data>
    </node>
    <node id="PTPN22">
      <data key="d0">GENE</data>
      <data key="d1">PTPN22 is a gene associated with autoimmune diseases. It is specifically linked to the development of multiple autoimmune conditions, including type I diabetes mellitus, rheumatoid arthritis, and systemic lupus erythematosus.</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">GENE</data>
    </node>
    <node id="TIDM">
      <data key="d0">DISEASE</data>
      <data key="d1">Type I diabetes mellitus, an autoimmune disease</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="STAT4">
      <data key="d0">GENE</data>
      <data key="d1">STAT4 is a gene involved in the signaling pathways of the immune system. It is also identified as a susceptibility gene for the development of systemic lupus erythematosus and rheumatoid arthritis.</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">GENE</data>
    </node>
    <node id="IRF5">
      <data key="d0">GENE</data>
      <data key="d1">IRF5 is a gene involved in the regulation of the immune response. Polymorphisms in IRF5 have been linked to systemic lupus erythematosus and systemic sclerosis, indicating its significant role in the pathogenesis of these autoimmune diseases.</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">GENE</data>
    </node>
    <node id="FAS">
      <data key="d0">GENE</data>
      <data key="d1">FAS is a gene involved in the regulation of programmed cell death. It is also associated with polymorphisms linked to systemic lupus erythematosus and systemic sclerosis.</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">GENE</data>
    </node>
    <node id="CREST">
      <data key="d0">SYMPTOM</data>
      <data key="d1">CREST syndrome includes Calcinosis, Raynaud&#8217;s phenomenon, Esophageal dysfunction, Sclerodactyly, and Telangiectasias</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="CALCINOSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Calcinosis is the formation of calcium deposits in the skin</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="RAYNAUD&#8217;S PHENOMENON">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Raynaud&#8217;s phenomenon is a condition where blood flow to extremities is reduced, often in response to cold or stress</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="ESOPHAGEAL DYSFUNCTION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Esophageal dysfunction involves problems with the esophagus, such as difficulty swallowing</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="SCLERODACTYLY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Sclerodactyly is the thickening and tightening of the skin on the fingers and hands</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="TELANGIECTASIAS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Telangiectasias are small, widened blood vessels on the skin</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="MYOSITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Myositis is an inflammatory disease characterized by inflammation of the muscles, leading to muscle weakness.</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="SJOGREN'S SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Sjogren's syndrome is an autoimmune disease characterized by dry eyes and dry mouth. It affects moisture-producing glands, leading to a significant reduction in the production of tears and saliva.</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="NORTH AMERICAN CAUCASIAN">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">North American Caucasian refers to the population group involved in the study</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="GENISOS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">GENISOS stands for Genetics versus Environment in Scleroderma Outcomes Study</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="AMERICAN COLLEGE OF RHEUMATOLOGY">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">American College of Rheumatology is an organization that provides criteria for disease classification</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="SCLERODERMA FAMILY REGISTRY AND DNA REPOSITORY">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Scleroderma Family Registry and DNA Repository is a resource for genetic and clinical data on scleroderma</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="UNIVERSITY OF TEXAS RHEUMATOLOGY DIVISION">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">University of Texas Rheumatology Division is an institution involved in the study</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="PERIPHERAL BLOOD CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Peripheral blood cells are blood cells circulating in the bloodstream</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14</data>
      <data key="d3">CELL</data>
    </node>
    <node id="TYPE I INTERFERON">
      <data key="d0">PROTEIN</data>
      <data key="d1">Type I interferon is a group of cytokines involved in the regulation of the immune response. These proteins play a crucial role in the immune system by mediating antiviral activities and modulating the function of various immune cells.</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="ANTINUCLEAR ANTIBODIES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Antinuclear antibodies are autoantibodies that bind to contents of the cell nucleus. These antibodies are detected using indirect immunofluorescence.</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="VASCULOPATHY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Vasculopathy is a disease affecting blood vessels</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="HEP-2 CELLS">
      <data key="d0">CELL</data>
      <data key="d1">HEp-2 cells, used as an antigen substrate in immunofluorescence assays</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="ANTI-CENTROMERE ANTIBODIES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Autoantibodies identified by their distinctive IIF pattern on HEp-2 cellsAnti-centromere antibodies, identified by their distinctive IIF pattern</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="TOPOISOMERASE I">
      <data key="d0">PROTEIN</data>
      <data key="d1">Topoisomerase I, targeted by autoantibodies in passive immunodiffusion</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="ANTI-RNA POLYMERASE III ANTIBODIES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Autoantibodies detected by enzyme-linked immunoassayAnti-RNA polymerase III antibodies, detected by enzyme-linked immunoassay</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="RS1234315">
      <data key="d0">SNP</data>
      <data key="d1">Single nucleotide polymorphism rs1234315 in the TNFSF4 gene region</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="RS12039904">
      <data key="d0">SNP</data>
      <data key="d1">Single nucleotide polymorphism rs12039904 in the TNFSF4 gene region</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="RS2795288">
      <data key="d0">SNP</data>
      <data key="d1">Single nucleotide polymorphism rs2795288 in the TNFSF4 gene region</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="RS844665">
      <data key="d0">SNP</data>
      <data key="d1">RS844665 is a single nucleotide polymorphism (SNP) located in the TNFSF4 gene region. Research on this SNP has produced mixed results regarding its association with systemic sclerosis. Some studies suggest that rs844665 is associated with systemic sclerosis, while other studies indicate that there is no significant association between rs844665 and the disease. Further research is needed to clarify the role of rs844665 in systemic sclerosis.</data>
      <data key="d2">c69c7fb997f95c56cc077b3975f41923,d8a485eb1e9435b083d5ef6a17f06ea5,f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="RS10912580">
      <data key="d0">SNP</data>
      <data key="d1">Single nucleotide polymorphism rs10912580 in the TNFSF4 gene region</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="PERIPHERAL BLOOD">
      <data key="d0">TISSUE</data>
      <data key="d1">Blood from which genomic DNA was extracted for SNP genotypingPeripheral blood, used for genomic DNA extraction</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="GENOMIC DNA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Genomic DNA, extracted from peripheral blood for SNP genotyping</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="CAUCASIAN">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Caucasian refers to a population group used in genetic studies. This population group is also utilized in candidate gene association studies.</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b,f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="HAPMAP">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Resource used for allele call validationHapMap, a resource used for allele call validation</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="CEPH">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Centre d&#8217;Etude du Polymorphisme Humain, used as positive controls in genotyping assays</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="HWE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Hardy&#8211;Weinberg equilibrium, a principle used in genetic studies</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="LD">
      <data key="d0">PATHWAY</data>
      <data key="d1">Linkage disequilibrium, a measure of association between genetic variants</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="OMNIBUS TEST">
      <data key="d0">PATHWAY</data>
      <data key="d1">Omnibus test, used to detect differences in haplotype frequency profiles</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="CART">
      <data key="d0">PATHWAY</data>
      <data key="d1">CART (Classification and Regression Tree) analysis is a statistical method used to explore the relationship between variables. It is particularly useful for examining interactions between single nucleotide polymorphisms (SNPs).</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b,f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="ACR">
      <data key="d0">PATHWAY</data>
      <data key="d1">American College of Rheumatology criteria, used for diagnosing SLE</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="ANTI-TOPOISOMERASE I ANTIBODIES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Autoantibodies targeting topoisomerase I, detected by passive immunodiffusion</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="PUREGENE GENOMIC DNA ISOLATION KIT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Kit used for extracting genomic DNA from peripheral blood</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="ABI TAQMAN SNP GENOTYPING ASSAY">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Assay used for genotyping SNPs</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="ABI 7900HT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Real-time thermocycler used for plate reading in SNP genotyping</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="SAS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Software used for statistical analysis</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="HAPLOVIEW">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Software used for determining linkage disequilibrium</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="SALFORD SYSTEMS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Software used for classification and regression tree analysis</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="LSSC">
      <data key="d0">DISEASE</data>
      <data key="d1">Limited systemic sclerosis (LSSC) is a subset of systemic sclerosis characterized by limited cutaneous involvement.</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b,c69c7fb997f95c56cc077b3975f41923</data>
    </node>
    <node id="DSSC">
      <data key="d0">DISEASE</data>
      <data key="d1">Diffuse systemic sclerosis (DSSC) is a subset of systemic sclerosis characterized by extensive cutaneous involvement.</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b,c69c7fb997f95c56cc077b3975f41923</data>
    </node>
    <node id="ACA">
      <data key="d0">PROTEIN</data>
      <data key="d1">Anticentromere antibodies, associated with a subset of systemic sclerosis</data>
      <data key="d2">c69c7fb997f95c56cc077b3975f41923</data>
    </node>
    <node id="ATA">
      <data key="d0">PROTEIN</data>
      <data key="d1">Anti-topoisomerase antibodies, associated with a subset of systemic sclerosis</data>
      <data key="d2">c69c7fb997f95c56cc077b3975f41923</data>
    </node>
    <node id="ARA">
      <data key="d0">PROTEIN</data>
      <data key="d1">Anti-RNA polymerase III antibodies, associated with a subset of systemic sclerosis</data>
      <data key="d2">c69c7fb997f95c56cc077b3975f41923</data>
    </node>
    <node id="PULMONARY FIBROSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Pulmonary Fibrosis is a lung disease that occurs when lung tissue becomes damaged and scarred. It is characterized by the thickening and scarring of lung tissue, leading to compromised respiratory function. Pulmonary fibrosis is a type of lung fibrosis and is often studied using bleomycin-induced mouse models to better understand its pathophysiology and potential treatments.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,5ec1ebf4e260eb1f8fda8acdf06cd39e,7c13f41d7349d9d2e56c36e00c0ca2d9,7f559ad7372a4e35e90b43cc67047b0f,c69c7fb997f95c56cc077b3975f41923</data>
    </node>
    <node id="RS855648">
      <data key="d0">SNP</data>
      <data key="d1">Single nucleotide polymorphism rs855648 of the TNFSF4 gene is associated with systemic sclerosis</data>
      <data key="d2">c69c7fb997f95c56cc077b3975f41923,d8a485eb1e9435b083d5ef6a17f06ea5</data>
    </node>
    <node id="ANTI-CENTROMERE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Anti-centromere antibodies are associated with systemic sclerosis. These antibodies target centromere proteins and are commonly found in patients with this autoimmune disease.</data>
      <data key="d2">40ad2241836485e0bf264bdfb62fd789,d8a485eb1e9435b083d5ef6a17f06ea5</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="ANTI-TOPOISOMERASE I">
      <data key="d0">PROTEIN</data>
      <data key="d1">Anti-topoisomerase I antibodies are associated with systemic sclerosis. These antibodies, which target topoisomerase I, are a significant marker in the diagnosis and understanding of systemic sclerosis.</data>
      <data key="d2">40ad2241836485e0bf264bdfb62fd789,d8a485eb1e9435b083d5ef6a17f06ea5</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="ANTI-RNA POLYMERASE III">
      <data key="d0">PROTEIN</data>
      <data key="d1">Anti-RNA polymerase III antibodies are associated with systemic sclerosis. These antibodies, specifically targeting RNA polymerase III, are a notable marker in the diagnosis and understanding of systemic sclerosis.</data>
      <data key="d2">40ad2241836485e0bf264bdfb62fd789,d8a485eb1e9435b083d5ef6a17f06ea5</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="LIMITED SYSTEMIC SCLEROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">A subtype of systemic sclerosis characterized by limited skin involvement</data>
      <data key="d2">40ad2241836485e0bf264bdfb62fd789</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="DIFFUSE SYSTEMIC SCLEROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">A subtype of systemic sclerosis characterized by widespread skin involvement</data>
      <data key="d2">40ad2241836485e0bf264bdfb62fd789</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="SNP">
      <data key="d0">SNP</data>
      <data key="d1">Single nucleotide polymorphism, a variation in a single nucleotide that occurs at a specific position in the genome</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
    </node>
    <node id="RS944648">
      <data key="d0">SNP</data>
      <data key="d1">Single nucleotide polymorphism rs944648 of the TNFSF4 gene is associated with systemic sclerosis</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
    </node>
    <node id="NK CELL">
      <data key="d0">CELL</data>
      <data key="d1">Natural killer cells are a type of lymphocyte that can kill tumor cells and virus-infected cells</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
    </node>
    <node id="ENDOTHELIAL CELL">
      <data key="d0">CELL</data>
      <data key="d1">Endothelial cells form the lining of blood vessels and play a role in vascular biology</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">CELL</data>
    </node>
    <node id="SMOOTH MUSCLE CELL">
      <data key="d0">CELL</data>
      <data key="d1">Smooth muscle cells are found in the walls of hollow organs and are involved in involuntary movements</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">CELL</data>
    </node>
    <node id="FOXP3+ REGULATORY T CELL">
      <data key="d0">CELL</data>
      <data key="d1">Foxp3+ regulatory T cells are a subset of T cells involved in maintaining immune tolerance</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">CELL</data>
    </node>
    <node id="C57/BL6">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">C57/BL6 is a common inbred strain of laboratory mouse</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="NON-OBESE DIABETIC MOUSE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Non-obese diabetic mouse is a model organism used to study autoimmune diabetes</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Experimental autoimmune encephalomyelitis is a model for multiple sclerosis</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="MHC CLASS II">
      <data key="d0">GENE</data>
      <data key="d1">Major histocompatibility complex class II is a gene involved in the immune response</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">GENE</data>
    </node>
    <node id="AIF1">
      <data key="d0">GENE</data>
      <data key="d1">AIF1 is a gene associated with immune response regulation</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">GENE</data>
    </node>
    <node id="AUTOANTIBODY">
      <data key="d0">PROTEIN</data>
      <data key="d1">Autoantibodies are antibodies that mistakenly target and react with a person's own tissues</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="GENE&#8211;GENE INTERACTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Gene&#8211;gene interaction refers to the interaction between different genes that can affect the development of diseases</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="GENE&#8211;ENVIRONMENT INTERACTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Gene&#8211;environment interaction refers to the interaction between genetic predisposition and environmental factors in the development of diseases</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="BENJAMINI AND HOCHBERG METHOD">
      <data key="d0">PATHWAY</data>
      <data key="d1">Benjamini and Hochberg method is a statistical method used to control the false discovery rate in multiple hypothesis testing</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="&#935;2">
      <data key="d0">PATHWAY</data>
      <data key="d1">Chi-squared test is a statistical test used to determine if there is a significant association between two categorical variables</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="LOGISTIC REGRESSION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Logistic regression is a statistical method used to model the relationship between a dependent variable and one or more independent variables</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="D&#8217;">
      <data key="d0">PATHWAY</data>
      <data key="d1">Disequilibrium coefficient D&#8217; is a measure of linkage disequilibrium between genetic markers</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="R">
      <data key="d0">PATHWAY</data>
      <data key="d1">Correlation coefficient r is a measure of the strength and direction of the relationship between two variables</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="HAPLOTYPE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Haplotype is a group of genes within an organism that was inherited together from a single parent</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="LINKAGE DISEQUILIBRIUM">
      <data key="d0">PATHWAY</data>
      <data key="d1">Linkage disequilibrium is the non-random association of alleles at different loci in a given population</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="HAPLOTYPE BLOCK">
      <data key="d0">PATHWAY</data>
      <data key="d1">Haplotype block is a region of the genome where genetic variations are inherited together</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PFDR">
      <data key="d0">PATHWAY</data>
      <data key="d1">Corrected p values using Benjamini and Hochberg false discovery rate method</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
    </node>
    <node id="PU">
      <data key="d0">PATHWAY</data>
      <data key="d1">Raw &#967;2 p values</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
    </node>
    <node id="DIABETES">
      <data key="d0">DISEASE</data>
      <data key="d1">Diabetes is a disease characterized by high blood sugar levels</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
    </node>
    <node id="GENDER">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Gender is a demographic variable often controlled for in genetic studies</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
    </node>
    <node id="NORTH AMERICAN">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">North American refers to a population group used in genetic studies</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
    </node>
    <node id="CAUCASIAN WOMEN">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Caucasian women refers to a specific demographic group used in genetic studies</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
    </node>
    <node id="SNPS">
      <data key="d0">SNP</data>
      <data key="d1">Single nucleotide polymorphisms within the promoter region of the TNFSF4 gene, associated with SSc susceptibility</data>
      <data key="d2">7b454335c2f5651d86f712037a0dc0ff</data>
    </node>
    <node id="UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON MEDICAL SCHOOL IRB">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The institutional review board that approved the study</data>
      <data key="d2">7b454335c2f5651d86f712037a0dc0ff</data>
    </node>
    <node id="ODDS RATIOS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Odds ratios are statistical measures used to determine the strength of association between two events</data>
      <data key="d2">7b454335c2f5651d86f712037a0dc0ff</data>
    </node>
    <node id="GENOTYPING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Genotyping is a process used to determine differences in the genetic make-up or genotype of an individual by examining their DNA sequence</data>
      <data key="d2">7b454335c2f5651d86f712037a0dc0ff</data>
    </node>
    <node id="DNA SEQUENCING">
      <data key="d0">PATHWAY</data>
      <data key="d1">DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule</data>
      <data key="d2">7b454335c2f5651d86f712037a0dc0ff</data>
    </node>
    <node id="PROMOTER REGION">
      <data key="d0">TISSUE</data>
      <data key="d1">The promoter region is a sequence of DNA needed to turn a gene on or off</data>
      <data key="d2">7b454335c2f5651d86f712037a0dc0ff</data>
    </node>
    <node id="GENETIC STRUCTURE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Genetic structure refers to the organization of and interaction between genes within a genome</data>
      <data key="d2">7b454335c2f5651d86f712037a0dc0ff</data>
    </node>
    <node id="LUNGS">
      <data key="d0">TISSUE</data>
      <data key="d1">The lungs are respiratory organs that play a crucial role in the exchange of oxygen and carbon dioxide. They are visceral organs that can be affected by a variety of fibrotic diseases, including pulmonary fibrosis. Additionally, the lungs are one of the organs impacted by systemic sclerosis, a condition that can lead to significant fibrotic changes within the lung tissue.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,5ec1ebf4e260eb1f8fda8acdf06cd39e,68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="HEART">
      <data key="d0">TISSUE</data>
      <data key="d1">The heart is a muscular organ responsible for pumping blood throughout the body. It is one of the visceral organs that can be affected by fibrotic diseases, including systemic sclerosis. Fibrosis can impact the heart's function, leading to complications in its ability to effectively circulate blood.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,5ec1ebf4e260eb1f8fda8acdf06cd39e,68015074236b0144899baa38d01ae467,a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="KIDNEY">
      <data key="d0">TISSUE</data>
      <data key="d1">The kidney is an organ involved in filtering blood, removing waste, and regulating fluid balance. Additionally, the kidney is one of the organs affected by fibrosis.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,080b1dc5fcc0eee3645a06983a0de603</data>
    </node>
    <node id="MYOFIBROBLASTS">
      <data key="d0">CELL</data>
      <data key="d1">Myofibroblasts are specialized, differentiated fibroblasts that play a crucial role in wound healing and fibrosis. These cells are responsible for the deposition of collagen and extracellular matrix proteins, contributing to smooth muscle hypertrophy in fibrotic tissues. Myofibroblasts are induced by TL1A in the lung and express OX40L in fibrotic tissues. Their numbers can be reduced by TAPI-1 treatment, highlighting their potential as therapeutic targets in fibrotic diseases.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,080b1dc5fcc0eee3645a06983a0de603,1b656cfce91ff9ccec4223703489dab3,5ec1ebf4e260eb1f8fda8acdf06cd39e,c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="TNFR1">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNF receptor I (TNFR1), also known as TNFR&#945;, p55, CD120a, or TNFAR, is a receptor for tumor necrosis factor (TNF) that plays a crucial role in various cellular processes. TNFR1 is involved in cell survival and death responses, inflammation, fibrosis, and apoptosis. It has the ability to signal for the activation of NF-&#954;B, which promotes cell survival, while also having the potential to induce cell death responses.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,5ec1ebf4e260eb1f8fda8acdf06cd39e,a10787d7fbb1307be263e86dc7b33a51,c95d22c2a90e77cd22bd0d280d55b26a,df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="TNFR2">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNF receptor II (TNFR2), also known as TNFR&#946;, p75, CD120b, or TNFBR, is a receptor for tumor necrosis factor (TNF) that plays a crucial role in various cellular processes. TNFR2 is involved in cell survival responses and is key for mediating fibrotic development. It recruits TNFR-associated factor (TRAF) 1 and 2 proteins, which signal to induce NF-&#954;B activation, thereby promoting cell survival. Additionally, TNFR2 is integral to the regulation of immune responses.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,5ec1ebf4e260eb1f8fda8acdf06cd39e,a10787d7fbb1307be263e86dc7b33a51,c95d22c2a90e77cd22bd0d280d55b26a,df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="NK CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Natural killer (NK) cells, also known as NK cells, are a type of lymphocyte involved in the innate immune response. They are critical to the innate immune system and can express CD27 and TNF.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,1b656cfce91ff9ccec4223703489dab3,4cf23e218b6aab3c77115173b5c7c2fd,7c13f41d7349d9d2e56c36e00c0ca2d9,d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="IDIOPATHIC PULMONARY FIBROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Idiopathic Pulmonary Fibrosis (IPF) is a type of chronic lung disease characterized by a progressive and irreversible decline in lung function. It involves the fibrosis of lung tissue, leading to a gradual worsening of respiratory capabilities. As a chronic and progressive condition, IPF results in the scarring and thickening of the lung tissue, which impairs the lungs' ability to function effectively.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,5f37466ca41c9b8b06ed8be0303d49f2,7f559ad7372a4e35e90b43cc67047b0f,df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="ACUTE RESPIRATORY DISTRESS SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Acute respiratory distress syndrome (ARDS) is a severe lung condition characterized by the rapid onset of widespread inflammation in the lungs. It is also associated with lung fibrosis, which involves the thickening and scarring of lung tissue.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,5f37466ca41c9b8b06ed8be0303d49f2</data>
    </node>
    <node id="CYSTIC FIBROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Cystic fibrosis is a type of lung fibrosis</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603</data>
    </node>
    <node id="MYOCARDITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Myocarditis is inflammation of the heart muscle. It is also associated with heart fibrosis, which involves the thickening and scarring of connective tissue in the heart.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="ISCHEMIC MYOCARDIAL INFARCTION">
      <data key="d0">DISEASE</data>
      <data key="d1">Ischemic myocardial infarction is a type of heart fibrosis</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603</data>
    </node>
    <node id="NON-ISCHEMIC HYPERTROPHIC CARDIOMYOPATHY">
      <data key="d0">DISEASE</data>
      <data key="d1">Non-ischemic hypertrophic cardiomyopathy is a type of heart fibrosis</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603</data>
    </node>
    <node id="ATOPIC ECZEMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Atopic eczema is a type of skin fibrosis.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="DUPUYTREN&#8217;S DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Dupuytren&#8217;s disease is a condition that affects the hands and fingers, characterized by a type of skin fibrosis. This disease leads to the thickening and tightening of the tissue under the skin of the palm and fingers, which can result in the fingers being pulled into a bent position.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="ACUTE KIDNEY INJURY">
      <data key="d0">DISEASE</data>
      <data key="d1">Acute kidney injury (AKI) is a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. It is characterized by a rapid decline in kidney function, which can lead to the accumulation of waste products in the blood and an imbalance of fluids and electrolytes in the body. Although AKI can be associated with kidney fibrosis, it is primarily defined by its acute onset and the potential for rapid progression.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,5f37466ca41c9b8b06ed8be0303d49f2</data>
    </node>
    <node id="CHRONIC KIDNEY DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Chronic kidney disease is a type of kidney fibrosis</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603</data>
    </node>
    <node id="NON-ALCOHOLIC STEATOHEPATITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Non-alcoholic steatohepatitis is a type of liver fibrosis</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603</data>
    </node>
    <node id="NON-ALCOHOLIC FATTY LIVER DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Non-alcoholic fatty liver disease (NAFLD) is a condition characterized by the accumulation of excess fat in the liver that is not due to alcohol use. This buildup of fat in the liver can lead to liver fibrosis, a condition where the liver tissue becomes scarred.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,5f37466ca41c9b8b06ed8be0303d49f2,df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="PRIMARY BILIARY CHOLANGITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Primary biliary cholangitis is a chronic liver disease characterized by the progressive destruction of the bile ducts. This condition leads to liver fibrosis, as the ongoing damage to the bile ducts results in scarring and hardening of liver tissue over time.</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="FR1">
      <data key="d0">PROTEIN</data>
      <data key="d1">FR1 contains a death domain (DD) and can recruit TNFR1-associated DD (TRADD)</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="TRADD">
      <data key="d0">PROTEIN</data>
      <data key="d1">TRADD is recruited by FR1 and is involved in signaling pathways</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="TRAF1">
      <data key="d0">PROTEIN</data>
      <data key="d1">TRAF1 is recruited by TNFR2 and is involved in signaling pathways</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="TRAF2">
      <data key="d0">PROTEIN</data>
      <data key="d1">TRAF2 is recruited by TNFR2 and is involved in signaling pathways</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="CERTOLIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Certolizumab is a TNF antagonist used in the treatment of inflammatory diseases</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="SPONDYLARTHROPATHIES">
      <data key="d0">DISEASE</data>
      <data key="d1">Spondylarthropathies are inflammatory diseases treated with TNF antagonists</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="TACE">
      <data key="d0">PROTEIN</data>
      <data key="d1">TACE, also known as TNF-alpha-converting enzyme, is involved in the cleavage of membrane-bound TNF. It processes pro-TNF and its receptors, including soluble TNFR1.</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e,a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="TAPI-1">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Tumor necrosis factor-alpha processing inhibitor-1 (TAPI-1) is used to block TACE</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="COL1A1">
      <data key="d0">GENE</data>
      <data key="d1">COL1A1 is a gene encoding the collagen type I alpha 1 chain, which plays a crucial role in fibrosis. Additionally, the mRNA expression of COL1A1 is reduced by TAPI-1 treatment.</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e,a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="&#913;SMA">
      <data key="d0">PROTEIN</data>
      <data key="d1">Alpha smooth muscle actin (&#945;SMA) is a protein that plays a crucial role in the contractile function of myofibroblasts. It is widely used as a marker to measure fibrosis and myofibroblast differentiation. The expression of &#945;SMA is found on myofibroblasts, including those expressing OX40L in fibrotic skin. Additionally, &#945;SMA expression can be influenced by various treatments and conditions; for instance, its mRNA expression is reduced by TAPI-1 treatment and suppressed by TNF in human dermal fibroblasts.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,1b656cfce91ff9ccec4223703489dab3,5ec1ebf4e260eb1f8fda8acdf06cd39e,5f37466ca41c9b8b06ed8be0303d49f2,a10787d7fbb1307be263e86dc7b33a51,b2aae16813e647959b783a39ef9a19a7,d4797ed1483e5057bcd8301eaa509d5e</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="DERMAL T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Dermal T cells from patients with diffuse cutaneous SSc show upregulated TNFR1 and TNFR2</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="TYPE 1 COLLAGEN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Type 1 collagen expression is elevated in fibroblasts after TNF-co-stimulation of SSc patient T cells</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="IPF">
      <data key="d0">DISEASE</data>
      <data key="d1">Idiopathic pulmonary fibrosis (IPF) is a disease where sTNFR1 is increased in fibroblast supernatant</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="BLEOMYCIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Bleomycin is a chemical and medication used in chemotherapy that is commonly employed in experimental models to induce cell injury and fibrosis. Specifically, it is used to induce skin fibrosis and pulmonary fibrosis in animal models, including mice. This makes Bleomycin a valuable tool for studying the mechanisms of fibrosis and testing potential therapeutic interventions.</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e,7c13f41d7349d9d2e56c36e00c0ca2d9,b2aae16813e647959b783a39ef9a19a7,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="TNF-/-">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">TNF-/- mice are genetically modified to lack TNF expression</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="TNFTM/TM">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">TNFtm/tm mice only express membrane-bound TNF (mTNF)</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="WT">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Wild-type (WT) mice are used as controls in experiments. The term "wild-type" refers to the normal, non-mutated genotype.</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e,a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="CD4+CD25+ T-CELL">
      <data key="d0">CELL</data>
      <data key="d1">CD4+CD25+ T-cell differentiation is inhibited by impaired TNF/TNFR2 signaling</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="BALF">
      <data key="d0">TISSUE</data>
      <data key="d1">Bronchoalveolar lavage fluid (BALF) is a sample of fluid from the lungs used for analysis in research. It is commonly employed to measure inflammatory cytokines, providing valuable insights into lung health and disease mechanisms.</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e,7c13f41d7349d9d2e56c36e00c0ca2d9,b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="HYPERSENSITIVITY PNEUMONITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Hypersensitivity pneumonitis (HP) is a condition where TNFR2 signaling is elevated in fibrotic samples</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="HUMAN DERMAL FIBROBLASTS">
      <data key="d0">CELL</data>
      <data key="d1">Human dermal fibroblasts are cells found in the dermis layer of the skin that play a crucial role in wound healing and fibrosis. These cells are responsible for producing collagen, which is essential for maintaining the structural integrity of the skin. Additionally, in vitro studies have shown that TNF (Tumor Necrosis Factor) can suppress the expression of &#945;SMA (alpha-Smooth Muscle Actin) in human dermal fibroblasts, indicating a regulatory mechanism that may influence fibrosis and tissue repair processes.</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e,a10787d7fbb1307be263e86dc7b33a51</data>
      <data key="d3">CELL</data>
    </node>
    <node id="PROFIBROTIC MACROPHAGES">
      <data key="d0">CELL</data>
      <data key="d1">Profibrotic macrophages are a type of immune cell that promotes fibrosisProfibrotic macrophages are cells whose numbers and programming status are affected by TNF</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
      <data key="d3">CELL</data>
    </node>
    <node id="VISCERAL ORGANS">
      <data key="d0">TISSUE</data>
      <data key="d1">Visceral organs including the lungs and heart are affected by systemic sclerosis</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="CELL DEATH">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="STNFR1">
      <data key="d0" />
      <data key="d1">Soluble TNFR1 is a form of TNFR1 that is increased in the fibroblast supernatant from IPF patients</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="TNF ANTAGONISTS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">TNF antagonists are drugs that inhibit the action of tumor necrosis factor and are used to treat inflammatory diseases</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="SOLUBLE TNFR1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Soluble TNFR1 is a form of TNFR1 that is found in the serum and correlates with disease severity in SSc</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="BLEOMYCIN-INDUCED MURINE MODEL">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Bleomycin-induced murine model is a mouse model used to study systemic sclerosis and pulmonary fibrosis</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="MTNF">
      <data key="d0">PROTEIN</data>
      <data key="d1">Membrane-bound TNF (mTNF) is a form of TNF that is expressed on the cell surface</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="STNF">
      <data key="d0">PROTEIN</data>
      <data key="d1">Soluble TNF (sTNF) is a form of Tumor Necrosis Factor (TNF) that is found in the serum. It plays a crucial role in the recruitment of lymphocytes and the expression of Transforming Growth Factor Beta 1 (TGF-&#946;1). Additionally, sTNF is notably upregulated in patients with non-fibrotic Hypersensitivity Pneumonitis (HP).</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e,a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="TGF-&#914;1">
      <data key="d0">PROTEIN</data>
      <data key="d1">TGF-&#946;1, also known as Transforming Growth Factor-beta 1, is a cytokine that plays a crucial role in various physiological and pathological processes. It is involved in the transition from pulmonary inflammation to fibrosis, highlighting its significance in respiratory diseases. Additionally, TGF-&#946;1 induces the transdifferentiation of dermal myofibroblasts, which is a key process in wound healing and tissue remodeling. This multifaceted protein is therefore integral to both pulmonary and dermal responses, underscoring its importance in the body's response to injury and inflammation.</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="REDENTE ET AL.">
      <data key="d0">AUTHOR</data>
      <data key="d1">Redente et al. conducted research on the role of TNF in pulmonary fibrosis</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="LI ET AL.">
      <data key="d0">AUTHOR</data>
      <data key="d1">Li et al. conducted research on the role of TNF/TNFR2 signaling in allergic airway inflammation</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="ALLERGIC AIRWAY INFLAMMATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Allergic airway inflammation is characterized by the inflammation of the airways due to an allergic reaction</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="TH2 INFLAMMATORY CYTOKINES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Th2 inflammatory cytokines are signaling molecules produced by Th2 cells that promote inflammation</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="TH17 INFLAMMATORY CYTOKINES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Th17 inflammatory cytokines are signaling molecules produced by Th17 cells that promote inflammation</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="HP">
      <data key="d0">DISEASE</data>
      <data key="d1">Hypersensitivity pneumonitis, a condition characterized by inflammation of the lungs</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="TGF&#914;1">
      <data key="d0">PROTEIN</data>
      <data key="d1">TGF&#946;1 is a cytokine that increases &#945;SMA expression and is involved in fibrosis</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="MYOFIBROBLAST">
      <data key="d0">CELL</data>
      <data key="d1">Myofibroblasts are cells that play a role in wound healing and fibrosis</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="DD">
      <data key="d0">DISEASE</data>
      <data key="d1">Dupuytren&#8217;s disease, a localized fibrotic condition of the hand</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="WNT SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Wnt signaling is a complex network of proteins known for its roles in cell development and disease</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="ST2">
      <data key="d0">PROTEIN</data>
      <data key="d1">ST2, also known as IL1RL1, is a receptor for IL-33 involved in immune response</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="INTESTINAL MYOFIBROBLASTS">
      <data key="d0">CELL</data>
      <data key="d1">Intestinal myofibroblasts are cells in the intestine involved in fibrosis and inflammation</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="TIMP-1">
      <data key="d0">PROTEIN</data>
      <data key="d1">TIMP-1 is a tissue inhibitor of metalloproteinases involved in the regulation of extracellular matrix</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="ERK1/2">
      <data key="d0">PROTEIN</data>
      <data key="d1">ERK1/2 are proteins involved in the MAPK/ERK signaling pathway, which regulates various cellular processes</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="LIVER FIBROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Liver fibrosis is a condition characterized by excessive tissue scarring in the liver. It involves the excessive accumulation of extracellular matrix proteins, leading to the formation of fibrous tissue. This condition is also associated with elevated levels of TL1A, a cytokine that may play a role in its pathogenesis.</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51,c525762bb827485bceeb9f09bb4bcfe0,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="HEMOSIDERIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Hemosiderin is an iron-storage complex found within cells</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="NAFLD">
      <data key="d0">DISEASE</data>
      <data key="d1">Non-alcoholic fatty liver disease (NAFLD) is a condition characterized by excess fat accumulation in the liver.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,a10787d7fbb1307be263e86dc7b33a51,b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="HFD">
      <data key="d0">CHEMICAL</data>
      <data key="d1">High-fat diet, used in experimental models to induce NAFLD</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="CARDIAC INFLAMMATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Cardiac inflammation is the inflammation of the heart tissue</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="CVD">
      <data key="d0">DISEASE</data>
      <data key="d1">Cardiovascular diseases, a class of diseases that involve the heart or blood vessels</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="MI">
      <data key="d0">DISEASE</data>
      <data key="d1">Myocardial infarction (MI), commonly known as a heart attack, is a condition caused by the interruption of blood supply to a part of the heart.</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51,d2c44662af9752fc9f82c86121ede7c0,df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="HCM">
      <data key="d0">DISEASE</data>
      <data key="d1">Hypertrophic cardiomyopathy (HCM) is a condition where the heart muscle becomes abnormally thick.</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51,d2c44662af9752fc9f82c86121ede7c0,df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="HF">
      <data key="d0">DISEASE</data>
      <data key="d1">Heart failure (HF) is a condition in which the heart is unable to pump sufficiently to maintain blood flow.</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51,d2c44662af9752fc9f82c86121ede7c0,df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="LDLR">
      <data key="d0">GENE</data>
      <data key="d1">Low-density lipoprotein receptor, involved in cholesterol metabolism</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="LT&#913;3">
      <data key="d0">PROTEIN</data>
      <data key="d1">Lymphotoxin-alpha homotrimer, involved in inflammation and immune response</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="ANG II">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Angiotensin II, a peptide hormone that causes blood vessels to constrict</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="CD34+CD45+ MONOCYTIC CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Monocytic cells expressing CD34 and CD45 markers, involved in fibrosis</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="CARDIAC FIBROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Cardiac fibrosis is the thickening and stiffening of the cardiac tissue due to the accumulation of excess fibrous connective tissue. This pathological condition can lead to impaired cardiac function and is often associated with various cardiovascular diseases.</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51,d2c44662af9752fc9f82c86121ede7c0,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="TNFR1-KO">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">TNFR1 knockout, a model organism with the TNFR1 gene deleted</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="TNFR2-KO">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">TNFR2 knockout, a model organism with the TNFR2 gene deleted</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="DOUBLE RECEPTOR KNOCKOUT">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Model organism with both TNFR1 and TNFR2 genes deleted</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="INFLAMMATORY DISEASES">
      <data key="d0" />
      <data key="d1">Inflammatory diseases are conditions characterized by inflammation, such as arthritis and inflammatory bowel disease</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="PALM">
      <data key="d0">TISSUE</data>
      <data key="d1">The palm is the inner surface of the hand, affected in Dupuytren&#8217;s disease</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="RATS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Rats are a model organism used in experimental studies of liver cirrhosis</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="CARDIAC TISSUE">
      <data key="d0">TISSUE</data>
      <data key="d1">Cardiac tissue is the muscle tissue of the heart involved in contraction and relaxation</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="ANG-II">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Angiotensin II (Ang-II) is a peptide hormone that causes blood vessels to constrict, leading to increased blood pressure.</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0,df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="CD34">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD34 is a cell surface glycoprotein and a marker of hematopoietic stem cells</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="M2-LIKE CELLS">
      <data key="d0">CELL</data>
      <data key="d1">M2-like cells are a type of macrophage involved in tissue repair and fibrosis</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="M1-LIKE CELLS">
      <data key="d0">CELL</data>
      <data key="d1">M1-like cells are a type of macrophage involved in pro-inflammatory responses</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="WT-BONE MARROW">
      <data key="d0">TISSUE</data>
      <data key="d1">Wild-type bone marrow, used in reconstitution experiments</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="AKT PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">AKT pathway is a signal transduction pathway that promotes survival and growth in response to extracellular signals</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="NF-&#922;B PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">NF-&#954;B pathway is a protein complex that controls transcription of DNA, cytokine production, and cell survival</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="ISCHEMIC CARDIOMYOPATHY">
      <data key="d0">DISEASE</data>
      <data key="d1">Ischemic cardiomyopathy is a condition where the heart's ability to pump blood is decreased due to coronary artery diseaseIschemic cardiomyopathy is a condition where heart muscle is weakened due to inadequate blood supply</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="NON-ISCHEMIC CARDIOMYOPATHY">
      <data key="d0">DISEASE</data>
      <data key="d1">Non-ischemic cardiomyopathy is a condition where the heart's ability to pump blood is decreased due to factors other than coronary artery diseaseNon-ischemic cardiomyopathy is a condition where heart muscle is weakened not due to blood supply issues</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="CARDIOMYOCYTE">
      <data key="d0">CELL</data>
      <data key="d1">Cardiomyocytes are the muscle cells of the heart</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="NECROSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Necrosis is the death of cells or tissues through injury or disease</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="AORTIC VALVE STENOSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Aortic valve stenosis is a condition where the aortic valve narrows, affecting blood flow from the heart</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="CARDIAC HYPERTROPHY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Cardiac hypertrophy is the thickening of the heart muscle, often due to increased workloadCardiac hypertrophy is the thickening of the heart muscle</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="VASCULAR RAREFACTION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Vascular rarefaction is the reduction in the density of blood vessels</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="POST-MI HF">
      <data key="d0">DISEASE</data>
      <data key="d1">Heart failure occurring after a myocardial infarction</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="LEFT CORONARY ARTERY">
      <data key="d0">TISSUE</data>
      <data key="d1">The left coronary artery supplies blood to the heart muscle</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="VENTRICULAR DILATATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Ventricular dilatation is the enlargement of the ventricles of the heartVentricular dilatation is the enlargement of the ventricles of the heart, often due to weakening of the heart muscle</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="LT&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Lymphotoxin alpha, a cytokine involved in the regulation of immune responses</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="LIGHT">
      <data key="d0">PROTEIN</data>
      <data key="d1">LIGHT (TNFSF14), also known as CD258 or HVEM-L, is a cytokine and a member of the TNF superfamily. It plays a significant role in regulating immune responses and is involved in both promoting and inhibiting fibrosis. LIGHT acts on structural and immune cells, driving pro-fibrotic and anti-fibrotic effects, and is known to promote inflammation in various tissues. It exerts its effects through receptors such as HVEM and LT&#946;R.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,516e41e96d2e72d45bf1e2c69da7f18a,5f37466ca41c9b8b06ed8be0303d49f2,68015074236b0144899baa38d01ae467,7f559ad7372a4e35e90b43cc67047b0f,c95d22c2a90e77cd22bd0d280d55b26a,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="HVEM">
      <data key="d0">PROTEIN</data>
      <data key="d1">HVEM, also known as CD270, ATAR, and TR2, is a protein that acts as a receptor for LIGHT. It is involved in the regulation of immune responses and plays a role in fibrosis. Additionally, HVEM is referred to as the Herpesvirus entry mediator, highlighting its function in immune response regulation.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,5f37466ca41c9b8b06ed8be0303d49f2,c95d22c2a90e77cd22bd0d280d55b26a,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="LT&#914;R">
      <data key="d0">PROTEIN</data>
      <data key="d1">LT&#946;R (Lymphotoxin Beta Receptor) is a receptor in the TNF superfamily, also known as CD18 or TNFCR. It acts as a receptor for LIGHT and is involved in the regulation of immune responses, fibrosis, and tissue organization.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,5f37466ca41c9b8b06ed8be0303d49f2,7f559ad7372a4e35e90b43cc67047b0f,c95d22c2a90e77cd22bd0d280d55b26a,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="DCR3">
      <data key="d0">PROTEIN</data>
      <data key="d1">Decoy receptor 3 (DcR3), also known as TR6 or M68, is a receptor in the TNF superfamily. It is a soluble receptor that neutralizes TL1A signaling and is involved in the regulation of immune responses. DcR3 also acts as a soluble receptor for LIGHT, further contributing to its role in modulating immune system activities.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,c95d22c2a90e77cd22bd0d280d55b26a,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="FIBROPROLIFERATIVE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Fibroproliferative refers to the excessive formation of fibrous tissue</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="CONNECTIVE TISSUE">
      <data key="d0">TISSUE</data>
      <data key="d1">Connective tissue supports, binds, or separates other tissues or organs</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="HVEM-L">
      <data key="d0">PROTEIN</data>
      <data key="d1">Herpesvirus entry mediator ligand, another name for LIGHT</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CD258">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD258 is another name for LIGHT</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="TNFRSF3">
      <data key="d0">GENE</data>
      <data key="d1">TNFRSF3 is the TNF receptor superfamily nomenclature for LT&#946;R. Additionally, TNFRSF3 is the gene encoding LT&#946;R.</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">GENE</data>
    </node>
    <node id="TNFRSF14">
      <data key="d0">GENE</data>
      <data key="d1">TNFRSF14 is the TNF receptor superfamily nomenclature for HVEM. Additionally, TNFRSF14 is the gene encoding HVEM.</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">GENE</data>
    </node>
    <node id="TNFRSF6B">
      <data key="d0">GENE</data>
      <data key="d1">TNFRSF6B is the TNF receptor superfamily nomenclature for DcR3. TNFRSF6B is also the gene encoding DcR3.</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">GENE</data>
    </node>
    <node id="MONOCYTIC INFILTRATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Monocytic infiltration refers to the accumulation of monocytes in tissue, often associated with inflammation</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="CARDIAC COLLAGEN DEPOSITION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Cardiac collagen deposition is the accumulation of collagen in the heart tissue, contributing to fibrosis</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="HEART FAILURE">
      <data key="d0">DISEASE</data>
      <data key="d1">Heart failure is a condition in which the heart is unable to pump blood effectively</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="MYOCARDIAL INFARCTION">
      <data key="d0">DISEASE</data>
      <data key="d1">Myocardial infarction, commonly known as a heart attack, occurs when blood flow to a part of the heart is blocked for a long enough time that part of the heart muscle is damaged or dies</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="CARDIOMYOCYTE NECROSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Cardiomyocyte necrosis is the death of heart muscle cells, often due to ischemia</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="REPLACEMENT FIBROSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Replacement fibrosis is the process where fibrous tissue replaces dead or damaged tissue, often seen after myocardial infarction</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="REACTIVE FIBROSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Reactive fibrosis is the formation of fibrous tissue in response to chronic low-grade inflammation</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="CONTRACTILE DYSFUNCTION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Contractile dysfunction is the impaired ability of the heart muscle to contract and pump blood</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="HOUSE DUST MITE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">House dust mites (HDM) are common allergens that can induce allergic reactions and asthma in susceptible individuals</data>
      <data key="d2">5f37466ca41c9b8b06ed8be0303d49f2</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="ACUTE HYPOXIC RESPIRATORY FAILURE">
      <data key="d0">DISEASE</data>
      <data key="d1">Acute hypoxic respiratory failure (AHRF) is a condition where the lungs cannot provide enough oxygen to the body's tissues</data>
      <data key="d2">5f37466ca41c9b8b06ed8be0303d49f2</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="NASH">
      <data key="d0">DISEASE</data>
      <data key="d1">Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD) characterized by inflammation and damage to liver cells. It is associated with elevated serum BAFF levels and fibrosis, indicating a progression from simple fatty liver to a more serious condition involving significant liver damage and potential long-term complications.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,5f37466ca41c9b8b06ed8be0303d49f2,b2aae16813e647959b783a39ef9a19a7,c525762bb827485bceeb9f09bb4bcfe0</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="SIMPLE STEATOSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Simple steatosis is a form of Non-Alcoholic Fatty Liver Disease (NAFLD) characterized by the accumulation of fat in the liver without significant inflammation or damage. It is a liver condition that can be distinguished from Non-Alcoholic Steatohepatitis (NASH) by serum BAFF levels.</data>
      <data key="d2">5f37466ca41c9b8b06ed8be0303d49f2,c525762bb827485bceeb9f09bb4bcfe0</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="STEATOSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Steatosis is the abnormal accumulation of fat in the liver, characterized by the abnormal retention of lipids within a cell. This condition is often observed in liver diseases, where the liver cells accumulate excessive amounts of fat, leading to potential liver dysfunction and other associated health issues.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="HUH7">
      <data key="d0">CELL</data>
      <data key="d1">Huh7 cells are a human hepatoma cell line used in liver disease research</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="H2O2">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hydrogen peroxide is a reactive oxygen species involved in oxidative stress</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="HEPATIC STEATOSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Hepatic steatosis is the accumulation of fat in the liver</data>
      <data key="d2">05c97152fe02249153103be341d65b67,b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="GI TRACT">
      <data key="d0">TISSUE</data>
      <data key="d1">The gastrointestinal tract is the organ system responsible for digestion and absorption of nutrients</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="EOE">
      <data key="d0">DISEASE</data>
      <data key="d1">Eosinophilic esophagitis (EOE) is a chronic immune system disease characterized by eosinophil accumulation in the esophagus, leading to inflammation and esophageal remodeling.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="ICAM-1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Intercellular adhesion molecule 1 is a protein involved in the adhesion of leukocytes to endothelial cells</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="CKD">
      <data key="d0">DISEASE</data>
      <data key="d1">Chronic kidney disease is a condition characterized by gradual loss of kidney function over time</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="UUO">
      <data key="d0">DISEASE</data>
      <data key="d1">Unilateral ureteral obstruction is a condition where one of the ureters is blocked, leading to kidney damage</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="LDO">
      <data key="d0">DISEASE</data>
      <data key="d1">Lacrimal duct obstruction is a condition where the tear ducts are blocked, leading to tear drainage issues</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="MONONUCLEAR CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Mononuclear cells are immune cells with a single round nucleus, including lymphocytes and monocytes</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="COLUMNAR EPITHELIAL CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Columnar epithelial cells are elongated cells found in the lining of the digestive tract and other organs</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
      <data key="d3">CELL</data>
    </node>
    <node id="TL1A">
      <data key="d0">PROTEIN</data>
      <data key="d1">TL1A (TNFSF15) is a cytokine and a member of the TNF superfamily, also known as VEGI or TL1. It plays a significant role in immune responses, inflammation, and fibrosis. TL1A acts on both structural and immune cells, driving pro-fibrotic and anti-fibrotic effects. It is particularly involved in severe bowel pathology and inflammation, making it a critical target for monoclonal antibody therapies aimed at treating inflammatory diseases.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,423195c6b63ad0a6773374364ebf3612,516e41e96d2e72d45bf1e2c69da7f18a,68015074236b0144899baa38d01ae467,7f559ad7372a4e35e90b43cc67047b0f,c525762bb827485bceeb9f09bb4bcfe0,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="DR3">
      <data key="d0">PROTEIN</data>
      <data key="d1">DR3 (Death Receptor 3) is a receptor involved in the regulation of immune responses. It is a receptor for TL1A, also known as Apo-3, TRAMP, LARD, and WS-1. DR3 interacts with TL1A to promote fibrosis, highlighting its role in both immune response regulation and pathological processes such as fibrosis.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,7f559ad7372a4e35e90b43cc67047b0f,c525762bb827485bceeb9f09bb4bcfe0,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="NF-KB">
      <data key="d0">PATHWAY</data>
      <data key="d1">NF-kB is a protein complex involved in regulating immune response and inflammation</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="COLITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Colitis is an inflammatory condition characterized by inflammation of the colon. It is treated with anti-TL1A antibody.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,68015074236b0144899baa38d01ae467,c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="TRANSGENIC MICE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Transgenic mice are genetically modified mice used in research to study gene function and disease</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="SMALL INTESTINE">
      <data key="d0">TISSUE</data>
      <data key="d1">The small intestine is a part of the gastrointestinal tract where T cells are primarily activated. Additionally, it plays a crucial role in nutrient absorption, making it an essential component of the digestive system.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="BOWEL">
      <data key="d0">TISSUE</data>
      <data key="d1">The bowel is part of the gastrointestinal tract involved in digestion and waste elimination. It is also affected by TL1A-driven pathology, indicating its role in certain autoimmune conditions.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="MURINE HEPATIC FIBROBLASTS">
      <data key="d0">CELL</data>
      <data key="d1">Murine hepatic fibroblasts are liver fibroblast cells derived from mice, involved in liver fibrosis research</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="SPLENECTOMY">
      <data key="d0">TISSUE</data>
      <data key="d1">Splenectomy is the surgical removal of the spleen</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="ESOPHAGEAL FIBROBLASTS">
      <data key="d0">CELL</data>
      <data key="d1">Esophageal fibroblasts are cells in the esophagus involved in tissue repair and fibrosis</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="RENAL TISSUE">
      <data key="d0">TISSUE</data>
      <data key="d1">Renal tissue refers to the tissue of the kidneys</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="LACRIMAL SAC">
      <data key="d0">TISSUE</data>
      <data key="d1">The lacrimal sac is part of the tear drainage system in the eye</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="MONONUCLEAR CELL INFILTRATES">
      <data key="d0">CELL</data>
      <data key="d1">Mononuclear cell infiltrates are immune cells that have migrated into tissues during inflammation</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="T LYMPHOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">T lymphocytes are a type of white blood cell involved in the immune response. They play a central role in cell-mediated immunity and express receptors for APRIL and BAFF.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,4cf23e218b6aab3c77115173b5c7c2fd,c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="ANTI-TL1A ANTIBODY">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Anti-TL1A antibody is a therapeutic antibody used to block TL1A signaling.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="OXIDATIVE STRESS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Oxidative stress is an imbalance between free radicals and antioxidants in the body, leading to cell damage</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="PATHOLOGY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Pathology refers to the study of diseases and the changes they cause in the body</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="TISSUE REMODELING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Tissue remodeling involves changes in tissue structure and is driven by TNFSF members. It is the process of renewal and reconstruction of tissue architecture.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,516e41e96d2e72d45bf1e2c69da7f18a</data>
    </node>
    <node id="FIBROTIC DISORDERS">
      <data key="d0">DISEASE</data>
      <data key="d1">Fibrotic disorders are conditions characterized by excessive fibrosis or scarring of tissues. These diseases involve the abnormal accumulation of fibrous connective tissue, leading to the thickening and stiffening of affected organs.</data>
      <data key="d2">05c97152fe02249153103be341d65b67,b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="LUNG INFLAMMATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Lung inflammation is the swelling and irritation of the lung tissue</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="BOWEL PATHOLOGY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Bowel pathology refers to diseases and disorders affecting the bowel</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="COLONIC FIBROBLASTS">
      <data key="d0">CELL</data>
      <data key="d1">Colonic fibroblasts are cells in the colon that contribute to fibrosis when activated by TL1A-DR3 signaling</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="MMP7">
      <data key="d0">PROTEIN</data>
      <data key="d1">MMP7 is a matrix metalloproteinase involved in the fibrotic pathway and reduced by anti-TL1A treatment</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="MMP10">
      <data key="d0">PROTEIN</data>
      <data key="d1">MMP10 is a matrix metalloproteinase involved in the fibrotic pathway and reduced by anti-TL1A treatment</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="HDM">
      <data key="d0">CHEMICAL</data>
      <data key="d1">HDM is an airway irritant used to study TL1A-driven inflammation and fibrosis in mice</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="MUCUS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Mucus is produced in the lung and its production is increased by TL1A-driven IL-13 signaling</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="TACI">
      <data key="d0">PROTEIN</data>
      <data key="d1">TACI, also known as CD267 and IGAD2, is a receptor for APRIL and BAFF. It plays a crucial role in immune responses and fibrosis.</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="BCMA">
      <data key="d0">PROTEIN</data>
      <data key="d1">BCMA, also known as CD269, is a receptor in the TNF superfamily. It serves as a receptor for APRIL and BAFF, playing a crucial role in immune responses and fibrosis.</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="BAFF-R">
      <data key="d0">PROTEIN</data>
      <data key="d1">BAFF-R is a receptor for BAFF involved in immune responses and fibrosis</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="B LYMPHOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">B lymphocytes are a type of white blood cell involved in the immune response. These immune cells play a crucial role in antibody production and express receptors for APRIL (A Proliferation-Inducing Ligand) and BAFF (B-cell Activating Factor), which are important for their survival and function.</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd,c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="AUTOIMMUNE HEPATITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Autoimmune hepatitis is a chronic disease in which the body's immune system attacks liver cells. This liver disease is associated with elevated BAFF levels and fibrosis.</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7,c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="INTESTINAL INFLAMMATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Intestinal inflammation is a condition associated with elevated TL1A levels</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="INTESTINAL FIBROSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Intestinal fibrosis is a condition associated with elevated TL1A levels</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="MACROPHAGE RECRUITMENT">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Macrophage recruitment is a process involved in inflammation and fibrosis</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="M1 POLARIZATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">M1 polarization is a process where macrophages adopt a pro-inflammatory phenotype</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="PATHOGENIC TISSUE REMODELING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Pathogenic tissue remodeling is a process involving changes in tissue structure due to disease</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="SERUM BAFF LEVELS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Serum BAFF levels are a biomarker associated with fibrosis severity</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="HEPATOCYTE BALLOONING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Hepatocyte ballooning is a condition associated with elevated serum BAFF levels and liver fibrosis</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="HEPATOCYTE">
      <data key="d0">CELL</data>
      <data key="d1">Hepatocytes are the main functional cells of the liver</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="BAFF-/- MICE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">BAFF-/- mice are genetically modified mice lacking the BAFF protein</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="MIXED CONNECTIVE TISSUE DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Mixed connective tissue disease is an autoimmune disorder with features of several connective tissue diseases</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="PF">
      <data key="d0">DISEASE</data>
      <data key="d1">Pulmonary fibrosis, a lung disease characterized by scarring of lung tissue</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="AE">
      <data key="d0">DISEASE</data>
      <data key="d1">Atopic eczema, a chronic skin condition similar to atopic dermatitis</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="BAFFR">
      <data key="d0">PROTEIN</data>
      <data key="d1">BAFFR

BAFFR, also known as CD268, is a receptor for BAFF. It plays a crucial role in B cell survival and maturation.</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="TSK/+ MICE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Tight skin (TSK/+) mice are a model organism used to study skin fibrosis</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="PBMC">
      <data key="d0">CELL</data>
      <data key="d1">Peripheral blood mononuclear cells, a type of blood cell that is critical in immune response</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="ANTI-TOPO I ANTIBODIES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Antibodies against topoisomerase I, associated with systemic sclerosis</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="TIMP1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Tissue inhibitor of metalloproteinases 1, involved in the regulation of extracellular matrix</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="RANKL">
      <data key="d0">PROTEIN</data>
      <data key="d1">RANKL, also known as CD254, TRANCE, OPGL, and ODF, is a ligand in the TNF superfamily. This protein, formally referred to as receptor activator of nuclear factor kappa-B ligand (RANKL), plays a crucial role in bone metabolism and is a significant target in clinical trials involving monoclonal antibodies. Additionally, RANKL is upregulated in multiple fibrotic liver diseases and is implicated in the pathogenesis of these conditions, highlighting its involvement in both bone metabolism and fibrosis.</data>
      <data key="d2">68015074236b0144899baa38d01ae467,b2aae16813e647959b783a39ef9a19a7,c95d22c2a90e77cd22bd0d280d55b26a,d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="RANK">
      <data key="d0">PROTEIN</data>
      <data key="d1">RANK (Receptor Activator of Nuclear Factor Kappa-&#914;) is a protein involved in bone metabolism and immune response. It functions as a receptor for RANKL, which is also known by several other names including CD265, ODFR, and FEO. This interaction between RANK and RANKL is crucial for various physiological processes, particularly in the regulation of bone remodeling and the modulation of immune responses.</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,b2aae16813e647959b783a39ef9a19a7,c95d22c2a90e77cd22bd0d280d55b26a,d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="OPG">
      <data key="d0">PROTEIN</data>
      <data key="d1">Osteoprotegerin (OPG) is a receptor in the TNF superfamily, also known as OCIF and TR1. It is a secreted glycoprotein that serves multiple roles in the body. As a member of the TNF superfamily, OPG functions as a soluble decoy receptor for both RANKL and TRAIL. By blocking RANKL-RANK interactions, OPG inhibits extracellular matrix (ECM) degradation, thereby playing a crucial role in bone metabolism and immune regulation.</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7,c95d22c2a90e77cd22bd0d280d55b26a,d2c44662af9752fc9f82c86121ede7c0,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="OSTEOCLAST">
      <data key="d0">CELL</data>
      <data key="d1">Osteoclasts are bone cells that break down bone tissue</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7,d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="OSTEOBLAST">
      <data key="d0">CELL</data>
      <data key="d1">Osteoblasts are bone cells that form new bone tissue</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="ECM">
      <data key="d0">TISSUE</data>
      <data key="d1">Extracellular matrix (ECM) is a network of proteins and other molecules that provide structural and biochemical support to surrounding cells. This intricate network is essential for maintaining the structural integrity of tissues and facilitating various cellular functions.</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7,d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="PBC">
      <data key="d0">DISEASE</data>
      <data key="d1">Primary biliary cholangitis (PBC) is a chronic liver disease characterized by injury to the small intrahepatic bile ducts.</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7,d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="BEFFS">
      <data key="d0">CELL</data>
      <data key="d1">Fibrotic B cells that produce IL-6</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="BREGS">
      <data key="d0">CELL</data>
      <data key="d1">Regulatory B cells that produce IL-10</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="FIBROSIS SCORE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Fibrosis score is a measure of the extent of fibrosis in tissue</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="HIGH FAT DIET">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A high fat diet is a diet that consists of a high proportion of fat, often used in research to induce metabolic disorders in animal models</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="SOLUBLE RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">A soluble receptor is a form of receptor that is not membrane-bound and can neutralize its ligand in the extracellular space</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="INFLAMMATORY DISORDERS">
      <data key="d0">DISEASE</data>
      <data key="d1">Inflammatory disorders are conditions characterized by inflammation, which can affect various tissues and organs</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="TNFRSF11A">
      <data key="d0">GENE</data>
      <data key="d1">TNFRSF11A is the TNF receptor superfamily nomenclature for RANK. TNFRSF11A is the gene encoding RANK, the receptor for RANKL.</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="TNFRSF11B">
      <data key="d0">GENE</data>
      <data key="d1">TNFRSF11B is the TNF receptor superfamily nomenclature for OPG. TNFRSF11B is the gene encoding OPG, a decoy receptor for RANKL.</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="BONE">
      <data key="d0">TISSUE</data>
      <data key="d1">Bone is a rigid organ that constitutes part of the vertebrate skeleton</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="BONE HOMEOSTASIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Bone homeostasis is the balance between bone formation and bone resorption</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="BONE RESORPTION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Bone resorption is the process by which osteoclasts break down bone tissue</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="CHOLANGIOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Cholangiocytes are the epithelial cells of the bile duct</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="LIVER CIRRHOSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Liver cirrhosis is a chronic liver disease characterized by significant fibrosis and impaired liver function. This condition often leads to complications such as low bone density and bone mass loss.</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9,d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="FIBROTIC LUNG DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Fibrotic lung disease is a condition characterized by the formation of excess fibrous connective tissue in the lungs</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="SILICOSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Silicosis is a type of pulmonary fibrosis caused by inhalation of silica dust</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="MMP-12">
      <data key="d0">PROTEIN</data>
      <data key="d1">Matrix metalloproteinase-12 (MMP-12) is an enzyme involved in the breakdown of extracellular matrix proteins</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="AC-SDKP">
      <data key="d0">CHEMICAL</data>
      <data key="d1">N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) is a naturally occurring tetrapeptide with potential therapeutic roles</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="CF">
      <data key="d0">DISEASE</data>
      <data key="d1">Cystic fibrosis (CF) is a genetic disorder affecting the lungs and other organs, characterized by thick, sticky mucus</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="CFTR">
      <data key="d0">GENE</data>
      <data key="d1">Cystic fibrosis transmembrane conductance regulator (CFTR) is a gene that, when mutated, causes cystic fibrosis</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="OSTEOBLASTS">
      <data key="d0">CELL</data>
      <data key="d1">Osteoblasts are bone-forming cells</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="INTERSTITIAL FIBROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Interstitial fibrosis is the formation of fibrous tissue in the interstitial spaces of organs</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="PERIVASCULAR FIBROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Perivascular fibrosis is the formation of fibrous tissue around blood vessels</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="CARDIOMYOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Cardiomyocytes are the muscle cells of the heart</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="PROCOLLAGEN &#913;1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Procollagen &#945;1 is a precursor of collagen, a major component of the extracellular matrix</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="FCERI">
      <data key="d0">PROTEIN</data>
      <data key="d1">Fc epsilon RI (FcERI) is a high-affinity receptor for the Fc region of immunoglobulin E (IgE)</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="NEONATAL CARDIOMYOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Neonatal cardiomyocytes are heart muscle cells from newborns</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
      <data key="d3">CELL</data>
    </node>
    <node id="CARDIAC FIBROBLAST">
      <data key="d0">CELL</data>
      <data key="d1">Cardiac fibroblasts are cells in the heart that produce extracellular matrix and collagen</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
      <data key="d3">CELL</data>
    </node>
    <node id="AORTIC STENOSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Aortic stenosis is a condition where the aortic valve narrows, reducing blood flow from the heart</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="LEFT VENTRICULAR MASS INDEX">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Left ventricular mass index is a measure of the mass of the left ventricle of the heart</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="MYOCARDIAL STIFFNESS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Myocardial stiffness is the rigidity of the heart muscle, affecting its ability to contract and relax</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="HF WITH PRESERVED EJECTION FRACTION">
      <data key="d0">DISEASE</data>
      <data key="d1">Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure where the heart muscle contracts normally but the ventricles do not relax as they should</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="GITR">
      <data key="d0">PROTEIN</data>
      <data key="d1">GITR, also known as TNFRSF18, CD357, and AITR, is a receptor for GITRL. It is a type I transmembrane protein that is constitutively expressed by regulatory T cells (Tregs) and resting CD25-CD4+ T cells. Its expression increases following T cell activation. Additionally, GITR is expressed by other immune cells and is part of the glucocorticoid-induced TNF receptor family.</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9,c95d22c2a90e77cd22bd0d280d55b26a,d2c44662af9752fc9f82c86121ede7c0</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CD25-CD4+ T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD25-CD4+ T cells are a subset of T cells that express the CD4 receptor but not the CD25 receptor. Additionally, these cells exhibit lower expression of GITR (Glucocorticoid-Induced TNFR-Related protein) compared to regulatory T cells (Tregs).</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9,d2c44662af9752fc9f82c86121ede7c0</data>
      <data key="d3">CELL</data>
    </node>
    <node id="TRAP">
      <data key="d0">PROTEIN</data>
      <data key="d1">Tartrate-resistant acid phosphatase (TRAP) is an enzyme expressed in osteoclasts and macrophages</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="MMP-1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Matrix metalloproteinase-1 (MMP-1) is an enzyme involved in the breakdown of extracellular matrix proteins</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="TNFRSF18">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNFRSF18, also known as GITR (Glucocorticoid-Induced TNFR-Related protein), is a type I transmembrane protein that plays a crucial role in T cell activation. It is part of the TNF receptor superfamily, which is reflected in its nomenclature.</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="GITRL">
      <data key="d0">PROTEIN</data>
      <data key="d1">GITRL, also known as TL6, AITRL, and TNFSF18, is a ligand in the TNF superfamily. It serves as the ligand for GITR and is primarily expressed on B cells, dendritic cells (DCs), macrophages, and endothelial cells.</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="TNFSF18">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNFSF18, also known as GITRL, is the ligand for GITR. It is part of the TNF superfamily, which is reflected in its nomenclature as TNFSF18.</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="4-1BB">
      <data key="d0">PROTEIN</data>
      <data key="d1">4-1BB is a member of the TNFRSF that acts as a costimulatory signal for T cells</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="DTA-1">
      <data key="d0">CHEMICAL</data>
      <data key="d1">DTA-1 is an agonistic anti-GITR antibody used to stimulate GITR</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="FOXP3">
      <data key="d0">PROTEIN</data>
      <data key="d1">Foxp3 is the master transcription factor that drives Treg development and functionalization</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="FLS">
      <data key="d0">CELL</data>
      <data key="d1">Fibroblast-like synoviocytes are cells derived from the synovial membrane that play a role in arthritis</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="MLE-12 CELLS">
      <data key="d0">CELL</data>
      <data key="d1">MLE-12 cells are an immortalized mouse lung type II epithelial cell line used in research</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="MENSC">
      <data key="d0">CELL</data>
      <data key="d1">MenSC, or human menstrual blood-derived mesenchymal stem cells, are used in research for their regenerative properties</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="GITR-/- MICE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">GITR-/- mice are genetically modified mice lacking the GITR gene, used in research to study GITR function</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="GITR+/+ MICE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">GITR+/+ mice are wild-type mice with normal GITR expression, used as controls in research</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="FC-GITR FUSION PROTEIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Fc-GITR fusion protein is a molecule used to disrupt GITRL/GITR signaling in experimental models</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="MPO">
      <data key="d0">PROTEIN</data>
      <data key="d1">Myeloperoxidase (MPO) is an enzyme found in neutrophils that is involved in the body's defense against pathogens</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="CD252">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD252, also known as OX40L or TNFSF4, is a gene encoding the OX40 ligand. CD252 is another name for OX40L, the ligand for OX40.</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3,7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="CD134">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD134 is another name for OX40, a marker of T-cell activation</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="CD25+CD4+ T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD25+CD4+ T cells, also known as regulatory T cells (Tregs), are a subset of T cells that maintain immune tolerance and prevent autoimmune disease</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="ARTHRITIC MOUSE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Arthritic mouse is a model organism used to study arthritis and related immune responses</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="SYNOVIA">
      <data key="d0">TISSUE</data>
      <data key="d1">Synovia is the soft tissue found in joint cavities that produces synovial fluid</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="FIBROTIC MODELS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Fibrotic models are experimental models used to study fibrosis and related mechanisms</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="GRANULOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Granulocytes are a type of white blood cell involved in the immune response. These immune cells can be influenced by LIGHT, a member of the tumor necrosis factor (TNF) superfamily, which plays a role in modulating immune functions.</data>
      <data key="d2">516e41e96d2e72d45bf1e2c69da7f18a,68015074236b0144899baa38d01ae467,7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="TH2 CYTOKINE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Th2 cytokine is a type of signaling molecule involved in the immune response and fibrosis</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="TH1 CYTOKINE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Th1 cytokine is a type of signaling molecule involved in the immune response and inflammation</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="ANTIGEN PRESENTING CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Antigen presenting cells are immune cells that present antigens to T cells to initiate an immune response</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="LUNG INJURY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Lung injury refers to damage to the lung tissue, often associated with inflammation and fibrosis</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="CELL INJURY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Cell injury refers to damage to cells, which can lead to cell death and tissue damage</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="EPITHELIAL TO MESENCHYMAL TRANSITION (EMT)">
      <data key="d0">PATHWAY</data>
      <data key="d1">EMT is a biological process where epithelial cells transform into mesenchymal cells, often associated with fibrosis</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="CIRRHOSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Cirrhosis is a chronic liver disease characterized by fibrosis, scarring, and impaired liver function.</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd,7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="HISTOLOGICAL SIGNS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Histological signs refer to microscopic changes in tissue structure, often used to diagnose diseases</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="PRO-INFLAMMATORY ENVIRONMENT">
      <data key="d0">SYMPTOM</data>
      <data key="d1">A pro-inflammatory environment is characterized by increased inflammation, which can lead to tissue damage and fibrosis</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="ANTI-INFLAMMATORY ENVIRONMENT">
      <data key="d0">SYMPTOM</data>
      <data key="d1">An anti-inflammatory environment is characterized by reduced inflammation, which can prevent tissue damage and fibrosis</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="C57BL/6 MICE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">C57BL/6 mice are a transgenic model used to study the effects of OX40L overexpression</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="CD90">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD90 is a protein marker found on cells expressing OX40L in fibrotic skin</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="LDLR-/- MICE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">LDLR-/- mice are a model used to study atherosclerosis and the effects of OX40-OX40L signaling</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="GATA-3">
      <data key="d0">PROTEIN</data>
      <data key="d1">GATA-3 is a protein involved in Th2 cell promotion, reduced by OX40-OX40L signaling disruption</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="HYDROXYPROLINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hydroxyproline is a marker for collagen content, used to assess fibrosis</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="ANTI-OX40L ANTIBODY">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Anti-OX40L antibody is used to block OX40L signaling in research studies</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="SOLUBLE OX40L">
      <data key="d0">PROTEIN</data>
      <data key="d1">Soluble OX40L is a form of OX40L found in serum, used as a biomarker for fibrosis</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="INFLAMMATION-DRIVEN FIBROSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Inflammation-driven fibrosis is a type of fibrosis caused by chronic inflammation</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="FIBROSING ALVEOLITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Fibrosing alveolitis is a lung disease characterized by inflammation and fibrosis</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="LUNG VESSEL REMODELING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Lung vessel remodeling is a pathological change in lung blood vessels associated with fibrosis</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
    </node>
    <node id="WESTERN-TYPE DIET">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Western-type diet is used to induce atherosclerosis in research models</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="CHOW DIET">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Chow diet is a standard diet used in research models</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="EFFECTOR T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Effector T cells are a type of T cell involved in the immune response, affected by CD27:CD70 signaling</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">CELL</data>
    </node>
    <node id="HEMATOPOIETIC STEM CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Hematopoietic stem cells are progenitor cells that give rise to blood cells, expressing CD27. These stem cells are crucial as they differentiate into various types of blood cells, playing a fundamental role in the hematopoietic system.</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3,4cf23e218b6aab3c77115173b5c7c2fd</data>
      <data key="d3">CELL</data>
    </node>
    <node id="PULMONARY ARTERIOLE">
      <data key="d0">TISSUE</data>
      <data key="d1">Pulmonary arteriole is a small artery in the lung affected by PAH</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="MEDIAL MUSCULAR HYPERTROPHY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Medial muscular hypertrophy is a thickening of the muscular layer of blood vessels, associated with PAH</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="INTIMAL FIBROSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Intimal fibrosis is the scarring of the innermost layer of blood vessels, associated with PAH</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="SCD27">
      <data key="d0">PROTEIN</data>
      <data key="d1">Soluble CD27 is a functionally active form of CD27 that is secreted after proteolytic cleavage</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="CD4 T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD4 T cells are a type of T lymphocyte that assists other cells in the immune response</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="TEM">
      <data key="d0">CELL</data>
      <data key="d1">Effector-memory T cells are a subset of T cells that have previously encountered antigens and can quickly respond upon re-exposure</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="CHRONIC RENAL NEPHRITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Chronic renal nephritis is a long-term inflammation of the kidneys</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="INTRARENAL LYMPHOID FOLLICLE-LIKE STRUCTURES">
      <data key="d0">TISSUE</data>
      <data key="d1">These are structures found within the kidneys that resemble lymphoid follicles</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="TNF-BETA">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNF-beta is a cytokine involved in systemic inflammation</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="CD95">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD95, also known as Fas, is a protein that mediates apoptosis</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="FASL">
      <data key="d0">PROTEIN</data>
      <data key="d1">Fas ligand is a protein that binds to Fas and induces apoptosis</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="ENDOTOXIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Endotoxin is a toxin released by certain bacteria that can cause inflammation</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="EAM">
      <data key="d0">DISEASE</data>
      <data key="d1">Experimental autoimmune myocarditis is a model of heart inflammation used in research</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="CARDIAC NK CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Cardiac NK cells are natural killer cells found in the heart</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="TRAIL">
      <data key="d0">PROTEIN</data>
      <data key="d1">TRAIL, also known as TNFSF10, Apo-2 ligand, or CD253, is a Type II membrane protein in the TNF superfamily. It is involved in inducing apoptosis, which is the process of programmed cell death. Additionally, TRAIL plays a role in fibrotic disease therapy. As a tumor necrosis factor-related apoptosis-inducing ligand, TRAIL is crucial in promoting cell death, making it a significant protein in both therapeutic and pathological contexts.</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd,c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="DR4">
      <data key="d0">PROTEIN</data>
      <data key="d1">DR4, also known as CD261, TRAILR1, Apo-2, or TNFRSF10A, is a receptor that binds to TRAIL (Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand). Upon binding to TRAIL, DR4 induces apoptosis, playing a crucial role in the regulation of cell death. This receptor is integral to the apoptotic signaling pathway, contributing to the elimination of cancerous or otherwise damaged cells.</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd,c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="DR5">
      <data key="d0">PROTEIN</data>
      <data key="d1">DR5, also known as CD262, TRAILR2, KILLER, or TNFRSF10B, is a receptor for TRAIL (Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand). This receptor, also referred to as Death Receptor 5, plays a crucial role in the induction of apoptosis. When TRAIL binds to DR5, it initiates a signaling cascade that leads to programmed cell death, making it a significant target in the study of autoimmune diseases and potential therapeutic interventions.</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd,c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="DCR1">
      <data key="d0">PROTEIN</data>
      <data key="d1">DcR1, also known as CD263, TRAILR3, LIT, TRID, or TNFRSF10C, is a receptor in the TNF superfamily. This receptor is characterized by its ability to bind to TRAIL (TNF-related apoptosis-inducing ligand) but does not induce apoptosis. Unlike other receptors in the same family, DcR1 lacks a death domain, which is essential for the transmission of apoptotic signals. Therefore, DcR1 functions as a decoy receptor, sequestering TRAIL and preventing it from binding to receptors that would otherwise trigger cell death.</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd,c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="DCR2">
      <data key="d0">PROTEIN</data>
      <data key="d1">DCR2, also known as CD264, TRAILR4, TRUNDD, or TNFRSF10D, is a receptor in the TNF superfamily. This receptor is commonly referred to as Decoy receptor 2. Unlike other receptors that bind to TRAIL (TNF-related apoptosis-inducing ligand) and induce apoptosis, DCR2 has a truncated, non-functional death domain, which means it binds to TRAIL but does not trigger the apoptotic pathway.</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd,c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="MEMORY T LYMPHOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Memory T lymphocytes are T cells that have previously encountered an antigen and can quickly respond upon re-exposure</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="NA&#207;VE B CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Na&#239;ve B cells are B lymphocytes that have not yet encountered their specific antigen</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="MEMORY B LYMPHOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Memory B lymphocytes are B cells that have previously encountered an antigen and can quickly respond upon re-exposure</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="FIBROTIC DISEASES">
      <data key="d0">DISEASE</data>
      <data key="d1">Fibrotic diseases are conditions characterized by excessive tissue fibrosis</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="ACUTE INFLAMMATORY STATE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Acute inflammatory state is a rapid onset of inflammation in response to injury or infection</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="RENAL DISEASES">
      <data key="d0">DISEASE</data>
      <data key="d1">Renal diseases are conditions that affect the kidneys</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="SYSTEMIC INFECTION">
      <data key="d0">DISEASE</data>
      <data key="d1">Systemic infection is an infection that affects the entire body</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="CARDIAC INFILTRATING EOSINOPHILS">
      <data key="d0">CELL</data>
      <data key="d1">Cardiac infiltrating eosinophils are eosinophils that have migrated into the heart tissue</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="CARDIAC FIBROBLASTS">
      <data key="d0">CELL</data>
      <data key="d1">Cardiac fibroblasts are fibroblasts found in the heart tissue</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="DISEASE PATHOGENESIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Disease pathogenesis is the process by which a disease develops and progresses</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="FAS LIGAND">
      <data key="d0">PROTEIN</data>
      <data key="d1">Fas ligand is a protein that TRAIL bears high levels of homology to</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="NATURAL KILLER CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Natural killer cells are a type of lymphocyte that primarily express TRAIL</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="FADD">
      <data key="d0">PROTEIN</data>
      <data key="d1">Fas-associated death domain is an adaptor protein recruited by DR4 and DR5 to form the death-inducing signaling complex</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="PROCASPASE-8">
      <data key="d0">PROTEIN</data>
      <data key="d1">Procaspase-8 is activated by FADD, leading to downstream signaling events that result in apoptosis</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="AHSCS">
      <data key="d0">CELL</data>
      <data key="d1">Activated hepatic stellate cells (AHSCS) are the primary cell type responsible for liver fibrosis. These cells are resistant to apoptosis but are sensitive to TRAIL (TNF-related apoptosis-inducing ligand).</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="DERMAL MYOFIBROBLASTS">
      <data key="d0">CELL</data>
      <data key="d1">Dermal myofibroblasts are the principal cell type responsible for fibrosis in scleroderma</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="TSK-1">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Tsk-1 is a genetic mouse model used to study systemic sclerosis</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="A FUMIGATUS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Aspergillus fumigatus is a species of fungus used in a mouse model to study EoE</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="MID-1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Midline-1 is an E3 ubiquitin-ligase whose downstream signaling events promote inflammation</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="PP2A">
      <data key="d0">PROTEIN</data>
      <data key="d1">Protein phosphatase 2A is an enzyme whose activity is inhibited by MID-1</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="CCL24">
      <data key="d0">PROTEIN</data>
      <data key="d1">CCL24 is a cytokine implicated in EoE pathogenesis</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="TNFSF10">
      <data key="d0">GENE</data>
      <data key="d1">TNFSF10, also known as TRAIL, is a Type II membrane protein that belongs to the TNF superfamily. It plays a crucial role in inducing apoptosis, which is a form of programmed cell death.</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="CD253">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD253 is another name for TRAIL, a Type II membrane protein involved in inducing apoptosis</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="TNFRSF10A">
      <data key="d0">GENE</data>
      <data key="d1">TNFRSF10A, also known as DR4, is a receptor that belongs to the TNF receptor superfamily. It plays a crucial role in the process of apoptosis by binding to TRAIL (TNF-related apoptosis-inducing ligand).</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="TNFRSF10B">
      <data key="d0">GENE</data>
      <data key="d1">TNFRSF10B, also known as DR5, is a receptor that belongs to the TNF receptor superfamily. It plays a crucial role in the process of apoptosis by binding to TRAIL (TNF-related apoptosis-inducing ligand).</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="TNFRSF10C">
      <data key="d0">GENE</data>
      <data key="d1">TNFRSF10C, also known as DcR1, is a decoy receptor that binds TRAIL. It is part of the TNF receptor superfamily, and its nomenclature within this family is TNFRSF10C.</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="TNFRSF10D">
      <data key="d0">GENE</data>
      <data key="d1">TNFRSF10D, also known as DcR2, is a decoy receptor that binds TRAIL. It is part of the TNF receptor superfamily, and its nomenclature within this family is TNFRSF10D.</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="PEGYLATED TRAIL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">PEGylated TRAIL is a modified form of TRAIL used to treat liver fibrosis</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="SIRNA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Small interfering RNA is used to target MID-1 in TRAIL deficient mice</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="ESOPHAGUS">
      <data key="d0">TISSUE</data>
      <data key="d1">The esophagus is the tissue affected in eosinophilic esophagitis</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="ESOPHAGEAL EOSINOPHIL">
      <data key="d0">CELL</data>
      <data key="d1">Esophageal eosinophils are immune cells involved in the inflammation of the esophagus in EoE</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="ESOPHAGEAL CIRCUMFERENCE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Enlargement of the esophageal circumference is a symptom of EoE</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="ESOPHAGEAL REMODELING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Esophageal remodeling is a histological change observed in EoE</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="CIRCULATION">
      <data key="d0">TISSUE</data>
      <data key="d1">Circulation refers to the blood flow system that can be affected by fibrosis</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="COLLAGEN DEPOSITION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Collagen deposition is a marker of fibrosis</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="APOPTOSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Apoptosis is the process of programmed cell death induced by TRAIL</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="MFBS">
      <data key="d0">CELL</data>
      <data key="d1">Myofibroblasts, resistant to apoptosis but sensitive to TRAIL</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="LUMBAR SPINAL FIBROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Lumbar Spinal Fibrosis is a condition characterized by the thickening and scarring of connective tissue in the lumbar spine. This fibrosis involves the formation of excessive fibrous connective tissue, leading to potential complications and discomfort in the affected region.</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="ANTI-TNF THERAPY">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Anti-TNF therapy involves the use of antibodies to inhibit TNF activity</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="SALINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Saline is a solution of salt in water, often used as a placebo in clinical trials.</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="TNF BLOCKER">
      <data key="d0">CHEMICAL</data>
      <data key="d1">TNF blocker is a type of medication that inhibits the activity of TNF. This drug functions by targeting and neutralizing Tumor Necrosis Factor (TNF), a substance in the body that causes inflammation and is involved in autoimmune processes. By inhibiting TNF, TNF blockers help reduce inflammation and are commonly used in the treatment of various autoimmune diseases.</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="IPAA">
      <data key="d0">PROCEDURE</data>
      <data key="d1">Ileal pouch-anal anastomosis is a surgical procedure for patients with ulcerative colitis</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="HAEMEK MEDICAL CENTER">
      <data key="d0">ORGANIZATION</data>
      <data key="d1">HaEmek Medical Center is a hospital in Israel</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="MOUNT SINAI HOSPITAL">
      <data key="d0">ORGANIZATION</data>
      <data key="d1">Mount Sinai Hospital is a hospital in Canada</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="UNIVERSITY OF TORONTO">
      <data key="d0">ORGANIZATION</data>
      <data key="d1">The University of Toronto is a university in Canada and an institution involved in clinical trials.</data>
      <data key="d2">68015074236b0144899baa38d01ae467,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="UNIVERSITY OF OXFORD">
      <data key="d0">ORGANIZATION</data>
      <data key="d1">University of Oxford is a university in the United Kingdom</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="DEPARTMENT OF HEALTH, UNITED KINGDOM">
      <data key="d0">ORGANIZATION</data>
      <data key="d1">Department of Health is a government department in the United Kingdom</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="WELLCOME TRUST">
      <data key="d0">ORGANIZATION</data>
      <data key="d1">Wellcome Trust is a biomedical research charity in the United Kingdom</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="180 THERAPEUTICS LP">
      <data key="d0">ORGANIZATION</data>
      <data key="d1">180 Therapeutics LP is a biotechnology company</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="ASSISTANCE PUBLIQUE - H&#212;PITAUX DE PARIS">
      <data key="d0">ORGANIZATION</data>
      <data key="d1">Assistance Publique - H&#244;pitaux de Paris is a hospital network in France</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="NCT03747068">
      <data key="d0">CLINICAL_TRIAL</data>
      <data key="d1">Clinical trial targeting TNF for treating inflammatory bowel disease</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="NCT03180957">
      <data key="d0">CLINICAL_TRIAL</data>
      <data key="d1">Clinical trial repurposing anti-TNF for treating Dupuytren&#8217;s disease</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="NCT00385086">
      <data key="d0">CLINICAL_TRIAL</data>
      <data key="d1">Clinical trial targeting TNF for treating lumbar spinal fibrosis</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="TNFSF2">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNFSF2, also known as TNF&#945;, is a cytokine involved in systemic inflammation. It is part of the TNF superfamily, which is reflected in its nomenclature as TNFSF2.</data>
      <data key="d2">68015074236b0144899baa38d01ae467,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="TNFRSF1B">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNFRSF1B is the TNF receptor superfamily nomenclature for TNFR2</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="TNFSF15">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNFSF15, also known as TL1A, is a cytokine involved in immune responses and fibrosis. It is part of the TNF superfamily, and the gene TNFSF15 encodes the protein TL1A.</data>
      <data key="d2">516e41e96d2e72d45bf1e2c69da7f18a,68015074236b0144899baa38d01ae467,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="TNFRSF25">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNFRSF25 is the TNF receptor superfamily nomenclature for DR3</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="TNFRSF13B">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNFRSF13B is the TNF receptor superfamily nomenclature for TACI</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="TNFRSF13A">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNFRSF13A is the TNF receptor superfamily nomenclature for BCMA</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="TNFRSF13C">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNFRSF13C is the TNF receptor superfamily nomenclature for BAFFR</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="TNFSF7">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNFSF7 is the TNF superfamily nomenclature for CD70</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="TNFRSF7">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNFRSF7 is the TNF receptor superfamily nomenclature for CD27</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="TNFR2-FC">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNFR2-Fc is a soluble TNF receptor fusion protein used to inhibit TNF activity</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="CBS001">
      <data key="d0">CHEMICAL</data>
      <data key="d1">CBS001 is an anti-LIGHT monoclonal antibody used in clinical trials</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="NON-EOSINOPHILIC ASTHMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Non-Eosinophilic Asthma is a type of asthma not characterized by high levels of eosinophils</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="AVTX-002">
      <data key="d0">CHEMICAL</data>
      <data key="d1">AVTX-002 is an anti-LIGHT monoclonal antibody used in clinical trials</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="COVID-19 PNEUMONIA">
      <data key="d0">DISEASE</data>
      <data key="d1">COVID-19 Pneumonia is a severe respiratory condition caused by the SARS-CoV-2 virus</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="ACUTE LUNG INJURY">
      <data key="d0">DISEASE</data>
      <data key="d1">Acute Lung Injury is a condition characterized by rapid onset of widespread inflammation in the lungs</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="ARDS">
      <data key="d0">DISEASE</data>
      <data key="d1">ARDS (Acute Respiratory Distress Syndrome) is a severe lung condition causing respiratory failure</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="CERC-002">
      <data key="d0">CHEMICAL</data>
      <data key="d1">CERC-002 is an anti-LIGHT monoclonal antibody used in clinical trials</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="CROHN DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Crohn Disease, also known as Crohn's disease, is a type of inflammatory bowel disease that affects the gastrointestinal tract.</data>
      <data key="d2">68015074236b0144899baa38d01ae467,7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="MDGN-002">
      <data key="d0">CHEMICAL</data>
      <data key="d1">MDGN-002 is an anti-LIGHT monoclonal antibody used in clinical trials</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="BAMINERCEPT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Baminercept is a lymphotoxin-beta receptor fusion protein used in clinical trials</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="PRIMARY SJ&#214;GREN&#8217;S SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Primary Sj&#246;gren&#8217;s Syndrome is an autoimmune disease characterized by dry eyes and mouth</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="PRA023">
      <data key="d0">CHEMICAL</data>
      <data key="d1">PRA023 is an anti-TL1A monoclonal antibody currently being tested for its efficacy in treating ulcerative colitis. It is used in clinical trials to evaluate its potential therapeutic benefits for patients suffering from this chronic inflammatory bowel disease.</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612,7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Diffuse Cutaneous Systemic Sclerosis is a form of systemic sclerosis characterized by skin thickening and fibrosis</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="PTX-35">
      <data key="d0">CHEMICAL</data>
      <data key="d1">PTX-35 is an anti-DR3 monoclonal antibody used in clinical trials</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="HEALTHY VOLUNTEER">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Healthy Volunteer refers to individuals participating in clinical trials who do not have the condition being studied</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="POST OPERATIVE SCIATICA">
      <data key="d0">DISEASE</data>
      <data key="d1">Post Operative Sciatica is a condition characterized by pain along the sciatic nerve following surgery</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="CHRONIC INFLAMMATORY DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Chronic Inflammatory Disease is a condition characterized by long-term inflammation</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="HEALTHY">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">"Healthy" refers to individuals without any diagnosed diseases or conditions.</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612,7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="MODERATELY TO SEVERELY ACTIVE CROHN&#8217;S DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Moderately to Severely Active Crohn&#8217;s Disease is a severe form of Crohn's Disease characterized by significant inflammation and symptoms</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Moderately to Severely Active Ulcerative Colitis is a severe form of Ulcerative Colitis characterized by significant inflammation and symptoms</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="ALIMUMAB">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="ANTI-TL1A MAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Anti-TL1A mAb is a monoclonal antibody targeting the TL1A protein</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="PF-06480605">
      <data key="d0">CHEMICAL</data>
      <data key="d1">PF-06480605 is a drug being tested for its efficacy in treating ulcerative colitis</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="TACI-FC FUSION PROTEIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">TACI-Fc fusion protein is a therapeutic agent designed to inhibit BAFF and APRIL, used in the treatment of autoimmune diseases. This fusion protein specifically targets both BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand), which are crucial in the regulation of B-cell function and survival. By inhibiting these molecules, TACI-Fc fusion protein aims to modulate the immune response, providing therapeutic benefits in conditions characterized by autoimmune dysregulation.</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,423195c6b63ad0a6773374364ebf3612,8e5a1be9981340d419f7b3ad27076009</data>
    </node>
    <node id="IGA NEPHROPATHY">
      <data key="d0">DISEASE</data>
      <data key="d1">IgA Nephropathy is a kidney disease characterized by the deposition of the IgA antibody, also known as immunoglobulin A, in the glomerulus of the kidneys. This condition leads to the accumulation of these protein deposits within the kidney tissues, which can result in impaired kidney function and various associated symptoms.</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612,8e5a1be9981340d419f7b3ad27076009</data>
    </node>
    <node id="RELAPSING-REMITTING MULTIPLE SCLEROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Relapsing-remitting multiple sclerosis is a form of multiple sclerosis characterized by episodes of new or worsening symptoms followed by periods of remission. This type of multiple sclerosis involves distinct periods of relapse, where symptoms flare up, and remission, where symptoms partially or completely subside.</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="OCRELIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Ocrelizumab is a monoclonal antibody used to treat multiple sclerosis</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="CHRONIC OBSTRUCTIVE PULMONARY DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Chronic obstructive pulmonary disease is a chronic inflammatory lung disease that causes obstructed airflow from the lungs</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="EMPHYSEMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Emphysema is a type of chronic obstructive pulmonary disease characterized by damage to the alveoli in the lungs</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="PROMETHEUS BIOSCIENCES, INC.">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Prometheus Biosciences, Inc. is a biotechnology company involved in the development of drugs for autoimmune diseases</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="CELERION">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Celerion is a clinical research organization involved in the testing of new drugs</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="REMEGEN CO., LTD.">
      <data key="d0">CHEMICAL</data>
      <data key="d1">RemeGen Co., Ltd. is a biotechnology company involved in the development of drugs for autoimmune diseases</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="JOHNS HOPKINS UNIVERSITY">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Johns Hopkins University is an academic institution involved in clinical research</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="GLAXOSMITHKLINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">GlaxoSmithKline is a pharmaceutical company involved in clinical trials and the development and testing of new drugs.</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="HOSPITAL FOR SPECIAL SURGERY, NEW YORK">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hospital for Special Surgery, New York is a medical institution involved in clinical research</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="UNIVERSITY OF ALABAMA AT BIRMINGHAM">
      <data key="d0">CHEMICAL</data>
      <data key="d1">University of Alabama at Birmingham is an academic institution involved in clinical research</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="VERA THERAPEUTICS, INC.">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Vera Therapeutics, Inc. is a biotechnology company involved in the development of drugs for autoimmune diseases</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="MMF">
      <data key="d0">CHEMICAL</data>
      <data key="d1">MMF (mycophenolate mofetil) is an immunosuppressive drug used to prevent organ rejection and treat autoimmune diseases</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="TABALUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Tabalumab is a monoclonal antibody targeting BAFF, used in the treatment of autoimmune diseases</data>
      <data key="d2">8e5a1be9981340d419f7b3ad27076009</data>
    </node>
    <node id="RC18">
      <data key="d0">CHEMICAL</data>
      <data key="d1">RC18 is a TACI-antibody fusion protein used in the treatment of autoimmune diseases</data>
      <data key="d2">8e5a1be9981340d419f7b3ad27076009</data>
    </node>
    <node id="ATACICEPT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Atacicept is a fusion protein that inhibits BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand), and is used in the treatment of autoimmune diseases.</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,8e5a1be9981340d419f7b3ad27076009</data>
    </node>
    <node id="ANTI-BAFF PEPTIBODY">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Anti-BAFF peptibody is a therapeutic agent targeting BAFF, used in the treatment of autoimmune diseases</data>
      <data key="d2">8e5a1be9981340d419f7b3ad27076009</data>
    </node>
    <node id="ANTI-BAFF MAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Anti-BAFF mAb is a monoclonal antibody that targets BAFF (B-cell activating factor). It is used as a therapeutic agent in the treatment of autoimmune diseases.</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,8e5a1be9981340d419f7b3ad27076009</data>
    </node>
    <node id="ELI LILLY AND COMPANY">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Eli Lilly and Company is a pharmaceutical company involved in clinical trials</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="HUMAN GENOME SCIENCES INC.">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Human Genome Sciences Inc. is a biopharmaceutical and biotechnology company involved in clinical trials.</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,68015074236b0144899baa38d01ae467</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="EMD SERONO">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">EMD Serono is a biopharmaceutical company involved in clinical trials</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="MERCK KGAA">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Merck KGaA is a pharmaceutical company involved in clinical trials</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="PLACEBO Q2W">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Placebo Q2W is a placebo administered every two weeks in clinical trials</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="PLACEBO Q4W">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Placebo Q4W is a placebo administered every four weeks in clinical trials</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="NCT00931086">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NCT00931086 is a clinical trial identifier for a study involving methotrexate and rheumatoid arthritis</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="NCT00882999">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NCT00882999 is a clinical trial identifier for a study involving belimumab and rheumatoid arthritis</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="NCT00853762">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NCT00853762 is a clinical trial identifier for a study involving LY2127399 and relapsing-remitting multiple sclerosis</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="NCT00837811">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NCT00837811 is a clinical trial identifier for a study involving atacicept and relapsing multiple sclerosis</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="NCT00785928">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NCT00785928 is a clinical trial identifier for a study involving LY2127399 and rheumatoid arthritis</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="NCT00689728">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NCT00689728 is a clinical trial identifier for a study involving LY2127399 and rheumatoid arthritis</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="NCT00664521">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NCT00664521 is a clinical trial identifier for a study involving atacicept and rheumatoid arthritis</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="NCT00642902">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NCT00642902 is a clinical trial identifier for a study involving atacicept and rheumatoid arthritis</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="NCT00595413">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NCT00595413 is a clinical trial identifier for a study involving atacicept and relapsing multiple sclerosis</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="NCT00583557">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NCT00583557 is a clinical trial identifier for a study involving atacicept and rheumatoid arthritis</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="NCT00430495">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NCT00430495 is a clinical trial identifier for a study involving belimumab and rheumatoid arthritis</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="NCT00308282">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NCT00308282 is a clinical trial identifier for a study involving atacicept and rheumatoid arthritis</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="NCT00071812">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NCT00071812 is a clinical trial identifier for a study involving belimumab and rheumatoid arthritis</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="NCT02321280">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NCT02321280 is a clinical trial identifier for a study involving RANK</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="LYMPHOSTAT-B">
      <data key="d0">CHEMICAL</data>
      <data key="d1">LymphoStat-B is a monoclonal anti-BLyS antibody used in clinical trials for rheumatoid arthritis</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="DENOSUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Denosumab is a monoclonal antibody used in clinical trials for Crohn's disease and osteoporosis</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="CALCIFIC AORTIC STENOSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Calcific aortic stenosis is a condition characterized by the narrowing of the aortic valve due to calcification</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="ALENDRONIC ACID">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Alendronic acid is a bisphosphonate drug used to treat osteoporosis</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="DIGESTIVE SYSTEM DISEASES">
      <data key="d0">DISEASE</data>
      <data key="d1">Digestive system diseases encompass a range of conditions affecting the gastrointestinal tract</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="GASTROINTESTINAL DISEASES">
      <data key="d0">DISEASE</data>
      <data key="d1">Gastrointestinal diseases affect the digestive tract</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="INTESTINAL DISEASES">
      <data key="d0">DISEASE</data>
      <data key="d1">Intestinal diseases affect the intestines</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="COLONIC DISEASES">
      <data key="d0">DISEASE</data>
      <data key="d1">Colonic diseases affect the colon</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="ABDOMINAL PAIN">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Abdominal pain is a common symptom in various gastrointestinal diseases</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="TNF&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNF&#945; (TNFSF2) is a cytokine involved in systemic inflammation and targeted by anti-TNF therapies</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="KIDNEYS">
      <data key="d0">TISSUE</data>
      <data key="d1">The kidneys are organs that filter blood and can be affected by fibrotic diseases</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="IMMUNE SYSTEM DISEASES">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="UNIVERSITY OF MANITOBA">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">University of Manitoba is an institution involved in clinical trials</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="MCMASTER UNIVERSITY">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">McMaster University is an institution involved in clinical trials</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="UNIVERSITY OF EDINBURGH">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">University of Edinburgh is an institution involved in clinical trials</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="BRITISH HEART FOUNDATION">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">British Heart Foundation is an organization involved in clinical trials</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="NHS LOTHIAN">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NHS Lothian is a healthcare organization involved in clinical trials</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="GENENTECH, INC.">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Genentech, Inc. is a biotechnology company involved in clinical trials</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="KYOWA KIRIN, INC.">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Kyowa Kirin, Inc. is a pharmaceutical company involved in clinical trials</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="KYOWA KIRIN CO., LTD.">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Kyowa Kirin Co., Ltd. is a pharmaceutical company involved in clinical trials</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="KYMAB LIMITED">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Kymab Limited is a biotechnology company involved in clinical trials</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="ICHNOS SCIENCES SA">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Ichnos Sciences SA is a biotechnology company involved in clinical trials</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="GLENMARK PHARMACEUTICALS S.A.">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Glenmark Pharmaceuticals S.A. is a pharmaceutical company involved in clinical trials</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="UC">
      <data key="d0">DISEASE</data>
      <data key="d1">Ulcerative colitis, a disease treated with TNF inhibitors</data>
      <data key="d2">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </node>
    <node id="JUVENILE IDIOPATHIC ARTHRITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Juvenile idiopathic arthritis is a type of arthritis that occurs in childrenJuvenile idiopathic arthritis, a disease treated with TNF inhibitors</data>
      <data key="d2">516e41e96d2e72d45bf1e2c69da7f18a</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Non-radiographic axial spondyloarthritis is a form of spondyloarthritis without visible changes on X-raysNon-radiographic axial spondyloarthritis, a disease treated with TNF inhibitors</data>
      <data key="d2">516e41e96d2e72d45bf1e2c69da7f18a</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="TNFSF MEMBERS">
      <data key="d0" />
      <data key="d1">TNFSF members are a group of proteins involved in inflammation, apoptosis, cell survival, fibrosis, and tissue remodeling</data>
      <data key="d2">516e41e96d2e72d45bf1e2c69da7f18a</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="FIBROTIC DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Fibrotic disease involves excessive tissue scarring and remodeling</data>
      <data key="d2">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </node>
    <node id="END STAGE FIBROSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">End stage fibrosis is a severe form of fibrosis where tissue function is significantly impaired</data>
      <data key="d2">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </node>
    <node id="ORGANS">
      <data key="d0">TISSUE</data>
      <data key="d1">Organs are collections of tissues that perform specific functions, often affected in fibrotic diseases</data>
      <data key="d2">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </node>
    <edge source="HIDRADENITIS SUPPURATIVA" target="ACNE INVERSA">
      <data key="d4">10.0</data>
      <data key="d5">Acne Inversa is another name for Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="ADALIMUMAB">
      <data key="d4">17.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) is a chronic skin condition characterized by painful lumps under the skin, often leading to abscesses and scarring. Adalimumab is a drug that has been approved for the treatment of Hidradenitis Suppurativa (HS). This approval underscores the efficacy of Adalimumab in managing the symptoms and progression of HS, providing a therapeutic option for patients suffering from this debilitating condition.</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff,661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="HAIR FOLLICLE">
      <data key="d4">10.0</data>
      <data key="d5">The hair follicle is the tissue primarily affected in Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="KERATINOCYTES">
      <data key="d4">15.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules, abscesses, and scarring, primarily affecting areas with apocrine glands. Keratinocytes, which are the predominant cell type in the epidermis, play a significant role in the pathophysiology of HS. These cells are involved in epithelial differentiation and inflammation within the context of HS. Additionally, keratinocytes in HS are known to produce pro-inflammatory cytokines such as IL-6 and IL-1&#946;, which contribute to the inflammatory milieu observed in this disease.</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff,661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="OBESITY">
      <data key="d4">13.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) and Obesity are closely linked, with obesity being both a comorbidity and an important risk factor for HS. This association underscores the significance of managing body weight in patients with HS to potentially mitigate the severity and progression of the disease.</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff,661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="METABOLIC SYNDROME">
      <data key="d4">7.0</data>
      <data key="d5">Metabolic Syndrome is considered an important risk factor for Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="INFLAMMATORY BOWEL DISEASE">
      <data key="d4">7.0</data>
      <data key="d5">Inflammatory Bowel Disease is a comorbid disorder associated with Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="ARTHRITIS">
      <data key="d4">7.0</data>
      <data key="d5">Arthritis is a comorbid disorder associated with Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="TYPE I DIABETES MELLITUS">
      <data key="d4">7.0</data>
      <data key="d5">Type I Diabetes Mellitus is a comorbid disorder associated with Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="ATHEROSCLEROSIS">
      <data key="d4">7.0</data>
      <data key="d5">Atherosclerosis is a comorbid disorder associated with Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="ADIPOGENESIS">
      <data key="d4">6.0</data>
      <data key="d5">Adipogenesis is a pathway involved in the comorbid disorders associated with Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="FOLLICULAR HYPERKERATOSIS">
      <data key="d4">8.0</data>
      <data key="d5">Follicular Hyperkeratosis is a consistent finding in Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="LYMPHOHISTIOCYTIC INFLAMMATION">
      <data key="d4">7.0</data>
      <data key="d5">Lymphohistiocytic Inflammation is an initial inflammatory response in Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="GRANULOMATOUS REACTION">
      <data key="d4">7.0</data>
      <data key="d5">Granulomatous Reaction is a type of inflammation associated with Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="SINUS TRACT FORMATION">
      <data key="d4">7.0</data>
      <data key="d5">Sinus Tract Formation is a symptom of Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="SCARRING">
      <data key="d4">14.0</data>
      <data key="d5">Scarring is a symptom of Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="EPITHELIAL SKIN CELLS">
      <data key="d4">8.0</data>
      <data key="d5">Epithelial Skin Cells are involved in the innate immunity response in Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="ADIPOSE TISSUE">
      <data key="d4">14.0</data>
      <data key="d5">Adipose Tissue is involved in Hidradenitis Suppurativa (HS).Adipose tissue is involved in Hidradenitis Suppurativa (HS) as shown in immune histochemical studies.</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="INVERSE VIRTUAL SCREENING">
      <data key="d4">12.0</data>
      <data key="d5">Inverse virtual screening is used to identify potential drugs for Hidradenitis Suppurativa (HS).Inverse Virtual Screening is used to identify potential drugs for Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="COMPUTATIONAL DRUG REPURPOSING">
      <data key="d4">12.0</data>
      <data key="d5">Computational Drug Repurposing is used to identify potential drugs for Hidradenitis Suppurativa (HS).Computational drug repurposing is used to identify potential drugs for Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="GENE EXPRESSION OMNIBUS">
      <data key="d4">5.0</data>
      <data key="d5">Gene Expression Omnibus is a database used for obtaining records related to Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="NATIONAL INSTITUTES OF HEALTH">
      <data key="d4">5.0</data>
      <data key="d5">National Institutes of Health is involved in the research of Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="TRANSCRIPTOME">
      <data key="d4">12.0</data>
      <data key="d5">Transcriptome studies are used to detect HS signature pathways.</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="PROTEOME">
      <data key="d4">12.0</data>
      <data key="d5">Proteome studies are used to detect HS signature pathways.</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="HUGO GENE NOMENCLATURE COMMITTEE">
      <data key="d4">2.0</data>
      <data key="d5">HUGO Gene Nomenclature Committee verifies gene nomenclature in studies related to Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="CHRONIC INFLAMMATION">
      <data key="d4">9.0</data>
      <data key="d5">Chronic inflammation is a major pathogenetic pathway of Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="DYSREGULATED EPITHELIAL DIFFERENTIATION">
      <data key="d4">9.0</data>
      <data key="d5">Dysregulated epithelial differentiation is a major pathogenetic pathway of Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="INFLAMMATION">
      <data key="d4">9.0</data>
      <data key="d5">Inflammation is a key component of the pathogenesis of Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="BACTERIAL COLONIZATION">
      <data key="d4">7.0</data>
      <data key="d5">Bacterial colonization is a possible secondary effect in Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="INNATE IMMUNITY RESPONSE">
      <data key="d4">8.0</data>
      <data key="d5">Innate immunity response is induced in epithelial skin cells in Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="IMPAIRED BARRIER FUNCTION">
      <data key="d4">8.0</data>
      <data key="d5">Impaired barrier function is detected at the follicular and epidermal keratinocyte level in Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="EPIDERMAL KERATINOCYTE">
      <data key="d4">8.0</data>
      <data key="d5">Epidermal keratinocytes are involved in the inflammatory process in Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="SKIN-GLAND LEVEL">
      <data key="d4">6.0</data>
      <data key="d5">The skin-gland level is involved to a minor degree in Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="APOCRINE GLAND">
      <data key="d4">7.0</data>
      <data key="d5">Apocrine glands are areas of the body commonly affected by Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="AXILLAE">
      <data key="d4">7.0</data>
      <data key="d5">The axillae are commonly affected areas in Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="INGUINAL REGION">
      <data key="d4">7.0</data>
      <data key="d5">The inguinal region is commonly affected in Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="ANOGENITAL REGION">
      <data key="d4">7.0</data>
      <data key="d5">The anogenital region is commonly affected in Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="FOLLICULAR RUPTURE">
      <data key="d4">8.0</data>
      <data key="d5">Follicular rupture is a consistent finding in Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="SINUS TRACT">
      <data key="d4">7.0</data>
      <data key="d5">Sinus tracts are formed as a result of Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="IMMUNE-RELATED DRIVERS">
      <data key="d4">8.0</data>
      <data key="d5">Immune-related drivers induce an innate immunity response in Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="DRUG REPURPOSING">
      <data key="d4">7.0</data>
      <data key="d5">Drug repurposing is a method used to find new treatments for Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="DRUG-GENE INTERACTION PROFILING">
      <data key="d4">7.0</data>
      <data key="d5">Drug-gene interaction profiling is used to identify potential drugs for Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="PLASMA CELLS">
      <data key="d4">9.0</data>
      <data key="d5">Plasma cells are involved in the pathogenesis of HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="B CELLS">
      <data key="d4">9.0</data>
      <data key="d5">B cells are involved in the pathogenesis of HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="IFN-&#915;">
      <data key="d4">8.0</data>
      <data key="d5">IFN-&#947; is implicated in the inflammatory responses in HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="IL-36">
      <data key="d4">8.0</data>
      <data key="d5">IL-36 is implicated in the inflammatory responses in HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="TNF">
      <data key="d4">8.0</data>
      <data key="d5">TNF is implicated in the inflammatory responses in HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="IL-17A">
      <data key="d4">6.0</data>
      <data key="d5">IL-17A has a lesser contribution to the inflammatory responses in HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="BRUTON&#8217;S TYROSINE KINASE">
      <data key="d4">7.0</data>
      <data key="d5">BTK is a potential therapeutic target in HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="SPLEEN TYROSINE KINASE">
      <data key="d4">7.0</data>
      <data key="d5">SYK is a potential therapeutic target in HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="SKIN">
      <data key="d4">10.0</data>
      <data key="d5">The skin is the primary tissue affected by HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="ABSCESS">
      <data key="d4">9.0</data>
      <data key="d5">Abscess formation is a characteristic symptom of HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="SINUS TRACTS">
      <data key="d4">9.0</data>
      <data key="d5">Sinus tracts are a characteristic symptom of HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="COMPLEMENT ACTIVATION">
      <data key="d4">8.0</data>
      <data key="d5">Complement activation is implicated in the pathogenesis of HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="C5A">
      <data key="d4">7.0</data>
      <data key="d5">C5a is elevated in HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="NEUTROPHILS">
      <data key="d4">8.0</data>
      <data key="d5">Neutrophils are prominent in HS skin</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="NETOSIS">
      <data key="d4">7.0</data>
      <data key="d5">NETosis is observed in HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="PLASMACYTOID DENDRITIC CELLS">
      <data key="d4">7.0</data>
      <data key="d5">Plasmacytoid dendritic cells are activated in HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="IL-6">
      <data key="d4">7.0</data>
      <data key="d5">IL-6 is involved in the inflammatory response in HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="IL-1&#914;">
      <data key="d4">7.0</data>
      <data key="d5">IL-1&#946; is involved in the inflammatory response in HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="CD19">
      <data key="d4">7.0</data>
      <data key="d5">CD19 is upregulated in HS skin</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="CD79A">
      <data key="d4">7.0</data>
      <data key="d5">CD79a is upregulated in HS skin</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="DEFB4A">
      <data key="d4">7.0</data>
      <data key="d5">DEFB4A is upregulated in HS skin</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="CXCL13">
      <data key="d4">7.0</data>
      <data key="d5">CXCL13 is upregulated in HS skin</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="IGLV3-27">
      <data key="d4">7.0</data>
      <data key="d5">IGLV3-27 is upregulated in HS skin</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="TNFRSF4">
      <data key="d4">7.0</data>
      <data key="d5">TNFRSF4 is upregulated in HS skin and blood</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="CCR4">
      <data key="d4">7.0</data>
      <data key="d5">CCR4 is upregulated in HS skin and blood</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="PBMCS">
      <data key="d4">6.0</data>
      <data key="d5">PBMCs are used in HS studies</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="NOTCH SIGNALING">
      <data key="d4">6.0</data>
      <data key="d5">Notch signaling is hypothesized to be involved in HS pathogenesis</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="GAMMA-SECRETASE COMPLEX">
      <data key="d4">6.0</data>
      <data key="d5">Gamma-secretase complex has genetic mutations associated with HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="TYPE I IFN">
      <data key="d4">7.0</data>
      <data key="d5">Type I IFNs are increased in HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="IMMUNOGLOBULINS">
      <data key="d4">7.0</data>
      <data key="d5">Immunoglobulins are increased in HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="AFRICAN AMERICANS">
      <data key="d4">6.0</data>
      <data key="d5">African Americans have a higher incidence of HS compared to Caucasians</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="CAUCASIANS">
      <data key="d4">6.0</data>
      <data key="d5">Caucasians have a lower incidence of HS compared to African Americans</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="HORMONAL COMPONENT">
      <data key="d4">6.0</data>
      <data key="d5">Hormonal components influence the development and progression of HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="QUALITY OF LIFE">
      <data key="d4">8.0</data>
      <data key="d5">Quality of life is significantly affected in patients with HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="PRURITUS">
      <data key="d4">8.0</data>
      <data key="d5">Pruritus is a common symptom of hidradenitis suppurativa</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="ADALIMUMAB" target="HS">
      <data key="d4">10.0</data>
      <data key="d5">Adalimumab is the only registered drug for Hidradenitis Suppurativa (HS). It is specifically used to treat this chronic skin condition, providing a targeted therapeutic option for patients suffering from HS.</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9,fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="ADALIMUMAB" target="TNF">
      <data key="d4">16.0</data>
      <data key="d5">Adalimumab inhibits TNF</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="ADALIMUMAB" target="DUPUYTREN&#8217;S DISEASE">
      <data key="d4">8.0</data>
      <data key="d5">Adalimumab is used to treat Dupuytren&#8217;s disease</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="ADALIMUMAB" target="ANTI-TNF THERAPY">
      <data key="d4">8.0</data>
      <data key="d5">Adalimumab is a drug used in anti-TNF therapy</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="ADALIMUMAB" target="NCT03180957">
      <data key="d4">14.0</data>
      <data key="d5">NCT03180957 is a clinical trial involving Adalimumab</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="ADALIMUMAB" target="RHEUMATOID ARTHRITIS">
      <data key="d4">16.0</data>
      <data key="d5">Adalimumab is used to treat rheumatoid arthritis</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3</data>
    </edge>
    <edge source="KERATINOCYTES" target="IL-17">
      <data key="d4">14.0</data>
      <data key="d5">IL-17 increases the expression of antimicrobial peptides in keratinocytes and heightens the responses in these cells.</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99,fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="KERATINOCYTES" target="ATOPIC DERMATITIS">
      <data key="d4">16.0</data>
      <data key="d5">Keratinocytes release cytokines in response to tissue damage in atopic dermatitis</data>
      <data key="d6">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="KERATINOCYTES" target="IL-22">
      <data key="d4">32.0</data>
      <data key="d5">IL-22 induces keratinocyte proliferation and plays a role in the downregulation of filaggrin (FLG) expression in keratinocytes.</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd,48288f3ec2832850282f95d4e38d10e1,4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="KERATINOCYTES" target="IL-33">
      <data key="d4">16.0</data>
      <data key="d5">IL-33 is produced by barrier-disrupted keratinocytes</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="KERATINOCYTES" target="HS">
      <data key="d4">7.0</data>
      <data key="d5">Keratinocytes show heightened inflammatory responses in HS</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="NOTCH SIGNALING PATHWAY">
      <data key="d4">6.0</data>
      <data key="d5">The Notch signaling pathway interacts with keratinocytes</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="IL18">
      <data key="d4">7.0</data>
      <data key="d5">IL18 is primarily derived from keratinocytes</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="IL-36">
      <data key="d4">7.0</data>
      <data key="d5">IL-36 responses are heightened in keratinocytes</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="DEFB4A">
      <data key="d4">7.0</data>
      <data key="d5">DEFB4A is highly expressed in keratinocytes</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="S100A7A">
      <data key="d4">7.0</data>
      <data key="d5">S100A7A is highly expressed in keratinocytes</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="IL36G">
      <data key="d4">7.0</data>
      <data key="d5">IL36G is highly expressed in keratinocytes</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="TNF">
      <data key="d4">7.0</data>
      <data key="d5">TNF responses are heightened in keratinocytes</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="IL-36G">
      <data key="d4">7.0</data>
      <data key="d5">IL-36G responses are heightened in keratinocytes</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="CYTOKINE">
      <data key="d4">7.0</data>
      <data key="d5">Cytokine responses are heightened in keratinocytes</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="ANTIMICROBIAL GENES">
      <data key="d4">7.0</data>
      <data key="d5">Antimicrobial genes are highly expressed in keratinocytes</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="INFLAMMATORY BURDEN">
      <data key="d4">7.0</data>
      <data key="d5">Keratinocytes show high inflammatory burden in HS</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="INFLAMMATORY SIGNATURE">
      <data key="d4">7.0</data>
      <data key="d5">Keratinocytes exhibit an inflammatory signature in HS</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="INFLAMMATORY STIMULI">
      <data key="d4">7.0</data>
      <data key="d5">Keratinocytes respond to inflammatory stimuli in HS</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="CYTOKINE RESPONSE">
      <data key="d4">7.0</data>
      <data key="d5">Keratinocytes exhibit cytokine responses in HS</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="IL-4">
      <data key="d4">16.0</data>
      <data key="d5">IL-4 reduces filaggrin expression in keratinocytes</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="KERATINOCYTES" target="IL-13">
      <data key="d4">16.0</data>
      <data key="d5">IL-13 reduces filaggrin expression in keratinocytes</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="KERATINOCYTES" target="AHR">
      <data key="d4">6.0</data>
      <data key="d5">AhR is expressed in keratinocytes</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="KERATINOCYTES" target="AD">
      <data key="d4">8.0</data>
      <data key="d5">Keratinocytes are involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="KERATINOCYTES" target="FLG">
      <data key="d4">8.0</data>
      <data key="d5">Keratinocytes are involved in the proliferation and downregulation of FLG by IL-22</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="KERATINOCYTES" target="LIGHT">
      <data key="d4">16.0</data>
      <data key="d5">LIGHT acts on keratinocytes to promote skin fibrosis</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="KERATINOCYTES" target="HVEM">
      <data key="d4">16.0</data>
      <data key="d5">HVEM is expressed on keratinocytes and mediates LIGHT-induced skin fibrosis</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="INFLAMMATORY BOWEL DISEASE" target="HS">
      <data key="d4">7.0</data>
      <data key="d5">Inflammatory bowel disease pathway is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="INFLAMMATORY BOWEL DISEASE" target="IL19">
      <data key="d4">7.0</data>
      <data key="d5">IL19 is associated with Inflammatory bowel disease</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="INFLAMMATORY BOWEL DISEASE" target="IL22">
      <data key="d4">7.0</data>
      <data key="d5">IL22 is associated with Inflammatory bowel disease</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="INFLAMMATORY BOWEL DISEASE" target="IL23A">
      <data key="d4">8.0</data>
      <data key="d5">IL23A is associated with Inflammatory bowel disease</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="INFLAMMATORY BOWEL DISEASE" target="IL26">
      <data key="d4">7.0</data>
      <data key="d5">IL26 is associated with Inflammatory bowel disease</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="INFLAMMATORY BOWEL DISEASE" target="IL37">
      <data key="d4">7.0</data>
      <data key="d5">IL37 is associated with Inflammatory bowel disease</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="INFLAMMATORY BOWEL DISEASE" target="TRAIL">
      <data key="d4">7.0</data>
      <data key="d5">TRAIL is being explored as a therapy for inflammatory bowel disease</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="INFLAMMATORY BOWEL DISEASE" target="TNF">
      <data key="d4">8.0</data>
      <data key="d5">TNF is targeted in therapies for inflammatory bowel disease</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="INFLAMMATORY BOWEL DISEASE" target="ANTI-TNF THERAPY">
      <data key="d4">8.0</data>
      <data key="d5">Anti-TNF therapy is used to treat inflammatory bowel disease</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="INFLAMMATORY BOWEL DISEASE" target="NCT03747068">
      <data key="d4">7.0</data>
      <data key="d5">NCT03747068 is a clinical trial targeting inflammatory bowel disease</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="INFLAMMATORY BOWEL DISEASE" target="PRA023">
      <data key="d4">14.0</data>
      <data key="d5">PRA023 is used in clinical trials to treat Inflammatory Bowel Disease</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="ARTHRITIS" target="IL17A">
      <data key="d4">8.0</data>
      <data key="d5">IL17A is associated with Arthritis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="ARTHRITIS" target="IL17R">
      <data key="d4">7.0</data>
      <data key="d5">IL17R is associated with Arthritis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="ARTHRITIS" target="IL23A">
      <data key="d4">8.0</data>
      <data key="d5">IL23A is associated with Arthritis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="ARTHRITIS" target="TNIP1">
      <data key="d4">14.0</data>
      <data key="d5">TNIP1 is associated with arthritis</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="TYPE I DIABETES MELLITUS" target="HS">
      <data key="d4">14.0</data>
      <data key="d5">Type I diabetes mellitus is associated with HS (Hidradenitis Suppurativa) through its pathway and signaling mechanisms. The Type I diabetes mellitus pathway is linked to HS, and the signaling involved in Type I diabetes mellitus is dysregulated in HS. This suggests a potential interplay between the autoimmune processes in Type I diabetes mellitus and the inflammatory responses observed in HS.</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719,fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="ATHEROSCLEROSIS" target="HS">
      <data key="d4">7.0</data>
      <data key="d5">Atherosclerosis signaling is dysregulated in HS</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="ATHEROSCLEROSIS" target="HEART">
      <data key="d4">8.0</data>
      <data key="d5">Atherosclerosis affects the heart</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="ATHEROSCLEROSIS" target="TNFR1">
      <data key="d4">7.0</data>
      <data key="d5">TNFR1 signaling is involved in the control of atherosclerosis</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="ATHEROSCLEROSIS" target="ADAM17">
      <data key="d4">7.0</data>
      <data key="d5">ADAM17 deficiency favors overactivation of TNFR2 and atherosclerosis progression</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="ATHEROSCLEROSIS" target="OX40L">
      <data key="d4">16.0</data>
      <data key="d5">OX40L is implicated in atherosclerosis</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="ADIPOGENESIS" target="HS">
      <data key="d4">15.0</data>
      <data key="d5">Adipogenesis is associated with HS (Hidradenitis Suppurativa). Adipogenesis, the process of cell differentiation by which preadipocytes become adipocytes, has been linked to the pathogenesis of HS, a chronic inflammatory skin condition characterized by painful nodules, abscesses, and scarring. This association suggests that the mechanisms driving adipogenesis may play a role in the development or exacerbation of HS, highlighting the importance of understanding adipogenic pathways in the context of this disease.</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719,f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="SCARRING" target="TNFSF MEMBERS">
      <data key="d4">8.0</data>
      <data key="d5">TNFSF members are involved in driving scarring</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="ADIPOSE TISSUE" target="BAFF">
      <data key="d4">7.0</data>
      <data key="d5">BAFF-/- mice show reduced adipose tissue fibrosis</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="GENE EXPRESSION OMNIBUS" target="GSE154775">
      <data key="d4">7.0</data>
      <data key="d5">GSE154775 is a data set in the Gene Expression Omnibus</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="GENE EXPRESSION OMNIBUS" target="GSE154773">
      <data key="d4">7.0</data>
      <data key="d5">GSE154773 is a data set in the Gene Expression Omnibus</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="GENE EXPRESSION OMNIBUS" target="NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION">
      <data key="d4">16.0</data>
      <data key="d5">National Center for Biotechnology Information hosts the Gene Expression Omnibus</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="TRANSCRIPTOME" target="AD">
      <data key="d4">14.0</data>
      <data key="d5">Transcriptome analysis is used to study gene expression in atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="HUGO GENE NOMENCLATURE COMMITTEE" target="EUROPEAN BIOINFORMATICS INSTITUTE">
      <data key="d4">6.0</data>
      <data key="d5">The HUGO Gene Nomenclature Committee collaborates with the European Bioinformatics Institute</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="CHRONIC INFLAMMATION" target="ATOPIC DERMATITIS">
      <data key="d4">8.0</data>
      <data key="d5">Chronic inflammation is a symptom of Atopic Dermatitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="CHRONIC INFLAMMATION" target="CD27">
      <data key="d4">7.0</data>
      <data key="d5">Chronic inflammation is associated with a lack of CD27 expression</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="INFLAMMATION" target="HS">
      <data key="d4">25.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) is characterized by chronic inflammation. Inflammation is a key symptom in HS, underscoring the persistent and often debilitating nature of this condition.</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="INFLAMMATION" target="AD">
      <data key="d4">44.0</data>
      <data key="d5">Inflammation is a common and key feature of atopic dermatitis (AD). It is a primary symptom not only in AD but also in other comorbidities associated with the condition.</data>
      <data key="d6">143d2dc302af5606656797bff162e23e,90f4809673ca34628b0e607908f0bf0b,a867a1e73cef039eb3f28e072463b838,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="SINUS TRACT" target="HS">
      <data key="d4">8.0</data>
      <data key="d5">Sinus tracts are associated with chronic inflammation in HS</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="CXCL10">
      <data key="d4">24.0</data>
      <data key="d5">CXCL10 is one of the differentially expressed genes in Hidradenitis Suppurativa (HS). Its expression is notably increased in HS, indicating a potential role in the pathogenesis or progression of this autoimmune condition.</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9,b62ecc47bf54393bc78dd65986b949d6</data>
    </edge>
    <edge source="HS" target="IL6">
      <data key="d4">8.0</data>
      <data key="d5">IL6 is one of the differentially expressed genes in Hidradenitis Suppurativa</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="HS" target="IL17A">
      <data key="d4">24.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) is associated with increased mRNA expression of IL17A. IL17A is one of the differentially expressed genes in Hidradenitis Suppurativa, indicating its potential role in the pathogenesis of this autoimmune condition.</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b,990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="HS" target="IL36A">
      <data key="d4">38.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) is associated with increased expression of IL36A. Specifically, IL36A shows elevated mRNA expression levels in HS, indicating that it is one of the differentially expressed genes in this condition.</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b,990bc0f89db6ad8683c7a06a3ab356d9,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="IL36G">
      <data key="d4">38.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) is associated with increased expression of IL36G. Specifically, IL36G has been identified as one of the differentially expressed genes in HS, with both its overall expression and mRNA levels being elevated in individuals suffering from this condition.</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b,990bc0f89db6ad8683c7a06a3ab356d9,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="S100A8">
      <data key="d4">8.0</data>
      <data key="d5">S100A8 is one of the differentially expressed genes in Hidradenitis Suppurativa</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="HS" target="S100A9">
      <data key="d4">8.0</data>
      <data key="d5">S100A9 is one of the differentially expressed genes in Hidradenitis Suppurativa</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="HS" target="SKIN">
      <data key="d4">94.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition that primarily affects the skin. Formalin-fixed, paraffin-embedded tissue slides obtained from HS patients were used for CyTOF imaging to study the disease. Lesional skin biopsies were collected from patients with HS, revealing differences between lesional and non-lesional areas. The skin is a key tissue affected by Hidradenitis Suppurativa, with significant pathological changes observed in affected regions.</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,411a4d246f0a9321e52971446a5a0606,990bc0f89db6ad8683c7a06a3ab356d9,b28eeca0ff01a7715947d55a04978a43,bae090d8a29c15868ba1c4f29ae79e99,e4d25b1cd44df240a29591bc46a875ab,f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="BLOOD">
      <data key="d4">35.0</data>
      <data key="d5">Blood is a tissue where differentially expressed genes and proteins are detected in Hidradenitis Suppurativa (HS) patients. Blood is used for biomarker studies in HS patients, and blood samples were collected from patients with HS.</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,990bc0f89db6ad8683c7a06a3ab356d9,f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="FIBROSIS">
      <data key="d4">7.0</data>
      <data key="d5">Fibrosis is a symptom often seen in chronic inflammatory diseases like Hidradenitis Suppurativa</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="HS" target="JAK-STAT SIGNALING PATHWAY">
      <data key="d4">16.0</data>
      <data key="d5">The JAK-STAT signaling pathway is involved in HS (Hidradenitis Suppurativa). This pathway is associated with HS, indicating a potential role in the pathogenesis or progression of the disease.</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719,f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="RHEUMATOID ARTHRITIS">
      <data key="d4">7.0</data>
      <data key="d5">Rheumatoid arthritis pathway is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="TH17 CELL DIFFERENTIATION PATHWAY">
      <data key="d4">8.0</data>
      <data key="d5">Th17 cell differentiation pathway is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="LIPID AND ATHEROSCLEROSIS PATHWAY">
      <data key="d4">7.0</data>
      <data key="d5">Lipid and atherosclerosis pathway is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="TLR PATHWAY">
      <data key="d4">7.0</data>
      <data key="d5">TLR pathway is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="C-TYPE LEPTIN RECEPTOR SIGNALING PATHWAY">
      <data key="d4">7.0</data>
      <data key="d5">C-type leptin receptor signaling pathway is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="TNF SIGNALING PATHWAY">
      <data key="d4">7.0</data>
      <data key="d5">TNF signaling pathway is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="IL-17">
      <data key="d4">32.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules, abscesses, and scarring. Interleukin-17 (IL-17) has been implicated in the pathogenesis of HS, with IL-17 signaling being closely associated with the disease. Given its significant role in the inflammatory processes underlying HS, anti-IL-17 compounds have been proposed as a potential treatment option for managing this debilitating condition.</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719,e340a83f7cba0ea5be731b1f682ea7c7,f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="IL-4">
      <data key="d4">19.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) and Interleukin-4 (IL-4) are interconnected in the context of autoimmune disease research. While IL-4 signaling is associated with HS, indicating a potential role in the disease's pathophysiology, it is important to note that IL-4 has no significant response in HS lesional skin. This suggests that although IL-4 may be involved in the broader signaling mechanisms related to HS, its direct impact on the affected skin areas is minimal.</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b,4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="IL-13">
      <data key="d4">7.0</data>
      <data key="d5">IL-13 signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="IL-10">
      <data key="d4">7.0</data>
      <data key="d5">IL-10 signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="IL-20 FAMILY">
      <data key="d4">7.0</data>
      <data key="d5">IL-20 family signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="IL-1 FAMILY">
      <data key="d4">7.0</data>
      <data key="d5">IL-1 family signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="IL-18">
      <data key="d4">7.0</data>
      <data key="d5">IL-18 signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="IL-36">
      <data key="d4">39.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules and abscesses. Interleukin-36 (IL-36) plays a significant role in the pathogenesis of HS. IL-36 has a notable response in HS lesional skin, indicating its involvement in the inflammatory processes of the disease. Additionally, IL-36 responses are particularly prominent in HS keratinocytes, the predominant cell type in the epidermis, suggesting that these cells may be key mediators of IL-36-driven inflammation in HS. Overall, IL-36 signaling is closely associated with HS, highlighting its potential as a therapeutic target for managing this debilitating condition.</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,2e0cdefd62bed7c674d7fb93ef336c2b,4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="IL-2 FAMILY">
      <data key="d4">7.0</data>
      <data key="d5">IL-2 family signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="IL-21">
      <data key="d4">7.0</data>
      <data key="d5">IL-21 signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="IL-12 FAMILY">
      <data key="d4">7.0</data>
      <data key="d5">IL-12 family signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="EPIDERMAL GROWTH FACTOR RECEPTOR">
      <data key="d4">7.0</data>
      <data key="d5">Epidermal growth factor receptor signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="IL-1 RECEPTOR">
      <data key="d4">7.0</data>
      <data key="d5">IL-1 receptor signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="CORNIFIED ENVELOPE">
      <data key="d4">7.0</data>
      <data key="d5">Formation of the cornified envelope is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="ANTIMICROBIAL PEPTIDES">
      <data key="d4">7.0</data>
      <data key="d5">Antimicrobial peptides are associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="INNATE IMMUNE SYSTEM">
      <data key="d4">8.0</data>
      <data key="d5">Innate immune system is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="IFNG SIGNALING">
      <data key="d4">7.0</data>
      <data key="d5">IFNG signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="SIGNAL TRANSDUCTION">
      <data key="d4">7.0</data>
      <data key="d5">Signal transduction is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="NUCLEAR RECEPTOR">
      <data key="d4">14.0</data>
      <data key="d5">Nuclear receptor signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="GPCR">
      <data key="d4">14.0</data>
      <data key="d5">G protein-coupled receptors (GPCRs) are associated with HSGPCR signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="LEPTIN">
      <data key="d4">14.0</data>
      <data key="d5">Leptin signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="DEVELOPMENTAL BIOLOGY">
      <data key="d4">7.0</data>
      <data key="d5">Developmental biology pathways are associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="ABAT">
      <data key="d4">14.0</data>
      <data key="d5">ABAT is a druggable gene associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="ADRA1A">
      <data key="d4">14.0</data>
      <data key="d5">ADRA1A is a druggable gene associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="CYP3A4">
      <data key="d4">14.0</data>
      <data key="d5">CYP3A4 is a druggable gene associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="GRM4">
      <data key="d4">14.0</data>
      <data key="d5">GRM4 is a druggable gene associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="HRH1">
      <data key="d4">14.0</data>
      <data key="d5">HRH1 is a druggable gene associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="OPRD1">
      <data key="d4">14.0</data>
      <data key="d5">OPRD1 is a druggable gene associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="OPRM">
      <data key="d4">14.0</data>
      <data key="d5">OPRM is a druggable gene associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="PRKAB1">
      <data key="d4">14.0</data>
      <data key="d5">PRKAB1 is a druggable gene associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="PTGS1">
      <data key="d4">14.0</data>
      <data key="d5">PTGS1 is a druggable gene associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="PTGS2">
      <data key="d4">14.0</data>
      <data key="d5">PTGS2 is a druggable gene associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="SLC6A4">
      <data key="d4">14.0</data>
      <data key="d5">SLC6A4 is a druggable gene associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="CD4+ LYMPHOCYTES">
      <data key="d4">24.0</data>
      <data key="d5">CD4+ lymphocytes are involved in the pathogenesis of HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719,fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="CD45+CD4+ T CELLS">
      <data key="d4">24.0</data>
      <data key="d5">CD45+CD4+ T cells are responsible for IL-17 production in HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719,fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="CD11C+CD1A-CD14+ DENDRITIC CELLS">
      <data key="d4">24.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules, abscesses, and scarring. CD11c+CD1a-CD14+ dendritic cells play a significant role in the pathogenesis of HS. These dendritic cells are known to produce the pro-inflammatory cytokine IL-1&#946;, which is particularly evident in lesional HS skin. The presence of IL-1&#946; produced by CD11c+CD1a-CD14+ dendritic cells in the affected areas underscores their contribution to the inflammatory processes observed in HS.</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719,fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="IL-1&#914;">
      <data key="d4">45.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules, abscesses, and scarring. Interleukin-1 beta (IL-1&#946;) is implicated in the pathogenesis of HS. IL-1&#946; is produced in HS, contributing to the inflammatory processes that underlie the disease.</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="IL-17 CYTOKINE FAMILY">
      <data key="d4">10.0</data>
      <data key="d5">IL-17 cytokine family is involved in HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="DEGS">
      <data key="d4">32.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) is associated with differentially expressed genes (DEGs). DEGs are differentially expressed in HS and have been identified in this condition. These DEGs are prominently clustered around BTK and SYK nodes, indicating a significant role in the pathophysiology of HS.</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,4a1ab1e50481cdd86d237db424a95719,e340a83f7cba0ea5be731b1f682ea7c7,f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="EGFR">
      <data key="d4">7.0</data>
      <data key="d5">Epidermal growth factor receptor (EGFR) signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="TLRS">
      <data key="d4">7.0</data>
      <data key="d5">Toll-like receptors (TLRs) are associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="RESISTIN">
      <data key="d4">14.0</data>
      <data key="d5">Resistin signaling is associated with Hidradenitis Suppurativa (HS) and is dysregulated in this condition.</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719,fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="IFNG">
      <data key="d4">39.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) is associated with increased expression of Interferon-gamma (IFNG). Specifically, IFNG expression is elevated at both the protein and mRNA levels in individuals with HS. This suggests that IFNG signaling plays a significant role in the pathophysiology of HS.</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b,4a1ab1e50481cdd86d237db424a95719,b62ecc47bf54393bc78dd65986b949d6</data>
    </edge>
    <edge source="HS" target="CD4+ T CELLS">
      <data key="d4">8.0</data>
      <data key="d5">CD4+ T cells are involved in the pathogenesis of HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="CD11C+ DENDRITIC CELLS">
      <data key="d4">8.0</data>
      <data key="d5">CD11c+ dendritic cells are involved in the pathogenesis of HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="EXTRANUCLEAR SIGNALING">
      <data key="d4">7.0</data>
      <data key="d5">Extranuclear signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="TH17">
      <data key="d4">8.0</data>
      <data key="d5">Th17 differentiation of CD4+ lymphocytes is activated in HS</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="IL-1">
      <data key="d4">8.0</data>
      <data key="d5">IL-1 signaling pathway is prominent in HS</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="PLIN1">
      <data key="d4">7.0</data>
      <data key="d5">PLIN1 is upregulated in HS</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="PPAR&#915;">
      <data key="d4">15.0</data>
      <data key="d5">HS (Hidradenitis Suppurativa) and PPAR&#947; (Peroxisome Proliferator-Activated Receptor Gamma) are closely related in the context of autoimmune diseases. PPAR&#947; is involved in HS, specifically in the regulation of adipocytes within HS lesions. Research indicates that the PPAR&#947; pathway is down-regulated in the adipocytes of HS lesions, suggesting a potential mechanism by which PPAR&#947; contributes to the pathophysiology of HS. This down-regulation may play a critical role in the inflammatory processes and tissue remodeling observed in HS, highlighting PPAR&#947; as a significant target for therapeutic intervention in this condition.</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9,fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="IGF">
      <data key="d4">7.0</data>
      <data key="d5">IGF transport and uptake of IGF-binding proteins pathway is dysregulated in HS</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="LIPID">
      <data key="d4">7.0</data>
      <data key="d5">Lipid metabolism is dysregulated in HS</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="C-TYPE LEPTIN RECEPTOR">
      <data key="d4">7.0</data>
      <data key="d5">C-type leptin receptor signaling is dysregulated in HS</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="INFLAMMATORY BOWEL DISEASES">
      <data key="d4">8.0</data>
      <data key="d5">HS is associated with inflammatory bowel diseases</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="CROHN&#8217;S DISEASE">
      <data key="d4">8.0</data>
      <data key="d5">HS is associated with Crohn&#8217;s disease</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="AXIAL SPONDYLARTHRITIS">
      <data key="d4">8.0</data>
      <data key="d5">HS is associated with axial spondylarthritis</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="PACHYONYCHIA CONGENITA">
      <data key="d4">8.0</data>
      <data key="d5">HS is associated with pachyonychia congenita</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="STEATOCYSTOMA MULTIPLEX">
      <data key="d4">8.0</data>
      <data key="d5">HS is associated with steatocystoma multiplex</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="DOWLING-DEGOS DISEASE">
      <data key="d4">8.0</data>
      <data key="d5">HS is associated with Dowling-Degos disease</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="KERATITIS&#8211;ICHTHYOSIS&#8211;DEAFNESS SYNDROME">
      <data key="d4">8.0</data>
      <data key="d5">HS is associated with keratitis&#8211;ichthyosis&#8211;deafness syndrome</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="DOWN SYNDROME">
      <data key="d4">8.0</data>
      <data key="d5">HS is associated with Down syndrome</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="INFLAMMATORY BOWEL DISEASE PATHWAY">
      <data key="d4">8.0</data>
      <data key="d5">HS is associated with the inflammatory bowel disease pathway</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="RHEUMATOID ARTHRITIS PATHWAY">
      <data key="d4">8.0</data>
      <data key="d5">HS is associated with the rheumatoid arthritis pathway</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="TYPE I DIABETES MELLITUS SIGNALING">
      <data key="d4">8.0</data>
      <data key="d5">HS is associated with type I diabetes mellitus signaling</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="LIPID AND ATHEROSCLEROSIS">
      <data key="d4">8.0</data>
      <data key="d5">HS is associated with lipid and atherosclerosis</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="ADIPOGENESIS SIGNALING">
      <data key="d4">8.0</data>
      <data key="d5">HS is associated with adipogenesis signaling</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="JAK-STAT INHIBITORS">
      <data key="d4">8.0</data>
      <data key="d5">JAK-STAT inhibitors are proposed for HS treatment</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="PI3K INHIBITORS">
      <data key="d4">8.0</data>
      <data key="d5">PI3K inhibitors are proposed for HS treatment</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="MMP INHIBITORS">
      <data key="d4">8.0</data>
      <data key="d5">MMP inhibitors are proposed for HS treatment</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="GENTAMICIN">
      <data key="d4">7.0</data>
      <data key="d5">Gentamicin is reported as a repurposing drug for HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="IBUDILAST">
      <data key="d4">7.0</data>
      <data key="d5">Ibudilast is reported as a repurposing drug for HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="SPIRONOLACTONE">
      <data key="d4">7.0</data>
      <data key="d5">Spironolactone is reported as a repurposing drug for HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="TRASTUZUMAB">
      <data key="d4">7.0</data>
      <data key="d5">Trastuzumab is reported as a repurposing drug for HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="THALIDOMIDE">
      <data key="d4">7.0</data>
      <data key="d5">Thalidomide is reported as a repurposing drug for HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="APREMILAST">
      <data key="d4">7.0</data>
      <data key="d5">Apremilast is reported as a repurposing drug for HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="GLUCOSAMINE">
      <data key="d4">7.0</data>
      <data key="d5">Glucosamine is reported as a repurposing drug for HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="INTERFERON-A-2B">
      <data key="d4">7.0</data>
      <data key="d5">Interferon-a-2b is reported as a repurposing drug for HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="BINIMETINIB">
      <data key="d4">7.0</data>
      <data key="d5">Binimetinib is reported as a repurposing drug for HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="MIDOSTAURIN">
      <data key="d4">7.0</data>
      <data key="d5">Midostaurin is reported as a repurposing drug for HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="TYROSINE KINASE RECEPTOR INHIBITORS">
      <data key="d4">8.0</data>
      <data key="d5">Tyrosine kinase receptor inhibitors are proposed for HS treatment</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="TNF INHIBITORS">
      <data key="d4">8.0</data>
      <data key="d5">TNF inhibitors are proposed for HS treatment</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="CYCLOOXYGENASE INHIBITORS">
      <data key="d4">8.0</data>
      <data key="d5">Cyclooxygenase inhibitors are proposed for HS treatment</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="EGF RECEPTOR INHIBITORS">
      <data key="d4">8.0</data>
      <data key="d5">EGF receptor inhibitors are proposed for HS treatment</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="PPAR&#915; LIGANDS">
      <data key="d4">8.0</data>
      <data key="d5">PPAR&#947; ligands are proposed for HS treatment</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="EPITHELIAL CELL DIFFERENTIATION">
      <data key="d4">9.0</data>
      <data key="d5">Dysregulated epithelial cell differentiation is involved in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="OBESITY SIGNALING">
      <data key="d4">8.0</data>
      <data key="d5">Obesity signaling is involved in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="ADAM12">
      <data key="d4">14.0</data>
      <data key="d5">ADAM12 is upregulated in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="ADIPOQ">
      <data key="d4">14.0</data>
      <data key="d5">ADIPOQ is downregulated in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="AR">
      <data key="d4">14.0</data>
      <data key="d5">AR is upregulated in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="BTK">
      <data key="d4">61.0</data>
      <data key="d5">HS (Hidradenitis Suppurativa) and BTK (Bruton's Tyrosine Kinase) are closely linked in the context of autoimmune disease research. BTK is identified as a key node in the network analysis of HS, indicating its central role in the disease's molecular pathways. It is involved in B cell signaling, which is crucial for immune response regulation. BTK shows diversified regulation in HS, suggesting that its activity and expression can vary significantly within the disease context. Notably, there is increased expression of BTK in HS-affected skin, highlighting its potential involvement in the pathophysiology of the condition. Consequently, BTK is considered a potential therapeutic target in HS, offering a promising avenue for developing targeted treatments for this chronic inflammatory skin disease.</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,b62ecc47bf54393bc78dd65986b949d6,e340a83f7cba0ea5be731b1f682ea7c7,e4d25b1cd44df240a29591bc46a875ab,f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="C3">
      <data key="d4">12.0</data>
      <data key="d5">C3 shows mixed regulation in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="C5AR1">
      <data key="d4">14.0</data>
      <data key="d5">C5AR1 is upregulated in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="CASP1">
      <data key="d4">14.0</data>
      <data key="d5">CASP1 is upregulated in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="CCL18">
      <data key="d4">14.0</data>
      <data key="d5">CCL18 is upregulated in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="CCL26">
      <data key="d4">14.0</data>
      <data key="d5">CCL26 is upregulated in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="CCR4">
      <data key="d4">8.0</data>
      <data key="d5">CCR4 is upregulated in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="KEGG GO">
      <data key="d4">7.0</data>
      <data key="d5">KEGG GO is used for pathway analysis in HS studies</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="IL-17 SIGNALING PATHWAY">
      <data key="d4">8.0</data>
      <data key="d5">IL-17 signaling pathway is involved in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="RECEPTOR INTERACTION PATHWAY">
      <data key="d4">1.0</data>
      <data key="d5">Receptor interaction pathway is involved in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="JAK INHIBITORS">
      <data key="d4">8.0</data>
      <data key="d5">JAK inhibitors are proposed for HS treatment</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="CYTOKINE INHIBITORS">
      <data key="d4">8.0</data>
      <data key="d5">Cytokine inhibitors are proposed for HS treatment</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="TYROSINE KINASE INHIBITORS">
      <data key="d4">8.0</data>
      <data key="d5">Tyrosine kinase inhibitors are proposed for HS treatment</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="TNF">
      <data key="d4">81.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) and Tumor Necrosis Factor (TNF) are closely linked in the context of autoimmune disease research. TNF is implicated in HS and is involved in the pathogenesis of the disease. It is primarily localized to plasma cells in HS skin and is colocalized with these cells, indicating a significant role in the inflammatory processes associated with HS. Despite some reports suggesting that TNF has no significant response in HS lesional skin, other studies have shown that TNF responses are elevated in HS keratinocytes. This discrepancy highlights the complexity of TNF's role in HS. Importantly, TNF is a target for biologic treatment in HS, underscoring its relevance in therapeutic strategies aimed at managing this chronic inflammatory condition.</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,2e0cdefd62bed7c674d7fb93ef336c2b,411a4d246f0a9321e52971446a5a0606,b62ecc47bf54393bc78dd65986b949d6,e340a83f7cba0ea5be731b1f682ea7c7,e4d25b1cd44df240a29591bc46a875ab,f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="CYCLOOXYGENASE">
      <data key="d4">8.0</data>
      <data key="d5">Cyclooxygenase is involved in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="EGF RECEPTOR">
      <data key="d4">8.0</data>
      <data key="d5">EGF receptor is involved in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="EPITHELIAL CELLS">
      <data key="d4">8.0</data>
      <data key="d5">Epithelial cells are involved in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="HORMONES">
      <data key="d4">8.0</data>
      <data key="d5">Hormones are involved in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="KEGG">
      <data key="d4">21.0</data>
      <data key="d5">HS (Hidradenitis Suppurativa) is a chronic inflammatory skin condition characterized by painful nodules and abscesses. KEGG (Kyoto Encyclopedia of Genes and Genomes) is a comprehensive database used for pathway analysis in various biological studies, including those focused on HS. In the context of HS research, KEGG pathways have been found to be enriched in differentially expressed genes (DEGs) in HS-affected skin, providing valuable insights into the molecular mechanisms underlying the disease.</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="GO">
      <data key="d4">7.0</data>
      <data key="d5">GO is used for pathway analysis in HS studies</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="RECEPTOR INTERACTION">
      <data key="d4">8.0</data>
      <data key="d5">Receptor interaction pathway is involved in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="IL-17 SIGNALING">
      <data key="d4">8.0</data>
      <data key="d5">IL-17 signaling pathway is involved in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="JAK-STAT SIGNALING">
      <data key="d4">8.0</data>
      <data key="d5">JAK-STAT signaling pathway is involved in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="TRANSCRIPTOMIC PROFILES">
      <data key="d4">8.0</data>
      <data key="d5">Transcriptomic profiles are used to study HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="PROTEIN EXPRESSION">
      <data key="d4">8.0</data>
      <data key="d5">Protein expression profiles are used to study HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="LESIONAL SKIN">
      <data key="d4">9.0</data>
      <data key="d5">Lesional skin is affected by HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="NON-LESIONAL SKIN">
      <data key="d4">9.0</data>
      <data key="d5">Non-lesional skin is not affected by HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="HEALTHY CONTROLS">
      <data key="d4">8.0</data>
      <data key="d5">Healthy controls are used as a comparison group in HS studies</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="BIOMARKERS">
      <data key="d4">8.0</data>
      <data key="d5">Biomarkers are used as indicators of HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="DEFB4A">
      <data key="d4">16.0</data>
      <data key="d5">DEFB4A is an antimicrobial gene with increased expression in HS</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </edge>
    <edge source="HS" target="CXCL13">
      <data key="d4">16.0</data>
      <data key="d5">CXCL13 is a B cell chemoattractant gene with increased expression in HS</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </edge>
    <edge source="HS" target="CXCL1">
      <data key="d4">16.0</data>
      <data key="d5">CXCL1 is a neutrophil chemokine gene with increased expression in HS</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </edge>
    <edge source="HS" target="IL17F">
      <data key="d4">16.0</data>
      <data key="d5">IL17F has increased mRNA expression in HS</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </edge>
    <edge source="HS" target="IL13">
      <data key="d4">14.0</data>
      <data key="d5">IL13 has decreased expression in HS</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </edge>
    <edge source="HS" target="IL17C">
      <data key="d4">14.0</data>
      <data key="d5">IL17C has decreased expression in HS</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </edge>
    <edge source="HS" target="IFN-&#915;">
      <data key="d4">54.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) and Interferon-gamma (IFN-&#947;) are closely linked in the context of autoimmune disease research. IFN-&#947; has a significant response in HS lesional skin, indicating its active role in the disease's pathology. This cytokine's responses are particularly prominent in HS keratinocytes, the predominant cell type in the epidermis. Increased levels of IFN-&#947; are consistently found in HS-affected skin, further implicating it in the pathogenesis of HS. Collectively, these findings underscore the critical involvement of IFN-&#947; in the development and progression of Hidradenitis Suppurativa.</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,2e0cdefd62bed7c674d7fb93ef336c2b,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="B CELLS">
      <data key="d4">51.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) and B cells are closely linked in the context of autoimmune research. B cells are identified as a potential therapeutic target in HS due to their involvement in the immune response associated with the disease. These cells are predominant in HS skin, where they exhibit significant molecular signatures. This suggests that B cells play a crucial role in the pathophysiology of HS, making them a focal point for potential therapeutic interventions.</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b,411a4d246f0a9321e52971446a5a0606,b62ecc47bf54393bc78dd65986b949d6,bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="HS" target="TH2">
      <data key="d4">16.0</data>
      <data key="d5">Th2 cells have significant signatures in HS skin</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </edge>
    <edge source="HS" target="CD4+">
      <data key="d4">16.0</data>
      <data key="d5">CD4+ cells have significant signatures in HS skin</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </edge>
    <edge source="HS" target="CD8+">
      <data key="d4">16.0</data>
      <data key="d5">CD8+ cells have significant signatures in HS skin</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </edge>
    <edge source="HS" target="RNA-SEQ">
      <data key="d4">38.0</data>
      <data key="d5">RNA-Seq was used to analyze gene expression in HS, providing insights into the transcriptomic characteristics and inflammatory processes associated with the disease.</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,2e0cdefd62bed7c674d7fb93ef336c2b,411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="SCRNA-SEQ">
      <data key="d4">18.0</data>
      <data key="d5">scRNA-Seq was used to characterize the inflammatory cell composition in HS and to outline the cellular composition of HS.</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </edge>
    <edge source="HS" target="PLASMA CELLS">
      <data key="d4">35.0</data>
      <data key="d5">Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules, abscesses, and scarring. Plasma cells, which are a type of white blood cell involved in the immune response, have been identified as a potential therapeutic target in HS. These cells are predominant in the skin of individuals with HS, suggesting their significant role in the disease's pathology. The involvement of plasma cells in the immune response in HS highlights their importance in the development and progression of this condition, making them a focal point for potential treatments.</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,b62ecc47bf54393bc78dd65986b949d6,bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="HS" target="CYTOF">
      <data key="d4">26.0</data>
      <data key="d5">CyTOF data demonstrated clear separation between HS and normal skin. Additionally, CyTOF imaging was used to identify and quantify infiltrating leukocytes in HS.</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="HS" target="T-SNE">
      <data key="d4">24.0</data>
      <data key="d5">t-SNE was used to analyze CyTOF data in HS and to visualize leukocyte clustering in HS.</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="HS" target="MONOCYTES">
      <data key="d4">12.0</data>
      <data key="d5">Monocytes are part of the leukocyte infiltration in HS</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="HS" target="LEUKOCYTES">
      <data key="d4">2.0</data>
      <data key="d5">Leukocytes are increased in HS skin</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="HS" target="LEUKOCYTE INFILTRATION">
      <data key="d4">8.0</data>
      <data key="d5">Leukocyte infiltration is observed in HS skin</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="HS" target="MONOCYTE/MACROPHAGES">
      <data key="d4">8.0</data>
      <data key="d5">Monocytes and macrophages are present in HS skin</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="CD8+ T CELLS">
      <data key="d4">8.0</data>
      <data key="d5">CD8+ T cells are present in HS skin</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="NEUTROPHILS">
      <data key="d4">8.0</data>
      <data key="d5">Neutrophils are present in HS skin</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="IMMUNOGLOBULIN">
      <data key="d4">23.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) is associated with increased immunoglobulin production in the skin. This heightened production of immunoglobulins is a notable feature in the pathology of HS, indicating an active immune response in the affected skin areas.</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="COMPLEMENT">
      <data key="d4">23.0</data>
      <data key="d5">Complement activation is increased in HS skin</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="BCR">
      <data key="d4">38.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) is associated with an increased diversity and expression of B-cell receptor (BCR) gene segments in the skin. Specifically, BCR diversity is heightened in HS-affected skin, indicating a broader range of BCR gene segments. This increased expression and diversity of BCR in HS skin suggest a potential role of B-cells and their receptors in the pathogenesis or progression of the disease.</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="TCR">
      <data key="d4">21.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) and T-Cell Receptor (TCR) are closely linked in the context of autoimmune responses. In HS, there is an increased expression of TCR in the affected skin, indicating a heightened immune activity. However, the gene segments of TCR in HS show less pronounced shifts, suggesting that while TCR expression is elevated, the genetic variability or rearrangement of TCR segments is not as significant. This combination of increased TCR expression with less pronounced gene segment shifts provides a nuanced understanding of the immune dynamics in HS.</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="C1Q">
      <data key="d4">24.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules and abscesses. Research has shown that C1q, a component of the complement system, is prominently expressed in the skin of HS patients. Immunohistochemistry studies of HS patient tissues have utilized C1q to better understand its role in the disease. These studies have consistently demonstrated increased levels of C1q in the skin affected by HS, suggesting a significant involvement of the complement system in the pathogenesis of this condition.</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="C3B">
      <data key="d4">22.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules, abscesses, and scarring. Research indicates that C3b, a component of the complement system, is prominently expressed in the skin of individuals with HS. Increased levels of C3b in HS skin suggest a significant role for the complement system in the pathogenesis of this disease, potentially contributing to the inflammatory processes observed in affected patients.</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="C4D">
      <data key="d4">22.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules, abscesses, and scarring. Research indicates that C4d, a component of the complement system, is prominently expressed in the skin of individuals with HS. Increased levels of C4d in HS skin suggest a significant role for the complement pathway in the pathogenesis of this disease.</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="CR1">
      <data key="d4">34.0</data>
      <data key="d5">HS (Hidradenitis Suppurativa) is associated with increased levels of CR1 (Complement Receptor 1) in the skin. CR1 has been observed to be elevated in the skin of HS patients, and its presence has been confirmed through immunohistochemistry studies conducted on tissues from these patients. This suggests a potential role of CR1 in the pathophysiology of HS.</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="CR2">
      <data key="d4">34.0</data>
      <data key="d5">HS (Hidradenitis Suppurativa) is associated with increased levels of CR2 (Complement Receptor 2) in the skin. CR2 has been observed to be elevated in the skin of HS patients, and this increase has been confirmed through immunohistochemistry studies conducted on tissues from individuals with HS.</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="IGG">
      <data key="d4">22.0</data>
      <data key="d5">HS (Hidradenitis Suppurativa) and IgG (Immunoglobulin G) are closely related in the context of autoimmune disease mechanisms. IgG immune complexes are deposited in the skin of individuals with HS, indicating a potential role of these complexes in the pathogenesis of the disease. Additionally, there is an overlap between gene expression in activated B cells treated with IgG and those observed in HS, suggesting that IgG may influence the gene expression patterns associated with HS. This relationship underscores the importance of IgG in the immune response and its potential impact on the development and progression of HS.</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="SYK">
      <data key="d4">49.0</data>
      <data key="d5">HS (Hidradenitis Suppurativa) is a chronic inflammatory skin condition characterized by painful nodules, abscesses, and scarring. Research has identified SYK (Spleen Tyrosine Kinase) as a significant player in the pathogenesis of HS. Increased expression of SYK has been observed in the skin of HS patients, indicating its active role in the disease. Network analysis has highlighted SYK as a key node, underscoring its central importance in the molecular pathways involved in HS. Furthermore, SYK is known to be involved in B cell signaling, which is crucial for immune responses. Given its pivotal role, SYK is considered a potential therapeutic target for HS, offering a promising avenue for the development of new treatments aimed at mitigating the symptoms and progression of this debilitating condition.</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,b62ecc47bf54393bc78dd65986b949d6,e340a83f7cba0ea5be731b1f682ea7c7,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="IL-17A">
      <data key="d4">16.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) is associated with elevated levels of the cytokine IL-17A. Research indicates that IL-17A has enriched signals in HS, and increased IL-17A levels are found in the skin of individuals with HS. This suggests a significant role for IL-17A in the pathophysiology of HS, potentially contributing to the inflammatory processes characteristic of the disease.</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="GRANZYME B">
      <data key="d4">8.0</data>
      <data key="d5">Granzyme B has enriched signals in HS</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="CCR5">
      <data key="d4">8.0</data>
      <data key="d5">CCR5 has enriched signals in HS</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="ACALABRUTINIB">
      <data key="d4">22.0</data>
      <data key="d5">HS (Hidradenitis Suppurativa) and Acalabrutinib are interconnected in the context of therapeutic research. Acalabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, is being explored as a potential therapeutic option for HS. This interest is driven by observed overlaps in gene expression profiles between activated B cells treated with Acalabrutinib and those found in HS, suggesting that Acalabrutinib may modulate pathways relevant to the pathophysiology of HS.</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="IBRUTINIB">
      <data key="d4">22.0</data>
      <data key="d5">Ibrutinib is used as a potential therapeutic in Hidradenitis Suppurativa (HS). There is an observed overlap between gene expression in activated B cells treated with Ibrutinib and those in HS, suggesting a possible mechanistic link and therapeutic potential of Ibrutinib in managing HS.</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="FOSTAMATINIB">
      <data key="d4">22.0</data>
      <data key="d5">Fostamatinib is used as a potential therapeutic in Hidradenitis Suppurativa (HS). There is an observed overlap between gene expression in activated B cells treated with Fostamatinib and those in HS, suggesting a possible mechanistic link or shared pathway that could be targeted for therapeutic benefit.</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="CCL4">
      <data key="d4">29.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules, abscesses, and scarring. CCL4, also known as macrophage inflammatory protein-1 beta (MIP-1&#946;), plays a significant role in the immune response associated with HS. Research indicates that CCL4 is highly expressed in the skin of individuals with HS, suggesting its involvement in the disease's pathogenesis. However, targeting B cells in HS has been shown to decrease the expression of CCL4, highlighting a potential therapeutic approach to modulate the immune response in this condition.</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,b62ecc47bf54393bc78dd65986b949d6,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="CD3+ T CELLS">
      <data key="d4">8.0</data>
      <data key="d5">CD3+ T cells are present in HS skin</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="CD20+ B CELLS">
      <data key="d4">8.0</data>
      <data key="d5">CD20+ B cells are present in HS skin</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="CD138+ PLASMA CELLS">
      <data key="d4">8.0</data>
      <data key="d5">CD138+ plasma cells are present in HS skin</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="PHOSPHO-BTK">
      <data key="d4">36.0</data>
      <data key="d5">HS (Hidradenitis Suppurativa) is associated with the activation of BTK (Bruton's Tyrosine Kinase) in the skin. Specifically, phospho-BTK, the phosphorylated and thus activated form of BTK, is increased in HS. This increase in phospho-BTK has been observed through immunohistochemistry studies conducted on tissues from HS patients.</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="PHOSPHO-SYK">
      <data key="d4">29.0</data>
      <data key="d5">HS (Hidradenitis Suppurativa) is a chronic inflammatory skin condition characterized by painful nodules and abscesses. Research has shown that the activation of SYK (Spleen Tyrosine Kinase) plays a significant role in the pathophysiology of HS. Specifically, Phospho-SYK, the phosphorylated and thus activated form of SYK, is notably increased in the skin of HS patients. This increase in Phospho-SYK has been confirmed through immunohistochemistry studies conducted on tissues from HS patients, highlighting its potential as a biomarker and therapeutic target in the management of the disease.</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="LEUKOCYTE">
      <data key="d4">22.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) is characterized by the clustering of leukocytes in the affected skin. Leukocytes are the dominant infiltrating cells in HS, playing a significant role in the inflammatory processes associated with the disease.</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="IGM">
      <data key="d4">22.0</data>
      <data key="d5">HS (Hidradenitis Suppurativa) and IgM (Immunoglobulin M) are interconnected in the context of immune response. IgM plays a role in the immune response associated with HS. Additionally, there is an observed overlap in gene expression between activated B cells treated with IgM and those involved in HS, indicating a potential link in the underlying immunological mechanisms of the disease.</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="SHANNON INDEX">
      <data key="d4">7.0</data>
      <data key="d5">The Shannon index was used to measure BCR diversity in HS</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="JACCARD DISTANCE">
      <data key="d4">7.0</data>
      <data key="d5">The Jaccard distance was used to measure dissimilarity in BCR sequences in HS</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="PCOA">
      <data key="d4">21.0</data>
      <data key="d5">Principal Coordinate Analysis (PCoA) was utilized to visualize the diversity of B-cell receptor (BCR) sequences in individuals with Hidradenitis Suppurativa (HS). The analysis demonstrated a clear separation of BCR sequences in HS, indicating distinct patterns in the immune repertoire associated with this autoimmune condition.</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="IHC">
      <data key="d4">22.0</data>
      <data key="d5">HS (Hidradenitis Suppurativa) and IHC (Immunohistochemistry) are closely related in the context of medical research. IHC is a crucial technique used to confirm the nature of the inflammatory infiltrate in HS. Additionally, IHC has been employed to validate various findings in HS, underscoring its importance in understanding the pathology and immune responses associated with this chronic skin condition.</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="GEPS">
      <data key="d4">21.0</data>
      <data key="d5">HS (Hidradenitis Suppurativa) and GEPS (Gene Expression Profiling System) are closely linked through research focused on understanding the inflammatory mechanisms underlying HS. GEPS network analysis has identified critical inflammatory nodes in HS, providing valuable insights into the disease's pathophysiology. By utilizing GEPS to analyze signal transduction networks in HS, researchers have been able to map out key pathways and molecular interactions that contribute to the chronic inflammation characteristic of this condition. This comprehensive approach underscores the importance of advanced genomic tools like GEPS in elucidating complex disease mechanisms and potentially guiding the development of targeted therapies for HS.</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="BCR SIGNALING">
      <data key="d4">9.0</data>
      <data key="d5">BCR signaling is enriched in HS</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="SYK SIGNALING">
      <data key="d4">9.0</data>
      <data key="d5">SYK signaling is enriched in HS</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="BTK SIGNALING">
      <data key="d4">9.0</data>
      <data key="d5">BTK signaling is enriched in HS</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="COMPLEMENT PATHWAY">
      <data key="d4">17.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules, abscesses, and scarring. Research indicates that components of the complement pathway are increased in HS skin, suggesting an upregulation of this immune system component. Furthermore, the complement pathway is activated in HS, contributing to the inflammatory processes observed in this disease. This activation likely plays a significant role in the pathogenesis and progression of HS, making it a potential target for therapeutic intervention.</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="C5A">
      <data key="d4">7.0</data>
      <data key="d5">C5a levels are elevated in HS</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="NEUTROPHIL">
      <data key="d4">7.0</data>
      <data key="d5">Neutrophils are prominent in HS</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="NETOSIS">
      <data key="d4">7.0</data>
      <data key="d5">NETosis is increased in HS</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="CD4+ T CELL">
      <data key="d4">7.0</data>
      <data key="d5">Increased number of CD4+ T cells in HS</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="IL-6">
      <data key="d4">21.0</data>
      <data key="d5">IL-6 is implicated in HS pathogenesis</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="TYPE I IFNS">
      <data key="d4">14.0</data>
      <data key="d5">Type I IFNs are implicated in HS</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="PDC">
      <data key="d4">14.0</data>
      <data key="d5">pDCs are implicated in HS</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="IL-36A">
      <data key="d4">7.0</data>
      <data key="d5">Increased IL-36A expression is found in HS</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="IL-36G">
      <data key="d4">7.0</data>
      <data key="d5">Increased IL-36G expression is found in HS</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="LCK">
      <data key="d4">28.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules and abscesses. Research indicates that there is increased expression of LCK in the skin of individuals with HS. LCK, or lymphocyte-specific protein tyrosine kinase, plays a crucial role in B cell signaling. Given its involvement in immune cell function, LCK has been identified as a potential therapeutic target for treating HS. This suggests that modulating LCK activity could be a promising strategy for managing the inflammatory processes associated with HS.</data>
      <data key="d6">b62ecc47bf54393bc78dd65986b949d6,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="MICE">
      <data key="d4">2.0</data>
      <data key="d5">No animal models exist for HS</data>
      <data key="d6">b62ecc47bf54393bc78dd65986b949d6</data>
    </edge>
    <edge source="HS" target="CD14">
      <data key="d4">12.0</data>
      <data key="d5">CD14 was one of the markers used in CyTOF imaging of HS patient tissues</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="HS" target="CD16">
      <data key="d4">12.0</data>
      <data key="d5">CD16 was one of the markers used in CyTOF imaging of HS patient tissues</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="HS" target="CD68">
      <data key="d4">12.0</data>
      <data key="d5">CD68 was one of the markers used in CyTOF imaging of HS patient tissues</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="HS" target="CD15">
      <data key="d4">12.0</data>
      <data key="d5">CD15 was one of the markers used in CyTOF imaging of HS patient tissues</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="HS" target="CD31">
      <data key="d4">12.0</data>
      <data key="d5">CD31 was one of the markers used in CyTOF imaging of HS patient tissues</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="HS" target="CD45">
      <data key="d4">12.0</data>
      <data key="d5">CD45 was one of the markers used in CyTOF imaging of HS patient tissues</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="HS" target="E-CADHERIN">
      <data key="d4">12.0</data>
      <data key="d5">E-Cadherin was one of the markers used in CyTOF imaging of HS patient tissues</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="HS" target="CD20">
      <data key="d4">26.0</data>
      <data key="d5">CD20 is expressed on B cells in HS (Hidradenitis Suppurativa) skin. Additionally, CD20 was one of the markers used in CyTOF imaging of HS patient tissues.</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="CD8">
      <data key="d4">12.0</data>
      <data key="d5">CD8 was one of the markers used in CyTOF imaging of HS patient tissues</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="HS" target="COLLAGEN">
      <data key="d4">12.0</data>
      <data key="d5">Collagen was one of the markers used in CyTOF imaging of HS patient tissues</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="HS" target="CD27">
      <data key="d4">12.0</data>
      <data key="d5">CD27 was one of the markers used in CyTOF imaging of HS patient tissues</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="HS" target="CD103">
      <data key="d4">12.0</data>
      <data key="d5">CD103 was one of the markers used in CyTOF imaging of HS patient tissues</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="HS" target="CD138">
      <data key="d4">26.0</data>
      <data key="d5">HS (Hidradenitis Suppurativa) is a chronic inflammatory skin condition characterized by painful nodules, abscesses, and scarring. CD138, also known as syndecan-1, is a cell surface protein that is expressed on plasma cells in the skin affected by HS. In the context of HS, CD138 has been utilized as one of the markers in CyTOF (Cytometry by Time-Of-Flight) imaging to analyze patient tissues, aiding in the detailed study of the cellular composition and immune landscape of the disease.</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="PAN-ACTIN">
      <data key="d4">12.0</data>
      <data key="d5">Pan-actin was one of the markers used in CyTOF imaging of HS patient tissues</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="HS" target="IGG1">
      <data key="d4">26.0</data>
      <data key="d5">HS (Hidradenitis Suppurativa) is associated with increased levels of IgG1 in the skin. IgG1 was used in immunohistochemistry of HS patient tissues, indicating its relevance in the study and understanding of this autoimmune condition.</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="CD3">
      <data key="d4">26.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules, abscesses, and scarring. CD3, a marker for T cells, is expressed in the inflammatory infiltrate in HS skin. This expression has been utilized in immunohistochemistry studies of HS patient tissues to better understand the immune cell involvement in the disease pathology.</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="B CELL">
      <data key="d4">32.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) is associated with heightened B cell responses in patients. This condition is characterized by increased immunoglobulin production and a greater diversity of antibodies in the skin affected by HS.</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="T CELL">
      <data key="d4">16.0</data>
      <data key="d5">T cell responses are enriched in the blood of patients with HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="PSORIASIS">
      <data key="d4">14.0</data>
      <data key="d5">Comparison of proinflammatory cytokine responses in HS skin with psoriasis</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="AD">
      <data key="d4">14.0</data>
      <data key="d5">Comparison of proinflammatory cytokine responses in HS skin with AD</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="KERATINOCYTE">
      <data key="d4">16.0</data>
      <data key="d5">Keratinocytes in HS skin show elevated inflammatory responses</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="ERASMUS MC">
      <data key="d4">12.0</data>
      <data key="d5">Patients with HS were recruited from Erasmus MC</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="CDR3">
      <data key="d4">14.0</data>
      <data key="d5">Increased BCR CDR3 expression in HS skin</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="PCA">
      <data key="d4">12.0</data>
      <data key="d5">PCA plots were used to analyze skin and blood samples in HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="PHENOGRAPH">
      <data key="d4">12.0</data>
      <data key="d5">Phenograph was used to identify cell populations in HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="MANN-WHITNEY U TEST">
      <data key="d4">10.0</data>
      <data key="d5">Mann-Whitney U test was used to analyze data in HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="STUDENT&#8217;S T TEST">
      <data key="d4">10.0</data>
      <data key="d5">Student&#8217;s t test was used to analyze data in HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="FDR">
      <data key="d4">10.0</data>
      <data key="d5">FDR was used to determine significance in RNA-Seq data in HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="DECLARATION OF HELSINKI">
      <data key="d4">10.0</data>
      <data key="d5">Study was conducted in accordance with Declaration of Helsinki principles</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="INSTITUTIONAL REVIEW BOARD">
      <data key="d4">10.0</data>
      <data key="d5">Study was approved by the Institutional Review Board</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="BIOPSY">
      <data key="d4">12.0</data>
      <data key="d5">Biopsies were collected from patients with HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="ABDOMINOPLASTY">
      <data key="d4">8.0</data>
      <data key="d5">Healthy controls were recruited from patients undergoing abdominoplasty</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="SURGERY">
      <data key="d4">12.0</data>
      <data key="d5">Patients with HS were undergoing surgery</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="PROINFLAMMATORY CYTOKINE">
      <data key="d4">14.0</data>
      <data key="d5">Proinflammatory cytokine responses were compared in HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="DEG">
      <data key="d4">14.0</data>
      <data key="d5">DEGs were identified in HS skin</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="RECEPTOR-LIGAND">
      <data key="d4">12.0</data>
      <data key="d5">Receptor-ligand interactions were mapped in HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="PLASMA CELL">
      <data key="d4">30.0</data>
      <data key="d5">Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules, abscesses, and scarring. Plasma cells are the predominant inflammatory infiltrate in HS skin, indicating their significant role in the disease's pathology. These plasma cells interact with the HS microenvironment, contributing to the inflammatory processes and potentially influencing disease progression and severity.</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="CD28">
      <data key="d4">14.0</data>
      <data key="d5">CD28 is overexpressed in patients with HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="CTLA-4">
      <data key="d4">14.0</data>
      <data key="d5">CTLA-4 is overexpressed in patients with HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="ICOS">
      <data key="d4">14.0</data>
      <data key="d5">ICOS is overexpressed in patients with HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="OX40L">
      <data key="d4">2.0</data>
      <data key="d5">OX40L is overexpressed in patients with HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="JUN">
      <data key="d4">14.0</data>
      <data key="d5">Increased expression of JUN in HS skin</data>
      <data key="d6">e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="STAT1">
      <data key="d4">14.0</data>
      <data key="d5">Increased expression of STAT1 in HS skin</data>
      <data key="d6">e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="BCR CDR3">
      <data key="d4">16.0</data>
      <data key="d5">Increased diversity of BCR CDR3 sequences in HS skin</data>
      <data key="d6">e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="BCR GENE SEGMENT">
      <data key="d4">16.0</data>
      <data key="d5">Increased diversity of BCR gene segments in HS skin</data>
      <data key="d6">e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="TCR V/J GENE SEGMENT">
      <data key="d4">14.0</data>
      <data key="d5">Increased expression of TCR V/J gene segments in HS skin</data>
      <data key="d6">e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="B CELL SIGNALING">
      <data key="d4">16.0</data>
      <data key="d5">B cell signaling pathways are enriched in HS skin</data>
      <data key="d6">e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="INFLAMMATORY NODES">
      <data key="d4">14.0</data>
      <data key="d5">Inflammatory nodes are critical in HS</data>
      <data key="d6">e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="SIGNAL TRANSDUCTION NETWORKS">
      <data key="d4">14.0</data>
      <data key="d5">Signal transduction networks are involved in HS</data>
      <data key="d6">e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="SHANNON DIVERSITY INDEX">
      <data key="d4">16.0</data>
      <data key="d5">Shannon diversity index shows increased BCR diversity in HS</data>
      <data key="d6">e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="JACCARD DISSIMILARITIES">
      <data key="d4">14.0</data>
      <data key="d5">Jaccard dissimilarities used in PCoA for HS</data>
      <data key="d6">e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="CLONAL ABUNDANCE">
      <data key="d4">14.0</data>
      <data key="d5">Clonal abundance analysis shows separation of HS from controls</data>
      <data key="d6">e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="IG HEAVY CHAIN">
      <data key="d4">14.0</data>
      <data key="d5">Ig heavy chain expression analyzed in HS</data>
      <data key="d6">e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="&#922; LIGHT CHAIN">
      <data key="d4">14.0</data>
      <data key="d5">&#954; light chain expression analyzed in HS</data>
      <data key="d6">e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="&#923; LIGHT CHAIN">
      <data key="d4">2.0</data>
      <data key="d5">&#955; light chain expression analyzed in HS</data>
      <data key="d6">e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="BERMEKIMAB">
      <data key="d4">14.0</data>
      <data key="d5">Bermekimab was developed for hidradenitis suppurativa</data>
      <data key="d6">6309eeea565f06479830cec32938abc9</data>
    </edge>
    <edge source="CXCL10" target="C&#8211;C RECEPTOR INTERACTION PATHWAY">
      <data key="d4">14.0</data>
      <data key="d5">CXCL10 is involved in the cytokine-cytokine receptor interaction pathway</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="CXCL10" target="C-X-C MOTIF CHEMOKINE LIGAND 10">
      <data key="d4">9.0</data>
      <data key="d5">CXCL10 encodes C-X-C Motif Chemokine Ligand 10</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="CXCL10" target="TYPE I IFNS">
      <data key="d4">16.0</data>
      <data key="d5">CXCL10 is an interferon response gene</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="CXCL10" target="AD">
      <data key="d4">8.0</data>
      <data key="d5">CXCL10 is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="IL6" target="JAK-STAT SIGNALING PATHWAY">
      <data key="d4">14.0</data>
      <data key="d5">IL6 is involved in the JAK-STAT signaling pathway</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="IL6" target="INTERLEUKIN 6">
      <data key="d4">9.0</data>
      <data key="d5">IL6 encodes Interleukin 6</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="IL6" target="DUPILUMAB">
      <data key="d4">8.0</data>
      <data key="d5">Dupilumab is a receptor antagonist targeting IL6</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL6" target="CALCITRIOL">
      <data key="d4">7.0</data>
      <data key="d5">Calcitriol is involved in the regulation of IL6</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL6" target="SILTUXIMAB">
      <data key="d4">8.0</data>
      <data key="d5">Siltuximab is a receptor antagonist targeting IL6</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL6" target="TOCILIZUMAB">
      <data key="d4">8.0</data>
      <data key="d5">Tocilizumab is a receptor antagonist targeting IL6</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL6" target="SARILUMAB">
      <data key="d4">8.0</data>
      <data key="d5">Sarilumab is a receptor antagonist targeting IL6</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL6" target="SATRALIZUMAB">
      <data key="d4">8.0</data>
      <data key="d5">Satralizumab is a receptor antagonist targeting IL6</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL6" target="VITAMIN C">
      <data key="d4">6.0</data>
      <data key="d5">Vitamin C is involved in the regulation of IL6</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL6" target="VITAMIN E">
      <data key="d4">6.0</data>
      <data key="d5">Vitamin E is involved in the regulation of IL6</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL6" target="ANDROGRAPHOLIDE">
      <data key="d4">7.0</data>
      <data key="d5">Andrographolide inhibits IL6</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="IL6" target="INFLIXIMAB">
      <data key="d4">14.0</data>
      <data key="d5">Infliximab inhibits IL6</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="IL17A" target="IL-17 SIGNALING PATHWAY">
      <data key="d4">14.0</data>
      <data key="d5">IL17A is involved in the IL-17 signaling pathway</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="IL17A" target="ALLERGIC CONTACT DERMATITIS">
      <data key="d4">8.0</data>
      <data key="d5">IL17A is associated with Allergic contact dermatitis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL17A" target="BIMEKIZUMAB">
      <data key="d4">14.0</data>
      <data key="d5">Bimekizumab inhibits IL17A</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="IL17A" target="SECUKINUMAB">
      <data key="d4">7.0</data>
      <data key="d5">Secukinumab inhibits IL17A</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="IL17A" target="T CELLS">
      <data key="d4">8.0</data>
      <data key="d5">IL17A is expressed by T cells in HS skin</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="IL17A" target="IL-17A">
      <data key="d4">8.0</data>
      <data key="d5">IL17A encodes the cytokine IL-17A</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="IL36A" target="TH17 CELL DIFFERENTIATION PATHWAY">
      <data key="d4">14.0</data>
      <data key="d5">IL36A is involved in the Th17 cell differentiation pathway</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="IL36A" target="PSORIASIS">
      <data key="d4">8.0</data>
      <data key="d5">IL36A is associated with Psoriasis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL36G" target="TOLL-LIKE RECEPTOR PATHWAY">
      <data key="d4">14.0</data>
      <data key="d5">IL36G is involved in the Toll-like receptor pathway</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="IL36G" target="PSORIASIS">
      <data key="d4">8.0</data>
      <data key="d5">IL36G is associated with Psoriasis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL36G" target="ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS">
      <data key="d4">8.0</data>
      <data key="d5">IL36G is associated with Acute generalized exanthematous pustulosis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="S100A8" target="INFLAMMATORY BOWEL DISEASE PATHWAY">
      <data key="d4">14.0</data>
      <data key="d5">S100A8 is involved in the inflammatory bowel disease pathway</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="S100A8" target="BRODALUMAB">
      <data key="d4">14.0</data>
      <data key="d5">Brodalumab targets S100A8</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="S100A8" target="AD">
      <data key="d4">7.0</data>
      <data key="d5">S100A8 is upregulated in atopic dermatitis lesions</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="S100A9" target="RHEUMATOID ARTHRITIS PATHWAY">
      <data key="d4">14.0</data>
      <data key="d5">S100A9 is involved in the rheumatoid arthritis pathway</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="S100A9" target="LIPID AND ATHEROSCLEROSIS PATHWAY">
      <data key="d4">8.0</data>
      <data key="d5">S100A9 is involved in the lipid and atherosclerosis pathway</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="S100A9" target="BRODALUMAB">
      <data key="d4">14.0</data>
      <data key="d5">Brodalumab targets S100A9</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="S100A9" target="AD">
      <data key="d4">7.0</data>
      <data key="d5">S100A9 is upregulated in atopic dermatitis lesions</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="SKIN" target="ATOPIC DERMATITIS">
      <data key="d4">48.0</data>
      <data key="d5">Atopic Dermatitis primarily affects the skin, causing inflammation and epidermal barrier dysfunction. The skin is the primary tissue impacted by this condition, leading to significant dermatological symptoms.</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603,693a2aac101eaaadf92614317a1e4da8,6ada075e562abd7bd445164e9fc309b4,cccfd5ff480e281556e2210cd0e5c4b5,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="SKIN" target="AD">
      <data key="d4">152.0</data>
      <data key="d5">Atopic Dermatitis (AD) primarily affects the skin. Skin biopsies were collected from patients with AD to analyze transcriptomic and proteomic profiles. The skin, being the primary tissue affected by AD, requires treatment to heal and reduce inflammation.</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d,104cc78517b2eca2e9cb7e00de1fe4b0,143d2dc302af5606656797bff162e23e,2cec06c4d46f5ff9ee936a78d8b077cd,2e9a8d71f6bd251a0b13458c39e69746,442e7fad2fab75fa2449309783294d89,475995d7d211bbfde6d8ba52f324d688,78e26c66107dba37ac4bab65406b43a0,8246ea974dfb00cb5e3d984004e21a9e,89dbac0da39e4de2b602052cd792b90d,90f4809673ca34628b0e607908f0bf0b,a867a1e73cef039eb3f28e072463b838,b62ecc47bf54393bc78dd65986b949d6,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="SKIN" target="PSORIASIS">
      <data key="d4">18.0</data>
      <data key="d5">Psoriasis affects the skin</data>
      <data key="d6">b62ecc47bf54393bc78dd65986b949d6</data>
    </edge>
    <edge source="SKIN" target="EPIDERMIS">
      <data key="d4">22.0</data>
      <data key="d5">The skin is composed of multiple layers, with the epidermis being the outermost layer. The epidermis serves as the outer layer of the skin, providing a protective barrier against environmental factors.</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,b62ecc47bf54393bc78dd65986b949d6</data>
    </edge>
    <edge source="SKIN" target="DERMIS">
      <data key="d4">16.0</data>
      <data key="d5">The dermis is the inner layer of the skin</data>
      <data key="d6">b62ecc47bf54393bc78dd65986b949d6</data>
    </edge>
    <edge source="SKIN" target="HUMAN">
      <data key="d4">8.0</data>
      <data key="d5">Skin samples were obtained from human patients</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="SKIN" target="MICROBIOME">
      <data key="d4">7.0</data>
      <data key="d5">The skin microbiome can be modulated to treat atopic dermatitis</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="SKIN" target="PHYTOCERAMIDES">
      <data key="d4">8.0</data>
      <data key="d5">Phytoceramides enhance the absorption into the deeper layers of the skin</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="BETAMETHASONE DIPROPIONATE (BMD)">
      <data key="d4">14.0</data>
      <data key="d5">Betamethasone Dipropionate (BMD) is used in nanostructured lipid carriers for skinBetamethasone Dipropionate (BMD) provides extended anti-inflammatory effects on the skin</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="VITAMIN E (VE)">
      <data key="d4">2.0</data>
      <data key="d5">Vitamin E (VE) is used in nanostructured lipid carriers for skinVitamin E (VE) improves skin moisture</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="PIOGLITAZONE (PGZ)">
      <data key="d4">7.0</data>
      <data key="d5">Pioglitazone (PGZ) is used in a nanoemulsion for treating skin diseases</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="HISTOPATHOLOGY">
      <data key="d4">7.0</data>
      <data key="d5">Histopathology studies show improved structural features of the skin</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="CLOBETASOL PROPIONATE (CP)">
      <data key="d4">7.0</data>
      <data key="d5">Clobetasol Propionate (CP) is used in a nanoemulsion for treating skin diseases</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="BMV">
      <data key="d4">14.0</data>
      <data key="d5">BMV, or Betamethasone Valerate, is utilized in various formulations to treat skin conditions. Specifically, BMV is incorporated into liposomes, which are microscopic vesicles used to deliver drugs effectively to targeted areas of the skin. Additionally, BMV-loaded chitosan gel formulations have been shown to enhance drug accumulation in the skin, thereby potentially increasing the efficacy of the treatment. These advanced delivery systems aim to improve the therapeutic outcomes for patients suffering from various dermatological issues.</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5,bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="DIFLUCORTOLONE VALERATE (DFV)">
      <data key="d4">7.0</data>
      <data key="d5">Diflucortolone Valerate (DFV) is used in liposomes for treating skin conditions</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="CHITOSAN">
      <data key="d4">7.0</data>
      <data key="d5">Chitosan gel is used to deliver drugs to the skin</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="ALBINO WISTAR RATS">
      <data key="d4">6.0</data>
      <data key="d5">Albino Wistar Rats are used to study skin conditions</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="TEWL">
      <data key="d4">8.0</data>
      <data key="d5">TEWL is a measure of water loss through the skin</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="MAST CELL">
      <data key="d4">7.0</data>
      <data key="d5">Mast cell activity is important in attenuating AD progression</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="NICOTINAMIDE (VITAMIN B3)">
      <data key="d4">7.0</data>
      <data key="d5">Nicotinamide (Vitamin B3) is used in topical formulations for skin</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="IGE">
      <data key="d4">7.0</data>
      <data key="d5">IgE levels are reduced in the skin</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="GLYCYRRHIZIC ACID (GA)">
      <data key="d4">7.0</data>
      <data key="d5">Glycyrrhizic Acid (GA) is used in hydrogel for treating skin conditions</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="CYCLOSPORINE A (CSA)">
      <data key="d4">7.0</data>
      <data key="d5">Cyclosporine A (CsA) is used in liposomal formulations for skin</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="TAC">
      <data key="d4">14.0</data>
      <data key="d5">TAC (Tacrolimus) is utilized in solid lipid nanoparticles for skin applications. TAC-loaded nanoparticles have been shown to enhance skin penetration, thereby improving the delivery and efficacy of the treatment.</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5,bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="NLCS">
      <data key="d4">8.0</data>
      <data key="d5">NLCs are used to improve skin moisture</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="VITAMIN E">
      <data key="d4">7.0</data>
      <data key="d5">Vitamin E is used to increase skin hydration</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="HG-NLCVE">
      <data key="d4">7.0</data>
      <data key="d5">HG-NLCVE could be utilized in cosmetic applications to improve skin hydration</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="METHOTREXATE (MTX)">
      <data key="d4">7.0</data>
      <data key="d5">MTX-loaded NLCs enhance dermal penetration</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="BECLOMETHASONE DIPROPIONATE (BDP)">
      <data key="d4">7.0</data>
      <data key="d5">BDP-loaded nanocrystals showed higher drug deposition through mouse skin</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="HA">
      <data key="d4">7.0</data>
      <data key="d5">HA-based nanoparticles improve skin penetration</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="CHOLESTEROL">
      <data key="d4">7.0</data>
      <data key="d5">Cholesterol-based nanoparticles improve skin penetration</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="NIC">
      <data key="d4">7.0</data>
      <data key="d5">NIC improves skin penetration when incorporated into nanoparticles</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="PLG">
      <data key="d4">7.0</data>
      <data key="d5">PLG-based nanoparticles are used for topical delivery to the skin</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="PLGA">
      <data key="d4">7.0</data>
      <data key="d5">PLGA-based nanoparticles enhance drug penetration into deeper skin layers</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="CSA">
      <data key="d4">7.0</data>
      <data key="d5">CsA-loaded nanoparticles enhance drug penetration into deeper skin layers</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="HYDROCORTISONE (HC)">
      <data key="d4">7.0</data>
      <data key="d5">HC-loaded chitosan-based nanoparticles increase drug accumulation in the skin</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="HYDROXYTYROSOL (HT)">
      <data key="d4">7.0</data>
      <data key="d5">HT-loaded chitosan-based nanoparticles increase drug accumulation in the skin</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="HYDROCORTISONE">
      <data key="d4">14.0</data>
      <data key="d5">Hydrocortisone and hydroxytyrosol showed increased accumulation in the skin</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="SKIN" target="HYDROXYTYROSOL">
      <data key="d4">14.0</data>
      <data key="d5">Hydrocortisone and hydroxytyrosol showed increased accumulation in the skin</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="SKIN" target="MICE">
      <data key="d4">12.0</data>
      <data key="d5">Mice treated with NPs exhibited improved control over skin thickness</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="SKIN" target="ER143">
      <data key="d4">14.0</data>
      <data key="d5">ER143 exhibited high drug retention and penetration in pig skin</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="SKIN" target="DESONIDE">
      <data key="d4">14.0</data>
      <data key="d5">DES-loaded NPs provided effective topical AD treatment</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="SKIN" target="BDP">
      <data key="d4">14.0</data>
      <data key="d5">BDP-loaded PMs showed superior drug permeation and deposition in CD-1 mouse skin</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="SKIN" target="HC">
      <data key="d4">8.0</data>
      <data key="d5">Skin biopsies were collected from healthy controls</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="SKIN" target="FORMALDEHYDE">
      <data key="d4">7.0</data>
      <data key="d5">Formaldehyde was used to fix skin biopsies</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="SKIN" target="TRYPTASE">
      <data key="d4">1.0</data>
      <data key="d5">Tryptase was analyzed in skin biopsies</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="SKIN" target="PARAFFIN">
      <data key="d4">7.0</data>
      <data key="d5">Paraffin was used to embed skin biopsies</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="SKIN" target="CITRATE-PHOSPHATE BUFFER">
      <data key="d4">7.0</data>
      <data key="d5">Citrate-Phosphate Buffer was used for antigen retrieval in skin biopsies</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="SKIN" target="DONKEY SERUM">
      <data key="d4">7.0</data>
      <data key="d5">Donkey Serum was used to block slides before staining skin biopsies</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="SKIN" target="ALEXA 488">
      <data key="d4">1.0</data>
      <data key="d5">Alexa 488 was used for staining in skin biopsies</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="SKIN" target="OX40">
      <data key="d4">26.0</data>
      <data key="d5">OX40 is co-localized in the skin and plays a role in immune cell recruitment and activation. Additionally, OX40 is co-localized with OX40L in the skin of atopic dermatitis (AD) patients.</data>
      <data key="d6">100dd7646c10899301b3c0631183da16,6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="SKIN" target="OX40L">
      <data key="d4">41.0</data>
      <data key="d5">Increased expression of OX40L is observed in the skin of patients with systemic sclerosis (SSc), particularly those with diffuse systemic sclerosis. OX40L is prominently expressed in the skin and plays a crucial role in the recruitment and activation of immune cells. Additionally, OX40L is co-localized with OX40 in the skin of patients with atopic dermatitis (AD), indicating its involvement in various skin-related autoimmune conditions.</data>
      <data key="d6">100dd7646c10899301b3c0631183da16,44f2592262cac835560b4c149fee8d2b,6b099960b0a39866e3aa6b908f1886e4,855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="SKIN" target="T CELL">
      <data key="d4">8.0</data>
      <data key="d5">T cells are recruited to and activated in the skin</data>
      <data key="d6">100dd7646c10899301b3c0631183da16</data>
    </edge>
    <edge source="SKIN" target="SSC">
      <data key="d4">20.0</data>
      <data key="d5">Systemic sclerosis (SSC) involves the fibrosis of the skin. The skin is affected by systemic sclerosis, leading to its thickening and hardening due to excessive collagen deposition.</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5,9867d43adab0ba5db44961fae4863eee,d8a485eb1e9435b083d5ef6a17f06ea5</data>
    </edge>
    <edge source="SKIN" target="ICOS">
      <data key="d4">7.0</data>
      <data key="d5">Increased expression of ICOS is observed in the skin of SSc patients</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="SKIN" target="CD112">
      <data key="d4">7.0</data>
      <data key="d5">Increased expression of CD112 is observed in the skin of SSc patients</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="SKIN" target="CD40">
      <data key="d4">7.0</data>
      <data key="d5">Increased expression of CD40 is observed in the skin of SSc patients</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="SKIN" target="FIBROSIS">
      <data key="d4">23.0</data>
      <data key="d5">Skin fibrosis is a clinical manifestation and a hallmark of systemic sclerosis (SSc). The skin can be affected by fibrosis, which is a key feature of this autoimmune disease.</data>
      <data key="d6">68015074236b0144899baa38d01ae467,855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="SKIN" target="DIGITAL ULCERS">
      <data key="d4">7.0</data>
      <data key="d5">Digital ulcers are a clinical manifestation observed in the skin of SSc patients</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="SKIN" target="NVC PATTERN">
      <data key="d4">7.0</data>
      <data key="d5">Nailfold videocapillaroscopy pattern is used to assess microvascular changes in the skin of SSc patients</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="SKIN" target="DERMAL FIBROSIS">
      <data key="d4">9.0</data>
      <data key="d5">Dermal fibrosis affects the skin</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="SKIN" target="SCLERODERMA">
      <data key="d4">8.0</data>
      <data key="d5">Scleroderma affects the skin</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="SKIN" target="ATOPIC ECZEMA">
      <data key="d4">8.0</data>
      <data key="d5">Atopic eczema affects the skin</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="SKIN" target="DUPUYTREN&#8217;S DISEASE">
      <data key="d4">8.0</data>
      <data key="d5">Dupuytren&#8217;s disease affects the skin</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="SKIN" target="SYSTEMIC SCLEROSIS">
      <data key="d4">16.0</data>
      <data key="d5">Systemic sclerosis presents with fibrosis mainly in the skin</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="SKIN" target="TAPI-1">
      <data key="d4">7.0</data>
      <data key="d5">TAPI-1 reduces skin thickness</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="SKIN" target="BAFF">
      <data key="d4">7.0</data>
      <data key="d5">BAFF mRNA expression is upregulated in the affected skin of SSc patients</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="SKIN" target="APRIL">
      <data key="d4">7.0</data>
      <data key="d5">APRIL is implicated in atopic skin diseases</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BLOOD" target="HUMAN">
      <data key="d4">8.0</data>
      <data key="d5">Blood samples were obtained from human patients</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="BLOOD" target="BUFFY COAT">
      <data key="d4">8.0</data>
      <data key="d5">Buffy coat is a fraction of blood containing most of the white blood cells and platelets</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="FIBROSIS" target="IL-4">
      <data key="d4">14.0</data>
      <data key="d5">IL-4 triggers tissue fibrosis</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="FIBROSIS" target="IL-13">
      <data key="d4">30.0</data>
      <data key="d5">IL-13 is a cytokine that plays a significant role in the development of fibrosis. It promotes fibrotic skin remodeling and triggers tissue fibrosis, contributing to the pathological changes observed in fibrotic diseases.</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30,48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="FIBROSIS" target="SSC">
      <data key="d4">39.0</data>
      <data key="d5">Fibrosis is a characteristic and key feature of systemic sclerosis (SSC). It is a pathological symptom that defines the disease, indicating that systemic sclerosis is characterized by the presence of fibrosis.</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,7b454335c2f5651d86f712037a0dc0ff,9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="FIBROSIS" target="OX40L">
      <data key="d4">34.0</data>
      <data key="d5">OX40L is implicated in fibrosis and plays a crucial role in linking immunity directly to the development and progression of this condition. It is predictive of the worsening of both dermal and lung fibrosis, indicating its potential as a biomarker for disease severity and progression in fibrotic disorders.</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3,44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="FIBROSIS" target="TNFSF">
      <data key="d4">9.0</data>
      <data key="d5">TNFSF members are involved in the process of fibrosis</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="FIBROSIS" target="FIBROBLASTS">
      <data key="d4">10.0</data>
      <data key="d5">Fibroblasts are responsible for collagen and extracellular matrix protein deposition in fibrosis</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="FIBROSIS" target="TGF&#914;">
      <data key="d4">10.0</data>
      <data key="d5">TGF&#946; is a central fibrogenic cytokine involved in fibrosis pathogenesis</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="FIBROSIS" target="MYOFIBROBLASTS">
      <data key="d4">10.0</data>
      <data key="d5">Myofibroblasts are responsible for collagen and extracellular matrix protein deposition and smooth muscle hypertrophy in fibrosis</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="FIBROSIS" target="TNF">
      <data key="d4">16.0</data>
      <data key="d5">Fibrosis is a pathological condition characterized by the excessive accumulation of extracellular matrix components, leading to tissue scarring and organ dysfunction. Tumor Necrosis Factor (TNF) plays a complex role in the process of fibrosis. On one hand, TNF is involved in the development of fibrosis, contributing to the inflammatory responses that can lead to tissue damage and scarring. On the other hand, TNF-mediated inflammation may also have a protective role by preventing the development of fibrosis driven by Transforming Growth Factor Beta 1 (TGF&#946;1). This dual role of TNF highlights the intricate balance of pro-fibrotic and anti-fibrotic mechanisms in the pathogenesis of fibrosis.</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603,a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="FIBROSIS" target="TNFR2">
      <data key="d4">8.0</data>
      <data key="d5">TNFR2 signaling appears to be key for mediating fibrotic development</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="FIBROSIS" target="MI">
      <data key="d4">16.0</data>
      <data key="d5">Myocardial infarction leads to replacement fibrosis</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="FIBROSIS" target="EXTRACELLULAR MATRIX">
      <data key="d4">16.0</data>
      <data key="d5">Extracellular matrix replaces dying cardiomyocytes in fibrosis</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="FIBROSIS" target="TNF INHIBITORS">
      <data key="d4">14.0</data>
      <data key="d5">TNF inhibitors are used in the treatment of fibrosis</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="FIBROSIS" target="LIGHT">
      <data key="d4">8.0</data>
      <data key="d5">LIGHT is a key regulator of fibrosis</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="FIBROSIS" target="TL1A">
      <data key="d4">9.0</data>
      <data key="d5">TL1A-mediated inflammation leads to fibrosis</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="FIBROSIS" target="BAFF">
      <data key="d4">15.0</data>
      <data key="d5">Higher serum BAFF levels are associated with advanced fibrosisHigh BAFF levels serve as a marker for severe skin fibrosis in SSc</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="FIBROSIS" target="APRIL">
      <data key="d4">7.0</data>
      <data key="d5">Increased production of APRIL is associated with greater skin fibrosis</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="FIBROSIS" target="TREGS">
      <data key="d4">8.0</data>
      <data key="d5">Functional downregulation of Tregs can create a pro-inflammatory environment leading to fibrosis</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="FIBROSIS" target="TEM">
      <data key="d4">6.0</data>
      <data key="d5">Effector-memory T cells are associated with enhanced fibrosis</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="FIBROSIS" target="LIVER FIBROSIS">
      <data key="d4">7.0</data>
      <data key="d5">Fibrosis is a characteristic of liver fibrosis</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="FIBROSIS" target="TRAIL">
      <data key="d4">8.0</data>
      <data key="d5">TRAIL is involved in the amelioration and reversal of fibrosis</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="FIBROSIS" target="LUNGS">
      <data key="d4">7.0</data>
      <data key="d5">The lungs can be affected by fibrosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="FIBROSIS" target="HEART">
      <data key="d4">7.0</data>
      <data key="d5">The heart can be affected by fibrosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="FIBROSIS" target="KIDNEYS">
      <data key="d4">7.0</data>
      <data key="d5">The kidneys can be affected by fibrosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="FIBROSIS" target="LIVER">
      <data key="d4">14.0</data>
      <data key="d5">The liver can be affected by fibrosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="FIBROSIS" target="GASTROINTESTINAL TRACT">
      <data key="d4">2.0</data>
      <data key="d5">The gastrointestinal tract can be affected by fibrosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="FIBROSIS" target="TNFSF MEMBERS">
      <data key="d4">9.0</data>
      <data key="d5">TNFSF members are implicated in driving fibrosis</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="NATIONAL CANCER INSTITUTE" target="G:PROFILER">
      <data key="d4">6.0</data>
      <data key="d5">The National Cancer Institute collaborates with g:Profiler</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="KYOTO ENCYCLOPEDIA OF GENES AND GENOMES (KEGG)" target="REACTOME">
      <data key="d4">6.0</data>
      <data key="d5">KEGG and Reactome are both databases used for pathway analysis</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="WIKIPATHWAYS" target="HUMAN PHENOTYPE ONTOLOGY (HP)">
      <data key="d4">6.0</data>
      <data key="d5">WikiPathways and Human Phenotype Ontology are both used for pathway and phenotype analysis</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="HUMAN PHENOTYPE ONTOLOGY (HP)" target="JACKSON LABORATORY FOR GENOMIC MEDICINE">
      <data key="d4">1.0</data>
      <data key="d5">The Jackson Laboratory for Genomic Medicine is involved in the Human Phenotype Ontology</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="THE DRUG REPURPOSING HUB" target="GENE CARDS">
      <data key="d4">6.0</data>
      <data key="d5">The Drug Repurposing Hub and Gene Cards are both used for drug and gene information</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="ELI AND EDY L. BROAD INSTITUTE" target="MIT">
      <data key="d4">6.0</data>
      <data key="d5">The Eli and Edy L. Broad Institute is affiliated with MIT</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="MIT" target="HARVARD UNIVERSITY">
      <data key="d4">6.0</data>
      <data key="d5">MIT and Harvard University collaborate on various research projects</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="WEIZMANN INSTITUTE OF SCIENCE" target="OREGON HEALTH AND SCIENCE UNIVERSITY">
      <data key="d4">6.0</data>
      <data key="d5">The Weizmann Institute of Science collaborates with Oregon Health and Science University</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="NEW YORK UNIVERSITY" target="ONTARIO INSTITUTE FOR CANCER RESEARCH">
      <data key="d4">6.0</data>
      <data key="d5">New York University collaborates with the Ontario Institute for Cancer Research</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="IL-17" target="HUMAN &#914;-DEFENSIN 2">
      <data key="d4">7.0</data>
      <data key="d5">IL-17 increases the expression of human &#946;-defensin 2</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="IL-17" target="PSORIASIN (S100A7)">
      <data key="d4">7.0</data>
      <data key="d5">IL-17 increases the expression of psoriasin (S100A7)</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="IL-17" target="CALPROTECTIN (S100A8/9)">
      <data key="d4">7.0</data>
      <data key="d5">IL-17 increases the expression of calprotectin (S100A8/9)</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="IL-17" target="AD">
      <data key="d4">23.0</data>
      <data key="d5">IL-17 is involved in inflammation and immune response in atopic dermatitis (AD). It plays a significant role in the pathophysiology of chronic atopic dermatitis lesions, contributing to the overall immune response associated with the disease.</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98,b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="IL-17" target="CAMP">
      <data key="d4">6.0</data>
      <data key="d5">cAMP mediates downstream events culminating in the inhibition of IL-17 secretion</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="IL-17" target="ATOPIC DERMATITIS">
      <data key="d4">14.0</data>
      <data key="d5">IL-17 is a cytokine involved in the immune response and is implicated in Atopic Dermatitis. This association highlights the role of IL-17 in the pathogenesis of Atopic Dermatitis, suggesting that it may be a critical factor in the inflammatory processes underlying this condition.</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1,6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="IL-17" target="IL-23">
      <data key="d4">8.0</data>
      <data key="d5">IL-23 is involved in the IL-23&#8211;IL-17 axis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-17" target="SECUKINUMAB">
      <data key="d4">8.0</data>
      <data key="d5">Secukinumab is an anti-IL-17A antibody</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-17" target="SSC">
      <data key="d4">8.0</data>
      <data key="d5">IL-17 is a proinflammatory cytokine involved in systemic sclerosis</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="IL-17" target="ICOS">
      <data key="d4">8.0</data>
      <data key="d5">ICOS induces the synthesis of IL-17 in activated T cells</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="IL-17" target="TH2">
      <data key="d4">14.0</data>
      <data key="d5">IL-17 is a cytokine involved in T helper cell responses</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="IL-17" target="OX40L">
      <data key="d4">14.0</data>
      <data key="d5">OX40L interaction may negatively regulate interleukin 17 production</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TH17 CELL" target="IL-1">
      <data key="d4">7.0</data>
      <data key="d5">IL-1 leads to the formation of Th17 cells</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="CYTOKINE" target="UMAP">
      <data key="d4">6.0</data>
      <data key="d5">UMAP is used to visualize cytokine response data</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="CYTOKINE" target="OX40">
      <data key="d4">8.0</data>
      <data key="d5">OX40 signaling promotes cytokine secretion</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="IL22RA1">
      <data key="d4">7.0</data>
      <data key="d5">IL22RA1 is associated with Rheumatoid arthritis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="TNIP1">
      <data key="d4">14.0</data>
      <data key="d5">TNIP1 is associated with rheumatoid arthritis</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="JAK INHIBITORS">
      <data key="d4">22.0</data>
      <data key="d5">Rheumatoid arthritis is a chronic inflammatory disorder that primarily affects joints, leading to pain, swelling, and potential joint destruction. JAK inhibitors, a class of medication targeting the Janus kinase (JAK) pathway, are initially employed for the treatment of rheumatoid arthritis. These inhibitors are currently in clinical development, showing promise in managing the symptoms and progression of this debilitating autoimmune disease.</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e,e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="JOINTS">
      <data key="d4">8.0</data>
      <data key="d5">Joints are affected in rheumatoid arthritis</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="ANTI-INFLAMMATORY COMPOUNDS">
      <data key="d4">7.0</data>
      <data key="d5">Anti-inflammatory compounds are used in the treatment of rheumatoid arthritis</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="DRUG&#8211;DRUG INTERACTIONS">
      <data key="d4">7.0</data>
      <data key="d5">Patients with rheumatoid arthritis have a higher risk of drug&#8211;drug interactions</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="ATOPIC DERMATITIS">
      <data key="d4">7.0</data>
      <data key="d5">Rheumatoid Arthritis is a condition that children with Atopic Dermatitis may develop</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="TACI-FC FUSION PROTEIN">
      <data key="d4">16.0</data>
      <data key="d5">Rheumatoid Arthritis (RA) is a chronic autoimmune disease characterized by inflammation and progressive destruction of the joints. TACI-Fc fusion protein is a therapeutic agent that is currently being tested for its efficacy in treating Rheumatoid Arthritis. This fusion protein is designed to modulate the immune response, potentially offering a new avenue for managing the symptoms and progression of RA.</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612,8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="MTX">
      <data key="d4">10.0</data>
      <data key="d5">Methotrexate (MTX) is used to treat Rheumatoid Arthritis.</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612,8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="TABALUMAB">
      <data key="d4">8.0</data>
      <data key="d5">Tabalumab is used in the treatment of Rheumatoid Arthritis</data>
      <data key="d6">8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="RC18">
      <data key="d4">8.0</data>
      <data key="d5">RC18 is used in the treatment of Rheumatoid Arthritis</data>
      <data key="d6">8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="PLACEBO">
      <data key="d4">14.0</data>
      <data key="d5">Rheumatoid Arthritis is a chronic inflammatory disorder that primarily affects joints, leading to pain, swelling, and potential joint destruction. In clinical trials and studies investigating treatments for Rheumatoid Arthritis, a placebo is commonly used as a control. This helps to determine the efficacy and safety of new therapeutic interventions by providing a baseline for comparison.</data>
      <data key="d6">68015074236b0144899baa38d01ae467,8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="ANTI-BAFF MAB">
      <data key="d4">8.0</data>
      <data key="d5">Anti-BAFF mAb is used in the treatment of Rheumatoid Arthritis</data>
      <data key="d6">8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="LY2127399">
      <data key="d4">24.0</data>
      <data key="d5">LY2127399 is used in clinical trials for treating rheumatoid arthritis. It is specifically employed in the treatment of Rheumatoid Arthritis.</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3,8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="BELIMUMAB">
      <data key="d4">32.0</data>
      <data key="d5">Belimumab is used in the treatment of Rheumatoid Arthritis. It is also being evaluated in clinical trials for its efficacy in managing this autoimmune disease.</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3,68015074236b0144899baa38d01ae467,8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="METHOTREXATE">
      <data key="d4">18.0</data>
      <data key="d5">Methotrexate is used to treat rheumatoid arthritis</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="BAFF">
      <data key="d4">14.0</data>
      <data key="d5">BAFF is a target for therapeutic intervention in rheumatoid arthritis</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="RITUXIMAB">
      <data key="d4">16.0</data>
      <data key="d5">Rituximab is used to treat rheumatoid arthritis</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="RANK">
      <data key="d4">2.0</data>
      <data key="d5">RANK is involved in the pathogenesis of rheumatoid arthritis</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="LYMPHOSTAT-B">
      <data key="d4">8.0</data>
      <data key="d5">LymphoStat-B is used in clinical trials for rheumatoid arthritis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="HUMAN GENOME SCIENCES INC.">
      <data key="d4">6.0</data>
      <data key="d5">Human Genome Sciences Inc. is involved in clinical trials for rheumatoid arthritis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="TNF INHIBITORS">
      <data key="d4">14.0</data>
      <data key="d5">TNF inhibitors are approved for the treatment of rheumatoid arthritis</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="IL-4" target="DUPILUMAB">
      <data key="d4">88.0</data>
      <data key="d5">Dupilumab is a therapeutic agent that targets the interleukin-4 (IL-4) pathway. Specifically, Dupilumab blocks IL-4 and inhibits its signaling by targeting the IL-4 receptor. This mechanism of action makes Dupilumab effective in modulating immune responses associated with conditions where IL-4 plays a critical role.</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41,286730b1c1f680ac465cc21d522fda0c,28f548554737fcc026b968db6bbafa30,48de7eebab3f3b418feb35a152df38fd,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="IL-4" target="T-HELPER (TH)2 CELLS">
      <data key="d4">18.0</data>
      <data key="d5">Th2 cells produce IL-4</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="IL-4" target="FILAGGRIN">
      <data key="d4">46.0</data>
      <data key="d5">IL-4, also known as Interleukin-4, is a cytokine that plays a significant role in the immune response. It has been observed to downregulate filaggrin expression. Filaggrin is a crucial protein involved in the formation of the skin barrier, and its reduced expression can lead to compromised skin integrity. Therefore, the interaction between IL-4 and filaggrin is of particular interest in the study of autoimmune diseases, as IL-4's ability to reduce filaggrin expression may contribute to the pathogenesis of conditions characterized by impaired skin barrier function.</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30,4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="LORICRIN">
      <data key="d4">44.0</data>
      <data key="d5">IL-4 downregulates loricrin expression.</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30,4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="IGE">
      <data key="d4">50.0</data>
      <data key="d5">IL-4 and IgE are closely related in the context of immune response regulation. IL-4 regulates IgE class switching, a crucial process in the adaptive immune system that allows B cells to produce IgE antibodies. Additionally, IL-4 stimulates IgE production, further emphasizing its role in modulating the levels of IgE in the body. This dual function of IL-4 highlights its importance in the immune system, particularly in allergic responses and autoimmune diseases.</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30,4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="ATOPIC DERMATITIS">
      <data key="d4">9.0</data>
      <data key="d5">IL-4 is implicated in tissue inflammation and epidermal barrier dysfunction in Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="IL-4" target="AD">
      <data key="d4">53.0</data>
      <data key="d5">IL-4 is a key cytokine involved in the pathophysiology of atopic dermatitis (AD). It plays a pivotal role in the immune response and inflammation associated with AD. As a Th2 cytokine, IL-4 is crucial in the pathogenesis of atopic dermatitis, contributing significantly to the disease's development and progression.</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30,41ccc4b41bd57cf2bda4dbb6c7ae4198,b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="IL-4" target="IL-13">
      <data key="d4">61.0</data>
      <data key="d5">IL-4 and IL-13 are cytokines involved in the immune response and share some signaling pathways. Both IL-4 and IL-13 utilize the IL-4R&#945; receptor for signaling, which underscores their overlapping functions. These cytokines are crucial in the pathophysiology of atopic dermatitis (AD) and enhance Staphylococcus aureus infections. The shared receptor and overlapping functions of IL-4 and IL-13 highlight their significant roles in immune regulation and disease processes.</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0,28f548554737fcc026b968db6bbafa30,3df8535e965efb96f5094169610507ff,48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="IL-13R&#913;1">
      <data key="d4">16.0</data>
      <data key="d5">IL-4 signals through a receptor that includes IL-13R&#945;1</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="IL-4R&#913;">
      <data key="d4">58.0</data>
      <data key="d5">IL-4 and IL-4R&#945; are closely related entities in the context of immune signaling. IL-4 binds to IL-4R&#945;, inducing receptor dimerization and initiating signal transduction. This interaction is crucial for IL-4 signaling, which occurs through a receptor complex that includes IL-4R&#945;.</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0,28f548554737fcc026b968db6bbafa30,48de7eebab3f3b418feb35a152df38fd,78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="IL-4" target="JAK1">
      <data key="d4">14.0</data>
      <data key="d5">IL-4 signaling involves JAK1-mediated phosphorylation</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="STAT6">
      <data key="d4">14.0</data>
      <data key="d5">IL-4 signaling activates STAT6</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="TYPE 1 IL-4 RECEPTOR">
      <data key="d4">14.0</data>
      <data key="d5">IL-4 signals through the type 1 IL-4 receptor</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="T CELLS">
      <data key="d4">14.0</data>
      <data key="d5">IL-4 signals through the type 1 IL-4 receptor on T cells</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="B CELLS">
      <data key="d4">14.0</data>
      <data key="d5">IL-4 signals through the type 1 IL-4 receptor on B cells</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="PLASMA CELLS">
      <data key="d4">16.0</data>
      <data key="d5">IL-4 stimulates plasma cells to produce IgE</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="TH2 CELLS">
      <data key="d4">16.0</data>
      <data key="d5">IL-4 stimulates Th2 cell development</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="EPIDERMAL BARRIER">
      <data key="d4">16.0</data>
      <data key="d5">IL-4 contributes to epidermal barrier dysfunction</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="INVOLUCRIN">
      <data key="d4">28.0</data>
      <data key="d5">IL-4 is known to downregulate involucrin. Specifically, IL-4 reduces involucrin expression, indicating a regulatory role in the modulation of this protein.</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30,48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="FIBROCYTES">
      <data key="d4">14.0</data>
      <data key="d5">IL-4 recruits fibrocytes to inflamed skin lesions</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="SENSORY NEURONS">
      <data key="d4">14.0</data>
      <data key="d5">IL-4 activates sensory neurons</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="MURINE MODELS">
      <data key="d4">12.0</data>
      <data key="d5">IL-4 is studied in murine models of AD</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="DORSAL ROOT GANGLIA">
      <data key="d4">12.0</data>
      <data key="d5">IL-4 activates sensory neurons in dorsal root ganglia</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="PERIOSTIN">
      <data key="d4">15.0</data>
      <data key="d5">IL-4 induces the production of periostin. Periostin is induced by IL-4.</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b,e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="IL-4" target="TH2 CELL">
      <data key="d4">14.0</data>
      <data key="d5">Th2 cells produce IL-4</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-4" target="CD4+ T CELL">
      <data key="d4">14.0</data>
      <data key="d5">CD4+ T cells produce IL-4</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-4" target="CD8+ T CELL">
      <data key="d4">14.0</data>
      <data key="d5">CD8+ T cells produce IL-4</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-4" target="MAST CELL">
      <data key="d4">14.0</data>
      <data key="d5">Mast cells produce IL-4</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-4" target="BASOPHIL">
      <data key="d4">14.0</data>
      <data key="d5">Basophils produce IL-4</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-4" target="EOSINOPHIL">
      <data key="d4">14.0</data>
      <data key="d5">Eosinophils produce IL-4</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-4" target="KERATINOCYTE">
      <data key="d4">14.0</data>
      <data key="d5">IL-4 promotes keratinocyte damage</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-4" target="MICE">
      <data key="d4">14.0</data>
      <data key="d5">IL-4 overexpression in mice results in AD-like phenotype</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-4" target="JAK/STAT PATHWAY">
      <data key="d4">8.0</data>
      <data key="d5">IL-4 signaling involves the JAK/STAT pathway</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0</data>
    </edge>
    <edge source="IL-4" target="TH2">
      <data key="d4">54.0</data>
      <data key="d5">IL-4 is a cytokine involved in T helper cell responses and is a primary determinant of the Th2 immune axis. It plays a crucial role in the TH2 immune response. TH2 cells, in turn, are involved in the immune response mediated by IL-4. Together, IL-4 and TH2 cells are integral components of the immune system, particularly in the context of the TH2 immune response.</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41,3df8535e965efb96f5094169610507ff,78e26c66107dba37ac4bab65406b43a0,855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="IL-4" target="ASLAN004">
      <data key="d4">16.0</data>
      <data key="d5">ASLAN004 blocks IL-4</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="IL-4" target="PERIPHERAL SENSORY NEURONS">
      <data key="d4">14.0</data>
      <data key="d5">Peripheral sensory neurons express receptors for IL-4</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="IL-4" target="NEURONS">
      <data key="d4">7.0</data>
      <data key="d5">Neurons express receptors for IL-4</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="IL-4" target="TSLP">
      <data key="d4">7.0</data>
      <data key="d5">TSLP promotes the production of IL-4</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-4" target="IL-33">
      <data key="d4">7.0</data>
      <data key="d5">IL-33 increases the production of IL-4</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-4" target="IL-4R">
      <data key="d4">16.0</data>
      <data key="d5">IL-4 and IL-4R are closely related entities in the context of immune signaling. IL-4R, or Interleukin-4 receptor, plays a crucial role in the signaling pathway of IL-4, or Interleukin-4. Specifically, IL-4R encourages the signaling of IL-4, facilitating its biological effects. Additionally, IL-4R serves as a common receptor chain for both IL-13 and IL-4, indicating its importance in mediating the actions of these cytokines in immune responses.</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-4" target="S. AUREUS">
      <data key="d4">14.0</data>
      <data key="d5">IL-4 enhances S. aureus infections</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="IL-4" target="PRURITUS">
      <data key="d4">12.0</data>
      <data key="d5">IL-4 is associated with pruritus in AD</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="IL-4" target="XEROSIS">
      <data key="d4">12.0</data>
      <data key="d5">IL-4 is associated with xerosis in AD</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="IL-4" target="JAK">
      <data key="d4">16.0</data>
      <data key="d5">JAK is involved in the signaling pathway of IL-4</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="IL-4" target="CSA">
      <data key="d4">14.0</data>
      <data key="d5">CsA-loaded nanoparticles reduce IL-4 levels</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="IL-4" target="HYDROCORTISONE">
      <data key="d4">14.0</data>
      <data key="d5">HC-NPs suppressed inflammatory cascades including IL-4</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="IL-4" target="MAST CELLS">
      <data key="d4">8.0</data>
      <data key="d5">Mast cells produce IL-4, central to the pathogenesis of Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="IL-4" target="SSC">
      <data key="d4">8.0</data>
      <data key="d5">IL-4 is a cytokine involved in promoting fibroblast activation in systemic sclerosis</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="IL-4" target="ICOS">
      <data key="d4">8.0</data>
      <data key="d5">ICOS induces the synthesis of IL-4 in activated T cells</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="IL-13" target="DUPILUMAB">
      <data key="d4">88.0</data>
      <data key="d5">Dupilumab is a therapeutic agent that targets IL-13 and its receptor. By blocking IL-13 and inhibiting its signaling pathways, Dupilumab effectively interferes with the biological activities mediated by IL-13. This mechanism of action makes Dupilumab a valuable treatment option for conditions where IL-13 plays a critical role in disease pathology.</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41,286730b1c1f680ac465cc21d522fda0c,28f548554737fcc026b968db6bbafa30,48de7eebab3f3b418feb35a152df38fd,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="IL-13" target="T-HELPER (TH)2 CELLS">
      <data key="d4">18.0</data>
      <data key="d5">Th2 cells produce IL-13</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="IL-13" target="FILAGGRIN">
      <data key="d4">32.0</data>
      <data key="d5">IL-13 downregulates filaggrin expression. IL-13 reduces filaggrin expression.</data>
      <data key="d6">4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="LORICRIN">
      <data key="d4">30.0</data>
      <data key="d5">IL-13 downregulates loricrin expression.</data>
      <data key="d6">4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="IGE">
      <data key="d4">34.0</data>
      <data key="d5">IL-13 stimulates IgE production</data>
      <data key="d6">4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="ATOPIC DERMATITIS">
      <data key="d4">9.0</data>
      <data key="d5">IL-13 is implicated in tissue inflammation and epidermal barrier dysfunction in Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="IL-13" target="AD">
      <data key="d4">68.0</data>
      <data key="d5">IL-13 is a Th2 cytokine that plays a pivotal role in atopic dermatitis (AD). It is critically involved in the immune response and inflammation associated with AD. IL-13 contributes to the inflammatory response and is a key cytokine in the pathophysiology and pathogenesis of atopic dermatitis. Additionally, IL-13 negatively impacts epidermal barrier function in AD, further exacerbating the condition.</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30,3ea70e257330c812b52334ca1f90d807,41ccc4b41bd57cf2bda4dbb6c7ae4198,a867a1e73cef039eb3f28e072463b838,b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="IL-13" target="IL-13R&#913;1">
      <data key="d4">50.0</data>
      <data key="d5">IL-13 binds to IL-13R&#945;1, inducing receptor dimerization and signal transduction. IL-13 signals through a receptor that includes IL-13R&#945;1.</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0,28f548554737fcc026b968db6bbafa30,48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="IL-4R&#913;">
      <data key="d4">40.0</data>
      <data key="d5">IL-13 and IL-4R&#945; are closely related entities in the context of immune signaling. IL-13 binds to IL-4R&#945; and signals through a receptor complex that includes IL-4R&#945;. This interaction is crucial for the signaling pathways mediated by IL-13, highlighting the importance of IL-4R&#945; in the function of IL-13.</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30,48de7eebab3f3b418feb35a152df38fd,78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="IL-13" target="JAK1">
      <data key="d4">14.0</data>
      <data key="d5">IL-13 signaling involves JAK1-mediated phosphorylation</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="STAT6">
      <data key="d4">14.0</data>
      <data key="d5">IL-13 signaling activates STAT6</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="PLASMA CELLS">
      <data key="d4">16.0</data>
      <data key="d5">IL-13 stimulates plasma cells to produce IgE</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="TH2 CELLS">
      <data key="d4">16.0</data>
      <data key="d5">IL-13 stimulates Th2 cell development</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="EPIDERMAL BARRIER">
      <data key="d4">16.0</data>
      <data key="d5">IL-13 contributes to epidermal barrier dysfunction</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="INVOLUCRIN">
      <data key="d4">14.0</data>
      <data key="d5">IL-13 downregulates involucrin</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="FIBROCYTES">
      <data key="d4">14.0</data>
      <data key="d5">IL-13 recruits fibrocytes to inflamed skin lesions</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="FIBROBLASTS">
      <data key="d4">14.0</data>
      <data key="d5">IL-13 recruits fibroblasts for fibrotic skin remodeling</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="COLLAGEN">
      <data key="d4">14.0</data>
      <data key="d5">IL-13 promotes collagen deposition</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="SENSORY NEURONS">
      <data key="d4">14.0</data>
      <data key="d5">IL-13 activates sensory neurons</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="MURINE MODELS">
      <data key="d4">12.0</data>
      <data key="d5">IL-13 is studied in murine models of AD</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="DORSAL ROOT GANGLIA">
      <data key="d4">12.0</data>
      <data key="d5">IL-13 activates sensory neurons in dorsal root ganglia</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="TRALOKINUMAB">
      <data key="d4">124.0</data>
      <data key="d5">Tralokinumab is a monoclonal antibody that specifically targets IL-13, a cytokine involved in inflammatory responses. By inhibiting IL-13, Tralokinumab prevents it from binding to its receptors, IL-13R&#945;1 and IL-13R&#945;2, thereby blocking its interaction with these receptors. This mechanism of action has shown potential efficacy in treating atopic dermatitis (AD), making Tralokinumab a promising therapeutic option for this condition.</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0,286730b1c1f680ac465cc21d522fda0c,28f548554737fcc026b968db6bbafa30,2cec06c4d46f5ff9ee936a78d8b077cd,3df8535e965efb96f5094169610507ff,48de7eebab3f3b418feb35a152df38fd,78e26c66107dba37ac4bab65406b43a0,8246ea974dfb00cb5e3d984004e21a9e,96e553a44a27e728c27c4892045ec5c2</data>
    </edge>
    <edge source="IL-13" target="LEBRIKIZUMAB">
      <data key="d4">96.0</data>
      <data key="d5">Lebrikizumab is a monoclonal antibody that targets interleukin-13 (IL-13). It binds soluble IL-13 with high affinity, selectively blocking its signaling pathways. By inhibiting IL-13, Lebrikizumab shows potential efficacy in the treatment of atopic dermatitis.</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41,104cc78517b2eca2e9cb7e00de1fe4b0,28f548554737fcc026b968db6bbafa30,3df8535e965efb96f5094169610507ff,48de7eebab3f3b418feb35a152df38fd,96e553a44a27e728c27c4892045ec5c2</data>
    </edge>
    <edge source="IL-13" target="IL-13R&#913;2">
      <data key="d4">32.0</data>
      <data key="d5">IL-13 is a cytokine that binds to IL-13R&#945;2, a receptor that acts as a decoy for IL-13. While IL-13R&#945;2 binds IL-13, its precise biological role remains unclear.</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41,78e26c66107dba37ac4bab65406b43a0,96e553a44a27e728c27c4892045ec5c2</data>
    </edge>
    <edge source="IL-13" target="IMA-638">
      <data key="d4">14.0</data>
      <data key="d5">IMA-638 prevents the IL-13/IL-13R&#945;1 complex from accessing IL-4R&#945;</data>
      <data key="d6">96e553a44a27e728c27c4892045ec5c2</data>
    </edge>
    <edge source="IL-13" target="IMA-026">
      <data key="d4">14.0</data>
      <data key="d5">IMA-026 interferes with IL-13 binding to IL-13R&#945;1 and IL-13R&#945;2</data>
      <data key="d6">96e553a44a27e728c27c4892045ec5c2</data>
    </edge>
    <edge source="IL-13" target="PERIOSTIN">
      <data key="d4">15.0</data>
      <data key="d5">IL-13 is a cytokine that plays a significant role in the immune response and is known to induce the production of periostin. Periostin, a matricellular protein, is upregulated in response to IL-13. This relationship highlights the interconnected roles of IL-13 and periostin in various biological processes, particularly in the context of immune and inflammatory responses.</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b,e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="IL-13" target="TH2 CELL">
      <data key="d4">14.0</data>
      <data key="d5">Th2 cells produce IL-13</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-13" target="CD4+ T CELL">
      <data key="d4">14.0</data>
      <data key="d5">CD4+ T cells produce IL-13</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-13" target="CD8+ T CELL">
      <data key="d4">14.0</data>
      <data key="d5">CD8+ T cells produce IL-13</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-13" target="MAST CELL">
      <data key="d4">14.0</data>
      <data key="d5">Mast cells produce IL-13</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-13" target="BASOPHIL">
      <data key="d4">14.0</data>
      <data key="d5">Basophils produce IL-13</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-13" target="EOSINOPHIL">
      <data key="d4">14.0</data>
      <data key="d5">Eosinophils produce IL-13</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-13" target="ILC">
      <data key="d4">14.0</data>
      <data key="d5">ILCs produce IL-13</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-13" target="INKT">
      <data key="d4">14.0</data>
      <data key="d5">iNKTs produce IL-13</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-13" target="MICE">
      <data key="d4">14.0</data>
      <data key="d5">IL-13 overexpression in mice results in AD-like phenotype</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-13" target="IL-33">
      <data key="d4">21.0</data>
      <data key="d5">IL-33 enhances type 2 responses through the induction of IL-13. Specifically, IL-33 induces and increases the production of IL-13, thereby playing a significant role in modulating immune responses.</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="IL-13" target="JAK/STAT PATHWAY">
      <data key="d4">8.0</data>
      <data key="d5">IL-13 signaling involves the JAK/STAT pathway</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0</data>
    </edge>
    <edge source="IL-13" target="TH2">
      <data key="d4">40.0</data>
      <data key="d5">IL-13 is a primary determinant of the Th2 immune axis and is involved in the TH2 immune response. TH2 cells are involved in the immune response mediated by IL-13.</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41,3df8535e965efb96f5094169610507ff,78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="IL-13" target="EYE DISORDERS">
      <data key="d4">14.0</data>
      <data key="d5">IL-13 blocking activity is attributed to the development of eye disorders</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="IL-13" target="ASLAN004">
      <data key="d4">16.0</data>
      <data key="d5">ASLAN004 blocks IL-13</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="IL-13" target="PERIPHERAL SENSORY NEURONS">
      <data key="d4">14.0</data>
      <data key="d5">Peripheral sensory neurons express receptors for IL-13</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="IL-13" target="NEURONS">
      <data key="d4">7.0</data>
      <data key="d5">Neurons express receptors for IL-13</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="IL-13" target="TSLP">
      <data key="d4">7.0</data>
      <data key="d5">TSLP promotes the production of IL-13</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-13" target="IL-4R">
      <data key="d4">9.0</data>
      <data key="d5">IL-4R is a common receptor chain between IL-13 and IL-4, and it encourages the signaling of IL-13.</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-13" target="S. AUREUS">
      <data key="d4">14.0</data>
      <data key="d5">IL-13 enhances S. aureus infections</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="IL-13" target="PRURITUS">
      <data key="d4">12.0</data>
      <data key="d5">IL-13 is associated with pruritus in AD</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="IL-13" target="XEROSIS">
      <data key="d4">12.0</data>
      <data key="d5">IL-13 is associated with xerosis in AD</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="IL-13" target="JAK">
      <data key="d4">16.0</data>
      <data key="d5">JAK is involved in the signaling pathway of IL-13</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="IL-13" target="HYDROCORTISONE">
      <data key="d4">14.0</data>
      <data key="d5">HC-NPs suppressed inflammatory cascades including IL-13</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="IL-13" target="LIGHT">
      <data key="d4">16.0</data>
      <data key="d5">LIGHT induces the expression of IL-13, a regulator of tissue remodeling</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="IL-13" target="TL1A">
      <data key="d4">16.0</data>
      <data key="d5">IL-13 and TL1A are closely associated in the context of inflammation. TL1A upregulates IL-13, indicating that TL1A-driven inflammation is characterized by elevated levels of IL-13. This relationship underscores the role of TL1A in promoting inflammatory responses through the modulation of IL-13.</data>
      <data key="d6">05c97152fe02249153103be341d65b67,c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="IL-13" target="TRAIL">
      <data key="d4">1.0</data>
      <data key="d5">TRAIL is necessary for the production of IL-13</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="IL-13" target="IL-5">
      <data key="d4">7.0</data>
      <data key="d5">IL-13 plays a supporting role to IL-5</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="IL-10" target="AD">
      <data key="d4">22.0</data>
      <data key="d5">IL-10 is a cytokine that plays a significant role in the immune response and inflammation associated with autoimmune diseases (AD). It is involved in modulating the immune system's activity, thereby influencing the inflammatory processes that are characteristic of AD.</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198,b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="IL-10" target="JAK2">
      <data key="d4">6.0</data>
      <data key="d5">IL-10 signaling is associated with JAK2</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="IL-10" target="SSC">
      <data key="d4">8.0</data>
      <data key="d5">IL-10 is an anti-inflammatory cytokine involved in systemic sclerosis</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="IL-10" target="TREG">
      <data key="d4">16.0</data>
      <data key="d5">IL-10 is secreted by Treg cells</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="IL-10" target="TNF">
      <data key="d4">14.0</data>
      <data key="d5">TNF-co-stimulation of SSc patient T cells results in decreased production of IL-10</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="IL-10" target="BAFF">
      <data key="d4">6.0</data>
      <data key="d5">BAFF antagonist inhibits IL-10 production in TSK/+ mice</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="IL-18" target="AD">
      <data key="d4">21.0</data>
      <data key="d5">IL-18 is involved in inflammation and immune response in AD. Additionally, IL-18 is used to monitor the severity of AD.</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-18" target="PSORIASIS">
      <data key="d4">7.0</data>
      <data key="d5">IL-18 is involved in inflammation and immune response in psoriasis</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-18" target="IL-18R&#913;">
      <data key="d4">8.0</data>
      <data key="d5">IL-18 provides a 50-fold-higher receptor affinity for IL-18R&#945;</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="IL-18" target="IL-37">
      <data key="d4">7.0</data>
      <data key="d5">IL-18 is relevant in relation to IL-37</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="IL-36" target="ATOPIC DERMATITIS">
      <data key="d4">7.0</data>
      <data key="d5">IL-36 is implicated in Atopic Dermatitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-36" target="AD">
      <data key="d4">7.0</data>
      <data key="d5">IL-36 is increased in the skin of AD patients</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-36" target="PSORIASIS">
      <data key="d4">14.0</data>
      <data key="d5">IL-36 is increased in the skin of psoriasis patientsIL-36 is involved in inflammation and immune response in psoriasis</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="INNATE IMMUNE SYSTEM" target="AD">
      <data key="d4">15.0</data>
      <data key="d5">The innate immune system is involved in the pathophysiology of atopic dermatitis (AD) and plays a role in the early phase of AD.</data>
      <data key="d6">143d2dc302af5606656797bff162e23e,3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="LEPTIN" target="JAK2">
      <data key="d4">7.0</data>
      <data key="d5">Leptin signaling is dependent on JAK2</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="PRKAB1" target="METFORMIN">
      <data key="d4">14.0</data>
      <data key="d5">Metformin targets PRKAB1</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="PTGS1" target="BALSALAZIDE">
      <data key="d4">7.0</data>
      <data key="d5">Balsalazide inhibits PTGS1</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="PTGS2" target="BALSALAZIDE">
      <data key="d4">7.0</data>
      <data key="d5">Balsalazide inhibits PTGS2</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="IL-1&#914;" target="AD">
      <data key="d4">24.0</data>
      <data key="d5">IL-1&#946; and AD: IL-1&#946; is a cytokine that plays a crucial role in the immune response and inflammation associated with Alzheimer's Disease (AD). This involvement highlights its significance in the pathophysiology of AD, where it contributes to the inflammatory processes that are characteristic of the disease.</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198,b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="IL-1&#914;" target="PIOGLITAZONE (PGZ)">
      <data key="d4">8.0</data>
      <data key="d5">Pioglitazone (PGZ) reduces the levels of inflammatory cytokine IL-1&#946;</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="IL-1&#914;" target="INFLAMMATORY CYTOKINES">
      <data key="d4">9.0</data>
      <data key="d5">IL-1&#946; is a type of inflammatory cytokine</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="IL-1&#914;" target="MTX">
      <data key="d4">14.0</data>
      <data key="d5">MTX-loaded NPs reduced levels of IL-1&#946;</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="IL-1&#914;" target="BAFF">
      <data key="d4">6.0</data>
      <data key="d5">BAFF inhibition reduces IL-1&#946; levels in a PF mouse model</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="DEGS" target="BTK">
      <data key="d4">8.0</data>
      <data key="d5">DEGs are prominently clustered around BTK nodes in HS</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="DEGS" target="SYK">
      <data key="d4">8.0</data>
      <data key="d5">DEGs are prominently clustered around SYK nodes in HS</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="EGFR" target="AG-490">
      <data key="d4">8.0</data>
      <data key="d5">AG-490 inhibits EGFR</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="EGFR" target="WHI-P154">
      <data key="d4">14.0</data>
      <data key="d5">WHI-P154 inhibits EGFR</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="TLRS" target="AD">
      <data key="d4">14.0</data>
      <data key="d5">TLRs are involved in the pathophysiology of AD</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="IFNG" target="INTERFERON &#915;">
      <data key="d4">9.0</data>
      <data key="d5">IFNG encodes Interferon &#947;</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="IFNG" target="3,3&#8217;-DIINDOLYLMETHANE">
      <data key="d4">6.0</data>
      <data key="d5">3,3&#8217;-Diindolylmethane regulates IFNG</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="IFNG" target="T CELLS">
      <data key="d4">8.0</data>
      <data key="d5">IFNG is expressed by T cells in HS skin</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="IFNG" target="IFN-&#915;">
      <data key="d4">8.0</data>
      <data key="d5">IFNG encodes the cytokine IFN-&#947;</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="CD4+ T CELLS" target="ATOPIC DERMATITIS">
      <data key="d4">8.0</data>
      <data key="d5">OX40 expression is increased on skin-homing CD4+ T cells in patients with Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="CD4+ T CELLS" target="OX40">
      <data key="d4">8.0</data>
      <data key="d5">CD4+ T cells in AD patients express OX40</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="CD4+ T CELLS" target="CD40">
      <data key="d4">14.0</data>
      <data key="d5">CD40 expression is increased in activated CD4+ T cells</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="CD4+ T CELLS" target="TCR">
      <data key="d4">16.0</data>
      <data key="d5">CD4+ T cells undergo expansion and differentiation during TCR binding</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="TH17" target="ATOPIC DERMATITIS">
      <data key="d4">21.0</data>
      <data key="d5">TH17 cells are involved in the adaptive immune response in atopic dermatitis. While their involvement can vary, they play a significant role in the immune mechanisms underlying this condition.</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="TH17" target="ROCATINLIMAB">
      <data key="d4">14.0</data>
      <data key="d5">Th17-related genes were downregulated after rocatinlimab treatment</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="TH17" target="AMLITELIMAB">
      <data key="d4">14.0</data>
      <data key="d5">Amlitelimab blocks Th17 inflammation</data>
      <data key="d6">b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="TH17" target="IL-17A">
      <data key="d4">8.0</data>
      <data key="d5">IL-17A is a key cytokine produced by Th17 cells</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="TH17" target="IL-17C">
      <data key="d4">7.0</data>
      <data key="d5">IL-17C is involved in the Th17-driven inflammatory response</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="TH17" target="IL-23">
      <data key="d4">8.0</data>
      <data key="d5">IL-23 drives the differentiation of Th17 cells</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="TH17" target="AD">
      <data key="d4">15.0</data>
      <data key="d5">T helper 17 (TH17) cells are implicated in atopic dermatitis (AD). These cells are involved in the immune response and inflammation associated with AD, highlighting their significant role in the pathogenesis of this autoimmune condition.</data>
      <data key="d6">143d2dc302af5606656797bff162e23e,41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="TH17" target="IL-22">
      <data key="d4">7.0</data>
      <data key="d5">IL-22 is induced by staphylococcal exotoxins in TH17 cells</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="TH17" target="TNFR2">
      <data key="d4">14.0</data>
      <data key="d5">Impaired TNF/TNFR2 signaling enhances Th17 polarization</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TH17" target="BALF">
      <data key="d4">14.0</data>
      <data key="d5">Inhibiting TNFR2 via antibody treatment led to increased expression of Th17 inflammatory cytokines in BALF</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TH17" target="LIGHT">
      <data key="d4">12.0</data>
      <data key="d5">LIGHT is associated with Th17 polarization in SSc</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="IL-1" target="AD">
      <data key="d4">7.0</data>
      <data key="d5">IL-1 expression is raised in AD</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-1" target="PSORIASIS">
      <data key="d4">7.0</data>
      <data key="d5">IL-1 expression is raised in psoriasis</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-1" target="TH2 CELL">
      <data key="d4">7.0</data>
      <data key="d5">IL-1 leads to the formation of Th2 cells</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-1" target="IL-1R">
      <data key="d4">8.0</data>
      <data key="d5">IL-1 and IL-1R are both highly produced in skin cells</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-1" target="ALOPECIA AREATA">
      <data key="d4">14.0</data>
      <data key="d5">IL-1 expression is raised in alopecia areata</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-1" target="BERMEKIMAB">
      <data key="d4">8.0</data>
      <data key="d5">Bermekimab is an anti-IL-1 monoclonal antibody</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-1" target="TH1 CELL">
      <data key="d4">7.0</data>
      <data key="d5">IL-1 increases Th1 cell expression</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL1R1" target="ANAKINRA">
      <data key="d4">16.0</data>
      <data key="d5">Anakinra antagonizes IL1R1</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="IL32" target="CUTANEOUS DIPHTHERIA">
      <data key="d4">7.0</data>
      <data key="d5">IL32 is associated with Cutaneous diphtheria</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL36B" target="PERIOSTITIS">
      <data key="d4">7.0</data>
      <data key="d5">IL36B is associated with Periostitis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL36RN" target="SPESOLIMAB">
      <data key="d4">7.0</data>
      <data key="d5">Spesolimab antagonizes IL36RN</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="IL37" target="STILL&#8217;S DISEASE">
      <data key="d4">7.0</data>
      <data key="d5">IL37 is associated with Still&#8217;s disease</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="S100A7" target="AD">
      <data key="d4">15.0</data>
      <data key="d5">S100A7 and AD (Atopic Dermatitis) are closely linked in the context of immune response. S100A7 is a protein that plays a significant role in the immune response associated with AD. It is notably upregulated in atopic dermatitis lesions, indicating its involvement in the pathophysiology of this chronic inflammatory skin condition.</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="S100A7A" target="BRODALUMAB">
      <data key="d4">14.0</data>
      <data key="d5">Brodalumab targets S100A7A</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="S100A12" target="AD">
      <data key="d4">8.0</data>
      <data key="d5">S100A12 is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="ADIPONECTIN" target="ADIPOQ">
      <data key="d4">7.0</data>
      <data key="d5">ADIPOQ encodes adiponectin</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="PPAR&#915;" target="THIAZOLIDINE DERIVATIVES">
      <data key="d4">7.0</data>
      <data key="d5">Thiazolidine derivatives act as PPAR&#947; agonists</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="INFLAMMATORY BOWEL DISEASES" target="JAK INHIBITORS">
      <data key="d4">16.0</data>
      <data key="d5">JAK inhibitors are in clinical development for treating inflammatory bowel diseases</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="CROHN&#8217;S DISEASE" target="IL26">
      <data key="d4">7.0</data>
      <data key="d5">IL26 is associated with Crohn&#8217;s disease</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="CROHN&#8217;S DISEASE" target="GASTROINTESTINAL TRACT">
      <data key="d4">8.0</data>
      <data key="d5">Crohn&#8217;s disease affects the gastrointestinal tract</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="CROHN&#8217;S DISEASE" target="TNF INHIBITORS">
      <data key="d4">14.0</data>
      <data key="d5">TNF inhibitors are approved for the treatment of Crohn&#8217;s disease</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="PACHYONYCHIA CONGENITA" target="KRT6A">
      <data key="d4">8.0</data>
      <data key="d5">KRT6A is associated with Pachyonychia congenita</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="PACHYONYCHIA CONGENITA" target="KRT16">
      <data key="d4">8.0</data>
      <data key="d5">KRT16 is associated with Pachyonychia congenita</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="NEUTROPHILS" target="ATOPIC DERMATITIS">
      <data key="d4">8.0</data>
      <data key="d5">Neutrophils are elevated in the skin of Atopic Dermatitis patients</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="NEUTROPHILS" target="METHOTREXATE">
      <data key="d4">14.0</data>
      <data key="d5">Methotrexate calms down hyperactive neutrophils</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="NEUTROPHILS" target="TNF">
      <data key="d4">1.0</data>
      <data key="d5">Neutrophils can express TNF</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="NEUTROPHILS" target="GITR">
      <data key="d4">8.0</data>
      <data key="d5">GITR is expressed on activated neutrophils.</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9,d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="INSULIN RESISTANCE" target="LIGHT">
      <data key="d4">7.0</data>
      <data key="d5">Genetic deletion of LIGHT results in reduced insulin resistance</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="ADIPOCYTES" target="HVEM">
      <data key="d4">14.0</data>
      <data key="d5">HVEM is expressed on adipocytes</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="TNF-&#913;" target="TSLP">
      <data key="d4">7.0</data>
      <data key="d5">TSLP promotes the production of TNF-&#945;</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="TNF-&#913;" target="PIOGLITAZONE (PGZ)">
      <data key="d4">8.0</data>
      <data key="d5">Pioglitazone (PGZ) reduces the levels of inflammatory cytokine TNF-&#945;</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="TNF-&#913;" target="INFLAMMATORY CYTOKINES">
      <data key="d4">9.0</data>
      <data key="d5">TNF-&#945; is a type of inflammatory cytokine</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="TNF-&#913;" target="HYDROCORTISONE">
      <data key="d4">14.0</data>
      <data key="d5">HC-NPs suppressed inflammatory cascades including TNF-&#945;</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="TNF-&#913;" target="MTX">
      <data key="d4">14.0</data>
      <data key="d5">MTX-loaded NPs reduced levels of TNF-&#945;</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="TNF-&#913;" target="AD">
      <data key="d4">14.0</data>
      <data key="d5">TNF-&#945; is involved in the pathophysiology of AD</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="IL-6" target="TOCILIZUMAB">
      <data key="d4">16.0</data>
      <data key="d5">Tocilizumab targets IL-6</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="IL-6" target="AD">
      <data key="d4">16.0</data>
      <data key="d5">IL-6 is involved in the immune response and inflammation in ADIL-6 is a cytokine involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="IL-6" target="PIOGLITAZONE (PGZ)">
      <data key="d4">8.0</data>
      <data key="d5">Pioglitazone (PGZ) reduces the levels of inflammatory cytokine IL-6</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="IL-6" target="INFLAMMATORY CYTOKINES">
      <data key="d4">9.0</data>
      <data key="d5">IL-6 is a type of inflammatory cytokine</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="IL-6" target="CSA">
      <data key="d4">7.0</data>
      <data key="d5">CsA-loaded nanoparticles reduce IL-6 levels</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="IL-6" target="HYDROCORTISONE">
      <data key="d4">14.0</data>
      <data key="d5">HC-NPs suppressed inflammatory cascades including IL-6</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="IL-6" target="MTX">
      <data key="d4">14.0</data>
      <data key="d5">MTX-loaded NPs reduced levels of IL-6</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="IL-6" target="SSC">
      <data key="d4">8.0</data>
      <data key="d5">IL-6 is a proinflammatory cytokine involved in systemic sclerosis</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="IL-6" target="TNFR1">
      <data key="d4">7.0</data>
      <data key="d5">TNFR1 is associated with reduced levels of IL-6 mRNA</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="IL-6" target="LIGHT">
      <data key="d4">14.0</data>
      <data key="d5">LIGHT increases IL-6 expression in dermal fibroblasts</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="IL-6" target="BAFF">
      <data key="d4">6.0</data>
      <data key="d5">BAFF antagonist inhibits IL-6 production in TSK/+ mice</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="TRASTUZUMAB" target="BREAST CANCER">
      <data key="d4">8.0</data>
      <data key="d5">Trastuzumab is used to treat breast cancer</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="APREMILAST" target="PSORIASIS">
      <data key="d4">9.0</data>
      <data key="d5">Apremilast is approved to treat moderate to severe forms of psoriasis</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="TNF INHIBITORS" target="UC">
      <data key="d4">7.0</data>
      <data key="d5">TNF inhibitors are approved for the treatment of ulcerative colitis</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="TNF INHIBITORS" target="PSORIATIC ARTHRITIS">
      <data key="d4">14.0</data>
      <data key="d5">TNF inhibitors are approved for the treatment of psoriatic arthritis</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="TNF INHIBITORS" target="ANKYLOSING SPONDYLITIS">
      <data key="d4">14.0</data>
      <data key="d5">TNF inhibitors are approved for the treatment of ankylosing spondylitis</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="TNF INHIBITORS" target="JUVENILE IDIOPATHIC ARTHRITIS">
      <data key="d4">14.0</data>
      <data key="d5">TNF inhibitors are approved for the treatment of juvenile idiopathic arthritis</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="TNF INHIBITORS" target="PLAQUE PSORIASIS">
      <data key="d4">14.0</data>
      <data key="d5">TNF inhibitors are approved for the treatment of plaque psoriasis</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="TNF INHIBITORS" target="NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS">
      <data key="d4">8.0</data>
      <data key="d5">TNF inhibitors are approved for the treatment of non-radiographic axial spondyloarthritis</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="TNF INHIBITORS" target="END STAGE FIBROSIS">
      <data key="d4">7.0</data>
      <data key="d5">TNF inhibitors are used to treat diseases presenting in end stage fibrosis</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="TNF INHIBITORS" target="ULCERATIVE COLITIS">
      <data key="d4">1.0</data>
      <data key="d5">TNF inhibitors are approved for the treatment of ulcerative colitis</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="AR" target="3,3&#8217;-DIINDOLYLMETHANE">
      <data key="d4">12.0</data>
      <data key="d5">3,3&#8217;-Diindolylmethane regulates AR</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="AR" target="CYPROTERONE ACETATE">
      <data key="d4">14.0</data>
      <data key="d5">Cyproterone acetate antagonizes AR</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="BTK" target="ACALABRUTINIB">
      <data key="d4">25.0</data>
      <data key="d5">BTK (Bruton's tyrosine kinase) is a critical enzyme involved in the signaling pathways of B cells, which are essential components of the immune system. Acalabrutinib is a BTK inhibitor that specifically targets and inhibits the activity of BTK. This inhibition is utilized in the treatment of various conditions, including hematologic malignancies and autoimmune diseases. Acalabrutinib is particularly noted for its use in treating HS (Hodgkin's lymphoma), where it helps to modulate the immune response by interfering with B cell receptor signaling.</data>
      <data key="d6">b62ecc47bf54393bc78dd65986b949d6,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="BTK" target="IBRUTINIB">
      <data key="d4">25.0</data>
      <data key="d5">BTK and Ibrutinib: Ibrutinib is a BTK inhibitor used to treat HS.</data>
      <data key="d6">b62ecc47bf54393bc78dd65986b949d6,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="BTK" target="SYK">
      <data key="d4">8.0</data>
      <data key="d5">SYK and BTK are both involved in B cell receptor signaling</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="BTK" target="PHOSPHO-BTK">
      <data key="d4">8.0</data>
      <data key="d5">Phospho-BTK is the phosphorylated form of BTK</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="C5AR1" target="AVACOPAN">
      <data key="d4">14.0</data>
      <data key="d5">Avacopan antagonizes C5AR1</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="CASP1" target="CASPASE 1">
      <data key="d4">9.0</data>
      <data key="d5">CASP1 encodes Caspase 1</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="CCL18" target="C-C MOTIF CHEMOKINE LIGAND 18">
      <data key="d4">9.0</data>
      <data key="d5">CCL18 encodes C-C Motif Chemokine Ligand 18</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="CCL18" target="AD">
      <data key="d4">22.0</data>
      <data key="d5">CCL18 is a chemokine involved in the immune response and inflammation in AD (Atopic Dermatitis).</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198,b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="CCL18" target="T CELL">
      <data key="d4">16.0</data>
      <data key="d5">CCL18 promotes the attraction of inflammatory T cells</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="CCL18" target="DC">
      <data key="d4">16.0</data>
      <data key="d5">CCL18 promotes the attraction of inflammatory DC subtypes</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="CCL26" target="C-C MOTIF CHEMOKINE LIGAND 26">
      <data key="d4">9.0</data>
      <data key="d5">CCL26 encodes C-C Motif Chemokine Ligand 26</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="CCR4" target="C-C MOTIF CHEMOKINE RECEPTOR 4">
      <data key="d4">9.0</data>
      <data key="d5">CCR4 encodes C-C Motif Chemokine Receptor 4</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="CCR4" target="TH2 CELL">
      <data key="d4">8.0</data>
      <data key="d5">CCR4 is a hallmark of memory TH2 cells</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="CCR4" target="RANTES">
      <data key="d4">8.0</data>
      <data key="d5">RANTES binds to CCR4</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="CCR4" target="MCP1">
      <data key="d4">8.0</data>
      <data key="d5">MCP1 binds to CCR4</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="CCR4" target="CCL22">
      <data key="d4">8.0</data>
      <data key="d5">CCL22 binds to CCR4</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="CCR4" target="CCL17">
      <data key="d4">8.0</data>
      <data key="d5">CCL17 binds to CCR4</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="CCR4" target="RPT193">
      <data key="d4">15.0</data>
      <data key="d5">CCR4 and RPT193 are closely related entities in the context of autoimmune diseases. CCR4 is a receptor that plays a significant role in the immune system, particularly in the regulation of T cell trafficking and function. RPT193 is a small-molecule antagonist that specifically targets the CCR4 receptor. By inhibiting CCR4, RPT193 can modulate immune responses, making it a potential therapeutic agent for treating autoimmune diseases.</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9,f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="JAK INHIBITORS" target="AD">
      <data key="d4">43.0</data>
      <data key="d5">JAK inhibitors are used for the therapy of atopic dermatitis (AD). These inhibitors offer an opportunity for the effective treatment of AD, providing a promising therapeutic option for managing this condition.</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e,dc905ba8b6eb7d84cf2776303211010d,e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="JAK INHIBITORS" target="JAK">
      <data key="d4">18.0</data>
      <data key="d5">JAK inhibitors block the signal transduction pathways of multiple cytokine receptors</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="JAK INHIBITORS" target="JAK1">
      <data key="d4">18.0</data>
      <data key="d5">JAK inhibitors block the signal transduction pathways of JAK1</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="JAK INHIBITORS" target="JAK2">
      <data key="d4">18.0</data>
      <data key="d5">JAK inhibitors block the signal transduction pathways of JAK2</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="JAK INHIBITORS" target="JAK3">
      <data key="d4">18.0</data>
      <data key="d5">JAK inhibitors block the signal transduction pathways of JAK3</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="JAK INHIBITORS" target="TYK2">
      <data key="d4">18.0</data>
      <data key="d5">JAK inhibitors block the signal transduction pathways of TYK2</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="JAK INHIBITORS" target="SARS-COV-2">
      <data key="d4">14.0</data>
      <data key="d5">JAK inhibitors were used successfully in treating the cytokine storm generated by SARS-CoV-2</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="JAK INHIBITORS" target="MYELOFIBROSIS">
      <data key="d4">6.0</data>
      <data key="d5">JAK inhibitors are initially employed for the treatment of myelofibrosis</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="TNF" target="ANDROGRAPHOLIDE">
      <data key="d4">7.0</data>
      <data key="d5">Andrographolide inhibits TNF</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="TNF" target="GOLIMUMAB">
      <data key="d4">16.0</data>
      <data key="d5">Golimumab inhibits TNF</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="TNF" target="INFLIXIMAB">
      <data key="d4">14.0</data>
      <data key="d5">Infliximab inhibits TNF</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="TNF" target="ALEXA FLUOR 488">
      <data key="d4">14.0</data>
      <data key="d5">Alexa Fluor 488 is used as a secondary antibody for TNF</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="TNF" target="DONKEY ANTI-RABBIT IGG">
      <data key="d4">7.0</data>
      <data key="d5">Donkey anti-rabbit IgG is used as a secondary antibody for TNF</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="TNF" target="SSC">
      <data key="d4">8.0</data>
      <data key="d5">TNF is a proinflammatory cytokine involved in systemic sclerosis</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="TNF" target="TH2">
      <data key="d4">14.0</data>
      <data key="d5">TNF is a cytokine involved in T helper cell responses</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="TNF" target="TNFR1">
      <data key="d4">16.0</data>
      <data key="d5">TNF (Tumor Necrosis Factor) is a cytokine that plays a crucial role in inflammation and immune system regulation. It binds to TNFR1 (Tumor Necrosis Factor Receptor 1), which is a receptor involved in mediating cell survival and death responses. The interaction between TNF and TNFR1 is essential for the activation of various signaling pathways that can lead to either cell survival or apoptosis, depending on the cellular context and the presence of other signaling molecules. This TNF-TNFR1 axis is significant in the pathophysiology of various autoimmune diseases, where dysregulation can contribute to chronic inflammation and tissue damage.</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="TNF" target="TNFR2">
      <data key="d4">16.0</data>
      <data key="d5">TNF (Tumor Necrosis Factor) binds to TNFR2 (Tumor Necrosis Factor Receptor 2). TNFR2 is a receptor for TNF that is involved in cell survival responses.</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="TNF" target="MONOCYTES">
      <data key="d4">7.0</data>
      <data key="d5">Monocytes produce TNF</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="TNF" target="MACROPHAGES">
      <data key="d4">7.0</data>
      <data key="d5">Macrophages produce TNF</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="TNF" target="T CELLS">
      <data key="d4">6.0</data>
      <data key="d5">T cells can express TNF</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="TNF" target="B CELLS">
      <data key="d4">6.0</data>
      <data key="d5">B cells can express TNF</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="TNF" target="NK CELLS">
      <data key="d4">6.0</data>
      <data key="d5">NK cells can express TNF</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="TNF" target="MAST CELLS">
      <data key="d4">6.0</data>
      <data key="d5">Mast cells can express TNF</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="TNF" target="&#913;SMA">
      <data key="d4">22.0</data>
      <data key="d5">TNF suppresses &#945;SMA expression in human dermal fibroblasts</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e,a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNF" target="TYPE 1 COLLAGEN">
      <data key="d4">16.0</data>
      <data key="d5">TNF-co-stimulation of SSc patient T cells results in elevated type 1 collagen expression by fibroblasts</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TNF" target="PULMONARY FIBROSIS">
      <data key="d4">16.0</data>
      <data key="d5">TNF is involved in fibrotic disease progression and resolution</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TNF" target="PROFIBROTIC MACROPHAGES">
      <data key="d4">14.0</data>
      <data key="d5">TNF affects the numbers and programming status of profibrotic macrophages</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TNF" target="PROFIBROTIC CYTOKINES">
      <data key="d4">8.0</data>
      <data key="d5">TNF-co-stimulation of SSc patient T cells results in increased secretion of profibrotic cytokines</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TNF" target="TGF&#914;1">
      <data key="d4">7.0</data>
      <data key="d5">TNF suppresses TGF&#946;1-induced myofibroblast genes</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNF" target="COL1A1">
      <data key="d4">7.0</data>
      <data key="d5">TNF suppresses TGF&#946;1-induced Col1a1 expression</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNF" target="FIBRONECTIN">
      <data key="d4">7.0</data>
      <data key="d5">TNF suppresses TGF&#946;1-induced fibronectin expression</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNF" target="MYOFIBROBLAST">
      <data key="d4">8.0</data>
      <data key="d5">TNF drives conversion to myofibroblasts in DD</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNF" target="WNT SIGNALING">
      <data key="d4">7.0</data>
      <data key="d5">TNF activates Wnt signaling in DD</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNF" target="IL-33">
      <data key="d4">7.0</data>
      <data key="d5">TNF signals through TNFR2 to initiate IL-33 production</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNF" target="INTESTINAL MYOFIBROBLASTS">
      <data key="d4">8.0</data>
      <data key="d5">TNF increases proliferation and collagen accumulation in intestinal myofibroblasts</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNF" target="TIMP-1">
      <data key="d4">7.0</data>
      <data key="d5">TNF induces expression of TIMP-1</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNF" target="ERK1/2">
      <data key="d4">7.0</data>
      <data key="d5">TNF induces activation of ERK1/2</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNF" target="DD">
      <data key="d4">8.0</data>
      <data key="d5">TNF treatment drives conversion to myofibroblasts in Dupuytren&#8217;s disease</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNF" target="STROMAL CELLS">
      <data key="d4">7.0</data>
      <data key="d5">TNF signals through TNFR2 on stromal cells to initiate IL-33 production</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNF" target="MI">
      <data key="d4">16.0</data>
      <data key="d5">TNF levels increase after myocardial infarction</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="TNF" target="ETANERCEPT">
      <data key="d4">9.0</data>
      <data key="d5">Etanercept inhibits TNF to treat autoimmune diseases</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="TNF" target="ALIMUMAB">
      <data key="d4">8.0</data>
      <data key="d5">Alimumab is an anti-TNF monoclonal antibody</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="TNF" target="LUMBAR SPINAL FIBROSIS">
      <data key="d4">7.0</data>
      <data key="d5">TNF is involved in the pathogenesis of Lumbar Spinal Fibrosis</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="EPITHELIAL CELLS" target="HVEM">
      <data key="d4">14.0</data>
      <data key="d5">HVEM is expressed on epithelial cells</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="EPITHELIAL CELLS" target="LT&#914;R">
      <data key="d4">14.0</data>
      <data key="d5">LT&#946;R is expressed on epithelial cells</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="EPITHELIAL CELLS" target="LIGHT">
      <data key="d4">16.0</data>
      <data key="d5">EPITHELIAL CELLS and LIGHT: LIGHT acts on epithelial cells to drive both pro-fibrotic and anti-fibrotic effects.</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a,68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="EPITHELIAL CELLS" target="TNFSF14">
      <data key="d4">8.0</data>
      <data key="d5">TNFSF14 can act on epithelial cells to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="LESIONAL SKIN" target="AD">
      <data key="d4">1.0</data>
      <data key="d5">Lesional skin is affected in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="NON-LESIONAL SKIN" target="AD">
      <data key="d4">21.0</data>
      <data key="d5">Non-lesional skin is affected in atopic dermatitis (AD). It shows molecular abnormalities in this condition, indicating that even areas of the skin that do not exhibit visible lesions are still impacted at a molecular level in individuals with AD.</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="HEALTHY CONTROLS" target="ATOPIC DERMATITIS">
      <data key="d4">2.0</data>
      <data key="d5">Healthy Controls are used as a comparison group in research on Atopic Dermatitis. They serve as a baseline to compare with patients who have atopic dermatitis, allowing researchers to identify differences and better understand the disease.</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd,691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="BIOMARKERS" target="OX40">
      <data key="d4">7.0</data>
      <data key="d5">Anti-OX40 therapy affects biomarkers in the treatment of atopic dermatitis</data>
      <data key="d6">100dd7646c10899301b3c0631183da16</data>
    </edge>
    <edge source="BIOMARKERS" target="AD">
      <data key="d4">7.0</data>
      <data key="d5">Biomarkers are used to assess the severity and progression of atopic dermatitis</data>
      <data key="d6">100dd7646c10899301b3c0631183da16</data>
    </edge>
    <edge source="ECZEMA" target="IGE">
      <data key="d4">7.0</data>
      <data key="d5">Increased levels of IgE are commonly detected in patients with eczema</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="ECZEMA" target="OMALIZUMAB">
      <data key="d4">1.0</data>
      <data key="d5">Omalizumab is used in the treatment of severe recalcitrant atopic eczema</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="ECZEMA" target="AD">
      <data key="d4">10.0</data>
      <data key="d5">Atopic dermatitis (AD) is a type of eczema. Eczema is a symptom of AD.</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89,89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="ECZEMA" target="ATOPIC DERMATITIS">
      <data key="d4">19.0</data>
      <data key="d5">Eczema and Atopic Dermatitis are closely related terms often used interchangeably in medical literature. Eczema is another term for Atopic Dermatitis, which is a chronic inflammatory skin condition characterized by itchy, red, and swollen skin. Eczema can be considered a symptom of Atopic Dermatitis, highlighting the condition's manifestation through various skin irritations. Both terms describe the same underlying condition, emphasizing the importance of understanding their synonymous use in clinical contexts.</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8,6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ECZEMA" target="NANOTECHNOLOGY">
      <data key="d4">7.0</data>
      <data key="d5">Nanotechnology offers a method for treating eczema</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="ECZEMA" target="METHOTREXATE">
      <data key="d4">16.0</data>
      <data key="d5">Methotrexate targets immune system cells causing eczema</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="CD80" target="CD80 MOLECULE">
      <data key="d4">9.0</data>
      <data key="d5">CD80 encodes CD80 Molecule</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="CD80" target="CD28">
      <data key="d4">41.0</data>
      <data key="d5">CD28 and CD80 are involved in positive costimulatory pathways. CD28 binds to CD80 to provide a costimulatory signal essential for T-cell activation. The interaction between CD80 and CD28 is crucial for the activation of T-cells, highlighting their significant role in the immune response.</data>
      <data key="d6">4842292208575bd45b2b5998513dd087,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="CD80" target="CTLA-4">
      <data key="d4">40.0</data>
      <data key="d5">CD80 and CTLA-4 are integral components involved in the regulation of immune responses through negative costimulatory pathways. CTLA-4 binds to CD80, a critical interaction that plays a significant role in reducing IL-2 production and subsequently diminishing T cell proliferation. This binding is essential for the modulation of immune responses, highlighting the importance of CTLA-4 and CD80 in maintaining immune homeostasis and preventing overactivation of the immune system.</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b,4d0e8ae9371a435885994b4161126bc3,855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="CD80" target="SCTLA-4">
      <data key="d4">28.0</data>
      <data key="d5">CD80 and sCTLA-4 are closely related in the context of immune regulation. sCTLA-4 blocks the interaction of CD80, which is a crucial mechanism in the immune response. Specifically, sCTLA-4 may inhibit early T-cell activation by blocking the interaction between CD80 and CD28. This inhibition is significant because the CD80&#8212;CD28 interaction is essential for the full activation of T-cells, which are pivotal in the body's immune response. Therefore, the blocking action of sCTLA-4 on CD80 can play a critical role in modulating immune responses, potentially impacting autoimmune disease mechanisms.</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b,9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="ABATACEPT" target="SSC">
      <data key="d4">40.0</data>
      <data key="d5">Abatacept is being evaluated for its effects in treating systemic sclerosis (SSc). It is used to block T-cell costimulation in systemic sclerosis, which helps prevent inflammation-driven fibrosis. Clinical studies have shown that Abatacept induced clinical improvement in SSc patients, highlighting its potential as a therapeutic option for this autoimmune disease.</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81,9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="ABATACEPT" target="ASSET TRIAL">
      <data key="d4">17.0</data>
      <data key="d5">The ASSET trial is a clinical trial assessing the efficacy of abatacept in systemic sclerosis. Specifically, the ASSET trial is studying the efficacy of subcutaneous abatacept in diffuse cutaneous systemic sclerosis (dcSSc).</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="ABATACEPT" target="INFLAMMATION-DRIVEN DERMAL FIBROSIS">
      <data key="d4">8.0</data>
      <data key="d5">Abatacept prevents and induces regression of inflammation-driven dermal fibrosis in SSc</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="ABATACEPT" target="DIGESTIVE INVOLVEMENT">
      <data key="d4">8.0</data>
      <data key="d5">Abatacept improves digestive involvement in SSc</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="ABATACEPT" target="LUNG FIBROSIS">
      <data key="d4">8.0</data>
      <data key="d5">Abatacept prevents lung fibrosis in SSc</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="ABATACEPT" target="PULMONARY HYPERTENSION">
      <data key="d4">8.0</data>
      <data key="d5">Abatacept attenuates pulmonary hypertension in SSc</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="ABATACEPT" target="INFLAMMATORY JOINT INVOLVEMENT">
      <data key="d4">7.0</data>
      <data key="d5">Abatacept shows effectiveness on inflammatory joint involvement in SSc</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="ABATACEPT" target="PLACEBO-CONTROLLED RANDOMIZED TRIAL">
      <data key="d4">7.0</data>
      <data key="d5">Abatacept showed clinical improvement of skin fibrosis in a placebo-controlled randomized trial</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="ABATACEPT" target="CTLA-4">
      <data key="d4">16.0</data>
      <data key="d5">Abatacept is a recombinant fusion protein comprising the extracellular domain of CTLA-4</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="ABATACEPT" target="FRA-2 TRANSGENIC MOUSE MODEL">
      <data key="d4">16.0</data>
      <data key="d5">Abatacept alleviates interstitial lung disease and pulmonary hypertension in the Fra-2 transgenic mouse model</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="ABATACEPT" target="CGVHD">
      <data key="d4">14.0</data>
      <data key="d5">Abatacept improves gastrointestinal involvement in chronic graft-vs.-host disease</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="ABATACEPT" target="LIVER">
      <data key="d4">14.0</data>
      <data key="d5">Abatacept decreases liver transaminase levels</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="ABATACEPT" target="COLON">
      <data key="d4">14.0</data>
      <data key="d5">Abatacept improves colon inflammation</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="ABATACEPT" target="EUSTAR">
      <data key="d4">14.0</data>
      <data key="d5">Abatacept induced clinical improvement in systemic sclerosis patients in the EUSTAR cohort</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="ABATACEPT" target="DCSSC">
      <data key="d4">22.0</data>
      <data key="d5">Abatacept is being evaluated for its effects in treating diffuse cutaneous systemic sclerosis (DCSSC). In clinical studies, Abatacept was added to standard therapy in patients with DCSSC to assess its therapeutic benefits.</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3,9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="ABATACEPT" target="JOINT">
      <data key="d4">7.0</data>
      <data key="d5">Abatacept showed effectiveness on inflammatory joint involvement in SSc</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="ABATACEPT" target="MRSS">
      <data key="d4">8.0</data>
      <data key="d5">Abatacept therapy led to a significant decrease in mRSS in SSc patients</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="ABATACEPT" target="RA">
      <data key="d4">9.0</data>
      <data key="d5">Abatacept is widely used in the treatment of rheumatoid arthritis</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="CHI3L1" target="CHITINASE 3-LIKE 1">
      <data key="d4">9.0</data>
      <data key="d5">CHI3L1 encodes Chitinase 3-Like 1</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="CSF1" target="COLONY-STIMULATING FACTOR 1">
      <data key="d4">9.0</data>
      <data key="d5">CSF1 encodes Colony-Stimulating Factor 1</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="CXCL1" target="C-X-C MOTIF CHEMOKINE LIGAND 1">
      <data key="d4">9.0</data>
      <data key="d5">CXCL1 encodes C-X-C Motif Chemokine Ligand 1</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="CXCL1" target="AD">
      <data key="d4">8.0</data>
      <data key="d5">CXCL1 is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="CXCL8" target="C-X-C MOTIF CHEMOKINE LIGAND 8">
      <data key="d4">9.0</data>
      <data key="d5">CXCL8 encodes C-X-C Motif Chemokine Ligand 8</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="MELANOMA" target="IL24">
      <data key="d4">7.0</data>
      <data key="d5">IL24 is associated with Melanoma</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="CXCL13" target="C-X-C MOTIF CHEMOKINE LIGAND 13">
      <data key="d4">9.0</data>
      <data key="d5">CXCL13 encodes C-X-C Motif Chemokine Ligand 13</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="CXCR5" target="C-X-C MOTIF CHEMOKINE RECEPTOR 5">
      <data key="d4">9.0</data>
      <data key="d5">CXCR5 encodes C-X-C Motif Chemokine Receptor 5</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="DCD" target="DERMCIDIN">
      <data key="d4">9.0</data>
      <data key="d5">DCD encodes Dermcidin</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="DEFB4A" target="DEFENSIN &#914; 4A">
      <data key="d4">9.0</data>
      <data key="d5">DEFB4A encodes Defensin &#946; 4A</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="DEFB103B" target="DEFENSIN &#914; 103B">
      <data key="d4">9.0</data>
      <data key="d5">DEFB103B encodes Defensin &#946; 103B</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="EGF" target="EPIDERMAL GROWTH FACTOR">
      <data key="d4">9.0</data>
      <data key="d5">EGF encodes Epidermal Growth Factor</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="EPGN" target="EPITHELIAL MITOGEN">
      <data key="d4">9.0</data>
      <data key="d5">EPGN encodes Epithelial Mitogen</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="ERBB4" target="ERB-B2 RECEPTOR TYROSINE KINASE 4">
      <data key="d4">9.0</data>
      <data key="d5">ERBB4 encodes Erb-B2 Receptor Tyrosine Kinase 4</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="FOSTAMATINIB" target="SYK">
      <data key="d4">24.0</data>
      <data key="d5">Fostamatinib is a SYK inhibitor used to treat HS.</data>
      <data key="d6">b62ecc47bf54393bc78dd65986b949d6,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="GAS6" target="GROWTH ARREST SPECIFIC 6">
      <data key="d4">9.0</data>
      <data key="d5">GAS6 encodes Growth Arrest Specific 6</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="GDNF" target="GLIAL CELL DERIVED NEUROTROPHIC FACTOR">
      <data key="d4">9.0</data>
      <data key="d5">GDNF encodes Glial Cell Derived Neurotrophic Factor</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="GJB2" target="GAP JUNCTION PROTEIN &#914;2">
      <data key="d4">9.0</data>
      <data key="d5">GJB2 encodes Gap Junction Protein &#946;2</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="HBEGF" target="HEPARIN BINDING EGF-LIKE GROWTH FACTOR">
      <data key="d4">9.0</data>
      <data key="d5">HBEGF encodes Heparin Binding EGF-Like Growth Factor</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="HGF" target="HEPATOCYTE GROWTH FACTOR">
      <data key="d4">9.0</data>
      <data key="d5">HGF encodes Hepatocyte Growth Factor</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="HRG" target="HISTIDINE-RICH GLYCOPROTEIN">
      <data key="d4">9.0</data>
      <data key="d5">HRG encodes Histidine-Rich Glycoprotein</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="IFNA1" target="INTERFERON &#913;1">
      <data key="d4">9.0</data>
      <data key="d5">IFNA1 encodes Interferon &#945;1</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="IGF2" target="INSULIN-LIKE GROWTH FACTOR 2">
      <data key="d4">9.0</data>
      <data key="d5">IGF2 encodes Insulin-Like Growth Factor 2</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="IGHD" target="IMMUNOGLOBULIN HEAVY CONSTANT &#916;">
      <data key="d4">9.0</data>
      <data key="d5">IGHD encodes Immunoglobulin Heavy Constant &#948;</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="IGHG3" target="IMMUNOGLOBULIN HEAVY CONSTANT &#915;3">
      <data key="d4">9.0</data>
      <data key="d5">IGHG3 encodes Immunoglobulin Heavy Constant &#947;3</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="IGKV1D-13" target="IMMUNOGLOBULIN &#922; VARIABLE 1D-13">
      <data key="d4">9.0</data>
      <data key="d5">IGKV1D-13 encodes Immunoglobulin &#954; Variable 1D-13</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="IGLV" target="IMMUNOGLOBULIN &#923; VARIABLE CLUSTER">
      <data key="d4">9.0</data>
      <data key="d5">IGLV encodes Immunoglobulin &#955; Variable Cluster</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="IL1A" target="INTERLEUKIN 1&#913;">
      <data key="d4">9.0</data>
      <data key="d5">IL1A encodes Interleukin 1&#945;</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="ACNE" target="BARICITINIB">
      <data key="d4">2.0</data>
      <data key="d5">There was no increase in acne under baricitinib</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="IL1B" target="INTERLEUKIN 1&#914;">
      <data key="d4">9.0</data>
      <data key="d5">IL1B encodes Interleukin 1&#946;</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="IL1B" target="ANDROGRAPHOLIDE">
      <data key="d4">7.0</data>
      <data key="d5">Andrographolide inhibits IL1B</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="IL2" target="INTERLEUKIN 2">
      <data key="d4">9.0</data>
      <data key="d5">IL2 encodes Interleukin 2</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="RITUXIMAB" target="CD20">
      <data key="d4">16.0</data>
      <data key="d5">Rituximab targets CD20 on B cells</data>
      <data key="d6">b62ecc47bf54393bc78dd65986b949d6</data>
    </edge>
    <edge source="RITUXIMAB" target="SYSTEMIC SCLEROSIS">
      <data key="d4">8.0</data>
      <data key="d5">Rituximab is being tested for its efficacy in treating systemic sclerosis</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="IL2RA" target="INTERLEUKIN 2 RECEPTOR SUBUNIT &#913;">
      <data key="d4">9.0</data>
      <data key="d5">IL2RA encodes Interleukin 2 Receptor Subunit &#945;</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="IL4" target="INTERLEUKIN 4">
      <data key="d4">9.0</data>
      <data key="d5">IL4 encodes Interleukin 4</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="ALLERGIC RHINITIS" target="IL13">
      <data key="d4">8.0</data>
      <data key="d5">IL13 is associated with Allergic rhinitis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="ALLERGIC RHINITIS" target="AD">
      <data key="d4">13.0</data>
      <data key="d5">Allergic rhinitis is an atopic comorbidity of atopic dermatitis (AD). Some patients with AD also have allergic rhinitis.</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d,89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="ALLERGIC RHINITIS" target="ATOPIC DERMATITIS">
      <data key="d4">15.0</data>
      <data key="d5">Allergic Rhinitis and Atopic Dermatitis are interconnected conditions. Allergic Rhinitis is a condition that children with Atopic Dermatitis may develop, indicating a potential progression or comorbidity between the two. Additionally, Allergic Rhinitis is associated with Atopic Dermatitis, further emphasizing the link between these allergic conditions.</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8,6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="FOOD ALLERGY" target="ATOPIC DERMATITIS">
      <data key="d4">7.0</data>
      <data key="d5">Food allergy is a comorbidity of AD</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </edge>
    <edge source="DUPILUMAB" target="ATOPIC DERMATITIS">
      <data key="d4">49.0</data>
      <data key="d5">Dupilumab is a biologic agent that targets interleukin-4 receptor alpha (IL-4R&#945;) and is approved for the treatment of moderate-to-severe atopic dermatitis (AD). It functions as an IL-4R&#945; inhibitor and is specifically used to manage and treat atopic dermatitis by interfering with the signaling pathways involved in the inflammatory response associated with this condition.</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524,3dfbb4c51838e0951f53ce951395225f,693a2aac101eaaadf92614317a1e4da8,e075bccd45593ae008b2ce7f9ed8ff6c,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="DUPILUMAB" target="IL-4R&#913;">
      <data key="d4">80.0</data>
      <data key="d5">Dupilumab is a monoclonal antibody that targets and binds to the IL-4R&#945; receptor subunit. By antagonizing IL-4R&#945;, dupilumab effectively blocks the signaling pathways of both IL-4 and IL-13. This mechanism of action is particularly significant in the treatment of atopic dermatitis, where dupilumab has demonstrated clinical efficacy. The IL-4R&#945; receptor subunit is the specific target of dupilumab, making it a crucial component in the therapeutic management of this autoimmune condition.</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0,48de7eebab3f3b418feb35a152df38fd,693a2aac101eaaadf92614317a1e4da8,78e26c66107dba37ac4bab65406b43a0,96e553a44a27e728c27c4892045ec5c2,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="DUPILUMAB" target="AD">
      <data key="d4">69.0</data>
      <data key="d5">Dupilumab has shown clinical efficacy in patients with atopic dermatitis (AD). It is approved for the treatment of moderate-to-severe atopic dermatitis and is widely used in the management of this condition. Dupilumab has been evaluated specifically for the treatment of AD and has demonstrated significant benefits for patients suffering from this chronic inflammatory skin disease.</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0,78e26c66107dba37ac4bab65406b43a0,96e553a44a27e728c27c4892045ec5c2,a867a1e73cef039eb3f28e072463b838,dc905ba8b6eb7d84cf2776303211010d,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="DUPILUMAB" target="FDA">
      <data key="d4">27.0</data>
      <data key="d5">Dupilumab is approved by the FDA for the treatment of atopic dermatitis. The FDA approved dupilumab specifically for AD treatment.</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c,dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="DUPILUMAB" target="IL-13R&#913;1">
      <data key="d4">16.0</data>
      <data key="d5">Dupilumab blocks IL-13 signaling through the type 2 receptor, which involves IL-13R&#945;1</data>
      <data key="d6">96e553a44a27e728c27c4892045ec5c2</data>
    </edge>
    <edge source="DUPILUMAB" target="SOLO 1">
      <data key="d4">16.0</data>
      <data key="d5">SOLO 1 is a clinical trial of Dupilumab</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="DUPILUMAB" target="SOLO 2">
      <data key="d4">16.0</data>
      <data key="d5">SOLO 2 is a clinical trial of Dupilumab</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="DUPILUMAB" target="CHRONOS">
      <data key="d4">16.0</data>
      <data key="d5">CHRONOS is a clinical trial of Dupilumab</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="DUPILUMAB" target="CONJUNCTIVITIS">
      <data key="d4">1.0</data>
      <data key="d5">Dupilumab can cause conjunctivitis as a side effect</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="DUPILUMAB" target="PHASE III PROGRAMME">
      <data key="d4">9.0</data>
      <data key="d5">Dupilumab's efficacy was supported by real-world data in the phase III programme</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="DUPILUMAB" target="EYE DISORDERS">
      <data key="d4">21.0</data>
      <data key="d5">Dupilumab is associated with the development of eye disorders, with 11% of patients experiencing such adverse effects.</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41,78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="DUPILUMAB" target="CHILDREN">
      <data key="d4">9.0</data>
      <data key="d5">Dupilumab is approved for children aged 6 years and older</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="DUPILUMAB" target="ADULTS">
      <data key="d4">9.0</data>
      <data key="d5">Dupilumab's efficacy was supported in adults</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="DUPILUMAB" target="PATIENTS">
      <data key="d4">9.0</data>
      <data key="d5">Dupilumab is used to treat patients with atopic dermatitis</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="DUPILUMAB" target="USA">
      <data key="d4">8.0</data>
      <data key="d5">Dupilumab is being studied in the USA</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="DUPILUMAB" target="EU">
      <data key="d4">1.0</data>
      <data key="d5">Dupilumab is being studied in the EU</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="DUPILUMAB" target="NASAL POLYPOSIS">
      <data key="d4">2.0</data>
      <data key="d5">Dupilumab is approved for the treatment of nasal polyposis</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="DUPILUMAB" target="ITCH">
      <data key="d4">16.0</data>
      <data key="d5">Dupilumab improves itch by targeting IL-4 and IL-13</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="DUPILUMAB" target="NERVE ENDINGS">
      <data key="d4">7.0</data>
      <data key="d5">Dupilumab affects nerve endings</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="DUPILUMAB" target="JAK">
      <data key="d4">16.0</data>
      <data key="d5">Dupilumab regulates the JAK/STAT pathway and inhibits JAK</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="DUPILUMAB" target="IL-4R">
      <data key="d4">9.0</data>
      <data key="d5">Dupilumab targets IL-4R and is used for treating AD</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="DUPILUMAB" target="IL-4RA">
      <data key="d4">18.0</data>
      <data key="d5">Dupilumab targets IL-4Ra</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="DUPILUMAB" target="SANOFI">
      <data key="d4">14.0</data>
      <data key="d5">Sanofi produces dupilumab</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="DUPILUMAB" target="REGENERON">
      <data key="d4">14.0</data>
      <data key="d5">Regeneron produces dupilumab</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="IL10" target="INTERLEUKIN 10">
      <data key="d4">1.0</data>
      <data key="d5">IL10 encodes Interleukin 10</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="IL10" target="NICOTINAMIDE">
      <data key="d4">7.0</data>
      <data key="d5">Nicotinamide is involved in the regulation of IL10</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL10" target="NIACIN">
      <data key="d4">7.0</data>
      <data key="d5">Niacin is involved in the regulation of IL10</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL10" target="CYCLOSPORINE A">
      <data key="d4">8.0</data>
      <data key="d5">Cyclosporine A is involved in the regulation of IL10</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="NICOTINAMIDE" target="TACROLIMUS">
      <data key="d4">14.0</data>
      <data key="d5">Tacrolimus and Nicotinamide are used together in nanotechnology-based therapeutic approaches</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="CYCLOSPORINE" target="AD">
      <data key="d4">7.0</data>
      <data key="d5">Cyclosporine is used in systemic therapy for AD</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="CYCLOSPORINE A" target="ATOPIC DERMATITIS">
      <data key="d4">6.0</data>
      <data key="d5">Cyclosporine A is an immunosuppressant used in the systemic treatment of Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="CYCLOSPORINE A" target="AD">
      <data key="d4">14.0</data>
      <data key="d5">Cyclosporine A is used to treat AD</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="CYCLOSPORINE A" target="HEADACHES">
      <data key="d4">12.0</data>
      <data key="d5">Headaches are a side effect of cyclosporine A</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="CYCLOSPORINE A" target="NEPHROTOXICITY">
      <data key="d4">12.0</data>
      <data key="d5">Nephrotoxicity is a side effect of cyclosporine A</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="CYCLOSPORINE A" target="HYPERTENSION">
      <data key="d4">12.0</data>
      <data key="d5">Hypertension is a side effect of cyclosporine A</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="CYCLOSPORINE A" target="TACROLIMUS">
      <data key="d4">14.0</data>
      <data key="d5">Cyclosporine A and Tacrolimus are used together in nanotechnology-based therapeutic approaches</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="METHOTREXATE" target="ATOPIC DERMATITIS">
      <data key="d4">14.0</data>
      <data key="d5">Methotrexate is an immunosuppressant used in the systemic treatment of Atopic Dermatitis (AD). It is specifically employed to treat severe forms of AD, providing relief by modulating the immune system's activity.</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524,693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="METHOTREXATE" target="AD">
      <data key="d4">21.0</data>
      <data key="d5">Methotrexate is used in systemic therapy for AD (Atopic Dermatitis). It is employed as a treatment option for managing the symptoms and progression of AD.</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd,48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="METHOTREXATE" target="ANAEMIA">
      <data key="d4">12.0</data>
      <data key="d5">Anaemia is a side effect of methotrexate</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="METHOTREXATE" target="LEUKOPENIA">
      <data key="d4">12.0</data>
      <data key="d5">Leukopenia is a side effect of methotrexate</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="METHOTREXATE" target="HEPATOTOXICITY">
      <data key="d4">2.0</data>
      <data key="d5">Hepatotoxicity is a side effect of methotrexate</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="METHOTREXATE" target="T CELLS">
      <data key="d4">16.0</data>
      <data key="d5">Methotrexate targets T cells in the skin</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="METHOTREXATE" target="CYTOKINES">
      <data key="d4">14.0</data>
      <data key="d5">Methotrexate modifies cytokines</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="METHOTREXATE" target="MONOCYTES">
      <data key="d4">14.0</data>
      <data key="d5">Methotrexate calms down hyperactive monocytes</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="MYCOPHENOLATE MOFETIL" target="ATOPIC DERMATITIS">
      <data key="d4">8.0</data>
      <data key="d5">Mycophenolate mofetil is used to treat severe forms of AD</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </edge>
    <edge source="MYCOPHENOLATE MOFETIL" target="SSC">
      <data key="d4">14.0</data>
      <data key="d5">Mycophenolate mofetil is used as a standard therapy drug in SSc</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="MYCOPHENOLATE MOFETIL" target="SYSTEMIC SCLEROSIS">
      <data key="d4">1.0</data>
      <data key="d5">Mycophenolate Mofetil is used in the treatment of Systemic Sclerosis</data>
      <data key="d6">8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="IL12A" target="ADAMANTIADES&#8211;BEH&#199;ET&#8217;S DISEASE">
      <data key="d4">7.0</data>
      <data key="d5">IL12A is associated with Adamantiades&#8211;Beh&#231;et&#8217;s disease</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL12A" target="PRIMARY BILIARY CHOLANGIITIS">
      <data key="d4">7.0</data>
      <data key="d5">IL12A is associated with Primary biliary cholangiitis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="USTEKINUMAB" target="FSH">
      <data key="d4">7.0</data>
      <data key="d5">Ustekinumab targets FSH</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="USTEKINUMAB" target="HCG">
      <data key="d4">7.0</data>
      <data key="d5">Ustekinumab targets HCG</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="USTEKINUMAB" target="LH">
      <data key="d4">7.0</data>
      <data key="d5">Ustekinumab targets LH</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="USTEKINUMAB" target="LTA4H">
      <data key="d4">7.0</data>
      <data key="d5">Ustekinumab targets LTA4H</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="USTEKINUMAB" target="IL-12">
      <data key="d4">8.0</data>
      <data key="d5">Ustekinumab targets IL-12 to treat moderate-to-severe atopic dermatitis</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="USTEKINUMAB" target="IL-23">
      <data key="d4">8.0</data>
      <data key="d5">Ustekinumab targets IL-23 to treat moderate-to-severe atopic dermatitis</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="IL12B" target="PSORIASIS">
      <data key="d4">8.0</data>
      <data key="d5">IL12B is associated with Psoriasis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="PSORIASIS" target="IL19">
      <data key="d4">8.0</data>
      <data key="d5">IL19 is associated with Psoriasis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="PSORIASIS" target="IL20">
      <data key="d4">8.0</data>
      <data key="d5">IL20 is associated with Psoriasis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="PSORIASIS" target="IL24">
      <data key="d4">8.0</data>
      <data key="d5">IL24 is associated with Psoriasis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="PSORIASIS" target="IL26">
      <data key="d4">8.0</data>
      <data key="d5">IL26 is associated with Psoriasis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="PSORIASIS" target="LCE3D">
      <data key="d4">1.0</data>
      <data key="d5">LCE3D is associated with Psoriasis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="PSORIASIS" target="AD">
      <data key="d4">26.0</data>
      <data key="d5">Psoriasis and Atopic Dermatitis (AD) are chronic inflammatory skin diseases that share several common features. Psoriasis has biomarkers indicative of disease progression that are similar to those found in AD, suggesting overlapping pathogenic mechanisms. Additionally, RNA-Seq data from both psoriasis and AD have been obtained for analysis, providing a valuable resource for comparative studies and further understanding of the molecular underpinnings of these conditions.</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c,b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="PSORIASIS" target="SECUKINUMAB">
      <data key="d4">9.0</data>
      <data key="d5">Secukinumab is FDA-approved for the treatment of moderate-to-severe plaque psoriasis</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="PSORIASIS" target="TAPINAROF">
      <data key="d4">16.0</data>
      <data key="d5">Tapinarof is a therapeutic agent that decreases inflammatory reactions in psoriasis. It effectively reduces inflammatory responses, making it a valuable treatment option for managing the symptoms of this autoimmune disease.</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="PSORIASIS" target="LY3471851">
      <data key="d4">1.0</data>
      <data key="d5">LY3471851 is investigated for the treatment of Psoriasis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="PSORIASIS" target="RHIL-2">
      <data key="d4">7.0</data>
      <data key="d5">Recombinant human IL-2 (rhIL-2) is being tested for its potential to restore tolerance and improve psoriasis</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="PSORIASIS" target="AKP-11">
      <data key="d4">7.0</data>
      <data key="d5">AKP-11 is in clinical development for psoriasis</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="PSORIASIS" target="PHASE I TRIAL">
      <data key="d4">6.0</data>
      <data key="d5">Phase I trial generated promising results for psoriasis</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="PSORIASIS" target="IL-36R">
      <data key="d4">7.0</data>
      <data key="d5">IL-36R is increased in psoriasis</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="PSORIASIS" target="SPESOLIMAB">
      <data key="d4">8.0</data>
      <data key="d5">Spesolimab is effective in treating a rare type of psoriasis</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="PSORIASIS" target="IL-22">
      <data key="d4">7.0</data>
      <data key="d5">IL-22 is involved in inflammation and immune response in psoriasis</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="PSORIASIS" target="IL-31">
      <data key="d4">7.0</data>
      <data key="d5">IL-31 is involved in inflammation and immune response in psoriasis</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="PSORIASIS" target="IL-37">
      <data key="d4">1.0</data>
      <data key="d5">IL-37 is involved in inflammation and immune response in psoriasis</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="PSORIASIS" target="NANOTECHNOLOGY">
      <data key="d4">7.0</data>
      <data key="d5">Nanotechnology offers a method for treating psoriasis</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="IL13" target="PENICILLIN ALLERGY">
      <data key="d4">8.0</data>
      <data key="d5">IL13 is associated with Penicillin allergy</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="OMALIZUMAB" target="IGE">
      <data key="d4">26.0</data>
      <data key="d5">Omalizumab is a monoclonal antibody that targets IgE. It is specifically designed to bind to IgE, thereby playing a crucial role in the treatment of allergic conditions. By targeting IgE, Omalizumab helps to mitigate the allergic response, making it an effective therapeutic option for individuals suffering from various allergic disorders.</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41,48288f3ec2832850282f95d4e38d10e1,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="OMALIZUMAB" target="AD">
      <data key="d4">8.0</data>
      <data key="d5">Omalizumab has shown clinical benefits in selected patients with atopic dermatitis</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0</data>
    </edge>
    <edge source="OMALIZUMAB" target="ATOPIC DERMATITIS">
      <data key="d4">15.0</data>
      <data key="d5">Omalizumab is used in the treatment of Atopic Dermatitis. Specifically, Omalizumab targets IgE in the management of this condition, providing a therapeutic approach for patients suffering from atopic dermatitis.</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="OMALIZUMAB" target="CLINICAL IMPROVEMENT">
      <data key="d4">8.0</data>
      <data key="d5">Omalizumab showed clinical improvement in patients</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="OMALIZUMAB" target="QUALITY OF LIFE">
      <data key="d4">1.0</data>
      <data key="d5">Omalizumab improved quality of life in patients</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="OMALIZUMAB" target="JAK">
      <data key="d4">16.0</data>
      <data key="d5">Omalizumab regulates the JAK/STAT pathway and inhibits JAK</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="OMALIZUMAB" target="IMMUNOGLOBULIN E">
      <data key="d4">8.0</data>
      <data key="d5">Omalizumab targets Immunoglobulin E</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="IL16" target="ALLERGIC ASTHMA">
      <data key="d4">7.0</data>
      <data key="d5">IL16 is associated with Allergic asthma</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="ALLERGIC ASTHMA" target="ATOPIC DERMATITIS">
      <data key="d4">7.0</data>
      <data key="d5">Allergic asthma is a comorbidity of AD</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </edge>
    <edge source="ALLERGIC ASTHMA" target="MEPOLIZUMAB">
      <data key="d4">8.0</data>
      <data key="d5">Mepolizumab is used to treat allergic asthma</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="ALLERGIC ASTHMA" target="AEROALLERGENS">
      <data key="d4">7.0</data>
      <data key="d5">Aeroallergens can trigger allergic asthma</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIMEKIZUMAB" target="IL17F">
      <data key="d4">14.0</data>
      <data key="d5">Bimekizumab inhibits IL17F</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="BRODALUMAB" target="IL17R">
      <data key="d4">14.0</data>
      <data key="d5">Brodalumab inhibits IL17R</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="BRODALUMAB" target="KRT6A">
      <data key="d4">14.0</data>
      <data key="d5">Brodalumab targets KRT6A</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="IL17F" target="CANDIDIASIS">
      <data key="d4">8.0</data>
      <data key="d5">IL17F is associated with Candidiasis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL17F" target="ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS">
      <data key="d4">8.0</data>
      <data key="d5">IL17F is associated with Acute generalized exanthematous pustulosis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL17F" target="MAIL DISEASES">
      <data key="d4">7.0</data>
      <data key="d5">IL17F is associated with Mail diseases</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="CANDIDIASIS" target="IL17R">
      <data key="d4">7.0</data>
      <data key="d5">IL17R is associated with Candidiasis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="CANDIDIASIS" target="IL22">
      <data key="d4">7.0</data>
      <data key="d5">IL22 is associated with Candidiasis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL22RA1" target="SPONDYLOARTHROPATHY">
      <data key="d4">7.0</data>
      <data key="d5">IL22RA1 is associated with Spondyloarthropathy</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL22RA1" target="AUTOIMMUNE UVEITIS">
      <data key="d4">7.0</data>
      <data key="d5">IL22RA1 is associated with Autoimmune uveitis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL23A" target="AUTOIMMUNE DISEASE">
      <data key="d4">8.0</data>
      <data key="d5">IL23A is associated with Autoimmune disease</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL24" target="CHRONIC SPONTANEOUS URTICARIA">
      <data key="d4">7.0</data>
      <data key="d5">IL24 is associated with Chronic spontaneous urticaria</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL24" target="SPONDYLARTHROPATHY">
      <data key="d4">7.0</data>
      <data key="d5">IL24 is associated with Spondylarthropathy</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="JAK3" target="NK CELL ENTEROPATHY">
      <data key="d4">7.0</data>
      <data key="d5">JAK3 is associated with NK cell enteropathy</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="JAK3" target="AG-490">
      <data key="d4">8.0</data>
      <data key="d5">AG-490 inhibits JAK3</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK3" target="ATRACTYLENOLIDE-I">
      <data key="d4">7.0</data>
      <data key="d5">Atractylenolide-I inhibits JAK3</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK3" target="AZD1480">
      <data key="d4">7.0</data>
      <data key="d5">AZD1480 inhibits JAK3</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK3" target="BMS-911543">
      <data key="d4">7.0</data>
      <data key="d5">BMS-911543 inhibits JAK3</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK3" target="CURCUMOL">
      <data key="d4">7.0</data>
      <data key="d5">Curcumol inhibits JAK3</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK3" target="CYT387">
      <data key="d4">7.0</data>
      <data key="d5">Cyt387 inhibits JAK3</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK3" target="DELGOCITINIB">
      <data key="d4">7.0</data>
      <data key="d5">Delgocitinib inhibits JAK3</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK3" target="FEDRATINIB">
      <data key="d4">7.0</data>
      <data key="d5">Fedratinib inhibits JAK3</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK3" target="UPADACITINIB">
      <data key="d4">16.0</data>
      <data key="d5">Upadacitinib inhibits JAK3</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="JAK3" target="WHI-P154">
      <data key="d4">14.0</data>
      <data key="d5">WHI-P154 inhibits JAK3</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="JAK3" target="XL019">
      <data key="d4">12.0</data>
      <data key="d5">XL019 inhibits JAK3</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="JAK3" target="JAK FAMILY">
      <data key="d4">16.0</data>
      <data key="d5">JAK3 is a member of the JAK family of tyrosine kinases</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="JAK3" target="ATI-1777">
      <data key="d4">8.0</data>
      <data key="d5">ATI-1777 targets JAK3</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="RUXOLITINIB" target="ATOPIC DERMATITIS">
      <data key="d4">16.0</data>
      <data key="d5">Ruxolitinib is used in the treatment of atopic dermatitis</data>
      <data key="d6">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="RUXOLITINIB" target="AD">
      <data key="d4">16.0</data>
      <data key="d5">Ruxolitinib is used for treating atopic dermatitis</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="RUXOLITINIB" target="VITILIGO">
      <data key="d4">14.0</data>
      <data key="d5">Ruxolitinib has potential for treating vitiligo</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="RUXOLITINIB" target="CUTANEOUS LUPUS">
      <data key="d4">14.0</data>
      <data key="d5">Ruxolitinib has potential for treating cutaneous lupus</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="RUXOLITINIB" target="JAK1">
      <data key="d4">16.0</data>
      <data key="d5">Ruxolitinib targets JAK1</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5,f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="RUXOLITINIB" target="JAK2">
      <data key="d4">8.0</data>
      <data key="d5">Ruxolitinib targets JAK2</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="RUXOLITINIB" target="NCT03745638">
      <data key="d4">7.0</data>
      <data key="d5">NCT03745638 is a clinical trial involving Ruxolitinib</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="RUXOLITINIB" target="NCT03745651">
      <data key="d4">7.0</data>
      <data key="d5">NCT03745651 is a clinical trial involving Ruxolitinib</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="RUXOLITINIB" target="JAK">
      <data key="d4">14.0</data>
      <data key="d5">Ruxolitinib is a selective JAK inhibitor</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="RUXOLITINIB" target="OPZELURA">
      <data key="d4">14.0</data>
      <data key="d5">Ruxolitinib is the active ingredient in Opzelura</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="CERDULATINIB" target="AD">
      <data key="d4">16.0</data>
      <data key="d5">Cerdulatinib is used for treating atopic dermatitis</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="CERDULATINIB" target="SYK">
      <data key="d4">24.0</data>
      <data key="d5">Cerdulatinib targets SYK</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e,f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="CERDULATINIB" target="PAN-JAK">
      <data key="d4">8.0</data>
      <data key="d5">Cerdulatinib targets Pan-JAK</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="CERDULATINIB" target="JAK">
      <data key="d4">14.0</data>
      <data key="d5">Cerdulatinib is a selective JAK inhibitor</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="CERDULATINIB" target="JAK1">
      <data key="d4">8.0</data>
      <data key="d5">Cerdulatinib targets JAK1</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="DELGOCITINIB" target="JAK2">
      <data key="d4">7.0</data>
      <data key="d5">Delgocitinib inhibits JAK2</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="DELGOCITINIB" target="JAK1">
      <data key="d4">15.0</data>
      <data key="d5">Delgocitinib is a pharmaceutical agent that targets and inhibits JAK1.</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d,cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="DELGOCITINIB" target="AD">
      <data key="d4">30.0</data>
      <data key="d5">Delgocitinib is a Janus kinase (JAK) inhibitor that has been under clinical development for the treatment of atopic dermatitis (AD). It is specifically used to manage and alleviate the symptoms associated with atopic dermatitis, a chronic inflammatory skin condition.</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b,c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="DELGOCITINIB" target="CHRONIC HAND ECZEMA">
      <data key="d4">14.0</data>
      <data key="d5">Delgocitinib is being developed for treating chronic hand eczema</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="DELGOCITINIB" target="JAPAN">
      <data key="d4">12.0</data>
      <data key="d5">Japan is a country where delgocitinib was approved for Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="DELGOCITINIB" target="PAN-JAK">
      <data key="d4">8.0</data>
      <data key="d5">Delgocitinib targets Pan-JAK</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="DELGOCITINIB" target="NCT03725722">
      <data key="d4">7.0</data>
      <data key="d5">NCT03725722 is a clinical trial involving Delgocitinib</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="DELGOCITINIB" target="JAK">
      <data key="d4">14.0</data>
      <data key="d5">Delgocitinib is a JAK inhibitor</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="DELGOCITINIB" target="TYK2">
      <data key="d4">14.0</data>
      <data key="d5">Delgocitinib is a TYK2 inhibitor</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="KRT6A" target="LINGUA PLICATA">
      <data key="d4">7.0</data>
      <data key="d5">KRT6A is associated with Lingua plicata</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="KRT6A" target="CHEILITIS">
      <data key="d4">7.0</data>
      <data key="d5">KRT6A is associated with Cheilitis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="KRT16" target="PALMOPLANTAR KERATODERMA">
      <data key="d4">7.0</data>
      <data key="d5">KRT16 is associated with Palmoplantar keratoderma</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="KRT16" target="ACITRETIN">
      <data key="d4">14.0</data>
      <data key="d5">Acitretin targets KRT16</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="KRT77" target="EPIDERMOLYTIC PALMOPLANTAR KERATODERMA">
      <data key="d4">7.0</data>
      <data key="d5">KRT77 is associated with Epidermolytic palmoplantar keratoderma</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="KRT77" target="BUSCHKE-OLLENDORFF SYNDROME">
      <data key="d4">7.0</data>
      <data key="d5">KRT77 is associated with Buschke-Ollendorff syndrome</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="MMP1" target="APRATASTAT">
      <data key="d4">7.0</data>
      <data key="d5">Apratastat inhibits MMP1</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="MMP1" target="DOXYCYCLINE">
      <data key="d4">14.0</data>
      <data key="d5">Doxycycline inhibits MMP1</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="MMP9" target="APRATASTAT">
      <data key="d4">7.0</data>
      <data key="d5">Apratastat inhibits MMP9</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="MMP12" target="AD">
      <data key="d4">8.0</data>
      <data key="d5">MMP12 is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="NERVE GROWTH FACTOR" target="TROPOMYOSIN RECEPTOR KINASE">
      <data key="d4">7.0</data>
      <data key="d5">Nerve growth factor is involved in pathways related to inflammation in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="PI3" target="3,3&#8217;-DIINDOLYLMETHANE">
      <data key="d4">6.0</data>
      <data key="d5">3,3&#8217;-Diindolylmethane regulates PI3</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="PI3" target="ACITRETIN">
      <data key="d4">14.0</data>
      <data key="d5">Acitretin targets PI3</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="PI3" target="DOXYCYCLINE">
      <data key="d4">14.0</data>
      <data key="d5">Doxycycline targets PI3</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="PI3" target="AD">
      <data key="d4">8.0</data>
      <data key="d5">PI3 is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="PSORIATIC ARTHRITIS" target="TNIP1">
      <data key="d4">14.0</data>
      <data key="d5">TNIP1 is associated with psoriatic arthritis</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="PSORIATIC ARTHRITIS" target="SECUKINUMAB">
      <data key="d4">9.0</data>
      <data key="d5">Secukinumab is FDA-approved for the treatment of active psoriatic arthritis</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="TNFRSF4" target="OX-40 LIGAND">
      <data key="d4">18.0</data>
      <data key="d5">TNFRSF4 encodes the receptor for OX-40 ligand</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="TNFSF11" target="AUTOIMMUNE DISEASES">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF11 is associated with autoimmune diseases</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="TNFSF13" target="AUTOIMMUNE DISEASES">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF13 is associated with autoimmune diseases</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="AUTOIMMUNE DISEASES" target="TNFSF13B">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF13B is associated with autoimmune diseases</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="AUTOIMMUNE DISEASES" target="WIF1">
      <data key="d4">14.0</data>
      <data key="d5">WIF1 is associated with autoimmune diseases</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="AUTOIMMUNE DISEASES" target="TNFSF4">
      <data key="d4">1.0</data>
      <data key="d5">TNFSF4 is a shared gene in multiple autoimmune diseases</data>
      <data key="d6">7b454335c2f5651d86f712037a0dc0ff</data>
    </edge>
    <edge source="TNFSF13B" target="SIALADENITIS">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF13B is associated with sialadenitis</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="TNFSF13B" target="SJOGREN SYNDROME">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF13B is associated with Sjogren syndrome</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="TNFSF13B" target="BAFF">
      <data key="d4">9.0</data>
      <data key="d5">BAFF is encoded by the TNFSF13B gene</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="BELIMUMAB" target="MULTIPLE SCLEROSIS">
      <data key="d4">8.0</data>
      <data key="d5">Belimumab is being tested for its efficacy in treating multiple sclerosis</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="BELIMUMAB" target="RELAPSING-REMITTING MULTIPLE SCLEROSIS">
      <data key="d4">8.0</data>
      <data key="d5">Belimumab is being tested for its efficacy in treating relapsing-remitting multiple sclerosis</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="BELIMUMAB" target="CHRONIC OBSTRUCTIVE PULMONARY DISEASE">
      <data key="d4">7.0</data>
      <data key="d5">Belimumab is being tested for its efficacy in treating chronic obstructive pulmonary disease</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="BELIMUMAB" target="EMPHYSEMA">
      <data key="d4">7.0</data>
      <data key="d5">Belimumab is being tested for its efficacy in treating emphysema</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="BELIMUMAB" target="JOHNS HOPKINS UNIVERSITY">
      <data key="d4">7.0</data>
      <data key="d5">Johns Hopkins University is involved in the clinical testing of Belimumab</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="BELIMUMAB" target="GLAXOSMITHKLINE">
      <data key="d4">8.0</data>
      <data key="d5">GlaxoSmithKline is developing Belimumab</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="BELIMUMAB" target="HOSPITAL FOR SPECIAL SURGERY, NEW YORK">
      <data key="d4">7.0</data>
      <data key="d5">Hospital for Special Surgery, New York is involved in the clinical testing of Belimumab</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="BELIMUMAB" target="UNIVERSITY OF ALABAMA AT BIRMINGHAM">
      <data key="d4">7.0</data>
      <data key="d5">University of Alabama at Birmingham is involved in the clinical testing of Belimumab</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="BELIMUMAB" target="SYSTEMIC SCLEROSIS">
      <data key="d4">8.0</data>
      <data key="d5">Belimumab is used in the treatment of Systemic Sclerosis</data>
      <data key="d6">8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="BELIMUMAB" target="BAFF">
      <data key="d4">18.0</data>
      <data key="d5">Belimumab inhibits BAFF</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3</data>
    </edge>
    <edge source="BLISIBIMOD" target="IGA NEPHROPATHY">
      <data key="d4">8.0</data>
      <data key="d5">Blisibimod is used in the treatment of IgA Nephropathy</data>
      <data key="d6">8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="TNFSF14" target="HERPES SIMPLEX">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF14 is associated with herpes simplex</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="TNFSF14" target="LIGHT">
      <data key="d4">27.0</data>
      <data key="d5">TNFSF14 is the gene encoding LIGHT. LIGHT is encoded by the TNFSF14 gene.</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a,df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="TNFSF14" target="FIBROBLASTS">
      <data key="d4">8.0</data>
      <data key="d5">TNFSF14 can act on fibroblasts to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="TNFSF14" target="MACROPHAGES">
      <data key="d4">8.0</data>
      <data key="d5">TNFSF14 can act on macrophages to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="TNFSF14" target="SMOOTH MUSCLE CELLS">
      <data key="d4">8.0</data>
      <data key="d5">TNFSF14 can act on smooth muscle cells to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="TNFSF14" target="GRANULOCYTES">
      <data key="d4">8.0</data>
      <data key="d5">TNFSF14 can act on granulocytes to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="HERPES SIMPLEX" target="BARICITINIB">
      <data key="d4">12.0</data>
      <data key="d5">Herpes simplex infections were more frequent in patients treated with baricitinib</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="TNIP1" target="SYSTEMIC LUPUS ERYTHEMATOSUS">
      <data key="d4">14.0</data>
      <data key="d5">TNIP1 is associated with systemic lupus erythematosus</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="SYSTEMIC LUPUS ERYTHEMATOSUS" target="LY3471851">
      <data key="d4">7.0</data>
      <data key="d5">LY3471851 is investigated for the treatment of Systemic Lupus Erythematosus</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="SYSTEMIC LUPUS ERYTHEMATOSUS" target="RHIL-2">
      <data key="d4">7.0</data>
      <data key="d5">Recombinant human IL-2 (rhIL-2) is being tested for its potential to restore tolerance and improve systemic lupus erythematosus</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="3,3&#8217;-DIINDOLYLMETHANE" target="HIF1A">
      <data key="d4">12.0</data>
      <data key="d5">3,3&#8217;-Diindolylmethane regulates HIF1A</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="AG-490" target="JAK2">
      <data key="d4">8.0</data>
      <data key="d5">AG-490 inhibits JAK2</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK2" target="ATRACTYLENOLIDE-I">
      <data key="d4">7.0</data>
      <data key="d5">Atractylenolide-I inhibits JAK2</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK2" target="AZD1480">
      <data key="d4">7.0</data>
      <data key="d5">AZD1480 inhibits JAK2</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK2" target="BMS-911543">
      <data key="d4">7.0</data>
      <data key="d5">BMS-911543 inhibits JAK2</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK2" target="CURCUMOL">
      <data key="d4">7.0</data>
      <data key="d5">Curcumol inhibits JAK2</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK2" target="CYT387">
      <data key="d4">7.0</data>
      <data key="d5">Cyt387 inhibits JAK2</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK2" target="FEDRATINIB">
      <data key="d4">7.0</data>
      <data key="d5">Fedratinib inhibits JAK2</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK2" target="FILGOTINIB">
      <data key="d4">7.0</data>
      <data key="d5">Filgotinib inhibits JAK2</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK2" target="UPADACITINIB">
      <data key="d4">16.0</data>
      <data key="d5">Upadacitinib inhibits JAK2</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="JAK2" target="WHI-P154">
      <data key="d4">14.0</data>
      <data key="d5">WHI-P154 inhibits JAK2</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="JAK2" target="XL019">
      <data key="d4">12.0</data>
      <data key="d5">XL019 inhibits JAK2</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="JAK2" target="BARICITINIB">
      <data key="d4">8.0</data>
      <data key="d5">JAK2 is targeted by baricitinib in the treatment of atopic dermatitis</data>
      <data key="d6">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="JAK2" target="JAK FAMILY">
      <data key="d4">16.0</data>
      <data key="d5">JAK2 is a member of the JAK family of tyrosine kinases</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="JAK2" target="GM-CSF">
      <data key="d4">7.0</data>
      <data key="d5">GM-CSF signaling is dependent on JAK2</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="JAK2" target="G-CSF">
      <data key="d4">7.0</data>
      <data key="d5">G-CSF signaling is dependent on JAK2</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="JAK2" target="EPO">
      <data key="d4">7.0</data>
      <data key="d5">EPO signaling is dependent on JAK2</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="JAK2" target="JAK1">
      <data key="d4">7.0</data>
      <data key="d5">JAK1 and JAK2 are both part of the Janus kinase family involved in cytokine receptor signaling</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="JAK2" target="CYTOKINES">
      <data key="d4">7.0</data>
      <data key="d5">JAK2 is linked to the receptors of cytokines</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="JAK2" target="ANTITUMOUR DEFENCE">
      <data key="d4">6.0</data>
      <data key="d5">JAK2 is involved in mechanisms of antitumour defence</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="ANDROGRAPHOLIDE" target="NFKB1">
      <data key="d4">7.0</data>
      <data key="d5">Andrographolide inhibits NFKB1</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="ANDROGRAPHOLIDE" target="NFKB2">
      <data key="d4">7.0</data>
      <data key="d5">Andrographolide inhibits NFKB2</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="APRATASTAT" target="ADAM17">
      <data key="d4">7.0</data>
      <data key="d5">Apratastat inhibits ADAM17</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="APRATASTAT" target="MMP13">
      <data key="d4">7.0</data>
      <data key="d5">Apratastat inhibits MMP13</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="ADAM17" target="TNFR2">
      <data key="d4">7.0</data>
      <data key="d5">ADAM17 deficiency favors overactivation of TNFR2</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="ADAM17" target="STNF">
      <data key="d4">8.0</data>
      <data key="d5">ADAM17 cleaves mTNF to release sTNF</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="ADAM17" target="LDLR">
      <data key="d4">7.0</data>
      <data key="d5">ADAM17 deficiency in Ldlr-deficient mice favors atherosclerosis progression</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="ATRACTYLENOLIDE-I" target="JAK1">
      <data key="d4">7.0</data>
      <data key="d5">Atractylenolide-I inhibits JAK1</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK1" target="AZD1480">
      <data key="d4">7.0</data>
      <data key="d5">AZD1480 inhibits JAK1</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK1" target="BMS-911543">
      <data key="d4">7.0</data>
      <data key="d5">BMS-911543 inhibits JAK1</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK1" target="CURCUMOL">
      <data key="d4">7.0</data>
      <data key="d5">Curcumol inhibits JAK1</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK1" target="CYT387">
      <data key="d4">7.0</data>
      <data key="d5">Cyt387 inhibits JAK1</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK1" target="FEDRATINIB">
      <data key="d4">7.0</data>
      <data key="d5">Fedratinib inhibits JAK1</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK1" target="FILGOTINIB">
      <data key="d4">7.0</data>
      <data key="d5">Filgotinib inhibits JAK1</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK1" target="UPADACITINIB">
      <data key="d4">41.0</data>
      <data key="d5">JAK1 and UPADACITINIB are closely related in the context of autoimmune disease treatment. JAK1 is a protein that plays a crucial role in the signaling pathways involved in immune responses. Upadacitinib is an oral medication that specifically inhibits JAK1. By targeting and inhibiting JAK1, upadacitinib is used in the treatment of atopic dermatitis, among other autoimmune conditions. This targeted inhibition helps to modulate the immune system and reduce inflammation associated with such diseases.</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60,cccfd5ff480e281556e2210cd0e5c4b5,e075bccd45593ae008b2ce7f9ed8ff6c,e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="JAK1" target="WHI-P154">
      <data key="d4">14.0</data>
      <data key="d5">WHI-P154 inhibits JAK1</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="JAK1" target="XL019">
      <data key="d4">12.0</data>
      <data key="d5">XL019 inhibits JAK1</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="JAK1" target="INCB 54707">
      <data key="d4">12.0</data>
      <data key="d5">INCB 54707 inhibits JAK1</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="JAK1" target="ABROCITINIB">
      <data key="d4">16.0</data>
      <data key="d5">Abrocitinib targets JAK1. JAK1 is targeted by abrocitinib in the treatment of atopic dermatitis.</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="JAK1" target="BARICITINIB">
      <data key="d4">8.0</data>
      <data key="d5">Baricitinib is an oral JAK1/JAK2 inhibitor</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="JAK1" target="PF-04965842">
      <data key="d4">8.0</data>
      <data key="d5">PF-04965842 is an oral JAK1 inhibitor</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="JAK1" target="JAK FAMILY">
      <data key="d4">16.0</data>
      <data key="d5">JAK1 is a member of the JAK family of tyrosine kinases</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="JAK1" target="BREPOCITINIB">
      <data key="d4">16.0</data>
      <data key="d5">Brepocitinib targets JAK1</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5,f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="JAK1" target="ATI-1777">
      <data key="d4">8.0</data>
      <data key="d5">ATI-1777 targets JAK1</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="JAK1" target="BACRICITINIB">
      <data key="d4">8.0</data>
      <data key="d5">Bacricitinib targets JAK1</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="JAK1" target="CIBINQO">
      <data key="d4">16.0</data>
      <data key="d5">Cibinqo inhibits JAK1</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="BALSALAZIDE" target="ALOX5">
      <data key="d4">7.0</data>
      <data key="d5">Balsalazide inhibits ALOX5</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="BALSALAZIDE" target="PPARG">
      <data key="d4">7.0</data>
      <data key="d5">Balsalazide inhibits PPARG</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="PPARG" target="CIGLITAZONE">
      <data key="d4">6.0</data>
      <data key="d5">Ciglitazone regulates PPARG</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="CIGLITAZONE" target="GPD1">
      <data key="d4">6.0</data>
      <data key="d5">Ciglitazone regulates GPD1</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="CIGLITAZONE" target="TBXA2R">
      <data key="d4">6.0</data>
      <data key="d5">Ciglitazone regulates TBXA2R</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="FEDRATINIB" target="BRD4">
      <data key="d4">7.0</data>
      <data key="d5">Fedratinib inhibits BRD4</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="FEDRATINIB" target="TYK2">
      <data key="d4">7.0</data>
      <data key="d5">Fedratinib inhibits TYK2</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="TYK2" target="JAK FAMILY">
      <data key="d4">9.0</data>
      <data key="d5">TYK2 is a member of the JAK family of tyrosine kinases</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="TYK2" target="BREPOCITINIB">
      <data key="d4">8.0</data>
      <data key="d5">Brepocitinib targets TYK2</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="NR1I2" target="RIFAMPICIN">
      <data key="d4">7.0</data>
      <data key="d5">Rifampicin targets NR1I2</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="UPADACITINIB" target="ATOPIC DERMATITIS">
      <data key="d4">24.0</data>
      <data key="d5">Upadacitinib is a Janus kinase (JAK) inhibitor used as a targeted therapy for atopic dermatitis. It is specifically employed in the treatment of atopic dermatitis, providing a targeted approach to managing this autoimmune condition.</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="UPADACITINIB" target="NCT02925117">
      <data key="d4">8.0</data>
      <data key="d5">NCT02925117 is a phase 2b trial for upadacitinib in AD</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="UPADACITINIB" target="NCT03569293">
      <data key="d4">8.0</data>
      <data key="d5">NCT03569293 is a phase 3 trial for upadacitinib monotherapy in AD</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="UPADACITINIB" target="NCT03607422">
      <data key="d4">8.0</data>
      <data key="d5">NCT03607422 is a phase 3 trial for upadacitinib monotherapy in AD</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="UPADACITINIB" target="NCT03568318">
      <data key="d4">8.0</data>
      <data key="d5">NCT03568318 is a phase 3 trial for upadacitinib with topical corticosteroids in AD</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="UPADACITINIB" target="AD">
      <data key="d4">16.0</data>
      <data key="d5">Upadacitinib is a JAK inhibitor used for treating moderate to severe atopic dermatitis (AD). It is specifically employed in the management of atopic dermatitis, providing therapeutic benefits for patients suffering from this chronic inflammatory skin condition.</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd,a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="UPADACITINIB" target="NCT03646604">
      <data key="d4">7.0</data>
      <data key="d5">NCT03646604 is a clinical trial involving Upadacitinib</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="UPADACITINIB" target="JAK">
      <data key="d4">14.0</data>
      <data key="d5">Upadacitinib is a JAK inhibitor</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="APRIL" target="BAFF">
      <data key="d4">32.0</data>
      <data key="d5">APRIL and BAFF are both involved in B cell regulation. They are members of the TNF Superfamily and play crucial roles in B cell maturation and fibrosis.</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3,8e5a1be9981340d419f7b3ad27076009,c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="APRIL" target="TACI">
      <data key="d4">15.0</data>
      <data key="d5">APRIL binds to TACI with high affinity.</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="APRIL" target="BCMA">
      <data key="d4">15.0</data>
      <data key="d5">APRIL binds to BCMA with high affinity.</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="APRIL" target="B LYMPHOCYTES">
      <data key="d4">8.0</data>
      <data key="d5">APRIL is involved in B cell maturation and differentiation</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="APRIL" target="T LYMPHOCYTES">
      <data key="d4">7.0</data>
      <data key="d5">APRIL is involved in T cell responses</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="APRIL" target="MONOCYTES">
      <data key="d4">7.0</data>
      <data key="d5">APRIL is involved in monocyte responses</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="APRIL" target="PATHOGENIC TISSUE REMODELING">
      <data key="d4">8.0</data>
      <data key="d5">APRIL contributes to pathogenic tissue remodeling</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="APRIL" target="ILD">
      <data key="d4">6.0</data>
      <data key="d5">Elevated serum APRIL levels are found in patients with ILD</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="APRIL" target="ATOPIC DERMATITIS">
      <data key="d4">7.0</data>
      <data key="d5">Elevated serum APRIL levels are associated with disease severity in AD</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="APRIL" target="AE">
      <data key="d4">7.0</data>
      <data key="d5">Elevated serum APRIL levels are associated with disease severity in AE</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="APRIL" target="SSC">
      <data key="d4">7.0</data>
      <data key="d5">Elevated serum APRIL levels are found in patients with SSc</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="APRIL" target="LUNG">
      <data key="d4">7.0</data>
      <data key="d5">High APRIL levels indicate pulmonary involvement in SSc</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="APRIL" target="ANTI-TOPO I ANTIBODIES">
      <data key="d4">6.0</data>
      <data key="d5">Increased production of APRIL is associated with increased anti-topo I antibodies</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="APRIL" target="ATOPIC ECZEMA">
      <data key="d4">7.0</data>
      <data key="d5">Elevated serum APRIL levels are associated with disease severity in pediatric atopic eczema</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="APRIL" target="TACI-FC FUSION PROTEIN">
      <data key="d4">27.0</data>
      <data key="d5">APRIL and TACI-Fc fusion protein are closely related entities in the context of autoimmune diseases. The TACI-Fc fusion protein specifically targets APRIL, a protein that plays a significant role in the immune system. By targeting the APRIL protein, the TACI-Fc fusion protein aims to modulate immune responses, which can be beneficial in the treatment of various autoimmune conditions.</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3,423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="APRIL" target="ATACICEPT">
      <data key="d4">18.0</data>
      <data key="d5">Atacicept inhibits APRIL</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3</data>
    </edge>
    <edge source="BAFF" target="TACI">
      <data key="d4">15.0</data>
      <data key="d5">BAFF binds to TACI with high affinity.</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="BAFF" target="BCMA">
      <data key="d4">14.0</data>
      <data key="d5">BAFF (B-cell activating factor) and BCMA (B-cell maturation antigen) are closely related entities in the context of autoimmune diseases. BAFF binds to BCMA, although it does so with lesser affinity compared to its binding with other receptors. This interaction plays a significant role in the regulation of B-cell survival and function, which is critical in the pathogenesis of various autoimmune conditions.</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="BAFF" target="BAFF-R">
      <data key="d4">8.0</data>
      <data key="d5">BAFF binds to BAFF-R with high affinity</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="BAFF" target="B LYMPHOCYTES">
      <data key="d4">8.0</data>
      <data key="d5">BAFF is involved in B cell maturation and differentiation</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="BAFF" target="T LYMPHOCYTES">
      <data key="d4">7.0</data>
      <data key="d5">BAFF is involved in T cell responses</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="BAFF" target="MONOCYTES">
      <data key="d4">7.0</data>
      <data key="d5">BAFF is involved in monocyte responses</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="BAFF" target="NASH">
      <data key="d4">16.0</data>
      <data key="d5">BAFF (B-cell activating factor) and NASH (Non-Alcoholic Steatohepatitis) are closely linked in the context of disease severity. Elevated serum BAFF levels are associated with increased severity of NASH, indicating that higher concentrations of BAFF in the bloodstream correlate with more severe manifestations of NASH. This relationship underscores the potential role of BAFF as a biomarker for assessing the progression and severity of NASH in patients.</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7,c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="BAFF" target="AUTOIMMUNE HEPATITIS">
      <data key="d4">9.0</data>
      <data key="d5">Elevated BAFF levels are associated with advanced fibrosis in autoimmune hepatitis</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7,c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="BAFF" target="PATHOGENIC TISSUE REMODELING">
      <data key="d4">8.0</data>
      <data key="d5">BAFF contributes to pathogenic tissue remodeling</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="BAFF" target="SERUM BAFF LEVELS">
      <data key="d4">8.0</data>
      <data key="d5">Elevated serum BAFF levels are associated with fibrosis severity</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="BAFF" target="HEPATOCYTE">
      <data key="d4">7.0</data>
      <data key="d5">Higher serum BAFF levels are associated with hepatocyte ballooning</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="NAFLD">
      <data key="d4">7.0</data>
      <data key="d5">BAFF-/- mice show reduced fibrosis and hepatic steatosis in NAFLD</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="MIXED CONNECTIVE TISSUE DISEASE">
      <data key="d4">7.0</data>
      <data key="d5">Elevated serum BAFF levels are found in patients with mixed connective tissue disease</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="ILD">
      <data key="d4">7.0</data>
      <data key="d5">Elevated serum BAFF levels are found in patients with ILD</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="BALF">
      <data key="d4">6.0</data>
      <data key="d5">Elevated BAFF levels are found in the BALF of a mouse model of PF</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="PF">
      <data key="d4">7.0</data>
      <data key="d5">BAFF inhibition reduces PF in a mouse model</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="SSC">
      <data key="d4">8.0</data>
      <data key="d5">Elevated serum BAFF levels are found in patients with SSc</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="B CELL">
      <data key="d4">21.0</data>
      <data key="d5">BAFF stimulates B cells to upregulate profibrotic markersB cell BAFFR expression is increased in SSc patients</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="TSK/+ MICE">
      <data key="d4">7.0</data>
      <data key="d5">Elevated serum BAFF levels are found in TSK/+ mice</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="COLLAGEN">
      <data key="d4">7.0</data>
      <data key="d5">BAFF-stimulated B cells upregulate collagen in SSc fibroblasts</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="&#913;SMA">
      <data key="d4">7.0</data>
      <data key="d5">BAFF-stimulated B cells upregulate &#945;SMA in SSc fibroblasts</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="TIMP1">
      <data key="d4">7.0</data>
      <data key="d5">BAFF-stimulated B cells upregulate TIMP1 in SSc fibroblasts</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="BEFFS">
      <data key="d4">6.0</data>
      <data key="d5">BAFF inhibition reduces fibrotic IL-6 producing Beffs</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="BREGS">
      <data key="d4">6.0</data>
      <data key="d5">BAFF inhibition does not affect regulatory IL-10 producing Bregs</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="FIBROSIS SCORE">
      <data key="d4">7.0</data>
      <data key="d5">Higher BAFF levels are associated with a higher fibrosis score</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="BLEOMYCIN">
      <data key="d4">7.0</data>
      <data key="d5">BAFF inhibition reduces fibrosis in a bleomycin-induced pulmonary fibrosis model</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="BAFFR">
      <data key="d4">7.0</data>
      <data key="d5">BAFF binds to BAFFR</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="BAFF" target="TACI-FC FUSION PROTEIN">
      <data key="d4">36.0</data>
      <data key="d5">BAFF, also known as B-cell activating factor, is a protein that plays a crucial role in the survival and maturation of B cells, which are essential components of the immune system. TACI-Fc fusion protein is a therapeutic agent designed to inhibit BAFF. By targeting and binding to the BAFF protein, TACI-Fc fusion protein effectively reduces the activity of BAFF, thereby modulating the immune response. This mechanism of action makes TACI-Fc fusion protein a potential treatment for autoimmune diseases where BAFF is implicated in the pathogenesis.</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3,423195c6b63ad0a6773374364ebf3612,8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="BAFF" target="RC18">
      <data key="d4">9.0</data>
      <data key="d5">RC18 inhibits BAFF</data>
      <data key="d6">8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="BAFF" target="ANTI-BAFF MAB">
      <data key="d4">18.0</data>
      <data key="d5">Anti-BAFF monoclonal antibody targets BAFF</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3</data>
    </edge>
    <edge source="BAFF" target="RELAPSING-REMITTING MULTIPLE SCLEROSIS">
      <data key="d4">14.0</data>
      <data key="d5">BAFF is involved in the pathogenesis of relapsing-remitting multiple sclerosis</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3</data>
    </edge>
    <edge source="BAFF" target="ATACICEPT">
      <data key="d4">18.0</data>
      <data key="d5">Atacicept inhibits BAFF</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3</data>
    </edge>
    <edge source="BAFF" target="FIBROBLASTS">
      <data key="d4">8.0</data>
      <data key="d5">BAFF acts on fibroblasts to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="BAFF" target="B CELLS">
      <data key="d4">8.0</data>
      <data key="d5">BAFF acts on B cells to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="TNFSF4" target="OX40L">
      <data key="d4">24.0</data>
      <data key="d5">TNFSF4, also known as OX40L, encodes the OX40 ligand.</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14,7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="TNFSF4" target="SLE">
      <data key="d4">32.0</data>
      <data key="d5">TNFSF4 is a susceptibility gene for systemic lupus erythematosus (SLE). It is associated with the development and progression of SLE, indicating its significant role in the pathogenesis of this autoimmune disease.</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14,8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="SSC">
      <data key="d4">43.0</data>
      <data key="d5">TNFSF4 is identified as a susceptibility gene for the development of systemic sclerosis (SSC). It is associated with systemic sclerosis and systemic sclerosis susceptibility.</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14,7b454335c2f5651d86f712037a0dc0ff,8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="RS1234314">
      <data key="d4">40.0</data>
      <data key="d5">TNFSF4 and the single nucleotide polymorphism (SNP) rs1234314 are associated with systemic sclerosis. rs1234314 is specifically a SNP located in the TNFSF4 gene region.</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789,c69c7fb997f95c56cc077b3975f41923,f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="TNFSF4" target="RS1234315">
      <data key="d4">16.0</data>
      <data key="d5">rs1234315 is a SNP in the TNFSF4 gene region</data>
      <data key="d6">f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="TNFSF4" target="RS2205960">
      <data key="d4">72.0</data>
      <data key="d5">TNFSF4 and the single nucleotide polymorphism (SNP) rs2205960 are associated with systemic sclerosis and its susceptibility. The SNP rs2205960 is located in the TNFSF4 gene region, further implicating this genetic locus in the disease's pathogenesis.</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789,8ce8c356713490cd2c680f505bcd050b,c69c7fb997f95c56cc077b3975f41923,d8a485eb1e9435b083d5ef6a17f06ea5,f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="TNFSF4" target="RS844644">
      <data key="d4">40.0</data>
      <data key="d5">TNFSF4 and the single nucleotide polymorphism (SNP) rs844644 are associated with systemic sclerosis. The SNP rs844644 is located in the TNFSF4 gene region, indicating a genetic link between this specific polymorphism and the disease.</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789,c69c7fb997f95c56cc077b3975f41923,f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="TNFSF4" target="RS12039904">
      <data key="d4">16.0</data>
      <data key="d5">rs12039904 is a SNP in the TNFSF4 gene region</data>
      <data key="d6">f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="TNFSF4" target="RS2795288">
      <data key="d4">16.0</data>
      <data key="d5">rs2795288 is a SNP in the TNFSF4 gene region</data>
      <data key="d6">f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="TNFSF4" target="RS844648">
      <data key="d4">40.0</data>
      <data key="d5">TNFSF4 and the single nucleotide polymorphism (SNP) rs844648 are associated with systemic sclerosis. TNFSF4 and SNP rs844648 are linked to systemic sclerosis, with rs844648 being a SNP located in the TNFSF4 gene region.</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789,c69c7fb997f95c56cc077b3975f41923,f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="TNFSF4" target="RS844665">
      <data key="d4">21.0</data>
      <data key="d5">TNFSF4 and the single nucleotide polymorphism (SNP) rs844665 are not significantly associated with systemic sclerosis. rs844665 is a SNP located in the TNFSF4 gene region.</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923,f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="TNFSF4" target="RS10912580">
      <data key="d4">16.0</data>
      <data key="d5">rs10912580 is a SNP in the TNFSF4 gene region</data>
      <data key="d6">f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="TNFSF4" target="RS855648">
      <data key="d4">16.0</data>
      <data key="d5">TNFSF4 and SNP rs855648 are linked to systemic sclerosis</data>
      <data key="d6">d8a485eb1e9435b083d5ef6a17f06ea5</data>
    </edge>
    <edge source="TNFSF4" target="RS944648">
      <data key="d4">16.0</data>
      <data key="d5">TNFSF4 and SNP rs944648 are linked to systemic sclerosis</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="RA">
      <data key="d4">16.0</data>
      <data key="d5">TNFSF4 is associated with rheumatoid arthritis</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="MHC CLASS II">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF4 is associated with MHC class II</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="PTPN22">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF4 is associated with PTPN22</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="AIF1">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF4 is associated with AIF1</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="IRF5">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF4 is associated with IRF5</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="STAT4">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF4 is associated with STAT4</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="FAS">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF4 is associated with FAS</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="GENE&#8211;GENE INTERACTION">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF4 is involved in gene&#8211;gene interactions</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="GENE&#8211;ENVIRONMENT INTERACTION">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF4 is involved in gene&#8211;environment interactions</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="CAUCASIAN">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF4 is associated with systemic sclerosis in North American Caucasians</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="LSSC">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF4 is associated with limited systemic sclerosis</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="DSSC">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF4 is associated with diffuse systemic sclerosis</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="AUTOANTIBODY">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF4 is associated with SSc-associated autoantibody subsets</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="SNPS">
      <data key="d4">8.0</data>
      <data key="d5">SNPs within the promoter region of TNFSF4 are associated with SSc susceptibility</data>
      <data key="d6">7b454335c2f5651d86f712037a0dc0ff</data>
    </edge>
    <edge source="TNFSF4" target="PROMOTER REGION">
      <data key="d4">8.0</data>
      <data key="d5">SNPs within the promoter region of TNFSF4 are associated with SSc</data>
      <data key="d6">7b454335c2f5651d86f712037a0dc0ff</data>
    </edge>
    <edge source="TNFSF4" target="GENETIC STRUCTURE">
      <data key="d4">7.0</data>
      <data key="d5">Determining the variation in the genetic structure of TNFSF4 will help understand its role in SSc</data>
      <data key="d6">7b454335c2f5651d86f712037a0dc0ff</data>
    </edge>
    <edge source="TNFSF4" target="OX40">
      <data key="d4">6.0</data>
      <data key="d5">OX40 is also known as TNFSF4</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="ACITRETIN" target="RARA">
      <data key="d4">14.0</data>
      <data key="d5">Acitretin targets RARA</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="ACITRETIN" target="RARB">
      <data key="d4">14.0</data>
      <data key="d5">Acitretin targets RARB</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="ACITRETIN" target="RARG">
      <data key="d4">14.0</data>
      <data key="d5">Acitretin targets RARG</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="ACITRETIN" target="RBP1">
      <data key="d4">14.0</data>
      <data key="d5">Acitretin targets RBP1</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="ACITRETIN" target="RXRA">
      <data key="d4">14.0</data>
      <data key="d5">Acitretin targets RXRA</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="ACITRETIN" target="RXRB">
      <data key="d4">14.0</data>
      <data key="d5">Acitretin targets RXRB</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="ACITRETIN" target="RXRG">
      <data key="d4">14.0</data>
      <data key="d5">Acitretin targets RXRG</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="ACITRETIN" target="STAT3">
      <data key="d4">14.0</data>
      <data key="d5">Acitretin targets STAT3</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="CYPROTERONE ACETATE" target="ADORA1">
      <data key="d4">14.0</data>
      <data key="d5">Cyproterone acetate antagonizes ADORA1</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="DOXYCYCLINE" target="MMP8">
      <data key="d4">14.0</data>
      <data key="d5">Doxycycline inhibits MMP8</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="ETANERCEPT" target="TNFRSF1A">
      <data key="d4">16.0</data>
      <data key="d5">Etanercept antagonizes TNFRSF1A</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="ETANERCEPT" target="LIVER FIBROSIS">
      <data key="d4">7.0</data>
      <data key="d5">Etanercept decreases liver fibrosis progression</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="ETANERCEPT" target="TNFR1">
      <data key="d4">7.0</data>
      <data key="d5">Etanercept decreases TNFR1 expression</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="ETANERCEPT" target="COLLAGEN">
      <data key="d4">7.0</data>
      <data key="d5">Etanercept decreases collagen accumulation</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="ETANERCEPT" target="HEMOSIDERIN">
      <data key="d4">7.0</data>
      <data key="d5">Etanercept decreases hemosiderin accumulation</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="ETANERCEPT" target="LIVER">
      <data key="d4">7.0</data>
      <data key="d5">Etanercept decreases collagen and hemosiderin accumulation in the liver</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="ETANERCEPT" target="PULMONARY FIBROSIS">
      <data key="d4">7.0</data>
      <data key="d5">Etanercept is used in clinical trials to treat Pulmonary Fibrosis</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="METFORMIN" target="ACACB">
      <data key="d4">14.0</data>
      <data key="d5">Metformin targets ACACB</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="RIFAMPICIN" target="SLCO1A2">
      <data key="d4">7.0</data>
      <data key="d5">Rifampicin targets SLCO1A2</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="RIFAMPICIN" target="SLCO1B1">
      <data key="d4">7.0</data>
      <data key="d5">Rifampicin targets SLCO1B1</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="RIFAMPICIN" target="SLCO1B3">
      <data key="d4">7.0</data>
      <data key="d5">Rifampicin targets SLCO1B3</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="SECUKINUMAB" target="IL-17A">
      <data key="d4">17.0</data>
      <data key="d5">Secukinumab targets IL-17A. Secukinumab targets IL-17A to treat moderate-to-severe atopic dermatitis.</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="SECUKINUMAB" target="ANKYLOSING SPONDYLITIS">
      <data key="d4">9.0</data>
      <data key="d5">Secukinumab is FDA-approved for the treatment of ankylosing spondylitis</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="SECUKINUMAB" target="ATOPIC DERMATITIS">
      <data key="d4">14.0</data>
      <data key="d5">Secukinumab is investigated for the treatment of Atopic Dermatitis. It is used to target IL-17A in the treatment of atopic dermatitis.</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="SECUKINUMAB" target="AD">
      <data key="d4">7.0</data>
      <data key="d5">Secukinumab was explored for AD treatment</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="SECUKINUMAB" target="PLAQUE PSORIASIS">
      <data key="d4">8.0</data>
      <data key="d5">Secukinumab is used to treat plaque psoriasis</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="SECUKINUMAB" target="INTERLEUKIN-17A">
      <data key="d4">8.0</data>
      <data key="d5">Secukinumab targets Interleukin-17a</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="SPESOLIMAB" target="AD">
      <data key="d4">19.0</data>
      <data key="d5">Spesolimab is being explored for the treatment of atopic dermatitis (AD) and is currently under investigation in a phase-II clinical trial for this condition.</data>
      <data key="d6">6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="SPESOLIMAB" target="ATOPIC DERMATITIS">
      <data key="d4">21.0</data>
      <data key="d5">Spesolimab is a biologic agent specifically designed to target interleukin-36 receptor (IL-36R) in the treatment of atopic dermatitis. This therapeutic approach aims to modulate the immune response associated with the condition, providing a targeted intervention for patients suffering from this chronic inflammatory skin disease.</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="SPESOLIMAB" target="IL-36R">
      <data key="d4">8.0</data>
      <data key="d5">Spesolimab targets IL-36R</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="VILOBELIMAB" target="C5">
      <data key="d4">1.0</data>
      <data key="d5">Vilobelimab inhibits C5</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="IL-17A" target="AD">
      <data key="d4">16.0</data>
      <data key="d5">IL-17A is involved in the immune response and inflammation in ADIL-17A is a cytokine involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="IL-36R" target="AD">
      <data key="d4">7.0</data>
      <data key="d5">IL-36R is increased in AD</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-36R" target="S. AUREUS">
      <data key="d4">7.0</data>
      <data key="d5">S. aureus infection leads to inflammation relying on IL-36R</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="JAK" target="AD">
      <data key="d4">29.0</data>
      <data key="d5">JAK (Janus kinase) is a critical component involved in the signaling pathways that regulate immune responses, playing a significant role in the pathophysiology of autoimmune diseases (AD). JAK inhibitors are utilized in the treatment of AD, targeting these signaling pathways to modulate the immune response and alleviate disease symptoms.</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c,2cec06c4d46f5ff9ee936a78d8b077cd,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="JAK" target="IL-31">
      <data key="d4">16.0</data>
      <data key="d5">JAK is involved in the signaling pathway of IL-31</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="JAK" target="ABROCITINIB">
      <data key="d4">14.0</data>
      <data key="d5">Abrocitinib is a JAK inhibitor</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="JAK" target="BARICITINIB">
      <data key="d4">14.0</data>
      <data key="d5">Baricitinib is a JAK inhibitor</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="JAK" target="BREPOCITINIB">
      <data key="d4">14.0</data>
      <data key="d5">Brepocitinib is a selective JAK inhibitor</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="IL-12" target="CAMP">
      <data key="d4">6.0</data>
      <data key="d5">cAMP mediates downstream events culminating in the inhibition of IL-12 secretion</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="IL-12" target="TH1">
      <data key="d4">8.0</data>
      <data key="d5">IL-12 drives the differentiation of Th1 cells</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="IL-23" target="CAMP">
      <data key="d4">6.0</data>
      <data key="d5">cAMP mediates downstream events culminating in the inhibition of IL-23 secretion</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="IL-23" target="ATOPIC DERMATITIS">
      <data key="d4">7.0</data>
      <data key="d5">IL-23 is implicated in Atopic Dermatitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-23" target="RISANKIZUMAB">
      <data key="d4">8.0</data>
      <data key="d5">Risankizumab is an anti-IL-23 antibody</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-23" target="AD">
      <data key="d4">8.0</data>
      <data key="d5">IL-23 is involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="OX40" target="OX40L">
      <data key="d4">205.0</data>
      <data key="d5">OX40 and OX40L are co-localized in the skin and interact to modulate immune responses. These molecules are involved in positive costimulatory pathways and play a significant role in the immune response. OX40 binds to its ligand OX40L, generating a costimulatory signal that is crucial for T cell activation and modulation of T-cell activity, particularly activated T-cells. This interaction is essential for the generation of Th2 memory cells, which are important in the pathogenesis of atopic dermatitis (AD). Consequently, OX40 and OX40L are targets for inhibitors in the treatment of atopic dermatitis. The binding of OX40 to OX40L potentiates pro-inflammatory T-cell responses, highlighting their central role in the disease's pathogenesis.</data>
      <data key="d6">100dd7646c10899301b3c0631183da16,1b656cfce91ff9ccec4223703489dab3,3287c502f10f4651d2f56bf39ee7bb7a,44f2592262cac835560b4c149fee8d2b,4842292208575bd45b2b5998513dd087,4d0e8ae9371a435885994b4161126bc3,6309eeea565f06479830cec32938abc9,691cb2e23ac3c6e591129d16714f8ef8,78e26c66107dba37ac4bab65406b43a0,7c13f41d7349d9d2e56c36e00c0ca2d9,855c455b4c9592746834ee3a4e0e6b81,89dbac0da39e4de2b602052cd792b90d,8ce8c356713490cd2c680f505bcd050b,c95d22c2a90e77cd22bd0d280d55b26a,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="OX40" target="ROCATINLIMAB">
      <data key="d4">68.0</data>
      <data key="d5">Rocatinlimab is an anti-OX40 monoclonal antibody that targets OX40 to deplete activated T-cells.</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688,4842292208575bd45b2b5998513dd087,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="OX40" target="EFFECTOR T-CELLS">
      <data key="d4">16.0</data>
      <data key="d5">OX40 potentiates the expansion of effector T-cells</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="OX40" target="REGULATORY T-CELLS">
      <data key="d4">14.0</data>
      <data key="d5">OX40 is expressed on regulatory T-cells</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="OX40" target="MEMORY T-CELLS">
      <data key="d4">14.0</data>
      <data key="d5">OX40 is expressed on reactivated memory T-cells</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="OX40" target="EFFECTOR MEMORY T-CELLS">
      <data key="d4">14.0</data>
      <data key="d5">OX40 promotes the expansion of effector memory T-cells</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="OX40" target="PERIPHERAL BLOOD MONONUCLEAR CELLS">
      <data key="d4">21.0</data>
      <data key="d5">OX40 is expressed on peripheral blood mononuclear cells in AD patients.</data>
      <data key="d6">4842292208575bd45b2b5998513dd087,89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="OX40" target="GBR 830">
      <data key="d4">56.0</data>
      <data key="d5">GBR 830 is a monoclonal antibody directed against OX40.</data>
      <data key="d6">4842292208575bd45b2b5998513dd087,6309eeea565f06479830cec32938abc9,dc905ba8b6eb7d84cf2776303211010d,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="OX40" target="AMLITELIMAB">
      <data key="d4">18.0</data>
      <data key="d5">Amlitelimab blocks interactions between OX40 and OX40L</data>
      <data key="d6">b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="OX40" target="T-CELL">
      <data key="d4">35.0</data>
      <data key="d5">OX40 is a molecule that is predominantly expressed on effector and regulatory T-cells. Its expression is notably upregulated when T-cells, including both effector and regulatory T-cells (Tregs), are stimulated. OX40 plays a crucial role in T-cell functioning, contributing to the regulation and activity of these immune cells.</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd,b201c6ff3e22b2475c8c59260a0eb6a7,dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="OX40" target="AD">
      <data key="d4">41.0</data>
      <data key="d5">OX40 is a molecule whose expression is notably increased in the context of atopic dermatitis (AD). Specifically, OX40 expression is elevated in the lesions and skin of patients suffering from AD. Additionally, OX40 expression has been analyzed on peripheral blood mononuclear cells (PBMCs) from these patients. It is also highly expressed in skin-homing T cells and monocytes in individuals with AD. This suggests that OX40 plays a significant role in the immunopathology of atopic dermatitis.</data>
      <data key="d6">100dd7646c10899301b3c0631183da16,2e9a8d71f6bd251a0b13458c39e69746,6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="OX40" target="KHK4083">
      <data key="d4">24.0</data>
      <data key="d5">OX40 and KHK4083 are closely related entities in the context of autoimmune disease research. OX40 is a protein that plays a significant role in the regulation of the immune system, particularly in the activation and survival of T cells. KHK4083 is an anti-OX40 monoclonal antibody, specifically designed to target and bind to the OX40 protein. By directing its action against OX40, KHK4083 aims to modulate the immune response, potentially offering therapeutic benefits in the treatment of autoimmune diseases.</data>
      <data key="d6">6309eeea565f06479830cec32938abc9,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="OX40" target="TH2 CELL">
      <data key="d4">8.0</data>
      <data key="d5">OX40 is involved in the Th2 pathway</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="OX40" target="T-CELLS">
      <data key="d4">16.0</data>
      <data key="d5">OX40 is expressed when T-cells are stimulated</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="OX40" target="TH22">
      <data key="d4">6.0</data>
      <data key="d5">Blocking OX40 may prevent further Th22 pathway activation</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="OX40" target="TREGS">
      <data key="d4">7.0</data>
      <data key="d5">Blocking OX40 may promote the proliferation of Tregs and T-cell tolerance</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="OX40" target="ATOPIC DERMATITIS">
      <data key="d4">17.0</data>
      <data key="d5">OX40 is a critical molecule involved in the pathogenesis of Atopic Dermatitis. It plays a central role in the disease's development and progression. Due to its significant involvement, OX40 is targeted by monoclonal antibodies in clinical trials aimed at treating Atopic Dermatitis. These trials are exploring the potential of OX40-targeted therapies to alleviate the symptoms and underlying causes of this chronic inflammatory skin condition.</data>
      <data key="d6">68015074236b0144899baa38d01ae467,691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="OX40" target="DERMIS">
      <data key="d4">8.0</data>
      <data key="d5">OX40+ cells are co-located within the dermis in Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="OX40" target="ANTIGEN-ACTIVATION">
      <data key="d4">7.0</data>
      <data key="d5">Antigen-Activation triggers T-cell expression of OX40 in Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="OX40" target="HC">
      <data key="d4">8.0</data>
      <data key="d5">OX40 expression was analyzed on PBMCs from healthy controls</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="OX40" target="CD4">
      <data key="d4">6.0</data>
      <data key="d5">CD4 was used to stain cells for OX40 analysis</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="OX40" target="CD8">
      <data key="d4">6.0</data>
      <data key="d5">CD8 was used to stain cells for OX40 analysis</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="OX40" target="CD14">
      <data key="d4">6.0</data>
      <data key="d5">CD14 was used to stain cells for OX40 analysis</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="OX40" target="CD45RO">
      <data key="d4">6.0</data>
      <data key="d5">CD45RO was used to stain cells for OX40 analysis</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="OX40" target="CD56">
      <data key="d4">6.0</data>
      <data key="d5">CD56 was used to stain cells for OX40 analysis</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="OX40" target="CLA">
      <data key="d4">6.0</data>
      <data key="d5">CLA was used to stain cells for OX40 analysis</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="OX40" target="SOX40">
      <data key="d4">8.0</data>
      <data key="d5">OX40 is the membrane-bound form of the soluble protein sOX40</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="OX40" target="SCORAD">
      <data key="d4">16.0</data>
      <data key="d5">OX40 expression in CD4+CD45RO+CLA+/- T cells inversely correlates with SCORAD</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="OX40" target="T CELLS">
      <data key="d4">17.0</data>
      <data key="d5">OX40 is expressed on T cells in atopic dermatitis (AD). It is highly expressed by skin-homing memory-prone CLA+ T cells in AD patients.</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="OX40" target="MONOCYTES">
      <data key="d4">8.0</data>
      <data key="d5">OX40 is highly expressed by monocytes in AD patients</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="OX40" target="CD8+ T CELLS">
      <data key="d4">7.0</data>
      <data key="d5">CD8+ T cells in AD patients express OX40</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="OX40" target="IGE">
      <data key="d4">5.0</data>
      <data key="d5">OX40 expression does not correlate with serum IgE levels</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="OX40" target="CLA+ T CELLS">
      <data key="d4">9.0</data>
      <data key="d5">OX40 is highly expressed by CLA+ T cells in AD patients</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="OX40" target="CLA- T CELLS">
      <data key="d4">8.0</data>
      <data key="d5">OX40 is expressed by CLA- T cells in AD patients</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="OX40" target="CD4+CD45RO+CLA+ T CELLS">
      <data key="d4">17.0</data>
      <data key="d5">OX40 is highly expressed by CD4+CD45RO+CLA+ T cells in patients with atopic dermatitis (AD). CD4+CD45RO+CLA+ T cells, which are a subset of T cells, exhibit elevated levels of OX40 in individuals suffering from AD. This suggests a significant role for OX40 in the pathophysiology of atopic dermatitis, potentially making it a valuable target for therapeutic intervention in this autoimmune condition.</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="OX40" target="CD4+CD45RO+CLA- T CELLS">
      <data key="d4">8.0</data>
      <data key="d5">OX40 is expressed by CD4+CD45RO+CLA- T cells in AD patients</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="OX40" target="CD8+CD45RO+CLA+ T CELLS">
      <data key="d4">7.0</data>
      <data key="d5">OX40 is expressed by CD8+CD45RO+CLA+ T cells in AD patients</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="OX40" target="CD8+CD45RO+CLA- T CELLS">
      <data key="d4">7.0</data>
      <data key="d5">OX40 is expressed by CD8+CD45RO+CLA- T cells in AD patients</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="OX40" target="T CELL">
      <data key="d4">40.0</data>
      <data key="d5">OX40 is a molecule that plays a significant role in the immune system, particularly in the function and regulation of T cells. It is expressed on both CD4+ and CD8+ T cells, indicating its broad involvement in T cell-mediated immune responses. OX40 expression is notably increased on skin-homing T cells, suggesting a specialized role in skin-related immune functions. Additionally, OX40 is crucial for T cell costimulation, a process essential for the activation and proliferation of T cells. This makes OX40 a key player in the modulation of immune responses, with potential implications for autoimmune diseases and therapeutic interventions targeting T cell activity.</data>
      <data key="d6">100dd7646c10899301b3c0631183da16,4d0e8ae9371a435885994b4161126bc3,8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40" target="SKIN THICKNESS">
      <data key="d4">7.0</data>
      <data key="d5">Anti-OX40 therapy affects skin thickness in the treatment of atopic dermatitis</data>
      <data key="d6">100dd7646c10899301b3c0631183da16</data>
    </edge>
    <edge source="OX40" target="EASI">
      <data key="d4">7.0</data>
      <data key="d5">Anti-OX40 therapy affects EASI score in the treatment of atopic dermatitis</data>
      <data key="d6">100dd7646c10899301b3c0631183da16</data>
    </edge>
    <edge source="OX40" target="ATOPIC DISEASES">
      <data key="d4">8.0</data>
      <data key="d5">OX40 system is closely correlated with atopic diseases</data>
      <data key="d6">100dd7646c10899301b3c0631183da16</data>
    </edge>
    <edge source="OX40" target="T-REG CELL">
      <data key="d4">7.0</data>
      <data key="d5">OX40 mediates inactivation of T-reg cell function</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="OX40" target="DC">
      <data key="d4">7.0</data>
      <data key="d5">OX40 unleashes DCs by inactivating T-reg cells, allowing adaptive immune response</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="OX40" target="SSC">
      <data key="d4">24.0</data>
      <data key="d5">OX40 levels are significantly increased in systemic sclerosis (SSC) patients. Serum levels of OX40 are elevated in patients with systemic sclerosis.</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b,8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40" target="SLE">
      <data key="d4">6.0</data>
      <data key="d5">OX40 levels are compared between systemic sclerosis and lupus patients</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="OX40" target="GITR">
      <data key="d4">6.0</data>
      <data key="d5">GITR possesses an intracellular domain with significant homology to OX40</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="OX40" target="CD134">
      <data key="d4">6.0</data>
      <data key="d5">OX40 is also known as CD134</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="OX40" target="ANTIGEN PRESENTING CELLS">
      <data key="d4">7.0</data>
      <data key="d5">OX40 is expressed on antigen presenting cells</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="OX40" target="ULCERATIVE COLITIS">
      <data key="d4">8.0</data>
      <data key="d5">OX40 is targeted by monoclonal antibodies in clinical trials for ulcerative colitis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="OX40L" target="AMLITELIMAB">
      <data key="d4">70.0</data>
      <data key="d5">Amlitelimab is an anti-OX40L antibody that binds to OX40L and blocks its interaction with OX40.</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="OX40L" target="DENDRITIC CELLS (DCS)">
      <data key="d4">16.0</data>
      <data key="d5">OX40L is expressed on dendritic cells</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="OX40L" target="ENDOTHELIAL CELLS">
      <data key="d4">30.0</data>
      <data key="d5">OX40L is expressed on endothelial cells</data>
      <data key="d6">4842292208575bd45b2b5998513dd087,b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="OX40L" target="MACROPHAGES">
      <data key="d4">14.0</data>
      <data key="d5">OX40L is expressed on macrophages</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="OX40L" target="B-CELLS">
      <data key="d4">14.0</data>
      <data key="d5">OX40L is expressed on activated B-cells</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="OX40L" target="PERIPHERAL BLOOD MONONUCLEAR CELLS">
      <data key="d4">14.0</data>
      <data key="d5">OX40L is expressed on peripheral blood mononuclear cells in AD patients</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="OX40L" target="GBR 830">
      <data key="d4">16.0</data>
      <data key="d5">GBR 830 treatment reduces OX40L expression</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="OX40L" target="ANTIGEN-PRESENTING CELLS">
      <data key="d4">26.0</data>
      <data key="d5">OX40L is expressed on activated antigen-presenting cells.</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7,dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="OX40L" target="AD">
      <data key="d4">58.0</data>
      <data key="d5">OX40L and AD (Atopic Dermatitis) are closely linked in the context of autoimmune diseases. OX40L expression is notably increased in the lesions of patients with AD, indicating its significant role in the disease's pathology. Studies have shown that OX40L is expressed by cells in the skin of AD patients and is highly expressed in monocytes. Additionally, OX40L expression has been analyzed on peripheral blood mononuclear cells (PBMCs) from patients with AD, further underscoring its involvement. OX40L is crucial in the pathogenesis of atopic dermatitis, playing a central role in pro-inflammatory T-cell responses, which are pivotal in the disease's progression.</data>
      <data key="d6">100dd7646c10899301b3c0631183da16,2e9a8d71f6bd251a0b13458c39e69746,6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d,b201c6ff3e22b2475c8c59260a0eb6a7,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="OX40L" target="T-CELL">
      <data key="d4">16.0</data>
      <data key="d5">OX40L blocks T-cell activation</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="OX40L" target="KY1005">
      <data key="d4">16.0</data>
      <data key="d5">KY1005 is an anti-OX40L biologic</data>
      <data key="d6">6309eeea565f06479830cec32938abc9</data>
    </edge>
    <edge source="OX40L" target="TSLP">
      <data key="d4">10.0</data>
      <data key="d5">TSLP (Thymic Stromal Lymphopoietin) activates antigen-presenting cells to produce OX40L (OX40 Ligand). This interaction is crucial in the immune response, as TSLP's activation of antigen-presenting cells leads to the production of OX40L, which plays a significant role in the modulation of immune functions.</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd,3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="OX40L" target="TH2">
      <data key="d4">21.0</data>
      <data key="d5">OX40L, also known as OX40 ligand, plays a crucial role in the immune system by encouraging and maintaining the growth of Th2 central memory cells. Additionally, the interaction of OX40L may promote the production of T helper 2 (Th2) cytokines, which are essential for the Th2 immune response. This dual function highlights the importance of OX40L in modulating Th2-mediated immune activities.</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd,8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40L" target="ATOPIC DERMATITIS">
      <data key="d4">17.0</data>
      <data key="d5">OX40L is a critical molecule involved in the pathogenesis of Atopic Dermatitis. It plays a central role in the disease's development and progression. Due to its significant involvement, OX40L is targeted by monoclonal antibodies in clinical trials aimed at treating Atopic Dermatitis. These trials are exploring the potential of OX40L inhibition as a therapeutic strategy to alleviate the symptoms and underlying causes of this chronic inflammatory skin condition.</data>
      <data key="d6">68015074236b0144899baa38d01ae467,691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="OX40L" target="DERMIS">
      <data key="d4">8.0</data>
      <data key="d5">OX40L+ cells are co-located within the dermis in Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="OX40L" target="APC">
      <data key="d4">7.0</data>
      <data key="d5">APCs express OX40L in Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="OX40L" target="MAST CELLS">
      <data key="d4">39.0</data>
      <data key="d5">Mast cells express OX40L in the skin of patients with Atopic Dermatitis (AD). This expression of OX40L on mast cells is a notable feature in the context of AD, indicating a potential role in the pathophysiology of the disease.</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8,6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="OX40L" target="ANTIGEN-ACTIVATION">
      <data key="d4">7.0</data>
      <data key="d5">Antigen-Activation triggers APC expression of OX40L in Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="OX40L" target="HC">
      <data key="d4">8.0</data>
      <data key="d5">OX40L expression was analyzed on PBMCs from healthy controls</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="OX40L" target="TRYPTASE">
      <data key="d4">5.0</data>
      <data key="d5">Both OX40L and Tryptase are targeted by specific monoclonal antibodies for analysis</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="OX40L" target="MONOCLONAL MOUSE ANTI-OX40L">
      <data key="d4">7.0</data>
      <data key="d5">Monoclonal mouse anti-OX40L is used to target OX40L in immunohistochemistry</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="OX40L" target="SOX40L">
      <data key="d4">8.0</data>
      <data key="d5">OX40L is the membrane-bound form of the soluble protein sOX40L</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="OX40L" target="MONOCYTES">
      <data key="d4">23.0</data>
      <data key="d5">OX40L is a molecule that is primarily expressed by monocytes. In the context of autoimmune diseases, particularly in AD (Atopic Dermatitis) patients, monocytes exhibit high levels of OX40L expression. This elevated expression is observed not only in AD patients but also in healthy controls, indicating that monocytes consistently express high levels of OX40L regardless of disease state.</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="OX40L" target="IGE">
      <data key="d4">7.0</data>
      <data key="d5">Increased expression of OX40L on B cells is associated with the level of total IgE in allergic asthma patients</data>
      <data key="d6">89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="OX40L" target="MURINE ASTHMA MODELS">
      <data key="d4">7.0</data>
      <data key="d5">OX40L is highly expressed by a variety of cells within the lung during an induced allergic reaction in murine asthma models</data>
      <data key="d6">89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="OX40L" target="B CELLS">
      <data key="d4">23.0</data>
      <data key="d5">OX40L is a molecule that is expressed on B cells, particularly in the context of allergic asthma. It is also expressed on activated B cells, indicating its role in immune responses where B cells are actively engaged.</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3,89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="OX40L" target="LUNG">
      <data key="d4">7.0</data>
      <data key="d5">OX40L is expressed in the lung during allergic reactions in murine asthma models</data>
      <data key="d6">89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="OX40L" target="ATOPIC DISEASES">
      <data key="d4">8.0</data>
      <data key="d5">OX40L is involved in the pathogenesis of atopic diseases</data>
      <data key="d6">100dd7646c10899301b3c0631183da16</data>
    </edge>
    <edge source="OX40L" target="T CELL">
      <data key="d4">25.0</data>
      <data key="d5">OX40L is a molecule that plays a crucial role in the immune system, particularly in the context of T cells. It is expressed on T cells and is involved in their costimulation, which is essential for their full activation and function. Additionally, OX40L is specifically implicated in the activation of T cells in the skin, highlighting its importance in localized immune responses.</data>
      <data key="d6">100dd7646c10899301b3c0631183da16,4d0e8ae9371a435885994b4161126bc3,8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40L" target="SSC">
      <data key="d4">36.0</data>
      <data key="d5">OX40L is implicated in systemic sclerosis (SSC) and is overexpressed in patients with this condition.</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="OX40L" target="T CELLS">
      <data key="d4">15.0</data>
      <data key="d5">OX40L is overexpressed in lesional skin T cellsOX40L enhances T cell survival</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="OX40L" target="IL-2">
      <data key="d4">8.0</data>
      <data key="d5">OX40L upregulates IL-2 production</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="OX40L" target="B CELL">
      <data key="d4">31.0</data>
      <data key="d5">OX40L is a molecule that plays a significant role in the immune system, particularly in relation to B cells. It enhances B cell proliferation and differentiation, which are crucial processes for the immune response. OX40L is overexpressed in lesional skin B cells, indicating its involvement in certain pathological conditions. Additionally, OX40L is expressed on B cells and is critical for their differentiation and antibody production. This highlights its importance in both normal immune function and in disease states where B cell activity is dysregulated.</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b,8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40L" target="DERMAL FIBROBLASTS">
      <data key="d4">14.0</data>
      <data key="d5">OX40L is overexpressed in resting and activated dermal fibroblasts</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="OX40L" target="MMP">
      <data key="d4">16.0</data>
      <data key="d5">OX40L and MMP are interconnected entities involved in various biological processes. OX40L modulates MMP expression in fibrotic mice, indicating a role in tissue remodeling and fibrosis. Additionally, OX40L signaling affects MMP-mediated proteolytic cleavage of CD27, suggesting a regulatory function in immune responses and cellular interactions. Together, these descriptions highlight the significance of OX40L in modulating MMP activity, which has implications for both fibrosis and immune regulation.</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3,44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="OX40L" target="BLEOMYCIN MOUSE MODEL">
      <data key="d4">30.0</data>
      <data key="d5">OX40L is a significant target in the context of dermal fibrosis, particularly studied using the Bleomycin mouse model. Research indicates that OX40L signaling plays a crucial role in the development of dermal fibrosis in this model. Furthermore, blockade of OX40L has been shown to prevent the onset of dermal fibrosis, highlighting its potential as a therapeutic target for conditions characterized by excessive fibrotic tissue formation.</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3,9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="OX40L" target="FRA-2 TRANSGENIC MOUSE MODEL">
      <data key="d4">16.0</data>
      <data key="d5">OX40L blockade alleviates pulmonary hypertension in the Fra-2 transgenic mouse model</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="OX40L" target="SERUM">
      <data key="d4">7.0</data>
      <data key="d5">Increased expression of OX40L is observed in the serum of SSc patients</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="OX40L" target="DENDRITIC CELL">
      <data key="d4">16.0</data>
      <data key="d5">OX40L is expressed on dendritic cells</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40L" target="MACROPHAGE">
      <data key="d4">16.0</data>
      <data key="d5">OX40L is expressed on macrophages</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40L" target="NK CELL">
      <data key="d4">16.0</data>
      <data key="d5">OX40L is expressed on natural killer cells</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40L" target="ENDOTHELIAL CELL">
      <data key="d4">16.0</data>
      <data key="d5">OX40L is expressed on endothelial cells</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40L" target="SMOOTH MUSCLE CELL">
      <data key="d4">16.0</data>
      <data key="d5">OX40L is expressed on smooth muscle cells</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40L" target="FOXP3+ REGULATORY T CELL">
      <data key="d4">14.0</data>
      <data key="d5">OX40L interactions inhibit the formation of Foxp3+ regulatory T cells</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40L" target="TYPE I INTERFERON">
      <data key="d4">14.0</data>
      <data key="d5">OX40L with type I interferon may have a Th1 inducing effect</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40L" target="C57/BL6">
      <data key="d4">12.0</data>
      <data key="d5">OX40L transgenic mice on the C57/BL6 background develop organ specific inflammation</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40L" target="NON-OBESE DIABETIC MOUSE">
      <data key="d4">12.0</data>
      <data key="d5">Blocking OX40&#8211;OX40L interactions prevented the development of diabetes in the non-obese diabetic mouse</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40L" target="EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS">
      <data key="d4">12.0</data>
      <data key="d5">Blocking OX40&#8211;OX40L interactions prevented the development of experimental autoimmune encephalomyelitis</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40L" target="CD252">
      <data key="d4">6.0</data>
      <data key="d5">OX40L is also known as CD252</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="OX40L" target="DENDRITIC CELLS">
      <data key="d4">16.0</data>
      <data key="d5">OX40L is expressed on dendritic cells</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="SLE">
      <data key="d4">18.0</data>
      <data key="d5">OX40L is implicated in systemic lupus erythematosus</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="PAH">
      <data key="d4">16.0</data>
      <data key="d5">OX40L overexpression is associated with pulmonary arterial hypertension</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="DERMAL FIBROSIS">
      <data key="d4">18.0</data>
      <data key="d5">OX40L is implicated in dermal fibrosis</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="LUNG FIBROSIS">
      <data key="d4">18.0</data>
      <data key="d5">OX40L is implicated in lung fibrosis</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="CD90">
      <data key="d4">14.0</data>
      <data key="d5">OX40L is expressed by cells positive for CD90 in fibrotic skin</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="&#913;SMA">
      <data key="d4">14.0</data>
      <data key="d5">OX40L is expressed by cells positive for &#945;SMA in fibrotic skin</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="LDLR-/- MICE">
      <data key="d4">14.0</data>
      <data key="d5">OX40L signaling affects atherosclerosis in LDLR-/- mice</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="GATA-3">
      <data key="d4">14.0</data>
      <data key="d5">OX40L signaling affects Th2 cell promotion, reducing GATA-3 positive cells</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="CD4">
      <data key="d4">14.0</data>
      <data key="d5">OX40L signaling affects CD4 positive T cells</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="SOLUBLE OX40L">
      <data key="d4">16.0</data>
      <data key="d5">Soluble OX40L levels are higher in SSc patients and serve as a biomarker for fibrosis</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="INFLAMMATION-DRIVEN FIBROSIS">
      <data key="d4">16.0</data>
      <data key="d5">OX40L is implicated in inflammation-driven fibrosis</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="FIBROSING ALVEOLITIS">
      <data key="d4">16.0</data>
      <data key="d5">OX40L is implicated in fibrosing alveolitis</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="LUNG VESSEL REMODELING">
      <data key="d4">16.0</data>
      <data key="d5">OX40L is implicated in lung vessel remodeling</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="HYDROXYPROLINE">
      <data key="d4">14.0</data>
      <data key="d5">OX40L signaling affects hydroxyproline content in fibrotic tissues</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="TH2 CELLS">
      <data key="d4">14.0</data>
      <data key="d5">OX40L signaling promotes Th2 cell polarization</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="PBS">
      <data key="d4">10.0</data>
      <data key="d5">PBS is used as a control in studies involving OX40L</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="ANTI-OX40L ANTIBODY">
      <data key="d4">16.0</data>
      <data key="d5">Anti-OX40L antibody is used to block OX40L signaling</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="PULMONARY ARTERIOLE">
      <data key="d4">14.0</data>
      <data key="d5">OX40L signaling affects pulmonary arterioles in PAH</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="MEDIAL MUSCULAR HYPERTROPHY">
      <data key="d4">14.0</data>
      <data key="d5">OX40L signaling affects medial muscular hypertrophy in PAH</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="INTIMAL FIBROSIS">
      <data key="d4">14.0</data>
      <data key="d5">OX40L signaling affects intimal fibrosis in PAH</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="WESTERN-TYPE DIET">
      <data key="d4">12.0</data>
      <data key="d5">Western-type diet is used to study the effects of OX40L signaling in atherosclerosis</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="CHOW DIET">
      <data key="d4">10.0</data>
      <data key="d5">Chow diet is used as a control in studies involving OX40L</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="ASTHMA">
      <data key="d4">8.0</data>
      <data key="d5">OX40L is targeted by monoclonal antibodies in clinical trials for asthma</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="ROCATINLIMAB" target="AD">
      <data key="d4">84.0</data>
      <data key="d5">Rocatinlimab is being studied as a treatment for atopic dermatitis (AD). It is currently being tested in clinical trials specifically targeting atopic dermatitis, with a focus on moderate-to-severe cases. Rocatinlimab is under investigation for its potential efficacy in managing and treating AD, making it a promising candidate in the therapeutic landscape for this condition.</data>
      <data key="d6">3287c502f10f4651d2f56bf39ee7bb7a,475995d7d211bbfde6d8ba52f324d688,4842292208575bd45b2b5998513dd087,b201c6ff3e22b2475c8c59260a0eb6a7,dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="ROCATINLIMAB" target="AMG 451">
      <data key="d4">32.0</data>
      <data key="d5">Rocatinlimab, also known as AMG 451, is a therapeutic agent currently being investigated in clinical trials.</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688,4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="ROCATINLIMAB" target="KHK4083">
      <data key="d4">16.0</data>
      <data key="d5">Rocatinlimab, also known as KHK4083, is a therapeutic agent currently being investigated in clinical trials.</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688,4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="ROCATINLIMAB" target="T-CELLS">
      <data key="d4">16.0</data>
      <data key="d5">Rocatinlimab selectively depletes OX40+ activated T-cells</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="TH2">
      <data key="d4">14.0</data>
      <data key="d5">Rocatinlimab is expected to control Th2-driven conditions</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="PYREXIA">
      <data key="d4">38.0</data>
      <data key="d5">Rocatinlimab is a therapeutic agent associated with several adverse effects, one of which is pyrexia. Pyrexia, or fever, has been observed as a side effect following the first administration of rocatinlimab. It is commonly reported as an infusion reaction in patients undergoing treatment with this drug. Additionally, pyrexia is frequently noted as a treatment-emergent adverse event in patients treated with rocatinlimab.</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688,b201c6ff3e22b2475c8c59260a0eb6a7,dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="ROCATINLIMAB" target="CHILLS">
      <data key="d4">33.0</data>
      <data key="d5">Rocatinlimab is a therapeutic agent associated with the treatment of certain conditions. Chills have been identified as a notable side effect following the first administration of rocatinlimab. These chills are commonly reported as an infusion reaction among patients receiving this treatment. Additionally, chills are frequently observed as a treatment-emergent adverse event in patients treated with rocatinlimab.</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688,b201c6ff3e22b2475c8c59260a0eb6a7,dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="ROCATINLIMAB" target="APHTHOUS ULCERS">
      <data key="d4">10.0</data>
      <data key="d5">Aphthous ulcers were reported in patients treated with rocatinlimab</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="BLOOD URIC ACID">
      <data key="d4">10.0</data>
      <data key="d5">Blood uric acid levels increased in some patients treated with rocatinlimab</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="NASOPHARYNGITIS">
      <data key="d4">22.0</data>
      <data key="d5">Rocatinlimab and nasopharyngitis are closely associated in clinical observations. Nasopharyngitis was reported as a treatment-emergent adverse event in patients treated with rocatinlimab. This indicates that individuals receiving rocatinlimab therapy experienced nasopharyngitis as a side effect during the course of their treatment.</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688,b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="ROCATINLIMAB" target="ERYTHEMA">
      <data key="d4">10.0</data>
      <data key="d5">Erythema was reported in patients treated with rocatinlimab</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="HORDEOLUM">
      <data key="d4">10.0</data>
      <data key="d5">Hordeolum was reported in patients treated with rocatinlimab</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="PRURITUS">
      <data key="d4">14.0</data>
      <data key="d5">Pruritus was measured using the NRS score in patients treated with rocatinlimab</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="TH1">
      <data key="d4">14.0</data>
      <data key="d5">Th1-related genes were downregulated after rocatinlimab treatment</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="TH22">
      <data key="d4">14.0</data>
      <data key="d5">Th22-related genes were downregulated after rocatinlimab treatment</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="MRNA">
      <data key="d4">14.0</data>
      <data key="d5">mRNA expression levels were analyzed to assess the impact of rocatinlimab treatment</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="POLYMERASE CHAIN REACTION">
      <data key="d4">16.0</data>
      <data key="d5">Polymerase chain reaction analysis revealed reduced OX40 mRNA expression after rocatinlimab treatment</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="TEAE">
      <data key="d4">12.0</data>
      <data key="d5">Treatment-emergent adverse events were reported in patients treated with rocatinlimab</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="TH2/TH22">
      <data key="d4">14.0</data>
      <data key="d5">Th2/Th22-related molecules were reduced in proteomic analysis after rocatinlimab treatment</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="PROTEOMIC ANALYSIS">
      <data key="d4">16.0</data>
      <data key="d5">Proteomic analysis was conducted to study protein expression changes in AD patients treated with rocatinlimab</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="GENOMIC PROFILE">
      <data key="d4">16.0</data>
      <data key="d5">Genomic profile analysis was conducted to study gene expression changes in AD patients treated with rocatinlimab</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="TRANSCRIPTOMIC PROFILE">
      <data key="d4">16.0</data>
      <data key="d5">Transcriptomic profile analysis was conducted to study RNA expression changes in AD patients treated with rocatinlimab</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="PLACEBO">
      <data key="d4">14.0</data>
      <data key="d5">Placebo was used as a control in clinical trials evaluating rocatinlimab</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="PHASE 1">
      <data key="d4">16.0</data>
      <data key="d5">Phase 1 clinical trial evaluated the safety and dosage of rocatinlimab in AD patients</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="PHASE 2B">
      <data key="d4">16.0</data>
      <data key="d5">Phase 2b clinical trial evaluated the efficacy and safety of rocatinlimab in AD patients</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="PHASE 3">
      <data key="d4">16.0</data>
      <data key="d5">Phase 3 clinical trial is planned to further evaluate rocatinlimab in AD patients</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="IGG1">
      <data key="d4">7.0</data>
      <data key="d5">IgG1 is a subclass of immunoglobulin G, which rocatinlimab belongs to</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="MONOCLONAL ANTIBODY">
      <data key="d4">7.0</data>
      <data key="d5">Monoclonal antibody is a type of protein that rocatinlimab is classified as</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="TH2-DRIVEN CONDITIONS">
      <data key="d4">7.0</data>
      <data key="d5">Th2-driven conditions are immune responses primarily mediated by Th2 cells, often associated with allergies and atopic dermatitis</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="CLONAL T-CELLS">
      <data key="d4">7.0</data>
      <data key="d5">Clonal T-cells are a population of T-cells that expand from a single cell, targeted by rocatinlimab</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="INFUSION REACTIONS">
      <data key="d4">6.0</data>
      <data key="d5">Infusion reactions are adverse effects that occur during or after the administration of a drug, such as rocatinlimab</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="HEAD AND NECK">
      <data key="d4">16.0</data>
      <data key="d5">Rocatinlimab doses resulted in greater head and neck EASI score improvements</data>
      <data key="d6">b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="ROCATINLIMAB" target="NCT05398445">
      <data key="d4">12.0</data>
      <data key="d5">NCT05398445 is the clinical trial identifier for evaluating rocatinlimab</data>
      <data key="d6">b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="ROCATINLIMAB" target="AMLITELIMAB">
      <data key="d4">16.0</data>
      <data key="d5">Both amlitelimab and rocatinlimab target the OX40-OX40L pathway</data>
      <data key="d6">dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="ROCATINLIMAB" target="PHASE 3 TRIAL">
      <data key="d4">8.0</data>
      <data key="d5">Rocatinlimab is being evaluated in a Phase 3 trial for atopic dermatitis</data>
      <data key="d6">dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="ROCATINLIMAB" target="SKIN TRANSCRIPTOMIC ANALYSIS">
      <data key="d4">1.0</data>
      <data key="d5">Skin transcriptomic analysis supports the durability of the response with rocatinlimab</data>
      <data key="d6">dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="ROCATINLIMAB" target="SOX40">
      <data key="d4">18.0</data>
      <data key="d5">Rocatinlimab selectively depletes sOX40+ activated T-cells</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="ROCATINLIMAB" target="NCT03096223">
      <data key="d4">14.0</data>
      <data key="d5">NCT03096223 is a clinical trial studying rocatinlimab in moderate-to-severe atopic dermatitis</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="ROCATINLIMAB" target="NCT03703102">
      <data key="d4">14.0</data>
      <data key="d5">NCT03703102 is a phase 2b clinical trial studying rocatinlimab in moderate-to-severe atopic dermatitis</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="ROCATINLIMAB" target="OX-40">
      <data key="d4">8.0</data>
      <data key="d5">Rocatinlimab targets OX-40</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="AMLITELIMAB" target="T-CELL">
      <data key="d4">16.0</data>
      <data key="d5">Amlitelimab aims to restore immune homeostasis between pro-inflammatory and anti-inflammatory T-cells</data>
      <data key="d6">b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="AMLITELIMAB" target="TH1">
      <data key="d4">14.0</data>
      <data key="d5">Amlitelimab blocks Th1 inflammation</data>
      <data key="d6">b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="AMLITELIMAB" target="TH22">
      <data key="d4">14.0</data>
      <data key="d5">Amlitelimab blocks Th22 inflammation</data>
      <data key="d6">b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="AMLITELIMAB" target="AD">
      <data key="d4">50.0</data>
      <data key="d5">Amlitelimab is being studied as a treatment for atopic dermatitis (AD). It is specifically used to treat moderate-to-severe atopic dermatitis. Amlitelimab was evaluated in a phase 2a trial for patients with atopic dermatitis, indicating its potential efficacy and safety in managing this condition.</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6,dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="AMLITELIMAB" target="HYPERSENSITIVITY">
      <data key="d4">12.0</data>
      <data key="d5">Amlitelimab caused a possible mild and self-limited hypersensitivity reaction in one subject</data>
      <data key="d6">b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="AMLITELIMAB" target="TEAE">
      <data key="d4">14.0</data>
      <data key="d5">TEAEs were reported in subjects treated with amlitelimab</data>
      <data key="d6">b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="AMLITELIMAB" target="NCT03161288">
      <data key="d4">26.0</data>
      <data key="d5">AMLITELIMAB is being evaluated in a clinical trial identified as NCT03161288. This clinical trial, NCT03161288, is focused on studying amlitelimab in healthy subjects.</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="AMLITELIMAB" target="NCT03754309">
      <data key="d4">16.0</data>
      <data key="d5">NCT03754309 is a phase 2a clinical trial studying amlitelimab in moderate-to-severe atopic dermatitis. This clinical trial identifier is specifically designated for evaluating the efficacy and safety of amlitelimab in patients suffering from this condition.</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="AMLITELIMAB" target="IL-22">
      <data key="d4">25.0</data>
      <data key="d5">Amlitelimab is a therapeutic agent that has been shown to reduce IL-22 serum levels. Specifically, treatment with Amlitelimab leads to a significant decrease in IL-22 serum levels, indicating its potential efficacy in modulating immune responses associated with elevated IL-22.</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd,dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="AMLITELIMAB" target="NCT05131477">
      <data key="d4">16.0</data>
      <data key="d5">Amlitelimab is being evaluated in a Phase 2b study (NCT05131477) for atopic dermatitis</data>
      <data key="d6">dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="AMLITELIMAB" target="NCT05492578">
      <data key="d4">16.0</data>
      <data key="d5">Amlitelimab is being evaluated in a long-term extension study (NCT05492578) for atopic dermatitis</data>
      <data key="d6">dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="AMLITELIMAB" target="NCT05421598">
      <data key="d4">14.0</data>
      <data key="d5">Amlitelimab is being evaluated for the treatment of moderate-to-severe asthma (NCT05421598)</data>
      <data key="d6">dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="AMLITELIMAB" target="HEADACHE">
      <data key="d4">12.0</data>
      <data key="d5">Headache was a treatment-emergent adverse event in patients treated with amlitelimab</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="AMLITELIMAB" target="VITAL SIGNS">
      <data key="d4">12.0</data>
      <data key="d5">Changes in vital signs were monitored in clinical trials of amlitelimab</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="AMLITELIMAB" target="LABORATORY SAFETY DATA">
      <data key="d4">12.0</data>
      <data key="d5">Laboratory safety data were monitored in clinical trials of amlitelimab</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="AMLITELIMAB" target="ANTI-VIRAL ANTIBODY">
      <data key="d4">12.0</data>
      <data key="d5">Anti-viral antibody levels were monitored in clinical trials of amlitelimab</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="AMLITELIMAB" target="VIRAL DNA">
      <data key="d4">12.0</data>
      <data key="d5">Viral DNA levels were monitored in clinical trials of amlitelimab</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="AMLITELIMAB" target="CYTOKINES">
      <data key="d4">12.0</data>
      <data key="d5">Cytokine levels were monitored in clinical trials of amlitelimab</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="AMLITELIMAB" target="ELECTROCARDIOGRAMS">
      <data key="d4">12.0</data>
      <data key="d5">Electrocardiograms were monitored in clinical trials of amlitelimab</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="PRURITUS">
      <data key="d4">36.0</data>
      <data key="d5">Atopic Dermatitis and Pruritus are closely related conditions. Pruritus, commonly known as itching, is a prevalent symptom of Atopic Dermatitis. This chronic inflammatory skin disease is often characterized by intense itching, which significantly impacts the quality of life of affected individuals. The persistent pruritus associated with Atopic Dermatitis can lead to scratching, further exacerbating the skin condition and potentially leading to secondary infections. Understanding the relationship between Atopic Dermatitis and Pruritus is crucial for developing effective treatment strategies aimed at alleviating symptoms and improving patient outcomes.</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b,691cb2e23ac3c6e591129d16714f8ef8,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TOPICAL CORTICOSTEROIDS">
      <data key="d4">24.0</data>
      <data key="d5">Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by itchy, red, and swollen skin. Topical corticosteroids are commonly used in the treatment of atopic dermatitis. These medications are particularly effective in managing and reducing the severity of AD flares, helping to alleviate symptoms and improve the quality of life for individuals affected by this condition.</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="CALCINEURIN INHIBITORS">
      <data key="d4">22.0</data>
      <data key="d5">Atopic Dermatitis is a chronic inflammatory skin condition characterized by itchy, red, and swollen skin. Calcineurin inhibitors, such as pimecrolimus and tacrolimus, are used as topical treatments for Atopic Dermatitis. These medications help manage the symptoms by modulating the immune response, thereby reducing inflammation and itching.</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="CRISABOROLE">
      <data key="d4">30.0</data>
      <data key="d5">Crisaborole is a topical treatment approved for Atopic Dermatitis. It is specifically used in the treatment of atopic dermatitis, also known as AD.</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524,693a2aac101eaaadf92614317a1e4da8,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="PHOTOTHERAPY">
      <data key="d4">22.0</data>
      <data key="d5">Atopic Dermatitis is a chronic inflammatory skin condition characterized by itchy, red, and swollen skin. Phototherapy is a treatment approach for Atopic Dermatitis that involves the use of ultraviolet light. This therapeutic method is employed to manage and alleviate the symptoms of atopic dermatitis, providing relief to patients by reducing inflammation and itching.</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="IMMUNOSUPPRESSANTS">
      <data key="d4">20.0</data>
      <data key="d5">Atopic Dermatitis and Immunosuppressants:

Conventional systemic immunosuppressants are used in the treatment of atopic dermatitis. These immunosuppressants are systemic agents that help manage the symptoms and progression of atopic dermatitis by modulating the immune response.</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TRALOKINUMAB">
      <data key="d4">46.0</data>
      <data key="d5">Atopic Dermatitis (AD) is a chronic inflammatory skin condition characterized by itchy, red, and swollen skin. Tralokinumab is a biologic agent specifically targeting interleukin-13 (IL-13), a cytokine implicated in the pathogenesis of atopic dermatitis. Tralokinumab functions as an anti-IL-13 inhibitor and has been approved for the treatment of AD. It is also currently in advanced-stage clinical trials for this condition. By targeting IL-13, Tralokinumab helps to alleviate the symptoms associated with atopic dermatitis, providing a targeted therapeutic option for patients suffering from this chronic skin disease.</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524,3dfbb4c51838e0951f53ce951395225f,693a2aac101eaaadf92614317a1e4da8,e075bccd45593ae008b2ce7f9ed8ff6c,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ABROCITINIB">
      <data key="d4">17.0</data>
      <data key="d5">Atopic Dermatitis is a chronic inflammatory skin condition characterized by itchy, red, and swollen skin. Abrocitinib is a Janus kinase (JAK) inhibitor that is used as a targeted therapy for the treatment of Atopic Dermatitis. By inhibiting the JAK pathway, Abrocitinib helps to reduce inflammation and alleviate the symptoms associated with this condition.</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="BARICITINIB">
      <data key="d4">33.0</data>
      <data key="d5">Baricitinib is a Janus kinase (JAK) inhibitor, specifically targeting JAK1 and JAK2, and is approved for the treatment of Atopic Dermatitis (AD). As a targeted therapy, Baricitinib is utilized to manage and alleviate the symptoms associated with atopic dermatitis, providing an effective treatment option for this chronic inflammatory skin condition.</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524,6ada075e562abd7bd445164e9fc309b4,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="LEBRIKIZUMAB">
      <data key="d4">29.0</data>
      <data key="d5">Atopic Dermatitis is a chronic inflammatory skin condition characterized by itchy, red, and swollen skin. Lebrikizumab is a biologic agent specifically targeting interleukin-13 (IL-13) in the treatment of atopic dermatitis. It is currently in advanced-stage clinical trials and is under clinical development for this purpose. Lebrikizumab's mechanism of action involves inhibiting IL-13, a cytokine implicated in the inflammatory processes of atopic dermatitis, thereby aiming to alleviate the symptoms and improve the quality of life for patients suffering from this condition.</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,693a2aac101eaaadf92614317a1e4da8,e075bccd45593ae008b2ce7f9ed8ff6c,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="NEMOLIZUMAB">
      <data key="d4">14.0</data>
      <data key="d5">Nemolizumab is in clinical development for the treatment of atopic dermatitis</data>
      <data key="d6">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TH2">
      <data key="d4">30.0</data>
      <data key="d5">ATOPIC DERMATITIS and TH2

Th2 cells are involved in the adaptive immune response in atopic dermatitis. They play a crucial role in the immune response and are associated with cytokine production in this condition.</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4,83eb9003d42977bb83fea1d123dd5ab9,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TH22">
      <data key="d4">23.0</data>
      <data key="d5">ATOPIC DERMATITIS and TH22 cells are closely linked in the context of the immune response. TH22 cells are a subset of T helper cells that play a significant role in the adaptive immune response associated with atopic dermatitis. These cells are involved in the immune mechanisms that contribute to the pathophysiology of this chronic inflammatory skin condition.</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TH1">
      <data key="d4">23.0</data>
      <data key="d5">ATOPIC DERMATITIS and TH1 cells are intricately linked in the context of the immune response. TH1 cells are a subset of T helper cells that play a crucial role in the adaptive immune response associated with atopic dermatitis. These cells are involved in orchestrating the immune mechanisms that contribute to the pathophysiology of this chronic inflammatory skin condition.</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="FILAGGRIN">
      <data key="d4">25.0</data>
      <data key="d5">Filaggrin (FLG) has the greatest genetic association with Atopic Dermatitis. Additionally, Filaggrin is downregulated in atopic dermatitis.</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="LORICRIN">
      <data key="d4">16.0</data>
      <data key="d5">Loricrin is downregulated in atopic dermatitis</data>
      <data key="d6">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TSLP">
      <data key="d4">16.0</data>
      <data key="d5">TSLP is involved in the immune response in atopic dermatitis</data>
      <data key="d6">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="IL-25">
      <data key="d4">23.0</data>
      <data key="d5">IL-25 is a cytokine involved in the immune response and is associated with Atopic Dermatitis. It plays a significant role in the pathophysiology of this condition by contributing to the immune dysregulation observed in patients.</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="IL-33">
      <data key="d4">16.0</data>
      <data key="d5">IL-33 is involved in the immune response in atopic dermatitis</data>
      <data key="d6">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="IGE">
      <data key="d4">47.0</data>
      <data key="d5">Atopic Dermatitis (AD) is a chronic inflammatory skin condition characterized by itchy and inflamed skin. Immunoglobulin E (IgE) plays a significant role in the pathophysiology of Atopic Dermatitis. IgE is involved in the sensitization to environmental allergens, which is a critical aspect of the immune response in AD. Elevated IgE levels are observed in up to 80% of patients with Atopic Dermatitis, making increased IgE serum levels a hallmark of the disease. Consequently, IgE levels are routinely measured in patients with Atopic Dermatitis to assess the severity and progression of the condition.</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd,48288f3ec2832850282f95d4e38d10e1,691cb2e23ac3c6e591129d16714f8ef8,83eb9003d42977bb83fea1d123dd5ab9,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="HISTAMINE">
      <data key="d4">9.0</data>
      <data key="d5">Histamine is involved in pruritus in atopic dermatitis</data>
      <data key="d6">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="EASI">
      <data key="d4">17.0</data>
      <data key="d5">Atopic Dermatitis is a chronic inflammatory skin condition characterized by itchy, red, and swollen skin. The Eczema Area and Severity Index (EASI) is a measure used to assess the severity and extent of Atopic Dermatitis. EASI provides a standardized method for evaluating the intensity of the disease, helping clinicians to monitor the condition and the effectiveness of treatments over time.</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="IL-31">
      <data key="d4">15.0</data>
      <data key="d5">Atopic Dermatitis (AD) is a chronic inflammatory skin condition characterized by intense itching and eczematous lesions. One of the key cytokines involved in the immune response associated with Atopic Dermatitis is IL-31. IL-31 plays a significant role in the pathophysiology of AD, particularly in mediating pruritus (itchiness), which is a hallmark symptom of the disease. This cytokine contributes to the immune response and the development of the characteristic symptoms of Atopic Dermatitis, making it a potential target for therapeutic interventions aimed at alleviating the discomfort and inflammation associated with the condition.</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="INTERCELLULAR LIPIDS">
      <data key="d4">8.0</data>
      <data key="d5">Intercellular lipids are disrupted in atopic dermatitis</data>
      <data key="d6">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TIGHT JUNCTIONS">
      <data key="d4">8.0</data>
      <data key="d5">Tight junctions are disrupted in atopic dermatitis</data>
      <data key="d6">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="EPIDERMIS">
      <data key="d4">16.0</data>
      <data key="d5">Atopic Dermatitis is a condition that affects the epidermis. The epidermis, which is the outermost layer of the skin, is significantly impacted in individuals suffering from Atopic Dermatitis. This chronic inflammatory skin disease leads to alterations in the epidermal barrier, contributing to the symptoms and complications associated with the condition.</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ALARMIN CYTOKINES">
      <data key="d4">1.0</data>
      <data key="d5">Alarmin cytokines are involved in the immune response in atopic dermatitis</data>
      <data key="d6">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TYPE 2 T HELPER CELLS">
      <data key="d4">9.0</data>
      <data key="d5">Type 2 T helper cells are inappropriately activated in Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TYPE 2 INNATE LYMPHOID CELLS">
      <data key="d4">9.0</data>
      <data key="d5">Type 2 innate lymphoid cells are inappropriately activated in Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="CORTICOSTEROIDS">
      <data key="d4">6.0</data>
      <data key="d5">Corticosteroids are systemic agents used in the treatment of Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="PIMECROLIMUS">
      <data key="d4">14.0</data>
      <data key="d5">Pimecrolimus is a topical treatment approved for Atopic Dermatitis (AD). It is specifically used to treat AD, providing a targeted therapeutic option for managing this chronic inflammatory skin condition.</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524,693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TACROLIMUS">
      <data key="d4">14.0</data>
      <data key="d5">Atopic Dermatitis (AD) is a chronic inflammatory skin condition characterized by itchy, red, and swollen skin. Tacrolimus is a topical treatment that has been approved for the management of Atopic Dermatitis. It is specifically used to treat AD, helping to alleviate the symptoms and improve the quality of life for those affected by this condition.</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524,693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="STAPHYLOCOCCUS AUREUS">
      <data key="d4">22.0</data>
      <data key="d5">Atopic Dermatitis (AD) is a chronic inflammatory skin condition characterized by itchy, red, and swollen skin. Patients with Atopic Dermatitis are at increased risk of infection from Staphylococcus aureus, a common bacterium that can exacerbate the symptoms of AD. Staphylococcus aureus tends to overgrow in the skin of atopic dermatitis patients, further complicating the management of the disease and potentially leading to more severe skin infections. The interplay between Atopic Dermatitis and Staphylococcus aureus highlights the importance of monitoring and managing bacterial colonization in individuals suffering from this condition.</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8,83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="HERPES SIMPLEX TYPE 1 VIRUS">
      <data key="d4">14.0</data>
      <data key="d5">Patients with Atopic Dermatitis are at increased risk of infection from Herpes simplex type 1 virus</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="CARDIOVASCULAR DISEASES">
      <data key="d4">12.0</data>
      <data key="d5">Cardiovascular diseases are comorbidities associated with Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="NEUROPSYCHIATRIC DISEASES">
      <data key="d4">12.0</data>
      <data key="d5">Neuropsychiatric diseases are comorbidities associated with Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="MALIGNANT DISEASES">
      <data key="d4">12.0</data>
      <data key="d5">Malignant diseases are comorbidities associated with Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ANXIETY">
      <data key="d4">12.0</data>
      <data key="d5">Anxiety is more common in patients with Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="DEPRESSION">
      <data key="d4">12.0</data>
      <data key="d5">Depression is more common in patients with Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ATTENTION-DEFICIT/HYPERACTIVITY DISORDER">
      <data key="d4">12.0</data>
      <data key="d5">ADHD is more common in patients with Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ITCH">
      <data key="d4">29.0</data>
      <data key="d5">Atopic Dermatitis and Itch are closely related, with itch being a common and persistent symptom associated with Atopic Dermatitis. Persistent itch is a primary symptom of Atopic Dermatitis, significantly impacting the quality of life of those affected by this chronic skin condition.</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8,83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="REDNESS">
      <data key="d4">20.0</data>
      <data key="d5">Marked redness is a primary symptom of Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="CRACKING">
      <data key="d4">16.0</data>
      <data key="d5">Cracking of the skin is a symptom of Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="DRYNESS">
      <data key="d4">16.0</data>
      <data key="d5">Dryness of the skin is a symptom of Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="T CELLS">
      <data key="d4">21.0</data>
      <data key="d5">Atopic Dermatitis (AD) is a chronic inflammatory skin condition characterized by itchy and inflamed skin. T cells play a crucial role as effectors in the inflammatory reaction associated with Atopic Dermatitis. In patients with AD, there is an observed increase in the number of T cells both in the circulation and within the skin tissue. This heightened presence of T cells contributes to the pathophysiology of the disease, driving the inflammatory processes that lead to the clinical manifestations of Atopic Dermatitis.</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8,83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="B CELLS">
      <data key="d4">9.0</data>
      <data key="d5">Atopic Dermatitis and B Cells:

B cells are increased in both the circulation and skin tissue of patients with Atopic Dermatitis. These cells play a crucial role in the immune response associated with this condition, contributing to the pathophysiology of Atopic Dermatitis.</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8,83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="CYTOKINES">
      <data key="d4">16.0</data>
      <data key="d5">Atopic Dermatitis and Cytokines are closely linked in the context of inflammatory responses and tissue inflammation. Cytokines, including IL-13 and IL-4, play a crucial role in the inflammatory response associated with Atopic Dermatitis. These cytokines contribute to tissue inflammation and epidermal barrier dysfunction, which are hallmark features of the disease. Due to their significant involvement in the pathophysiology of Atopic Dermatitis, cytokines are targeted by biologic therapies aimed at mitigating the inflammatory processes and improving clinical outcomes for patients.</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8,83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="EMOLLIENTS">
      <data key="d4">6.0</data>
      <data key="d5">Emollients are used as topical therapies to moisturize and soothe the skin in Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="AZATHIOPRINE">
      <data key="d4">14.0</data>
      <data key="d5">Azathioprine is an immunosuppressant used in the systemic treatment of Atopic Dermatitis (AD). It is specifically employed to treat severe forms of AD, providing relief for patients who suffer from this chronic inflammatory skin condition.</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524,693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="T HELPER CELLS">
      <data key="d4">8.0</data>
      <data key="d5">T helper cells, including Th2 cells, are involved in the immune response in Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="INNATE LYMPHOID CELLS">
      <data key="d4">8.0</data>
      <data key="d5">Innate lymphoid cells, including ILC2 cells, are involved in the immune response in Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="EPIDERMAL BARRIER">
      <data key="d4">27.0</data>
      <data key="d5">Atopic Dermatitis (AD) is characterized by a compromised and dysfunctional epidermal barrier. Epidermal barrier dysfunction is a key feature of AD, contributing significantly to the pathophysiology of the disease. This compromised barrier in individuals with Atopic Dermatitis leads to increased susceptibility to irritants, allergens, and microbial infections, exacerbating the condition.</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524,693a2aac101eaaadf92614317a1e4da8,6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="CICLOSPORIN A">
      <data key="d4">8.0</data>
      <data key="d5">Ciclosporin A is used to treat severe forms of AD</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="IMMUNE RESPONSE">
      <data key="d4">9.0</data>
      <data key="d5">Dysregulated immune response is involved in AD</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="SKIN MICROBIOME">
      <data key="d4">15.0</data>
      <data key="d5">Atopic dermatitis (AD) and the skin microbiome are closely interconnected. The skin microbiome can influence the development and progression of atopic dermatitis. This relationship highlights the significant role that the diverse community of microorganisms residing on the skin plays in the pathophysiology of AD. Understanding the interactions between the skin microbiome and atopic dermatitis is crucial for developing targeted therapies and management strategies for this chronic inflammatory skin condition.</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524,83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ITCH-SCRATCH CYCLE">
      <data key="d4">8.0</data>
      <data key="d5">Itch-scratch cycle worsens AD symptoms</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ALLERGIC RHINO-CONJUNCTIVITIS">
      <data key="d4">7.0</data>
      <data key="d5">Allergic rhino-conjunctivitis is a comorbidity of AD</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="CARDIOVASCULAR DISORDERS">
      <data key="d4">12.0</data>
      <data key="d5">Atopic Dermatitis (AD) and Cardiovascular Disorders are closely linked, with cardiovascular disorders being significant comorbidities associated with Atopic Dermatitis. This relationship highlights the potential for individuals with AD to also experience cardiovascular disorders, underscoring the importance of monitoring cardiovascular health in patients with Atopic Dermatitis.</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524,6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="NEUROPSYCHIATRIC DISORDERS">
      <data key="d4">7.0</data>
      <data key="d5">Atopic Dermatitis (AD) and Neuropsychiatric Disorders are closely linked, with neuropsychiatric disorders being significant comorbidities associated with Atopic Dermatitis. These disorders are potential comorbidities of AD, highlighting the importance of considering mental health in patients suffering from this chronic skin condition.</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524,6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="AD">
      <data key="d4">1.0</data>
      <data key="d5">Atopic Dermatitis is also referred to as AD</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="SCORAD">
      <data key="d4">25.0</data>
      <data key="d5">ATOPIC DERMATITIS is a chronic inflammatory skin condition characterized by itchy, red, and swollen skin. SCORAD (Scoring Atopic Dermatitis) is a clinical tool used to assess the severity of atopic dermatitis. This scoring system evaluates the extent and intensity of the disease, providing a standardized method for clinicians to monitor and manage the condition effectively.</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd,48288f3ec2832850282f95d4e38d10e1,691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TCS">
      <data key="d4">8.0</data>
      <data key="d5">Topical corticosteroids are used to reduce inflammation in Atopic Dermatitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="IL-22">
      <data key="d4">15.0</data>
      <data key="d5">Atopic Dermatitis (AD) is a chronic inflammatory skin condition characterized by itchy and inflamed skin. IL-22, a cytokine involved in the immune response, plays a significant role in the pathogenesis of Atopic Dermatitis. It is part of the transcriptomic signature in AD, indicating its involvement at the molecular level in this disease. The presence of IL-22 in the immune response highlights its importance in the inflammatory processes associated with Atopic Dermatitis.</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1,6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="RISANKIZUMAB">
      <data key="d4">14.0</data>
      <data key="d5">Risankizumab is investigated for the treatment of Atopic Dermatitis. It is used to target IL-23 in the treatment of this condition.</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TREG CELL">
      <data key="d4">8.0</data>
      <data key="d5">Treg cells do not properly exert their dampening activity in Atopic Dermatitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="INTRINSIC AD">
      <data key="d4">8.0</data>
      <data key="d5">Intrinsic AD is a subtype of Atopic Dermatitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ASIAN PATIENTS">
      <data key="d4">7.0</data>
      <data key="d5">Asian patients are studied in the context of Atopic Dermatitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TRANSCRIPTOMIC SIGNATURE">
      <data key="d4">8.0</data>
      <data key="d5">IL-22 is part of the transcriptomic signature in Atopic Dermatitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="POLYSENSITIZATION">
      <data key="d4">7.0</data>
      <data key="d5">Polysensitization is a symptom of Atopic Dermatitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="OLIGOSENSITIZATION">
      <data key="d4">7.0</data>
      <data key="d5">Oligosensitization is a symptom of Atopic Dermatitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ETRASIMOD">
      <data key="d4">8.0</data>
      <data key="d5">Etrasimod is being advanced into phase 3 clinical trials for the treatment of atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ASLAN004">
      <data key="d4">22.0</data>
      <data key="d5">ATOPIC DERMATITIS and ASLAN004:

ASLAN004 is a biologic agent specifically designed to target interleukin-13 receptor alpha 1 (IL-13R&#945;1) in the treatment of atopic dermatitis. This therapeutic approach is currently being evaluated through multiple ascending dose studies to determine its efficacy and safety in managing this chronic inflammatory skin condition. By focusing on IL-13R&#945;1, ASLAN004 aims to modulate the immune response implicated in atopic dermatitis, offering a potential new avenue for patients suffering from this disease.</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,83eb9003d42977bb83fea1d123dd5ab9,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="FB-401">
      <data key="d4">36.0</data>
      <data key="d5">ATOPIC DERMATITIS and FB-401

FB-401 is currently being tested in clinical trials for the treatment of atopic dermatitis in both children and adults. This therapeutic approach involves using FB-401 as a bacterial replacement therapy, aiming to restore a healthy bacterial balance on the skin. Additionally, FB-401 targets TNFR (Tumor Necrosis Factor Receptor) activation, which plays a crucial role in the inflammatory processes associated with atopic dermatitis. By addressing both bacterial substitution and TNFR activation, FB-401 offers a multifaceted strategy for managing and potentially alleviating the symptoms of atopic dermatitis.</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,83eb9003d42977bb83fea1d123dd5ab9,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="KY1005">
      <data key="d4">15.0</data>
      <data key="d5">ATOPIC DERMATITIS and KY1005:

KY1005 has demonstrated positive phase 2a results for the treatment of moderate to severe atopic dermatitis. This therapeutic agent is specifically used to target OX40L in the management of atopic dermatitis, indicating its potential efficacy in addressing this chronic inflammatory skin condition.</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="DIFAMILAST">
      <data key="d4">8.0</data>
      <data key="d5">Difamilast (OPA-15406) is a drug candidate for atopic dermatitis, currently in phase 3 studies in Japan</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="RPT193">
      <data key="d4">15.0</data>
      <data key="d5">ATOPIC DERMATITIS and RPT193 are closely related in the context of therapeutic research. RPT193 is currently being tested in a phase 1b trial specifically for the treatment of atopic dermatitis. This investigational drug targets CCR4, a receptor implicated in the inflammatory processes associated with atopic dermatitis. The ongoing clinical trial aims to evaluate the efficacy and safety of RPT193 in managing this chronic skin condition.</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="STAPHYLOCOCCUS HOMINIS">
      <data key="d4">7.0</data>
      <data key="d5">Staphylococcus hominis can help in the recovery of skin microbiome in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="STAPHYLOCOCCUS EPIDERMIDIS">
      <data key="d4">7.0</data>
      <data key="d5">Staphylococcus epidermidis can help in the recovery of skin microbiome in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ARYL-HYDROCARBON RECEPTOR">
      <data key="d4">7.0</data>
      <data key="d5">Aryl-hydrocarbon receptor is targeted for intervention in the early stages of atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ALARMINS">
      <data key="d4">7.0</data>
      <data key="d5">Alarmins are targeted for intervention in the early stages of atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="SPHINGOSINE 1-PHOSPHATE RECEPTOR">
      <data key="d4">7.0</data>
      <data key="d5">Sphingosine 1-phosphate receptor is involved in the migratory activity of T cells in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="C-C CHEMOKINE RECEPTOR 4">
      <data key="d4">7.0</data>
      <data key="d5">C-C chemokine receptor 4 is involved in the migration of T cells into the skin in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="JANUS KINASES">
      <data key="d4">7.0</data>
      <data key="d5">Janus kinases are involved in the signal transduction of cytokine receptors and are targeted by JAK inhibitors in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TROPOMYOSIN RECEPTOR KINASE">
      <data key="d4">7.0</data>
      <data key="d5">Tropomyosin receptor kinase is involved in pathways related to nerve growth factor in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="BRUTON TYROSINE KINASE">
      <data key="d4">7.0</data>
      <data key="d5">Bruton tyrosine kinase is involved in the signal transduction of the B cell receptor in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="HISTAMINE RECEPTOR 4">
      <data key="d4">7.0</data>
      <data key="d5">Histamine receptor 4 is involved in immunomodulatory mechanisms in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="PHOSPHODIESTERASE 4">
      <data key="d4">25.0</data>
      <data key="d5">Atopic Dermatitis and Phosphodiesterase 4 (PDE4) are closely linked in the context of therapeutic interventions aimed at reducing inflammation. Inhibitors of Phosphodiesterase 4 (PDE4) are employed to manage atopic dermatitis by increasing cellular levels of cyclic adenosine monophosphate (cAMP). This elevation in cAMP levels subsequently leads to a reduction in inflammation, which is a hallmark of atopic dermatitis. Thus, targeting PDE4 with specific inhibitors serves as an effective strategy to mitigate the inflammatory processes associated with this chronic skin condition.</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="MAST CELLS">
      <data key="d4">15.0</data>
      <data key="d5">Atopic Dermatitis is a chronic inflammatory skin condition characterized by itchy and inflamed skin. In patients with Atopic Dermatitis, mast cells are elevated in the skin. These mast cells play a crucial role in the immune response associated with the disease. They express high-affinity receptors for IgE, which are integral to their function in mediating allergic reactions and contributing to the inflammation observed in Atopic Dermatitis.</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4,83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="DENDRITIC CELLS">
      <data key="d4">7.0</data>
      <data key="d5">Dendritic cells express high-affinity receptors for IgE and are involved in the immune response in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="SENSING NEURONS">
      <data key="d4">2.0</data>
      <data key="d5">Sensing neurons in the skin can be activated by multiple mediators generated during the inflammatory reaction in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="INNATE IMMUNITY">
      <data key="d4">8.0</data>
      <data key="d5">Innate immunity is the first line of defense activated in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ADAPTIVE IMMUNITY">
      <data key="d4">8.0</data>
      <data key="d5">Adaptive immunity is activated following innate immunity in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="IMMUNOLOGICAL MARCH">
      <data key="d4">8.0</data>
      <data key="d5">The immunological march describes the progression of immune responses in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="IL-31 RECEPTOR">
      <data key="d4">16.0</data>
      <data key="d5">Blockade of IL-31 receptor (IL-31R) is a strategy to reduce itching in atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="NEUROKININ 1 RECEPTOR">
      <data key="d4">16.0</data>
      <data key="d5">Blockade of Neurokinin 1 receptor (NK1R) is a strategy to reduce itching in atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="PURINORECEPTOR 3">
      <data key="d4">16.0</data>
      <data key="d5">Blockade of Purinoreceptor 3 (P2X3) is a strategy to reduce itching in atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="OX40 LIGAND">
      <data key="d4">14.0</data>
      <data key="d5">OX40L is involved in the immune response in atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="T HELPER CELL">
      <data key="d4">14.0</data>
      <data key="d5">T helper cells (TH cells) play a crucial role in the immune response in atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="THYMIC STROMAL LYMPHOPOIETIN">
      <data key="d4">14.0</data>
      <data key="d5">TSLP is involved in the initiation of allergic inflammation in atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="B244">
      <data key="d4">28.0</data>
      <data key="d5">ATOPIC DERMATITIS and B244

B244 is utilized in the treatment of atopic dermatitis, serving dual purposes. It functions as a nitric oxide donor, which plays a role in alleviating the symptoms of this chronic inflammatory skin condition. Additionally, B244 is employed for microbiome modulation, aiming to restore and maintain a healthy skin microbiome, which is crucial for managing atopic dermatitis. This multifaceted approach underscores the therapeutic potential of B244 in addressing the complex pathophysiology of atopic dermatitis.</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="SHA9">
      <data key="d4">28.0</data>
      <data key="d5">Atopic dermatitis is a chronic inflammatory skin condition characterized by itchy, red, and swollen skin. ShA9 is a microbiota specifically selected for transplant in the treatment of atopic dermatitis. This targeted microbiome transplant aims to restore a healthy balance of skin microbiota, thereby alleviating the symptoms associated with atopic dermatitis.</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="CLS-001">
      <data key="d4">28.0</data>
      <data key="d5">ATOPIC DERMATITIS is a chronic inflammatory skin condition characterized by itchy, red, and swollen skin. It is commonly treated with various medications to manage symptoms and improve skin barrier function. CLS-001 is a small molecule specifically used in the treatment of atopic dermatitis. It functions as a cell membrane enhancer, which helps to improve the integrity and function of the skin barrier, thereby alleviating the symptoms associated with the condition.</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ATX201">
      <data key="d4">28.0</data>
      <data key="d5">ATOPIC DERMATITIS and ATX201:

ATx201 is a small molecule utilized in the treatment of atopic dermatitis. It is specifically employed for its protonophore activity, which plays a crucial role in managing this chronic inflammatory skin condition.</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="EDP1815">
      <data key="d4">28.0</data>
      <data key="d5">ATOPIC DERMATITIS and EDP1815: EDP1815 is utilized for the regulation and modulation of systemic inflammation in the treatment of atopic dermatitis.</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="STMC-103H">
      <data key="d4">28.0</data>
      <data key="d5">ATOPIC DERMATITIS and STMC-103H are closely related in the context of treatment strategies. STMC-103H is employed for microbiome modulation in the treatment of atopic dermatitis. Specifically, it is used to modulate the immune system through microbiome manipulation, thereby addressing the underlying immune dysregulation associated with atopic dermatitis.</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TAPINAROF">
      <data key="d4">28.0</data>
      <data key="d5">Atopic dermatitis is a chronic inflammatory skin condition characterized by itchy, red, and swollen skin. Tapinarof is a biologic agent utilized in the treatment of atopic dermatitis. It functions as an aryl hydrocarbon receptor (AhR) agonist, which helps to modulate the immune response and reduce inflammation associated with the condition.</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TEZEPELUMAB">
      <data key="d4">28.0</data>
      <data key="d5">Atopic dermatitis is a chronic inflammatory skin condition characterized by itchy, red, and swollen skin. Tezepelumab is a biologic agent specifically designed to target thymic stromal lymphopoietin (TSLP), a key cytokine involved in the pathogenesis of atopic dermatitis. By inhibiting TSLP, Tezepelumab helps to reduce the inflammatory response and alleviate the symptoms associated with atopic dermatitis.</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ETOKIMAB">
      <data key="d4">28.0</data>
      <data key="d5">Atopic dermatitis is a chronic inflammatory skin condition characterized by itchy, red, and swollen skin. Etokimab is a biologic agent specifically designed to target interleukin-33 (IL-33) in the treatment of atopic dermatitis. By inhibiting IL-33, Etokimab aims to reduce the inflammatory response associated with this condition, thereby alleviating symptoms and improving the quality of life for patients suffering from atopic dermatitis.</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="REGN3500">
      <data key="d4">28.0</data>
      <data key="d5">ATOPIC DERMATITIS and REGN3500:

REGN3500 is a biologic agent specifically designed to target interleukin-33 (IL-33) in the treatment of atopic dermatitis. This therapeutic approach aims to mitigate the symptoms of atopic dermatitis by inhibiting the activity of IL-33, a cytokine implicated in the inflammatory processes associated with this chronic skin condition.</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ASTEGOLIMAB">
      <data key="d4">21.0</data>
      <data key="d5">Astegolimab is a biologic agent used in the treatment of atopic dermatitis. It specifically targets interleukin-33 (IL-33), playing a crucial role in managing this chronic inflammatory skin condition.</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="MEDI3506">
      <data key="d4">21.0</data>
      <data key="d5">ATOPIC DERMATITIS and MEDI3506: MEDI3506 is a biologic agent specifically designed to target interleukin-33 (IL-33) in the treatment of atopic dermatitis. This therapeutic approach aims to mitigate the symptoms and underlying causes of atopic dermatitis by modulating the activity of IL-33, a cytokine implicated in the inflammatory processes associated with this chronic skin condition.</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="BERMEKIMAB">
      <data key="d4">21.0</data>
      <data key="d5">Atopic Dermatitis and Bermekimab:

Bermekimab is a biologic agent specifically designed to target interleukin-1&#945; (IL-1&#945;) in the treatment of atopic dermatitis. This therapeutic approach aims to mitigate the inflammatory processes associated with atopic dermatitis by inhibiting the activity of IL-1&#945;, a cytokine known to play a significant role in the pathogenesis of this chronic skin condition.</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="GBR 830">
      <data key="d4">7.0</data>
      <data key="d5">GBR 830 is used to target OX40 in the treatment of atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="KHK4083">
      <data key="d4">7.0</data>
      <data key="d5">KHK4083 is used to target OX40 in the treatment of atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="CBP-201">
      <data key="d4">14.0</data>
      <data key="d5">ATOPIC DERMATITIS and CBP-201:

CBP-201 is a biologic agent specifically designed to target interleukin-4 receptor alpha (IL-4R&#945;) in the treatment of atopic dermatitis. This therapeutic approach aims to modulate the immune response associated with the condition, providing a targeted intervention for patients suffering from this chronic inflammatory skin disease.</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="AK120">
      <data key="d4">7.0</data>
      <data key="d5">AK120 is used to target IL-4R&#945; in the treatment of atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="BENRALIZUMAB">
      <data key="d4">7.0</data>
      <data key="d5">Benralizumab is used to target IL-5R&#945; in the treatment of atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="FB825">
      <data key="d4">7.0</data>
      <data key="d5">FB825 is used to target mIgE in the treatment of atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="FEZAKINUMAB">
      <data key="d4">7.0</data>
      <data key="d5">Fezakinumab is used to target IL-22 in the treatment of atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="LEO 138559">
      <data key="d4">7.0</data>
      <data key="d5">LEO 138559 is used to target IL-22R1 in the treatment of atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="LY3471851">
      <data key="d4">7.0</data>
      <data key="d5">LY3471851 is used to target rhIL-2 to Treg cells in the treatment of atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="EOSINOPHILS">
      <data key="d4">8.0</data>
      <data key="d5">Eosinophils are elevated in the skin of Atopic Dermatitis patients</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="LYMPHOCYTES">
      <data key="d4">8.0</data>
      <data key="d5">Lymphocytes infiltrate the skin in Atopic Dermatitis patients</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="IMMUNOGLOBULIN E">
      <data key="d4">8.0</data>
      <data key="d5">Immunoglobulin E (IgE) levels are increased in Atopic Dermatitis patients</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ITCHING">
      <data key="d4">9.0</data>
      <data key="d5">Itching is a common symptom of Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="RASH">
      <data key="d4">9.0</data>
      <data key="d5">Rash is a common symptom of Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="BLEEDING">
      <data key="d4">7.0</data>
      <data key="d5">Bleeding can occur in Atopic Dermatitis patients due to intense scratching</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="EROSIONS">
      <data key="d4">7.0</data>
      <data key="d5">Erosions are areas of skin damage that can occur in Atopic Dermatitis patients due to scratching</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="PLAQUES">
      <data key="d4">8.0</data>
      <data key="d5">Plaques are thickened areas of skin that are common in Atopic Dermatitis patients</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ASTHMA">
      <data key="d4">23.0</data>
      <data key="d5">Atopic Dermatitis and Asthma are closely related conditions, often observed together in clinical settings. Asthma is a common comorbidity in patients with Atopic Dermatitis, indicating a significant overlap between these two conditions. Specifically, Asthma is a respiratory condition that children with Atopic Dermatitis may develop, highlighting the interconnected nature of these diseases. The association between Atopic Dermatitis and Asthma underscores the importance of monitoring patients with Atopic Dermatitis for potential respiratory complications, such as Asthma.</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd,691cb2e23ac3c6e591129d16714f8ef8,6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="FOOD ALLERGIES">
      <data key="d4">7.0</data>
      <data key="d5">Food Allergies are conditions that children with Atopic Dermatitis may develop</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="COMMON COLD">
      <data key="d4">6.0</data>
      <data key="d5">The common cold is a condition that children with Atopic Dermatitis have a 75% risk of developing</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="GENETICS">
      <data key="d4">8.0</data>
      <data key="d5">Genetics is a factor in the onset and severity of Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="SKIN BARRIER">
      <data key="d4">9.0</data>
      <data key="d5">Abnormalities in the skin barrier contribute to the pathophysiology of Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="IMMUNE SYSTEM">
      <data key="d4">9.0</data>
      <data key="d5">Dysregulation of the immune system plays a significant role in the pathogenesis of Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="INTERLEUKINS">
      <data key="d4">8.0</data>
      <data key="d5">Interleukins influence the immunological pathway in Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="JANUS KINASE">
      <data key="d4">8.0</data>
      <data key="d5">Janus Kinase inhibitors like Baricitinib, Upadacitinib, and Abrocitinib are used as targeted therapies for Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="BIOLOGIC MEDICATIONS">
      <data key="d4">7.0</data>
      <data key="d5">Biologic medications are in various stages of approval or development for treating Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="SMALL MOLECULES">
      <data key="d4">7.0</data>
      <data key="d5">Small molecules have emerged as non-biologic targeted therapies for Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="PERSONALIZED MEDICINE">
      <data key="d4">7.0</data>
      <data key="d5">Personalized medicine is a potential approach for targeted translational research in Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="CLINICAL TRIALS">
      <data key="d4">7.0</data>
      <data key="d5">Clinical trials explore the efficacy and safety of new treatments for Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="PSYCHOLOGICAL FACTORS">
      <data key="d4">6.0</data>
      <data key="d5">Psychological factors can influence the onset and severity of Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="DRUGS">
      <data key="d4">7.0</data>
      <data key="d5">Drugs, including both biologic and non-biologic therapies, are used to treat or manage Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ENVIRONMENTAL INFLUENCES">
      <data key="d4">7.0</data>
      <data key="d5">Environmental influences affect the onset and severity of Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="FLG GENE">
      <data key="d4">9.0</data>
      <data key="d5">The FLG gene encodes filaggrin, which is crucial for skin barrier function and is associated with Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="SKIN MICROORGANISMS">
      <data key="d4">7.0</data>
      <data key="d5">Skin microorganisms can influence the development and severity of Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TOPICAL TREATMENTS">
      <data key="d4">7.0</data>
      <data key="d5">Topical treatments are used to manage Atopic Dermatitis symptoms</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="SYSTEMIC TREATMENTS">
      <data key="d4">7.0</data>
      <data key="d5">Systemic treatments are used to manage Atopic Dermatitis symptoms</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="STRATUM CORNEUM FORMATION">
      <data key="d4">8.0</data>
      <data key="d5">Stratum corneum formation is affected in Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="EPIDERMAL COMPLEX">
      <data key="d4">1.0</data>
      <data key="d5">The epidermal complex is affected in Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="BDP">
      <data key="d4">14.0</data>
      <data key="d5">BDP-loaded PMs provided better AD skin healing</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="NICLOSAMIDE">
      <data key="d4">14.0</data>
      <data key="d5">Niclosamide is a small molecule used in atopic dermatitis treatment</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="OMIGANAN">
      <data key="d4">14.0</data>
      <data key="d5">Omiganan is a small molecule used in atopic dermatitis treatment</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TH2 CELLS">
      <data key="d4">9.0</data>
      <data key="d5">Th2 cells dominate in Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="SOX40">
      <data key="d4">15.0</data>
      <data key="d5">Atopic Dermatitis is a chronic inflammatory skin condition characterized by itchy and inflamed skin. Research has shown that serum levels of sOX40, a soluble form of the OX40 protein, are decreased in patients with Atopic Dermatitis. sOX40 levels are routinely measured in these patients to better understand the disease's pathophysiology and potentially guide therapeutic interventions.</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd,691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="DRY SKIN">
      <data key="d4">9.0</data>
      <data key="d5">Dry skin is a symptom of Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="MEMORY T CELLS">
      <data key="d4">8.0</data>
      <data key="d5">Memory T cells are central for the chronicity of Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="PBMCS">
      <data key="d4">7.0</data>
      <data key="d5">PBMCs are isolated for research in Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="PLASMA">
      <data key="d4">7.0</data>
      <data key="d5">Plasma is collected for research in Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ENZYME-LINKED IMMUNOASSAY (ELISA)">
      <data key="d4">7.0</data>
      <data key="d5">ELISA is used to measure the concentration of soluble OX40 in blood samples from patients with Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="FLOW CYTOMETRY">
      <data key="d4">7.0</data>
      <data key="d5">Flow Cytometry is used to analyze the expression of OX40 by activated skin-homing CD4+ T cells in Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="IMMUNOFLUORESCENCE">
      <data key="d4">7.0</data>
      <data key="d5">Immunofluorescence shows the co-location of OX40+ and OX40L+ cells within the dermis in Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="EPIDERMAL BARRIER DYSFUNCTION">
      <data key="d4">8.0</data>
      <data key="d5">Epidermal Barrier Dysfunction causes dry skin and inflammation in Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="HANIFIN &amp; RAJKA CRITERIA">
      <data key="d4">7.0</data>
      <data key="d5">Hanifin &amp; Rajka Criteria are used to diagnose patients with Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="RHINITIS">
      <data key="d4">8.0</data>
      <data key="d5">Rhinitis is a common comorbidity in patients with atopic dermatitis</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="SOX40L">
      <data key="d4">8.0</data>
      <data key="d5">sOX40L levels are measured in patients with atopic dermatitis</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="PERIPHERAL BLOOD MONONUCLEAR CELLS">
      <data key="d4">7.0</data>
      <data key="d5">PBMCs from patients with atopic dermatitis are analyzed by flow cytometry</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="LIGHT">
      <data key="d4">30.0</data>
      <data key="d5">ATOPIC DERMATITIS (AD) is a chronic inflammatory skin condition characterized by itchy and inflamed skin. LIGHT, a member of the tumor necrosis factor (TNF) superfamily, is induced in atopic dermatitis. It plays a significant role in the pathogenesis of AD by regulating skin fibrosis, contributing to the chronic and relapsing nature of the disease.</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2,df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="PLACEBO">
      <data key="d4">7.0</data>
      <data key="d5">Placebo is used as a control in clinical trials for atopic dermatitis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="KYMAB LIMITED">
      <data key="d4">6.0</data>
      <data key="d5">Kymab Limited is involved in clinical trials for atopic dermatitis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ICHNOS SCIENCES SA">
      <data key="d4">6.0</data>
      <data key="d5">Ichnos Sciences SA is involved in clinical trials for atopic dermatitis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="GLENMARK PHARMACEUTICALS S.A.">
      <data key="d4">6.0</data>
      <data key="d5">Glenmark Pharmaceuticals S.A. is involved in clinical trials for atopic dermatitis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="PRURITUS" target="IL-31">
      <data key="d4">44.0</data>
      <data key="d5">IL-31 is a cytokine that plays a significant role in the pathophysiology of pruritus, commonly known as itch. It functions to evoke itch, thereby amplifying pruritus symptoms. This is particularly evident in patients with atopic dermatitis (AD), where IL-31 induces pruritus, contributing to the discomfort and severity of the condition.</data>
      <data key="d6">3df8535e965efb96f5094169610507ff,4842292208575bd45b2b5998513dd087,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="PRURITUS" target="HISTAMINE">
      <data key="d4">18.0</data>
      <data key="d5">Histamine amplifies pruritus</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="PRURITUS" target="AD">
      <data key="d4">98.0</data>
      <data key="d5">Pruritus, or itching, is a common symptom associated with Atopic Dermatitis (AD). It is frequently observed in individuals suffering from this condition, highlighting its prevalence as a significant and characteristic feature of AD.</data>
      <data key="d6">143d2dc302af5606656797bff162e23e,28f548554737fcc026b968db6bbafa30,3287c502f10f4651d2f56bf39ee7bb7a,90f4809673ca34628b0e607908f0bf0b,b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="PRURITUS" target="NRS">
      <data key="d4">26.0</data>
      <data key="d5">NRS is used to measure the intensity of pruritus</data>
      <data key="d6">3287c502f10f4651d2f56bf39ee7bb7a,b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="PRURITUS" target="NEMOLIZUMAB">
      <data key="d4">8.0</data>
      <data key="d5">Nemolizumab is used to mitigate IL-31&#8211;dependent processes, including pruritus</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="PRURITUS" target="PP-NRS-11">
      <data key="d4">8.0</data>
      <data key="d5">Pruritus is measured by the PP-NRS-11 tool</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="PRURITUS" target="B244">
      <data key="d4">7.0</data>
      <data key="d5">B244 induced significant improvement of pruritus in AD</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="PRURITUS" target="LEBRIKIZUMAB">
      <data key="d4">14.0</data>
      <data key="d5">Lebrikizumab showed improvement in pruritus NRS</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="PRURITUS" target="MEPOLIZUMAB">
      <data key="d4">12.0</data>
      <data key="d5">Mepolizumab failed to show a significant decrease in pruritus</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="PRURITUS" target="H1R">
      <data key="d4">8.0</data>
      <data key="d5">H1R in the skin induces pruritus</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="TOPICAL CORTICOSTEROIDS" target="AD">
      <data key="d4">8.0</data>
      <data key="d5">Topical corticosteroids are used to reduce inflammation in atopic dermatitis</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="TOPICAL CORTICOSTEROIDS" target="TRALOKINUMAB">
      <data key="d4">8.0</data>
      <data key="d5">Tralokinumab is used with topical corticosteroids for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="CRISABOROLE" target="PHOSPHODIESTERASE-4">
      <data key="d4">7.0</data>
      <data key="d5">Crisaborole targets Phosphodiesterase-4 in the treatment of Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="CRISABOROLE" target="PDE-4">
      <data key="d4">9.0</data>
      <data key="d5">Crisaborole is a topical PDE-4 inhibitor</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="CRISABOROLE" target="AD">
      <data key="d4">41.0</data>
      <data key="d5">Crisaborole is a topical PDE4 inhibitor that is approved for the treatment of mild to moderate atopic dermatitis (AD). It is specifically used for treating AD, providing a therapeutic option for managing this chronic inflammatory skin condition.</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c,442e7fad2fab75fa2449309783294d89,90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="CRISABOROLE" target="EMA">
      <data key="d4">14.0</data>
      <data key="d5">The European Medicines Agency is responsible for the approval of drugs like crisaborole in Europe</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="TRALOKINUMAB" target="AD">
      <data key="d4">33.0</data>
      <data key="d5">Tralokinumab has shown initial success in treating atopic dermatitis (AD). It is evaluated for the treatment of AD and is used to treat this condition.</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0,96e553a44a27e728c27c4892045ec5c2,dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="TRALOKINUMAB" target="EMA">
      <data key="d4">8.0</data>
      <data key="d5">Tralokinumab received a positive opinion from the EMA</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="TRALOKINUMAB" target="ECZTRA1">
      <data key="d4">24.0</data>
      <data key="d5">Tralokinumab was evaluated in the ECZTRA1 study, where it showed superiority to placebo.</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41,78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="TRALOKINUMAB" target="ECZTRA2">
      <data key="d4">24.0</data>
      <data key="d5">Tralokinumab was evaluated in the ECZTRA2 study, where it demonstrated superiority to placebo.</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41,78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="TRALOKINUMAB" target="EMA/CHMP/202204/2021">
      <data key="d4">8.0</data>
      <data key="d5">Tralokinumab received a positive opinion from the EMA</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="TRALOKINUMAB" target="ITCH">
      <data key="d4">16.0</data>
      <data key="d5">Tralokinumab improves itch by targeting IL-13</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="TRALOKINUMAB" target="NERVE ENDINGS">
      <data key="d4">7.0</data>
      <data key="d5">Tralokinumab affects nerve endings</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="TRALOKINUMAB" target="INTERLEUKIN-13RA1">
      <data key="d4">8.0</data>
      <data key="d5">Tralokinumab targets Interleukin-13Ra1</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="ABROCITINIB" target="AD">
      <data key="d4">16.0</data>
      <data key="d5">Abrocitinib is a JAK inhibitor used for treating moderate to severe atopic dermatitis (AD). It is specifically employed in the management of atopic dermatitis, providing therapeutic benefits for patients suffering from this chronic inflammatory skin condition.</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd,a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="ABROCITINIB" target="NCT03627767">
      <data key="d4">7.0</data>
      <data key="d5">NCT03627767 is a clinical trial involving Abrocitinib</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="BARICITINIB" target="NCT02576938">
      <data key="d4">8.0</data>
      <data key="d5">NCT02576938 is a phase 2 trial for baricitinib in AD</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="BARICITINIB" target="BREEZE-AD1">
      <data key="d4">8.0</data>
      <data key="d5">BREEZE-AD1 is a phase 3 trial for baricitinib in AD</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="BARICITINIB" target="BREEZE-AD2">
      <data key="d4">8.0</data>
      <data key="d5">BREEZE-AD2 is a phase 3 trial for baricitinib in AD</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="BARICITINIB" target="BREEZE-AD3">
      <data key="d4">8.0</data>
      <data key="d5">BREEZE-AD3 is a phase 3 trial for baricitinib in AD</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="BARICITINIB" target="BREEZE-AD5">
      <data key="d4">8.0</data>
      <data key="d5">BREEZE-AD5 is a phase 3 trial for baricitinib in AD</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="BARICITINIB" target="BREEZE-AD6">
      <data key="d4">8.0</data>
      <data key="d5">BREEZE-AD6 is a phase 3 trial for baricitinib in AD</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="BARICITINIB" target="BREEZE-AD4">
      <data key="d4">8.0</data>
      <data key="d5">BREEZE-AD4 is a phase 3 trial for baricitinib in AD patients with inadequate response to cyclosporine</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="BARICITINIB" target="NCT03428100">
      <data key="d4">8.0</data>
      <data key="d5">NCT03428100 is a phase 3 trial for baricitinib in AD patients with inadequate response to cyclosporine</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="BARICITINIB" target="AD">
      <data key="d4">39.0</data>
      <data key="d5">Baricitinib is a JAK1/JAK2 inhibitor that is used for treating moderate to severe atopic dermatitis (AD). It has been approved for the treatment of atopic dermatitis and is currently being studied for its efficacy in managing this condition.</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d,2cec06c4d46f5ff9ee936a78d8b077cd,a867a1e73cef039eb3f28e072463b838,c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="BARICITINIB" target="ECZEMA HERPETICUM">
      <data key="d4">12.0</data>
      <data key="d5">Eczema herpeticum was more frequent in patients treated with baricitinib</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="BARICITINIB" target="NCT03952559">
      <data key="d4">7.0</data>
      <data key="d5">NCT03952559 is a clinical trial involving Baricitinib</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="LEBRIKIZUMAB" target="AD">
      <data key="d4">24.0</data>
      <data key="d5">Lebrikizumab has shown initial success in treating atopic dermatitis (AD). It is currently being evaluated for the treatment of AD, indicating its potential as a therapeutic option for this autoimmune condition.</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0,96e553a44a27e728c27c4892045ec5c2</data>
    </edge>
    <edge source="LEBRIKIZUMAB" target="PERIOSTIN">
      <data key="d4">8.0</data>
      <data key="d5">Lebrikizumab's efficacy in asthma is higher in patients with high levels of periostin</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="LEBRIKIZUMAB" target="FEV1">
      <data key="d4">1.0</data>
      <data key="d5">Lebrikizumab increases FEV1 in asthma patients</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="LEBRIKIZUMAB" target="ASTHMA">
      <data key="d4">8.0</data>
      <data key="d5">Lebrikizumab is used in the treatment of asthma</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="LEBRIKIZUMAB" target="ARBAN">
      <data key="d4">16.0</data>
      <data key="d5">ARBAN is a clinical trial of Lebrikizumab</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="LEBRIKIZUMAB" target="TREBLE">
      <data key="d4">16.0</data>
      <data key="d5">TREBLE is a clinical trial of Lebrikizumab</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="LEBRIKIZUMAB" target="EASI">
      <data key="d4">14.0</data>
      <data key="d5">Lebrikizumab showed improvement in EASI scores</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="LEBRIKIZUMAB" target="ITCH">
      <data key="d4">16.0</data>
      <data key="d5">Lebrikizumab improves itch by targeting IL-13</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="LEBRIKIZUMAB" target="NERVE ENDINGS">
      <data key="d4">7.0</data>
      <data key="d5">Lebrikizumab affects nerve endings</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="LEBRIKIZUMAB" target="INTERLEUKIN-13">
      <data key="d4">8.0</data>
      <data key="d5">Lebrikizumab targets Interleukin-13</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="NEMOLIZUMAB" target="IL-31">
      <data key="d4">18.0</data>
      <data key="d5">Nemolizumab is a therapeutic agent that targets IL-31 and its receptor to treat moderate-to-severe atopic dermatitis. By antagonizing the IL-31 receptor, Nemolizumab effectively mitigates IL-31&#8211;dependent processes, thereby alleviating symptoms associated with this condition.</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,f14a13d54127c3baadeb0b34d40928c9,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="NEMOLIZUMAB" target="ITCH">
      <data key="d4">16.0</data>
      <data key="d5">Nemolizumab reduces pruritus in atopic dermatitis</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="NEMOLIZUMAB" target="IL-31R&#913;">
      <data key="d4">16.0</data>
      <data key="d5">Nemolizumab targets IL-31R&#945;</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="NEMOLIZUMAB" target="PRURIGO NODULARIS">
      <data key="d4">14.0</data>
      <data key="d5">Nemolizumab shows promising results in prurigo nodularis</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="NEMOLIZUMAB" target="PHASE IIA STUDY">
      <data key="d4">7.0</data>
      <data key="d5">Phase IIa study showed nemolizumab reduced pruritus</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="NEMOLIZUMAB" target="PHASE III STUDY">
      <data key="d4">7.0</data>
      <data key="d5">Phase III study confirmed nemolizumab's efficacy in pruritus</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="NEMOLIZUMAB" target="NCT03989349">
      <data key="d4">7.0</data>
      <data key="d5">NCT03989349 is a clinical trial involving Nemolizumab</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="NEMOLIZUMAB" target="NCT03985943">
      <data key="d4">7.0</data>
      <data key="d5">NCT03985943 is a clinical trial involving Nemolizumab</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="NEMOLIZUMAB" target="IL-31RA">
      <data key="d4">16.0</data>
      <data key="d5">Nemolizumab targets IL-31RA to control AD inflammation and pruritus</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="NEMOLIZUMAB" target="INTERLEUKIN-31">
      <data key="d4">8.0</data>
      <data key="d5">Nemolizumab targets Interleukin-31</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="TH2" target="AD">
      <data key="d4">25.0</data>
      <data key="d5">T helper 2 (TH2) cells play a key role in the pathogenesis of atopic dermatitis (AD). These cells are critically involved in the immune response and inflammation associated with AD. The TH2 pathway is specifically implicated in the development and progression of this condition, highlighting the importance of TH2 cells in the underlying mechanisms of atopic dermatitis.</data>
      <data key="d6">143d2dc302af5606656797bff162e23e,41ccc4b41bd57cf2bda4dbb6c7ae4198,a867a1e73cef039eb3f28e072463b838,dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="TH2" target="IL-31">
      <data key="d4">7.0</data>
      <data key="d5">IL-31 is produced by Th2 cells</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="TH2" target="SPINK5">
      <data key="d4">7.0</data>
      <data key="d5">SPINK5 mutations favor a pro-TH2 micromilieu</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="TH2" target="IL-5">
      <data key="d4">7.0</data>
      <data key="d5">IL-5 is involved in the TH2 immune response</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="TH2" target="IGE">
      <data key="d4">8.0</data>
      <data key="d5">Increased IgE serum level is a hallmark of a TH2 immune response</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="TH2" target="IMMUNE POLARIZATION">
      <data key="d4">8.0</data>
      <data key="d5">TH2 cells are involved in immune polarization</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="TH2" target="IFN&#915;">
      <data key="d4">14.0</data>
      <data key="d5">IFN&#947; is a cytokine involved in T helper cell responses</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="TH2" target="TNFR2">
      <data key="d4">14.0</data>
      <data key="d5">Impaired TNF/TNFR2 signaling enhances Th2 polarization</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TH2" target="BALF">
      <data key="d4">14.0</data>
      <data key="d5">Inhibiting TNFR2 via antibody treatment led to increased expression of Th2 inflammatory cytokines in BALF</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TH2" target="LIGHT">
      <data key="d4">12.0</data>
      <data key="d5">LIGHT is associated with Th2 polarization in SSc</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="TH22" target="AD">
      <data key="d4">22.0</data>
      <data key="d5">T helper 22 (Th22) cells are implicated in the pathogenesis of atopic dermatitis (AD). Th22 cells are involved in the immune response and inflammation associated with AD, playing a significant role in the disease's development and progression. The Th22 pathway is a critical component in understanding the mechanisms underlying atopic dermatitis.</data>
      <data key="d6">143d2dc302af5606656797bff162e23e,41ccc4b41bd57cf2bda4dbb6c7ae4198,dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="TH1" target="AD">
      <data key="d4">7.0</data>
      <data key="d5">Th1 pathway is implicated in the pathogenesis of atopic dermatitis</data>
      <data key="d6">dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="TH1" target="INTERFERON-&#915;">
      <data key="d4">16.0</data>
      <data key="d5">Interferon-&#947; production is impaired in OX40 deficient models affecting Th1 differentiation</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="TH1" target="IL-22">
      <data key="d4">7.0</data>
      <data key="d5">IL-22 is induced by staphylococcal exotoxins in TH1 cells</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="TH1" target="TNFR2">
      <data key="d4">14.0</data>
      <data key="d5">Impaired TNF/TNFR2 signaling inhibits Th1 differentiation</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TH1" target="LIGHT">
      <data key="d4">19.0</data>
      <data key="d5">TH1 and LIGHT are two entities involved in the immune response. LIGHT suppresses Th1 chemokine expression, which is consistent with the polarization towards Th2 and Th17 pathways observed in systemic sclerosis (SSc). This suppression of Th1 chemokines by LIGHT indicates a shift in the immune response, contributing to the pathophysiology of SSc.</data>
      <data key="d6">05c97152fe02249153103be341d65b67,5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="FILAGGRIN" target="IL-22">
      <data key="d4">24.0</data>
      <data key="d5">IL-22 downregulates filaggrin expression</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1,4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="FILAGGRIN" target="AD">
      <data key="d4">32.0</data>
      <data key="d5">Filaggrin is a protein that plays a crucial role in the immune response associated with atopic dermatitis (AD). It is known to be suppressed in chronic cases of atopic dermatitis. Mutations in the filaggrin gene significantly impact the epidermal barrier function, which is a critical factor in the pathogenesis of AD. These genetic mutations are directly implicated in the development and severity of atopic dermatitis, highlighting the importance of filaggrin in both the immune response and the maintenance of skin integrity in this condition.</data>
      <data key="d6">143d2dc302af5606656797bff162e23e,3ea70e257330c812b52334ca1f90d807,b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="FILAGGRIN" target="IL-33">
      <data key="d4">14.0</data>
      <data key="d5">IL-33 downregulates the expression of filaggrin, contributing to epidermal barrier dysfunctionIL-33 contributes to epidermal barrier dysfunction by downregulating filaggrin expression</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="FILAGGRIN" target="VTP-38543">
      <data key="d4">6.0</data>
      <data key="d5">VTP-38543 increased mRNA expression of filaggrin</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="FILAGGRIN" target="PRO-FLG">
      <data key="d4">8.0</data>
      <data key="d5">Pro-FLG is dephosphorylated and proteolytically cleaved to form FLG monomers</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="FILAGGRIN" target="STRATUM CORNEUM">
      <data key="d4">8.0</data>
      <data key="d5">Filaggrin is crucial for Stratum Corneum formation and keratin buildup</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="LORICRIN" target="AD">
      <data key="d4">15.0</data>
      <data key="d5">Loricrin is involved in the immune response in atopic dermatitis (AD). In cases of chronic atopic dermatitis, loricrin is suppressed.</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="LORICRIN" target="VTP-38543">
      <data key="d4">6.0</data>
      <data key="d5">VTP-38543 increased mRNA expression of loricrin</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="TSLP" target="DENDRITIC CELLS (DCS)">
      <data key="d4">16.0</data>
      <data key="d5">TSLP activates dendritic cells to express OX40L</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="TSLP" target="DENDRITIC CELLS">
      <data key="d4">8.0</data>
      <data key="d5">TSLP is highly expressed in skin epithelial cells in AD and its receptor TSLPR is expressed on dendritic cells</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="TSLP" target="TSLPR">
      <data key="d4">8.0</data>
      <data key="d5">TSLP binds to its receptor TSLPR</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="TSLP" target="TEZEPELUMAB">
      <data key="d4">23.0</data>
      <data key="d5">Tezepelumab is an anti-TSLP monoclonal antibody. TSLP, or thymic stromal lymphopoietin, is a cytokine involved in the pathogenesis of various autoimmune diseases. Tezepelumab specifically targets and neutralizes TSLP, thereby modulating the immune response and offering therapeutic potential in conditions characterized by dysregulated TSLP activity.</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807,849e0980ffd6a7e1cf0b8d3d1fbacd98,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="TSLP" target="T CELLS">
      <data key="d4">8.0</data>
      <data key="d5">TSLP is highly expressed in skin epithelial cells in AD and its receptor TSLPR is expressed on T cells</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="TSLP" target="B CELLS">
      <data key="d4">8.0</data>
      <data key="d5">TSLP is highly expressed in skin epithelial cells in AD and its receptor TSLPR is expressed on B cells</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="TSLP" target="MAST CELLS">
      <data key="d4">8.0</data>
      <data key="d5">TSLP is highly expressed in skin epithelial cells in AD and its receptor TSLPR is expressed on mast cells</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="TSLP" target="BASOPHILS">
      <data key="d4">8.0</data>
      <data key="d5">TSLP is highly expressed in skin epithelial cells in AD and its receptor TSLPR is expressed on basophils</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="TSLP" target="EOSINOPHILS">
      <data key="d4">8.0</data>
      <data key="d5">TSLP is highly expressed in skin epithelial cells in AD and its receptor TSLPR is expressed on eosinophils</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="TSLP" target="AD">
      <data key="d4">31.0</data>
      <data key="d5">Thymic stromal lymphopoietin (TSLP) is a cytokine that plays a significant role in the immune response and inflammation associated with atopic dermatitis (AD). TSLP expression is elevated in AD, and it promotes Th2 responses, which are increased in the skin of individuals with AD. This cytokine is crucial in the pathogenesis of AD, contributing to the heightened immune response observed in this condition.</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807,41ccc4b41bd57cf2bda4dbb6c7ae4198,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="TSLP" target="HY209">
      <data key="d4">7.0</data>
      <data key="d5">HY209 significantly decreased TSLP levels</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="TSLP" target="DC">
      <data key="d4">7.0</data>
      <data key="d5">TSLP affects DCs</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="TSLP" target="SPINK5">
      <data key="d4">7.0</data>
      <data key="d5">SPINK5 infiltrates TSLP during inflammation</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="TSLP" target="TH2 CELL">
      <data key="d4">8.0</data>
      <data key="d5">TSLP activates Th2 cells</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="TSLP" target="IL-5">
      <data key="d4">7.0</data>
      <data key="d5">TSLP promotes the production of IL-5</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="TSLP" target="MAST CELL">
      <data key="d4">7.0</data>
      <data key="d5">TSLP affects mast cells</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="TSLP" target="NATURAL KILLER CELL">
      <data key="d4">7.0</data>
      <data key="d5">TSLP affects natural killer cells</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="TSLP" target="ENDOTHELIAL CELLS">
      <data key="d4">8.0</data>
      <data key="d5">TSLP activates endothelial cells during inflammation</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="TSLP" target="DCS">
      <data key="d4">8.0</data>
      <data key="d5">TSLP activates dendritic cells (DCs) during inflammation</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="TSLP" target="TRAIL">
      <data key="d4">7.0</data>
      <data key="d5">TRAIL is necessary for the upregulation of TSLP</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="IL-25" target="DENDRITIC CELLS (DCS)">
      <data key="d4">16.0</data>
      <data key="d5">IL-25 activates dendritic cells to express OX40L</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="IL-25" target="AD">
      <data key="d4">21.0</data>
      <data key="d5">IL-25 is a cytokine involved in the immune response and inflammation in AD (Atopic Dermatitis).</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807,41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="IL-25" target="FLG">
      <data key="d4">7.0</data>
      <data key="d5">IL-25 reduces FLG expression</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="IL-25" target="SPINK5">
      <data key="d4">7.0</data>
      <data key="d5">SPINK5 infiltrates IL-25 during inflammation</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-25" target="MAST CELLS">
      <data key="d4">8.0</data>
      <data key="d5">Mast cells produce IL-25, central to the pathogenesis of Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="IL-33" target="DENDRITIC CELLS (DCS)">
      <data key="d4">16.0</data>
      <data key="d5">IL-33 stimulates dendritic cells to express OX40L</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="IL-33" target="TYPE 2 INNATE LYMPHOID CELLS">
      <data key="d4">16.0</data>
      <data key="d5">IL-33 stimulates type 2 innate lymphoid cells</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="IL-33" target="IL-5">
      <data key="d4">21.0</data>
      <data key="d5">IL-33 increases the production of IL-5. IL-33 induces the production of IL-5 and enhances type 2 responses through the induction of IL-5.</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="IL-33" target="IFN-&#915;">
      <data key="d4">14.0</data>
      <data key="d5">IL-33 enhances type 1 responses through the induction of IFN-&#947;IL-33 induces the production of IFN-&#947;</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="IL-33" target="ANB020">
      <data key="d4">8.0</data>
      <data key="d5">ANB020 is an anti&#8211;IL-33 monoclonal antibody</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="IL-33" target="PF-06817024">
      <data key="d4">8.0</data>
      <data key="d5">PF-06817024 is an anti&#8211;IL-33 monoclonal antibody</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="IL-33" target="AD">
      <data key="d4">29.0</data>
      <data key="d5">IL-33 is a cytokine involved in the immune response and inflammation in atopic dermatitis (AD). It is released by keratinocytes in AD, contributing to the disease's inflammatory processes.</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807,41ccc4b41bd57cf2bda4dbb6c7ae4198,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-33" target="SPINK5">
      <data key="d4">7.0</data>
      <data key="d5">SPINK5 infiltrates IL-33 during inflammation</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-33" target="TH2 CELL">
      <data key="d4">8.0</data>
      <data key="d5">IL-33 activates Th2 responses</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-33" target="ETOKIMAB">
      <data key="d4">8.0</data>
      <data key="d5">Etokimab is an anti-IL-33 monoclonal antibody</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-33" target="ITEPEKIMAB">
      <data key="d4">8.0</data>
      <data key="d5">Itepekimab is an IL-33 inhibitor</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-33" target="TNFR2">
      <data key="d4">7.0</data>
      <data key="d5">TNFR2 signaling initiates IL-33 production</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="IL-33" target="ST2">
      <data key="d4">7.0</data>
      <data key="d5">IL-33 signals via ST2 on local immune cells</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="IGE" target="PLASMA CELLS">
      <data key="d4">16.0</data>
      <data key="d5">Plasma cells produce IgE in response to IL-4 and IL-13 stimulation in atopic dermatitis</data>
      <data key="d6">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="IGE" target="AD">
      <data key="d4">37.0</data>
      <data key="d5">Immunoglobulin E (IgE) and Atopic Dermatitis (AD) are closely linked in the context of immune response and inflammation. IgE is involved in the immune response and inflammation in AD, and its responses correlate with the severity of atopic dermatitis. IgE sensitization plays a significant role in the pathogenesis of atopic dermatitis, and increased levels of IgE are commonly detected in patients suffering from AD. This relationship underscores the importance of IgE in the clinical manifestation and progression of atopic dermatitis.</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41,143d2dc302af5606656797bff162e23e,41ccc4b41bd57cf2bda4dbb6c7ae4198,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="IGE" target="DC">
      <data key="d4">14.0</data>
      <data key="d5">IgE-bearing dendritic cells capture and present allergens</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="IGE" target="ADAPT">
      <data key="d4">14.0</data>
      <data key="d5">The ADAPT study was designed to verify the role of IgE in atopic dermatitis</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="IGE" target="ANTI-IGE">
      <data key="d4">9.0</data>
      <data key="d5">Anti-IgE biologics target IgE to treat allergic conditions</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IGE" target="IMMUNOADSORPTION">
      <data key="d4">8.0</data>
      <data key="d5">Immunoadsorption is used to remove IgE from the blood</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IGE" target="ALLERGIC REACTIONS">
      <data key="d4">9.0</data>
      <data key="d5">IgE is involved in allergic reactions</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IGE" target="ENVIRONMENTAL ALLERGENS">
      <data key="d4">8.0</data>
      <data key="d5">IgE mediates allergic reactions to environmental allergens</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IGE" target="ALLERGIC DISEASES">
      <data key="d4">9.0</data>
      <data key="d5">IgE is involved in allergic diseases</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IGE" target="SYK">
      <data key="d4">14.0</data>
      <data key="d5">SYK is a crucial signaling molecule for the high-affinity receptor for IgE</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="IGE" target="LANGERHANS CELLS">
      <data key="d4">12.0</data>
      <data key="d5">IgE is expressed on Langerhans cells</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="IGE" target="INFLAMMATORY DENDRITIC EPIDERMAL CELLS">
      <data key="d4">12.0</data>
      <data key="d5">IgE is expressed on inflammatory dendritic epidermal cells</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="IGE" target="HY209">
      <data key="d4">7.0</data>
      <data key="d5">HY209 significantly decreased serum IgE levels</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="IGE" target="TH2 CELL">
      <data key="d4">8.0</data>
      <data key="d5">IgE is involved in the Th2 immune response</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IGE" target="NICOTINAMIDE (VITAMIN B3)">
      <data key="d4">7.0</data>
      <data key="d5">Nicotinamide (Vitamin B3) decreases IgE titers</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="IGE" target="HYDROCORTISONE">
      <data key="d4">14.0</data>
      <data key="d5">HC-NPs suppressed inflammatory cascades including IgE</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="IGE" target="CARDIAC FIBROBLAST">
      <data key="d4">12.0</data>
      <data key="d5">IgE treatment induces activation and matrix protein production in cardiac fibroblasts</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="PLASMA CELLS" target="B CELLS">
      <data key="d4">9.0</data>
      <data key="d5">B cells differentiate into plasma cells to produce antibodies</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="PLASMA CELLS" target="COMPLEMENT ACTIVATION">
      <data key="d4">6.0</data>
      <data key="d5">Complement activation is enriched in the plasma cell population</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="PLASMA CELLS" target="B CELL ACTIVATION">
      <data key="d4">6.0</data>
      <data key="d5">Positive regulation of B cell activation is enriched in the plasma cell population</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="PLASMA CELLS" target="ANTIBACTERIAL HUMORAL RESPONSE">
      <data key="d4">6.0</data>
      <data key="d5">Antibacterial humoral response is enriched in the plasma cell population</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="PLASMA CELLS" target="CD138">
      <data key="d4">25.0</data>
      <data key="d5">CD138 is a marker found on plasma cells</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,b62ecc47bf54393bc78dd65986b949d6</data>
    </edge>
    <edge source="PLASMA CELLS" target="CD70">
      <data key="d4">8.0</data>
      <data key="d5">CD70:CD27 interactions promote the differentiation of B cells into plasma cells</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="HISTAMINE" target="HYDROCORTISONE">
      <data key="d4">14.0</data>
      <data key="d5">HC-NPs suppressed inflammatory cascades including histamine release</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="EASI" target="AD">
      <data key="d4">120.0</data>
      <data key="d5">The Eczema Area Severity Index (EASI) is a clinical tool used to assess the severity of atopic dermatitis (AD). It is specifically designed to measure the extent and severity of eczema in patients with AD. The EASI score provides a standardized method for evaluating disease severity, making it a valuable instrument in both clinical practice and research settings.</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d,100dd7646c10899301b3c0631183da16,143d2dc302af5606656797bff162e23e,28f548554737fcc026b968db6bbafa30,2cec06c4d46f5ff9ee936a78d8b077cd,3287c502f10f4651d2f56bf39ee7bb7a,3ea70e257330c812b52334ca1f90d807,475995d7d211bbfde6d8ba52f324d688,8246ea974dfb00cb5e3d984004e21a9e,849e0980ffd6a7e1cf0b8d3d1fbacd98,89dbac0da39e4de2b602052cd792b90d,b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="EASI" target="IL-22">
      <data key="d4">16.0</data>
      <data key="d5">IL-22 serum levels correlate with the EASI score</data>
      <data key="d6">dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="EASI" target="EASI75">
      <data key="d4">9.0</data>
      <data key="d5">EASI75 represents a 75% improvement in EASI from baseline</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="EASI" target="EASI90">
      <data key="d4">9.0</data>
      <data key="d5">EASI90 represents a 90% improvement in EASI from baseline</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="EASI" target="PP-NRS-11">
      <data key="d4">6.0</data>
      <data key="d5">PP-NRS-11 correlates weakly with EASI</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="EASI" target="SKIN LESIONS">
      <data key="d4">8.0</data>
      <data key="d5">Skin lesions are measured by EASI in atopic dermatitis</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="EASI" target="KHK4083">
      <data key="d4">8.0</data>
      <data key="d5">KHK4083 resulted in a 74% reduction in the EASI score in a phase Ib trial</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="IL-31" target="T-HELPER (TH)2 CELLS">
      <data key="d4">18.0</data>
      <data key="d5">Th2 cells produce IL-31</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="IL-31" target="GBR 830">
      <data key="d4">16.0</data>
      <data key="d5">GBR 830 treatment reduces IL-31 mRNA levels</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="IL-31" target="AD">
      <data key="d4">48.0</data>
      <data key="d5">IL-31 is a cytokine that plays a significant role in the inflammatory response and immune regulation in atopic dermatitis (AD). It is a key cytokine involved in the pathophysiology of AD and is closely associated with the sensation of itch, which is a prominent symptom of the disease. Additionally, IL-31 levels correlate with disease severity in atopic dermatitis, indicating its potential as a biomarker for monitoring the progression and intensity of the condition.</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b,849e0980ffd6a7e1cf0b8d3d1fbacd98,a867a1e73cef039eb3f28e072463b838,b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="IL-31" target="DENDRITIC CELL">
      <data key="d4">7.0</data>
      <data key="d5">IL-31 is produced by mature dendritic cells</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="IL-31" target="TH2 CELLS">
      <data key="d4">24.0</data>
      <data key="d5">IL-31 is produced by TH2 cells.</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="IL-31" target="DENDRITIC CELLS">
      <data key="d4">8.0</data>
      <data key="d5">IL-31 is produced by mature dendritic cells</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="IL-31" target="FLG">
      <data key="d4">7.0</data>
      <data key="d5">IL-31 reduces FLG expression</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="IL-4R&#913;" target="AD">
      <data key="d4">9.0</data>
      <data key="d5">IL-4R&#945; is important in the pathobiology of atopic dermatitis</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0</data>
    </edge>
    <edge source="IL-4R&#913;" target="JAK/STAT PATHWAY">
      <data key="d4">16.0</data>
      <data key="d5">IL-4R&#945; is involved in the JAK/STAT signaling pathway</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0</data>
    </edge>
    <edge source="IL-4R&#913;" target="IL-2R&#915;">
      <data key="d4">7.0</data>
      <data key="d5">IL-4R&#945; is part of the type I receptor with IL-2R&#947;</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="IL-4R&#913;" target="IL-13R&#913;1">
      <data key="d4">21.0</data>
      <data key="d5">IL-4R&#945; and IL-13R&#945;1 heterodimerize to mediate signal transduction. IL-4R&#945; is part of the type II receptor with IL-13R&#945;1.</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41,78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="IL-4R&#913;" target="CBP-201">
      <data key="d4">8.0</data>
      <data key="d5">CBP-201 is an IL-4R&#945; antagonist</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="IL-4R&#913;" target="AK120">
      <data key="d4">7.0</data>
      <data key="d5">AK120 is an antibody directed against IL-4R&#945;</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="IL-4R&#913;" target="TYPE I RECEPTOR">
      <data key="d4">7.0</data>
      <data key="d5">IL-4R&#945; is part of the type I receptor</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="IL-4R&#913;" target="TYPE II RECEPTOR">
      <data key="d4">7.0</data>
      <data key="d5">IL-4R&#945; is part of the type II receptor</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="TH2 CELLS" target="GITR">
      <data key="d4">7.0</data>
      <data key="d5">Th2 cells are responsive to GITR stimulation</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="TH1 CELLS" target="GITR">
      <data key="d4">7.0</data>
      <data key="d5">Th1 cells are not responsive to GITR stimulation</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="EPIDERMIS" target="AD">
      <data key="d4">9.0</data>
      <data key="d5">The epidermis is affected by atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="EPIDERMIS" target="TH2 CELL">
      <data key="d4">8.0</data>
      <data key="d5">TH2 cells are an important component of the epidermal infiltrates in atopic dermatitis</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="EPIDERMIS" target="TAC">
      <data key="d4">7.0</data>
      <data key="d5">Higher TAC levels were observed in the epidermis with PLG-based nanoparticles</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="EPIDERMAL BARRIER" target="AD">
      <data key="d4">34.0</data>
      <data key="d5">The epidermal barrier plays a crucial role in the context of atopic dermatitis (AD). Epidermal barrier disruption significantly contributes to the pathogenesis of atopic dermatitis. This dysfunction is a hallmark characteristic of the disease, indicating that the epidermal barrier is consistently compromised in individuals suffering from atopic dermatitis.</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d,143d2dc302af5606656797bff162e23e,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="IL-22" target="AD">
      <data key="d4">65.0</data>
      <data key="d5">IL-22 is a cytokine that plays a significant role in the inflammatory response and immune mechanisms associated with atopic dermatitis (AD). It is involved in the pathogenesis and pathophysiology of chronic atopic dermatitis lesions, contributing to the overall inflammatory and immune response observed in AD.</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98,a867a1e73cef039eb3f28e072463b838,b19f42c9497f71b231222cd953036d6b,b876251511f570468eb5b6ee6a239cc6,dc905ba8b6eb7d84cf2776303211010d,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="IL-22" target="SCORAD">
      <data key="d4">16.0</data>
      <data key="d5">IL-22 serum levels correlate with the SCORAD score</data>
      <data key="d6">dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="IL-22" target="FEZAKINUMAB">
      <data key="d4">24.0</data>
      <data key="d5">Fezakinumab is an anti-IL-22 antibody that has been investigated for the treatment of atopic dermatitis (AD). It functions by targeting and downregulating IL-22, a cytokine implicated in the pathogenesis of moderate-to-severe atopic dermatitis. By inhibiting IL-22, Fezakinumab aims to alleviate the symptoms associated with this chronic inflammatory skin condition.</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,2cec06c4d46f5ff9ee936a78d8b077cd,48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-22" target="KERATINOCYTE">
      <data key="d4">7.0</data>
      <data key="d5">IL-22 inhibits keratinocyte differentiation</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="IL-22" target="IL-22R">
      <data key="d4">9.0</data>
      <data key="d5">IL-22 binds to its receptor IL-22R</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-22" target="IL-22R1">
      <data key="d4">9.0</data>
      <data key="d5">IL-22R1 binds IL-22 and forms a receptor complex</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-22" target="STAPHYLOCOCCAL EXOTOXINS">
      <data key="d4">8.0</data>
      <data key="d5">Staphylococcal exotoxins induce IL-22 production</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-22" target="FLG">
      <data key="d4">15.0</data>
      <data key="d5">IL-22 is known to downregulate FLG in keratinocytes, effectively reducing FLG expression.</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd,41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="GBR 830">
      <data key="d4">34.0</data>
      <data key="d5">GBR 830 is being investigated for the treatment of atopic dermatitis (AD). In a phase IIa trial, GBR 830 showed promising results for this condition.</data>
      <data key="d6">4842292208575bd45b2b5998513dd087,6309eeea565f06479830cec32938abc9</data>
    </edge>
    <edge source="AD" target="SERUM">
      <data key="d4">38.0</data>
      <data key="d5">Atopic Dermatitis (AD) and Serum are closely linked in the context of biomarker research. Serum biomarkers are notably increased in individuals with moderate-to-severe atopic dermatitis. These biomarkers are not only elevated but also serve a critical role in predicting therapeutic responses in AD patients. To further understand the disease, serum samples are collected from AD patients to analyze their proteomic profiles. This comprehensive approach helps in identifying specific biomarkers that can be used for both diagnostic and prognostic purposes in the management of atopic dermatitis.</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0,475995d7d211bbfde6d8ba52f324d688,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="HEAD AND NECK">
      <data key="d4">14.0</data>
      <data key="d5">Head and neck regions were specifically evaluated for EASI score improvements in AD patients</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="AD" target="NRS">
      <data key="d4">30.0</data>
      <data key="d5">Atopic Dermatitis (AD) and Numeric Rating Scale (NRS) are closely related in the context of measuring pruritus. The Numeric Rating Scale (NRS) is a tool used to quantify the severity of pruritus, or itching, in patients with Atopic Dermatitis (AD). This scale provides a standardized method for assessing the intensity of pruritus, which is a common and significant symptom in individuals suffering from AD. By using the NRS, healthcare providers can better evaluate the severity of pruritus and monitor the effectiveness of treatments in managing this symptom in AD patients.</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30,475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="AD" target="EASI75">
      <data key="d4">16.0</data>
      <data key="d5">EASI75 is a measure indicating a 75% improvement in the Eczema Area and Severity Index score</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="AD" target="EASI SCORE">
      <data key="d4">8.0</data>
      <data key="d5">EASI score is a measure used to assess the severity of atopic dermatitis</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="AD" target="PRURITUS NRS SCORE">
      <data key="d4">7.0</data>
      <data key="d5">Pruritus NRS score is a measure used to assess the severity of itching in atopic dermatitis patients</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="AD" target="SKIN BIOPSY">
      <data key="d4">8.0</data>
      <data key="d5">Skin biopsy specimens were collected to analyze the effects of rocatinlimab on gene and protein expression</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="AD" target="SERUM SAMPLES">
      <data key="d4">8.0</data>
      <data key="d5">Serum samples were collected to analyze the effects of rocatinlimab on protein expression</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="AD" target="HEAD AND NECK EASI SCORE">
      <data key="d4">1.0</data>
      <data key="d5">Head and neck EASI score is a measure used to assess the severity of atopic dermatitis in the head and neck regions</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="AD" target="VIGA">
      <data key="d4">28.0</data>
      <data key="d5">The validated Investigator Global Assessment (vIGA) is a tool used to evaluate and assess the severity of atopic dermatitis (AD). This assessment method is crucial for determining the extent and intensity of the condition, thereby aiding in the management and treatment of patients with AD.</data>
      <data key="d6">143d2dc302af5606656797bff162e23e,b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="AD" target="SCORAD">
      <data key="d4">48.0</data>
      <data key="d5">AD, or atopic dermatitis, is a chronic inflammatory skin condition characterized by itchy, red, and swollen skin. SCORAD, which stands for Scoring of Atopic Dermatitis, is a clinical tool specifically designed to assess the severity of AD. It evaluates both the intensity and extent of the condition, providing a comprehensive measure of disease severity. This tool is widely used in clinical settings to monitor the progression of atopic dermatitis and to guide treatment decisions.</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d,143d2dc302af5606656797bff162e23e,28f548554737fcc026b968db6bbafa30,2cec06c4d46f5ff9ee936a78d8b077cd,b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="AD" target="PLACEBO">
      <data key="d4">12.0</data>
      <data key="d5">Placebo was used as a control in the clinical trials for atopic dermatitis</data>
      <data key="d6">b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="AD" target="EASI-75">
      <data key="d4">2.0</data>
      <data key="d5">EASI-75 is a measure used to assess improvement in atopic dermatitis</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="AD" target="TH2 CELL">
      <data key="d4">18.0</data>
      <data key="d5">TH2 cells are a numerically important component of the dermal and epidermal infiltrates in atopic dermatitis (AD). They are excessively activated in AD, contributing significantly to the pathophysiology of the disease.</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9,442e7fad2fab75fa2449309783294d89,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="ILC2">
      <data key="d4">8.0</data>
      <data key="d5">ILC2 cells are excessively activated in atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="IL-5">
      <data key="d4">40.0</data>
      <data key="d5">Atopic Dermatitis (AD) and Interleukin-5 (IL-5) are closely linked in the context of immune response and inflammation. IL-5 is a Th2 cytokine that plays a pivotal role in AD. It is a key cytokine involved in the pathophysiology of atopic dermatitis, contributing significantly to the inflammatory response. IL-5's involvement in AD includes mediating the immune response and driving the inflammation characteristic of this condition.</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198,a867a1e73cef039eb3f28e072463b838,b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="IFN-&#915;">
      <data key="d4">32.0</data>
      <data key="d5">AD (Atopic Dermatitis) and IFN-&#947; (Interferon-gamma) are closely linked in the context of immune response and inflammation. IFN-&#947; is a cytokine that plays a significant role in the immune response and inflammation associated with AD. It is particularly involved in the pathophysiology of chronic atopic dermatitis lesions, contributing to the disease's persistence and severity.</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198,b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="K16">
      <data key="d4">15.0</data>
      <data key="d5">Keratin 16 (K16) is involved in the immune response in atopic dermatitis (AD). Specifically, K16 is increased in atopic dermatitis lesions, indicating its role in the pathophysiology of this autoimmune condition.</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="KI67">
      <data key="d4">22.0</data>
      <data key="d5">Ki67 is a protein that plays a crucial role in cell proliferation and is notably increased in atopic dermatitis (AD) lesions. In the context of AD, Ki67 is involved in the immune response, indicating its significant role in the pathophysiology of this autoimmune condition.</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="PERIPLAKIN">
      <data key="d4">7.0</data>
      <data key="d5">Periplakin is suppressed in chronic atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="T CELL">
      <data key="d4">8.0</data>
      <data key="d5">T cells are involved in the pathophysiology of atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="DC">
      <data key="d4">8.0</data>
      <data key="d5">Dendritic cells are involved in the pathophysiology of atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="MYELOID CELL">
      <data key="d4">8.0</data>
      <data key="d5">Myeloid cells are involved in the pathophysiology of atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="SPONGIOSIS">
      <data key="d4">7.0</data>
      <data key="d5">Spongiosis is seen in atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="EPIDERMAL THICKNESS">
      <data key="d4">14.0</data>
      <data key="d5">Epidermal thickness is increased in atopic dermatitis lesions</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="EPIDERMAL HYPERPLASIA">
      <data key="d4">14.0</data>
      <data key="d5">Epidermal hyperplasia is seen in atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="ITCH">
      <data key="d4">18.0</data>
      <data key="d5">Atopic Dermatitis (AD) is characterized by itch, which is a common and key symptom of the condition.</data>
      <data key="d6">143d2dc302af5606656797bff162e23e,3ce96e927d65736b305f792977fed4b9,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="LESION">
      <data key="d4">9.0</data>
      <data key="d5">Lesions are areas of damaged skin in atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="CHRONIC LESION">
      <data key="d4">16.0</data>
      <data key="d5">Chronic lesions are characterized by increased inflammation in atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="ACUTE LESION">
      <data key="d4">16.0</data>
      <data key="d5">Acute lesions are characterized by significant increases in type 2 and type 22 cytokines in atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="BIOMARKER">
      <data key="d4">16.0</data>
      <data key="d5">Biomarkers are indicators of atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="HISTOLOGIC PROFILING">
      <data key="d4">14.0</data>
      <data key="d5">Histologic profiling is used to study tissue structure in atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="TYPE 2 PATHWAY">
      <data key="d4">27.0</data>
      <data key="d5">The type 2 pathway is involved in the pathophysiology of atopic dermatitis (AD). It plays a crucial role in the immune response associated with AD, contributing to the disease's development and progression.</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="TYPE 22 PATHWAY">
      <data key="d4">24.0</data>
      <data key="d5">The type 22 pathway is involved in the immune response in atopic dermatitis (AD). Specifically, it plays a significant role in chronic atopic dermatitis, contributing to the pathophysiology of this condition.</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="TYPE 1 PATHWAY">
      <data key="d4">24.0</data>
      <data key="d5">The type 1 pathway is involved in the immune response in atopic dermatitis (AD). Specifically, it plays a significant role in chronic atopic dermatitis, contributing to the underlying immune mechanisms that drive the disease.</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="TYPE 17 PATHWAY">
      <data key="d4">24.0</data>
      <data key="d5">The type 17 pathway is involved in atopic dermatitis (AD). It plays a crucial role in the immune response associated with AD, contributing to the pathophysiology of this autoimmune disease.</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="TYPE 9 PATHWAY">
      <data key="d4">2.0</data>
      <data key="d5">The type 9 pathway is involved in atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="IL-9">
      <data key="d4">8.0</data>
      <data key="d5">IL-9 is involved in the pathophysiology of atopic dermatitis, particularly in pediatric cases</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="CORTICOSTEROIDS">
      <data key="d4">22.0</data>
      <data key="d5">Corticosteroids are used in the treatment of AD (Atopic Dermatitis).</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd,48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="AD" target="TCS">
      <data key="d4">28.0</data>
      <data key="d5">Topical corticosteroids (TCS) are commonly used in combination therapy for the treatment of atopic dermatitis (AD). Studies have shown that TCS is effective when used as part of a combination therapy regimen for managing AD, highlighting its importance in therapeutic strategies for this autoimmune condition.</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30,96e553a44a27e728c27c4892045ec5c2</data>
    </edge>
    <edge source="AD" target="CYTOKINES">
      <data key="d4">14.0</data>
      <data key="d5">AD is characterized by dysfunction in multiple immune pathways involving cytokines</data>
      <data key="d6">96e553a44a27e728c27c4892045ec5c2</data>
    </edge>
    <edge source="AD" target="CYTOKINE RECEPTORS">
      <data key="d4">2.0</data>
      <data key="d5">AD involves dysfunction in pathways mediated by cytokine receptors</data>
      <data key="d6">96e553a44a27e728c27c4892045ec5c2</data>
    </edge>
    <edge source="AD" target="TYPE 1 IMMUNE PATHWAY">
      <data key="d4">7.0</data>
      <data key="d5">AD involves dysfunction in the type 1 immune pathway</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="AD" target="TYPE 2 IMMUNE PATHWAY">
      <data key="d4">7.0</data>
      <data key="d5">AD involves dysfunction in the type 2 immune pathway</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="AD" target="TYPE 17 IMMUNE PATHWAY">
      <data key="d4">7.0</data>
      <data key="d5">AD involves dysfunction in the type 17 immune pathway</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="AD" target="TYPE 22 IMMUNE PATHWAY">
      <data key="d4">7.0</data>
      <data key="d5">AD involves dysfunction in the type 22 immune pathway</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="AD" target="INTRINSIC AD">
      <data key="d4">6.0</data>
      <data key="d5">Intrinsic AD is a subtype of atopic dermatitis</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="AD" target="EXTRINSIC AD">
      <data key="d4">6.0</data>
      <data key="d5">Extrinsic AD is a subtype of atopic dermatitis</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="AD" target="ADULT AD">
      <data key="d4">6.0</data>
      <data key="d5">Adult AD is a subtype of atopic dermatitis</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="AD" target="PAEDIATRIC AD">
      <data key="d4">6.0</data>
      <data key="d5">Paediatric AD is a subtype of atopic dermatitis</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="AD" target="ETHNIC ORIGIN AD">
      <data key="d4">6.0</data>
      <data key="d5">Ethnic origin AD is a subtype of atopic dermatitis</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="AD" target="ENDOTYPES">
      <data key="d4">7.0</data>
      <data key="d5">Endotypes are subsets of AD patients with common underlying mechanisms</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="AD" target="CCL5">
      <data key="d4">10.0</data>
      <data key="d5">CCL5 is a chemokine involved in the immune response and inflammation in AD.</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198,b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="CCL13">
      <data key="d4">8.0</data>
      <data key="d5">CCL13 is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="IL-32">
      <data key="d4">8.0</data>
      <data key="d5">IL-32 is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="MX1">
      <data key="d4">8.0</data>
      <data key="d5">MX1 is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="CXCL9">
      <data key="d4">8.0</data>
      <data key="d5">CXCL9 is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="IL-23P19">
      <data key="d4">8.0</data>
      <data key="d5">IL-23p19 is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="IL-23P40">
      <data key="d4">8.0</data>
      <data key="d5">IL-23p40 is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="T CELLS">
      <data key="d4">9.0</data>
      <data key="d5">T cells are involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="ILC2S">
      <data key="d4">16.0</data>
      <data key="d5">AD (Atopic Dermatitis) and ILC2s (Type 2 Innate Lymphoid Cells) are closely linked in the context of immune response and inflammation. ILC2s play a significant role in the immune response in AD, contributing to the inflammatory processes associated with the disease. These cells are integral to the pathophysiology of AD, highlighting their importance in both the immune response and the broader inflammatory mechanisms underlying this condition.</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198,b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="DCS">
      <data key="d4">9.0</data>
      <data key="d5">DCs are involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="IDECS">
      <data key="d4">8.0</data>
      <data key="d5">IDECs are involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="INVOLUCRIN">
      <data key="d4">8.0</data>
      <data key="d5">Involucrin is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="PPL">
      <data key="d4">8.0</data>
      <data key="d5">PPL is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="IVL">
      <data key="d4">8.0</data>
      <data key="d5">IVL is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="ELAFIN">
      <data key="d4">8.0</data>
      <data key="d5">Elafin is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="TCI">
      <data key="d4">14.0</data>
      <data key="d5">TCI is used as rescue therapy in combination therapy for atopic dermatitis</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="AD" target="IGA">
      <data key="d4">23.0</data>
      <data key="d5">IGA, or the Investigator's Global Assessment, is a measure of disease severity in atopic dermatitis (AD). It is used to evaluate and quantify the severity of atopic dermatitis, providing a standardized method for assessing the condition's impact on patients.</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="AD" target="VAS">
      <data key="d4">16.0</data>
      <data key="d5">VAS is used to measure pruritus in atopic dermatitis</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="AD" target="BSA">
      <data key="d4">2.0</data>
      <data key="d5">BSA is used to measure the extent of atopic dermatitis</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="AD" target="TOPICAL CALCINEURIN INHIBITOR">
      <data key="d4">8.0</data>
      <data key="d5">Topical calcineurin inhibitors are used to treat atopic dermatitis</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="AD" target="NCT02300701">
      <data key="d4">8.0</data>
      <data key="d5">NCT02300701 is a study focused on severe recalcitrant atopic eczema</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0</data>
    </edge>
    <edge source="AD" target="IL-13R&#913;1">
      <data key="d4">8.0</data>
      <data key="d5">IL-13R&#945;1 is involved in the signaling pathways of atopic dermatitis</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0</data>
    </edge>
    <edge source="AD" target="IMMUNE RESPONSE">
      <data key="d4">27.0</data>
      <data key="d5">The immune response is a critical pathway in the pathogenesis and treatment of Atopic Dermatitis (AD). It is intricately involved in the pathophysiology of AD, highlighting its central role in both the development and management of this condition.</data>
      <data key="d6">143d2dc302af5606656797bff162e23e,90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="INFLAMMATORY RESPONSE">
      <data key="d4">9.0</data>
      <data key="d5">The inflammatory response is involved in the pathophysiology of atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="LANGERHANS CELLS">
      <data key="d4">8.0</data>
      <data key="d5">Langerhans cells are defective in atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="STAPHYLOCOCCUS AUREUS">
      <data key="d4">7.0</data>
      <data key="d5">Staphylococcus aureus may trigger atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="KERATINOCYTE">
      <data key="d4">8.0</data>
      <data key="d5">Keratinocyte damage contributes to barrier dysfunction in atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="DENDRITIC CELLS">
      <data key="d4">16.0</data>
      <data key="d5">Dendritic cells play a crucial role in the pathogenesis of atopic dermatitis (AD). They are involved in the immune response and inflammation associated with AD. Specifically, dendritic cells activate the adaptive immune response in atopic dermatitis, highlighting their importance in the disease's immunological landscape.</data>
      <data key="d6">143d2dc302af5606656797bff162e23e,41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="ERYTHEMA">
      <data key="d4">16.0</data>
      <data key="d5">Erythema is a clinical sign of atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="OEDEMA">
      <data key="d4">16.0</data>
      <data key="d5">Oedema is a clinical sign of atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="INDURATION">
      <data key="d4">16.0</data>
      <data key="d5">Induration is a clinical sign of atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="PAPULATION">
      <data key="d4">16.0</data>
      <data key="d5">Papulation is a clinical sign of atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="EXCORIATION">
      <data key="d4">16.0</data>
      <data key="d5">Excoriation is a clinical sign of atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="LICHENIFICATION">
      <data key="d4">16.0</data>
      <data key="d5">Lichenification is a clinical sign of atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="OOZING">
      <data key="d4">16.0</data>
      <data key="d5">Oozing is a clinical sign of atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="DRYNESS">
      <data key="d4">16.0</data>
      <data key="d5">Dryness is a clinical sign of atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="SLEEPLESSNESS">
      <data key="d4">14.0</data>
      <data key="d5">Sleeplessness is a symptom of atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="QUALITY OF LIFE">
      <data key="d4">23.0</data>
      <data key="d5">Atopic Dermatitis (AD) is a chronic inflammatory skin condition that significantly impacts patients' quality of life. Better management of AD aims to improve the quality of life for those affected, as the condition can lead to discomfort, itching, and other symptoms that interfere with daily activities and overall well-being. Therefore, effective treatment strategies are essential to alleviate the burden of AD and enhance the quality of life for patients.</data>
      <data key="d6">143d2dc302af5606656797bff162e23e,e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="DISEASE CONTROL">
      <data key="d4">16.0</data>
      <data key="d5">Disease control is a key aspect in the management of atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="EPIGENETIC">
      <data key="d4">7.0</data>
      <data key="d5">Epigenetic mechanisms may play a role in the pathophysiology of atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="ADAPTIVE IMMUNE SYSTEM">
      <data key="d4">8.0</data>
      <data key="d5">The adaptive immune system is involved in the pathophysiology of atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="TH2 RESPONSE">
      <data key="d4">9.0</data>
      <data key="d5">TH2 response plays a key role in atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="TH17 RESPONSE">
      <data key="d4">7.0</data>
      <data key="d5">TH17 response is implicated in atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="TH22 RESPONSE">
      <data key="d4">7.0</data>
      <data key="d5">TH22 response is implicated in atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="NEURO-IMMUNOLOGICAL">
      <data key="d4">7.0</data>
      <data key="d5">Neuro-immunological mechanisms are relevant in atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="KERATINOCYTE DAMAGE">
      <data key="d4">8.0</data>
      <data key="d5">Keratinocyte damage contributes to barrier dysfunction in atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="DENDRITIC CELL ACTIVATION">
      <data key="d4">8.0</data>
      <data key="d5">Dendritic cell activation plays a role in the immune response in atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="B244">
      <data key="d4">8.0</data>
      <data key="d5">B244 is in clinical development for treating AD</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="AD" target="S. AUREUS">
      <data key="d4">24.0</data>
      <data key="d5">Atopic Dermatitis (AD) and Staphylococcus aureus (S. aureus) are closely linked in the context of immune system interactions and inflammatory responses. High colonization with S. aureus significantly impacts the immune system and exacerbates the inflammatory reaction in patients with AD. S. aureus is frequently found on the skin of individuals suffering from AD, where it contributes to the severity and persistence of the disease. This relationship underscores the importance of managing S. aureus colonization in the treatment and understanding of AD.</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807,41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="PETROLATUM">
      <data key="d4">6.0</data>
      <data key="d5">Petrolatum modulates antimicrobial and epidermal barrier function in AD</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="AD" target="AHR">
      <data key="d4">23.0</data>
      <data key="d5">Aryl hydrocarbon receptor (AhR) is involved in the pathophysiology of atopic dermatitis (AD). AhR plays a dual role in the development of skin inflammation, including AD.</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807,6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="AD" target="TAPINAROF">
      <data key="d4">16.0</data>
      <data key="d5">Tapinarof is known to decrease inflammatory reactions and reduce inflammatory responses in Atopic Dermatitis (AD).</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="AD" target="SPINK5">
      <data key="d4">7.0</data>
      <data key="d5">Mutations in SPINK5 favor inflammation in AD</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="AD" target="TEZEPELUMAB">
      <data key="d4">28.0</data>
      <data key="d5">Tezepelumab, an investigational drug, has demonstrated promising results in the treatment of atopic dermatitis (AD). Specifically, Tezepelumab was tested in a phase IIa clinical trial for AD, where it showed significant efficacy.</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807,6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="AD" target="EASI50">
      <data key="d4">1.0</data>
      <data key="d5">EASI50 is a clinical endpoint in AD studies</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="AD" target="EPIDERMAL BARRIER FUNCTION">
      <data key="d4">8.0</data>
      <data key="d5">Epidermal barrier function is disturbed in AD</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="AD" target="EMOLLIENTS">
      <data key="d4">7.0</data>
      <data key="d5">Emollients are used to improve barrier function in AD</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="AD" target="MOISTURIZERS">
      <data key="d4">7.0</data>
      <data key="d5">Moisturizers are used to improve barrier function in AD</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="AD" target="ETOKIMAB">
      <data key="d4">35.0</data>
      <data key="d5">Etokimab is a drug that has been investigated for the treatment of Atopic Dermatitis (AD). In a proof-of-concept study, Etokimab showed improvement in patients with AD, indicating potential efficacy. However, in a subsequent phase IIb clinical trial, Etokimab failed to meet the primary endpoint, suggesting that the initial promising results were not replicated in a larger, more rigorous study. Despite the initial positive findings, the phase IIb results highlight the challenges in developing effective treatments for AD.</data>
      <data key="d6">6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98,90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="BERMEKIMAB">
      <data key="d4">21.0</data>
      <data key="d5">Bermekimab, an investigational drug, has shown promising efficacy in a phase IIa study for atopic dermatitis (AD). Additionally, Bermekimab was tested in phase-II trials for AD, further supporting its potential as a therapeutic option for this autoimmune condition.</data>
      <data key="d6">6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="AD" target="KHK4083">
      <data key="d4">16.0</data>
      <data key="d5">KHK4083 showed promising results in a phase Ib trial for atopic dermatitis</data>
      <data key="d6">6309eeea565f06479830cec32938abc9</data>
    </edge>
    <edge source="AD" target="KY1005">
      <data key="d4">16.0</data>
      <data key="d5">KY1005 is a drug that completed phase 2a clinical trials for Atopic Dermatitis (AD). In these trials, KY1005 showed interesting results, indicating its potential efficacy in treating this autoimmune condition.</data>
      <data key="d6">6309eeea565f06479830cec32938abc9,90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="EOSINOPHILS">
      <data key="d4">22.0</data>
      <data key="d5">Eosinophils are involved in the immune response and inflammation in atopic dermatitis (AD). They play a significant role in the inflammatory infiltrate characteristic of AD, contributing to the overall pathology of the disease.</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41,41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="RHIL-2">
      <data key="d4">7.0</data>
      <data key="d5">Recombinant human IL-2 (rhIL-2) is being tested for its potential to restore tolerance and improve atopic dermatitis</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="AD" target="PDE4">
      <data key="d4">8.0</data>
      <data key="d5">Increased PDE4 activity is a target for the therapy of allergic disorders including atopic dermatitis</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="AD" target="LOTAMILAST">
      <data key="d4">7.0</data>
      <data key="d5">Lotamilast is in development for the treatment of atopic dermatitis</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="AD" target="DIFAMILAST">
      <data key="d4">7.0</data>
      <data key="d5">Difamilast is in development for the treatment of atopic dermatitis</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="AD" target="ROFLUMILAST">
      <data key="d4">6.0</data>
      <data key="d5">Roflumilast is tested for the treatment of atopic dermatitis</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="AD" target="HISTAMINE H4 RECEPTOR">
      <data key="d4">8.0</data>
      <data key="d5">Histamine H4 receptor (H4R) is a target for immunomodulation in inflammatory skin disorders including atopic dermatitis</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="AD" target="AKP-11">
      <data key="d4">7.0</data>
      <data key="d5">AKP-11 is in clinical development for AD</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="AD" target="BREPOCITINIB">
      <data key="d4">14.0</data>
      <data key="d5">Brepocitinib is in clinical development for treating atopic dermatitis</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="AD" target="JAKTINIB">
      <data key="d4">14.0</data>
      <data key="d5">Jaktinib is in clinical development for treating atopic dermatitis</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="AD" target="ATI-1777">
      <data key="d4">14.0</data>
      <data key="d5">ATI-1777 is in clinical development for treating atopic dermatitis</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="AD" target="CEE321">
      <data key="d4">14.0</data>
      <data key="d5">CEE321 is in clinical development for treating atopic dermatitis</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="AD" target="SHR0302">
      <data key="d4">21.0</data>
      <data key="d5">SHR0302 is in clinical development for treating atopic dermatitis (AD).</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838,c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="AD" target="BEN2293">
      <data key="d4">15.0</data>
      <data key="d5">BEN2293 is in development for the treatment of atopic dermatitis (AD). It is currently being tested in a phase I/II study to evaluate its efficacy and safety for this condition.</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d,a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="AD" target="TAUREOXYCHOLIC ACID">
      <data key="d4">6.0</data>
      <data key="d5">Taureoxycholic acid is used in an animal model of atopic dermatitis</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="AD" target="JAKI">
      <data key="d4">32.0</data>
      <data key="d5">JAK inhibitors (JAKI) are small molecules that have demonstrated efficacy in the treatment of Atopic Dermatitis (AD). They are particularly noted for providing rapid relief from pruritus and inflammation associated with AD.</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d,90f4809673ca34628b0e607908f0bf0b,a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="AD" target="HY209">
      <data key="d4">7.0</data>
      <data key="d5">HY209 reduced TH2 inflammation in an animal model of atopic dermatitis</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="AD" target="LXR&#913;">
      <data key="d4">8.0</data>
      <data key="d5">LXR&#945; is involved in the regulation of epidermal barrier function and skin inflammation in atopic dermatitis</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="AD" target="LXR&#914;">
      <data key="d4">8.0</data>
      <data key="d5">LXR&#946; is involved in the regulation of epidermal barrier function and skin inflammation in atopic dermatitis</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="AD" target="VTP-38543">
      <data key="d4">7.0</data>
      <data key="d5">VTP-38543 is being tested in a phase I/II study for atopic dermatitis</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="AD" target="ALX 101">
      <data key="d4">7.0</data>
      <data key="d5">ALX 101 is being tested in a phase IIb study for atopic dermatitis</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="AD" target="ASTHMA">
      <data key="d4">13.0</data>
      <data key="d5">Atopic dermatitis (AD) and asthma are closely related conditions, often co-occurring in patients. Asthma is an atopic comorbidity of atopic dermatitis, meaning that individuals with AD are more likely to also suffer from asthma. This relationship is evident as some patients with AD also have asthma, highlighting the interconnected nature of these atopic diseases.</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d,89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="AD" target="ANXIETY">
      <data key="d4">7.0</data>
      <data key="d5">Anxiety is a neuropsychiatric comorbidity of atopic dermatitis</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="AD" target="DEPRESSION">
      <data key="d4">7.0</data>
      <data key="d5">Depression is a neuropsychiatric comorbidity of atopic dermatitis</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="AD" target="CARDIOVASCULAR DISORDERS">
      <data key="d4">7.0</data>
      <data key="d5">Cardiovascular disorders are non-atopic comorbidities of atopic dermatitis</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="AD" target="MICROBIOME">
      <data key="d4">15.0</data>
      <data key="d5">The microbiome, encompassing both skin and gut microbiomes, plays a significant role in the pathogenesis and treatment of Atopic Dermatitis (AD). Microbiome-derived signals contribute to the development and progression of AD, highlighting the importance of microbial communities in influencing the disease's clinical outcomes. Understanding the interactions between the microbiome and host immune responses is crucial for developing targeted therapies for AD.</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d,90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="TAPE-STRIP">
      <data key="d4">1.0</data>
      <data key="d5">Tape-strip specimens are used to study atopic dermatitis</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="AD" target="GUT MICROBIOME">
      <data key="d4">16.0</data>
      <data key="d5">The gut microbiome is involved in the pathogenesis and treatment of Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="BIOLOGICS">
      <data key="d4">23.0</data>
      <data key="d5">Biologics are drugs with a slow but pathway-specific mode of action used for long-term control and disease modification in Atopic Dermatitis (AD). However, JAK inhibitors help overcome some drawbacks of biologics in the treatment of AD.</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b,e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="EPITHELIAL EVENTS">
      <data key="d4">14.0</data>
      <data key="d5">Epithelial events are dynamic processes involved in the immune response in Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="ETRASIMOD">
      <data key="d4">14.0</data>
      <data key="d5">Etrasimod is a drug advancing into phase 3 clinical trials for Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="AOBIOME">
      <data key="d4">12.0</data>
      <data key="d5">AOBiome is a company conducting clinical trials for pruritus associated with Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="ARENA PHARMACEUTICALS">
      <data key="d4">12.0</data>
      <data key="d5">Arena Pharmaceuticals is advancing etrasimod into phase 3 clinical trials for Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="EUROPE">
      <data key="d4">7.0</data>
      <data key="d5">Europe is a region where cost-effectiveness considerations impact drug development for Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="HEALTH TECHNOLOGY ASSESSMENT AGENCIES">
      <data key="d4">7.0</data>
      <data key="d5">Health technology assessment agencies influence drug development and market access in dermatology</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="THIRD-PARTY PAYERS">
      <data key="d4">7.0</data>
      <data key="d5">Third-party payers are entities that impact drug development and patient access in dermatology</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="ATOPIC MARCH">
      <data key="d4">8.0</data>
      <data key="d5">The atopic march refers to the progression of allergic diseases, which can be impacted by early intervention in Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="COMORBIDITIES">
      <data key="d4">8.0</data>
      <data key="d5">Comorbidities are additional diseases or conditions that occur with Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="BIOREPOSITORIES">
      <data key="d4">7.0</data>
      <data key="d5">Biorepositories collect samples like microbiome, cellular, and fluid blood samples for research in Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="TAPE-STRIP SPECIMENS">
      <data key="d4">7.0</data>
      <data key="d5">Tape-strip specimens are non-invasive samples collected for research in Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="PREDICTIVE BIOMARKERS">
      <data key="d4">8.0</data>
      <data key="d5">Predictive biomarkers are used for innovative molecular taxonomy and companion diagnostics in Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="PROGNOSTIC BIOMARKERS">
      <data key="d4">8.0</data>
      <data key="d5">Prognostic biomarkers are used for predicting disease outcomes and guiding treatment in Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="DRUG TARGETS">
      <data key="d4">8.0</data>
      <data key="d5">Drug targets are specific molecules or pathways identified for therapeutic intervention in Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="THERAPEUTICS">
      <data key="d4">8.0</data>
      <data key="d5">Therapeutics are drugs or treatments developed for managing Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="TRANSLATIONAL EFFORTS">
      <data key="d4">7.0</data>
      <data key="d5">Translational efforts convert scientific knowledge into drug discovery and development for Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="PRECLINICAL DEVELOPMENT">
      <data key="d4">7.0</data>
      <data key="d5">Preclinical development involves testing new drugs in the lab before clinical trials in Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="CLINICAL DEVELOPMENT">
      <data key="d4">7.0</data>
      <data key="d5">Clinical development involves testing new drugs in human trials for Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="COMPANION DIAGNOSTICS">
      <data key="d4">8.0</data>
      <data key="d5">Companion diagnostics are tests used alongside therapeutics to guide treatment decisions in Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="MARKET ACCESS">
      <data key="d4">7.0</data>
      <data key="d5">Market access involves the process of making new drugs available to patients, influenced by cost-effectiveness considerations</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="COST-EFFECTIVENESS">
      <data key="d4">7.0</data>
      <data key="d5">Cost-effectiveness is a consideration for third-party payers when evaluating new drugs for Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="REAL-WORLD DATA">
      <data key="d4">7.0</data>
      <data key="d5">Real-world data provides evidence from actual patient experiences to support drug development in Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="PATIENT ADVOCACY">
      <data key="d4">7.0</data>
      <data key="d5">Patient advocacy involves efforts by patients to influence drug development and access in Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="PHARMACOLOGICAL INTERVENTION">
      <data key="d4">8.0</data>
      <data key="d5">Pharmacological intervention involves using drugs to treat or prevent Atopic Dermatitis and its comorbidities</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="SYSTEMIC THERAPY">
      <data key="d4">8.0</data>
      <data key="d5">Systemic therapy involves using drugs that affect the entire body to treat Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="TOPICAL THERAPY">
      <data key="d4">8.0</data>
      <data key="d5">Topical therapy involves applying drugs directly to the skin to treat Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="SEVERITY SCALES">
      <data key="d4">7.0</data>
      <data key="d5">Severity scales are used to define the severity of Atopic Dermatitis and guide treatment decisions</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="DISEASE MODIFICATION">
      <data key="d4">8.0</data>
      <data key="d5">Disease modification involves altering the course of Atopic Dermatitis to prevent progression and comorbidities</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="PHARMACEUTICAL COMPANIES">
      <data key="d4">7.0</data>
      <data key="d5">Pharmaceutical companies develop and market new drugs for Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="DRUG DISCOVERY">
      <data key="d4">7.0</data>
      <data key="d5">Drug discovery involves identifying new compounds for treating Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="FLG">
      <data key="d4">9.0</data>
      <data key="d5">Decreased levels of FLG are associated with the development and progression of AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="IL-8">
      <data key="d4">16.0</data>
      <data key="d5">IL-8 is a cytokine involved in the immune response and inflammation in ADIL-8 is involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="MIP-1&#913;">
      <data key="d4">14.0</data>
      <data key="d5">MIP-1&#945; is involved in the immune response and inflammation in ADMIP-1&#945; is a chemokine involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="MIP-1&#914;">
      <data key="d4">14.0</data>
      <data key="d5">MIP-1&#946; is involved in the immune response and inflammation in ADMIP-1&#946; is a chemokine involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="MCP-1">
      <data key="d4">14.0</data>
      <data key="d5">MCP-1 is a chemokine involved in the immune response and inflammation in ADMCP-1 is involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="KLK7">
      <data key="d4">14.0</data>
      <data key="d5">KLK7 is involved in the skin barrier function in ADKLK7 is a serine protease involved in skin barrier function in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="STAT 6">
      <data key="d4">7.0</data>
      <data key="d5">STAT 6 is a protein involved in the immune response in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="CTLA4">
      <data key="d4">25.0</data>
      <data key="d5">CTLA4 is a protein involved in the immune response in atopic dermatitis (AD). It plays a crucial role in the development of AD by modulating the immune system's activity.</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198,6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="AD" target="CCL22">
      <data key="d4">14.0</data>
      <data key="d5">CCL22 is involved in the immune response and inflammation in ADCCL22 is a chemokine involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="CCL17">
      <data key="d4">14.0</data>
      <data key="d5">CCL17 is a chemokine involved in the immune response and inflammation in ADCCL17 is involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="CCL11">
      <data key="d4">14.0</data>
      <data key="d5">CCL11 is involved in the immune response and inflammation in ADCCL11 is a chemokine involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="POLLUTION">
      <data key="d4">8.0</data>
      <data key="d5">Exposure to pollution can weaken the skin&#8217;s microbial barrier, potentially leading to AD development</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="SOAP">
      <data key="d4">8.0</data>
      <data key="d5">Excessive use of soap can weaken the skin&#8217;s microbial barrier, potentially leading to AD development</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="BASOPHILS">
      <data key="d4">8.0</data>
      <data key="d5">Basophils are involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="MAST CELLS">
      <data key="d4">8.0</data>
      <data key="d5">Mast cells are involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="MACROPHAGES">
      <data key="d4">8.0</data>
      <data key="d5">Macrophages are involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="SPINK">
      <data key="d4">7.0</data>
      <data key="d5">SPINK is involved in the skin barrier function in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="CLAUDINS">
      <data key="d4">7.0</data>
      <data key="d5">Claudins are involved in the skin barrier function in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="STAT6">
      <data key="d4">25.0</data>
      <data key="d5">STAT6 is a critical molecule involved in the immune response in atopic dermatitis (AD). It plays a significant role in the development of AD, highlighting its importance in the pathophysiology of this autoimmune disease.</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198,6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="AD" target="CTLA-4">
      <data key="d4">7.0</data>
      <data key="d5">CTLA-4 is involved in the immune response in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="MSB-01">
      <data key="d4">14.0</data>
      <data key="d5">MSB-01 is used to investigate microbiome transplantation and bacterial modulation in AD</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="AD" target="DB-001">
      <data key="d4">14.0</data>
      <data key="d5">DB-001 is used to investigate microbiome transplantation and bacterial modulation in AD</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="AD" target="ROSEMONAS MUCOSA">
      <data key="d4">12.0</data>
      <data key="d5">Rosemonas mucosa is found in greater abundance in the skin microbiome of AD patients</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="AD" target="NITROSOMONAS EUTROPHA">
      <data key="d4">14.0</data>
      <data key="d5">Nitrosomonas eutropha is used to treat AD by producing nitric oxide</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="AD" target="OMEGANAN PENTACHLORIDE">
      <data key="d4">12.0</data>
      <data key="d5">Omeganan pentachloride is undergoing clinical testing as a topical treatment for managing dysbiosis in AD</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="AD" target="EDP1815">
      <data key="d4">12.0</data>
      <data key="d5">EDP1815 is a microbiome modifier in phase I trials for AD treatment</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="AD" target="STMC-103H">
      <data key="d4">12.0</data>
      <data key="d5">STMC-103H is a microbiome modifier in phase I trials for AD treatment</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="AD" target="KBL69">
      <data key="d4">12.0</data>
      <data key="d5">KBL69 is a microbiome modifier in phase I trials for AD treatment</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="AD" target="ITCHINESS">
      <data key="d4">7.0</data>
      <data key="d5">Itchiness is a common symptom in AD</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="AD" target="ITEPEKIMAB">
      <data key="d4">7.0</data>
      <data key="d5">Itepekimab was tested in a phase II clinical trial for AD</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="AD" target="IL-37">
      <data key="d4">14.0</data>
      <data key="d5">Atopic Dermatitis (AD) and Interleukin-37 (IL-37) are closely linked in the context of inflammation and immune response. Children with AD exhibit significantly lower levels of IL-37 in their skin barrier, which suggests a potential deficiency in this anti-inflammatory cytokine. IL-37 plays a crucial role in modulating inflammation and immune responses in AD, indicating that its reduced presence may contribute to the exacerbation of inflammatory symptoms associated with the disease.</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="AD" target="FOLLICULITIS">
      <data key="d4">6.0</data>
      <data key="d5">Folliculitis is a common adverse event in AD treatment</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="AD" target="UPPER-RESPIRATORY-TRACT INFECTIONS">
      <data key="d4">6.0</data>
      <data key="d5">Upper-respiratory-tract infections are a common adverse event in AD treatment</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="AD" target="PAIN">
      <data key="d4">7.0</data>
      <data key="d5">Pain is a common symptom in AD</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="AD" target="AZATHIOPRINE">
      <data key="d4">7.0</data>
      <data key="d5">Azathioprine is used in systemic therapy for AD</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="AD" target="TOPICAL CALCINEURIN INHIBITORS">
      <data key="d4">8.0</data>
      <data key="d5">Topical calcineurin inhibitors (TCIs) are used for anti-inflammatory therapy in AD</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="AD" target="ITCHING">
      <data key="d4">9.0</data>
      <data key="d5">Itching is a common symptom of AD that treatments aim to eliminate</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="AD" target="DLQI">
      <data key="d4">8.0</data>
      <data key="d5">DLQI is used to evaluate the impact of AD on quality of life</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="PRURITUS/ITCH NUMERIC RATING SCALE">
      <data key="d4">8.0</data>
      <data key="d5">The Pruritus/Itch Numeric Rating Scale is used to evaluate the severity of itching in AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="NANOTECHNOLOGY">
      <data key="d4">7.0</data>
      <data key="d5">Nanotechnology offers a method for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="NANOPARTICLES">
      <data key="d4">8.0</data>
      <data key="d5">Nanoparticles are used in drug delivery systems for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="POLYMERIC PARTICULATES">
      <data key="d4">7.0</data>
      <data key="d5">Polymeric particulates are used as carriers in drug delivery systems for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="DENDRIMERS">
      <data key="d4">7.0</data>
      <data key="d5">Dendrimers are used as carriers in drug delivery systems for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="DENDRITIC-CORE MULTI-SHELL NANO TRANSPORTERS">
      <data key="d4">7.0</data>
      <data key="d5">Dendritic-core multi-shell nano transporters are used as carriers in drug delivery systems for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="LIPID NANOPARTICLES">
      <data key="d4">7.0</data>
      <data key="d5">Lipid nanoparticles serve as carriers in drug delivery systems for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="CHITOSAN-BASED NANOPARTICLES">
      <data key="d4">8.0</data>
      <data key="d5">Chitosan-based nanoparticles are used for drug delivery in treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="NIC-CS-NPS">
      <data key="d4">8.0</data>
      <data key="d5">NIC-CS-NPs are used for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="EAR SKIN">
      <data key="d4">7.0</data>
      <data key="d5">Ear skin thickness is measured in AD studies</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="SPLEEN INDEX">
      <data key="d4">7.0</data>
      <data key="d5">Spleen index is measured to assess immune activation in AD studies</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="HISTOPATHOLOGY">
      <data key="d4">7.0</data>
      <data key="d5">Histopathology is used to examine DNCB-induced AD skin lesions</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="HYALURONIC ACID (HA)-DECORATED TAC-LOADED NPS">
      <data key="d4">8.0</data>
      <data key="d5">Hyaluronic Acid (HA)-decorated TAC-loaded NPs are used for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="NIOSOMES">
      <data key="d4">7.0</data>
      <data key="d5">Niosomes are used for drug delivery in treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="POLYMERIC NANOPARTICLES">
      <data key="d4">7.0</data>
      <data key="d5">Polymeric nanoparticles are used for the topical administration of medicinal compounds in treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="BETAMETHASONE VALERATE (BMV)-LOADED CHITOSAN NPS">
      <data key="d4">8.0</data>
      <data key="d5">Betamethasone Valerate (BMV)-loaded chitosan NPs are used for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="PHYTOCERAMIDES">
      <data key="d4">7.0</data>
      <data key="d5">Phytoceramides are used for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="NLCS">
      <data key="d4">8.0</data>
      <data key="d5">NLCs emerged as an innovative topical treatment for AD</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="AD" target="BECLOMETHASONE DIPROPIONATE (BDP)">
      <data key="d4">8.0</data>
      <data key="d5">BDP is used as a topical medication for treating AD</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="AD" target="PLA">
      <data key="d4">7.0</data>
      <data key="d5">PLA-based NPs are used for targeted and topical SC administration in AD</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="AD" target="BALB/C MICE">
      <data key="d4">6.0</data>
      <data key="d5">BALB/c mice are used in in vivo skin irritation tests for AD</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="AD" target="ADBRY">
      <data key="d4">16.0</data>
      <data key="d5">ADBRY is approved for AD treatment</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="AD" target="OPZELURA">
      <data key="d4">16.0</data>
      <data key="d5">Opzelura is approved for AD treatment</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="AD" target="NF-&#922;B">
      <data key="d4">14.0</data>
      <data key="d5">NF-&#954;B is involved in the pathophysiology of AD</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="AD" target="IL-4R">
      <data key="d4">14.0</data>
      <data key="d5">IL-4R is involved in the pathophysiology of AD</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="AD" target="IL-13R">
      <data key="d4">14.0</data>
      <data key="d5">IL-13R is involved in the pathophysiology of AD</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="AD" target="NOS2">
      <data key="d4">14.0</data>
      <data key="d5">NOS2 is used to monitor the severity of AD</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="AD" target="INOS">
      <data key="d4">14.0</data>
      <data key="d5">iNOS is used to monitor the severity of AD</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="AD" target="BIOLOGICAL THERAPIES">
      <data key="d4">16.0</data>
      <data key="d5">Biological therapies are advanced treatments for AD</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="AD" target="NANOCARRIERS">
      <data key="d4">9.0</data>
      <data key="d5">Nanocarriers are innovative therapeutic delivery systems specifically designed for the management of autoimmune diseases (AD). These advanced delivery systems aim to enhance the efficacy and precision of treatments for AD, offering a promising approach to improve patient outcomes.</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c,e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="BIOLOGICAL PHARMACEUTICALS">
      <data key="d4">8.0</data>
      <data key="d5">Biological pharmaceuticals are used as viable options for the management of AD</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="NANOPARTICLE SYSTEMS">
      <data key="d4">7.0</data>
      <data key="d5">Nanoparticle systems are fine-tuned for AD management</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="NANOMEDICINE">
      <data key="d4">8.0</data>
      <data key="d5">Nanomedicine techniques are set to revolutionize the treatment of AD</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="BIOTHERAPEUTICS">
      <data key="d4">8.0</data>
      <data key="d5">Biotherapeutics targeting pathways implicated in AD hold huge promise</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="PATHWAYS">
      <data key="d4">1.0</data>
      <data key="d5">Pathways are implicated in the pathophysiology of AD</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="THERAPEUTIC STRATEGIES">
      <data key="d4">8.0</data>
      <data key="d5">Therapeutic strategies are tailored for the management of AD</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="PATHOPHYSIOLOGY">
      <data key="d4">8.0</data>
      <data key="d5">Understanding the pathophysiology of AD helps in developing therapeutic strategies</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="DRUG DELIVERY MECHANISMS">
      <data key="d4">7.0</data>
      <data key="d5">Advanced drug delivery mechanisms are being developed for AD</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="THERAPEUTIC TARGETS">
      <data key="d4">8.0</data>
      <data key="d5">Therapeutic targets are identified for the treatment of AD</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="PRECLINICAL RESEARCH">
      <data key="d4">7.0</data>
      <data key="d5">Preclinical research has facilitated the development of treatments for AD</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="CLINICAL RESEARCH">
      <data key="d4">8.0</data>
      <data key="d5">Clinical research has led to more treatment options for AD</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="MULTIDISCIPLINARY APPROACH">
      <data key="d4">7.0</data>
      <data key="d5">A multidisciplinary approach enhances the management of AD</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="THERAPY COMPLIANCE">
      <data key="d4">6.0</data>
      <data key="d5">Improved therapy compliance is a goal in the treatment of AD</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="SEVERE AD">
      <data key="d4">8.0</data>
      <data key="d5">New therapies have significantly advanced the management of severe AD</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="NANOTECHNOLOGY-BASED DRUG DELIVERY SYSTEMS">
      <data key="d4">1.0</data>
      <data key="d5">Nanotechnology-based drug delivery systems may significantly improve the treatment of AD</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="PBMCS">
      <data key="d4">8.0</data>
      <data key="d5">PBMCs were collected from patients with AD</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="AD" target="SOX40">
      <data key="d4">22.0</data>
      <data key="d5">AD (Atopic Dermatitis) and sOX40 (soluble OX40) are closely related in the context of autoimmune diseases. Serum levels of sOX40 are decreased in patients with AD. Additionally, sOX40 serum levels are associated with atopic comorbidities and disease activity in children with AD. Measurements of sOX40 in serum from patients with AD have been conducted to further understand this relationship.</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746,6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="AD" target="SOX40L">
      <data key="d4">13.0</data>
      <data key="d5">AD (Atopic Dermatitis) and sOX40L (soluble OX40 Ligand) have been subjects of research to understand their potential relationship. Serum levels of sOX40L were measured in patients with AD to investigate any possible differences compared to healthy controls. However, the findings indicate that there are no significant differences in the serum levels of sOX40L between patients with AD and healthy individuals.</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746,89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="AD" target="PLASMA">
      <data key="d4">8.0</data>
      <data key="d5">Plasma was collected from patients with AD</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="AD" target="ATOPIC DISEASES">
      <data key="d4">1.0</data>
      <data key="d5">Atopic dermatitis is a type of atopic disease</data>
      <data key="d6">100dd7646c10899301b3c0631183da16</data>
    </edge>
    <edge source="AD" target="SKIN THICKNESS">
      <data key="d4">7.0</data>
      <data key="d5">Skin thickness is used to evaluate the severity of atopic dermatitis</data>
      <data key="d6">100dd7646c10899301b3c0631183da16</data>
    </edge>
    <edge source="TNFSF" target="FIBROBLASTS">
      <data key="d4">9.0</data>
      <data key="d5">TNFSF members can act on fibroblasts to perpetuate fibrosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="TNFSF" target="MACROPHAGES">
      <data key="d4">9.0</data>
      <data key="d5">TNFSF members can act on macrophages to perpetuate fibrosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="TNFSF" target="T CELLS">
      <data key="d4">9.0</data>
      <data key="d5">TNFSF members can act on T cells to perpetuate fibrosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="ENDOTHELIAL CELLS" target="NOTCH SIGNALING PATHWAY">
      <data key="d4">6.0</data>
      <data key="d5">The Notch signaling pathway interacts with endothelial cells</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="ENDOTHELIAL CELLS" target="HVEM">
      <data key="d4">14.0</data>
      <data key="d5">HVEM is expressed on endothelial cells</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="ENDOTHELIAL CELLS" target="GITRL">
      <data key="d4">7.0</data>
      <data key="d5">GITRL is mainly expressed on endothelial cells</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="MACROPHAGES" target="M2 MACROPHAGES">
      <data key="d4">16.0</data>
      <data key="d5">M2 macrophages are a profibrotic phenotype of macrophages</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="MACROPHAGES" target="HVEM">
      <data key="d4">14.0</data>
      <data key="d5">HVEM is expressed on macrophages</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="MACROPHAGES" target="TACI">
      <data key="d4">7.0</data>
      <data key="d5">TACI is expressed in macrophages and plays a role in M1 polarization and inflammation</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="MACROPHAGES" target="RANKL">
      <data key="d4">14.0</data>
      <data key="d5">RANKL activates lung macrophages in silicosis</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="MACROPHAGES" target="MMP-12">
      <data key="d4">12.0</data>
      <data key="d5">Macrophages in silicosis exhibit a high MMP-12 phenotype</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="MACROPHAGES" target="GITRL">
      <data key="d4">7.0</data>
      <data key="d5">GITRL is mainly expressed on macrophages</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="MACROPHAGES" target="TNF&#913;">
      <data key="d4">8.0</data>
      <data key="d5">TNF&#945; can act on macrophages to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="MACROPHAGES" target="LIGHT">
      <data key="d4">16.0</data>
      <data key="d5">MACROPHAGES and LIGHT: LIGHT acts on macrophages to drive both pro-fibrotic and anti-fibrotic effects.</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a,68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="MACROPHAGES" target="TNFSF2">
      <data key="d4">8.0</data>
      <data key="d5">TNFSF2 can act on macrophages to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="MACROPHAGES" target="TL1A">
      <data key="d4">8.0</data>
      <data key="d5">TL1A acts on macrophages to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="CD86" target="CD28">
      <data key="d4">41.0</data>
      <data key="d5">CD28 and CD86 are involved in positive costimulatory pathways. CD28 binds to CD86 to provide a costimulatory signal essential for T-cell activation. The interaction between CD28 and CD86 is crucial for the activation of T-cells, highlighting their significant role in the immune response.</data>
      <data key="d6">4842292208575bd45b2b5998513dd087,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="CD86" target="CTLA-4">
      <data key="d4">40.0</data>
      <data key="d5">CTLA-4 and CD86 are involved in negative costimulatory pathways. CTLA-4 binds to CD86, reducing IL-2 production and T cell proliferation. This interaction between CTLA-4 and CD86 plays a crucial role in the regulation of immune responses.</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b,4d0e8ae9371a435885994b4161126bc3,855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="CD86" target="SCTLA-4">
      <data key="d4">16.0</data>
      <data key="d5">CD86 and sCTLA-4 are critical components in the regulation of immune responses. sCTLA-4 blocks the interaction of CD86, which is essential for the activation of T-cells. By inhibiting the CD86&#8212;CD28 interaction, sCTLA-4 may play a role in preventing early T-cell activation. This mechanism suggests that sCTLA-4 could be a significant factor in modulating immune responses, potentially impacting the development and progression of autoimmune diseases.</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b,9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="CD28" target="SSC">
      <data key="d4">19.0</data>
      <data key="d5">CD28 is implicated in the pathogenesis of systemic sclerosis (SSC). It is overexpressed in patients with systemic sclerosis, suggesting a significant role in the disease's development and progression.</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="CD28" target="IL-2 SECRETION">
      <data key="d4">8.0</data>
      <data key="d5">CD28 binding to CD80 and CD86 induces IL-2 secretion</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="CD28" target="SERUM">
      <data key="d4">7.0</data>
      <data key="d5">Increased expression of CD28 is observed in the serum of SSc patients</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="CD28" target="T CELL">
      <data key="d4">8.0</data>
      <data key="d5">CD28 is involved in T cell costimulation</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="PERIPHERAL BLOOD MONONUCLEAR CELLS" target="FLOW CYTOMETRY">
      <data key="d4">7.0</data>
      <data key="d5">Flow cytometry is used to analyze PBMCs from patients with atopic dermatitis</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="GBR 830" target="ECZEMA AREA AND SEVERITY INDEX (EASI)">
      <data key="d4">16.0</data>
      <data key="d5">GBR 830 treatment improves EASI scores</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="GBR 830" target="CCL11">
      <data key="d4">16.0</data>
      <data key="d5">GBR 830 treatment reduces CCL11 mRNA levels</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="GBR 830" target="CCL17">
      <data key="d4">16.0</data>
      <data key="d5">GBR 830 treatment reduces CCL17 mRNA levels</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="GBR 830" target="S100">
      <data key="d4">16.0</data>
      <data key="d5">GBR 830 treatment reduces S100 mRNA levels</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="MRNA" target="POLY(A)">
      <data key="d4">7.0</data>
      <data key="d5">Poly(A) is a sequence of adenine nucleotides added to RNA molecules</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="MRNA" target="STRANDED MRNA LIBRARIES">
      <data key="d4">7.0</data>
      <data key="d5">Stranded mRNA libraries are collections of mRNA sequences used for sequencing</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="CCL11" target="T CELL">
      <data key="d4">16.0</data>
      <data key="d5">CCL11 promotes the attraction of inflammatory T cells</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="CCL11" target="DC">
      <data key="d4">16.0</data>
      <data key="d5">CCL11 promotes the attraction of inflammatory DC subtypes</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="CCL11" target="TRAIL">
      <data key="d4">7.0</data>
      <data key="d5">TRAIL is necessary for the upregulation of CCL11</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="CCL17" target="T CELL">
      <data key="d4">16.0</data>
      <data key="d5">CCL17 promotes the attraction of inflammatory T cells</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="CCL17" target="DC">
      <data key="d4">16.0</data>
      <data key="d5">CCL17 promotes the attraction of inflammatory DC subtypes</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="KHK4083" target="IGA">
      <data key="d4">7.0</data>
      <data key="d5">KHK4083 led to IGA 0/1 in 35% of patients in a phase Ib trial</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="KHK4083" target="PHASE IB TRIAL">
      <data key="d4">8.0</data>
      <data key="d5">KHK4083 was tested in a phase Ib trial</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="KHK4083" target="PHASE IIB TRIAL">
      <data key="d4">7.0</data>
      <data key="d5">KHK4083 results from the phase IIb trial are pending</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="ERYTHEMA" target="INFANTILE ATOPIC DERMATITIS">
      <data key="d4">7.0</data>
      <data key="d5">Erythema is poorly defined redness of the skin, often seen in infantile Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ERYTHEMA" target="MICE">
      <data key="d4">12.0</data>
      <data key="d5">Mice treated with NPs exhibited improved control over erythema intensity</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="ERYTHEMA" target="ER143">
      <data key="d4">14.0</data>
      <data key="d5">ER143 reduced erythema by 98% after local use on mouse ears</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="SERUM" target="SOX40">
      <data key="d4">15.0</data>
      <data key="d5">SERUM and SOX40: Serum levels of sOX40 are measured in patients with atopic dermatitis (AD).</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd,89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="SERUM" target="SOX40L">
      <data key="d4">15.0</data>
      <data key="d5">Serum levels of sOX40L are measured in patients with atopic dermatitis (AD).</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd,89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="SERUM" target="ICOS">
      <data key="d4">7.0</data>
      <data key="d5">Increased expression of ICOS is observed in the serum of SSc patients</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="SERUM" target="CTLA-4">
      <data key="d4">7.0</data>
      <data key="d5">Increased expression of CTLA-4 is observed in the serum of SSc patients</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="SERUM" target="PD1">
      <data key="d4">7.0</data>
      <data key="d5">Increased expression of PD1 is observed in the serum of SSc patients</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="SERUM" target="DCSSC">
      <data key="d4">7.0</data>
      <data key="d5">Increased levels of certain proteins in serum correlate with disease activity and severity in dcSSc</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="SERUM" target="PH">
      <data key="d4">7.0</data>
      <data key="d5">Increased levels of certain proteins in serum correlate with disease severity in pulmonary hypertension</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="SERUM" target="SCD27">
      <data key="d4">7.0</data>
      <data key="d5">Serum levels of soluble CD27 correlate with disease severity in SSc</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="HEAD AND NECK" target="CATINLIMAB">
      <data key="d4">14.0</data>
      <data key="d5">Catinlimab is being evaluated for its efficacy in treating head and neck disease</data>
      <data key="d6">b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="EASI75" target="ASLAN004">
      <data key="d4">8.0</data>
      <data key="d5">ASLAN004 achieved EASI75 in 67% of patients</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="PLACEBO" target="CLINICAL TRIALS">
      <data key="d4">6.0</data>
      <data key="d5">Placebo is used as a control in clinical trials</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="PLACEBO" target="SALINE">
      <data key="d4">6.0</data>
      <data key="d5">Saline is often used as a placebo in clinical trials</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="PLACEBO" target="PRA023">
      <data key="d4">7.0</data>
      <data key="d5">PRA023 is compared to a placebo in clinical trials</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="PLACEBO" target="IGA NEPHROPATHY">
      <data key="d4">7.0</data>
      <data key="d5">Placebo is used as a control in studies for IgA Nephropathy</data>
      <data key="d6">8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="PLACEBO" target="SYSTEMIC SCLEROSIS">
      <data key="d4">1.0</data>
      <data key="d5">Placebo is used as a control in studies for Systemic Sclerosis</data>
      <data key="d6">8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="PLACEBO" target="CROHN DISEASE">
      <data key="d4">7.0</data>
      <data key="d5">Placebo is used as a control in clinical trials for Crohn's disease</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="PLACEBO" target="CALCIFIC AORTIC STENOSIS">
      <data key="d4">7.0</data>
      <data key="d5">Placebo is used as a control in clinical trials for calcific aortic stenosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="PLACEBO" target="ASTHMA">
      <data key="d4">7.0</data>
      <data key="d5">Placebo is used as a control in clinical trials for asthma</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="PLACEBO" target="ULCERATIVE COLITIS">
      <data key="d4">7.0</data>
      <data key="d5">Placebo is used as a control in clinical trials for ulcerative colitis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="VIGA" target="PP-NRS-11">
      <data key="d4">6.0</data>
      <data key="d5">PP-NRS-11 correlates weakly with vIGA</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="SCORAD" target="OSCORAD">
      <data key="d4">8.0</data>
      <data key="d5">oSCORAD is a version of SCORAD excluding subjective symptoms</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="SCORAD" target="SCORAD75">
      <data key="d4">9.0</data>
      <data key="d5">SCORAD75 represents a 75% improvement in SCORAD from baseline</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="SCORAD" target="ITCH">
      <data key="d4">7.0</data>
      <data key="d5">Itch is a subjective symptom considered in the SCORAD assessment</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="SCORAD" target="SLEEPLESSNESS">
      <data key="d4">7.0</data>
      <data key="d5">Sleeplessness is a subjective symptom considered in the SCORAD assessment</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="SCORAD" target="SKIN LESIONS">
      <data key="d4">8.0</data>
      <data key="d5">Skin lesions are measured by SCORAD in atopic dermatitis</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="SCORAD" target="MEPOLIZUMAB">
      <data key="d4">12.0</data>
      <data key="d5">Mepolizumab failed to show a significant decrease in SCORAD</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="SCORAD" target="SOX40">
      <data key="d4">6.0</data>
      <data key="d5">sOX40 levels in children with AD correlated with SCORAD</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="ASTHMA" target="FEV1">
      <data key="d4">7.0</data>
      <data key="d5">FEV1 is a measure of lung function in asthma</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="ASTHMA" target="IL-5">
      <data key="d4">14.0</data>
      <data key="d5">IL-5 is important in asthma</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="ASTHMA" target="SOX40">
      <data key="d4">7.0</data>
      <data key="d5">sOX40 serum levels are significantly higher in AD patients with asthma compared to those without</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="ASTHMA" target="LIGHT">
      <data key="d4">30.0</data>
      <data key="d5">ASTHMA and LIGHT: LIGHT is induced in asthma and regulates fibrosis in the lungs.</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2,df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="ASTHMA" target="TL1A">
      <data key="d4">7.0</data>
      <data key="d5">Blocking TL1A signaling attenuates pathology in asthma models</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="ASTHMA" target="GENENTECH, INC.">
      <data key="d4">6.0</data>
      <data key="d5">Genentech, Inc. is involved in clinical trials for asthma</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="VIRUS-SPECIFIC ANTIBODY" target="CYTOTOXIC T-CELL">
      <data key="d4">12.0</data>
      <data key="d5">Virus-specific antibody production and cytotoxic T-cell response were not affected in the viral infection model</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="SOX40" target="MAST CELL DEGRANULATION">
      <data key="d4">8.0</data>
      <data key="d5">Soluble OX40 inhibits Mast Cell Degranulation, reducing the inflammatory response in Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="SOX40" target="HC">
      <data key="d4">7.0</data>
      <data key="d5">sOX40 was measured in serum from healthy controls</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="SOX40" target="ENZYME-LINKED IMMUNOASSAY">
      <data key="d4">8.0</data>
      <data key="d5">ELISA is used to measure serum levels of sOX40 in patients with atopic dermatitis</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="SOX40" target="CHILDREN WITH AD">
      <data key="d4">8.0</data>
      <data key="d5">Serum levels of sOX40 are measured in children with atopic dermatitis</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="SOX40" target="ADULTS WITH AD">
      <data key="d4">8.0</data>
      <data key="d5">Serum levels of sOX40 are measured in adults with atopic dermatitis</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="CYTOKINES" target="BIOLOGICS">
      <data key="d4">8.0</data>
      <data key="d5">Biologics target key effectors like cytokines in immune responses</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="CYTOKINES" target="PDE4">
      <data key="d4">14.0</data>
      <data key="d5">PDE4 helps immune cells release cytokines</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="B CELLS" target="B CELL RECEPTOR SIGNALING PATHWAY">
      <data key="d4">6.0</data>
      <data key="d5">B cell receptor signaling pathway is enriched in B cells</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="B CELLS" target="IFN-&#915; MEDIATED SIGNALING PATHWAY">
      <data key="d4">6.0</data>
      <data key="d5">IFN-&#947; mediated signaling pathway is enriched in B cells</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="B CELLS" target="CD20">
      <data key="d4">9.0</data>
      <data key="d5">CD20 is a marker found on B cells</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="B CELLS" target="GITRL">
      <data key="d4">7.0</data>
      <data key="d5">GITRL is mainly expressed on B cells</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="B CELLS" target="CD27">
      <data key="d4">14.0</data>
      <data key="d5">CD27 is expressed on specific subsets of B cells</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="IFN-&#915;" target="STROMAL CELLS">
      <data key="d4">7.0</data>
      <data key="d5">IFN-&#947; interacts with various stromal cell clusters</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="IFN-&#915;" target="CAMP">
      <data key="d4">6.0</data>
      <data key="d5">cAMP mediates downstream events culminating in the inhibition of IFN-&#947; secretion</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="IFN-&#915;" target="HYDROCORTISONE">
      <data key="d4">14.0</data>
      <data key="d5">HC-NPs suppressed inflammatory cascades including IFN-&#947;</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="IFN-&#915;" target="SSC">
      <data key="d4">8.0</data>
      <data key="d5">IFN-&#947; is a proinflammatory cytokine involved in systemic sclerosis</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="IFN-&#915;" target="ICOS">
      <data key="d4">8.0</data>
      <data key="d5">ICOS induces the synthesis of IFN-&#947; in activated T cells</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="PBMCS" target="FICOLL-PAQUE">
      <data key="d4">8.0</data>
      <data key="d5">Ficoll-Paque is a reagent used for density gradient centrifugation to isolate Peripheral Blood Mononuclear Cells (PBMCs). This technique is commonly employed in research on various conditions, including Atopic Dermatitis. By utilizing Ficoll-Paque, researchers can effectively separate PBMCs from other blood components, facilitating further study and analysis of these cells in the context of immune-related diseases.</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746,691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="PBMCS" target="HC">
      <data key="d4">8.0</data>
      <data key="d5">PBMCs were collected from healthy controls</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="PBMCS" target="MOUSE IGG">
      <data key="d4">6.0</data>
      <data key="d5">Mouse IgG was used to block unspecific binding in PBMCs</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="PBMCS" target="BOVINE SERUM ALBUMIN (BSA)">
      <data key="d4">6.0</data>
      <data key="d5">Bovine Serum Albumin was used in wash buffer for PBMCs</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="PBMCS" target="SODIUM AZIDE">
      <data key="d4">6.0</data>
      <data key="d5">Sodium Azide was used in wash buffer for PBMCs</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="PBMCS" target="FORMALDEHYDE">
      <data key="d4">7.0</data>
      <data key="d5">Formaldehyde was used to fix PBMCs</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="NOTCH SIGNALING" target="GAMMA-SECRETASE">
      <data key="d4">9.0</data>
      <data key="d5">Gamma-secretase is involved in the regulation of Notch signaling</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="RNA-SEQ" target="RNA">
      <data key="d4">8.0</data>
      <data key="d5">RNA is analyzed using RNA-Seq</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="RNA-SEQ" target="GRCH38">
      <data key="d4">8.0</data>
      <data key="d5">GRCh38 is a reference genome assembly used for mapping reads in RNA-Seq experiments</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="RNA-SEQ" target="DESEQ">
      <data key="d4">8.0</data>
      <data key="d5">DESeq is a software tool used for differential expression analysis in RNA-Seq data</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="RNA-SEQ" target="SCIDAP">
      <data key="d4">16.0</data>
      <data key="d5">SciDAP is a platform used for scientific data analysis, including RNA-Seq dataSciDAP is used for analyzing RNA-Seq data</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="RNA-SEQ" target="TRIM GALORE">
      <data key="d4">7.0</data>
      <data key="d5">Trim Galore is used for trimming adapters in RNA-Seq data</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="RNA-SEQ" target="CELLPHONEDB">
      <data key="d4">7.0</data>
      <data key="d5">CellPhoneDB is used for analyzing cell-cell communication in RNA-Seq data</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="RNA-SEQ" target="PCA">
      <data key="d4">14.0</data>
      <data key="d5">PCA is used for principal component analysis in RNA-Seq data</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="RNA-SEQ" target="FDR">
      <data key="d4">14.0</data>
      <data key="d5">FDR is used to control the false discovery rate in RNA-Seq data</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="RNA-SEQ" target="STUDENT&#8217;S T TEST">
      <data key="d4">12.0</data>
      <data key="d5">Student&#8217;s t test is used for statistical analysis in RNA-Seq data</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="RNA-SEQ" target="MANN-WHITNEY U TEST">
      <data key="d4">12.0</data>
      <data key="d5">Mann-Whitney U test is used for statistical analysis in RNA-Seq data</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="RNA-SEQ" target="ILLUMINA NOVASEQ 6000">
      <data key="d4">16.0</data>
      <data key="d5">Illumina NovaSeq 6000 is used for sequencing in RNA-Seq</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="RNA-SEQ" target="NEW ENGLAND BIOLABS">
      <data key="d4">14.0</data>
      <data key="d5">New England Biolabs provides reagents for RNA-Seq</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="RNA-SEQ" target="GENOMATIX">
      <data key="d4">14.0</data>
      <data key="d5">Genomatix is used for creating biological networks from RNA-Seq data</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="RNA-SEQ" target="TRIM GALORE RNA-SEQ PIPELINE">
      <data key="d4">7.0</data>
      <data key="d5">Trim Galore RNA-Seq pipeline is a software tool used for trimming adapters in RNA-Seq data</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="RNA-SEQ" target="SSC">
      <data key="d4">7.0</data>
      <data key="d5">RNA sequencing is used to analyze the transcriptome of SSc patients</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="IMMUNOPATHOGENESIS" target="SSC">
      <data key="d4">1.0</data>
      <data key="d5">The study furthers understanding of the complex immunopathogenesis of SSc</data>
      <data key="d6">7b454335c2f5651d86f712037a0dc0ff</data>
    </edge>
    <edge source="FALSE DISCOVERY RATE" target="BENJAMINI AND HOCHBERG METHOD">
      <data key="d4">7.0</data>
      <data key="d5">Benjamini and Hochberg method is used to control the false discovery rate</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="CLINICAL TRIALS" target="TREATMENT-EMERGENT ADVERSE EVENT">
      <data key="d4">7.0</data>
      <data key="d5">Treatment-emergent adverse events are monitored during clinical trials</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="FIBROBLASTS" target="CD34+CD45+ MONOCYTIC CELLS">
      <data key="d4">7.0</data>
      <data key="d5">CD34+CD45+ monocytic cells differentiate into collagen-producing fibroblasts</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="FIBROBLASTS" target="HVEM">
      <data key="d4">14.0</data>
      <data key="d5">HVEM is expressed on fibroblasts</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="FIBROBLASTS" target="LT&#914;R">
      <data key="d4">14.0</data>
      <data key="d5">LT&#946;R is expressed on fibroblasts</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="FIBROBLASTS" target="CD70">
      <data key="d4">21.0</data>
      <data key="d5">CD70 is expressed on fibroblasts and is proposed as a target in fibrotic diseases.</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3,4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="FIBROBLASTS" target="SCD27">
      <data key="d4">7.0</data>
      <data key="d5">sCD27 inhibits fibroblast extracellular matrix protein production</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="FIBROBLASTS" target="CD4 T CELLS">
      <data key="d4">6.0</data>
      <data key="d5">Activated CD4 T cells drive fibroblast CD70 activation</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="FIBROBLASTS" target="TNF&#913;">
      <data key="d4">8.0</data>
      <data key="d5">TNF&#945; can act on fibroblasts to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="FIBROBLASTS" target="LIGHT">
      <data key="d4">16.0</data>
      <data key="d5">LIGHT acts on fibroblasts to drive both pro-fibrotic and anti-fibrotic effects.</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a,68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="FIBROBLASTS" target="TL1A">
      <data key="d4">16.0</data>
      <data key="d5">FIBROBLASTS and TL1A: TL1A acts on fibroblasts to drive both pro-fibrotic and anti-fibrotic effects. This dual role indicates that TL1A can influence fibroblasts in complex ways, potentially contributing to the regulation of fibrosis in various tissues.</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a,68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="FIBROBLASTS" target="TNFSF2">
      <data key="d4">8.0</data>
      <data key="d5">TNFSF2 can act on fibroblasts to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="FIBROBLASTS" target="TNFSF15">
      <data key="d4">8.0</data>
      <data key="d5">TNFSF15 can act on fibroblasts to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="SMOOTH MUSCLE CELLS" target="HVEM">
      <data key="d4">14.0</data>
      <data key="d5">HVEM is expressed on smooth muscle cells</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="SMOOTH MUSCLE CELLS" target="LT&#914;R">
      <data key="d4">14.0</data>
      <data key="d5">LT&#946;R is expressed on smooth muscle cells</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="SMOOTH MUSCLE CELLS" target="LIGHT">
      <data key="d4">16.0</data>
      <data key="d5">LIGHT acts on smooth muscle cells to drive both pro-fibrotic and anti-fibrotic effects.</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a,68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="T CELLS" target="CCL20">
      <data key="d4">7.0</data>
      <data key="d5">Keratinocyte-derived CCL20 interacts with T cells</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="T CELLS" target="T CELL RECEPTOR SIGNALING PATHWAY">
      <data key="d4">6.0</data>
      <data key="d5">T cell receptor signaling pathway is enriched in T cells</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="T CELLS" target="T CELL COSTIMULATION">
      <data key="d4">6.0</data>
      <data key="d5">T cell costimulation is enriched in T cells</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="T CELLS" target="TNF-MEDIATED SIGNALING">
      <data key="d4">6.0</data>
      <data key="d5">Regulation of TNF-mediated signaling is enriched in T cells</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="T CELLS" target="S1P">
      <data key="d4">14.0</data>
      <data key="d5">S1P affects the segregation of T cells</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="T CELLS" target="CLA">
      <data key="d4">7.0</data>
      <data key="d5">CLA is expressed on T cells in AD</data>
      <data key="d6">89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="T CELLS" target="CD4">
      <data key="d4">7.0</data>
      <data key="d5">CD4 is expressed on T cells in AD</data>
      <data key="d6">89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="T CELLS" target="CD45RO">
      <data key="d4">7.0</data>
      <data key="d5">CD45RO is expressed on T cells in AD</data>
      <data key="d6">89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="T CELLS" target="CD8">
      <data key="d4">7.0</data>
      <data key="d5">CD8 is expressed on T cells in AD</data>
      <data key="d6">89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="T CELLS" target="ICOS">
      <data key="d4">8.0</data>
      <data key="d5">ICOS induces proinflammatory and pro-fibrotic cytokine synthesis in activated T cells</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="T CELLS" target="MMP">
      <data key="d4">14.0</data>
      <data key="d5">MMPs condition human na&#239;ve T cells to prime TH2 phenotype via an OX40L-dependent pathway</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="T CELLS" target="HVEM">
      <data key="d4">14.0</data>
      <data key="d5">HVEM is expressed on T cells</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="T CELLS" target="TL1A">
      <data key="d4">16.0</data>
      <data key="d5">TL1A acts on T cells to drive both pro-fibrotic and anti-fibrotic effects. Additionally, TL1A is required for severe bowel pathology through the activation of T cells.</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a,c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="T CELLS" target="CD27">
      <data key="d4">14.0</data>
      <data key="d5">CD27 is expressed on specific subsets of T cells</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="T CELLS" target="TNF&#913;">
      <data key="d4">8.0</data>
      <data key="d5">TNF&#945; can act on T cells to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="T CELLS" target="TNFSF2">
      <data key="d4">8.0</data>
      <data key="d5">TNFSF2 can act on T cells to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="MYELOID CELLS" target="INFLAMMATORY RESPONSE">
      <data key="d4">6.0</data>
      <data key="d5">Inflammatory response is enriched in the myeloid cell population</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="MYELOID CELLS" target="NEUTROPHIL CHEMOTAXIS">
      <data key="d4">6.0</data>
      <data key="d5">Neutrophil chemotaxis is enriched in the myeloid cell population</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="MAST CELLS" target="HIGH-AFFINITY IGE RECEPTOR">
      <data key="d4">7.0</data>
      <data key="d5">High-affinity IgE receptor is expressed in mast cells in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="MAST CELLS" target="TRYPTASE">
      <data key="d4">9.0</data>
      <data key="d5">MAST CELLS and TRYPTASE: Tryptase staining confirms the presence of mast cells, including those expressing OX40L, in atopic dermatitis (AD) skin.</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="MAST CELLS" target="DERMIS">
      <data key="d4">7.0</data>
      <data key="d5">Mast cells are located in the dermis of patients with AD</data>
      <data key="d6">89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="CTLA-4" target="SSC">
      <data key="d4">47.0</data>
      <data key="d5">CTLA-4 is overexpressed in patients with systemic sclerosis (SSC) and might contribute to the development of this autoimmune disease. Additionally, polymorphisms in the CTLA-4 gene have been found to confer susceptibility to systemic sclerosis, suggesting a significant role for CTLA-4 in the pathogenesis of SSC.</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="CTLA-4" target="CTLA4-B7">
      <data key="d4">8.0</data>
      <data key="d5">CTLA-4 is involved in the CTLA4-B7 negative costimulatory pathway</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="CTLA-4" target="SCTLA-4">
      <data key="d4">14.0</data>
      <data key="d5">sCTLA-4 competes with CTLA-4 for binding</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="CTLA-4" target="M2 MACROPHAGES">
      <data key="d4">14.0</data>
      <data key="d5">Blocking CTLA-4 decreases M2 macrophage differentiation</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="ICOS" target="SSC">
      <data key="d4">17.0</data>
      <data key="d5">ICOS is overexpressed in patients with systemic sclerosis</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="ICOS" target="B7RP1">
      <data key="d4">24.0</data>
      <data key="d5">ICOS and B7RP1 are involved in positive costimulatory pathways. ICOS binds to B7RP1 in the ICOS-B7RP1 costimulatory pathway.</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="ICOS" target="FIBROBLAST">
      <data key="d4">7.0</data>
      <data key="d5">ICOS promotes fibroblast activation</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="ICOS" target="EXTRACELLULAR MATRIX">
      <data key="d4">7.0</data>
      <data key="d5">ICOS promotes extracellular matrix synthesis</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="ICOS" target="T CELL">
      <data key="d4">8.0</data>
      <data key="d5">ICOS is involved in T cell costimulation</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="CD70" target="CD27">
      <data key="d4">48.0</data>
      <data key="d5">CD70 and CD27 are integral components of the immune system, playing crucial roles in T and B cell activation. CD70 binds to CD27, forming the CD70-CD27 costimulatory pathway, which is essential for providing stimulatory signals necessary for the activation and signaling of both T and B cells. This interaction is pivotal in the immune response, facilitating effective communication and activation within the immune system.</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3,4cf23e218b6aab3c77115173b5c7c2fd,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="CD70" target="T CELL">
      <data key="d4">8.0</data>
      <data key="d5">CD70 is involved in T cell activation</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="CD70" target="SSC">
      <data key="d4">7.0</data>
      <data key="d5">Differential expression of CD70 is associated with disease severity in SSc</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD70" target="FIBROTIC DISEASES">
      <data key="d4">7.0</data>
      <data key="d5">CD70 is proposed as a target in fibrotic diseases</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD70" target="EPIGENETIC">
      <data key="d4">7.0</data>
      <data key="d5">Differential expression of CD70 is associated with epigenetic changes in SSc</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD70" target="DISEASE PATHOGENESIS">
      <data key="d4">1.0</data>
      <data key="d5">CD70 is involved in the disease pathogenesis of SSc</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="T CELL">
      <data key="d4">8.0</data>
      <data key="d5">CD27 is involved in T cell activation</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="CD27" target="GITR">
      <data key="d4">6.0</data>
      <data key="d5">GITR possesses an intracellular domain with significant homology to CD27</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="CD27" target="NK CELLS">
      <data key="d4">14.0</data>
      <data key="d5">CD27 is expressed on NK cells</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="CD27" target="HEMATOPOIETIC STEM CELLS">
      <data key="d4">14.0</data>
      <data key="d5">CD27 is expressed on hematopoietic stem cells</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="CD27" target="EFFECTOR T CELLS">
      <data key="d4">14.0</data>
      <data key="d5">CD27 signaling affects the formation of effector T cells</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="CD27" target="MEMORY T CELLS">
      <data key="d4">14.0</data>
      <data key="d5">CD27 signaling affects the formation of memory T cells</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="CD27" target="NA&#207;VE T CELLS">
      <data key="d4">21.0</data>
      <data key="d5">CD27 is expressed on na&#239;ve T cells and plays a crucial role in their activation. CD27 signaling primes na&#239;ve T cells, preparing them for subsequent immune responses.</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3,4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="SCD27">
      <data key="d4">8.0</data>
      <data key="d5">CD27 is cleaved to form soluble CD27</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="CHRONIC RENAL NEPHRITIS">
      <data key="d4">7.0</data>
      <data key="d5">CD27+ B cells are increased in chronic renal nephritis</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="CIRRHOSIS">
      <data key="d4">7.0</data>
      <data key="d5">CD27+ B cells are depleted in cirrhotic patients</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="TNF-BETA">
      <data key="d4">6.0</data>
      <data key="d5">Loss of CD27+ B cells is accompanied by impaired TNF-beta secretion</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="IGG">
      <data key="d4">6.0</data>
      <data key="d5">Loss of CD27+ B cells is accompanied by impaired IgG production</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="CD95">
      <data key="d4">6.0</data>
      <data key="d5">CD27+ B cells in cirrhotic patients show increased levels of CD95</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="FASL">
      <data key="d4">6.0</data>
      <data key="d5">Increased FasL exposure drives depletion of CD27+ B cells</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="ENDOTOXIN">
      <data key="d4">6.0</data>
      <data key="d5">Increased endotoxin exposure drives depletion of CD27+ B cells</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="EAM">
      <data key="d4">7.0</data>
      <data key="d5">Depletion of CD27+ NK cells during EAM increases disease severity</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="EOSINOPHILS">
      <data key="d4">6.0</data>
      <data key="d5">CD27+ NK cells limit eosinophil infiltration</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="SSC">
      <data key="d4">7.0</data>
      <data key="d5">Serum levels of soluble CD27 correlate with disease severity in SSc</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="MEMORY T LYMPHOCYTES">
      <data key="d4">7.0</data>
      <data key="d5">CD27 is expressed on memory T lymphocytes</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="NA&#207;VE B CELLS">
      <data key="d4">7.0</data>
      <data key="d5">CD27 expression is absent from na&#239;ve B cells</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="MEMORY B LYMPHOCYTES">
      <data key="d4">7.0</data>
      <data key="d5">CD27 is upregulated in memory B lymphocytes</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="ACUTE INFLAMMATORY STATE">
      <data key="d4">7.0</data>
      <data key="d5">High CD27 expression and sCD27 secretion occur in an acute inflammatory state</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="RENAL DISEASES">
      <data key="d4">7.0</data>
      <data key="d5">CD27+ B cells are found in renal diseases</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="SYSTEMIC INFECTION">
      <data key="d4">7.0</data>
      <data key="d5">Depletion of CD27+ memory B cells contributes to systemic infection risk</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="CARDIAC INFILTRATING EOSINOPHILS">
      <data key="d4">7.0</data>
      <data key="d5">Depletion of CD27+ NK cells results in an influx of cardiac infiltrating eosinophils</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="CARDIAC FIBROBLASTS">
      <data key="d4">7.0</data>
      <data key="d5">CD27+ NK cells alter eosinophil-related chemokines by cardiac fibroblasts</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD40" target="CD154">
      <data key="d4">48.0</data>
      <data key="d5">CD40 and CD154 are integral components of the immune system, playing crucial roles in immune response regulation. CD154 binds to CD40, activating antigen-presenting cells, which is a key step in initiating immune responses. Both CD40 and CD154 are involved in positive costimulatory pathways, essential for the effective activation and proliferation of T cells. The interaction between CD40 and CD154, known as the CD40-CD154 costimulatory pathway, is vital for the modulation and amplification of immune responses, highlighting their importance in maintaining immune system functionality.</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="CD40" target="FIBROBLAST">
      <data key="d4">14.0</data>
      <data key="d5">CD40 expression is increased in skin fibroblasts</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="CD40" target="SSC">
      <data key="d4">14.0</data>
      <data key="d5">CD40 expression is increased in the serum of systemic sclerosis patients</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="B CELL" target="CD20">
      <data key="d4">9.0</data>
      <data key="d5">CD20 is expressed on the surface of B cells</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="B CELL" target="CD138">
      <data key="d4">8.0</data>
      <data key="d5">CD138 is expressed on plasma cells, which are derived from B cells</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="B CELL" target="FOSTAMATINIB DISODIUM">
      <data key="d4">7.0</data>
      <data key="d5">Fostamatinib disodium is used in B cell stimulation experiments</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="B CELL" target="IBRUTINIB">
      <data key="d4">7.0</data>
      <data key="d5">Ibrutinib is used in B cell stimulation experiments</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="B CELL" target="ACALABRUTINIB">
      <data key="d4">7.0</data>
      <data key="d5">Acalabrutinib is used in B cell stimulation experiments</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="B CELL" target="DMSO">
      <data key="d4">6.0</data>
      <data key="d5">DMSO is used as a control in B cell stimulation experiments</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="B CELL" target="PBS">
      <data key="d4">12.0</data>
      <data key="d5">PBS is used to wash B cells in experiments</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="B CELL" target="EASYSEP">
      <data key="d4">14.0</data>
      <data key="d5">EasySep is used for isolating B cells</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="B CELL" target="LYMPHOPREP">
      <data key="d4">14.0</data>
      <data key="d5">Lymphoprep is used for isolating lymphocytes, including B cells</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="B CELL" target="GOAT F(AB&#8242;)2 ANTI-HUMAN IGM">
      <data key="d4">14.0</data>
      <data key="d5">Goat F(ab&#8242;)2 Anti-Human IgM is used for stimulating B cells</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="B CELL" target="GOAT F(AB&#8242;)2 ANTI-HUMAN IGG">
      <data key="d4">14.0</data>
      <data key="d5">Goat F(ab&#8242;)2 Anti-Human IgG is used for stimulating B cells</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="B CELL" target="MIGE">
      <data key="d4">7.0</data>
      <data key="d5">B cells express membrane-bound IgE</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="B CELL" target="LYMPHOBLASTS">
      <data key="d4">7.0</data>
      <data key="d5">Lymphoblasts are immature B cells</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="B CELL" target="SSC">
      <data key="d4">9.0</data>
      <data key="d5">B cells are involved in the pathogenesis of systemic sclerosis</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="T CELL" target="CD3">
      <data key="d4">9.0</data>
      <data key="d5">CD3 is a protein complex and T cell co-receptor involved in activating T cells</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="T CELL" target="TREG CELL">
      <data key="d4">9.0</data>
      <data key="d5">Treg cells are a subset of T cells that help regulate the immune response</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="T CELL" target="TH2 CELL">
      <data key="d4">8.0</data>
      <data key="d5">TH2 cells are a subset of T cells involved in the immune response</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="T CELL" target="CCL22">
      <data key="d4">16.0</data>
      <data key="d5">CCL22 promotes the attraction of inflammatory T cells</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="T CELL" target="CCL5">
      <data key="d4">16.0</data>
      <data key="d5">CCL5 promotes the attraction of inflammatory T cells</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="T CELL" target="SSC">
      <data key="d4">18.0</data>
      <data key="d5">T cells and systemic sclerosis (SSC) are intricately linked in the pathogenesis of the disease. T cell costimulatory pathways play a critical role in the development and progression of systemic sclerosis, highlighting the importance of T cells in the disease mechanism. This involvement underscores the potential of targeting T cell pathways for therapeutic interventions in systemic sclerosis.</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="T CELL" target="SCTLA-4">
      <data key="d4">16.0</data>
      <data key="d5">sCTLA-4 may inhibit early T-cell activation</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="T CELL" target="PD-1">
      <data key="d4">16.0</data>
      <data key="d5">PD-1 regulates T cell tolerance</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="T CELL" target="IL-2">
      <data key="d4">8.0</data>
      <data key="d5">IL-2 is involved in the activation and proliferation of T cells</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="T-SNE" target="DIMENSIONAL REDUCTION">
      <data key="d4">6.0</data>
      <data key="d5">t-SNE is a dimensional reduction technique</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="GENES" target="TRANSCRIPTS">
      <data key="d4">9.0</data>
      <data key="d5">Genes are transcribed into RNA molecules called transcripts</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="CELLPHONEDB" target="LIGAND">
      <data key="d4">8.0</data>
      <data key="d5">CellPhoneDB is used to analyze ligand-receptor interactions</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="CELLPHONEDB" target="RECEPTOR">
      <data key="d4">8.0</data>
      <data key="d5">CellPhoneDB is used to analyze receptor-ligand interactions</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="LIGAND" target="CIRCOS PLOT">
      <data key="d4">7.0</data>
      <data key="d5">Circos plot visualizes interactions between ligands and receptors</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="RECEPTOR" target="CIRCOS PLOT">
      <data key="d4">7.0</data>
      <data key="d5">Circos plot visualizes interactions between receptors and ligands</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="MARKER GENES" target="SUBCLUSTERS">
      <data key="d4">7.0</data>
      <data key="d5">Marker genes identify specific subclusters of keratinocytes</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="CD8+ T CELLS" target="CD8">
      <data key="d4">9.0</data>
      <data key="d5">CD8 is a marker found on CD8+ T cells</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="CD8+ T CELLS" target="DNAM-1">
      <data key="d4">14.0</data>
      <data key="d5">Upregulation of DNAM-1 in CD8+ T cells is associated with disease severity in systemic sclerosis</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="BCR" target="TCR">
      <data key="d4">16.0</data>
      <data key="d5">MiXCR software was used to extract TCR and BCR CDR3 sequences from RNA-Seq data</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="TCR" target="MHC">
      <data key="d4">16.0</data>
      <data key="d5">TCR binds to MHC molecules carrying peptide antigens</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="C1Q" target="C3B">
      <data key="d4">7.0</data>
      <data key="d5">C1q and C3b are both involved in the complement system</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="C1Q" target="C4D">
      <data key="d4">7.0</data>
      <data key="d5">C1q and C4d are both involved in the complement system</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="IGG" target="TL1A">
      <data key="d4">6.0</data>
      <data key="d5">IgG is used as a control in studies of TL1A-driven inflammation</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="SYK" target="PHOSPHO-SYK">
      <data key="d4">8.0</data>
      <data key="d5">Phospho-SYK is the phosphorylated form of SYK</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="ACALABRUTINIB" target="CCL4">
      <data key="d4">8.0</data>
      <data key="d5">Acalabrutinib suppresses CCL4 expression</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="IBRUTINIB" target="CCL4">
      <data key="d4">8.0</data>
      <data key="d5">Ibrutinib suppresses CCL4 expression</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="CCL4" target="LIVER FIBROSIS">
      <data key="d4">14.0</data>
      <data key="d5">CCl4 is used to induce liver fibrosis in experimental models</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51,d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="CD3+ T CELLS" target="CD3">
      <data key="d4">9.0</data>
      <data key="d5">CD3 is a marker found on T cells</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="LEUKOCYTE" target="H4R">
      <data key="d4">8.0</data>
      <data key="d5">H4R exerts immunoregulatory activities on leukocytes</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="LEUKOCYTE" target="GITR">
      <data key="d4">7.0</data>
      <data key="d5">GITR signaling affects leukocyte recruitment</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="CD20" target="ALEXA FLUOR 594">
      <data key="d4">14.0</data>
      <data key="d5">Alexa Fluor 594 is used as a secondary antibody for CD20</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="CD20" target="DONKEY ANTI-MOUSE IGG">
      <data key="d4">7.0</data>
      <data key="d5">Donkey anti-mouse IgG is used as a secondary antibody for CD20</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="CD138" target="ALEXA FLUOR 594">
      <data key="d4">14.0</data>
      <data key="d5">Alexa Fluor 594 is used as a secondary antibody for CD138</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="CD138" target="DONKEY ANTI-MOUSE IGG">
      <data key="d4">7.0</data>
      <data key="d5">Donkey anti-mouse IgG is used as a secondary antibody for CD138</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="GEPS" target="GENOMATIX">
      <data key="d4">2.0</data>
      <data key="d5">GePS is a version of Genomatix software</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="GAMMA-SECRETASE" target="NCSTN">
      <data key="d4">8.0</data>
      <data key="d5">NCSTN is a component of the gamma-secretase complex</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="GAMMA-SECRETASE" target="PSENEN">
      <data key="d4">8.0</data>
      <data key="d5">PSENEN is a component of the gamma-secretase complex</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="GAMMA-SECRETASE" target="PSEN1">
      <data key="d4">8.0</data>
      <data key="d5">PSEN1 is a component of the gamma-secretase complex</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="TYPE I IFNS" target="MX1">
      <data key="d4">16.0</data>
      <data key="d5">MX1 is an interferon response gene</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="TYPE I IFNS" target="IFI27">
      <data key="d4">16.0</data>
      <data key="d5">IFI27 is an interferon response gene</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="IFI27" target="NETS">
      <data key="d4">14.0</data>
      <data key="d5">IFI27 expression is proposed to be driven by NETs</data>
      <data key="d6">b62ecc47bf54393bc78dd65986b949d6</data>
    </edge>
    <edge source="NETS" target="PDCS">
      <data key="d4">16.0</data>
      <data key="d5">NETs interact with pDCs in lesional HS skin</data>
      <data key="d6">b62ecc47bf54393bc78dd65986b949d6</data>
    </edge>
    <edge source="DERMIS" target="TH2 CELL">
      <data key="d4">8.0</data>
      <data key="d5">TH2 cells are an important component of the dermal infiltrates in atopic dermatitis</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="DERMIS" target="TAC">
      <data key="d4">7.0</data>
      <data key="d5">Higher TAC levels were observed in the dermis with PLG-based nanoparticles</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="MICE" target="S. AUREUS">
      <data key="d4">12.0</data>
      <data key="d5">Mice are used to study the effects of S. aureus on skin inflammation</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="MICE" target="TEWL">
      <data key="d4">12.0</data>
      <data key="d5">Mice treated with NPs exhibited improved control over TEWL</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="MICE" target="DERMATITIS">
      <data key="d4">12.0</data>
      <data key="d5">Mice treated with NPs exhibited improved control over dermatitis index</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="MICE" target="ER143">
      <data key="d4">14.0</data>
      <data key="d5">ER143 reduced erythema and swelling in mice</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="MICE" target="DNAM-1">
      <data key="d4">14.0</data>
      <data key="d5">DNAM-1 gene invalidation is studied in mice</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="ILLUMINA NEXTSEQ" target="RNA">
      <data key="d4">16.0</data>
      <data key="d5">RNA sequencing was performed using the Illumina NextSeq platform</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="RNA" target="QIAGEN">
      <data key="d4">14.0</data>
      <data key="d5">QIAGEN provides reagents for RNA isolation</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="COLLAGEN" target="LIGHT">
      <data key="d4">20.0</data>
      <data key="d5">LIGHT, a member of the TNF superfamily, plays a significant role in collagen deposition. Research indicates that the genetic deletion of LIGHT reduces collagen deposition in UUO-induced mice, suggesting that LIGHT is a key factor in promoting collagen accumulation. This duality highlights LIGHT's critical involvement in the regulation of collagen, where its presence induces collagen deposition, while its absence mitigates this process.</data>
      <data key="d6">05c97152fe02249153103be341d65b67,5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="COLLAGEN" target="ANTI-TL1A ANTIBODY">
      <data key="d4">8.0</data>
      <data key="d5">Anti-TL1A antibody reduces collagen deposition</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="COLLAGEN" target="LIVER FIBROSIS">
      <data key="d4">7.0</data>
      <data key="d5">Collagen deposition is measured to assess liver fibrosis</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="FORMALIN-FIXED, PARAFFIN-EMBEDDED TISSUE" target="TISSUE">
      <data key="d4">7.0</data>
      <data key="d5">Formalin-fixed, paraffin-embedded tissue is a method of preserving tissue samples for histological analysis</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="DAPI" target="4&#8242;,6-DIAMIDINO-2-PHENYLINDOLE">
      <data key="d4">9.0</data>
      <data key="d5">DAPI is a fluorescent stain that binds strongly to DNA</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="DAPI" target="VECTASHIELD">
      <data key="d4">14.0</data>
      <data key="d5">VECTASHIELD is used as a mounting medium with DAPI</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="DONKEY SERUM" target="IMMUNOFLUORESCENCE">
      <data key="d4">12.0</data>
      <data key="d5">Donkey serum is used as a blocking agent in immunofluorescence</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="ZEISS AXIOSKOP 2" target="IMMUNOFLUORESCENCE">
      <data key="d4">14.0</data>
      <data key="d5">Zeiss Axioskop 2 is used for imaging in immunofluorescence</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="KERATINOCYTE" target="AHR">
      <data key="d4">8.0</data>
      <data key="d5">AhR involves keratinocyte expression</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="KERATINOCYTE" target="SPINK5">
      <data key="d4">7.0</data>
      <data key="d5">SPINK5 is prevalent in keratinocytes</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="CORTICOSTEROIDS" target="GLUCOSE INTOLERANCE">
      <data key="d4">12.0</data>
      <data key="d5">Glucose intolerance is a side effect of corticosteroids</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="CORTICOSTEROIDS" target="HEADACHES">
      <data key="d4">12.0</data>
      <data key="d5">Headaches are a side effect of corticosteroids</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="CORTICOSTEROIDS" target="DEPRESSION">
      <data key="d4">12.0</data>
      <data key="d5">Depression is a side effect of corticosteroids</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="PIMECROLIMUS" target="LEO 29102">
      <data key="d4">6.0</data>
      <data key="d5">LEO 29102 was compared with pimecrolimus in a phase II study</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="PIMECROLIMUS" target="CALCINEURIN INHIBITOR">
      <data key="d4">8.0</data>
      <data key="d5">Pimecrolimus is a topical calcineurin inhibitor</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="TACROLIMUS" target="HYALURONIC ACID">
      <data key="d4">14.0</data>
      <data key="d5">Tacrolimus and Hyaluronic acid are used together in nanotechnology-based therapeutic approaches</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="STAPHYLOCOCCUS AUREUS" target="STAPHYLOCOCCUS HOMINIS A9">
      <data key="d4">9.0</data>
      <data key="d5">Staphylococcus hominis A9 targets Staphylococcus aureus and inhibits its toxin production</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="ITCH" target="SCRATCH">
      <data key="d4">8.0</data>
      <data key="d5">Scratching is a response to itch, exacerbating atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="ITCH" target="VIXARELIMAB">
      <data key="d4">16.0</data>
      <data key="d5">Vixarelimab reduces pruritus in atopic dermatitis</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="ITCH" target="SUBSTANCE P">
      <data key="d4">16.0</data>
      <data key="d5">Substance P is involved in the initiation and transmission of itch</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="ITCH" target="NK1R">
      <data key="d4">16.0</data>
      <data key="d5">NK1R is involved in the transmission of itch signals</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="ITCH" target="SERLOPITANT">
      <data key="d4">14.0</data>
      <data key="d5">Serlopitant reduces pruritus</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="ITCH" target="TRADIPITANT">
      <data key="d4">14.0</data>
      <data key="d5">Tradipitant reduces pruritus</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="ITCH" target="P2XR3">
      <data key="d4">14.0</data>
      <data key="d5">P2XR3 is associated with itch</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="ITCH" target="BLU-5937">
      <data key="d4">14.0</data>
      <data key="d5">BLU-5937 is in development to treat pruritus</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="CRACKING" target="POEM">
      <data key="d4">8.0</data>
      <data key="d5">Cracking is one of the symptoms assessed in the POEM tool</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="TH2 CELL" target="CHEMOTACTIC MEDIATOR">
      <data key="d4">7.0</data>
      <data key="d5">TH2 cells are recruited by locally produced chemotactic mediators</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="TH2 CELL" target="IMMUNE SYSTEM">
      <data key="d4">1.0</data>
      <data key="d5">TH2 cells are part of the immune system</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="TH2 CELL" target="CRTH2">
      <data key="d4">8.0</data>
      <data key="d5">CRTH2 is preferentially expressed on TH2 cells and directs their migration into the skin in AD</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="TH2 CELL" target="RPT193">
      <data key="d4">7.0</data>
      <data key="d5">RPT193 selectively blocks the recruitment of TH2 cells in allergic diseases</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="ILC2" target="TL1A">
      <data key="d4">14.0</data>
      <data key="d5">TL1A activates ILC2 cells and acts as a costimulatory molecule for ILC2s.</data>
      <data key="d6">05c97152fe02249153103be341d65b67,c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="IL-5" target="EOSINOPHILS">
      <data key="d4">34.0</data>
      <data key="d5">IL-5 and eosinophils are closely related in the context of immune response. IL-5 is a cytokine that plays a crucial role in eosinophil biology. It is responsible for the migration of eosinophils, guiding these cells to sites where they are needed in the body. This relationship underscores the importance of IL-5 in the regulation and function of eosinophils, which are key players in the immune system, particularly in the context of allergic reactions and certain autoimmune diseases.</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41,3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="IL-5" target="MEPOLIZUMAB">
      <data key="d4">16.0</data>
      <data key="d5">Mepolizumab targets IL-5</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="IL-5" target="EOSINOPHILIC ESOPHAGITIS">
      <data key="d4">14.0</data>
      <data key="d5">IL-5 is important in eosinophilic esophagitis</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="IL-5" target="CSA">
      <data key="d4">14.0</data>
      <data key="d5">CsA-loaded nanoparticles reduce IL-5 levels</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="IL-5" target="HYDROCORTISONE">
      <data key="d4">14.0</data>
      <data key="d5">HC-NPs suppressed inflammatory cascades including IL-5</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="IL-5" target="TRAIL">
      <data key="d4">7.0</data>
      <data key="d5">TRAIL is necessary for the production of IL-5</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="DC" target="LANGERHANS CELLS">
      <data key="d4">14.0</data>
      <data key="d5">Langerhans cells are a type of dendritic cell</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="DC" target="CCL22">
      <data key="d4">16.0</data>
      <data key="d5">CCL22 promotes the attraction of inflammatory DC subtypes</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="DC" target="CCL5">
      <data key="d4">16.0</data>
      <data key="d5">CCL5 promotes the attraction of inflammatory DC subtypes</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="DC" target="AHR">
      <data key="d4">8.0</data>
      <data key="d5">AhR involves epidermal DCs&#8217; residence</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="DC" target="MMP-2">
      <data key="d4">14.0</data>
      <data key="d5">MMP-2 stimulates dendritic cells to up-regulate OX40L</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="DC" target="MMP">
      <data key="d4">14.0</data>
      <data key="d5">MMPs condition dendritic cells to prime TH2 phenotype via an OX40L-dependent pathway</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="IL-13R&#913;1" target="JAK/STAT PATHWAY">
      <data key="d4">16.0</data>
      <data key="d5">IL-13R&#945;1 is involved in the JAK/STAT signaling pathway</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0</data>
    </edge>
    <edge source="IL-13R&#913;1" target="ASLAN004">
      <data key="d4">8.0</data>
      <data key="d5">ASLAN004 is directed against IL-13R&#945;1</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="IL-13R&#913;1" target="TYPE II RECEPTOR">
      <data key="d4">7.0</data>
      <data key="d5">IL-13R&#945;1 is part of the type II receptor</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="HYPERTENSION" target="HCM">
      <data key="d4">14.0</data>
      <data key="d5">Hypertension can induce hypertrophic cardiomyopathy</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="HYPERTENSION" target="ANG-II">
      <data key="d4">14.0</data>
      <data key="d5">Ang-II-induced hypertension is associated with cardiac hypertrophy</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="BIOLOGICS" target="CYTOKINE RECEPTORS">
      <data key="d4">8.0</data>
      <data key="d5">Biologics target cytokine receptors in immune responses</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="IL-13R&#913;2" target="MOUSE MODEL">
      <data key="d4">12.0</data>
      <data key="d5">Loss of IL-13R&#945;2 was shown to be deleterious in a mouse model of cutaneous inflammation</data>
      <data key="d6">96e553a44a27e728c27c4892045ec5c2</data>
    </edge>
    <edge source="PF-04965842" target="NCT02780167">
      <data key="d4">8.0</data>
      <data key="d5">NCT02780167 is a phase 2 study for PF-04965842 in AD</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="PF-04965842" target="JADE MONO-1">
      <data key="d4">8.0</data>
      <data key="d5">JADE Mono-1 is a phase 3 trial for PF-04965842 in AD</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="PF-04965842" target="JADE MONO-2">
      <data key="d4">8.0</data>
      <data key="d5">JADE Mono-2 is a phase 3 trial for PF-04965842 in AD</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="PF-04965842" target="JADE EXTEND">
      <data key="d4">1.0</data>
      <data key="d5">JADE EXTEND is a phase 3 long-term extension study for PF-04965842 in AD</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="PDE-4" target="CAMP">
      <data key="d4">7.0</data>
      <data key="d5">Inhibition of PDE-4 increases levels of cAMP</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="PERIOSTIN" target="LIGHT">
      <data key="d4">14.0</data>
      <data key="d5">LIGHT induces periostin production in keratinocytes</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="ILC2S" target="TL1A">
      <data key="d4">8.0</data>
      <data key="d5">TL1A acts on ILC2s to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="DCS" target="AHR">
      <data key="d4">6.0</data>
      <data key="d5">AhR is expressed in dendritic cells</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="DCS" target="S1P">
      <data key="d4">12.0</data>
      <data key="d5">S1P affects dendritic cells</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="DCS" target="GITRL">
      <data key="d4">7.0</data>
      <data key="d5">GITRL is mainly expressed on DCs</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="MAST CELL" target="NIC-CS-NPS">
      <data key="d4">7.0</data>
      <data key="d5">NIC-CS-NPs decreased mast cell infiltration in DNCB-induced AD skin lesions</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="MAST CELL" target="EOE">
      <data key="d4">7.0</data>
      <data key="d5">Mast cells are involved in the inflammation of the esophagus in EoE</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="IL-17C" target="MOR106">
      <data key="d4">9.0</data>
      <data key="d5">MOR106 targets IL-17C to treat moderate-to-severe atopic dermatitis</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="FEZAKINUMAB" target="PHASE IIA STUDY">
      <data key="d4">7.0</data>
      <data key="d5">Fezakinumab is being investigated in a Phase IIa study</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="FEZAKINUMAB" target="PROOF-OF-CONCEPT STUDY">
      <data key="d4">7.0</data>
      <data key="d5">Fezakinumab was investigated in a proof-of-concept study</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="FEZAKINUMAB" target="PLACEBO GROUP">
      <data key="d4">7.0</data>
      <data key="d5">Fezakinumab was compared to a placebo group in a study</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="INTERLEUKIN" target="IMMUNE SYSTEM">
      <data key="d4">8.0</data>
      <data key="d5">Interleukins play important roles in the immune system</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="IGG1&#922;" target="MONOCLONAL ANTIBODIES">
      <data key="d4">7.0</data>
      <data key="d5">IgG1&#954; is used in monoclonal antibodies for therapeutic purposes</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="IGG1&#923;" target="MONOCLONAL ANTIBODIES">
      <data key="d4">1.0</data>
      <data key="d5">IgG1&#955; is used in monoclonal antibodies for therapeutic purposes</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="IMMUNE SYSTEM" target="TREG CELL">
      <data key="d4">8.0</data>
      <data key="d5">Treg cells are part of the immune system</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="DENDRITIC CELLS" target="HIGH-AFFINITY IGE RECEPTOR">
      <data key="d4">7.0</data>
      <data key="d5">High-affinity IgE receptor is expressed in dendritic cells in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="TEZEPELUMAB" target="EASI50">
      <data key="d4">7.0</data>
      <data key="d5">Tezepelumab showed results in achieving EASI50 in AD</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="TEZEPELUMAB" target="SEVERE AND UNCONTROLLED ALLERGIC ASTHMA">
      <data key="d4">1.0</data>
      <data key="d5">Tezepelumab showed results in severe and uncontrolled allergic asthma</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="TEZEPELUMAB" target="SEVERE ALLERGIC ASTHMA">
      <data key="d4">8.0</data>
      <data key="d5">Tezepelumab showed convincing results in patients with severe and uncontrolled allergic asthma</data>
      <data key="d6">6309eeea565f06479830cec32938abc9</data>
    </edge>
    <edge source="TEZEPELUMAB" target="THYMIC STROMAL LYMPHOPOIETIN">
      <data key="d4">16.0</data>
      <data key="d5">Tezepelumab targets TSLP to modulate the immune response in atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="BASOPHILS" target="BENRALIZUMAB">
      <data key="d4">16.0</data>
      <data key="d5">Benralizumab depletes basophils</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="EOSINOPHILS" target="EOSINOPHIL-DERIVED NEUROTOXIN">
      <data key="d4">14.0</data>
      <data key="d5">Eosinophil-derived neurotoxin is released by eosinophils</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="EOSINOPHILS" target="EOSINOPHIL CATIONIC PROTEIN">
      <data key="d4">14.0</data>
      <data key="d5">Eosinophil cationic protein is released by eosinophils</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="EOSINOPHILS" target="MEPOLIZUMAB">
      <data key="d4">14.0</data>
      <data key="d5">Mepolizumab reduces eosinophilia</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="EOSINOPHILS" target="BENRALIZUMAB">
      <data key="d4">16.0</data>
      <data key="d5">Benralizumab depletes eosinophils</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="EOSINOPHILS" target="HVEM">
      <data key="d4">14.0</data>
      <data key="d5">HVEM is expressed on eosinophils</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="IMMUNOGLOBULIN E" target="FB825/ANTI-C&#917;MX">
      <data key="d4">8.0</data>
      <data key="d5">FB825/anti-C&#949;mX targets Immunoglobulin E</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="ALLERGIC RHINO-CONJUNCTIVITIS" target="AEROALLERGENS">
      <data key="d4">7.0</data>
      <data key="d5">Aeroallergens can trigger allergic rhino-conjunctivitis</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="PHOSPHODIESTERASE 4" target="ANTI-INFLAMMATORY CYTOKINES">
      <data key="d4">7.0</data>
      <data key="d5">Anti-inflammatory cytokines are generated by increasing cAMP levels through PDE4 inhibitors in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="FIBROBLAST" target="HYDROCORTISONE">
      <data key="d4">14.0</data>
      <data key="d5">HC-NPs blocked or significantly decreased fibroblast infiltration</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="FIBROBLAST" target="SSC">
      <data key="d4">9.0</data>
      <data key="d5">Fibroblasts are involved in the fibrosis seen in systemic sclerosis</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="FIBROBLAST" target="EXTRACELLULAR MATRIX">
      <data key="d4">1.0</data>
      <data key="d5">Fibroblasts produce extracellular matrix, contributing to fibrosis</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="FIBROBLAST" target="M2 MACROPHAGES">
      <data key="d4">16.0</data>
      <data key="d5">M2 macrophages promote fibroblast activation</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="FIBROBLAST" target="TNFR1">
      <data key="d4">16.0</data>
      <data key="d5">TNFR1 signaling is essential for fibroblast formation</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="INTERLEUKIN-22" target="FEZAKIMUAB">
      <data key="d4">8.0</data>
      <data key="d5">Fezakimuab targets Interleukin-22</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="INTERLEUKIN-23" target="RISANKIZUMAB">
      <data key="d4">8.0</data>
      <data key="d5">Risankizumab targets Interleukin-23</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="EDEMA" target="INFANTILE ATOPIC DERMATITIS">
      <data key="d4">7.0</data>
      <data key="d5">Edema is swelling of the skin, often seen in infantile Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="EDEMA" target="CLOBETASOL PROPIONATE (CP)">
      <data key="d4">7.0</data>
      <data key="d5">Clobetasol Propionate (CP) significantly inhibits edema</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="LICHENIFICATION" target="CHILDHOOD ATOPIC DERMATITIS">
      <data key="d4">7.0</data>
      <data key="d5">Lichenification is the thickening of the skin due to chronic scratching, often seen in childhood Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="XEROSIS" target="CHILDHOOD ATOPIC DERMATITIS">
      <data key="d4">7.0</data>
      <data key="d5">Xerosis is increased dryness of the skin, often seen in childhood Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ELASTIN" target="MMP-12">
      <data key="d4">14.0</data>
      <data key="d5">MMP-12 may lead to elastin degradation</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="FIBRONECTIN" target="LIGHT">
      <data key="d4">6.0</data>
      <data key="d5">Genetic deletion of LIGHT reduces fibronectin expression in UUO-induced mice</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="KERATIN" target="STRATUM CORNEUM FORMATION">
      <data key="d4">8.0</data>
      <data key="d5">Keratin buildup is crucial for the formation of the stratum corneum</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="MICROBIOME" target="MSB-01">
      <data key="d4">7.0</data>
      <data key="d5">MSB-01 is a topical product in clinical development for modulating the skin microbiome</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="MICROBIOME" target="DB-001">
      <data key="d4">7.0</data>
      <data key="d5">DB-001 is a topical product in clinical development for modulating the skin microbiome</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="POEM" target="RECAP">
      <data key="d4">8.0</data>
      <data key="d5">POEM correlates well with RECAP</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="POEM" target="BLEEDING">
      <data key="d4">8.0</data>
      <data key="d5">Bleeding is one of the symptoms assessed in the POEM tool</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="POEM" target="WEEPING/OOZING">
      <data key="d4">8.0</data>
      <data key="d5">Weeping/oozing is one of the symptoms assessed in the POEM tool</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="POEM" target="FLAKING">
      <data key="d4">8.0</data>
      <data key="d5">Flaking is one of the symptoms assessed in the POEM tool</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="POEM" target="DRYNESS OF THE SKIN">
      <data key="d4">8.0</data>
      <data key="d5">Dryness of the skin is one of the symptoms assessed in the POEM tool</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="ROSEOMONAS MUCOSA" target="FB-401">
      <data key="d4">8.0</data>
      <data key="d5">FB-401 is a product combining three strains of Roseomonas mucosa</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="FB-401" target="TLR5">
      <data key="d4">22.0</data>
      <data key="d5">FB-401 and TLR5 are closely related in their biological functions. FB-401 is known to activate tissue repair and anti-inflammatory activity through its interaction with TLR5. However, there is also evidence suggesting that FB-401 can inhibit TLR5 signaling. This dual role indicates that FB-401 may have a complex regulatory effect on TLR5, potentially modulating its activity in a context-dependent manner to balance tissue repair and inflammation.</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a,f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="FB-401" target="TNFR">
      <data key="d4">22.0</data>
      <data key="d5">FB-401 and TNFR are closely related entities in the context of autoimmune diseases. FB-401 activates tissue repair and anti-inflammatory activity via TNFR, suggesting a beneficial role in modulating immune responses and promoting healing. However, FB-401 also inhibits TNFR signaling, indicating a complex mechanism of action where it may simultaneously dampen excessive inflammatory responses mediated by TNFR. This dual role highlights FB-401's potential as a therapeutic agent in managing autoimmune conditions by balancing tissue repair and inflammation through its interaction with TNFR.</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a,f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="FB-401" target="FORTE BIOSCIENCES">
      <data key="d4">8.0</data>
      <data key="d5">Forte Biosciences is conducting clinical trials of FB-401 for atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="STAPHYLOCOCCUS HOMINIS A9" target="SHA9">
      <data key="d4">8.0</data>
      <data key="d5">ShA9 is a lyophilized strain of Staphylococcus hominis A9</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="STAPHYLOCOCCUS HOMINIS A9" target="S. AUREUS">
      <data key="d4">16.0</data>
      <data key="d5">Staphylococcus hominis A9 kills S. aureus and inhibits its toxins</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="NITRIC OXIDE" target="B244">
      <data key="d4">8.0</data>
      <data key="d5">B244 produces nitric oxide</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="NITROSOMONAS EUTROPHA" target="B244">
      <data key="d4">8.0</data>
      <data key="d5">B244 contains Nitrosomonas eutropha</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="B244" target="INFLAMMATORY REACTION">
      <data key="d4">7.0</data>
      <data key="d5">B244 is used to measure the clinical response of the inflammatory reaction in atopic dermatitis</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="B244" target="AOBIOME">
      <data key="d4">1.0</data>
      <data key="d5">AOBiome is involved in the development of B244 for atopic dermatitis</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="B244" target="RCT">
      <data key="d4">7.0</data>
      <data key="d5">B244 was tested in a randomized controlled trial</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="B244" target="PHASE IIA">
      <data key="d4">7.0</data>
      <data key="d5">B244 was tested in a phase IIa trial</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="B244" target="PHASE IB">
      <data key="d4">7.0</data>
      <data key="d5">B244 was tested in a phase Ib trial</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="B244" target="PHASE IIB">
      <data key="d4">7.0</data>
      <data key="d5">B244 is currently in a phase IIb trial</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="S. AUREUS" target="NICLOSAMIDE">
      <data key="d4">7.0</data>
      <data key="d5">Niclosamide inhibits the growth of S. aureus</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="S. AUREUS" target="OMIGANAN PENTACHLORIDE">
      <data key="d4">7.0</data>
      <data key="d5">Omiganan pentachloride is used to control the overgrowth of S. aureus in AD</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="S. AUREUS" target="ADAPTIVE IMMUNE RESPONSE">
      <data key="d4">7.0</data>
      <data key="d5">High colonization with S. aureus impacts the adaptive immune response</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="S. AUREUS" target="&#916;-TOXIN">
      <data key="d4">14.0</data>
      <data key="d5">&#948;-toxin is produced by S. aureus and can trigger mast cells</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="S. AUREUS" target="&#913;-TOXIN">
      <data key="d4">14.0</data>
      <data key="d5">&#945;-toxin is produced by S. aureus and can damage host cells</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="NICLOSAMIDE" target="HISTOLOGICAL MODIFICATIONS">
      <data key="d4">6.0</data>
      <data key="d5">Niclosamide showed significant histological modifications</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="NICLOSAMIDE" target="TRANSCRIPTIONAL MODIFICATIONS">
      <data key="d4">6.0</data>
      <data key="d5">Niclosamide showed significant transcriptional modifications</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="NICLOSAMIDE" target="BARRIER FUNCTION">
      <data key="d4">6.0</data>
      <data key="d5">Niclosamide impacts the barrier function</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="OMIGANAN PENTACHLORIDE" target="DYSBIOSIS">
      <data key="d4">7.0</data>
      <data key="d5">Omiganan pentachloride is used to control dysbiosis</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="AHR" target="COAL TAR">
      <data key="d4">14.0</data>
      <data key="d5">Coal tar binds to the aryl hydrocarbon receptor (AhR). This interaction not only facilitates the binding process but also plays a crucial role in restoring filaggrin expression.</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="AHR" target="TAPINAROF">
      <data key="d4">17.0</data>
      <data key="d5">Tapinarof is a natural agonist of the aryl hydrocarbon receptor (AhR). As an AhR agonist, Tapinarof plays a significant role in modulating immune responses. Specifically, it has been shown to decrease inflammatory reactions, making it a potential therapeutic agent for conditions characterized by excessive inflammation.</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807,6059a6e2710b7df94c6a09e5eb7b024a,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="AHR" target="FLG">
      <data key="d4">14.0</data>
      <data key="d5">Coal tar binds to AhR and restores FLG expression</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="COAL TAR" target="FLG">
      <data key="d4">7.0</data>
      <data key="d5">Coal tar restores FLG expression</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="TAPINAROF" target="INVESTIGATOR GLOBAL ASSESSMENT (IGA)">
      <data key="d4">7.0</data>
      <data key="d5">Tapinarof showed results in achieving IGA 0/1 in AD</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="SPINK5" target="ALARMINS">
      <data key="d4">7.0</data>
      <data key="d5">SPINK5 mutations lead to the generation of alarmins</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="ADAPTIVE IMMUNE RESPONSE" target="TREG CELL">
      <data key="d4">8.0</data>
      <data key="d5">Treg cells are involved in the adaptive immune response</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="ADAPTIVE IMMUNE RESPONSE" target="ANTIGEN">
      <data key="d4">8.0</data>
      <data key="d5">Antigen presentation is the starting point for the adaptive immune response</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="ETOKIMAB" target="CXCR1">
      <data key="d4">12.0</data>
      <data key="d5">Etokimab inhibited CXCR1-dependent neutrophil migration</data>
      <data key="d6">6309eeea565f06479830cec32938abc9</data>
    </edge>
    <edge source="KY1005" target="TEFF CELL">
      <data key="d4">8.0</data>
      <data key="d5">KY1005 inhibits the effector T cell response</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="KY1005" target="TREG CELL">
      <data key="d4">8.0</data>
      <data key="d5">KY1005 maintains regulatory T cell activity</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="KY1005" target="PHASE IIA STUDY">
      <data key="d4">8.0</data>
      <data key="d5">KY1005 showed interesting results in a phase IIa study</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="KY1005" target="KYMAB">
      <data key="d4">16.0</data>
      <data key="d5">KY1005, developed by Kymab, has shown positive phase 2a results in the treatment of atopic dermatitis.</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0,83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="KY1005" target="OX40 LIGAND">
      <data key="d4">16.0</data>
      <data key="d5">KY1005 targets OX40L to modulate the immune response in atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="KY1005" target="IMMUNE SYSTEM DISEASES">
      <data key="d4">8.0</data>
      <data key="d5">KY1005 is used in clinical trials for immune system diseases</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="TREG CELL" target="IL-2">
      <data key="d4">8.0</data>
      <data key="d5">IL-2 is involved in the activation and proliferation of Treg cells</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="TREG CELL" target="LY3471851">
      <data key="d4">8.0</data>
      <data key="d5">LY3471851 leads to activation and proliferation of Treg cells</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="TREG CELL" target="AUTOIMMUNE DISORDERS">
      <data key="d4">8.0</data>
      <data key="d5">Treg cells are involved in autoimmune disorders</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="TREG CELL" target="RHIL-2">
      <data key="d4">9.0</data>
      <data key="d5">Recombinant human IL-2 (rhIL-2) targets the IL-2 receptor complex on T cells, leading to activation and proliferation of Treg cells</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="TREG CELL" target="NCT04081350">
      <data key="d4">7.0</data>
      <data key="d5">NCT04081350 is a clinical trial involving Treg cells</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="IL-2R&#915;" target="TYPE I RECEPTOR">
      <data key="d4">7.0</data>
      <data key="d5">IL-2R&#947; is part of the type I receptor</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="CBP-201" target="PLACEBO GROUP">
      <data key="d4">8.0</data>
      <data key="d5">CBP-201 showed better results compared to the placebo group</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="AK120" target="MODERATE-TO-SEVERE AD">
      <data key="d4">7.0</data>
      <data key="d5">AK120 is being tested in patients with moderate-to-severe AD</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="AK120" target="HEALTHY SUBJECTS">
      <data key="d4">7.0</data>
      <data key="d5">AK120 is being tested in healthy subjects</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="ASLAN004" target="ASLAN">
      <data key="d4">8.0</data>
      <data key="d5">ASLAN004 is developed by ASLAN</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="ASLAN004" target="ASAN PHARMACEUTICALS">
      <data key="d4">8.0</data>
      <data key="d5">Asan Pharmaceuticals is conducting studies on ASLAN004 for atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ASLAN004" target="INTERLEUKIN-4RA">
      <data key="d4">8.0</data>
      <data key="d5">ASLAN004 targets Interleukin-4Ra</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="KYMAB" target="BIOLOGIC THERAPIES">
      <data key="d4">6.0</data>
      <data key="d5">Kymab develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="MEPOLIZUMAB" target="TARC">
      <data key="d4">12.0</data>
      <data key="d5">Mepolizumab failed to show a significant decrease in TARC</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="MEPOLIZUMAB" target="IL5R">
      <data key="d4">16.0</data>
      <data key="d5">Mepolizumab inhibits IL-5 by targeting IL5R</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="MEPOLIZUMAB" target="INTERLEUKIN-5">
      <data key="d4">8.0</data>
      <data key="d5">Mepolizumab targets Interleukin-5</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="BENRALIZUMAB" target="IL-5R&#913;">
      <data key="d4">16.0</data>
      <data key="d5">Benralizumab targets IL-5R&#945;</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="BENRALIZUMAB" target="IL5R">
      <data key="d4">16.0</data>
      <data key="d5">Benralizumab inhibits IL-5 by targeting IL5R</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="BENRALIZUMAB" target="INTERLEUKIN-5RA">
      <data key="d4">8.0</data>
      <data key="d5">Benralizumab targets Interleukin-5Ra</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="MIGE" target="ANTI-C&#917;MX (FB825)">
      <data key="d4">8.0</data>
      <data key="d5">Anti-C&#949;mX (FB825) targets mIgE to deplete IgE-committed B cells</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-22R" target="IL-22R1">
      <data key="d4">7.0</data>
      <data key="d5">IL-22R1 is a subunit of the IL-22 receptor complex</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-22R" target="IL-10R2">
      <data key="d4">7.0</data>
      <data key="d5">IL-10R2 is a subunit of the IL-22 receptor complex</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-22R1" target="IL-20">
      <data key="d4">7.0</data>
      <data key="d5">IL-20 binds to IL-22R1 and IL-20R2 receptor complexes</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-22R1" target="IL-24">
      <data key="d4">7.0</data>
      <data key="d5">IL-24 binds to IL-22R1 and IL-20R2 receptor complexes</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-22R1" target="LEO 138559">
      <data key="d4">7.0</data>
      <data key="d5">LEO 138559 is an antibody directed against IL-22R1</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-22R1" target="IL-20R2">
      <data key="d4">8.0</data>
      <data key="d5">IL-20R2 forms a complex with IL-22R1</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-22R1" target="RECEPTOR COMPLEX">
      <data key="d4">7.0</data>
      <data key="d5">IL-22R1 forms part of the receptor complex</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="LEO 138559" target="PHASE I STUDIES">
      <data key="d4">7.0</data>
      <data key="d5">LEO 138559 is being investigated in Phase I studies</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-2" target="LY3471851">
      <data key="d4">8.0</data>
      <data key="d5">LY3471851 is designed to target the IL-2 receptor complex on T cells</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-2" target="RECOMBINANT HUMAN IL-2">
      <data key="d4">8.0</data>
      <data key="d5">Recombinant human IL-2 is a lab-produced form of IL-2</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-2" target="IL-2 RECEPTOR">
      <data key="d4">9.0</data>
      <data key="d5">IL-2 binds to the IL-2 receptor on T cells, leading to their activation and proliferation</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="IL-2" target="TAC">
      <data key="d4">7.0</data>
      <data key="d5">TAC-loaded PLG-based NPs reduce IL-2 expression</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="IL-2" target="SSC">
      <data key="d4">8.0</data>
      <data key="d5">IL-2 is a cytokine involved in systemic sclerosis</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="LY3471851" target="ULCERATIVE COLITIS">
      <data key="d4">7.0</data>
      <data key="d5">LY3471851 is investigated for the treatment of Ulcerative Colitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="ULCERATIVE COLITIS" target="RHIL-2">
      <data key="d4">7.0</data>
      <data key="d5">Recombinant human IL-2 (rhIL-2) is being tested for its potential to restore tolerance and improve ulcerative colitis</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="ULCERATIVE COLITIS" target="GASTROINTESTINAL TRACT">
      <data key="d4">8.0</data>
      <data key="d5">Ulcerative colitis affects the gastrointestinal tract</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="ULCERATIVE COLITIS" target="TL1A">
      <data key="d4">8.0</data>
      <data key="d5">TL1A is targeted by anti-TL1A antibody in the treatment of ulcerative colitis</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="ULCERATIVE COLITIS" target="ANTI-TNF THERAPY">
      <data key="d4">16.0</data>
      <data key="d5">Anti-TNF therapy is used to treat ulcerative colitis</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="ULCERATIVE COLITIS" target="MDGN-002">
      <data key="d4">14.0</data>
      <data key="d5">MDGN-002 is used in clinical trials to treat Ulcerative Colitis</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="ULCERATIVE COLITIS" target="PF-06480605">
      <data key="d4">8.0</data>
      <data key="d5">PF-06480605 is being tested for its efficacy in treating ulcerative colitis</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="ULCERATIVE COLITIS" target="KYOWA KIRIN, INC.">
      <data key="d4">6.0</data>
      <data key="d5">Kyowa Kirin, Inc. is involved in clinical trials for ulcerative colitis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="ULCERATIVE COLITIS" target="KYOWA KIRIN CO., LTD.">
      <data key="d4">6.0</data>
      <data key="d5">Kyowa Kirin Co., Ltd. is involved in clinical trials for ulcerative colitis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="IL-20R2" target="IL-20R1">
      <data key="d4">8.0</data>
      <data key="d5">IL-20R1 forms a complex with IL-20R2</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="RECOMBINANT HUMAN IL-2" target="PEGYLATED">
      <data key="d4">7.0</data>
      <data key="d5">Recombinant human IL-2 is pegylated to improve its properties</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="PDE4" target="LEO 29102">
      <data key="d4">15.0</data>
      <data key="d5">LEO 29102 is a PDE inhibitor that specifically targets the PDE4 enzyme, with a particular selectivity for the PDE4D isoform.</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89,f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="PDE4" target="PDE4 INHIBITOR">
      <data key="d4">8.0</data>
      <data key="d5">PDE4 inhibitors target PDE4 to reduce inflammation</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="PDE4" target="LOTAMILAST">
      <data key="d4">8.0</data>
      <data key="d5">Lotamilast targets the PDE4 enzyme</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="PDE4" target="DIFAMILAST">
      <data key="d4">8.0</data>
      <data key="d5">Difamilast targets the PDE4 enzyme</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="PDE4" target="DRM02">
      <data key="d4">8.0</data>
      <data key="d5">DRM02 targets the PDE4 enzyme</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="PDE4" target="ROFLUMILAST">
      <data key="d4">8.0</data>
      <data key="d5">Roflumilast targets the PDE4 enzyme</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="PDE4" target="HEMAY-808">
      <data key="d4">8.0</data>
      <data key="d5">Hemay-808 targets the PDE4 enzyme</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="PDE4" target="PF-07038124">
      <data key="d4">8.0</data>
      <data key="d5">PF-07038124 targets the PDE4 enzyme</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="LOTAMILAST" target="NCT03394677">
      <data key="d4">7.0</data>
      <data key="d5">NCT03394677 is a clinical trial involving Lotamilast</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="LOTAMILAST" target="NCT02950922">
      <data key="d4">7.0</data>
      <data key="d5">NCT02950922 is a clinical trial involving Lotamilast</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="DIFAMILAST" target="OTSUKA">
      <data key="d4">8.0</data>
      <data key="d5">Otsuka is conducting phase 3 studies on difamilast for atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="DIFAMILAST" target="NCT02945657">
      <data key="d4">7.0</data>
      <data key="d5">NCT02945657 is a clinical trial involving Difamilast</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="ROFLUMILAST" target="NCT04156191">
      <data key="d4">7.0</data>
      <data key="d5">NCT04156191 is a clinical trial involving Roflumilast</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="LEO 29102" target="NCT01037881">
      <data key="d4">7.0</data>
      <data key="d5">NCT01037881 is a clinical trial involving LEO 29102</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="HISTAMINE H4 RECEPTOR" target="ADRIFORANT">
      <data key="d4">7.0</data>
      <data key="d5">Adriforant is an H4R antagonist tested for inflammatory skin disorders</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="HISTAMINE H4 RECEPTOR" target="LEO 152020">
      <data key="d4">6.0</data>
      <data key="d5">LEO 152020 is an oral H4R antagonist currently in phase I</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="ADRIFORANT" target="H4R">
      <data key="d4">8.0</data>
      <data key="d5">Adriforant targets the H4R receptor</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="ADRIFORANT" target="NCT03517566">
      <data key="d4">7.0</data>
      <data key="d5">NCT03517566 is a clinical trial involving Adriforant</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="LEO 152020" target="HISTAMINE RECEPTOR 4">
      <data key="d4">16.0</data>
      <data key="d5">LEO 152020 targets Histamine Receptor 4 (H4R) to reduce inflammation in atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="H2R" target="GASTROINTESTINAL TRACT">
      <data key="d4">7.0</data>
      <data key="d5">H2R is mainly localized in the gastrointestinal tract</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="H3R" target="CENTRAL NERVOUS SYSTEM">
      <data key="d4">7.0</data>
      <data key="d5">H3R is localized in the central nervous system</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="GASTROINTESTINAL TRACT" target="EOSINOPHILIC ESOPHAGITIS">
      <data key="d4">8.0</data>
      <data key="d5">Eosinophilic esophagitis affects the gastrointestinal tract</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="GASTROINTESTINAL TRACT" target="TL1A">
      <data key="d4">7.0</data>
      <data key="d5">TL1A is studied in disease models involving the gastrointestinal tract</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="H4R" target="LEO 152020/JW1601">
      <data key="d4">8.0</data>
      <data key="d5">LEO 152020/JW1601 targets the H4R receptor</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="CRTH2" target="FEVIPIPRANT">
      <data key="d4">7.0</data>
      <data key="d5">Fevipiprant is a CRTH2 antagonist</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="CRTH2" target="TEMAPIPRANT">
      <data key="d4">7.0</data>
      <data key="d5">Temapiprant is a CRTH2 antagonist</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="RPT193" target="RAPT THERAPEUTICS">
      <data key="d4">8.0</data>
      <data key="d5">RAPT Therapeutics is conducting a phase 1b trial of RPT193 for atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="RPT193" target="NCT04271514">
      <data key="d4">7.0</data>
      <data key="d5">NCT04271514 is a clinical trial involving RPT193</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="S1P" target="S1PR1">
      <data key="d4">8.0</data>
      <data key="d5">S1P acts via S1PR1</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="S1P" target="S1PR3">
      <data key="d4">8.0</data>
      <data key="d5">S1P acts via S1PR3</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="S1P" target="S1PR4">
      <data key="d4">8.0</data>
      <data key="d5">S1P acts via S1PR4</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="S1P" target="S1PR5">
      <data key="d4">8.0</data>
      <data key="d5">S1P acts via S1PR5</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="S1P" target="EPIDERMAL KERATINOCYTES">
      <data key="d4">12.0</data>
      <data key="d5">S1P has biological activity on epidermal keratinocytes</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="S1PR1" target="FINGOLIMOD">
      <data key="d4">8.0</data>
      <data key="d5">Fingolimod is an S1PR1 agonist</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="S1PR1" target="SIPONIMOD">
      <data key="d4">8.0</data>
      <data key="d5">Siponimod is an S1PR1 agonist</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="S1PR1" target="ETRASIMOD">
      <data key="d4">16.0</data>
      <data key="d5">Etrasimod targets the S1PR1 receptor and induces sustained internalization of this receptor.</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9,f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="S1PR1" target="AKP-11">
      <data key="d4">8.0</data>
      <data key="d5">AKP-11 is a highly selective S1PR1 agonist</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="S1PR1" target="SCD-044">
      <data key="d4">8.0</data>
      <data key="d5">SCD-044 targets the S1PR1 receptor</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="S1PR1" target="LC51-0255">
      <data key="d4">8.0</data>
      <data key="d5">LC51-0255 targets the S1PR1 receptor</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="S1PR1" target="BMS-986166">
      <data key="d4">8.0</data>
      <data key="d5">BMS-986166 targets the S1PR1 receptor</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="S1PR1" target="KT-474">
      <data key="d4">8.0</data>
      <data key="d5">KT-474 targets the S1PR1 receptor</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="S1PR1" target="AKP-19">
      <data key="d4">8.0</data>
      <data key="d5">AKP-19 targets the S1PR1 receptor</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="S1PR3" target="FINGOLIMOD">
      <data key="d4">8.0</data>
      <data key="d5">Fingolimod is an S1PR3 agonist</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="S1PR4" target="FINGOLIMOD">
      <data key="d4">8.0</data>
      <data key="d5">Fingolimod is an S1PR4 agonist</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="S1PR4" target="ETRASIMOD">
      <data key="d4">8.0</data>
      <data key="d5">Etrasimod targets the S1PR4 receptor</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="S1PR5" target="FINGOLIMOD">
      <data key="d4">8.0</data>
      <data key="d5">Fingolimod is an S1PR5 agonist</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="S1PR5" target="SIPONIMOD">
      <data key="d4">8.0</data>
      <data key="d5">Siponimod is an S1PR5 agonist</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="S1PR5" target="ETRASIMOD">
      <data key="d4">8.0</data>
      <data key="d5">Etrasimod targets the S1PR5 receptor</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="ETRASIMOD" target="ARENA PHARMACEUTICALS">
      <data key="d4">8.0</data>
      <data key="d5">Arena Pharmaceuticals is advancing etrasimod into phase 3 clinical trials for atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ETRASIMOD" target="NCT04162769">
      <data key="d4">7.0</data>
      <data key="d5">NCT04162769 is a clinical trial involving Etrasimod</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="SCD-044" target="NCT04684485">
      <data key="d4">7.0</data>
      <data key="d5">NCT04684485 is a clinical trial involving SCD-044</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="BMS-986166" target="NCT03038711">
      <data key="d4">7.0</data>
      <data key="d5">NCT03038711 is a clinical trial involving BMS-986166</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="KT-474" target="NCT04772885">
      <data key="d4">7.0</data>
      <data key="d5">NCT04772885 is a clinical trial involving KT-474</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="MULTIPLE SCLEROSIS" target="OCRELIZUMAB">
      <data key="d4">8.0</data>
      <data key="d5">Ocrelizumab is used to treat multiple sclerosis</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="IL-31R&#913;" target="OSMR&#914;">
      <data key="d4">18.0</data>
      <data key="d5">IL-31 signals through the heterodimerization of IL-31R&#945; and OSMR&#946;</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="OSMR&#914;" target="VIXARELIMAB">
      <data key="d4">24.0</data>
      <data key="d5">OSMR&#946; and Vixarelimab are closely related entities in the context of autoimmune diseases. Vixarelimab is a therapeutic agent that specifically targets the OSMR&#946; receptor. This receptor, OSMR&#946;, plays a significant role in the pathophysiology of various autoimmune conditions. By targeting the OSMR&#946; receptor, Vixarelimab aims to modulate the immune response, potentially offering a novel treatment approach for patients suffering from these diseases.</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b,f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="VIXARELIMAB" target="PHASE IB STUDY">
      <data key="d4">7.0</data>
      <data key="d5">Phase Ib study showed vixarelimab reduced pruritus</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="VIXARELIMAB" target="NCT03816891">
      <data key="d4">7.0</data>
      <data key="d5">NCT03816891 is a clinical trial involving Vixarelimab</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="SUBSTANCE P" target="NK1R">
      <data key="d4">18.0</data>
      <data key="d5">Substance P signals through NK1R</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="NK1R" target="SERLOPITANT">
      <data key="d4">22.0</data>
      <data key="d5">Serlopitant is an NK1R antagonist that specifically targets the NK1R receptor.</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b,f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="NK1R" target="TRADIPITANT">
      <data key="d4">22.0</data>
      <data key="d5">NK1R and TRADIPITANT: Tradipitant is a NK1R antagonist that specifically targets the NK1R receptor.</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b,f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="SERLOPITANT" target="ATOMIK STUDY">
      <data key="d4">6.0</data>
      <data key="d5">ATOMIK study evaluated serlopitant in atopic dermatitis</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="SERLOPITANT" target="NCT02975206">
      <data key="d4">7.0</data>
      <data key="d5">NCT02975206 is a clinical trial involving Serlopitant</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="TRADIPITANT" target="EPIONE STUDY">
      <data key="d4">6.0</data>
      <data key="d5">EPIONE study evaluated tradipitant in reducing pruritus</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="TRADIPITANT" target="NCT03568331">
      <data key="d4">7.0</data>
      <data key="d5">NCT03568331 is a clinical trial involving Tradipitant</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="P2XR3" target="BLU-5937">
      <data key="d4">14.0</data>
      <data key="d5">BLU-5937 is a selective P2X3 antagonist</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="BLU-5937" target="BLUEPRINT TRIAL">
      <data key="d4">1.0</data>
      <data key="d5">BLUEPRINT trial is exploring the effect of BLU-5937 on pruritus</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="BLU-5937" target="P2X3">
      <data key="d4">8.0</data>
      <data key="d5">BLU-5937 targets the P2X3 receptor</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="BLU-5937" target="NCT04693195">
      <data key="d4">7.0</data>
      <data key="d5">NCT04693195 is a clinical trial involving BLU-5937</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="BREPOCITINIB" target="NCT03903822">
      <data key="d4">7.0</data>
      <data key="d5">NCT03903822 is a clinical trial involving Brepocitinib</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="JAKTINIB" target="PAN-JAK">
      <data key="d4">8.0</data>
      <data key="d5">Jaktinib targets Pan-JAK</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="JAKTINIB" target="NCT04539639">
      <data key="d4">7.0</data>
      <data key="d5">NCT04539639 is a clinical trial involving Jaktinib</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="ATI-1777" target="NCT04598269">
      <data key="d4">7.0</data>
      <data key="d5">NCT04598269 is a clinical trial involving ATI-1777</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="CEE321" target="PAN-JAK">
      <data key="d4">8.0</data>
      <data key="d5">CEE321 targets Pan-JAK</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="CEE321" target="NCT04612062">
      <data key="d4">7.0</data>
      <data key="d5">NCT04612062 is a clinical trial involving CEE321</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="SHR0302" target="NCT04717310">
      <data key="d4">7.0</data>
      <data key="d5">NCT04717310 is a clinical trial involving SHR0302</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="SHR0302" target="NCT04162899">
      <data key="d4">1.0</data>
      <data key="d5">NCT04162899 is a clinical trial involving SHR0302</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="TRKS" target="NEUROTROPHINS">
      <data key="d4">6.0</data>
      <data key="d5">Neurotrophins bind to tropomyosin receptor kinases</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="BEN2293" target="TRK">
      <data key="d4">8.0</data>
      <data key="d5">BEN2293 targets the TRK receptor</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="BEN2293" target="NCT04737304">
      <data key="d4">7.0</data>
      <data key="d5">NCT04737304 is a clinical trial involving BEN2293</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="TAUREOXYCHOLIC ACID" target="NF-&#922;B">
      <data key="d4">6.0</data>
      <data key="d5">Taureoxycholic acid inhibits NF-&#954;B</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="TAUREOXYCHOLIC ACID" target="P38 KINASE">
      <data key="d4">1.0</data>
      <data key="d5">Taureoxycholic acid inhibits P38 kinase</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="NF-&#922;B" target="HY209">
      <data key="d4">6.0</data>
      <data key="d5">HY209 inhibits nuclear factor &#954;B</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="NF-&#922;B" target="TNFR1">
      <data key="d4">8.0</data>
      <data key="d5">TNFR1 signals to induce NF-&#954;B activation</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="P38 KINASE" target="HY209">
      <data key="d4">6.0</data>
      <data key="d5">HY209 inhibits p38 kinase</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="JAKI" target="POST-AUTHORIZATION SAFETY STUDIES">
      <data key="d4">7.0</data>
      <data key="d5">Post-authorization safety studies are important for evaluating the safety profile of JAK inhibitors</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="JAKI" target="REAL-WORLD REGISTRIES">
      <data key="d4">7.0</data>
      <data key="d5">Real-world registries are important for evaluating the safety profile of JAK inhibitors</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="JAKI" target="PHARMACOVIGILANCE">
      <data key="d4">8.0</data>
      <data key="d5">Pharmacovigilance is the process of monitoring the benefit-risk ratio of drugs like JAK inhibitors in Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="HY209" target="CCL17/TARC">
      <data key="d4">7.0</data>
      <data key="d5">HY209 significantly decreased CCL17/TARC levels</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="HY209" target="GPCR19">
      <data key="d4">8.0</data>
      <data key="d5">HY209 targets the GPCR19 receptor</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="HY209" target="NCT04530643">
      <data key="d4">7.0</data>
      <data key="d5">NCT04530643 is a clinical trial involving HY209</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="VTP-38543" target="LIVER X RECEPTOR-&#914;">
      <data key="d4">8.0</data>
      <data key="d5">VTP-38543 targets the Liver X receptor-&#946;</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="VTP-38543" target="NCT02655679">
      <data key="d4">7.0</data>
      <data key="d5">NCT02655679 is a clinical trial involving VTP-38543</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="ALX 101" target="LIVER X RECEPTOR">
      <data key="d4">8.0</data>
      <data key="d5">ALX 101 targets the Liver X receptor</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="ALX 101" target="NCT03859986">
      <data key="d4">7.0</data>
      <data key="d5">NCT03859986 is a clinical trial involving ALX 101</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="SPHINGOSINE 1-PHOSPHATE RECEPTOR" target="SPHINGOSINE 1-PHOSPHATE">
      <data key="d4">7.0</data>
      <data key="d5">Sphingosine 1-phosphate is a signaling molecule involved in the migration of T cells in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="C-C CHEMOKINE RECEPTOR 4" target="C-C CHEMOKINE">
      <data key="d4">7.0</data>
      <data key="d5">C-C chemokine is involved in the migration of T cells into the skin in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="JANUS KINASES" target="JANUS KINASE INHIBITORS">
      <data key="d4">7.0</data>
      <data key="d5">Janus kinase inhibitors target JAKs involved in cytokine receptor signal transduction in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="BRUTON TYROSINE KINASE" target="B CELL RECEPTOR">
      <data key="d4">7.0</data>
      <data key="d5">B cell receptor is involved in the immune response in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="INNATE IMMUNITY" target="TL1A">
      <data key="d4">7.0</data>
      <data key="d5">TL1A signals through innate immunity</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="ADAPTIVE IMMUNITY" target="TL1A">
      <data key="d4">7.0</data>
      <data key="d5">TL1A signals through adaptive immunity</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="OX40 LIGAND" target="REGULATORY T CELL">
      <data key="d4">8.0</data>
      <data key="d5">OX40 ligand is involved in the activation of regulatory T cells</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="THYMIC STROMAL LYMPHOPOIETIN" target="LIGHT">
      <data key="d4">16.0</data>
      <data key="d5">LIGHT controls the expression of TSLP</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="LEO 152020/JW1601" target="NCT04203836">
      <data key="d4">7.0</data>
      <data key="d5">NCT04203836 is a clinical trial involving LEO 152020/JW1601</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="DRM02" target="NCT01993420">
      <data key="d4">7.0</data>
      <data key="d5">NCT01993420 is a clinical trial involving DRM02</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="HEMAY-808" target="NCT04352595">
      <data key="d4">7.0</data>
      <data key="d5">NCT04352595 is a clinical trial involving Hemay-808</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="PF-07038124" target="NCT04664153">
      <data key="d4">7.0</data>
      <data key="d5">NCT04664153 is a clinical trial involving PF-07038124</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="ABBVIE">
      <data key="d4">6.0</data>
      <data key="d5">AbbVie develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="ALLMIRAL">
      <data key="d4">6.0</data>
      <data key="d5">Allmiral develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="ANAPTYSBIO">
      <data key="d4">6.0</data>
      <data key="d5">AnaptysBio develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="ARENA">
      <data key="d4">6.0</data>
      <data key="d5">Arena develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="ASANA BIOSCIENCES">
      <data key="d4">6.0</data>
      <data key="d5">Asana Biosciences develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="BAYER HEALTH">
      <data key="d4">6.0</data>
      <data key="d5">Bayer Health develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="BIOVERSYS">
      <data key="d4">6.0</data>
      <data key="d5">BioVerSys develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="B&#214;HRINGER-INGELHEIM">
      <data key="d4">6.0</data>
      <data key="d5">B&#246;hringer-Ingelheim develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="BRISTOL MYERS SQUIBB">
      <data key="d4">6.0</data>
      <data key="d5">Bristol Myers Squibb develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="DOMAIN THERAPEUTICS">
      <data key="d4">6.0</data>
      <data key="d5">Domain Therapeutics develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="GALAPAGOS/MORPHOSYS">
      <data key="d4">6.0</data>
      <data key="d5">Galapagos/MorphoSys develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="GALDERMA">
      <data key="d4">6.0</data>
      <data key="d5">Galderma develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="GLENMARK">
      <data key="d4">6.0</data>
      <data key="d5">Glenmark develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="GSK">
      <data key="d4">6.0</data>
      <data key="d5">GSK develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="INCYTE">
      <data key="d4">6.0</data>
      <data key="d5">Incyte develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="IQVIA">
      <data key="d4">6.0</data>
      <data key="d5">IQVIA develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="JANSSEN">
      <data key="d4">6.0</data>
      <data key="d5">Janssen develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="KIRIN">
      <data key="d4">6.0</data>
      <data key="d5">Kirin develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="LEO PHARMA">
      <data key="d4">6.0</data>
      <data key="d5">LEO Pharma develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="LG CHEM">
      <data key="d4">6.0</data>
      <data key="d5">LG Chem develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="LILLY">
      <data key="d4">6.0</data>
      <data key="d5">Lilly develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="L&#8217;OR&#201;AL">
      <data key="d4">6.0</data>
      <data key="d5">L&#8217;Or&#233;al develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="MENLOTX">
      <data key="d4">6.0</data>
      <data key="d5">MenloTx develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="NOVARTIS">
      <data key="d4">6.0</data>
      <data key="d5">Novartis develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="VIFOR PHARMA">
      <data key="d4">6.0</data>
      <data key="d5">Vifor Pharma develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="PFIZER">
      <data key="d4">6.0</data>
      <data key="d5">Pfizer develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="PIERRE FABRE">
      <data key="d4">6.0</data>
      <data key="d5">Pierre Fabre develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="SANOFI/REGENERON">
      <data key="d4">6.0</data>
      <data key="d5">Sanofi/Regeneron develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="UCB">
      <data key="d4">6.0</data>
      <data key="d5">UCB develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="DAVOS BIOSCIENCES">
      <data key="d4">1.0</data>
      <data key="d5">Davos Biosciences is involved in the development of biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="EOSINOPHILIC ASTHMA" target="AEROALLERGENS">
      <data key="d4">7.0</data>
      <data key="d5">Aeroallergens can trigger eosinophilic asthma</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="PFIZER" target="PF-06480605">
      <data key="d4">8.0</data>
      <data key="d5">Pfizer is developing PF-06480605</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="LYMPHOCYTES" target="TL1A">
      <data key="d4">7.0</data>
      <data key="d5">TL1A promotes mucus production independently of lymphocytes</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="PLAQUES" target="ELBOWS">
      <data key="d4">6.0</data>
      <data key="d5">The elbows are one of the common sites affected by Atopic Dermatitis plaques</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="PLAQUES" target="KNEES">
      <data key="d4">6.0</data>
      <data key="d5">The knees are one of the common sites affected by Atopic Dermatitis plaques</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="PLAQUES" target="FACE">
      <data key="d4">6.0</data>
      <data key="d5">The face is one of the common sites affected by Atopic Dermatitis plaques</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="PLAQUES" target="NECK">
      <data key="d4">6.0</data>
      <data key="d5">The neck is one of the common sites affected by Atopic Dermatitis plaques</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="PLAQUES" target="WRISTS">
      <data key="d4">6.0</data>
      <data key="d5">The wrists are one of the common sites affected by Atopic Dermatitis plaques</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="VESICLES" target="INFANTILE ATOPIC DERMATITIS">
      <data key="d4">7.0</data>
      <data key="d5">Vesicles are small blisters seen in infantile Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="EXCORIATIONS" target="INFANTILE ATOPIC DERMATITIS">
      <data key="d4">7.0</data>
      <data key="d5">Excoriations are scratch marks seen in infantile Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="SEROUS EXUDATE" target="INFANTILE ATOPIC DERMATITIS">
      <data key="d4">7.0</data>
      <data key="d5">Serous Exudate is a clear fluid discharge seen in infantile Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="CHEEKS" target="INFANTILE ATOPIC DERMATITIS">
      <data key="d4">6.0</data>
      <data key="d5">The cheeks are one of the common sites affected by infantile Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="SCALP" target="INFANTILE ATOPIC DERMATITIS">
      <data key="d4">6.0</data>
      <data key="d5">The scalp is one of the common sites affected by infantile Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="HANDS" target="ADULT ATOPIC DERMATITIS">
      <data key="d4">6.0</data>
      <data key="d5">The hands are commonly affected by chronic hand eczema in adult Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="HEAD&#8211;NECK DERMATITIS" target="ADULT ATOPIC DERMATITIS">
      <data key="d4">6.0</data>
      <data key="d5">Head&#8211;Neck Dermatitis is a form of Atopic Dermatitis affecting the upper trunk, shoulders, and scalp in adults</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="INTERLEUKINS" target="CIBINQO">
      <data key="d4">16.0</data>
      <data key="d5">Cibinqo controls interleukins</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="DNA METHYLATION" target="FLG GENE">
      <data key="d4">7.0</data>
      <data key="d5">DNA methylation can influence the expression of the FLG gene associated with Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="FLG GENE" target="FLG NULL MUTATIONS">
      <data key="d4">8.0</data>
      <data key="d5">FLG null mutations result in a lack of functional filaggrin protein, increasing the risk of Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="FLG GENE" target="FLG COPY NUMBER VARIATIONS">
      <data key="d4">8.0</data>
      <data key="d5">FLG copy number variations can affect filaggrin levels and Atopic Dermatitis risk</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="IL-8" target="CSA">
      <data key="d4">7.0</data>
      <data key="d5">CsA-loaded nanoparticles reduce IL-8 levels</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="IL-8" target="LIGHT">
      <data key="d4">7.0</data>
      <data key="d5">LIGHT stimulates the release of IL-8 from human hepatoma cells</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="IL-8" target="H2O2">
      <data key="d4">6.0</data>
      <data key="d5">H2O2 amplifies LIGHT-stimulated release of IL-8</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="MCP-1" target="ANG II">
      <data key="d4">7.0</data>
      <data key="d5">Ang II induces the synthesis of MCP-1</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="MCP-1" target="CD34+CD45+ MONOCYTIC CELLS">
      <data key="d4">7.0</data>
      <data key="d5">MCP-1 mediates the cardiac infiltration of CD34+CD45+ monocytic cells</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="EOSINOPHILIC ESOPHAGITIS" target="LIGHT">
      <data key="d4">28.0</data>
      <data key="d5">Eosinophilic esophagitis (EoE) is a chronic, immune-mediated esophageal disease characterized by eosinophil infiltration in the esophagus. Research indicates that LIGHT, a member of the tumor necrosis factor (TNF) superfamily, is induced in eosinophilic esophagitis. LIGHT plays a significant role in the pathophysiology of EoE by regulating fibrosis, which contributes to the tissue remodeling and dysfunction observed in this condition.</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2,df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="TREGS" target="GITR">
      <data key="d4">25.0</data>
      <data key="d5">TREGS (Regulatory T cells) and GITR (Glucocorticoid-Induced TNFR-Related protein) are closely associated in the immune system. GITR is constitutively expressed by Tregs and plays a crucial role in their function. This expression is essential for the regulatory activities of Tregs, which are vital for maintaining immune homeostasis and preventing autoimmune responses.</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9,d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="TREGS" target="FLS">
      <data key="d4">7.0</data>
      <data key="d5">FLS expressing GITRL cause a reduction in Foxp3 expression in Tregs</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="NANOTECHNOLOGY" target="CANCER">
      <data key="d4">7.0</data>
      <data key="d5">Nanotechnology offers a method for treating cancer</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="CHITOSAN" target="BETAMETHASONE VALERATE (BMV)">
      <data key="d4">7.0</data>
      <data key="d5">Betamethasone Valerate is loaded into chitosan nanoparticles for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="CHITOSAN" target="BMV">
      <data key="d4">13.0</data>
      <data key="d5">CHITOSAN and BMV: BMV is encapsulated in chitosan gel for extended drug retention. Additionally, BMV is encapsulated in chitosan-based nanoparticles. This encapsulation strategy leverages the properties of chitosan to enhance the stability and retention of BMV, potentially improving its therapeutic efficacy.</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5,bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="CHITOSAN" target="HYDROCORTISONE (HC)">
      <data key="d4">6.0</data>
      <data key="d5">HC is used in chitosan-based nanoparticles for topical administration</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="CHITOSAN" target="HYDROXYTYROSOL (HT)">
      <data key="d4">1.0</data>
      <data key="d5">HT is used in chitosan-based nanoparticles for topical administration</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="CHITOSAN" target="HYDROXYTYROSOL">
      <data key="d4">16.0</data>
      <data key="d5">Chitosan-based NPs were used for the topical administration of hydroxytyrosol</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="CHITOSAN" target="FUCOIDAN">
      <data key="d4">16.0</data>
      <data key="d5">Fucoidan/chitosan-based NPs were formulated for the topical application of MTX</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="CHITOSAN" target="MTX">
      <data key="d4">16.0</data>
      <data key="d5">Fucoidan/chitosan-based NPs were formulated for the topical application of MTX</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="TACROLIMUS (FK506)" target="NIC-CS-NPS">
      <data key="d4">8.0</data>
      <data key="d5">NIC-CS-NPs contain Tacrolimus (FK506) for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="NICOTINAMIDE (NIC)" target="NIC-CS-NPS">
      <data key="d4">8.0</data>
      <data key="d5">NIC-CS-NPs contain Nicotinamide (NIC) for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="SPRAGUE DAWLEY RATS" target="NIC-CS-NPS">
      <data key="d4">7.0</data>
      <data key="d5">NIC-CS-NPs showed sustained skin permeation in Sprague Dawley rats</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="BABL/C MICE" target="DNCB">
      <data key="d4">7.0</data>
      <data key="d5">DNCB is used to induce AD-like skin lesions in BABL/c mice</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="HYALURONIC ACID (HA)" target="TAC-LOADED NANOPARTICLES">
      <data key="d4">7.0</data>
      <data key="d5">Hyaluronic Acid is used to decorate TAC-loaded nanoparticles for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="CARBOPOL&#174;980" target="PHYTOCERAMIDES">
      <data key="d4">14.0</data>
      <data key="d5">Carbopol&#174;980 and phytoceramides are utilized in conjunction for drug delivery applications. Specifically, Carbopol&#174;980 serves as a gel medium in nanocarriers that contain phytoceramides, facilitating the effective delivery of these compounds. This combination leverages the gel-forming properties of Carbopol&#174;980 to enhance the stability and bioavailability of phytoceramides, thereby improving their therapeutic efficacy.</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5,8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="PHYTOCERAMIDES" target="STARCH">
      <data key="d4">6.0</data>
      <data key="d5">Phytoceramides are included in starch-based nanocarriers for drug delivery</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="PHYTOCERAMIDES" target="LECITHIN">
      <data key="d4">6.0</data>
      <data key="d5">Phytoceramides are included in lecithin-based nanocarriers for drug delivery</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="PHYTOCERAMIDES" target="MICROEMULSIONS">
      <data key="d4">1.0</data>
      <data key="d5">Phytoceramides are included in microemulsions for drug delivery</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="PHYTOCERAMIDES" target="STARCH-BASED MICROEMULSIONS">
      <data key="d4">7.0</data>
      <data key="d5">Starch-based microemulsions are used in nanocarriers containing phytoceramides for drug delivery</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="PHYTOCERAMIDES" target="LECITHIN-BASED MICROEMULSIONS">
      <data key="d4">1.0</data>
      <data key="d5">Lecithin-based microemulsions are used in nanocarriers containing phytoceramides for drug delivery</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="PHYTOCERAMIDES" target="SC">
      <data key="d4">8.0</data>
      <data key="d5">Phytoceramides are concentrated within the stratum corneum</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="STARCH" target="ER143">
      <data key="d4">14.0</data>
      <data key="d5">ER143 was encapsulated in starch-based nanocapsules</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="SC" target="TAC">
      <data key="d4">7.0</data>
      <data key="d5">Higher TAC levels were observed in the stratum corneum with PLG-based nanoparticles</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="ALBINO WISTAR RATS" target="TEWL">
      <data key="d4">6.0</data>
      <data key="d5">Albino Wistar Rats showed reduced TEWL with treatment</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="TEWL" target="CSA">
      <data key="d4">8.0</data>
      <data key="d5">CsA-loaded nanoparticles reduce TEWL</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="GLYCYRRHIZIC ACID (GA)" target="BALB/C MICE">
      <data key="d4">8.0</data>
      <data key="d5">Glycyrrhizic Acid (GA) reduces scratching and erythema in BALB/c mice</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="CYCLOSPORINE A (CSA)" target="HUMAN EPIDERMIS">
      <data key="d4">7.0</data>
      <data key="d5">Cyclosporine A (CsA) is delivered effectively in the human epidermis</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="TAC" target="RABBITS">
      <data key="d4">6.0</data>
      <data key="d5">TAC showed no irritation in rabbits</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="TAC" target="HA">
      <data key="d4">7.0</data>
      <data key="d5">HA-based nanoparticles improve TAC deposition</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="TAC" target="CHOLESTEROL">
      <data key="d4">7.0</data>
      <data key="d5">Cholesterol-based nanoparticles improve TAC deposition</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="TAC" target="NIC">
      <data key="d4">7.0</data>
      <data key="d5">NIC improves TAC solubility and skin penetration</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="TAC" target="PLG">
      <data key="d4">7.0</data>
      <data key="d5">PLG-based NPs are used for the topical delivery of TAC</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="NLCS" target="METHOTREXATE (MTX)">
      <data key="d4">7.0</data>
      <data key="d5">MTX-loaded NLCs enhance MTX bioavailability and dermal penetration</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="MOUSE" target="RANKL">
      <data key="d4">12.0</data>
      <data key="d5">RANKL signaling is reduced in a mouse model of silicosis treated with Ac-SDKP</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="MOUSE" target="AC-SDKP">
      <data key="d4">12.0</data>
      <data key="d5">Ac-SDKP reduces RANKL signaling in a mouse model of silicosis</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="HACAT CELLS" target="C6">
      <data key="d4">6.0</data>
      <data key="d5">C6-loaded HA&#8211;Chol&#8211;NPs with NIC exhibited similar green fluorescence to HA&#8211;Chol&#8211;NPs alone in HaCaT cells</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="PLGA" target="CSA">
      <data key="d4">7.0</data>
      <data key="d5">PLGA-based nanoparticles are used for topical delivery of CsA</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="CSA" target="INF-&#915;">
      <data key="d4">14.0</data>
      <data key="d5">CsA-loaded nanoparticles reduce INF-&#947; levels</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="CSA" target="OVA-IGE">
      <data key="d4">14.0</data>
      <data key="d5">CsA-loaded nanoparticles reduce OVA-IgE serum levels</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="HYDROCORTISONE" target="IL-12P70">
      <data key="d4">14.0</data>
      <data key="d5">HC-NPs suppressed inflammatory cascades including IL-12p70</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="HYDROCORTISONE" target="PROSTAGLANDIN-E2">
      <data key="d4">14.0</data>
      <data key="d5">HC-NPs suppressed inflammatory cascades including prostaglandin-E2 expression</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="HYDROCORTISONE" target="VEGF-&#913;">
      <data key="d4">14.0</data>
      <data key="d5">HC-NPs suppressed inflammatory cascades including VEGF-&#945;</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="HYDROCORTISONE" target="ELASTIC FIBER">
      <data key="d4">14.0</data>
      <data key="d5">HC-NPs blocked or significantly decreased elastic fiber fragmentation</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="HNE" target="ER143">
      <data key="d4">16.0</data>
      <data key="d5">ER143 is a synthetic HNE inhibitor</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="DESONIDE" target="EUDRAGIT&#174; RL100">
      <data key="d4">14.0</data>
      <data key="d5">Desonide was encapsulated in Eudragit&#174; RL100 nanocapsules</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="DESONIDE" target="ACAI OIL">
      <data key="d4">14.0</data>
      <data key="d5">Desonide was encapsulated using acai oil as the core</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="DESONIDE" target="MEDIUM-CHAIN TRIGLYCERIDES">
      <data key="d4">14.0</data>
      <data key="d5">Desonide was encapsulated using medium-chain triglycerides as the core</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="BDP" target="HPMC">
      <data key="d4">14.0</data>
      <data key="d5">BDP-loaded polymeric micelles were incorporated into an HPMC hydrogel</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="AMDITELIMAB" target="OX-40">
      <data key="d4">8.0</data>
      <data key="d5">Amditelimab targets OX-40</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="HYALURONIC ACID" target="BETAMETHASONE">
      <data key="d4">14.0</data>
      <data key="d5">Betamethasone and Hyaluronic acid are used together in nanotechnology-based therapeutic approaches</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="BETAMETHASONE" target="DIFLUCORTOLONE VALERATE">
      <data key="d4">14.0</data>
      <data key="d5">Betamethasone and Diflucortolone valerate are used together in nanotechnology-based therapeutic approaches</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="CIBINQO" target="JADE TEEN">
      <data key="d4">14.0</data>
      <data key="d5">JADE TEEN trial supports cibinqo label expansion</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="SEVERE AD" target="TRADITIONAL TREATMENTS">
      <data key="d4">7.0</data>
      <data key="d5">Severe AD was previously resistant to traditional treatments</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="PLASMA" target="HC">
      <data key="d4">8.0</data>
      <data key="d5">Plasma was collected from healthy controls</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="HC" target="SOX40L">
      <data key="d4">7.0</data>
      <data key="d5">sOX40L was measured in serum from healthy controls</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="SOX40L" target="ENZYME-LINKED IMMUNOASSAY">
      <data key="d4">8.0</data>
      <data key="d5">ELISA is used to measure serum levels of sOX40L in patients with atopic dermatitis</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="SOX40L" target="CHILDREN WITH AD">
      <data key="d4">8.0</data>
      <data key="d5">Serum levels of sOX40L are measured in children with atopic dermatitis</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="SOX40L" target="ADULTS WITH AD">
      <data key="d4">1.0</data>
      <data key="d5">Serum levels of sOX40L are measured in adults with atopic dermatitis</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="TRYPTASE" target="MONOCLONAL RABBIT ANTI-TRYPTASE">
      <data key="d4">7.0</data>
      <data key="d5">Monoclonal rabbit anti-tryptase is used to target tryptase in immunohistochemistry</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="MONOCLONAL RABBIT ANTI-TRYPTASE" target="DONKEY ANTI-RABBIT ALEXA 647">
      <data key="d4">6.0</data>
      <data key="d5">Donkey anti-rabbit Alexa 647 is used as a secondary antibody for monoclonal rabbit anti-tryptase</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="MONOCLONAL MOUSE ANTI-OX40L" target="DONKEY ANTI-MOUSE ALEXA 488">
      <data key="d4">6.0</data>
      <data key="d5">Donkey anti-mouse Alexa 488 is used as a secondary antibody for monoclonal mouse anti-OX40L</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="MONOCLONAL MOUSE ANTI-OX40L" target="MOUSE IGG1 ISOTYPE CONTROL">
      <data key="d4">5.0</data>
      <data key="d5">Mouse IgG1 isotype control is used as a negative control for monoclonal mouse anti-OX40L</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="MOUNTING MEDIUM" target="TISSUE SECTIONS">
      <data key="d4">5.0</data>
      <data key="d5">Mounting Medium is used to fix tissue sections for microscopy analysis</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="PRISM 6" target="STATISTICAL ANALYSIS">
      <data key="d4">6.0</data>
      <data key="d5">Prism 6 is used for statistical analysis and graphing</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="MANN-WHITNEY RANK SUM TEST" target="UNPAIRED DATA">
      <data key="d4">6.0</data>
      <data key="d5">Mann-Whitney rank sum test is used for comparing unpaired data</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="WILCOXON SIGNED-RANK TEST" target="PAIRED DATA">
      <data key="d4">6.0</data>
      <data key="d5">Wilcoxon signed-rank test is used for comparing paired data</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="SPEARMAN&#8217;S RHO" target="CORRELATION">
      <data key="d4">6.0</data>
      <data key="d5">Spearman&#8217;s rho is used to test correlations</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="LUNG" target="ILD">
      <data key="d4">8.0</data>
      <data key="d5">Interstitial lung disease affects the lungs in SSc</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="LUNG" target="PULMONARY HYPERTENSION">
      <data key="d4">1.0</data>
      <data key="d5">Pulmonary hypertension affects the lungs in SSc</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="LUNG" target="TL1A">
      <data key="d4">14.0</data>
      <data key="d5">TL1A is a membrane-restricted protein in the lung that plays a crucial role in activating both innate and adaptive immunity. It is also associated with inflammation and fibrosis of the lung, indicating its significant involvement in the pathogenesis of various pulmonary conditions.</data>
      <data key="d6">05c97152fe02249153103be341d65b67,c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="LUNG" target="GITR">
      <data key="d4">8.0</data>
      <data key="d5">GITR signaling was studied in the context of lung injury and fibrosis</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="SYSTEMIC SCLEROSIS" target="SSC">
      <data key="d4">10.0</data>
      <data key="d5">Systemic sclerosis is also referred to as SSc</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="SYSTEMIC SCLEROSIS" target="VISCERAL ORGANS">
      <data key="d4">16.0</data>
      <data key="d5">Systemic sclerosis presents with fibrosis in visceral organs</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="SYSTEMIC SCLEROSIS" target="LUNGS">
      <data key="d4">16.0</data>
      <data key="d5">Systemic sclerosis presents with fibrosis in the lungs</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="SYSTEMIC SCLEROSIS" target="HEART">
      <data key="d4">2.0</data>
      <data key="d5">Systemic sclerosis presents with fibrosis in the heart</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="SYSTEMIC SCLEROSIS" target="LIGHT">
      <data key="d4">16.0</data>
      <data key="d5">LIGHT is induced in SSc and regulates skin fibrosis</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="SYSTEMIC SCLEROSIS" target="MMF">
      <data key="d4">1.0</data>
      <data key="d5">MMF is used to treat systemic sclerosis</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="SYSTEMIC SCLEROSIS" target="ANTI-BAFF MAB">
      <data key="d4">8.0</data>
      <data key="d5">Anti-BAFF mAb is used in the treatment of Systemic Sclerosis</data>
      <data key="d6">8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="SSC" target="RA">
      <data key="d4">7.0</data>
      <data key="d5">Rheumatoid arthritis is an autoimmune disease that shares some pathogenesis mechanisms with systemic sclerosis</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="SSC" target="SLE">
      <data key="d4">21.0</data>
      <data key="d5">Systemic lupus erythematosus (SLE) is an autoimmune disease that shares some pathogenesis mechanisms with systemic sclerosis (SSC). Patients were excluded from the study if they met the American College of Rheumatology (ACR) criteria for SLE, although one patient was diagnosed with SLE.</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5,f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="SSC" target="SJ&#214;GREN'S SYNDROME">
      <data key="d4">7.0</data>
      <data key="d5">Sj&#246;gren's syndrome is an autoimmune disease that shares some pathogenesis mechanisms with systemic sclerosis</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="SSC" target="POLYMYOSITIS">
      <data key="d4">7.0</data>
      <data key="d5">Polymyositis is an autoimmune disease that shares some pathogenesis mechanisms with systemic sclerosis</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="SSC" target="DCSSC">
      <data key="d4">9.0</data>
      <data key="d5">Diffuse cutaneous systemic sclerosis is a subtype of systemic sclerosis</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="SSC" target="CD226">
      <data key="d4">14.0</data>
      <data key="d5">CD226 polymorphisms are associated with genetic susceptibility to systemic sclerosis</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="SSC" target="DNAM-1">
      <data key="d4">14.0</data>
      <data key="d5">DNAM-1 is overexpressed in the skin of systemic sclerosis patients</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="SSC" target="SCTLA-4">
      <data key="d4">30.0</data>
      <data key="d5">Systemic sclerosis (SSC) is associated with elevated levels of soluble CTLA-4 (sCTLA-4). Increased sCTLA-4 serum levels are consistently observed in patients with systemic sclerosis, indicating a potential link between sCTLA-4 and the pathophysiology of this autoimmune disease.</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b,9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="PD-L1">
      <data key="d4">16.0</data>
      <data key="d5">Soluble PD-L1 is elevated in systemic sclerosis patients</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="PD-L2">
      <data key="d4">16.0</data>
      <data key="d5">Soluble PD-L2 is elevated in systemic sclerosis patients</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="PD-1">
      <data key="d4">16.0</data>
      <data key="d5">Soluble PD-1 is elevated in systemic sclerosis patients</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="BLEOMYCIN MOUSE MODEL">
      <data key="d4">16.0</data>
      <data key="d5">The Bleomycin mouse model mimics early and inflammatory stages of systemic sclerosis</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="FRA-2 TRANSGENIC MOUSE MODEL">
      <data key="d4">16.0</data>
      <data key="d5">The Fra-2 transgenic mouse model mimics features of systemic sclerosis</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="RODNAN SKIN SCORE">
      <data key="d4">8.0</data>
      <data key="d5">The Rodnan skin score is used to measure skin thickness in systemic sclerosis</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="MONOCYTE">
      <data key="d4">7.0</data>
      <data key="d5">Monocyte infiltration is reduced in systemic sclerosis lesions with Abatacept treatment</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="PROINFLAMMATORY CYTOKINES">
      <data key="d4">8.0</data>
      <data key="d5">Proinflammatory cytokines are involved in systemic sclerosis</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="PROFIBROTIC CYTOKINES">
      <data key="d4">8.0</data>
      <data key="d5">Profibrotic cytokines are involved in systemic sclerosis</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="TIGHT SKIN-1 MOUSE MODEL">
      <data key="d4">8.0</data>
      <data key="d5">The Tight skin-1 mouse model is used to study non-inflammatory dermal fibrosis in systemic sclerosis</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="GASTROINTESTINAL INVOLVEMENT">
      <data key="d4">8.0</data>
      <data key="d5">Gastrointestinal involvement is a symptom of systemic sclerosis</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="CARDIAC HEMODYNAMIC IMPAIRMENT">
      <data key="d4">8.0</data>
      <data key="d5">Cardiac hemodynamic impairment is a symptom of systemic sclerosis</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="FIBROGENIC MARKERS">
      <data key="d4">8.0</data>
      <data key="d5">Fibrogenic markers are elevated in systemic sclerosis</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="T-CELL PROLIFERATION">
      <data key="d4">8.0</data>
      <data key="d5">T-cell proliferation is observed in systemic sclerosis</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="M1 MACROPHAGES">
      <data key="d4">1.0</data>
      <data key="d5">M1 macrophages are involved in systemic sclerosis</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="PEMBROLIZUMAB">
      <data key="d4">14.0</data>
      <data key="d5">Pembrolizumab induced sclerodermoid reactions resembling SSc</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="SSC" target="CYCLOPHOSPHAMIDE">
      <data key="d4">14.0</data>
      <data key="d5">Cyclophosphamide is used as a standard therapy drug in SSc</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="SSC" target="ANIMAL MODELS">
      <data key="d4">7.0</data>
      <data key="d5">Animal models are used to study the pathogenesis of systemic sclerosis</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="SSC" target="AUTOIMMUNITY">
      <data key="d4">1.0</data>
      <data key="d5">Systemic sclerosis is an autoimmune disease</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="SSC" target="RS1234314">
      <data key="d4">42.0</data>
      <data key="d5">SNP rs1234314 is associated with systemic sclerosis (SSC) and is linked to an increased susceptibility to this autoimmune disease.</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14,40ad2241836485e0bf264bdfb62fd789,d8a485eb1e9435b083d5ef6a17f06ea5</data>
    </edge>
    <edge source="SSC" target="RS2205960">
      <data key="d4">64.0</data>
      <data key="d5">SNP rs2205960 is associated with systemic sclerosis (SSC) and is linked to an increased susceptibility to this autoimmune disease.</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14,40ad2241836485e0bf264bdfb62fd789,8ce8c356713490cd2c680f505bcd050b,c69c7fb997f95c56cc077b3975f41923,d8a485eb1e9435b083d5ef6a17f06ea5</data>
    </edge>
    <edge source="SSC" target="RS844648">
      <data key="d4">50.0</data>
      <data key="d5">SNP rs844648 is associated with systemic sclerosis (SSC) and is linked to an increased susceptibility to this autoimmune disease.</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14,40ad2241836485e0bf264bdfb62fd789,c69c7fb997f95c56cc077b3975f41923,d8a485eb1e9435b083d5ef6a17f06ea5</data>
    </edge>
    <edge source="SSC" target="RS844644">
      <data key="d4">42.0</data>
      <data key="d5">SNP rs844644 is associated with systemic sclerosis (SSC) and has been identified as having a protective effect against the development of this autoimmune disease.</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14,40ad2241836485e0bf264bdfb62fd789,d8a485eb1e9435b083d5ef6a17f06ea5</data>
    </edge>
    <edge source="SSC" target="IRF5">
      <data key="d4">14.0</data>
      <data key="d5">IRF5 is associated with systemic sclerosis</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="SSC" target="FAS">
      <data key="d4">14.0</data>
      <data key="d5">FAS is associated with systemic sclerosis</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="SSC" target="PERIPHERAL BLOOD CELLS">
      <data key="d4">12.0</data>
      <data key="d5">Peripheral blood cells from SSc patients show upregulation of type I interferon associated gene transcripts</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="SSC" target="TYPE I INTERFERON">
      <data key="d4">12.0</data>
      <data key="d5">Type I interferon associated gene transcripts are upregulated in SSc</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="SSC" target="ANTINUCLEAR ANTIBODIES">
      <data key="d4">14.0</data>
      <data key="d5">Patients with SSc have circulating antinuclear antibodies</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="SSC" target="EXTRACELLULAR MATRIX">
      <data key="d4">16.0</data>
      <data key="d5">Excessive extracellular matrix deposition is a feature of systemic sclerosis</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="SSC" target="VASCULOPATHY">
      <data key="d4">16.0</data>
      <data key="d5">Vasculopathy is a feature of systemic sclerosis</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="SSC" target="PULMONARY FIBROSIS">
      <data key="d4">6.0</data>
      <data key="d5">Pulmonary fibrosis is a symptom associated with systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="SSC" target="PULMONARY HYPERTENSION">
      <data key="d4">1.0</data>
      <data key="d5">Pulmonary hypertension is a symptom associated with systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="SSC" target="RS844665">
      <data key="d4">19.0</data>
      <data key="d5">SNP rs844665 has been studied in the context of systemic sclerosis (SSC). While some research suggests that SNP rs844665 is associated with systemic sclerosis, other studies have found that this association is not statistically significant. Therefore, the relationship between SNP rs844665 and systemic sclerosis remains inconclusive, indicating the need for further investigation to clarify its potential role in the disease.</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923,d8a485eb1e9435b083d5ef6a17f06ea5</data>
    </edge>
    <edge source="SSC" target="RS855648">
      <data key="d4">21.0</data>
      <data key="d5">SNP rs855648 is associated with systemic sclerosis (SSC) and is linked to an increased susceptibility to this autoimmune disease.</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923,d8a485eb1e9435b083d5ef6a17f06ea5</data>
    </edge>
    <edge source="SSC" target="ANTI-CENTROMERE">
      <data key="d4">30.0</data>
      <data key="d5">Anti-centromere antibodies are associated with systemic sclerosis</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789,d8a485eb1e9435b083d5ef6a17f06ea5</data>
    </edge>
    <edge source="SSC" target="ANTI-TOPOISOMERASE I">
      <data key="d4">30.0</data>
      <data key="d5">Anti-topoisomerase I antibodies are associated with systemic sclerosis</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789,d8a485eb1e9435b083d5ef6a17f06ea5</data>
    </edge>
    <edge source="SSC" target="ANTI-RNA POLYMERASE III">
      <data key="d4">18.0</data>
      <data key="d5">Anti-RNA polymerase III antibodies are associated with systemic sclerosis</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789,d8a485eb1e9435b083d5ef6a17f06ea5</data>
    </edge>
    <edge source="SSC" target="RS944648">
      <data key="d4">14.0</data>
      <data key="d5">SNP rs944648 is associated with systemic sclerosis susceptibility</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="SSC" target="ODDS RATIOS">
      <data key="d4">6.0</data>
      <data key="d5">Odds ratios observed in the study are statistically significant for SSc</data>
      <data key="d6">7b454335c2f5651d86f712037a0dc0ff</data>
    </edge>
    <edge source="SSC" target="TNFR1">
      <data key="d4">9.0</data>
      <data key="d5">Elevated serum concentration of soluble TNFR1 correlates with SSc disease severity</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="SSC" target="FIBROPROLIFERATIVE">
      <data key="d4">16.0</data>
      <data key="d5">Systemic sclerosis is a fibroproliferative disease</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="SSC" target="LIGHT">
      <data key="d4">8.0</data>
      <data key="d5">LIGHT is involved in the pathogenesis of systemic sclerosis</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="SSC" target="TRAIL">
      <data key="d4">8.0</data>
      <data key="d5">TRAIL treatment is investigated for its efficacy in systemic sclerosis</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="SSC" target="DERMAL MYOFIBROBLASTS">
      <data key="d4">8.0</data>
      <data key="d5">Dermal myofibroblasts are the principal cell type responsible for fibrosis in systemic sclerosis</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="SSC" target="BLEOMYCIN">
      <data key="d4">7.0</data>
      <data key="d5">Bleomycin is used to induce skin fibrosis in a mouse model of systemic sclerosis</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="SSC" target="TSK-1">
      <data key="d4">7.0</data>
      <data key="d5">Tsk-1 is a genetic mouse model used to study systemic sclerosis</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="RA" target="PTPN22">
      <data key="d4">16.0</data>
      <data key="d5">PTPN22 is associated with rheumatoid arthritis</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="RA" target="STAT4">
      <data key="d4">16.0</data>
      <data key="d5">STAT4 is a susceptibility gene for rheumatoid arthritis</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="SLE" target="PTPN22">
      <data key="d4">16.0</data>
      <data key="d5">PTPN22 is associated with systemic lupus erythematosus</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="SLE" target="STAT4">
      <data key="d4">16.0</data>
      <data key="d5">STAT4 is a susceptibility gene for systemic lupus erythematosus</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="SLE" target="IRF5">
      <data key="d4">14.0</data>
      <data key="d5">IRF5 is associated with systemic lupus erythematosus</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="SLE" target="FAS">
      <data key="d4">14.0</data>
      <data key="d5">FAS is associated with systemic lupus erythematosus</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="SLE" target="PERIPHERAL BLOOD CELLS">
      <data key="d4">12.0</data>
      <data key="d5">Peripheral blood cells from SLE patients show upregulation of type I interferon associated gene transcripts</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="SLE" target="TYPE I INTERFERON">
      <data key="d4">12.0</data>
      <data key="d5">Type I interferon associated gene transcripts are upregulated in SLE</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="SLE" target="ANTINUCLEAR ANTIBODIES">
      <data key="d4">14.0</data>
      <data key="d5">Patients with SLE have circulating antinuclear antibodies</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="DCSSC" target="MRSS">
      <data key="d4">8.0</data>
      <data key="d5">Modified-Rodnan skin score is used to measure skin thickness in diffuse cutaneous systemic sclerosis</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="ASSET TRIAL" target="NCT02161406">
      <data key="d4">7.0</data>
      <data key="d5">ASSET trial is identified by the clinical trial identifier NCT02161406</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="PD1-PDL1/2" target="PD1">
      <data key="d4">8.0</data>
      <data key="d5">PD1 is involved in the PD1-PDL1/2 negative costimulatory pathway</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="PULMONARY HYPERTENSION" target="RS2205960">
      <data key="d4">1.0</data>
      <data key="d5">SNP rs2205960 is not significantly associated with pulmonary hypertension in systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="PULMONARY HYPERTENSION" target="RS844648">
      <data key="d4">5.0</data>
      <data key="d5">SNP rs844648 is not significantly associated with pulmonary hypertension in systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="PULMONARY HYPERTENSION" target="RS844644">
      <data key="d4">5.0</data>
      <data key="d5">SNP rs844644 is not significantly associated with pulmonary hypertension in systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="PULMONARY HYPERTENSION" target="RS1234314">
      <data key="d4">5.0</data>
      <data key="d5">SNP rs1234314 is not significantly associated with pulmonary hypertension in systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="T CELL RECEPTOR (TCR)" target="NAIVE T CELLS">
      <data key="d4">8.0</data>
      <data key="d5">T cell receptor (TCR) is involved in the activation of naive T cells</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="PD1" target="PDL1">
      <data key="d4">16.0</data>
      <data key="d5">PD1 and PDL1 are involved in negative costimulatory pathways</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="PD1" target="PDL2">
      <data key="d4">16.0</data>
      <data key="d5">PD1 and PDL2 are involved in negative costimulatory pathways</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="PD1" target="PD1-L">
      <data key="d4">8.0</data>
      <data key="d5">PD1 interacts with PD1-L in immune response regulation</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="DERMAL FIBROBLASTS" target="LT&#914;R">
      <data key="d4">14.0</data>
      <data key="d5">LT&#946;R is expressed on dermal fibroblasts and mediates LIGHT-induced fibrosis</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="DERMAL FIBROBLASTS" target="HVEM">
      <data key="d4">14.0</data>
      <data key="d5">HVEM is expressed on dermal fibroblasts and mediates LIGHT-induced fibrosis</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="MMP-2" target="CARDIAC FIBROSIS">
      <data key="d4">12.0</data>
      <data key="d5">Activation of MMP-2 is associated with fibrosis resolution in cardiac fibrosis</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="PAH" target="CD40L">
      <data key="d4">14.0</data>
      <data key="d5">Soluble CD40L serum concentrations are associated with pulmonary arterial hypertension</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="DIGITAL ULCERS" target="CD40L">
      <data key="d4">14.0</data>
      <data key="d5">Soluble CD40L serum concentrations are associated with digital ulcers</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="PERIPHERAL MICROANGIOPATHY" target="CD40L">
      <data key="d4">14.0</data>
      <data key="d5">Soluble CD40L serum concentrations are associated with peripheral microangiopathy</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="IMATINIB MESYLATE" target="CD40L">
      <data key="d4">14.0</data>
      <data key="d5">CD40L levels are associated with clinical improvement during Imatinib Mesylate treatment</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="DNAM-1" target="CD226">
      <data key="d4">16.0</data>
      <data key="d5">CD226 encodes DNAM-1</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="DNAM-1" target="BLEOMYCIN MOUSE MODEL">
      <data key="d4">16.0</data>
      <data key="d5">DNAM-1 gene invalidation prevents dermal fibrosis in the Bleomycin mouse model</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="DNAM-1" target="CD112">
      <data key="d4">8.0</data>
      <data key="d5">CD112 interacts with DNAM-1 in immune response modulation</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="DNAM-1" target="CD155">
      <data key="d4">8.0</data>
      <data key="d5">CD155 interacts with DNAM-1 in immune response modulation</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="PD-1" target="PD-L1">
      <data key="d4">14.0</data>
      <data key="d5">PD-1 is antagonized by PD-L1</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="PD-1" target="PD-L2">
      <data key="d4">14.0</data>
      <data key="d5">PD-1 is antagonized by PD-L2</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="PD-1" target="PEMBROLIZUMAB">
      <data key="d4">18.0</data>
      <data key="d5">Pembrolizumab is a PD-1 inhibitor</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="M2 MACROPHAGES" target="TREG">
      <data key="d4">16.0</data>
      <data key="d5">Treg cells promote M2 macrophage polarization and activation</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="INTERSTITIAL LUNG DISEASE" target="LUNGS">
      <data key="d4">8.0</data>
      <data key="d5">Interstitial lung disease affects the lungs</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="INTERSTITIAL LUNG DISEASE" target="PRA023">
      <data key="d4">14.0</data>
      <data key="d5">PRA023 is used in clinical trials to treat Interstitial Lung Disease</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="LIVER" target="NON-ALCOHOLIC STEATOHEPATITIS">
      <data key="d4">8.0</data>
      <data key="d5">Non-alcoholic steatohepatitis affects the liver</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="LIVER" target="NON-ALCOHOLIC FATTY LIVER DISEASE">
      <data key="d4">8.0</data>
      <data key="d5">Non-alcoholic fatty liver disease affects the liver</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="LIVER" target="PRIMARY BILIARY CHOLANGITIS">
      <data key="d4">1.0</data>
      <data key="d5">Primary biliary cholangitis affects the liver</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="LIVER" target="TNFR1">
      <data key="d4">8.0</data>
      <data key="d5">TNFR1 plays a key role in liver fibrosis formation</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="LIVER" target="TL1A">
      <data key="d4">7.0</data>
      <data key="d5">TL1A is upregulated in liver tissue in fibrosis</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="LIVER" target="GITR">
      <data key="d4">7.0</data>
      <data key="d5">GITR signaling is implicated in liver disease</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="DNAM" target="CD112">
      <data key="d4">16.0</data>
      <data key="d5">DNAM and CD112 are involved in positive costimulatory pathways</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="TREG" target="TGF&#914;">
      <data key="d4">16.0</data>
      <data key="d5">TGF&#946; is secreted by Treg cells</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="TGF&#914;" target="TAPI-1">
      <data key="d4">14.0</data>
      <data key="d5">TAPI-1 reduces mRNA expression of TGF&#946;</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TGF&#914;" target="LIGHT">
      <data key="d4">23.0</data>
      <data key="d5">TGF&#946; and LIGHT are closely related in the context of fibrotic processes. LIGHT induces the expression of TGF&#946;, which is a primary fibrotic cytokine. Additionally, LIGHT may specifically induce TGF&#946; in hepatic macrophages, highlighting a potential mechanism through which LIGHT contributes to fibrosis in the liver.</data>
      <data key="d6">05c97152fe02249153103be341d65b67,5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="TGF&#914;" target="TRAIL">
      <data key="d4">7.0</data>
      <data key="d5">TRAIL is necessary for the upregulation of TGF&#946;</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="MMPS" target="APCS">
      <data key="d4">9.0</data>
      <data key="d5">MMPs stimulate APCs to upregulate positive costimulatory molecules</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="ILD" target="DERMAL FIBROSIS">
      <data key="d4">7.0</data>
      <data key="d5">Dermal fibrosis correlates with more severe interstitial lung disease</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="PH" target="NVC">
      <data key="d4">6.0</data>
      <data key="d5">Nailfold vascular capillaroscopy is used to diagnose and monitor pulmonary hypertension</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="RS1234314" target="LSSC">
      <data key="d4">7.0</data>
      <data key="d5">SNP rs1234314 is more common in limited systemic sclerosis compared to controls</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS1234314" target="DSSC">
      <data key="d4">7.0</data>
      <data key="d5">SNP rs1234314 is more common in diffuse systemic sclerosis compared to controls</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS1234314" target="ACA">
      <data key="d4">7.0</data>
      <data key="d5">SNP rs1234314 is associated with ACA-positive systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS1234314" target="ATA">
      <data key="d4">7.0</data>
      <data key="d5">SNP rs1234314 is associated with ATA-positive systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS1234314" target="ARA">
      <data key="d4">5.0</data>
      <data key="d5">SNP rs1234314 is not significantly associated with ARA-positive systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS1234314" target="PULMONARY FIBROSIS">
      <data key="d4">5.0</data>
      <data key="d5">SNP rs1234314 is not significantly associated with pulmonary fibrosis in systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS1234314" target="LIMITED SYSTEMIC SCLEROSIS">
      <data key="d4">12.0</data>
      <data key="d5">SNP rs1234314 is associated with limited systemic sclerosis</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789</data>
    </edge>
    <edge source="RS1234314" target="DIFFUSE SYSTEMIC SCLEROSIS">
      <data key="d4">12.0</data>
      <data key="d5">SNP rs1234314 is associated with diffuse systemic sclerosis</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789</data>
    </edge>
    <edge source="RS2205960" target="LSSC">
      <data key="d4">7.0</data>
      <data key="d5">SNP rs2205960 is more common in limited systemic sclerosis compared to controls</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS2205960" target="DSSC">
      <data key="d4">7.0</data>
      <data key="d5">SNP rs2205960 is more common in diffuse systemic sclerosis compared to controls</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS2205960" target="ATA">
      <data key="d4">7.0</data>
      <data key="d5">SNP rs2205960 is more frequent in ATA-positive systemic sclerosis compared to controls</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS2205960" target="RS855648">
      <data key="d4">7.0</data>
      <data key="d5">SNP rs2205960 and SNP rs855648 interact to increase the risk of systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS2205960" target="ARA">
      <data key="d4">5.0</data>
      <data key="d5">SNP rs2205960 is not significantly associated with ARA-positive systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS2205960" target="PULMONARY FIBROSIS">
      <data key="d4">5.0</data>
      <data key="d5">SNP rs2205960 is not significantly associated with pulmonary fibrosis in systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS2205960" target="LIMITED SYSTEMIC SCLEROSIS">
      <data key="d4">12.0</data>
      <data key="d5">SNP rs2205960 is associated with limited systemic sclerosis</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789</data>
    </edge>
    <edge source="RS2205960" target="DIFFUSE SYSTEMIC SCLEROSIS">
      <data key="d4">12.0</data>
      <data key="d5">SNP rs2205960 is associated with diffuse systemic sclerosis</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789</data>
    </edge>
    <edge source="RS844648" target="DSSC">
      <data key="d4">7.0</data>
      <data key="d5">SNP rs844648 is more common in diffuse systemic sclerosis compared to controls</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS844648" target="ARA">
      <data key="d4">7.0</data>
      <data key="d5">SNP rs844648 is associated with ARA-positive systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS844648" target="ACA">
      <data key="d4">5.0</data>
      <data key="d5">SNP rs844648 is not significantly associated with ACA-positive systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS844648" target="PULMONARY FIBROSIS">
      <data key="d4">5.0</data>
      <data key="d5">SNP rs844648 is not significantly associated with pulmonary fibrosis in systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS844648" target="LIMITED SYSTEMIC SCLEROSIS">
      <data key="d4">12.0</data>
      <data key="d5">SNP rs844648 is associated with limited systemic sclerosis</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789</data>
    </edge>
    <edge source="RS844648" target="DIFFUSE SYSTEMIC SCLEROSIS">
      <data key="d4">12.0</data>
      <data key="d5">SNP rs844648 is associated with diffuse systemic sclerosis</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789</data>
    </edge>
    <edge source="RS844644" target="DSSC">
      <data key="d4">7.0</data>
      <data key="d5">SNP rs844644 is less common in diffuse systemic sclerosis compared to controls</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS844644" target="ACA">
      <data key="d4">5.0</data>
      <data key="d5">SNP rs844644 is not significantly associated with ACA-positive systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS844644" target="ATA">
      <data key="d4">5.0</data>
      <data key="d5">SNP rs844644 is not significantly associated with ATA-positive systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS844644" target="ARA">
      <data key="d4">5.0</data>
      <data key="d5">SNP rs844644 is not significantly associated with ARA-positive systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS844644" target="PULMONARY FIBROSIS">
      <data key="d4">5.0</data>
      <data key="d5">SNP rs844644 is not significantly associated with pulmonary fibrosis in systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS844644" target="LIMITED SYSTEMIC SCLEROSIS">
      <data key="d4">12.0</data>
      <data key="d5">SNP rs844644 is associated with limited systemic sclerosis</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789</data>
    </edge>
    <edge source="RS844644" target="DIFFUSE SYSTEMIC SCLEROSIS">
      <data key="d4">12.0</data>
      <data key="d5">SNP rs844644 is associated with diffuse systemic sclerosis</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789</data>
    </edge>
    <edge source="PTPN22" target="TIDM">
      <data key="d4">16.0</data>
      <data key="d5">PTPN22 is associated with type I diabetes mellitus</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="ANTINUCLEAR ANTIBODIES" target="HEP-2 CELLS">
      <data key="d4">16.0</data>
      <data key="d5">HEp-2 cells were used as an antigen substrate to test for antinuclear antibodies</data>
      <data key="d6">f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="HEP-2 CELLS" target="ANTI-CENTROMERE ANTIBODIES">
      <data key="d4">16.0</data>
      <data key="d5">HEp-2 cells were used to identify anti-centromere antibodies</data>
      <data key="d6">f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="TOPOISOMERASE I" target="ANTI-RNA POLYMERASE III ANTIBODIES">
      <data key="d4">12.0</data>
      <data key="d5">Topoisomerase I and anti-RNA polymerase III antibodies were determined by different assays</data>
      <data key="d6">f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="PERIPHERAL BLOOD" target="GENOMIC DNA">
      <data key="d4">14.0</data>
      <data key="d5">Genomic DNA was extracted from peripheral blood</data>
      <data key="d6">f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="GENOMIC DNA" target="HAPMAP">
      <data key="d4">12.0</data>
      <data key="d5">HapMap data was used for allele call validation</data>
      <data key="d6">f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="GENOMIC DNA" target="CEPH">
      <data key="d4">12.0</data>
      <data key="d5">CEPH samples were used as positive controls in genotyping assays</data>
      <data key="d6">f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="CAUCASIAN" target="HWE">
      <data key="d4">12.0</data>
      <data key="d5">HWE testing was performed on SNPs in Caucasian controls</data>
      <data key="d6">f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="HWE" target="LD">
      <data key="d4">14.0</data>
      <data key="d5">HWE and LD were calculated for TNFSF4 SNPs</data>
      <data key="d6">f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="OMNIBUS TEST" target="CART">
      <data key="d4">2.0</data>
      <data key="d5">Omnibus test and CART analysis were used to explore SNP interactions</data>
      <data key="d6">f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="PULMONARY FIBROSIS" target="LUNGS">
      <data key="d4">8.0</data>
      <data key="d5">Pulmonary fibrosis affects the lungs</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="PULMONARY FIBROSIS" target="BLEOMYCIN">
      <data key="d4">16.0</data>
      <data key="d5">Bleomycin is used to induce pulmonary fibrosis in mouse models</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="PULMONARY FIBROSIS" target="TNF-/-">
      <data key="d4">14.0</data>
      <data key="d5">TNF-/- mice are protected from pulmonary fibrosis</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="PULMONARY FIBROSIS" target="TNFTM/TM">
      <data key="d4">14.0</data>
      <data key="d5">TNFtm/tm mice are protected from pulmonary fibrosis</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="PULMONARY FIBROSIS" target="GITR">
      <data key="d4">1.0</data>
      <data key="d5">GITR signaling is implicated in the development of pulmonary fibrosis</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="SNPS" target="GENOTYPING">
      <data key="d4">7.0</data>
      <data key="d5">Higher resolution genotyping will help identify SNPs involved in SSc pathogenesis</data>
      <data key="d6">7b454335c2f5651d86f712037a0dc0ff</data>
    </edge>
    <edge source="SNPS" target="DNA SEQUENCING">
      <data key="d4">7.0</data>
      <data key="d5">DNA sequencing of the TNFSF4 gene region will help identify SNPs involved in SSc</data>
      <data key="d6">7b454335c2f5651d86f712037a0dc0ff</data>
    </edge>
    <edge source="LUNGS" target="IDIOPATHIC PULMONARY FIBROSIS">
      <data key="d4">8.0</data>
      <data key="d5">Idiopathic pulmonary fibrosis affects the lungs</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="LUNGS" target="ACUTE RESPIRATORY DISTRESS SYNDROME">
      <data key="d4">8.0</data>
      <data key="d5">Acute respiratory distress syndrome affects the lungs</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="LUNGS" target="CYSTIC FIBROSIS">
      <data key="d4">8.0</data>
      <data key="d5">Cystic fibrosis affects the lungs</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="HEART" target="MYOCARDITIS">
      <data key="d4">8.0</data>
      <data key="d5">Myocarditis affects the heart</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="HEART" target="ISCHEMIC MYOCARDIAL INFARCTION">
      <data key="d4">8.0</data>
      <data key="d5">Ischemic myocardial infarction affects the heart</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="HEART" target="NON-ISCHEMIC HYPERTROPHIC CARDIOMYOPATHY">
      <data key="d4">8.0</data>
      <data key="d5">Non-ischemic hypertrophic cardiomyopathy affects the heart</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="HEART" target="TNFR1">
      <data key="d4">8.0</data>
      <data key="d5">TNFR1 signaling is essential for cardiac fibrosis</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="KIDNEY" target="ACUTE KIDNEY INJURY">
      <data key="d4">8.0</data>
      <data key="d5">Acute kidney injury affects the kidney</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="KIDNEY" target="CHRONIC KIDNEY DISEASE">
      <data key="d4">8.0</data>
      <data key="d5">Chronic kidney disease affects the kidney</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="MYOFIBROBLASTS" target="TAPI-1">
      <data key="d4">14.0</data>
      <data key="d5">TAPI-1 reduces the number of myofibroblasts</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="MYOFIBROBLASTS" target="TL1A">
      <data key="d4">8.0</data>
      <data key="d5">TL1A induces differentiation of lung fibroblasts to myofibroblasts</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="TNFR1" target="CELL DEATH">
      <data key="d4">7.0</data>
      <data key="d5">TNFR1 has potential to induce cell death response</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TNFR1" target="TACE">
      <data key="d4">8.0</data>
      <data key="d5">TACE processes soluble TNFR1</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TNFR1" target="DERMAL T CELLS">
      <data key="d4">16.0</data>
      <data key="d5">TNFR1 is upregulated on dermal T cells from patients with diffuse cutaneous SSc</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TNFR1" target="SOLUBLE TNFR1">
      <data key="d4">9.0</data>
      <data key="d5">Elevated serum concentration of soluble TNFR1 correlates with SSc disease severity</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TNFR1" target="LIVER FIBROSIS">
      <data key="d4">24.0</data>
      <data key="d5">TNFR1 plays a key role in liver fibrosis formationTNFR1 inhibition reduces liver fibrosis</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNFR1" target="NAFLD">
      <data key="d4">16.0</data>
      <data key="d5">TNFR1 inhibition reduces NAFLD activity</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNFR1" target="LT&#913;3">
      <data key="d4">7.0</data>
      <data key="d5">LT&#945;3 signals through TNFR1</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNFR1" target="CARDIAC FIBROSIS">
      <data key="d4">26.0</data>
      <data key="d5">TNFR1 and Cardiac Fibrosis: TNFR1 signaling is essential for cardiac fibrosis, as it plays a critical role in the development and progression of this condition. Studies have shown that TNFR1-KO (knockout) mice, which lack the TNFR1 receptor, exhibit reduced cardiac fibrosis, indicating that the absence of TNFR1 signaling can mitigate the fibrotic response in cardiac tissue. This suggests that TNFR1 is a key mediator in the pathological process of cardiac fibrosis and could be a potential therapeutic target for preventing or treating this condition.</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51,df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="TNFR1" target="CARDIAC TISSUE">
      <data key="d4">8.0</data>
      <data key="d5">TNFR1 signaling is essential for decreasing cardiac collagen deposition</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNFR1" target="CD34+CD45+ MONOCYTIC CELLS">
      <data key="d4">7.0</data>
      <data key="d5">TNFR1 signaling is essential for reducing CD34+CD45+ monocytic infiltration</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNFR1" target="M2-LIKE CELLS">
      <data key="d4">16.0</data>
      <data key="d5">TNFR1 signaling is essential for the presence of pro-fibrotic M2-like cells</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="TNFR1" target="M1-LIKE CELLS">
      <data key="d4">12.0</data>
      <data key="d5">TNFR1 signaling does not affect early pro-inflammatory M1-like cells</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="TNFR1" target="WT-BONE MARROW">
      <data key="d4">14.0</data>
      <data key="d5">Reconstitution with WT-bone marrow restores TNFR1 signaling</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="TNFR2" target="TRAF1">
      <data key="d4">8.0</data>
      <data key="d5">TNFR2 recruits TRAF1</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TNFR2" target="TRAF2">
      <data key="d4">8.0</data>
      <data key="d5">TNFR2 recruits TRAF2</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TNFR2" target="DERMAL T CELLS">
      <data key="d4">16.0</data>
      <data key="d5">TNFR2 is upregulated on dermal T cells from patients with diffuse cutaneous SSc</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TNFR2" target="CD4+CD25+ T-CELL">
      <data key="d4">14.0</data>
      <data key="d5">Impaired TNF/TNFR2 signaling inhibits CD4+CD25+ T-cell differentiation</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TNFR2" target="HYPERSENSITIVITY PNEUMONITIS">
      <data key="d4">14.0</data>
      <data key="d5">TNFR2 signaling is elevated in fibrotic samples of hypersensitivity pneumonitis</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TNFR2" target="STNF">
      <data key="d4">7.0</data>
      <data key="d5">sTNF is upregulated in non-fibrotic HP patients</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNFR2" target="INTESTINAL MYOFIBROBLASTS">
      <data key="d4">8.0</data>
      <data key="d5">TNFR2 mediates TNF-induced proliferation and collagen accumulation in intestinal myofibroblasts</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNFR2" target="CARDIAC FIBROSIS">
      <data key="d4">19.0</data>
      <data key="d5">TNFR2 does not significantly affect cardiac fibrosis, as evidenced by studies showing that TNFR2-KO mice do not exhibit reduced cardiac fibrosis. This suggests that TNFR2 is not a critical factor in the development or progression of cardiac fibrosis.</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51,df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="TNFR2" target="AKT PATHWAY">
      <data key="d4">14.0</data>
      <data key="d5">TNFR2 activates the AKT pathway</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="TNFR2" target="NF-&#922;B PATHWAY">
      <data key="d4">14.0</data>
      <data key="d5">TNFR2 inhibits the NF-&#954;B pathway</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="NK CELLS" target="GITR">
      <data key="d4">18.0</data>
      <data key="d5">GITR is expressed on activated NK cells.</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9,d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="IDIOPATHIC PULMONARY FIBROSIS" target="LIGHT">
      <data key="d4">30.0</data>
      <data key="d5">Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive lung disease characterized by the thickening and scarring (fibrosis) of lung tissue, which leads to a decline in lung function. LIGHT, a member of the tumor necrosis factor (TNF) superfamily, is induced in IPF and plays a regulatory role in the fibrotic processes within the lungs. This suggests that LIGHT may be a significant factor in the pathogenesis of IPF, contributing to the progression of fibrosis in affected individuals.</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2,df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="IDIOPATHIC PULMONARY FIBROSIS" target="TNFR2-FC">
      <data key="d4">7.0</data>
      <data key="d5">TNFR2-Fc is used in clinical trials to treat Idiopathic Pulmonary Fibrosis</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="ACUTE RESPIRATORY DISTRESS SYNDROME" target="LIGHT">
      <data key="d4">14.0</data>
      <data key="d5">Elevated LIGHT is associated with ARDS in bacterial sepsis</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="MYOCARDITIS" target="CVD">
      <data key="d4">7.0</data>
      <data key="d5">Myocarditis is a type of cardiovascular disease</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="DUPUYTREN&#8217;S DISEASE" target="ANTI-TNF THERAPY">
      <data key="d4">8.0</data>
      <data key="d5">Anti-TNF therapy is used to treat Dupuytren&#8217;s disease</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="DUPUYTREN&#8217;S DISEASE" target="NCT03180957">
      <data key="d4">7.0</data>
      <data key="d5">NCT03180957 is a clinical trial targeting Dupuytren&#8217;s disease</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="ACUTE KIDNEY INJURY" target="LIGHT">
      <data key="d4">14.0</data>
      <data key="d5">Elevated LIGHT is associated with AKI in bacterial sepsis</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="NON-ALCOHOLIC FATTY LIVER DISEASE" target="LIGHT">
      <data key="d4">28.0</data>
      <data key="d5">NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) is a condition characterized by the accumulation of fat in the liver in individuals who consume little to no alcohol. LIGHT, a member of the tumor necrosis factor (TNF) superfamily, is induced in NAFLD. It plays a significant role in the disease's progression by regulating liver fibrosis, a process where excessive connective tissue builds up in the liver, potentially leading to cirrhosis. Thus, LIGHT is a critical factor in the pathophysiology of NAFLD, influencing both the onset and severity of liver fibrosis associated with the disease.</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2,df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="NON-ALCOHOLIC FATTY LIVER DISEASE" target="HVEM">
      <data key="d4">12.0</data>
      <data key="d5">HVEM mRNA expression is increased in NAFLD tissue</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="NON-ALCOHOLIC FATTY LIVER DISEASE" target="LT&#914;R">
      <data key="d4">2.0</data>
      <data key="d5">LT&#946;R mRNA expression is increased in NAFLD tissue</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="PRIMARY BILIARY CHOLANGITIS" target="RANKL">
      <data key="d4">1.0</data>
      <data key="d5">RANKL is upregulated in primary biliary cholangitis</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="FR1" target="TRADD">
      <data key="d4">8.0</data>
      <data key="d5">FR1 recruits TRADD</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TACE" target="TAPI-1">
      <data key="d4">16.0</data>
      <data key="d5">TAPI-1 blocks TACE</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TACE" target="SOLUBLE TNFR1">
      <data key="d4">8.0</data>
      <data key="d5">TACE processes soluble TNFR1</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TACE" target="STNF">
      <data key="d4">8.0</data>
      <data key="d5">TACE cleaves mTNF to release sTNF</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TAPI-1" target="COL1A1">
      <data key="d4">14.0</data>
      <data key="d5">TAPI-1 reduces mRNA expression of Col1a1</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TAPI-1" target="&#913;SMA">
      <data key="d4">14.0</data>
      <data key="d5">TAPI-1 reduces mRNA expression of &#945;SMA</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="&#913;SMA" target="TGF&#914;1">
      <data key="d4">8.0</data>
      <data key="d5">TGF&#946;1 increases &#945;SMA expression</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="&#913;SMA" target="LIGHT">
      <data key="d4">21.0</data>
      <data key="d5">LIGHT is known to increase &#945;SMA expression in murine hepatic fibroblasts. Additionally, LIGHT induces &#945;SMA accumulation.</data>
      <data key="d6">05c97152fe02249153103be341d65b67,5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="&#913;SMA" target="LIVER FIBROSIS">
      <data key="d4">7.0</data>
      <data key="d5">&#945;SMA is used as a marker to measure liver fibrosis</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="IPF" target="STNFR1">
      <data key="d4">14.0</data>
      <data key="d5">sTNFR1 is increased in the fibroblast supernatant from IPF patients</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="BLEOMYCIN" target="MLE-12 CELLS">
      <data key="d4">7.0</data>
      <data key="d5">Bleomycin is used to treat MLE-12 cells to induce cell injury</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="BALF" target="GITR">
      <data key="d4">6.0</data>
      <data key="d5">GITR-/- BALF has lower cellularity compared to GITR+/+ BALF</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="SOLUBLE TNFR1" target="BLEOMYCIN-INDUCED MURINE MODEL">
      <data key="d4">8.0</data>
      <data key="d5">Soluble TNFR1 levels are increased in the bleomycin-induced murine model of SSc</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TGF-&#914;1" target="DERMAL MYOFIBROBLASTS">
      <data key="d4">8.0</data>
      <data key="d5">TGF-&#946;1 induces dermal myofibroblasts transdifferentiation</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="LIVER FIBROSIS" target="TL1A">
      <data key="d4">7.0</data>
      <data key="d5">TL1A is associated with liver fibrosis</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="LIVER FIBROSIS" target="PEGYLATED TRAIL">
      <data key="d4">8.0</data>
      <data key="d5">PEGylated TRAIL is used to treat liver fibrosis</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="LIVER FIBROSIS" target="COLLAGEN DEPOSITION">
      <data key="d4">7.0</data>
      <data key="d5">Collagen deposition is a marker of liver fibrosis</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="NAFLD" target="HFD">
      <data key="d4">7.0</data>
      <data key="d5">HFD is used to induce NAFLD in experimental models</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="NAFLD" target="LIGHT">
      <data key="d4">7.0</data>
      <data key="d5">Serum LIGHT is significantly increased in NAFLD patients</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="NAFLD" target="HVEM">
      <data key="d4">6.0</data>
      <data key="d5">HVEM mRNA expression is significantly increased in NAFLD tissue</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="NAFLD" target="LT&#914;R">
      <data key="d4">6.0</data>
      <data key="d5">LT&#946;R mRNA expression is significantly increased in NAFLD tissue</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="CARDIAC INFLAMMATION" target="CVD">
      <data key="d4">7.0</data>
      <data key="d5">Cardiac inflammation is a common feature of many cardiovascular diseases</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="CVD" target="MI">
      <data key="d4">7.0</data>
      <data key="d5">Myocardial infarction is a type of cardiovascular disease</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="CVD" target="HCM">
      <data key="d4">7.0</data>
      <data key="d5">Hypertrophic cardiomyopathy is a type of cardiovascular disease</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="CVD" target="HF">
      <data key="d4">7.0</data>
      <data key="d5">Heart failure is a type of cardiovascular disease</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="MI" target="ISCHEMIC CARDIOMYOPATHY">
      <data key="d4">18.0</data>
      <data key="d5">Myocardial infarction is a form of ischemic cardiomyopathy</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="MI" target="NECROSIS">
      <data key="d4">18.0</data>
      <data key="d5">Myocardial infarction is characterized by cardiomyocyte necrosis</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="MI" target="POST-MI HF">
      <data key="d4">16.0</data>
      <data key="d5">Heart failure can develop after a myocardial infarction</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="MI" target="LEFT CORONARY ARTERY">
      <data key="d4">14.0</data>
      <data key="d5">Myocardial infarction can be induced by ligating the left coronary artery</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="MI" target="VENTRICULAR DILATATION">
      <data key="d4">14.0</data>
      <data key="d5">Loss of TNFR2 signal exaggerates ventricular dilatation after MI</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="MI" target="LT&#913;">
      <data key="d4">16.0</data>
      <data key="d5">LT&#945; levels increase after myocardial infarction</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="MI" target="OPG">
      <data key="d4">14.0</data>
      <data key="d5">OPG levels are significantly higher in patients with chronic fibrosis after myocardial infarction</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="HCM" target="ANG II">
      <data key="d4">7.0</data>
      <data key="d5">Ang II induces HCM in a mouse model</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="HCM" target="NON-ISCHEMIC CARDIOMYOPATHY">
      <data key="d4">16.0</data>
      <data key="d5">Hypertrophic cardiomyopathy is a form of non-ischemic cardiomyopathy</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="HCM" target="AORTIC VALVE STENOSIS">
      <data key="d4">14.0</data>
      <data key="d5">Aortic valve stenosis can induce hypertrophic cardiomyopathy</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="HCM" target="CARDIAC HYPERTROPHY">
      <data key="d4">16.0</data>
      <data key="d5">Hypertrophic cardiomyopathy is characterized by cardiac hypertrophy</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="HCM" target="VASCULAR RAREFACTION">
      <data key="d4">14.0</data>
      <data key="d5">Hypertrophic cardiomyopathy is characterized by vascular rarefaction</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="HF" target="ISCHEMIC CARDIOMYOPATHY">
      <data key="d4">16.0</data>
      <data key="d5">Ischemic cardiomyopathy can lead to heart failure</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="HF" target="NON-ISCHEMIC CARDIOMYOPATHY">
      <data key="d4">16.0</data>
      <data key="d5">Non-ischemic cardiomyopathy can lead to heart failure</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="HF" target="OPG">
      <data key="d4">14.0</data>
      <data key="d5">Higher OPG levels are associated with increased left ventricular mass index and myocardial stiffness in HF patients</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="LT&#913;3" target="INFLAMMATORY DISEASES">
      <data key="d4">8.0</data>
      <data key="d5">LT&#945;3 signals through TNFR1 and has unique roles in initiation and exacerbation of some inflammatory diseasesLT&#945;3 has unique roles in initiation and exacerbation of some inflammatory diseases</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="ANG II" target="CARDIAC FIBROSIS">
      <data key="d4">7.0</data>
      <data key="d5">Ang II induces the development of cardiac fibrosis</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="CARDIAC FIBROSIS" target="TNFR1-KO">
      <data key="d4">7.0</data>
      <data key="d5">TNFR1-KO mice show reduced cardiac fibrosis</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="CARDIAC FIBROSIS" target="TNFR2-KO">
      <data key="d4">7.0</data>
      <data key="d5">TNFR2-KO mice do not show reduced cardiac fibrosis</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="CARDIAC FIBROSIS" target="DOUBLE RECEPTOR KNOCKOUT">
      <data key="d4">8.0</data>
      <data key="d5">Double receptor knockout mice are protected from cardiac fibrosis</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="CARDIAC FIBROSIS" target="ANG-II">
      <data key="d4">16.0</data>
      <data key="d5">Ang-II induces the development of cardiac fibrosis</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="CARDIAC FIBROSIS" target="OPG">
      <data key="d4">16.0</data>
      <data key="d5">OPG pathways are involved in the pathology of cardiac fibrosis</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="CARDIAC FIBROSIS" target="PROCOLLAGEN &#913;1">
      <data key="d4">12.0</data>
      <data key="d5">Inactivation of procollagen &#945;1 synthesis is associated with less interstitial cardiac fibrosis</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="LIGHT" target="HVEM">
      <data key="d4">41.0</data>
      <data key="d5">LIGHT and HVEM are closely related entities in the context of autoimmune diseases. LIGHT acts through HVEM to regulate fibrosis, indicating a functional relationship where LIGHT's activity is mediated by its interaction with HVEM. Additionally, LIGHT binds to HVEM, further supporting the direct interaction between these two molecules. This binding is crucial for the regulatory role that LIGHT plays in fibrosis, highlighting the importance of the LIGHT-HVEM axis in the pathophysiology of autoimmune conditions.</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2,c95d22c2a90e77cd22bd0d280d55b26a,df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="LIGHT" target="LT&#914;R">
      <data key="d4">34.0</data>
      <data key="d5">LIGHT and LT&#946;R are closely related entities in the context of autoimmune diseases. LIGHT binds to LT&#946;R and acts through this receptor to regulate fibrosis. This interaction is crucial for understanding the mechanisms underlying fibrotic processes in autoimmune conditions.</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2,df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="LIGHT" target="DCR3">
      <data key="d4">16.0</data>
      <data key="d5">LIGHT binds to DcR3</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="LIGHT" target="FIBROPROLIFERATIVE">
      <data key="d4">14.0</data>
      <data key="d5">LIGHT is involved in fibroproliferative diseases</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="LIGHT" target="HVEM-L">
      <data key="d4">18.0</data>
      <data key="d5">HVEM-L is another name for LIGHT</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="LIGHT" target="CD258">
      <data key="d4">18.0</data>
      <data key="d5">CD258 is another name for LIGHT</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="LIGHT" target="ACUTE HYPOXIC RESPIRATORY FAILURE">
      <data key="d4">14.0</data>
      <data key="d5">Elevated LIGHT is associated with AHRF in bacterial sepsis</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="LIGHT" target="NASH">
      <data key="d4">7.0</data>
      <data key="d5">LIGHT is involved in the transition from NAFLD to NASH</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="LIGHT" target="HEPATIC STEATOSIS">
      <data key="d4">7.0</data>
      <data key="d5">Genetic deletion of LIGHT results in reduced hepatic steatosis</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="LIGHT" target="EOE">
      <data key="d4">7.0</data>
      <data key="d5">LIGHT promotes inflammation and remodeling in eosinophilic esophagitis</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="LIGHT" target="ICAM-1">
      <data key="d4">6.0</data>
      <data key="d5">LIGHT controls tethering of eosinophils to fibroblasts via ICAM-1</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="LIGHT" target="CKD">
      <data key="d4">7.0</data>
      <data key="d5">LIGHT is implicated in the development of renal fibrosis in chronic kidney disease</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="LIGHT" target="UUO">
      <data key="d4">7.0</data>
      <data key="d5">Genetic deletion of LIGHT reduces renal fibrosis in UUO-induced mice</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="LIGHT" target="LDO">
      <data key="d4">6.0</data>
      <data key="d5">LIGHT plays a significant role in connective tissue remodeling in primary acquired lacrimal duct obstruction</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="LIGHT" target="CBS001">
      <data key="d4">8.0</data>
      <data key="d5">CBS001 is an anti-LIGHT monoclonal antibody</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="LIGHT" target="GRANULOCYTES">
      <data key="d4">16.0</data>
      <data key="d5">LIGHT acts on granulocytes to drive both pro-fibrotic and anti-fibrotic effects.</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a,68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="HVEM" target="TNFRSF14">
      <data key="d4">18.0</data>
      <data key="d5">TNFRSF14 is the gene encoding HVEM</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="HVEM" target="LDO">
      <data key="d4">6.0</data>
      <data key="d5">HVEM is expressed in lacrimal sac walls and correlates with fibrosis severity</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="LT&#914;R" target="TNFRSF3">
      <data key="d4">18.0</data>
      <data key="d5">TNFRSF3 is the gene encoding LT&#946;R</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="LT&#914;R" target="LDO">
      <data key="d4">6.0</data>
      <data key="d5">LT&#946;R is expressed in lacrimal sac walls and correlates with fibrosis severity</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="LT&#914;R" target="BAMINERCEPT">
      <data key="d4">16.0</data>
      <data key="d5">Baminercept is a lymphotoxin-beta receptor fusion protein</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="DCR3" target="TNFRSF6B">
      <data key="d4">2.0</data>
      <data key="d5">TNFRSF6B is the gene encoding DcR3</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="DCR3" target="TL1A">
      <data key="d4">6.0</data>
      <data key="d5">TL1A signal can be neutralized by its soluble decoy receptor, DcR3</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="FIBROPROLIFERATIVE" target="CONNECTIVE TISSUE">
      <data key="d4">14.0</data>
      <data key="d5">Fibroproliferative diseases affect connective tissue</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="NASH" target="SERUM BAFF LEVELS">
      <data key="d4">8.0</data>
      <data key="d5">Elevated serum BAFF levels are associated with NASH severity</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="SIMPLE STEATOSIS" target="SERUM BAFF LEVELS">
      <data key="d4">7.0</data>
      <data key="d5">Serum BAFF levels help distinguish NASH from simple steatosis</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="EOE" target="TRAIL">
      <data key="d4">15.0</data>
      <data key="d5">Eosinophilic esophagitis (EoE) is a chronic, immune-mediated esophageal disease characterized by eosinophil infiltration and esophageal remodeling. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been identified as a significant factor in the pathophysiology of EoE. Research indicates that TRAIL expression is required for esophageal remodeling in EoE, suggesting its crucial role in the structural changes observed in the esophagus of affected patients. Additionally, TRAIL is significantly upregulated in EoE patients, further underscoring its importance in the disease process. These findings highlight TRAIL as a potential therapeutic target for managing EoE.</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="EOE" target="A FUMIGATUS">
      <data key="d4">6.0</data>
      <data key="d5">A fumigatus is used in a mouse model to study EoE</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="EOE" target="ESOPHAGUS">
      <data key="d4">7.0</data>
      <data key="d5">The esophagus is the tissue affected in eosinophilic esophagitis</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="EOE" target="ESOPHAGEAL EOSINOPHIL">
      <data key="d4">7.0</data>
      <data key="d5">Esophageal eosinophils are involved in the inflammation of the esophagus in EoE</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="EOE" target="ESOPHAGEAL CIRCUMFERENCE">
      <data key="d4">6.0</data>
      <data key="d5">Enlargement of the esophageal circumference is a symptom of EoE</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="EOE" target="ESOPHAGEAL REMODELING">
      <data key="d4">6.0</data>
      <data key="d5">Esophageal remodeling is a histological change observed in EoE</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="TL1A" target="DR3">
      <data key="d4">23.0</data>
      <data key="d5">TL1A and DR3 are closely related entities in the context of autoimmune diseases. TL1A binds to DR3, and this interaction is crucial for signaling processes within the cell. Specifically, TL1A signals through DR3 to induce the NF-kB pathway, a key regulator of immune response and inflammation. Additionally, TL1A-DR3 signaling has been shown to promote fibrosis, which is the thickening and scarring of connective tissue, often as a result of chronic inflammation. This pathway is significant in the study of autoimmune diseases due to its role in both immune regulation and tissue remodeling.</data>
      <data key="d6">05c97152fe02249153103be341d65b67,c525762bb827485bceeb9f09bb4bcfe0,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="TL1A" target="COLITIS">
      <data key="d4">15.0</data>
      <data key="d5">TL1A is a significant target in the treatment of colitis. Blocking TL1A signaling has been shown to attenuate pathology in colitis models, indicating its crucial role in the disease's progression. The therapeutic approach involves targeting TL1A with an anti-TL1A antibody, which has demonstrated efficacy in managing colitis.</data>
      <data key="d6">05c97152fe02249153103be341d65b67,c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="TL1A" target="TRANSGENIC MICE">
      <data key="d4">6.0</data>
      <data key="d5">Transgenic mice expressing membrane-restricted TL1A show elevated proinflammatory cytokines</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="TL1A" target="SMALL INTESTINE">
      <data key="d4">6.0</data>
      <data key="d5">Membrane-restricted TL1A in the small intestine primarily activates T cells</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="TL1A" target="BOWEL">
      <data key="d4">9.0</data>
      <data key="d5">TL1A is associated with pathology of the bowel. Soluble TL1A leads to bowel pathology, indicating a significant role in the development and progression of bowel-related diseases.</data>
      <data key="d6">05c97152fe02249153103be341d65b67,c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="TL1A" target="HDM">
      <data key="d4">7.0</data>
      <data key="d5">TL1A-driven inflammation is studied using HDM as an airway irritant</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="TL1A" target="MUCUS">
      <data key="d4">8.0</data>
      <data key="d5">TL1A-driven IL-13 signaling increases mucus production</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="TL1A" target="INTESTINAL INFLAMMATION">
      <data key="d4">8.0</data>
      <data key="d5">TL1A is associated with intestinal inflammation</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="TL1A" target="INTESTINAL FIBROSIS">
      <data key="d4">8.0</data>
      <data key="d5">TL1A is associated with intestinal fibrosis</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="TL1A" target="MACROPHAGE RECRUITMENT">
      <data key="d4">7.0</data>
      <data key="d5">TL1A promotes macrophage recruitment</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="TL1A" target="PRA023">
      <data key="d4">16.0</data>
      <data key="d5">PRA023 is an anti-TL1A monoclonal antibody</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="TL1A" target="ANTI-TL1A MAB">
      <data key="d4">9.0</data>
      <data key="d5">Anti-TL1A mAb targets the TL1A protein</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="TL1A" target="TNFSF15">
      <data key="d4">9.0</data>
      <data key="d5">TL1A is encoded by the TNFSF15 gene</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="DR3" target="COLONIC FIBROBLASTS">
      <data key="d4">8.0</data>
      <data key="d5">DR3 signaling on colonic fibroblasts promotes intestinal fibrosis</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="DR3" target="PTX-35">
      <data key="d4">16.0</data>
      <data key="d5">PTX-35 is an anti-DR3 monoclonal antibody</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="ANTI-TL1A ANTIBODY" target="MMP7">
      <data key="d4">7.0</data>
      <data key="d5">Anti-TL1A antibody reduces expression of MMP7</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="ANTI-TL1A ANTIBODY" target="MMP10">
      <data key="d4">7.0</data>
      <data key="d5">Anti-TL1A antibody reduces expression of MMP10</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="TISSUE REMODELING" target="TNFSF MEMBERS">
      <data key="d4">17.0</data>
      <data key="d5">TNFSF members are involved in driving tissue remodelingTNFSF members are implicated in driving tissue remodeling</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="TACI" target="M1 POLARIZATION">
      <data key="d4">7.0</data>
      <data key="d5">TACI is involved in M1 polarization</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="SERUM BAFF LEVELS" target="HEPATOCYTE BALLOONING">
      <data key="d4">8.0</data>
      <data key="d5">Elevated serum BAFF levels are associated with hepatocyte ballooning</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="RANKL" target="RANK">
      <data key="d4">15.0</data>
      <data key="d5">RANKL and RANK are closely related entities in the context of bone metabolism and autoimmune diseases. RANKL binds to RANK, a receptor on the surface of osteoclast precursors. This binding interaction is crucial for the activation and differentiation of osteoclasts, which are cells responsible for bone resorption. The RANKL-RANK signaling pathway plays a significant role in maintaining bone homeostasis and is implicated in various autoimmune conditions where bone destruction is a feature.</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="RANKL" target="OPG">
      <data key="d4">32.0</data>
      <data key="d5">RANKL (Receptor Activator of Nuclear Factor Kappa-&#914; Ligand) and OPG (Osteoprotegerin) are critical regulators in bone metabolism and immune system function. OPG binds to RANKL, preventing the interaction between RANKL and its receptor RANK. This inhibition is crucial as it blocks the RANKL-RANK interactions, thereby preventing extracellular matrix (ECM) degradation. By binding to RANKL, OPG effectively inhibits the signaling pathways that would otherwise lead to bone resorption and degradation, highlighting its role as a protective factor in maintaining bone integrity and preventing excessive bone loss.</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7,c95d22c2a90e77cd22bd0d280d55b26a,d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="RANKL" target="OSTEOCLAST">
      <data key="d4">24.0</data>
      <data key="d5">RANKL and OSTEOCLAST are closely related entities in the context of bone metabolism and autoimmune diseases. RANKL, or Receptor Activator of Nuclear Factor Kappa-&#914; Ligand, plays a crucial role in bone remodeling by stimulating osteoclast formation. It activates and differentiates osteoclasts, which are specialized cells responsible for bone resorption. Through these mechanisms, RANKL is essential for maintaining bone homeostasis, but its dysregulation can contribute to pathological conditions such as osteoporosis and rheumatoid arthritis.</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7,d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="RANKL" target="ECM">
      <data key="d4">7.0</data>
      <data key="d5">Elevated levels of OPG can inhibit ECM degradation by blocking RANKL-RANK interactions</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="RANKL" target="PBC">
      <data key="d4">17.0</data>
      <data key="d5">RANKL is upregulated in multiple fibrotic liver diseases, including Primary Biliary Cholangitis (PBC), and may play a key role in the pathogenesis of PBC.</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7,d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="RANKL" target="BONE">
      <data key="d4">8.0</data>
      <data key="d5">RANKL is involved in maintaining bone homeostasis</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="RANKL" target="BONE RESORPTION">
      <data key="d4">8.0</data>
      <data key="d5">RANKL activates osteoclasts to promote bone resorption</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="RANKL" target="CHOLANGIOCYTES">
      <data key="d4">14.0</data>
      <data key="d5">Cholangiocytes in PBC patients express elevated levels of RANKL</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="RANKL" target="LIVER CIRRHOSIS">
      <data key="d4">16.0</data>
      <data key="d5">RANKL expression is significantly elevated in the serum of patients with liver cirrhosis</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="RANKL" target="FIBROTIC LUNG DISEASE">
      <data key="d4">14.0</data>
      <data key="d5">The RANKL-RANK-OPG axis is implicated in fibrotic lung disease</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="RANKL" target="SILICOSIS">
      <data key="d4">16.0</data>
      <data key="d5">RANKL is involved in the pathogenesis of silicosis</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="RANKL" target="OSTEOBLASTS">
      <data key="d4">14.0</data>
      <data key="d5">Human osteoblasts with a CFTR mutation show RANKL overexpression</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="RANKL" target="DENOSUMAB">
      <data key="d4">9.0</data>
      <data key="d5">Denosumab targets RANKL in clinical trials</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="OPG" target="OSTEOCLAST">
      <data key="d4">7.0</data>
      <data key="d5">OPG inhibits osteoclast activation</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="OPG" target="OSTEOBLAST">
      <data key="d4">6.0</data>
      <data key="d5">OPG is expressed mostly by osteoblasts</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="OPG" target="BONE RESORPTION">
      <data key="d4">7.0</data>
      <data key="d5">OPG inhibits bone resorption by blocking RANKL-RANK interactions</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="OPG" target="OSTEOBLASTS">
      <data key="d4">14.0</data>
      <data key="d5">Human osteoblasts with a CFTR mutation show decreased OPG production</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="OPG" target="TRAIL">
      <data key="d4">6.0</data>
      <data key="d5">TRAIL binds to OPG, a soluble decoy receptor</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="LIVER CIRRHOSIS" target="GITR">
      <data key="d4">8.0</data>
      <data key="d5">GITR is upregulated in patients with liver cirrhosis</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="CF" target="CFTR">
      <data key="d4">18.0</data>
      <data key="d5">CFTR mutation is associated with cystic fibrosis</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="GITR" target="CD25-CD4+ T CELLS">
      <data key="d4">21.0</data>
      <data key="d5">GITR is expressed at a lower level by resting CD25-CD4+ T cells.</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9,d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="GITR" target="GITRL">
      <data key="d4">16.0</data>
      <data key="d5">GITR and GITRL are closely related entities in the immune system. GITR, which stands for Glucocorticoid-Induced TNFR-Related protein, is activated by its ligand, GITRL (Glucocorticoid-Induced TNFR-Related Ligand). The interaction between GITR and GITRL is crucial, as GITRL binds to GITR, facilitating its activation. This binding and activation play significant roles in modulating immune responses, particularly in the context of autoimmune diseases.</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="GITR" target="4-1BB">
      <data key="d4">6.0</data>
      <data key="d5">GITR possesses an intracellular domain with significant homology to 4-1BB</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="DTA-1">
      <data key="d4">8.0</data>
      <data key="d5">Stimulation of GITR with DTA-1 results in promotion of proliferative responses and cytokine production</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="FOXP3">
      <data key="d4">8.0</data>
      <data key="d5">GITR signaling dampens Foxp3-mediated suppressive action in Tregs</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="GITR-/- MICE">
      <data key="d4">7.0</data>
      <data key="d5">GITR-/- mice lack the GITR gene and are used to study GITR function</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="GITR+/+ MICE">
      <data key="d4">7.0</data>
      <data key="d5">GITR+/+ mice have normal GITR expression and are used as controls</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="FC-GITR FUSION PROTEIN">
      <data key="d4">7.0</data>
      <data key="d5">Fc-GITR fusion protein is used to disrupt GITRL/GITR signaling</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="MPO">
      <data key="d4">6.0</data>
      <data key="d5">GITR-/- mice show reduced MPO activity compared to GITR+/+ mice</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="CD25+CD4+ T CELLS">
      <data key="d4">9.0</data>
      <data key="d5">GITR is constitutively expressed by CD25+CD4+ T cells (Tregs) and plays a role in their function</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="ARTHRITIC MOUSE">
      <data key="d4">7.0</data>
      <data key="d5">GITR signaling was studied in arthritic mouse models</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="SYNOVIA">
      <data key="d4">7.0</data>
      <data key="d5">GITR signaling was studied in inflamed synovia</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="FIBROTIC MODELS">
      <data key="d4">7.0</data>
      <data key="d5">GITR signaling was studied in fibrotic models</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="GRANULOCYTES">
      <data key="d4">7.0</data>
      <data key="d5">GITR signaling affects granulocyte infiltration in lung tissue</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="TH2 CYTOKINE">
      <data key="d4">7.0</data>
      <data key="d5">GITR signaling influences Th2 cytokine production</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="TH1 CYTOKINE">
      <data key="d4">7.0</data>
      <data key="d5">GITR signaling does not influence Th1 cytokine production</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="LUNG INJURY">
      <data key="d4">8.0</data>
      <data key="d5">GITR signaling is implicated in lung injury</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="CELL INJURY">
      <data key="d4">7.0</data>
      <data key="d5">GITR signaling is implicated in cell injury</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="EPITHELIAL TO MESENCHYMAL TRANSITION (EMT)">
      <data key="d4">7.0</data>
      <data key="d5">GITR signaling is implicated in EMT</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="CIRRHOSIS">
      <data key="d4">8.0</data>
      <data key="d5">GITR is upregulated in patients with cirrhosis</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="HISTOLOGICAL SIGNS">
      <data key="d4">7.0</data>
      <data key="d5">GITR-/- mice show reduced histological signs of lung injury</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="PRO-INFLAMMATORY ENVIRONMENT">
      <data key="d4">8.0</data>
      <data key="d5">GITR signaling creates a pro-inflammatory environment</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="ANTI-INFLAMMATORY ENVIRONMENT">
      <data key="d4">1.0</data>
      <data key="d5">Disruption of GITR signaling creates an anti-inflammatory environment</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="MLE-12 CELLS" target="MENSC">
      <data key="d4">8.0</data>
      <data key="d5">MenSC reduce bleomycin-induced cell injury in MLE-12 cells</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="TRAIL" target="DR4">
      <data key="d4">25.0</data>
      <data key="d5">TRAIL binds to DR4, initiating apoptosis.</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd,c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="TRAIL" target="DR5">
      <data key="d4">25.0</data>
      <data key="d5">TRAIL binds to DR5, initiating apoptosis.</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd,c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="TRAIL" target="DCR1">
      <data key="d4">20.0</data>
      <data key="d5">TRAIL (TNF-related apoptosis-inducing ligand) binds to DcR1 (Decoy Receptor 1). Although TRAIL binds to DcR1, it does not induce apoptosis because DcR1 lacks a death domain.</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd,c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="TRAIL" target="DCR2">
      <data key="d4">15.0</data>
      <data key="d5">TRAIL (TNF-related apoptosis-inducing ligand) binds to DcR2 (Decoy Receptor 2). Although TRAIL binds to DcR2, this interaction does not induce apoptosis. This is because DcR2 has a truncated, non-functional death domain, which prevents the apoptotic signaling cascade from being initiated.</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd,c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="TRAIL" target="AHSCS">
      <data key="d4">17.0</data>
      <data key="d5">TRAIL, also known as TNF-related apoptosis-inducing ligand, is a molecule that has shown potential in the treatment of liver fibrosis. It can induce apoptosis in activated hepatic stellate cells (aHSCs), which are key players in the development and progression of liver fibrosis. By selectively targeting aHSCs, TRAIL offers a promising therapeutic approach to mitigate liver fibrosis, potentially improving liver function and patient outcomes.</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="TRAIL" target="MID-1">
      <data key="d4">7.0</data>
      <data key="d5">TRAIL upregulates MID-1 expression</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="TRAIL" target="CCL24">
      <data key="d4">7.0</data>
      <data key="d5">TRAIL is necessary for the upregulation of CCL24</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="TRAIL" target="TNFSF10">
      <data key="d4">9.0</data>
      <data key="d5">TRAIL is also known as TNFSF10</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="TRAIL" target="CD253">
      <data key="d4">9.0</data>
      <data key="d5">TRAIL is also known as CD253</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="TRAIL" target="APOPTOSIS">
      <data key="d4">1.0</data>
      <data key="d5">Apoptosis is induced by TRAIL</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="TRAIL" target="MFBS">
      <data key="d4">9.0</data>
      <data key="d5">TRAIL can induce apoptosis in MFBs</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="DR4" target="FADD">
      <data key="d4">8.0</data>
      <data key="d5">DR4 recruits FADD to form the death-inducing signaling complex</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="DR4" target="TNFRSF10A">
      <data key="d4">8.0</data>
      <data key="d5">DR4 is also known as TNFRSF10A</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="DR5" target="FADD">
      <data key="d4">8.0</data>
      <data key="d5">DR5 recruits FADD to form the death-inducing signaling complex</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="DR5" target="TNFRSF10B">
      <data key="d4">8.0</data>
      <data key="d5">DR5 is also known as TNFRSF10B</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="DCR1" target="TNFRSF10C">
      <data key="d4">7.0</data>
      <data key="d5">DcR1 is also known as TNFRSF10C</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="DCR2" target="TNFRSF10D">
      <data key="d4">7.0</data>
      <data key="d5">DcR2 is also known as TNFRSF10D</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="FADD" target="PROCASPASE-8">
      <data key="d4">8.0</data>
      <data key="d5">FADD recruits and activates procaspase-8</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="MID-1" target="PP2A">
      <data key="d4">7.0</data>
      <data key="d5">MID-1 inhibits PP2A activity</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="MID-1" target="SIRNA">
      <data key="d4">7.0</data>
      <data key="d5">siRNA targets MID-1 in TRAIL deficient mice</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="LUMBAR SPINAL FIBROSIS" target="TNF BLOCKER">
      <data key="d4">8.0</data>
      <data key="d5">TNF blocker is used to treat lumbar spinal fibrosis</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="LUMBAR SPINAL FIBROSIS" target="ANTI-TNF THERAPY">
      <data key="d4">8.0</data>
      <data key="d5">Anti-TNF therapy is used to treat lumbar spinal fibrosis</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="LUMBAR SPINAL FIBROSIS" target="NCT00385086">
      <data key="d4">7.0</data>
      <data key="d5">NCT00385086 is a clinical trial targeting lumbar spinal fibrosis</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="LUMBAR SPINAL FIBROSIS" target="POST OPERATIVE SCIATICA">
      <data key="d4">7.0</data>
      <data key="d5">Post Operative Sciatica can be caused by Lumbar Spinal Fibrosis</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="ANTI-TNF THERAPY" target="NCT03747068">
      <data key="d4">14.0</data>
      <data key="d5">NCT03747068 is a clinical trial involving anti-TNF therapy</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="ANTI-TNF THERAPY" target="TNF BLOCKER">
      <data key="d4">8.0</data>
      <data key="d5">TNF blocker is a type of anti-TNF therapy</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="TNF BLOCKER" target="NCT00385086">
      <data key="d4">2.0</data>
      <data key="d5">NCT00385086 is a clinical trial involving TNF blocker</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="TNF BLOCKER" target="POST OPERATIVE SCIATICA">
      <data key="d4">7.0</data>
      <data key="d5">TNF blockers are used in clinical trials to treat Post Operative Sciatica</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="UNIVERSITY OF TORONTO" target="CROHN DISEASE">
      <data key="d4">6.0</data>
      <data key="d5">University of Toronto is involved in clinical trials for Crohn's disease</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="CBS001" target="CHRONIC INFLAMMATORY DISEASE">
      <data key="d4">7.0</data>
      <data key="d5">CBS001 is used in clinical trials to treat Chronic Inflammatory Disease</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="NON-EOSINOPHILIC ASTHMA" target="AVTX-002">
      <data key="d4">14.0</data>
      <data key="d5">AVTX-002 is used in clinical trials to treat Non-Eosinophilic Asthma</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="COVID-19 PNEUMONIA" target="CERC-002">
      <data key="d4">16.0</data>
      <data key="d5">CERC-002 is used in clinical trials to treat COVID-19 Pneumonia</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="ACUTE LUNG INJURY" target="CERC-002">
      <data key="d4">16.0</data>
      <data key="d5">CERC-002 is used in clinical trials to treat Acute Lung Injury</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="ARDS" target="CERC-002">
      <data key="d4">16.0</data>
      <data key="d5">CERC-002 is used in clinical trials to treat ARDS</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="CROHN DISEASE" target="MDGN-002">
      <data key="d4">14.0</data>
      <data key="d5">MDGN-002 is used in clinical trials to treat Crohn Disease</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="CROHN DISEASE" target="DENOSUMAB">
      <data key="d4">7.0</data>
      <data key="d5">Denosumab is used in clinical trials for Crohn's disease</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="CROHN DISEASE" target="UNIVERSITY OF MANITOBA">
      <data key="d4">6.0</data>
      <data key="d5">University of Manitoba is involved in clinical trials for Crohn's disease</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="CROHN DISEASE" target="MCMASTER UNIVERSITY">
      <data key="d4">6.0</data>
      <data key="d5">McMaster University is involved in clinical trials for Crohn's disease</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="BAMINERCEPT" target="PRIMARY SJ&#214;GREN&#8217;S SYNDROME">
      <data key="d4">14.0</data>
      <data key="d5">Baminercept is used in clinical trials to treat Primary Sj&#246;gren&#8217;s Syndrome</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="PRA023" target="DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS">
      <data key="d4">14.0</data>
      <data key="d5">PRA023 is used in clinical trials to treat Diffuse Cutaneous Systemic Sclerosis</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="PRA023" target="HEALTHY VOLUNTEER">
      <data key="d4">7.0</data>
      <data key="d5">PRA023 is tested in clinical trials involving Healthy Volunteers</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="PRA023" target="MODERATELY TO SEVERELY ACTIVE CROHN&#8217;S DISEASE">
      <data key="d4">7.0</data>
      <data key="d5">PRA023 is used in clinical trials to treat Moderately to Severely Active Crohn&#8217;s Disease</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="PRA023" target="MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS">
      <data key="d4">7.0</data>
      <data key="d5">PRA023 is used in clinical trials to treat Moderately to Severely Active Ulcerative Colitis</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="PRA023" target="HEALTHY">
      <data key="d4">1.0</data>
      <data key="d5">PRA023 is tested in clinical trials involving Healthy individuals</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="PRA023" target="PROMETHEUS BIOSCIENCES, INC.">
      <data key="d4">8.0</data>
      <data key="d5">Prometheus Biosciences, Inc. is developing PRA023</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="PRA023" target="CELERION">
      <data key="d4">7.0</data>
      <data key="d5">Celerion is involved in the clinical testing of PRA023</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="TACI-FC FUSION PROTEIN" target="IGA NEPHROPATHY">
      <data key="d4">8.0</data>
      <data key="d5">TACI-Fc fusion protein is being tested for its efficacy in treating IgA nephropathy</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="TACI-FC FUSION PROTEIN" target="REMEGEN CO., LTD.">
      <data key="d4">8.0</data>
      <data key="d5">RemeGen Co., Ltd. is developing TACI-Fc fusion protein</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="TACI-FC FUSION PROTEIN" target="VERA THERAPEUTICS, INC.">
      <data key="d4">8.0</data>
      <data key="d5">Vera Therapeutics, Inc. is developing TACI-Fc fusion protein</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="IGA NEPHROPATHY" target="ATACICEPT">
      <data key="d4">8.0</data>
      <data key="d5">Atacicept is used in the treatment of IgA Nephropathy</data>
      <data key="d6">8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="IGA NEPHROPATHY" target="ANTI-BAFF PEPTIBODY">
      <data key="d4">8.0</data>
      <data key="d5">Anti-BAFF peptibody is used in the treatment of IgA Nephropathy</data>
      <data key="d6">8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="RELAPSING-REMITTING MULTIPLE SCLEROSIS" target="ATACICEPT">
      <data key="d4">16.0</data>
      <data key="d5">Atacicept is used in clinical trials for treating relapsing-remitting multiple sclerosis</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3</data>
    </edge>
    <edge source="DENOSUMAB" target="CALCIFIC AORTIC STENOSIS">
      <data key="d4">7.0</data>
      <data key="d5">Denosumab is used in clinical trials for calcific aortic stenosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="CALCIFIC AORTIC STENOSIS" target="ALENDRONIC ACID">
      <data key="d4">7.0</data>
      <data key="d5">Alendronic acid is used in clinical trials for calcific aortic stenosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="CALCIFIC AORTIC STENOSIS" target="UNIVERSITY OF EDINBURGH">
      <data key="d4">6.0</data>
      <data key="d5">University of Edinburgh is involved in clinical trials for calcific aortic stenosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="CALCIFIC AORTIC STENOSIS" target="BRITISH HEART FOUNDATION">
      <data key="d4">6.0</data>
      <data key="d5">British Heart Foundation is involved in clinical trials for calcific aortic stenosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="CALCIFIC AORTIC STENOSIS" target="NHS LOTHIAN">
      <data key="d4">6.0</data>
      <data key="d5">NHS Lothian is involved in clinical trials for calcific aortic stenosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="IMMUNE SYSTEM DISEASES" target="KYMAB LIMITED">
      <data key="d4">6.0</data>
      <data key="d5">Kymab Limited is involved in clinical trials for immune system diseases</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="TNFSF MEMBERS" target="FIBROTIC DISEASE">
      <data key="d4">9.0</data>
      <data key="d5">TNFSF members are upregulated in fibrotic disease states</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
  </graph>
</graphml>